<SEC-DOCUMENT>0000950170-25-043859.txt : 20250324
<SEC-HEADER>0000950170-25-043859.hdr.sgml : 20250324
<ACCEPTANCE-DATETIME>20250324162012
ACCESSION NUMBER:		0000950170-25-043859
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250324
DATE AS OF CHANGE:		20250324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALISADE BIO, INC.
		CENTRAL INDEX KEY:			0001357459
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				522007292
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33672
		FILM NUMBER:		25764402

	BUSINESS ADDRESS:	
		STREET 1:		7750 EL CAMINO REAL, SUITE 5200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009
		BUSINESS PHONE:		(858) 704-4900

	MAIL ADDRESS:	
		STREET 1:		7750 EL CAMINO REAL, SUITE 5200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seneca Biopharma, Inc.
		DATE OF NAME CHANGE:	20200127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neuralstem, Inc.
		DATE OF NAME CHANGE:	20060324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pali-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-24T15:04:38.0503+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:pali="http://www.palisadebio.com/20241231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_0adc1245-a6ae-40b8-bf92-6e192f60c11d" name="dei:AmendmentFlag" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_ee9de4a7-011c-465a-b950-4735d28ab749" name="dei:EntityCentralIndexKey" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb">0001357459</ix:nonNumeric><ix:nonNumeric id="F_6194d79e-72db-45e2-89e2-cb51e1ab1a1d" name="dei:DocumentFiscalPeriodFocus" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb">FY</ix:nonNumeric><ix:nonFraction id="F_41a02ef9-ef41-402f-a4a8-05fe4612c034" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1ef91e9f-cd0d-43f4-90e4-9dfe50bab27e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_0ffa1e3a-3c65-4853-b3c6-1a6c686c9e2d" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pali-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_800199c1-afa8-43b6-9911-358e1907566a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_818ca5b3-48b6-4160-92ed-c3b213c95caf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81df8d1c-b732-4f34-b1db-4b541732537e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pali:InsuranceFinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8426ec92-90f5-4884-8a80-f0b476e31550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8645eaec-898b-48e4-befe-b013c00071ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_871f11a5-0df3-4821-9459-e430d23f2e22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:April2023OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89ee88e7-ca37-400a-8b0f-b936d897aea2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8adee270-45e0-4d2c-a675-0eb8595fa4df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:WarrantInducementAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b845079-c037-4485-9046-bc648460b149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eff58aa-d87c-40ad-9ed7-ea2c72cee31b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f070788-1b85-4e49-a494-ec7bbbbb19f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f0ecb26-e051-44ad-94f8-a05944e7fc18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:SeptemberTwoThousandAndTwentyThreeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-11</xbrli:startDate><xbrli:endDate>2023-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9360a9a6-4319-458b-a705-b8de13df423c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94a47a15-71e6-4ad0-8919-73628f2b0419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:WarrantInducementAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96ce46ae-4e1d-4e12-9e91-5be0b6992fac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:JanuaryTwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9845b157-d40c-4027-97c2-a0fd4385089a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:LegacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_989d323e-90bd-4bc1-84ab-7e972e39245f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:JanuaryTwoThousandAndTwentyThreeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-04</xbrli:startDate><xbrli:endDate>2023-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98ae9a8f-1e7d-4c2d-ba28-e6b7c8ca5a22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99e41a4e-a74b-43bc-991a-d6f51c9aeaa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassAUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a5cce76-d0fc-4cb9-bb7b-be35e5885dd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a79efb8-eb68-42c2-a8fa-55c0d8aa5fda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b87aaa7-9c2f-4572-baaa-95cb98ab911a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c31b2dd-531d-464b-9a92-f5f7289500d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2023-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c3eea55-6dac-475a-8dd9-570c44c3ad63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c81c8a6-3ae0-4c51-b74d-11500c011143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e634a16-0f0c-47a0-b175-926c827758d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pali:InsuranceFinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ebb78c1-151a-4750-8ce8-05e1baf42364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f691187-dbba-46aa-957f-8451263e8080"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a049a491-7334-498c-b8d3-99fbfcde6601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0bdf278-32cb-4874-b9d5-b39d0aa6c3f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a24647e4-47f9-4d57-a123-b33e432c6857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4cf7202-92fd-4462-bf25-87c0570b5099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:September2023OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6268737-830c-4d22-b51b-e3c071317b8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassBUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aba08c8a-3298-4ff6-87c6-223993191a45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad71c156-c72e-4679-bf89-118f467d7baf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:August2024OfferingSeries2CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad8d582e-2dde-4db3-8d6f-4a779f360888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1540c36-2dc4-4c82-81de-598e5062281b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2023-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b326ac9a-3edc-4669-a12a-a44223068a1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4194f6e-7d8f-4de8-9fdb-21da6a505d2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b47952f8-e25d-4791-a542-4d8bd701e282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b74d1b57-b99f-46a7-91d3-48efac8c1858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b898e598-304f-4ea7-864c-b785cdbc5739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b957477c-5568-4340-967f-f75d2478e99a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:AprilTwoThousandAndTwentyThreeOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-03</xbrli:startDate><xbrli:endDate>2023-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb50a5e7-6ed1-4053-bfca-ab15e7b28b4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-30</xbrli:startDate><xbrli:endDate>2024-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc157d16-357e-4df0-8664-94e2436271d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd03d751-b219-4043-84ae-de9c81d5698b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd447e9d-307f-412a-8859-7e1a2091a009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:UnregisteredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfdab209-cc24-443e-af8d-5930cc4c3149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pali:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c88b6c40-1467-497e-aa09-abf945fe9976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cee46443-8d64-412f-b41e-41a2367bf1f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2013PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0f8faa6-225c-4d7d-8f77-da0c5084bd1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d36c00ce-2fa2-47f1-a66c-21a67e4857fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3c9c2d7-95dc-49bb-98bf-59ffcaac2dcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5ec44e5-acfe-425d-94c1-cba3b6c5a935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8e2d363-b0b1-4013-b25f-43acf427f165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da789c28-414e-4ccd-947d-5e1f11d5ee32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db7afb64-6e06-473b-8d9a-ceeac08c60c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc6265aa-95b8-4ea1-85f9-00aa6ae27844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dca63de9-3d4a-4b50-a74f-1090217fcb16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:RepricedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-12</xbrli:startDate><xbrli:endDate>2024-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd1ca615-f781-4979-a8ac-e2d5b4aab50b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:AllOtherCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de9ce026-379c-4626-83e2-28087fada0ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3a8e347-dc37-40b0-851c-4ceba3d07be3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementReplacementCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e42cccf2-0558-4a1d-8434-967432a7ef50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4f02a44-93b6-4104-9ffb-23aeab786d9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5488fc7-f4ab-4fdb-a268-96c258ed7b00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e55e3216-27d9-421d-a685-8982258e7fbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassBUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e678878a-0c3f-4ca9-be27-f1041b0e7025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6fca467-ed31-4675-ab98-dc0f25b03fbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7194555-4ab8-40fd-b397-92bd0b1f7bb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e786d4a3-2e6a-4337-8144-697692254d24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee8693bb-92aa-44a4-880d-83926ceee699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee931db3-063b-4b61-9205-fc476769857a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f15cfeb5-6c1f-45a8-9c16-b9c0acc83ad6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:Series2WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f399e54c-6ccd-4ae9-97a2-1db3bdc4468e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:BridgeJanuary2021AndJuly2021CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3aab31d-1085-44a6-848c-14e1390b99a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f40fb1ae-32d9-4be3-b219-d5d71698de2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:September2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4816ad5-6544-4cc3-8edc-993c725f05ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4c47b93-0a6c-459a-94b1-6b86830d25bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:August2024OfferingSeries2CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f507e9fa-1c64-4a5c-b79d-ad17dd341e37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f73a25a6-b329-46fd-a117-c2bcc90c783a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:January2023OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9f17689-3835-44ab-86c4-7ce94e9a6825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9ff4d32-3399-4339-9015-2a14b777cd9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:PALITwoOneZeroEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feec2dcc-5780-4073-a999-74c92a2f28c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff902a0c-401a-4796-873a-f487d5f3927d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffa661a6-473a-4c79-8a7f-48832923f5d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00c99cd4-9ed2-49c9-94cb-b920b598790f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01126dbc-d04a-4b1c-9f6b-d2a1bf5c9e96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01f7368c-fa1b-4d5d-a9c9-07ba03a45b8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0396c3a7-c3c7-4970-b67a-c7d717b609c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pali:InsuranceFinancingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04026d27-31da-458f-9340-63004096eee6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05d7c843-a34b-479a-88d4-a12a886a60f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_064f0da6-66e3-4594-9a33-dd0538609aca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_065287e3-70be-4640-bc93-2e29518133d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06862901-f3a4-4bd2-bd72-90b6eae2c329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:January2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_070fbbd6-0133-4fd9-a92e-3a59027648e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0769ff66-ee84-425c-88ee-5721d253b14e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07bbc911-5220-457e-b6ff-5ac9e1cf7eb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:January2023OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09342590-da6c-45b7-8387-a049a00b0407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_099a2990-8f62-4736-908a-75e3e70bef39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ac0e42c-71fc-4569-afd4-fccf25d6e52e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ce6c868-1e07-4b9e-ac58-05460a42652b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cf6a60b-d394-429d-82ae-cbe7825fb226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d1eb655-c370-425c-8e10-3bf6703f37a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-06</xbrli:startDate><xbrli:endDate>2024-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e805a01-b80a-43a2-b2d3-6b7c1b32fbd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e9b1aec-3b94-4255-8d2d-686c1a773637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11a397d8-f76e-4123-8ffc-90b0d4bba3ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12a10425-82c0-439c-a876-125097f2fbf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:RepricedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12dc02fb-eac4-4610-bad8-fe8e9ad4d610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15b1b95a-f0a8-45cc-8b88-bb5a5b75d92d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1647ede8-9b3a-4985-acc0-f4909695082f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16734ac9-5f7d-4564-bb8b-aff2052903ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16f011be-773b-4769-92b0-515dab2809dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:LegacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ab29fa5-66c6-45ad-818c-b0bfb6693551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b2b7036-6d4a-4dda-b9b5-3fef242b5750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1daf9a02-8b5d-48fd-8804-9977e84acb12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e5799eb-2dde-4495-859d-82b3ce5341eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ea433f0-bf37-4d98-8e23-9f24084ab798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:Nsi532Igf1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-27</xbrli:startDate><xbrli:endDate>2022-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2007472e-785f-4e66-8b90-31974e6c2d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-06</xbrli:startDate><xbrli:endDate>2023-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_210c21f0-b090-4433-b5b4-a390a090d368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_215542bf-2dd7-470b-b7be-f61e7050c227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22d62b69-795d-4d94-914a-263cdadcd8a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24d8c3be-2445-4bb1-aa0d-5f552876a8bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:AllOtherCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25437a64-b804-49d4-a583-6149701ed82e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25e9e99e-093d-49a0-982e-33f5812e37b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:September2023OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_272eb503-8300-45b6-8c62-5bd2086f945b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_281c192c-92de-47d8-8a46-d3ac8f6e44b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pali:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a44715d-6d67-4a8c-9146-cda1c95f1181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32effecb-dcdb-418d-b9ab-602e1ecc9121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementReplacementCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_339a2504-3ac9-410d-8ca6-961361ccd1aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33afec80-d974-4667-ab99-82569d37d0b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_348f4f92-6daf-4dc1-aff7-04ba4780b100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_386963f7-adcd-4589-ad1e-18c92d7f72e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39580d8d-37fd-4134-8e15-fc3336a39dd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39cecd10-468f-4aba-9f46-454343174b91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d9e481b-d117-4e88-951d-c039596d2643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ec4089f-24f1-40c5-a1ee-41580353eddb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:RepricedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4166f110-68a3-43b8-9e9a-a8db08091181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_418106b0-0eb9-4bd1-a9d8-1a674eb12eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_456ae310-d956-4c7f-aca2-b537a393db0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46b8f935-7e06-4909-98e0-8a09b69ca511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:April2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_494b0e96-ca6c-4dd0-aada-9c385796b28c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a7340ec-c1ef-4e8f-b685-40b983c0d414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c38a0f6-0e17-4097-a741-e8528d218109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d65b8a8-159b-4e62-9b59-1b4091249817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f54001b-6421-4019-8e41-db056882bcd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fedbd90-4e26-4897-b395-ac4b7cdb1342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:PALITwoOneZeroEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51618521-fa5c-465f-afce-888db78121fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53120144-37f7-483b-a872-d0f02ddccfbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:SeriesA4Point5PercentConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5506b90a-1f64-4934-8403-8f83e8522373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:WarrantInducementAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56df2920-b057-4c20-af0b-3fb60d22d643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57444f7a-2496-4f31-9eac-285e8dbbc2a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_582ecc46-b417-4c17-b3ac-7494c5aa8bda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingPreFundedCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ad66f61-3eb3-4d36-903d-7bac0116fcc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5affaffb-555c-4738-91d1-a014135e69c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b7ce63d-492e-48d6-b155-482c37907109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:ReplacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b914c39-e156-49cc-b150-f585bc3b48b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5be85942-60b4-4ca7-b41c-6a7af1aea32f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c1b7f20-1f1a-46c6-b1ce-e72714e8e6c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f66a802-eff0-4fee-9465-2edf3990258c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_659e2af0-b6fd-4530-954e-5b638bb46b1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66aae2c0-5abe-49b9-befa-ef1108555742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:BridgeJanuary2021AndJuly2021CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_671d8ff9-d06e-44e8-8753-0d285732a4c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_691877b9-f2f5-489e-a81b-02e81e212a3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:AprilTwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a4f9f7a-6ab6-414e-a396-2c7f3c0ae7ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:April2023OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b08194e-e220-4a67-9b3b-b24bf7d2dc89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ffb0979-629b-4688-a29a-73f1f89ce426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_708ff3fe-8eaf-45eb-9adb-df47251abc06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70ce8c11-9f45-440b-9b1d-6046060ca1af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73bb4959-69c7-4db1-8a36-8a4200ea4201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassAUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73c82250-26a7-4e8c-bbde-5150f68a53ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:ReplacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-30</xbrli:startDate><xbrli:endDate>2024-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76e3614d-9c9a-46c6-a850-919f190aaaca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_790040b9-b57e-4116-8804-a4572f9ba17c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_795c51ad-a42a-4991-8de6-80e768ef9af0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b587e1b-52d0-4b29-b97d-1630d7f21d83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-06</xbrli:startDate><xbrli:endDate>2023-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bdff01b-c6cb-4014-8bf2-6623ec18a56e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-06</xbrli:startDate><xbrli:endDate>2023-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d3732a3-912c-4fce-90de-1cf88fb0bb7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001357459</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Days"><xbrli:measure>pali:Days</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pali:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Agreement"><xbrli:measure>pali:Agreement</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_1cae901f-db24-4481-ad3f-2ed437509eae" fromRefs="F_ccbb254a-2085-465e-8ec8-ae210579281a F_0f258028-16ee-47ec-b30a-a72e7909933d F_52f8c5ac-0778-4aeb-b48d-5ca369d4f1c9 F_2d214d75-f0d4-46b6-a346-1086df1e7442 F_bb5c5b37-1ce9-43b5-b2e5-323e82bd6b35 F_3befa2c4-75ca-4fc6-ae21-d8d6d7a77d6d F_dd2d9c2e-d568-4109-9a93-3600a95d4bb8 F_f295b006-8721-42a1-9ac3-52f7a33c05b0"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd" fromRefs="F_f57a0064-dc8e-4fa8-a52f-54517bbe3c18 F_319d8403-72a4-41d4-af2c-c72e7618880c F_89a5ab14-b2e0-4738-a557-61eb27d9e8b7 F_bfea37a1-9005-48a7-8355-3aa202c9ac1b F_a9aaa239-ef30-4d3b-a071-c1561afdc27d F_d411c7b8-b584-4e13-97b4-511b622f1b23 F_32d51079-3301-4b4a-876e-bfb122660164 F_199eb8a0-6b97-4beb-b1bb-be7bf186d9a0 F_6f3be1d1-75d4-43bb-ba1c-fefea07a2041 F_65e1e41b-e592-45d0-9e65-6d7e4f5027a5 F_9fa2496c-4ca6-423d-a620-e2e7efcb12e5 F_d36e42da-1750-4bfd-8ccc-25d155d540fb F_a2c67c24-ea99-467d-b763-290b87654180 F_c7397b9f-06bf-42db-afdc-18d7fcca3a92 F_bf86ad15-f481-43bc-95fd-ed93392090db F_9511cfd1-2c72-40fd-82a4-ff06fe15d67d F_bddb3b34-6a85-4acb-b78f-4f2ccd352734 F_58475b22-3533-4cb1-afde-56be185c8979 F_fd270e0c-1614-4dab-8b8e-e5417adf32f7 F_0d8986ce-d38e-4bda-ab78-06023757e6ab F_e7cc059f-57cd-4370-8109-52aebcece734 F_598beaea-107c-4159-af0f-159afd92aecb F_b466cb16-964d-49e3-96e0-9a33a892309c F_d939f84e-22a7-443b-8c7d-9877fdf3af00 F_2467db4a-5cce-40b8-8e36-9c08cd303c89 F_b9fb2141-4746-4cf1-a213-25ff041b13d7 F_481c1e2d-9068-4ae3-9ba7-c8d2ae60a338 F_97d2faa5-3929-43e4-9b99-b2b09b8e728b F_e68f6333-1c2a-4508-ada0-e03960169271 F_bce6c0dd-8418-4daf-adfd-5db44bf2a01a F_913a4536-6c4b-4315-bf67-d5c1533e34fb F_9745b3d0-2782-465e-b09b-34f7e43e40e7 F_59ca71c2-b250-44d8-8b8a-4e88355311e3 F_8cc691d2-c99f-43b3-b37d-ba6cb755b8af F_6d752654-4a66-4b6d-98c9-36e92bc3213d F_c976ce42-1091-4cc0-944a-f361caf66be6 F_dee46229-4244-4ad9-b50c-f0b17e03436a F_417255a2-0c2e-47c2-964a-37873d64eabb F_5d0c4430-3d06-42b8-b111-3e61fdac3cd0 F_ebfb9068-25fc-4457-81e6-4ab7d1e6695f F_e1dac30b-227b-4798-a021-13173d491f7b F_7228d524-4406-4b0c-8431-766f31a3570e F_223c3c04-379a-4125-84e0-9d7da2e2a28a F_5efb6687-ed6e-45e6-9dfd-e297f64b1113 F_cc72025c-7121-4942-ac82-720a8dcaf5c6 F_bdd775a9-38c9-4488-93ee-6a859c8265b1 F_f68d14e1-3be6-4e28-bab4-237421dd1b76 F_25fe3de5-adc1-472b-9089-7ffa1ad3b53b"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430" fromRefs="F_de0ee860-249f-4ea5-a15f-2253e20d2e60 F_e17dc50e-fb87-4771-bb28-42b133ce3025 F_af472992-0b5c-4fd7-8629-5a80bacda3e1 F_9ec4bd57-f51b-4896-87de-7ea6b3c54805 F_578d8f4a-3f98-4fcb-b04c-47dfd425f18e F_fce4d946-4eaa-49bf-bf56-389a9c946b62 F_0190b23d-8df3-4c80-9a8d-d863afd3dc7c F_93846c07-d6b2-4f83-a4ae-e0b232e0b38d F_5632091e-04bc-4913-8599-b692f8c15eb4"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a24d421d-7967-41bf-b49a-e381503e1600" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ca9fd075-3b0b-48e6-a17b-5dce988d59db" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bea2a263-4d90-4447-9d4d-f86e5a60fde7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3be08f57-5463-468e-ac05-0e5cf68788f7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63f2eb06-28c7-4385-a8c0-f8afd82af0f9" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a87dcac2-2700-4cfc-be9a-cc9c4c720a21" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89087063-d005-415b-8a4c-9c54bcab9c46" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-33672</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01d5fbc2-d243-485e-95b4-89aee47be85f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALISADE BIO, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_2f6b1304-eb44-4394-9ade-03a9038a2d5d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_08ee8fb4-e20b-41ef-b374-ca7cff50e7f5" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52-2007292</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_423e17b4-e34d-46e3-b9dd-7e1ae77186ca" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">7750 El Camino Real, Suite 2A</span></ix:nonNumeric></span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_53beb5e4-86b5-43d6-82ad-ab72f0fd11b5" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carlsbad</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_8c148566-9a0a-4c04-b963-69aaa5080f54" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c68724b4-4347-432e-ae46-1cd49b4e671d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92009</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c97224c2-df23-4cb6-a779-61f89f7132c0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f9b8018-d300-44d8-85f8-0be090fd202a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">704-4900</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b4f215ec-5154-46e1-88d9-5aea9b152674" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">common stock, $0.01 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_fdbf22f6-1b0a-4b7a-883f-67b06d52e24f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PALI</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_94bba7fa-9ed5-4316-ba17-bdc2c2624fdb" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fdd609a-c6a7-4bf0-9744-397bbffffa87" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d893492-4a59-4cf9-94da-b389730dd4ec" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78edcef9-f9c9-47f1-b142-30989ce203a7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6504e39-1604-4c03-8772-16e20561db80" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:55.84%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:20.1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_7f50356a-b9d1-4ed1-a354-e0079d45e4f2" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_47617a90-2ba5-48e7-8000-bd9d6fbbc956" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f535781b-2dd4-4bdc-b42b-eb30fc799a85" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a3322ea-c1f2-4da6-bb26-fd7e95b5dbbe" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f576efe9-5301-47b1-a537-facda5f4a7a7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_358c5caa-a3bb-456b-b2e9-adc9b128be02" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant, based on the closing price of a share of the registrant&#8217;s common stock on June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as reported by the Nasdaq Capital Market on such date, was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ea8f85c-af1e-4688-a950-87af61da3734" contextRef="C_e6fca467-ed31-4675-ab98-dc0f25b03fbd" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Shares o</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the registrant, have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 19, 2025, the registrant </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d18a7461-8e26-40fe-9f18-b452cc21c17b" contextRef="C_dc6265aa-95b8-4ea1-85f9-00aa6ae27844" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,396,646</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares o</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f common stock, $0.01 par value per share, outstanding.</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e66df829-0892-42d5-90ad-f6cade468dfa" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:82%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#forward_looking_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements and Risk Factor Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#business_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factors_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comment_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#properties_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#legal_proceedings_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mine_safety_disclosures_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#market_for_registrant_common_equity_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#selected_financial_data_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_condition_results_operations_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#quantitative_and_qualitative_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements_supplementary_data_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#changes_in_disagreements_financial_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#controls_and_procedures_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#other_information_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#disclosure_foreign_jurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii_item_10"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii_item_11"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii_item_12"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii_item_13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii_item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits_financial_statement_schedules_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#form_summary_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i_"><span id="part_i">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="forward_looking_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cautionary Note Regarding </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Risk Factor Summary</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, (the "Exchange Act"). These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Some of these factors are more fully discussed in section 1A of this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and elsewhere herein</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Forward-looking statements may include, but are not limited to, statements about:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">the results of our preclinical and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue to be realized;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">future regulatory, judicial, and legislative changes or developments in the United States ("U.S.") and foreign countries and the impact of these changes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to successfully develop our licensed technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to build a commercial infrastructure in the U.S. and other markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to compete effectively in a competitive industry;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to identify and qualify additional manufacturers to provide active pharmaceutical ingredients ("API") and manufacture drug product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to enter into commercial supply agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">the success of competing technologies that are or may become available; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to attract and retain key scientific or management personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our ability to attract collaborators and partners.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; "intend," &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. There can be no assurance that any of the events anticipated by forward-looking statements will occur or, if any of them do occur, what impact they will have on our business, results of operations and financial condition. You should not rely on forward-looking statements as predictions of future events. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions, and other factors described in Part I, Item 1A Risk Factors and elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on any forward-looking statements contained in this Annual Report. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Except as required by law, we undertake no obligation to update or revise any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this Annual Report on Form 10-K, together with the documents that we have previously filed with the Securities and Exchange Commission ("SEC") completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all the forward-looking statements in the foregoing documents by these cautionary statements.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTOR SUMMARY</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face many risks and uncertainties, as more fully described in this Annual Report on Form 10-K under the heading &#8220;Risk Factors.&#8221; The summary below does not contain all the information that may be important to you, and you should read this summary together with the more detailed discussion of these risks and uncertainties contained in &#8220;Risk Factors.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Development, Commercialization and Regulatory Approval of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business depends on the successful clinical development, regulatory approval, and commercialization of our therapeutic compounds, including our lead asset PALI-2108.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are substantial risks in drug development, and, as a result, we may not be able to successfully develop any product candidate, including our lead product candidate, PALI-2108.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on our license agreement with Giiant Pharma Inc. ("Giiant") to permit us to use patents and patent applications relating to PALI-2108. Termination of these rights or the failure to comply with our obligations under the license agreement could materially harm our business and prevent us from developing or commercializing PALI-2108, our lead product candidate.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical drug development is expensive, time-consuming and uncertain.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting a Phase 1 clinical trial of PALI-2108 in Canada, and the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or applicable foreign regulatory authorities may not accept data from such trials, or any other trial we conduct outside of the U.S.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our operations and development of PALI-2108 will require substantially more capital than we currently have, and we cannot guarantee when or if we will be able to secure such additional funding.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates, including our lead product candidate PALI-2108, may cause undesirable side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that our product candidates will obtain regulatory approval.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If clinical studies of PALI-2108 do not yield successful results, we may discontinue the development of PALI-2108.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may take us longer than we estimate to complete clinical trials, and we may not be able to complete them at all.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if PALI-2108 is approved for commercialization, future regulatory reviews or inspections may result in its suspension or withdrawal, closure of a facility or substantial fines.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful commercialization of PALI-2108, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and we may need to limit our commercialization. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history and have never generated any revenues from product sales.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business model assumes revenue from, among other activities, marketing or out-licensing the products we develop. PALI-2108 is in the early stages of clinical development, and because we have a short development history with PALI-2108, there is a limited amount of information about us upon which you can evaluate our business and prospects.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends on the attracting and retaining senior management and scientists with relevant expertise.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to discontinue the development or commercialization of any of our product candidates, or may choose not to commercialize product candidates in approved indications, at any time during development or after approval, which could adversely affect us and our operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to successfully in-license, acquire, develop and market additional product candidates or approved products could impair our ability to grow our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in funding for the FDA and, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent these agencies or authorities from performing normal business functions on which the operations of our business may rely, which could negatively impact our business.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate relying on third-party Contract Research Organizations ("CROs") and other third parties to conduct and oversee our clinical trials. If these third parties do not meet our requirements or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations for, obtain regulatory approval for, or commercialize our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on two qualified suppliers for the active pharmaceutical ingredient used in the clinical trials of PALI-2108. Insufficient availability of the API or other raw materials necessary to manufacture PALI-2108, or the inability of our suppliers to manufacture and supply our products on commercially reasonable terms, could adversely impact our business, results of operations and financial condition.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to rely on collaborations with third parties for the successful development and commercialization of our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Operations</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have expressed substantial doubt about our ability to continue as a going concern.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a history of net operating losses, and we expect to continue to incur net operating losses and may never achieve profitability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements in our consolidated financial statements.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important to our business.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Risks Related to Our Securities</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock price may be highly volatile.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock could be delisted from the Nasdaq Stock Market if we are unable to maintain compliance with the Nasdaq Stock Market&#8217;s continued listing standards.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors ("Board" or "Board of Directors") has broad discretion to issue additional securities, which might dilute the net tangible book value per share of our common stock for existing stockholders.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, &#8220;Palisade,&#8221; &#8220;Palisade Bio,&#8221; the "Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; or similar designations refer to Palisade Bio, Inc., a Delaware Corporation, and its subsidiaries. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any reference to &#8220;common shares&#8221; or &#8220;common stock,&#8221; refers to our $0.01 par v</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alue common stock. Any reference to &#8220;Series A Preferred Stock&#8221; refers to our Series A 4.5% Convertible Preferred Stock. Any reference to &#8220;Leading Biosciences, Inc.&#8221; or &#8220;LBS&#8221; refers to our operations prior to the completion of our merger with Seneca Biopharma, Inc. ("Seneca") on April 27, 2021 (the "Merger"). Any technology that we currently own or may acquire the rights to in the future is referred to by us as either a &#8220;product candidate&#8221; or "product candidates." Additionally, any reference herein that refers to preclinical studies also refers to nonclinical studies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="business_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (&#8220;IBD&#8221;), including ulcerative colitis (&#8220;UC&#8221;) and Fibrostenotic Crohn&#8217;s disease (&#8220;FSCD&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our objective is to establish ourselves as a leader in the development of differentiated product candidates targeting the autoimmune, inflammatory, and fibrotic disease markets, which we believe will address a large, well-established need among patients living with autoimmune and inflammatory diseases.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the key elements of our strategy include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advancing our lead product candidate, PALI-2108 through human clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">leveraging our drug development platform infrastructure to identify product candidates that target autoimmune, inflammatory, and fibrotic diseases;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuing strategic partnerships to further expand our programs and maximize the worldwide potential of our product candidates and platform; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuing strategy of in-licensing/acquisition or out-licensing/sale of our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently advancing clinical trials of PALI-2108 for the treatment of IBD, including UC and FSCD. The following table summarizes the current stages of our clinical and research programs:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img61919486_0.jpg" alt="img61919486_0.jpg" style="width:624px;height:226px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Precision Medicine Approach</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a biomarker-based patient selection approach that we believe may aid clinicians in identifying patients who may better respond to PALI-2108, thereby improving the rate of clinical response previously demonstrated with enzyme phosphodiesterase-4 (&#8220;PDE4&#8221;) inhibitors. Our approach involves the use of clinical and multiomics data from large patient populations to identify PDE4-related biomarkers that are correlated with IBD, its severity, and which are modified with local PDE4-inhibitor therapy in the colon. Based on our research, we have initiated the development of corresponding biomarker assays for these PDE4-related biomarkers that we expect to use in our current and future clinical studies with the aim of developing regulatory approved tests for selecting potential responders to PALI-2108.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead product candidate, PALI-2108, is a prodrug inhibitor designed to help treat UC and FSCD by targeting the key PDE4 in colon tissues and preventing it from breaking down cyclic Adenosine Monophosphate (&#8220;cAMP&#8221;) molecules which regulate inflammation in the body. By inhibiting PDE4, intracellular cAMP molecule levels become elevated, which may lead to a reduction of inflammatory molecules and an increase of anti-inflammatory molecules within tissues of the colon. Additionally, we believe that PALI-2108 may help prevent the movement of inflammatory cells from the blood into colon tissues, thereby lowering the activity of certain proteins that contribute to fibrosis (a type of tissue scarring).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With a glucuronic-derived sugar moiety, PALI-2108 remains minimally absorbed until activated by the colonic bacterium enzyme &#946;-glucuronidase. We believe that localized bioactivation may help focus the effects of PALI-2108 where it would be most beneficial to a patient suffering from IBD.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108 for UC</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In UC mouse models, we have demonstrated the dose-dependent efficacy of PALI-2108. Specifically, we utilized Dextran Sodium Sulfate (&#8220;DSS&#8221;)-induced UC mouse models and target engagement in oxazolone-induced colitis. Thus, based on the research conducted on these mouse models, we demonstrated that PALI-2108 has preferential colon activation. This preferential colon activation offers a unique approach to delivering the PDE4 inhibitor locally within the colon. The local bioactivation of PALI-2108 prodrug is designed to prevent the systemic toxicity inherent with immunosuppression and avoid the known tolerability issues of PDE4 inhibitors.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108 for FSCD</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Studies have shown that patients with intestinal fibrosis exhibit elevated PDE4 B and D enzyme levels in intestinal tissues. Also, preclinical research using a chronic DSS-induced mouse model of intestinal fibrosis shows similarly decreased PDE4 enzyme levels and demonstrated that systemic administration of PDE4 inhibitors improve clinical symptoms and reduce known biomarkers of fibrosis associated with FSCD. In these studies, systemically delivered PDE4 inhibitors significantly improved clinical outcomes, including body weight, disease activity, colon length, and key biomarkers of intestinal fibrosis, such as &#945;-SMA and MMPs, with these markers returning to baseline levels upon treatment. Additionally, PDE4 inhibition was found to prevent the breakdown of cAMP, which in turn inhibits fibroblast functions, including tissue remodeling. Further research indicates that TGF-beta, a key driver of fibrosis, modulates cAMP levels, and PDE4 inhibition exerts particularly strong anti-fibrotic effects when TGF-beta-induced fibroblast stimulation is present.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted a study evaluating the anti-inflammatory and anti-fibrotic effects of PALI-2108, a locally bioactivated PDE4 inhibitor, in an acute DSS-induced mouse model. Treatment with PALI-2108 resulted in dose-dependent improvements in clinical outcomes, including disease activity and colon length. Additionally, PDE4B expression in colon tissues was reduced in a dose-dependent manner, intracellular cAMP levels increased, and TNF-alpha levels in colon tissues were normalized in most of the mice treated.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bioinformatics analysis of colon biopsy gene expression data (RNA-seq) further supports the effects of PALI-2108. The analysis reveals a dose-dependent modulation of 187 genes associated with four major fibrotic pathways in IBD. Furthermore, the treatment shows a dose-dependent improvement in fibrosis enrichment scores for FSCD markers. These findings suggest that PALI-2108 is a promising dual-acting drug candidate, with both anti-inflammatory and anti-fibrotic properties, for the treatment of FSCD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img61919486_1.jpg" alt="img61919486_1.jpg" style="width:624px;height:351px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Clinical Study of PALI-2108</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 clinical study of PALI-2108 is a single-center, randomized, double-blinded, placebo-controlled clinical study focused on safety, tolerability, and pharmacokinetics (&#8220;PK&#8221;) in both healthy volunteers and UC patients. The clinical study includes an open-label UC patient cohort with multiple dosing arms in which we will evaluate the pharmacodynamics of PALI-2108 in healthy volunteers. We plan to complete enrollment of approximately 90 subjects across several arms of this Phase 1 clinical study including, (i) at five subject cohorts receiving a Single Ascending Dose (&#8220;SAD&#8221;) with a crossover to evaluate food effects (&#8220;FE&#8221;), (ii) three or more subject cohorts receiving a Multiple</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascending Dose (&#8220;MAD&#8221;), and (iii) at least one multiple dose in a UC patient cohort. The primary objective of the study is to assess the safety and tolerability of single (healthy subjects) and repeated (healthy subjects and UC patients) oral doses of PALI-2108. Secondary objectives include determining plasma, urine, colon tissue, and fecal (MAD healthy subjects and UC patients only) PK, as well as the FE of PALI-2108 and its metabolites following a single oral dose in healthy subjects and repeated oral doses in both healthy subjects and UC patients. We anticipate announcing topline data from this study during the second quarter of 2025. If the trial meets its primary objectives, we plan to initiate a Phase 1b/2a clinical studies in UC patients and FSCD patients in the first quarter of 2026.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase I Clinical Study of PALI-2108 in Canada</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 9, 2024, Health Canada issued a No Objection Letter for our Phase 1 human clinical study of PALI-2108 for the treatment of UC. We officially began studying on November 7, 2024. As of the date of this report, we have dosed five subject cohorts in a SAD study, two subject cohorts in a crossover study to evaluate FE, and four subject cohorts in a MAD study. Each of the SAD and MAD cohorts consisted of eight subjects, with six subjects receiving the drug and two subjects receiving a placebo. The FE study included two cohorts each of six subjects, of which one cohort was in a fasted state and the other cohort in a fed state. Finally, we have initiated the dosing of a cohort of UC patients, of which one patient has completed the study to date.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Planned Clinical Trial of PALI-2108 in the U.S.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to conducting clinical studies in Canada, we anticipate submitting an Investigational New Drug Application (&#8220;IND&#8221;) with the FDA during 2025. If our IND is approved, we anticipate commencing clinical trials of PALI-2108 in the U.S. during the first quarter of 2026.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that if developed and approved for marketing, PALI-2108 could be an effective treatment for IBD. Our initial indications for PALI-2108 are:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ulcerative Colitis</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UC is a chronic IBD that primarily affects the colon and rectum, leading to long-lasting inflammation and ulcers in the digestive tract. Common symptoms include abdominal pain, diarrhea, and rectal bleeding. The prevalence of UC is estimated to range from 156 to 291 cases per 100,000 people globally. In the eight major markets (&#8220;8MM&#8221;), diagnosed incident cases of UC are projected to increase from 160,122 cases in 2021 to 168,467 cases by 2031, reflecting an annual growth rate (&#8220;AGR&#8221;) of 0.52%. The U.S. is expected to have the highest number of diagnosed incident cases in 2031, totaling 104,795, while France will have the fewest at 2,972 cases. Additionally, diagnosed prevalent cases are anticipated to rise from 1,946,428 in 2021 to 2,069,770 in 2031, with an AGR of 0.63%. The U.S. is again projected to lead in prevalence in 2031 with 655,317 cases, whereas Canada is projected to report the lowest with 91,186 cases. This growth in diagnosed cases is largely attributed to changes in population dynamics across these markets. The market for 8MM for UC treatments was valued at approximately $7.3 billion in 2021 and is expected to grow to over $9.5 billion in 2031 at a compound annual growth rate ("CAGR") of approximately 2.78%. Market expansion is driven by the increasing prevalence of the disease, advancements in diagnostic techniques, and the development of more effective and targeted therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fibrostenotic Crohn&#8217;s Disease</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Crohn&#8217;s disease ("CD") is an IBD that can affect any part of the gastrointestinal tract, from the mouth to the anus. It is characterized by inflammation that can penetrate deep into the layers of the affected bowel tissue, leading to a range of symptoms including abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. In the 8MM, diagnosed incident cases of CD are expected to increase from 118,885 cases in 2022 to 122,175 cases by 2032, reflecting an AGR of 0.28%. The U.S. is projected to have the highest number of diagnosed incident cases of CD in 2032, with 68,815 cases, while France is projected to report the fewest at 4,560 cases. Additionally, diagnosed prevalent cases of CD are anticipated to rise from 1,626,752 in 2022 to 1,695,580 in 2032, with an AGR of 0.42%. The U.S. is again projected to lead in prevalence in 2032, with 755,802 cases, whereas Japan is projected to have the fewest diagnosed prevalent cases of CD at 44,732. These increases in diagnosed cases are attributed to changes in population dynamics across these markets. The global market for CD treatments was valued at $13.9 billion in 2022 and is projected to grow to approximately $25.5 billion in 2032 at a CAGR of approximately 6%. This market growth is fueled by the rising prevalence of the disease, improved diagnostic techniques, and ongoing advancements in research and development activities for new drug therapies.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FSCD, a severe form of CD, is characterized by the formation of fibrotic tissue, or strictures, in the bowel, which can result in obstruction and significant complications. Approximately half of CD patients will develop stricture formation within the first 10 years of diagnosis. Currently, treatment options for FSCD are limited, with no approved therapies specifically addressing this indication. Existing treatment approaches are primarily invasive, including balloon dilation, strictureplasty, and, in more severe cases, bowel resection. These procedures, while necessary, pose significant risks and can greatly impact the quality of life.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the lack of effective treatment options, we believe PALI-2108 has the potential to provide a much needed first-in-class therapy for these patients. PDE4 inhibitors are a clinically and commercially proven dual-acting anti-inflammatory and anti-fibrotic candidate, offering a unique approach to addressing both the inflammatory and fibrotic components of CD. With its innovative mechanism of action, PALI-2108 has the potential to transform the lives of individuals suffering from FSCD by providing a less invasive and more effective treatment alternative.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unmet Needs in IBD</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the availability of various treatments, there are significant unmet needs in managing IBD. These challenges impact patient outcomes and overall disease management. We believe improvements to key existing therapies in IBD are necessary.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inadequate Primary Response to Medical Treatment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> - Many patients experience low rates of clinical response to initial medical treatments. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secondary Loss of Clinical Response or Drug Intolerance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> &#8211; A portion of patients initially respond well to treatment but later experience a loss of clinical response or develop intolerance to currently available drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient Selection</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> - Identifying patients likely to respond to specific drugs is critical. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety Concerns and Long-Term Medication Use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">- Existing drugs may have side effects and safety concerns, including black box warnings, associated with prolonged use.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limited Options for Refractory or Severe Disease &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A portion of patients face refractory or severe disease that does not respond adequately to available treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enhancing Treatment Adherence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">--</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Frequent or inconvenient dosing regimens, including infusions and injections, can hinder patient adherence. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our clinical research and development, we believe that PALI-2108 has the potential to address many of these areas of needed improvement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic Agreements and Collaborations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Giiant License Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, we entered into a research collaboration and license agreement (the &#8220;Giiant License Agreement&#8221;) with Giiant. Under the terms of the Giiant License Agreement, we obtained the rights to develop, manufacture, and commercialize all compounds from Giiant, existing now and in the future, and any product containing or delivering any licensed compound, in any formulation or dosage for all human and non-human therapeutic uses for any and all indications worldwide, including those technologies that are the basis of PALI-2108. Pursuant to the terms of the Giiant License Agreement, preclinical development of PALI-2108 was jointly undertaken by us and representatives of Giiant. Pursuant to the Giiant License Agreement, we paid, or reimbursed or advanced to Giiant, a portion of the joint development costs. Additionally, per the terms of the Giiant License Agreement, we will pay (i) certain milestone payments (in cash or our common stock at our sole election) (the &#8220;Giiant Milestone Payments&#8221;) and (ii) royalty payments upon sales or sublicenses to third parties, with such Giiant Milestone Payments and royalty payments (the &#8220;Giiant License Payments&#8221;) subject to a payment cap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-Development and Distribution Agreement with Newsoara</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LBS entered into a co-development and distribution agreement with Newsoara, a joint venture established with Biolead Medical Technology Limited, as amended, (the &#8220;Newsoara Co-Development Agreement&#8221;). Pursuant to the Newsoara Co-Development Agreement (and subsequent assignment agreement), LBS granted or licensed Newsoara an exclusive right under certain patents to develop, use, sell, offer to sell, import, and otherwise commercialize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">licensed products (the &#8220;Newsoara Licensed Products&#8221;) for any and all indications in the People&#8217;s Republic of China, including the regions of Hong Kong and Macao, but excluding Taiwan (the &#8220;Territory&#8221;). The Newsoara Licensed Products only include the drug asset referred to as LB1148. The right includes the right to grant sublicenses to third parties, subject to LBS&#8217; written consent, provided that both parties agreed that Newsoara would be permitted to use a certain partner for development purposes. The Newsoara Co-Development Agreement obligates Newsoara to initially use LBS as the exclusive supplier for all of Newsoara&#8217;s requirements for Newsoara Licensed Products in the Territory. During the term of the Newsoara Co-Development Agreement, Newsoara may request to manufacture the Newsoara Licensed Products in the Territory, subject to satisfying certain conditions to LBS' reasonable satisfaction. LBS is obligated to approve Newsoara manufacturing rights without undue refusal or delay.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of the rights granted to Newsoara under the Newsoara Co-Development Agreement, Newsoara paid LBS a one-time upfront fee of $1.0 million. In addition, Newsoara is obligated to make (i) payments of up to $6.75 million in the aggregate upon achievement of certain regulatory and commercial milestones, (ii) payments in the low six-digit range per licensed product upon achievement of a regulatory milestone, and (iii) tiered royalty payments ranging from the mid-single-digit to low-double-digit percentage range on annual net sales of Licensed Products, subject to adjustment to the royalty percentage in certain events, including a change of control, the expiration of certain patents rights, and royalties paid by Newsoara third parties. To date, Newsoara has met all of its payment obligations under the Newsoara Co-Development Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Newsoara Co-Development Agreement will expire upon the expiration date of the last valid claim of any licensed patent covering the Newsoara Licensed Products in the Territory. In addition, the Newsoara Co-Development Agreement can be terminated (i) by either party for the other party&#8217;s material breach that remains uncured for a specified time period after written notice or for events related to the other party&#8217;s insolvency, (ii) by LBS if Newsoara challenges or attempts to interfere with any licensed patent rights and, (iii) by Newsoara for any reason upon specified prior written notice.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements with the Regents of the University of California</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into three license agreements, as amended, with the Regents of the University of California (&#8220;Regents&#8221;) for exclusive commercial rights to certain patents, technology and know-how related to LB1148. Concurrent with our decision to terminate the development of LB1148, on October 20, 2023 we terminated two of our license agreements with Regents. As of December 31, 2024, the only license agreement remaining with Regents is that entered into with LBS in August 2015, as amended in December 2019 and September 2022 (the &#8220;2015 UC License&#8221;). The 2015 UC License was retained for the sole purpose of maintaining the Newsoara Co-Development Agreement under which we may receive future milestone or royalty payments through the term of the license. Accordingly, pursuant to the 2015 UC License, we are obligated to pay a percentage of non-royalty licensing revenue we receive from Newsoara under the Newsoara Co-Development Agreement to Regents ranging from 30 percent to 35 percent of one-third of the upfront payment and milestone payments received from Newsoara.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2015 UC License will expire upon the expiration date of the longest-lived patent right licensed under the 2015 UC License. The Regents may terminate the 2015 UC License if: (i) a material breach by us is not cured within 60 days, (ii) we file a claim asserting the Regents licensed patent rights are invalid or unenforceable, or (iii) we file for bankruptcy. We also have the right to terminate the 2015 UC License at any time upon at least 90 days&#8217; written notice.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the U.S. and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution capabilities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We rely on third parties for our clinical supply of our API used in PALI-2108 and to supply the Newsoara Licensed Products to Newsoara.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we progress through the research and clinical trials of our lead product candidates, our strategy for manufacturing and supply chain management is designed to ensure the highest quality, compliance, and efficiency in producing our product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support the clinical manufacture of the product candidates we are developing we engage a network of third-party Contract Development and Manufacturing Organizations ("CDMOs") and Contract Manufacturing Organizations ("CMOs"). These partnerships are strategically chosen based on a rigorous review of criteria including technological capabilities, regulatory compliance, quality assurance systems, and production capacity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our selection process for CDMOs and CMOs involves an in-depth evaluation of potential partners to ensure alignment with our quality standards, production needs, and timeline requirements. These organizations are responsible for various stages of drug development and manufacturing, including but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">API Production:</span><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> High-quality synthesis of active ingredients under stringent regulatory standards.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Formulation Development:</span><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Design and development of stable and effective drug formulations suitable for clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Material Manufacturing:</span><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Production of investigational medicinal products in compliance with current Good Manufacturing Practice ("cGMP") regulations for use in clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Packaging and Labeling:</span><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Secure and compliant packaging and labeling solutions for clinical trial materials, ensuring patient safety and regulatory adherence.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quality Control and Assurance:</span><span style="color:#0e101a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Comprehensive testing and validation processes to ensure the safety, efficacy, and quality of the clinical supplies.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PALI-2108</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have agreements in place with third parties to provide the necessary clinical supply of our API. These agreements are generally non-specific master services agreements that allow an entity to begin the process of future manufacturing or toxicology services, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LB1148</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our Newsoara Co-Development Agreement, we are Newsoara&#8217;s exclusive supplier of the Newsoara Licensed Products. We currently have an agreement with ThermoFisher Scientific to supply us with the Newsoara Licensed Product as required under the Newsoara Co-Development Agreement. The agreement with ThermoFisher Scientific is a non-specific master services agreement that allows us to alter the scope of services as needed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a clinical biopharmaceutical company, we face competition from a wide array of companies in the pharmaceutical and biotechnology industries. This competition includes both small companies and large companies with greater financial and technical resources and longer operating histories than our own. We also compete with the intellectual property, technology, and product development efforts of academic, governmental, and private research institutions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors may have significantly greater financial resources; a more established presence in the market; greater expertise in research and development, manufacturing, preclinical and clinical testing; more experience in obtaining regulatory approvals and reimbursement; and greater expertise in marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel; establishing clinical trial sites and patient registration for clinical trials; and in acquiring technologies complementary to, or necessary for, our programs. Smaller or earlier-stage companies may also prove to be significant competitors, particularly if they establish collaborative arrangements with larger companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in a competitive landscape within the biopharmaceutical industry. Our focus on PDE4 inhibitor prodrugs that are locally acting and the use of precision medicine for IBD presents both opportunities and challenges.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While PDE4 inhibitors that are systemically available have been demonstrated to have significant efficacy, most have demonstrated dose-limiting toxicity. Also, precision medicine has been successfully applied in oncology and its adoption in IBD remains an unmet need. Our competitors include established biopharmaceutical companies, emerging biopharmaceutical companies, and generic manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Large pharmaceutical companies with extensive resources and established pipelines compete in the IBD space. Their existing products and research efforts pose a significant challenge to our ability to compete. These competitors have a track record of developing and commercializing therapies for IBD, which may impact on our market share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging public and private biotech companies are also working to develop novel therapeutics for the treatment of IBD. However, we are not aware of other PDE4 inhibitors in development for UC or FSCD. Emerging biotech companies have similar agility and focus to us allowing them to explore novel approaches. We compete with these emerging companies for funding, talent, and market attention.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generic and biosimilar manufacturers are developing generic versions of existing IBD drugs and biosimilars are a threat to the market. As patents expire, competition intensifies. We believe that by using a precision medicine approach, we can differentiate our PDE4 inhibitor from generic alternatives, although we are not currently aware of any PDE4 inhibitors approved for IBD that will become generic.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key competitive factors affecting the success of any products that we develop, if approved, are likely to be their efficacy, safety, convenience, price, and the availability of reimbursement from government and other third-party payors. Our commercial opportunity for any of our product candidates could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, and they may commercialize products more quickly than we do.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved for the treatment of patients with moderate-to-severe IBD, our portfolio of products would compete with TNF antibodies including Humira (AbbVie), Remicade (Johnson &amp; Johnson), and Simponi (Johnson &amp; Johnson); IL-12/23 and IL-23 antibodies including Stelara (Johnson &amp; Johnson) and Skyrizi (AbbVie); &#945;4&#223;7 antibody Entyvio (Takeda); JAK inhibitors including Xeljanz (Pfizer), Rinvoq (AbbVie); and S1P1 receptor modulating therapies including Zeposia (Bristol Myers Squibb).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of several companies with product candidates in development for the treatment of patients with IBD, including Merck&#8217;s MK-7240, Roivant&#8217;s RVT-3101, and Teva&#8217;s TEV-48574 TL1A antibodies and Spyre&#8217;s SPY002; additional IL-23s including Tremfya (Johnson &amp; Johnson) and mirikizumab (Lilly) and Spyre&#8217;s SPY003; additional S1P1 modulator etrasimod (Pfizer); and oral anti-integrin agents including Morphic Therapeutic&#8217;s MORF-057, Gilead&#8217;s GS-1427, Ventyx&#8217;s VTX002, Spyre&#8217;s SPY001 and a discovery program at Dice Therapeutics (Lilly).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These technologies, along with other modalities, such as small molecules and biologics, may be used to develop therapeutic candidates that would compete against our current, and potentially future, product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patents</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have exclusively licensed a worldwide patent portfolio from Giiant consisting of pending patent applications related to the assets licensed, including PALI-2108. In the U.S., we have exclusive rights to one pending patent application (Application no. 17927827). Internationally, we have seven patent applications pending (Application Nos. (i) 2021280418, (ii) 3174137, (iii) 20218005868815, (iv) 21813913, (v) 2022-573665, (vi) 1020227045933, and (vii) MX/a/2022/014416).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pending patents all relate to (i) the methods of making pharmaceutical composition, (ii) the pharmaceutical compositions, and (iii) the methods of using the pharmaceutical composition of PALI-2108 and the other assets licensed from Giiant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also completed a provisional patent application No. 63/733,390 (Personalized Methods of Administering PDE4 inhibitors) relating to personalized PALI-2108 treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and other countries with respect to our technology, including PALI-2108 and the other assets licensed from Giiant. We also rely in part on trade secret, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the U.S. and abroad related to our technology and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our pending patents related to PALI-2108, we also maintain the patent family related to LB1148. The remaining patent family is directed to compositions comprising four components of LB1148 and their therapeutic use in treating shock and other indications. This patent family includes a patent in Europe, three granted patents in the U.S., two granted patents in Taiwan, granted patents in Australia, India, Japan, Mexico, Korea (KR 2397379) and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canada (CA 2942358), and a pending application in the U.S., all of which we solely own. In addition, this family includes a granted patent in China that we previously assigned to Newsoara to support our co-development agreement, which is described above. The expected expiration date of the issued patents (or any patents that may issue from pending applications) is 2035, excluding any adjustments or extensions of patent term that may be available.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Government Regulation and Product Approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act ("FDCA"), the Provincial Health Services Authority ("PHSA"), and regulations and guidance documents implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving pharmaceutical products. Consent from the FDA is required before conducting human clinical testing of drug products. FDA approval of a new drug application ("NDA") also must be obtained before marketing a new drug product. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the continued expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Small Molecule New Drug Product Development Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any new drug product must be approved by the FDA before it may be legally marketed in the U.S. FDA approval is also required before marketing an approved drug product for a new indication or condition of use. The process required by the FDA before a new drug product candidate may be marketed in the U.S. generally involves the following:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completion of preclinical laboratory tests and in vivo studies in accordance with the FDA&#8217;s Good Laboratory Practice ("GLP") regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Submission to the FDA of an IND application, which allows human clinical trials to begin unless FDA objects (issues a &#8220;clinical hold&#8221;) within 30 calendar days;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval by an independent institutional review board ("IRB"), reviewing each proposed clinical trial and clinical site before each clinical trial may be initiated;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance of adequate and well-controlled human clinical trials in accordance with the protocol contained in the approved IND and in accordance with the FDA&#8217;s Good Clinical Practice ("GCP") regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed product candidate for its intended use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preparation and submission to the FDA of an NDA for marketing approval that includes substantial evidence of safety and efficacy from results of preclinical testing and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Review of the product by an FDA advisory committee, if applicable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product candidate is produced to assess compliance with cGMP regulations and to assure that the facilities, methods and controls are adequate to preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential FDA audit of the preclinical and clinical trial sites that generated the data supporting the NDA; and,</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of user fees and FDA review and approval of the ND</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of the FDA&#8217;s pre-market approval requirements typically takes many years, and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Before testing any product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as in vivo animal studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs regulations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP regulations. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes active 30 calendar days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose partial or full clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not begin or recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, that issues arise that partially or fully suspend or terminate such studies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Human Clinical Trials in the U.S. Under an IND</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, which are generally physicians not employed by, or under, the control of the trial sponsor. Clinical trials must be conducted under written study protocols detailing, among other things, the objectives of the trial, subject selection and exclusion, the trial procedures, the parameters to be used in monitoring safety, the criteria to be evaluated, and a statistical analysis plan. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical trials must be conducted in accordance with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval by an IRB at each study site participating in the clinical trial or a central IRB. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1. The product candidate initially is introduced into a small number of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early understanding of its value in treating patients. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2. The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3. Phase 3 clinical trials are commonly referred to as &#8220;pivotal&#8221; or &#8220;registrational&#8221; studies, which typically denotes a study that presents data the FDA or other relevant regulatory agency will use to determine whether to approve a product. In Phase 3 studies, the product candidate is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites in adequate and well-controlled clinical trials to generate sufficient data to statistically demonstrate the efficacy and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be required by FDA, or may be voluntarily conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written IND safety reports must be promptly submitted to the FDA and the investigators for: serious and unexpected adverse events; any findings from other studies, in vivo laboratory tests or in vitro testing that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Relevant additional information obtained by the sponsor that pertains to a previously submitted IND safety report must be submitted as a follow-up IND safety report. Such report should be submitted within 15 calendar days after the sponsor receives the additional information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about certain clinical trials, including a description of the study and, in some cases, study results, must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their clinicaltrials.gov website. Manufacturers or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious or life-threatening diseases or conditions where no other comparable or satisfactory therapeutic options exist must also have a publicly available policy on evaluating and responding to requests for expanded access, sometimes called &#8220;compassionate use&#8221; requests.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor that regularly reviews accumulated data and advises the study sponsor regarding the continuing safety of the trial. This group, known as a Data and Safety Monitoring Board or Data and Safety Monitoring Committee, may also review interim data to assess the continuing validity and scientific merit of the clinical trial. This group receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the trial poses unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with cGMP Regulations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers of pharmaceutical products must comply with applicable cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections by government authorities to ensure compliance with cGMP regulations and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved NDA, and may extend to requiring withdrawal of the product from the market. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP regulations and adequate to assure consistent production of the product within required specification.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP regulations. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of small molecule products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted, to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In relation to the clinical trials that may be conducted in other countries with a view to obtaining a marketing authorization, there are comparable cGMP regulations and other regulatory rules that are implemented nationally.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. FDA Review and Approval Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of the required clinical and preclinical testing, the results of the preclinical tests and clinical trials together with detailed information relating to the product&#8217;s CMC, including negative or ambiguous results as well as positive findings, and proposed labeling, among other things, are submitted to the FDA for NDA approval to market the product for one or more indications.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act ("PDUFA"), as amended, each NDA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for approved therapeutic products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for product candidates designated as orphan drugs, unless the product candidate also includes a non-orphan indication.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the Pediatric Research Equity Act ("PREA"), an NDA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must contain data that are adequate to assess the safety and potential of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe. Also, applications for product candidates intended for the treatment of adult cancer directed at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, in place of the PREA investigations, sponsors must submit, with the application, reports from molecularly targeted pediatric cancer investigations designed to yield clinically meaningful pediatric study data, using appropriate formulations, to inform potential pediatric labeling. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Orphan products are also exempt from the PREA requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews an NDA within 60 days of submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the NDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews the NDA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMP regulations to assure and preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel therapeutic products or therapeutic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, ("REMS") is necessary to assure the safe use of the product candidate. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without a REMS, if required.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate if it determines that the manufacturing processes and facilities are not in compliance with cGMP regulations or otherwise are not adequate to assure consistent production of the product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidate within required specifications. Additionally, before approving an NDA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On the basis of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. The FDA may also require post-marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a product&#8217;s safety, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Every five years, the FDA agrees to specified performance goals in the review of NDAs under the PDUFA. One such current goal is to review standard NDAs in ten months after the FDA accepts the NDA for filing, and priority NDAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Expedited Development and Review Programs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for Fast Track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product may be eligible for priority review if it is intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product may also be eligible for accelerated approval if it is intended to treat a serious or life-threatening condition and generally provide a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality ("IMM"), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a drug may be eligible for designation as a Breakthrough Therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval but may expedite the development or approval process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Post-Approval Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After approval, there also are continuing annual program user fee requirements for approved products, excluding, under certain circumstances, orphan products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rigorous and extensive FDA regulation of pharmaceutical products continues after approval, particularly with respect to cGMP regulations. Manufacturers are required to comply with applicable cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the U.S. and between states.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other post-approval requirements applicable to pharmaceutical products include reporting of deviations from cGMP regulations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, and potency of pharmacological products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and certain state agencies, list their products, and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMP regulations and other requirements, which impose certain procedural and documentation requirements upon us and third-party manufacturers. Manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMP regulations. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, changes to the manufacturing process or facility generally require prior FDA approval or notification before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the Drug Quality and Security Act imposes obligations on manufacturers of pharmaceutical products related to product tracking and tracing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse event reporting and submission of periodic reports, including annual reports and deviation reports, are required following FDA approval of an NDA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal to approve pending applications, license suspension or revocation, imposition of a partial or full clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and result in adverse publicity, among other adverse consequences.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor also must comply with the FDA&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in patient populations that are inconsistent with the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;). The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Violations relating to the promotion of off-label uses may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Companies, however, may generally share truthful and non-misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. Discovery of previously unknown problems or the failure to comply with the applicable regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal actions and adverse publicity. These actions could include refusal to approve pending applications or supplemental applications, withdrawal of an approval, clinical hold, suspension or termination of a clinical trial by an IRB, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines or other monetary penalties, refusals of government contracts, mandated corrective advertising or communications with healthcare providers, debarment, restitution, disgorgement of profits or other civil or criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broadly equivalent requirements and controls typically apply in other countries to the submission of marketing authorization applications and, post-approval, to the holding of such marketing authorizations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Hatch-Waxman Amendments and Generic Competition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orange Book Listing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a drug product is approved under an NDA, the product is listed in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. An NDA-approved drug product will be designated in the Orange Book as a Reference Listed Drug ("RLD"). Sponsors of approved NDAs are required to list with the FDA patents whose claims cover the product&#8217;s active ingredient, formulation, or an approved method of using the drug.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Extensions</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments to the FDCA ("Hatch-Waxman&#8221;). Hatch-Waxman permits a patent restoration term of up to five years as compensation for patent term lost during drug product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA(s).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANDA Approval Process for Generic Drugs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hatch-Waxman also established an abbreviated FDA approval process for generic drugs that are shown to be pharmaceutically equivalent and bioequivalent to drugs previously approved by the FDA through the NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application ("ANDA"), with the FDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the API, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. In some cases involving drugs with no or limited systemic absorption, an ANDA must include clinical endpoint (efficacy) studies in order to demonstrate bioequivalence. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 505(b)(2) NDA Approval Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA under a &#8220;full&#8221; NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and enables the applicant to rely, in part, on the FDA&#8217;s previous approval of a similar product, and/or published literature, in support of the safety and/or efficacy of its drug product. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA&#8217;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved or for any new indication sought by the Section 505(b)(2) applicant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANDA and 505(b)(2) products may be significantly less costly to bring to market than the reference listed drug, and companies that produce generic products are generally able to offer them at lower prices. Moreover, generic versions of RLDs are often automatically substituted for the RLD by pharmacies when dispensing a prescription written for the RLD. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ANDA and 505(b)(2) NDA Patent Certification Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA, as applicable, that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is, in the applicant&#8217;s opinion, invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. If an ANDA or 505(b)(2) NDA is submitted to FDA with a Paragraph IV Certification, the applicant must also provide a &#8220;Paragraph IV Notification&#8221; to the holder of the NDA for the RLD and to the owner of the listed patent(s) being challenged by the applicant, providing a detailed written statement of the bases for the applicant&#8217;s position that the relevant patent(s) is invalid or would not be infringed. If the patent owner brings a patent infringement lawsuit against the applicant within 45 days of the Paragraph IV Notification, FDA approval of the ANDA or 505(b)(2) NDA will be automatically stayed for 30 months, or until 7 &#189; years after the RLD&#8217;s NDA approval date if the ANDA or 505(b)(2) NDA was filed between 4 years and 5 years after the NDA approval. Any such stay will be terminated earlier if the court rules that the patent is invalid or would not be infringed. The applicant may, in certain circumstances, elect to submit a &#8220;section viii&#8221; statement with respect to a listed method of use patent, certifying that the proposed ANDA or 505(b)(2) product&#8217;s labeling does not contain (or carves out) any language that would infringe a method of use patented listed in the Orange Book for the RLD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference drug has expired as described in further detail below.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Exclusivities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Chemical Entity Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Hatch-Waxman Amendments provide a period of five years of non-patent marketing exclusivity for the first approved drug containing a new chemical entity (&#8220;NCE&#8221;) as an active ingredient. An NCE is an active moiety that has not been approved by the FDA in any other NDA. A fixed combination drug product may receive NCE exclusivity if one of its active ingredients is an NCE, but not if all of its active ingredients have previously been approved. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA or 505(b)(2) NDA seeking approval of a product that contains the same active moiety, except that the FDA may accept such an application for filing after four years if the application includes a paragraph IV certification to a listed patent. In the case of such applications accepted for filing between four and five years after approval of the reference drug, the 30-Month Stay of approval triggered by a timely patent infringement lawsuit is extended by the amount of time necessary to extend the stay until 7 &#189; years after the approval of the reference drug NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Clinical Trial (3-Year) Exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular indication or condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability studies) was essential to the approval of the application or supplemental application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or Section 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the three-year exclusivity period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Orphan Exclusivity Under the Orphan Drug Act</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the U.S. but for which there is no reasonable expectation that the cost of developing and making the product available in the U.S. for this type of disease or condition will be recovered from sales of the product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products is designated as an orphan drug and receives marketing approval for an indication broader than that for which it is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the U.S. and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor conducts pediatric research and submits new clinical information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data need not support a label change for pediatric use; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other U.S. Healthcare Laws and Regulations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education, and other activities following product approval will be subject to regulation by numerous federal and state regulatory and law enforcement authorities in the U.S. in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services ("HHS") and its various divisions, including the Office of Inspector General, the Centers for Medicare &amp; Medicaid Services ("CMS") and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Healthcare providers and third-party payors play a primary role in the recommendation and use of pharmaceutical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">products that are granted marketing approval. Arrangements with third-party payors, existing or potential customers and referral sources, including healthcare providers, are subject to broadly applicable fraud and abuse laws and regulations, and these laws and regulations may constrain the business or financial arrangements and relationships through which manufacturers conduct clinical research, market, sell and distribute the products for which they obtain marketing approval. Such restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other individuals and entities on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, "the ACA") amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to commit a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal civil and criminal false claims, including the civil FCA, and Civil Monetary Penalties Laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. Certain marketing practices, including off-label promotion, also may implicate the FCA. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, therapeutic products and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the CMS, information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health Insurance Portability and Accountability Act of 1996 ("HIPAA") prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers and drug pricing and/or marketing expenditures; and state and local laws requiring the registration of pharmaceutical sales representatives and state laws governing the privacy and security of health information in certain circumstances, many of </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we may be subject to data privacy and security regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009 ("HITECH"), and its respective implementing regulations imposes certain requirements, including mandatory contractual terms, on covered entities, business associates and their covered subcontractors relating to the privacy, security, and transmission of certain individually identifiable health information known as protected health information. Among other things, HITECH, through its implementing regulations, makes HIPAA&#8217;s security standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. HITECH also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, subcontractors, and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, other federal and state laws may govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in significant ways and may not be pre-empted by HIPAA, thus complicating compliance efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, the data privacy laws are generally perceived to be stricter than those that apply in the U.S. and include specific requirements for the transfer of personal data outside the EU to the U.S. to ensure that EU standards of data privacy will be applied to such data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violation of the laws described above or any other governmental laws and regulations may result in significant penalties, including administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, and additional reporting requirements and oversight if a person becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly for manufacturers of branded prescription products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health Reform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By way of example, in March 2010, the ACA was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the healthcare industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our business are:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> An annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical research, along with funding for such research.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, re-examining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, in August 2022, President Biden signed the Inflation Reduction Act of 2022 (the "IRA") into law, which among other things, extends enhanced subsidies for individuals purchasing coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted in the U.S. since the ACA. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year that went into effect in April 2013 and, following passage of the Bipartisan Budget Act of 2015 and the Infrastructure Investment and Jobs Act, will remain in effect until 2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The heightened governmental scrutiny in the U.S. of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics, also has resulted in executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, President Trump used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders, and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA concurrently released a final rule and guidance in September 2020 implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of the rule has been delayed until 2032. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA directs the Secretary of HHS to establish a Drug Price Negotiation Program (the Program) to lower prices for certain single-source prescription drugs and biologics covered under Medicare Parts B and D, based on criteria established under the IRA. Under the Program, the Secretary of HHS will publish a list of &#8220;selected drugs,&#8221; and will then negotiate maximum fair prices with their manufacturers. Beginning in 2026, the first year of the Program, the number will be limited to 10 Part D drugs and biologics. By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Part D and Part B. Agreements between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &#8220;selected drug&#8221; for negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax based on a percentage of total sales of a &#8220;selected drug&#8221; up to 95% and the potential of civil monetary penalties. Further, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. In addition, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, individual states in the U.S. have increasingly passed legislation and implemented regulations designed to control pharmaceutical and therapeutic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some third-party payors also require pre-approval of coverage for new or innovative devices or therapies before they will reimburse healthcare providers that use such therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that these initiatives, as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Privacy and Security</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we collect, process and store confidential and sensitive information, including personal information, intellectual property, trade secrets, and proprietary information owned or controlled by ourselves or other third parties. We, and third parties upon whom we rely, use sophisticated information technology, software and services to process, store, use, generate, transfer and disclose information, as well as other sensitive information controlled by ourselves or other third parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to federal, state, and foreign data privacy and security laws and regulations. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners, vendors, or other third parties on whom we rely. The legislative and regulatory framework related to the collection, use, retention, safeguarding, disclosure, sharing, transfer, security and other processing of personal data worldwide is rapidly evolving. The number and scope of data protection laws and regulations is changing, subject to differing applications and interpretations, and may be inconsistent among jurisdictions, or in conflict with other rules, laws or other data processing obligations. Efforts to ensure that our current and future business arrangements, including our relationship with our CROs or other vendors who process data on our behalf, comply with applicable data privacy and data security laws and regulations will involve substantial costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, HIPAA, as amended by HITECH, and its implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information on certain health care providers,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">health plans and health care clearinghouses, known as covered entities, as well as their business associates and covered subcontractors that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to civil and criminal penalties. Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5 of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the EU and other jurisdictions, such as the California Consumer Privacy Act of 2018 ("CCPA"), which has been characterized as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the U.S. Although the CCPA exempts certain data processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to the personal information we maintain about California residents. The CCPA among other effects, creates individual privacy rights for California consumers (as defined in the law), places increased privacy and security obligations on entities handling certain personal data of consumers or households, requires covered companies to provide disclosures to consumers regarding data collection, use and sharing practices, requires covered companies to allow users to opt-out of certain sales or transfers of personal information, and provides consumers with a private right of action for certain data breaches. The CCPA became effective on January 1, 2020, and the California Attorney General&#8217;s authority to begin bringing enforcement actions began July 1, 2020. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Further, the California Privacy Rights Act ("CPRA") was recently voted into law by California residents. The CPRA significantly amends the CCPA and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA went into effect on January 1, 2023, and become enforceable on July 1, 2023. A similar law, the Consumer Data Protection Act was recently passed in Virginia and went into effect on January 1, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also are or will become subject to privacy laws in the jurisdictions in which we are established or in which we sell or market our products or run clinical trials. For example, in the EU, we are subject to Regulation (EU) 2016/679, the GDPR, in relation to our collection, control, processing, and other use of personal data (i.e. data relating to an identified or identifiable living individual). We process personal data in relation to participants in our clinical trials in the European Economic Area ("EEA"), including the health and medical information of these participants. The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations that could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. As noted above, the GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EEA rules with respect to cross-border transfers of personal data outside of the EEA. As noted above, recent legal developments in the EU have created complexity and uncertainty regarding transfers of personal data from the EEA to the U.S., e.g. on July 16, 2020, the Court of Justice of the European Union ("CJEU"), invalidated the EU-U.S. Privacy Shield Framework, or the Privacy Shield, under which personal data could be transferred from the EEA to U.S. entities who had self-certified under the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. On June 4, 2021, the European Commission adopted new standard contractual clauses under the GDPR for data transfers from entities that are subject to the GDPR to transfer personal data outside of the EEA. The new standard contractual clauses impose additional obligations, including the obligation to conduct a transfer impact assessment and, depending on a party&#8217;s role in the transfer, to implement additional security measures and to update internal privacy practices. If we elect to rely on the standard contractual clauses for data transfers, we may be required to incur significant time and resources to update our contractual arrangements and to comply with new obligations. Additionally, on September 8, 2020, the Swiss Data Protection Authority (the Federal Data Protection and Information Commissioner) concluded that the Swiss-U.S. Privacy Shield does not provide an adequate level of protection for personal data transfer from Switzerland to the U.S. pursuant to the Swiss Federal Act on Data Protection. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#8364;20.0 million or 4% of total global annual turnover. Further, following the withdrawal of the United Kingdom from the EU on January 31, 2020, pursuant to the transitional arrangements agreed between the United Kingdom and the EU, we will have to comply with the GDPR and separately the GDPR as implemented in the United Kingdom, each regime having the ability to fine up to the greater of &#8364;20 million / &#163;17 million or 4% of global turnover. Following December 31, 2020, and the expiry of the post-Brexit transitional arrangements between the United Kingdom and EU, although it is likely that the data protection obligations of the GDPR will continue to apply to UK-related processing of personal data in substantially unvaried form and fashion, for at least the short term thereafter, the relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear. For example, it is not yet clear whether the United Kingdom will be the subject of a so-called adequacy decision of the European Commission, and it is therefore unclear how data transfers between EU/EEA Member States and the United Kingdom will be treated. Any changes relating to the UK and EU position regarding aspects of data protection law may lead to additional compliance costs and could increase our overall risk. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, an inability to process personal data or to operate in certain jurisdictions, or potential civil claims including class action type litigation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we use third-party service providers and sub-processors to help us operate our business and engage in processing on our behalf. If we, our service providers, partners, or other relevant third-parties have experienced, or in the future experience, any security incident(s) that result in any data loss, deletion or destruction, unauthorized access to, loss of, unauthorized acquisition or disclosure of, or inadvertent exposure or disclosure of sensitive information, or compromise related to the security, confidentiality, integrity of our (or their) information technology, software, services, communications or data, it may result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions, litigation, or an inability to process data in some jurisdictions. Furthermore, applicable data protection laws, privacy policies and data protection obligations may require us to notify relevant stakeholders of security breaches, including affected individuals, customers, and regulators. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional U.S. Regulation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Foreign Corrupt Practices Act</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. Foreign Corrupt Practices Act ("FCPA") prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value, directly or indirectly, to any foreign government official, government staff member, official or employee of a public international organization, or a political party or political candidate for the purpose of influencing any act or decision of the foreign entity in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes interactions with healthcare professionals of foreign state-owned or affiliated hospitals, universities, or research institutions. The FCPA also obligates companies whose securities are listed in the U.S. to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the U.S., can result in criminal and civil fines, imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts. Equivalent laws have been adopted in other foreign countries that impose similar or arguably broader obligations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canadian Government Regulation and Product Approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Canada, our product candidates and our research and development activities are primarily regulated by the Food and Drugs Act and the rules and regulations thereunder, which are enforced by Health Canada (including its Biologic and Radio-pharmaceutical Drugs Directorate). Health Canada&#8217;s regulatory process for review, approval and regulatory oversight of products is similar to the regulatory process conducted by the FDA. To initiate clinical testing of a drug candidate in human subjects in Canada, a Clinical Trial Application (&#8220;CTA&#8221;) must be filed with and approved by Health Canada. In addition, all federally regulated trials must be approved and monitored by research ethics boards. The review boards study and approve study-related documents and monitor trial data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to being given market authorization for a drug product, a manufacturer must present substantive scientific evidence of a product&#8217;s safety, efficacy and quality as required by the Food and Drugs Act (Canada) and its associated regulations, including the Food and Drug Regulations. This information is usually submitted in the form of a New Drug Submission (&#8220;NDS&#8221;). Health Canada reviews the submitted information, sometimes using external consultants and advisory committees, to evaluate the potential benefits and risks of a drug. If after the review, the conclusion is that the patient benefits outweigh the risks associated with the drug, the drug is issued a Drug Identification Number (&#8220;DIN&#8221;), followed by a Notice of Compliance (&#8220;NOC&#8221;), which permits the market authorization holder (i.e., the NOC and DIN holder) to market the drug in Canada. Drugs granted an NOC may be subject to additional post-market surveillance and reporting requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal steps required for drug approval in Canada are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Toxicology Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-clinical studies are conducted in vitro and in animals to evaluate pharmacokinetics, metabolism and possible toxic effects to provide evidence of the safety of the drug candidate prior to its administration to humans in clinical studies and throughout development. Such studies are conducted in accordance with applicable laws and GLP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initiation of Human Testing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Canada, the process of conducting human clinical with a new drug cannot begin until a CTA has been submitted, and the required number of days has lapsed without objection from Health Canada. Similar regulations apply in Canada to a CTA as to an IND in the United States. If the CTA is deemed by Health Canada to be acceptable, a No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Objection Letter is issued. A Not Satisfactory Notice will be issued by Health Canada if significant deficiencies are identified or if timely responses to information requested have not been received.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar regulations apply in Canada regarding clinical trials as in the U.S. In Canada, Research Ethics Boards, or REBs, instead of IRBs, are used to review and approve clinical trial plans. Clinical trials involve the administration of an investigational new drug to human subjects under the supervision of qualified investigators, in most cases a physician, in accordance with current Good Clinical Practices, or cGCP, requirements, which include review and approval by REBs. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Similar to in the U.S., human clinical trials for new drugs are typically conducted in three sequential phases, Phase 1, Phase 2 and Phase 3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into Canada are also subject to regulation by Health Canada relating to their labeling and distribution. Progress reports detailing the results of the clinical trials must be submitted at least annually to Health Canada and the applicable REBs, and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, in Canada, Health Canada or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an REB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the REB&#8217;s requirements or if the drug has been associated with unexpected serious harm to subjects. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group regularly reviews accumulated data and advises the study sponsor regarding the continuing safety of trial subjects, potential trial subjects and the continuing validity and scientific merit of the clinical trial. A sponsor may also suspend or terminate a clinical trial based on evolving business objectives or competitive climate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Drug Submission</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon successful completion of Phase 3 clinical trials in Canada, the company sponsoring a new drug then assembles all the preclinical and clinical data and other testing relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls, and submits it to Health Canada as part of a New Drug Submission, or NDS. The NDS is then reviewed by Health Canada for approval to market the drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the approval process, Health Canada will inspect the facility or the facilities at which the drug is manufactured. Health Canada will not approve the product unless compliance with cGMP is satisfactory and the NDS contains data that provide substantial evidence that the drug is safe and effective in the indication studied. In addition, before approving an NDS, Health Canada will typically inspect one or more clinical sites to assure compliance with GCP.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if Health Canada approves a product candidate, it may limit the approved indications for use of the product candidate, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiaries</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We two wholly owned subsidiaries, Suzhou Neuralstem Biopharmaceutical Co., Ltd. ("Suzhou"), organized under the laws of the People&#8217;s Republic of China, and LBS. Suzhou was established by Seneca to sponsor the non-GDP Phase 2 clinical trial of NSI-566 that was conducted between 2013 and 2016 in Beijing, China. As of December 31, 2024, Suzhou has no employees or other operations. We are currently in the process of dissolving the Suzhou subsidiary. Our other subsidiary is LBS, which is our operating entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingent Value Right</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to the closing of the Merger, Seneca issued each share of its common stock held by Seneca stockholders of record, one contingent value right (&#8220;CVR&#8221;). The CVR entitled the holder (the &#8220;CVR Holder&#8221;) to receive, pro rata with the other CVR Holders, 80% of the net proceeds, if any and subject to certain minimum distribution limitations (&#8220;CVR Payment Amount&#8221;), received from the sale or licensing of the intellectual property owned, licensed or controlled by Seneca immediately prior to the closing of the Merger (the &#8220;Legacy Technology&#8221;); provided however that the CVR Holders are only entitled to receive such CVR Payment Amount if the sale or licensing of such Legacy Technology occurred on or before October 27, 2022 (&#8220;Legacy Monetization&#8221;). Pursuant to the terms of the CVR agreement (&#8220;CVR Agreement&#8221;), CVR Holders are only entitled to receive CVR Payment Amounts received within 48-months following the closing of the Merger. The CVR Agreement also provides that no distributions will be made to the CVR Holders in the event such distribution is less than $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NSI-189 &#8211; Exclusive License and Subsequent Exercise of Purchase Option</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Merger, Seneca exclusively licensed certain patents and technologies, including a sublicense covering a synthetic intermediate, of our NSI-189 assets (&#8220;189 License&#8221;), along with a purchase option through December 16, 2023 (&#8220;Purchase Option&#8221;). On October 22, 2021, Alto Neuroscience ("Alto") agreed to terms of an early exercise of the Purchase Option under the 189 License and entered into an asset transfer agreement ("ATA"). Alto is a U.S. based public, clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the CVR Agreement, no distribution was required to be made to the CVR Holders as the CVR Payment Amount after deducting costs and expenses required to maintain the 189 License was less than $0.3 million. In accordance with the terms of the CVR Agreement, the net proceeds from the sale of the NSI-189 assets, less any applicable transaction costs and expenses, were deposited into the CVR escrow to be used to pay costs and expenses associated with the monetization of our other Legacy Technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Alto will be required to pay us up to an aggregate of $4.5 million upon the achievement of certain development and regulatory approval milestones for NSI-189 (or a product containing or otherwise derived from NSI-189), which is now known as ALTO-100. If Alto sells or grants to a third party a license to the patents and other rights specific to ALTO-100 prior to the achievement of a specified clinical development milestone, Alto will be required to pay us a low-double digit percentage of any consideration received by Alto from such license or sale, provided that the maximum aggregate consideration Alto will be required to pay us under the ATA, including the upfront payment and all potential milestones and transaction-related payments, will not exceed $5.0 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 22, 2024, Alto announced that its Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint. Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in 2026. Upon the enrollment of a patient in a Phase 3 clinical trial of ALTO-100, if it occurs, a milestone payment of $1.5 million will be due from Alto to us under the ATA. If this occurs within 48-months of the closing of the Merger, the CVR Holders will be entitled to a CVR Payment Amount, with the remaining 20% of the net proceeds deposited into the CVR escrow. If the milestone is met after 48-months of the closing of the Merger, all the net proceeds will be paid to us. There can be no assurance that CVR holders will receive CVR Payment Amounts from the sale of the NSI-189 assets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NSI-532.IGF-1</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2022, we entered an agreement to license NSI-532.IGF-1 to the Regents of the University of Michigan ("University of Michigan") for maintaining NSI-532.IGF-1 cell lines, continued development, maintaining patent protection, and seeking licensees. We received no upfront fees for the license. NSI-532.IGF-1 is a pre-clinical cell therapy being investigated as a potential therapy for prevention and treatment of Alzheimer&#8217;s disease. The University of Michigan shall bear 100% of the costs for patent filing, prosecution, maintenance, and enforcement of the patent rights. We will receive 50% of net revenues received by the University of Michigan from the licensing of patent rights through the last-to-expire patent in patent rights, unless otherwise earlier terminated, less all reasonable and actual out-of-pocket costs incurred in the litigation of patent rights. There can be no assurance that NSI-532.IGF-1 will ever be successfully monetized or that CVR holders will receive CVR Payment Amounts from the sale of the NSI-532.IGF-1 assets.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had eight full-time employees and no part-time employees. Of the full-time employees, three employees are engaged in primarily research and development activities and five employees are primarily engaged in finance, corporate strategy and business development, and other general administrative functions. We engage a number of consultants to assist with finance, operations, human resources, legal, investor relations and information technology functions, as well as, to the extent needed, our clinical operations. We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider our relations with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation, Benefits, and Professional Development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compensation programs, including our equity incentive programs, are designed to align our employees' interests with the drivers of growth and stockholder returns by supporting achievement of our primary business goals. Our goal is to attract and retain employees whose talents, expertise, leadership, and contributions are expected to support and facilitate growth and drive long-term stockholder value. Consequently, we provide employee wages that we believe are competitive within our industry, and we regularly evaluate the effectiveness of our compensation and benefit programs against industry benchmarks. We seek to align our employees' interests with those of stockholders by linking annual changes in compensation to overall company performance, as well as each individual&#8217;s contribution to the results achieved. The emphasis on overall company performance is intended to align the employee&#8217;s financial interests with the interests of shareholders. We are also committed to providing comprehensive benefit options and it is our intention to offer benefits that will allow our employees and their families to live healthier and more secure lives. All employees are eligible for medical, dental, and vision insurance, paid and unpaid leaves, group life and personal accident insurance coverage as well as the option to participate in our 401(k) plan and supplemental group life and short-term disability coverage.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant was originally incorporated in 2001 in the State of Delaware under the name Neuralstem, Inc. In October of 2019, Neuralstem, Inc. changed its name to Seneca Biopharma, Inc. In April of 2021, we effected the Merger, whereby LBS became a wholly owned subsidiary of Seneca. In April of 2021, we changed our name from Seneca Biopharma, Inc. to Palisade Bio, Inc. Our principal executive offices are located at 7750 El Camino Real, Suite 2A, Carlsbad, California 92009, our telephone number is (858) 704-4900 and our website address is www.palisadebio.com.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information on our website is not incorporated by reference in this annual report on Form 10-K or in any other filings we make with the SEC. We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="risk_factors_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sk Factors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. We have described below a number of uncertainties and risks that, in addition to uncertainties and risks presented elsewhere in this Annual Report on Form 10-K, may adversely affect our business, operating results and financial condition. The uncertainties and risks enumerated below as well as those presented elsewhere in this Annual Report on Form 10-K should be considered carefully when evaluating us, our business and the value of our securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Development, Commercialization and Regulatory Approval of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business depends on the successful clinical development, regulatory approval, and commercialization of our therapeutic compounds, including our lead asset PALI-2108.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 9, 2024, Health Canada approved our Canadian Clinical Trial Application (&#8220;CTA&#8221;) to commence a Phase 1 clinical trial for PALI-2108 in Canada. On November 7, 2024, we commenced the Phase 1 clinical trial of PALI-2108. Our success depends on the development and clinical success of PALI-2108, which is subject to a number of risks, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the continued enforceability of our research collaboration and license agreement with Giiant;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely and successful completion of required clinical trials, which may be significantly slower or costlier than we anticipate and/or produces results that do not achieve the primary or secondary endpoints of the trial(s);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop and implement clinical trial designs and protocols;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the successful initiation and completion of our current planned clinical trials and any additionally required preclinical studies, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to retain third-party CROs on terms acceptable to us for the conduct and oversight of our anticipated clinical trials, including our Phase 1 clinical trial for PALI-2108;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to fund the development costs related to PALI-2108&#8217;s clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval by Health Canada or other regulatory authorities to commence the marketing of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability for us and third-parties, if applicable, to achieve and maintain compliance with our contractual obligations and applicable regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our contract manufacturers to manufacture sufficient supply of our product candidates to meet the required clinical trial supplies and any additional required preclinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our contract manufacturers to remain in good standing with regulatory agencies and to develop, validate and maintain commercially viable manufacturing facilities and processes that are compliant with cGMP regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain favorable labeling for our product candidates through regulators that allows for successful commercialization;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by physicians, insurers, payors, and patients of the beneficial quality, safety and efficacy of our product candidates, if approved, including relative to alternative and competing treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to price our product candidates to recover our development costs and applicable milestone or royalty payments, and generate a satisfactory profit margin; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and our applicable collaboration and licensing partners&#8217; ability to establish and enforce intellectual property rights related to our product candidates and technologies.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to obtain regulatory approvals or commercialize our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proposed product candidates. For example, we are currently enrolling and dosing subjects in our initial Phase 1 clinical trial of PALI-2108 in Canada. We may experience delays or difficulties in finding suitable trial subjects, or in completing enrollment. Such delays may result in increased costs and the failure to complete the Phase 1 clinical trial of PALI-2108 in Canada in a timely manner. Even if successfully completed, we must complete a number of additional clinical trials prior to obtaining regulatory approval to commercialize our product candidates. Accordingly, we cannot make assurances that we will ever be able to generate sufficient revenue through the sale of any product candidates, if approved, to internally fund our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There are substantial risks in drug development, and, as a result, we may not be able to successfully develop any product candidate. including our lead product candidate, PALI-2108.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initiated a Phase 1 clinical trial of PALI-2108 in our target indication of IBD. Drug development requires a significant amount of capital and can take a long time to reach commercial viability, if it can be achieved at all. During the development process, we may experience technological barriers that we may be unable to overcome. Further, certain underlying premises in our development programs have not been proven. Because of these and similar uncertainties, it is possible that our product candidates will not reach commercialization. If we are unable to successfully develop and commercialize our product candidates, including our lead product candidate, PALI-2108, we will be unable to generate revenue or build a sustainable or profitable business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on our license agreement with Giiant to permit us to use patents and patent applications relating to PALI-2108. Termination of these rights or the failure to comply with our obligations under the license agreement could materially harm our business and prevent us from developing or commercializing PALI-2108, our lead product candidate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a party to the Giiant License Agreement under which we have been granted rights to patents and patent applications that are important to our business. We rely on this license agreement to be able to use various proprietary technologies that are material to our business, including patents, and patent applications that cover PALI-2108. Our rights to PALI-2108 are subject to the continuation of, and our compliance with, the terms of the Giiant License Agreement. If we fail to comply with any of our obligations under the Giiant License Agreement, Giiant may have the right to terminate the Giiant License agreement, in which event we would not be able to continue the development or our proposed commercialization of PALI-2108. Additionally, disputes may arise under the Giiant License Agreement regarding the intellectual property that is subject to such agreement. If disputes over intellectual property that we have licensed, or in the future may license, prevent or impair our ability to maintain any of our license agreements, including the Giiant License Agreement, on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technologies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical drug development is expensive, time-consuming and uncertain.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical development of product candidates is very expensive, time-consuming, difficult to design and implement, and the outcomes are inherently uncertain. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization and of those that are approved, many do not generate sufficient revenue to cover their costs of development. In addition, we, any partner with which we may collaborate, Health Canada, any similar regulatory authority, state and local agencies, counterpart agencies in foreign countries, or the applicable Institutional Review Board ("IRB") at our trial sites, may suspend, delay, require modifications to or terminate our clinical trials, once begun, at any time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are currently conducting a Phase 1 clinical trial of PALI-2108 in Canada, and the FDA or applicable foreign regulatory authorities may not accept data from such trials, or any other trial we conduct outside of the U.S.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have commenced a Phase 1 clinical trial for ulcerative colitis in Canada. However, we have not received approval from the FDA to commence any clinical trials in the U.S., and there is no guarantee that we will be able to obtain such approval in a timely manner, if at all. If our Phase 1 clinical trial is successful and we seek to initiate a Phase 2 clinical trial in the U.S, there is no certainty that the FDA will accept the data generated from our Canadian trial. The FDA&#8217;s acceptance of foreign clinical data is subject to certain conditions, including whether the trial was conducted in accordance with good clinical practices (&#8220;GCP&#8221;) and whether the FDA can validate the trial data through on-site inspections or other means. Moreover, the FDA will assess whether the trial design, patient population, endpoints, and other factors meet the standards expected for clinical trials conducted within the U.S.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, regulatory approval for clinical trials and eventual drug approval in the U.S. is a complex process, influenced by several factors, including:</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the adequacy and relevance of the Phase 1 trial data in supporting progression to Phase 2, as evaluated by the FDA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of the trial to meet safety, efficacy, and other scientific requirements set by the FDA, which may differ from those of Health Canada;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the foreign clinical trial was conducted under an FDA-recognized regulatory authority, and whether FDA oversight is possible through monitoring or inspection of clinical sites; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA&#8217;s consideration of the risk-benefit ratio for continuing clinical development in the U.S., particularly based on data from a non-U.S. population.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, while the FDA does have the ability to approve drugs that have undergone clinical trials in foreign jurisdictions, including Canada, approval is generally contingent on demonstrating that the trial data align with FDA standards and regulatory expectations. It is also possible that we may be required to conduct additional trials in the U.S. to address any concerns regarding the applicability of the foreign trial data to the U.S. population or regulatory environment. There can be no assurance that we will successfully obtain FDA approval to initiate a Phase 1 clinical trial in the U.S. or that if our Canadian trial is successful, a subsequent Phase 2 trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently enrolling subjects in the Phase 1 clinical trial of PALI-2108 in Canada. Identifying and qualifying subjects to participate in our current and anticipated future clinical trials is critical to our success. Our inability to enroll patients in our clinical trials on a timely basis could result in the trials being delayed or never completed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient enrollment and trial completion are affected by numerous additional factors, including the:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">process for identifying patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">design of the trial protocol;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility and exclusion criteria;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of the product candidate under study;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of competing therapies and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease under investigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to obtain and maintain patients&#8217; consents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk that enrolled patients will drop out before completion of the clinical trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians; and,</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to monitor patients adequately during and after treatment.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects. There can be no assurances that we will be able to complete enrollment for our anticipated Phase 1 clinical trial for PALI-2108, and if we fail to do so, we may not be able to complete the trial on a timely basis, or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect that our operations and development of PALI-2108 will require substantially more capital than we currently have, and we cannot guarantee when or if we will be able to secure such additional funding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have historically funded our operations and prior development efforts through the sale of our securities. Based on our existing cash resources and our current business plan, we do not have adequate capital to fund our anticipated operations through the completion of the development of PALI-2108. As a result, we will need to secure additional funding. If we are not able to obtain additional capital in the future or on acceptable terms, we may need to curtail our anticipated clinical trials as well as our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates, including our lead product candidate, PALI-2108, may cause undesirable side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unforeseen side effects from PALI-2108 could arise either during clinical development or, if approved, after it has been marketed. Undesirable side effects could cause us, any partners with which we may collaborate, or regulatory authorities to interrupt, extend, modify, delay or halt clinical trials and could result in a more restrictive or narrower label or the delay or denial of regulatory approval by Health Canada, or comparable regulatory authorities like the FDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated, and Health Canada or comparable regulatory authorities, like the FDA, could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may have an adverse material effect on our business, financial condition, operating results and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by a product after obtaining regulatory approval, a number of potentially negative consequences could result, which could prevent us or our potential partners from achieving or maintaining market acceptance of the product and could substantially increase the costs of commercializing such product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There can be no assurance that our product candidates will obtain regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sale of human therapeutic products in the U.S. and foreign jurisdictions is subject to extensive and time-consuming regulatory approval, which requires, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical data required for the submission of an IND or CTA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">controlled research and human clinical testing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of the safety and efficacy of the proposed product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government review and approval of a submission containing manufacturing, preclinical and clinical data; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adherence to cGMP regulations during production and storage.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108 will require significant development, clinical testing, possibly additional preclinical studies, and the investment of significant funds to gain regulatory approval before it can be commercialized. Although we commenced a Phase 1 clinical trial in Canada, there can be no assurances that gaining regulatory approval in Canada will result in regulatory approval from any other regulatory agency, including the FDA of the U.S. The results of our human clinical testing of PALI-2108 may not meet applicable regulatory requirements. If approved in a jurisdiction, PALI-2108 may also require the completion of post-market studies. The process of completing clinical testing and obtaining the required approvals is expected to take a number of years and require the use of substantial resources. Further, there can be no assurance that PALI-2108 will be shown to be safe and effective in clinical trials or receive applicable regulatory approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the U.S. Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure Act &#8220;must exercise their independent judgment&#8221; and &#8220;may not defer to an agency interpretation of the law simply because a statute is ambiguous.&#8221; The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations of law, including those by the FDA and other agencies with significant oversight of the biopharmaceutical industry. The new framework is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government previously prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation and judicial scrutiny.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to obtain regulatory approvals, or if there are significant changes in regulatory policies that result in increased litigation and judicial scrutiny leading to unexpected delays and increased cost, we may not be able to market PALI-2108 and our operations will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If clinical studies of PALI-2108 do not yield successful results, we may discontinue the development of PALI-2108.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must demonstrate that PALI-2108 is safe and efficacious in humans through extensive clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of preclinical studies that we have completed may not be indicative of results that will be obtained in human clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety and efficacy results attained in preclinical studies may not be indicative of results that are obtained in our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after reviewing early clinical trial results, we may abandon projects that we previously believed to be promising;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our regulators may suspend or terminate our clinical trials because the participating subjects or patients are being exposed to unacceptable health risks; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108 may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">It may take us longer than we estimate to complete clinical trials, and we may not be able to complete them at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although for planning purposes we project the commencement, continuation and completion of our clinical trials; a number of factors, including scheduling conflicts with participating researchers and/or CROs, clinicians and research or clinical institutions, and difficulties in identifying or enrolling patients who meet trial eligibility criteria, may cause significant delays. Even if we were to commence and complete our clinical trials involving PALI-2108 as currently contemplated, they may not be successful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if PALI-2108 is approved for commercialization, future regulatory reviews or inspections may result in its suspension or withdrawal, closure of a facility or substantial fines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval to market and commercialize PALI-2108 is received, regulatory agencies will subject PALI-2108, as well as the manufacturing facilities, to continual review and periodic inspection. If previously unknown problems with a product or manufacturing and laboratory facility are discovered, or we fail to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions on PALI-2108 or us. The agency may require the withdrawal of PALI-2108 from the market, closure of the facility or substantial fines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful commercialization of PALI-2108, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs in the applicable jurisdiction, including, for example, Medicare and Medicaid in the U.S., private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers will not offer coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly approved drugs. Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement could harm our business or future revenues, if any. If we partner with third parties with respect to any of our product candidates, we may be reliant on that partner to obtain reimbursement from government and private payors for the drug, if approved, and any failure of that partner to establish adequate reimbursement could have a negative impact on our revenues and profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, both the federal and state governments in the U.S. and foreign governments continue to propose and pass new legislation, regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care. Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity. There may be future changes that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>If future reimbursement for PALI-2108, subject to approval, is substantially less than projected, or rebate obligations associated with them are substantially greater than expected, our future net revenue and profitability, if any, could be materially diminished.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and we may need to limit our commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, consumers, health-care providers, pharmaceutical companies, or others selling our products. If we cannot successfully defend ourselves against these claims, we may incur substantial liabilities. Regardless of merit or eventual outcomes of such claims, product liability claims may result in:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of our business reputation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs of litigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to patients or other claimants; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenues.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insurance coverage may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates, if approved, will depend significantly on attaining broad adoption and use of the drug by physicians and patients. The degree and rate of physician and patient adoption of a product, if approved, will depend on a number of factors, including but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient demand for approved products that treat the indication for which they are approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of a product compared to other available therapies or treatment regimens;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement from managed care plans and other healthcare payors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments and willingness to pay on the part of patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insurers&#8217; willingness to see the applicable indication as a disease worth treating;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proper administration by physicians or patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient satisfaction with the results, administration and overall treatment experience;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or contraindications, warnings, precautions or approved indications for use different than those sought by us that are contained in the final approved labeling;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any requirement of an authoritative regulatory body to undertake a risk evaluation and mitigation strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales, marketing, pricing, reimbursement and access, government affairs, and distribution efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity about a product or favorable publicity about competitive products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new government regulations and programs, including price controls and/or limits or prohibitions on ways to commercialize drugs, such as increased scrutiny on direct-to-consumer advertising of pharmaceuticals; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product liability claims or other product-related litigation.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates are approved for use but fail to achieve the broad degree of physician and patient adoption necessary for commercial success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history and have never generated any revenues from product sales.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. While we were initially formed in 2001, our operations, to date, have been limited to business planning, raising capital and other research and development activities related to our product candidates. We additionally adopted a new business plan in September 2023 upon entering into the Giiant License Agreement. Since that time, we have not yet demonstrated an ability to successfully complete any clinical trials and have never completed the development of any product candidate, nor have we ever generated any revenue from product sales. Consequently, we have no meaningful operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing biopharmaceutical products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business model assumes revenue from, among other activities, marketing or out-licensing the products we develop. PALI-2108 is in the early stages of clinical development and because we have a short development history with PALI-2108, there is a limited amount of information about us upon which you can evaluate our business and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no approved drugs and thus have not begun to market or generate revenues from the commercialization of any products. We only have a limited history upon which we can evaluate our ability to develop PALI-2108. We commenced our initial Phase 1 clinical trial of PALI-2108 in November of 2024. Thus, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, to execute our business plan, we will need to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Execute product development activities using unproven technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Build, maintain, and protect a strong intellectual property portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Demonstrate safety and efficacy of our drug candidates in multiple human clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receive approval from Health Canada and/or approval from similar foreign regulatory bodies, such as the FDA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retain qualified CROs to oversee and manage our Phase 1 clinical trial for PALI-2108 and future clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gain market acceptance for the development and commercialization of any drugs we develop;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensure our products are reimbursed by commercial and/or government payors at a rate that permits commercial viability;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Develop and maintain successful strategic relationships with suppliers, distributors, and commercial licensing partners;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manage our spending and cash requirements as our expenses will increase in the near term if we add programs and additional preclinical and clinical trials; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effectively market any products for which we obtain marketing approval.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unsuccessful in accomplishing these objectives, we may not be able to develop our proposed products, raise capital, expand our business or continue our operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success depends on attracting and retaining senior management and scientists with relevant expertise.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends to a significant extent on the continued services of our key employees, including our senior scientific, technical and managerial personnel. We do not maintain key person life insurance for any of our executives. Competition for qualified employees in the pharmaceutical industry is high, and our ability to execute our strategy will depend in part on our ability to continue to attract and retain qualified scientists and management. If we are unable to find, hire, and retain qualified individuals, we may be unable to execute our business plan in a timely manner, if at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may choose to discontinue development or commercialization any of our product candidates, or may choose not to commercialize product candidates in approved indications, at any time during development or after approval, which could adversely affect us and our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At any time, we may decide to discontinue the development of, or temporarily pause the development of, any of our product candidates then in existence for a variety of reasons, including the appearance of new technologies that make our product candidates obsolete, competition from competing product(s) or changes in or failure to comply with applicable regulatory requirements. If we temporarily pause or terminate a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity to have allocated those resources to potentially more productive uses, which could have an adverse effect on us and our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our inability to successfully in-license, acquire, develop and market additional product candidates or approved products could impair our ability to grow our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108 is currently our only product candidate being actively developed. We may in-license, acquire, develop and market additional products and product candidates. Since our internal research and development capabilities are limited, we may be dependent on pharmaceutical companies, academic or government scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly on our ability to identify and select promising pharmaceutical product candidates and approved products, negotiate licensing or acquisition agreements with their current owners, and finance these arrangements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of identifying, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional approved products or product candidates on terms that we find acceptable, or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, any product candidate that we acquire or license may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the applicable regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any approved products that we acquire will be manufactured or sold profitably or achieve market acceptance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in funding for the FDA and, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent these agencies or authorities from performing normal business functions on which the operations of our business may rely, which could negatively impact our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;">Th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e ability of the FDA or comparable foreign regulatory authorities to review and approve new products, to provide feedback on clinical trials and development programs, to meet with sponsors and to otherwise review regulatory submissions can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key leadership and other personnel, the sufficiency of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies or comparable foreign regulatory authorities on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other, other government agencies or comparable foreign regulatory authorities may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We anticipate relying on third-party CROs and other third parties to conduct and oversee our clinical trials. If these third parties do not meet our requirements or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations for obtain regulatory approval for, or commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have retained a CRO to oversee our Phase 1 clinical trial for PALI-2108 in Canada. We are likely to rely on third-party CROs to conduct and oversee our other anticipated clinical trials and other aspects of product development. We also expect to rely on various medical institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA&#8217;s regulations and GCP requirements, which are an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and state regulations governing the handling, storage, security and recordkeeping for drug and biologic products. These CROs and other third parties are expected to play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials. We expect to rely heavily on these parties for the execution of our clinical trials and any additionally required preclinical studies and will control only certain aspects of their activities. We and our CROs and other third-party contractors will be required to comply with GCP and GLP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities, such as Health Canada, with respect to our Phase 1 clinical trial for PALI-2108. Regulatory authorities enforce these GCP or GLP regulations through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP and GLP regulations, or reveal noncompliance from an audit or inspection, any clinical data generated in our clinical trials may be deemed unreliable, and the FDA or other regulatory authorities may require us to perform additional clinical trials before approving our or our partners&#8217; marketing applications. We cannot assure that upon inspection by a given regulatory authority such regulatory authority will determine whether any of our clinical trials comply with applicable GCP or GLP regulations. In addition, our clinical trials generally must be conducted with compounds produced under cGMP regulations. Our failure to comply with these regulations and policies may require us to repeat clinical trials, which would be costly and delay the regulatory approval process. In the event that we are unable to retain a qualified CRO for our Phase 1 clinical trial for PALI-2108, or any other anticipated clinical trial, it would delay planned clinical operations and result in additional cost and expense. Additionally, if our current CRO for our Phase 1 clinical trial in Canada or if any of our CROs that we retain in the future were to terminate their involvement with us, there is no assurance that we would be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on two qualified suppliers for the active pharmaceutical ingredient used in the clinical trials of PALI-2108. Insufficient availability of the API or other raw materials necessary to manufacture PALI-2108, or the inability of our suppliers to manufacture and supply our products on commercially reasonable terms, could adversely impact our business, results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have two qualified suppliers for the API used in PALI-2108. We do not have, and we do not intend to establish in the foreseeable future, internal manufacturing capabilities. Instead, we intend to use the facilities of third-party manufacturers to produce the materials used in our clinical trials. Our dependence on third parties for the supply and manufacture of PALI-2108 and any future product candidates may adversely affect our ability to obtain our products in a timely or competitive manner, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any supply shortages, quality concerns, or failure to obtain sufficient API, excipients, or components from our suppliers, including disruptions caused by, among other things, supply chain delays, public health emergencies, climate events, or political unrest would adversely affect our business, results of operations and financial condition. In particular, our suppliers may be impacted by epidemics, pandemics or other disease outbreaks or public health emergencies and general macroeconomic conditions, including inflationary pressures, economic slowdown or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recession, relatively high interest rates, imposed tariffs, changes in monetary policy, potential U.S. federal government shutdowns, geopolitical conflicts and financial institution instability, all of which may result in supply delays and cost increases.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process for pharmaceutical products is highly regulated, and regulatory agencies may from time to time shut down facilities that they believe do not comply with regulations. Our third-party manufacturers and suppliers are subject to numerous FDA and Health Canada regulations, including those governing manufacturing processes, stability testing, record keeping, product serialization, and quality standards. Similar regulations apply in other jurisdictions where we may conduct business. Our third-party manufacturers and suppliers are independent entities who are subject to their own operational and financial risks which are out of our control.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we, our third-party manufacturers, or our suppliers fail to comply with these regulations, our ability to deliver adequate supplies of PALI-2108 for clinical trials in a timely and cost-effective manner may be adversely affected. Should any of these risks materialize and adversely affect such third-party manufacturers&#8217; and/or suppliers&#8217; performance obligations to us, and we are unable to secure sufficient of the API used in the manufacture of PALI-2108 on commercially acceptable terms, or if we encounter delays and difficulties in our relationships with manufacturers or suppliers, our business, results of operations and financial condition could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to rely on collaborations with third parties for the successful development and commercialization of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on and expect to continue to rely upon the efforts of third parties for the successful development and commercialization of our product candidates. The clinical and commercial success of our product candidates may depend upon maintaining successful relationships with third-party partners, which are subject to a number of significant risks, including the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our partners&#8217; ability to execute their responsibilities in a timely, cost-efficient and compliant manner;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced control over delivery and manufacturing schedules;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price increases;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing deviations from internal or regulatory specifications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quality incidents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of partners to perform their obligations for technical, market or other reasons;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">misappropriation of our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other risks in potentially meeting our product commercialization schedule or satisfying the requirements of our end-users.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot provide any assurance that we will be able to establish or maintain third-party relationships in order to successfully develop and commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently rely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have, nor do we currently plan to acquire, the infrastructure or capability to supply, store, manufacture or distribute clinical or commercial quantities of drug substances or products. Although we have entered into a commercial supply agreement to provide us with such drug substances or products for our current Phase 1 clinical trial, our future ability to develop and commercialize, if approved, our product candidates is dependent on our ability to obtain the APIs and other substances and materials used in our product candidates successfully from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply and other technical relationships with these third parties, we may be unable to continue to develop or commercialize our products and product candidates, which could adversely affect us and our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on our contract suppliers and manufacturers for day-to-day compliance with applicable laws and cGMP regulations for production of our proposed products and API. If the safety or quality of any product or product candidate or component is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to commercialize or obtain regulatory approval for the affected product or product candidates successfully, and we may be held liable as a result.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to depend on third-party contract suppliers and manufacturers. Our supply and manufacturing agreements do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. Additionally, any damage to or destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment, even by force majeure, may significantly impair our ability to have our products and product candidates manufactured on a timely basis. Our reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their facilities, may misappropriate our trade secrets or other proprietary information. Furthermore, the manufacturing facilities of our suppliers are located outside of the U.S. This may give rise to difficulties in importing our products or product candidates or their components into the U.S. or other countries.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have agreements in place with foreign third parties in China and other countries to provide the necessary clinical supply of our API. Termination of or limitations on our relationships with foreign third parties that manufacture the API used in PALI-2108 may arise if U.S. legislation, tariffs, sanctions, trade restrictions, or other U.S. and foreign regulatory requirements, or prohibitions restrict our ability to engage with these foreign third parties. Further, any such actions could adversely impact our current and future arrangements with our foreign suppliers, including our current Chinese drug manufacturer, which could increase the cost or reduce the supply of material available to us or delay the procurement or supply of such material used in our clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have expressed substantial doubt about our ability to continue as a going concern.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management has determined that there is substantial doubt about our ability to continue as a going concern for a period of one year following the issuance of this Annual Report on Form 10-K. This determination was based on conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued, including our available cash as of the date of this filing, which is not sufficient to fund our anticipated level of operations for the next 12 months. Our future consolidated financial statements may include a similar qualification about our ability to continue as a going concern. Our year-end and interim consolidated financial statements were prepared assuming that we will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a history of net losses, and we expect to continue to incur net losses and may never achieve profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses since our inception, including net losses of $14.4 million and $12.3 million for the years ended December 31, 2024 and December 31, 2023, respectively. We expect that our operating losses will continue for the foreseeable future as we continue our drug development and discovery efforts. To achieve profitability, we must, either directly or through licensing and/or partnering relationships, meet certain milestones, successfully develop and obtain regulatory approval for one or more drug candidates and effectively manufacture, market and sell any drugs we successfully develop. Even if we are able to successfully commercialize product candidates that receive regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability. Accordingly, we may never generate significant revenue and, even if we generate significant revenue, we may never achieve profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements in our consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has identified a material weakness in our internal control over financial reporting. The material weakness was due to a lack of controls in the financial closing and reporting process, including a lack of segregation of duties and the documentation and design of formalized processes and procedures surrounding the creation and posting of journal entries and account reconciliations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our remaining material weakness, which management concluded is still present as of the date of these financial statements, is not remediated, or if we identify further material weaknesses in our internal controls, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our consolidated financial statements and a failure to meet our reporting and financial obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success with respect to our current and future product candidates will depend, in part, on our ability to obtain and maintain patent protection in both the U.S. and other countries, to preserve our trade secrets and to prevent third parties from infringing on our proprietary rights. Our ability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents in certain countries.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner in all the countries that are desirable. It is also possible that we or our current, or future licensors and licensees will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, our competitors independently may develop equivalent knowledge, methods and know-how or discover workarounds to our patents that would not constitute infringement. Any of these outcomes could impair our ability to enforce the exclusivity of any issued or pending patents we may have or the ability to obtain future patent protections, which may have an adverse impact on our business, financial condition and operating results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to obtain, maintain and/or enforce patents is uncertain and involves complex legal and factual questions, especially across varying countries. Accordingly, rights under any existing patents or any patents we might obtain or license may not cover our product candidates or may not provide us with sufficient protection for our product candidates to afford a sustainable commercial advantage against competitive products or processes, including those from branded, generic and over-the-counter pharmaceutical companies. In addition, we cannot guarantee that any patents or other intellectual property rights will be issued from any pending or future patent or other similar applications owned by or licensed to us. Even if patents or other intellectual property rights have issued or will issue, we cannot guarantee that the claims of these patents and other rights are or will be held valid or enforceable by the courts, through injunction or otherwise, or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us in every country of commercial significance that we may target.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and prior art make it patentable. We do not have outstanding issued patents covering all of the recent developments in our technology and we are unsure of the patent protection that we will be successful in obtaining, if any. Even if the patents are successfully issued, third parties may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates are challenged, it could dissuade companies from collaborating with us to develop or threaten our ability to commercialize or finance our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The laws of some foreign jurisdictions do not provide intellectual property rights to the same extent or duration as in the U.S., and many companies have encountered significant difficulties in acquiring, maintaining, protecting, defending and especially enforcing such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed, especially internationally.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how by entering into confidentiality agreements with third parties, and intellectual property assignment and protection agreements with officers, directors, employees, and certain consultants and advisors, there can be no assurance that such agreements will not be breached or enforced by courts,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that we would have adequate remedies for any breach, including injunctive and other equitable relief, or that our trade secrets and unpatented know-how will not otherwise become known, inadvertently disclosed by us or our agents and representatives, or be independently discovered by our competitors. If our trade secrets are independently discovered, we would not be able to prevent their use and if we or our agents or representatives inadvertently disclose trade secrets and/or unpatented know-how, we may not be allowed to retrieve these trade secrets and/or unpatented know-how and maintain the exclusivity we previously held.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on our product candidates does not guarantee exclusivity. The requirements for patentability vary between countries, particularly developing nations. In addition, the laws of some countries do not protect intellectual property rights to the same extent as the laws of all other countries or jurisdictions, especially when it comes to granting use and other types of patents and what kind of enforcement rights will be allowed, especially injunctive relief in a civil infringement proceeding. Consequently, we may not be able to prevent third parties from using our inventions or even in launching an identical version of our product even if we hold a valid patent. Competitors may use our technologies in jurisdictions where we have not obtained patent protection, or they may produce copy products, and, further, may export otherwise infringing products to territories where we have patent protection but enforcement against such activities is inadequate or where we have no patents. These products could compete with ours, and our patents or other intellectual property rights may not prevent them from competing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance and annuity fees on any issued patent are due to be paid to applicable patent agencies, which require compliance with a number of procedures, including certain documentary, fee payment and other similar provisions during the patent application process. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees in prescribed time periods, and failure to properly legalize and submit formal documents in the format and style the country requires. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction just for failure to know about and/or timely pay a prosecution fee. If we or our licensors fail to maintain the patents and patent applications covering our product candidates for any reason, our competitors might be able to enter the market, which would have an adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Giiant License Agreement pursuant to which we license PALI-2108, and other assets of Giiant, contains certain requirements related to diligence, milestone, royalty, insurance, expense reimbursement, and other obligations. If we fail to comply with these obligations, Giiant may have the ability to terminate the license, subject to certain requirements as more fully set forth in the Giiant License Agreement. If the license granted thereunder were to be terminated, our business, financial condition, operating results, and prospects would be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to patent infringement claims, which could result in substantial costs and liabilities, and could prevent us from commercializing our potential products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because the intellectual property landscape in the fields in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. If any patent infringement claims are brought against us, regardless of whether successful, we may incur significant expenses and divert the attention of our management and key personnel from other business concerns. This could negatively affect our results of operations and prospects. We cannot be certain that patents owned or licensed by us will not be challenged, potentially successfully, by others.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our customers, licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of such claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of customers, licensees, and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on behalf of those parties or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, we may be unable to continue selling such products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our officers, directors, employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former employers or their former or current customers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our product candidates, many of whom were previously employed at, or may have previously been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that our employees or consultants have inadvertently or otherwise wrongfully used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. Even if we are successful in defending against any such claims, the related litigation could be protracted, expensive, a distraction to our management team, and not viewed favorably by investors and other third parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Risks Related to Our Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have used and we intend to use the proceeds from our previous offerings and any future offerings, to, among other uses, advance PALI-2108 through clinical development, advancing the remainder of the existing portfolio through preclinical studies and into INDs or their equivalent in foreign jurisdictions, our research and development activities and for general working capital needs. We will require substantial additional capital to fund our operations and conduct the costly and time-consuming research and development and clinical work necessary to pursue regulatory approval of product candidates. Our future capital requirements will depend upon a number of factors, including: the number and timing of product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete clinical trials or any additional preclinical studies required; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain, which could inhibit our ability to achieve our business objectives. Given our limited cash reserves and the significant amount of capital that we will likely need to fund our operations and business plan, our stockholders will likely experience significant dilution to their ownership interests. If we raise additional funds through public or private equity sales of our securities, the terms of these securities may include liquidation or other preferences that adversely impact the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, our stockholders&#8217; ownership percentage will be decreased. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances, or licensing arrangements with third parties, we may need to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. Even if we obtain additional funding, there can be no assurance that it will be available on terms acceptable to us or our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our common stock price may be highly volatile.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the completion of the merger with Seneca on April 27, 2021, the price of our common stock has been subject to significant fluctuation. Market prices for securities of biotechnology and other life sciences companies historically have been particularly volatile and may be subject to large daily price swings. Some of the factors that may cause the market price of our shares to fluctuate include, but are not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our product candidates to show safety and/or efficacy in our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain timely regulatory approvals for our product candidates, and delays or failures to obtain such approvals;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our clinical trials, including our decision to pause or terminate any such trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our product candidates, if approved, to achieve commercial success;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the entry into, or termination of, or breach by partners of key agreements, including the Giiant License Agreement, and employment agreements with our named executive officers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation of, material developments in, or conclusion of any litigation to enforce or defend any intellectual property rights or defend against the intellectual property rights of others;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of any financings;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack of, significant contracts, commercial relationships or capital commitments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to elicit meaningful stock analyst coverage and downgrades of our stock by analysts; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the loss of key personnel.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility in the biotechnology industry, particularly in the micro-cap and nano-cap companies, that has often been unrelated to the operating performance of individual companies or a certain industry segment. These broad market fluctuations may also adversely affect the trading price of our shares. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our common stock could be delisted from the Nasdaq Stock Market if we are unable to maintain compliance with the Nasdaq Stock Market&#8217;s continued listing standards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on the Nasdaq Stock Market. There are a number of continued listing requirements that we must satisfy in order to maintain our listing on The Nasdaq Stock Market, including the requirement to maintain a minimum bid price of at least $1.00 (the &#8220;Bid Price Rule&#8221;). Although we are currently in compliance with the Bid Price Rule, we have been unable to comply with this rule in the past. For example, in October 2023, we were notified that we were no longer in compliance with the Bid Price Rule and had 180 days to cure such deficiency. On April 5, 2024, we effected a 1-for-15 reverse stock split and we were notified by the Nasdaq Stock Market that as of April 19, 2024, we were back in compliance with the Bid Price Rule. Although we are in compliance with the Bid Price Rule as of the date of this Annual Report on Form 10-K, on March 17, 2025, our stock price began trading below $1.00. Notwithstanding our current compliance with the Bid Price Rule, in the event that our common stock trades below $1.00 for 30 consecutive business days, Nasdaq may notify us that we are no longer in compliance with the Bid Price Rule and may have 180 days to cure such deficiency. If we are unable to cure such deficiency, we may be subject to delisting. If we fail to comply with the Bid Price Rule in the future, or any of the other continued listing requirements, there can be no assurance that we will be able to regain compliance. The delisting of our common stock would likely adversely affect the market liquidity and market price of our common stock and our ability to obtain financing for the continuation of our operations and/or result in the loss of confidence by investors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2024, the last business day of our most recently completed second fiscal quarter, our public float was less than $250 million and therefore, we qualify as a smaller reporting company under SEC rules. As a smaller reporting company, we can take advantage of reduced disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements in our SEC filings. Such reduced disclosures in our SEC filings may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of the reporting exemptions applicable to a smaller reporting company until we are no longer a smaller reporting company, which status would end once we have a public float greater than $250 million. In that event, we could still be a smaller reporting company if our annual revenues are below $100 million and we have a public float of less than $700 million.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not anticipate paying any dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not anticipate paying any dividends in the foreseeable future. We currently plan to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our shares will likely be the sole source of gain, if any, for our stockholders for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock is and will be influenced by reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrades our stock or issues other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future sales in the public market of shares of our common stock, including shares issued upon exercise of our outstanding stock options or warrants, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation, as amended (&#8220;Certificate of Incorporation&#8221;), and bylaws, as amended (&#8220;Bylaws&#8221;) may delay or prevent an acquisition or a change in management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove management by making it more difficult for stockholders to replace members of the Board, which is responsible for appointing the members of management.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. This has required that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management identified a material weakness in our internal control over financial reporting. If we do not remediate this material weakness, or if we identify further material weaknesses in our internal controls, our failure to establish and maintain effective internal financial and accounting controls and procedures could result in material misstatements in our consolidated financial statements and a failure to meet our reporting and financial obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate consolidated financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Board has broad discretion to issue additional securities, which might dilute the net tangible book value per share of our common stock for existing stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are entitled under our Certificate of Incorporation to issue up to 280,000,000 shares of common stock and 7,000,000 &#8220;blank check&#8221; shares of preferred stock. Shares of our blank check preferred stock provide our Board with broad authority to determine voting, dividend, conversion, and other rights of such preferred stock. As of December 31, 2024, we had outstanding, common stock or securities convertible into common stock, totaling 9,567,496 shares. As a result, we are authorized to issue up to an additional 270,432,507 shares of common stock or common stock equivalents under our Certificate of Incorporation. Additionally, pursuant to the initial issuance of (i) 1,000,000 shares of Series A 4.5% Convertible Preferred Stock, of which 200,000 shares are outstanding and (ii) 1,460 shares of Series B Convertible Preferred Stock, of which no shares are outstanding, we are authorized to issue up to an additional 6,800,000 shares of preferred stock. We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our existing stockholders will likely experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner that we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors will likely be materially diluted by the initial and subsequent sales. Additionally, new investors may gain rights superior to existing stockholders, depending on the terms of such transactions and types of securities. Pursuant to our equity incentive plans and employee stock purchase plan, management is authorized to grant stock options, restricted stock units and other equity-based awards to employees, directors and consultants, and to sell common stock to employees, respectively. Any increase in the number of shares outstanding as a result of the exercise of outstanding options, the vesting or settlement of outstanding stock awards, or the purchase of shares pursuant to the employee stock purchase plan will cause stockholders to experience additional dilution, which could cause our stock price to fall.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business could be adversely affected by the effects of health pandemics or epidemics, such as the COVID-19 pandemic, which could cause significant disruptions in our operations and those of our current or future CMOs, CROs, and other third parties upon whom we rely.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health pandemics or epidemics, such as the COVID-19 pandemic, have in the past and could again in the future result in quarantines, stay-at-home orders, remote work policies, or other similar events that may disrupt businesses, delay our research and development programs and timelines, negatively impact productivity and increase risks associated with cybersecurity, the future magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations. More specifically, these types of events may negatively impact personnel at third-party manufacturing facilities or the availability or cost of materials, which could disrupt our supply chain. Moreover, our trials may be negatively affected. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources. Some patients may not be able or willing to comply with trial protocols if quarantines impede patient movement or interrupt healthcare services. Our ability to recruit and retain patients, principal investigators, and site staff (who as healthcare providers may have heightened exposure) may be hindered, which would adversely affect our trial operations. Disruptions or restrictions on our ability to travel to monitor data from our trials, or to conduct trials, or the ability of patients enrolled in our trials or staff at trial sites to travel, as well as temporary closures of our trial partners and CMOs&#8217; facilities, would negatively impact our trial activities. In addition, we rely on independent clinical investigators, CROs, and other third-party service providers to assist us in managing, monitoring, and otherwise carrying out certain of our preclinical studies and clinical trials, including the collection of data from our trials, and the effects of health pandemics or epidemics, such as the COVID-19 pandemic, may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. Similarly, our trials could be delayed and/or disrupted. As a result, the expected timeline for data readouts, including incompleteness in data collection and analysis and other related activities, and certain regulatory filings may be negatively impacted, which would adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and adversely affect our business, financial condition, results of operations, and prospects. In addition, impact on the operations of the FDA or comparable foreign regulatory authorities could negatively affect our planned trials and approval processes. Finally, economic conditions and business activity may be negatively impacted and may not recover as quickly as anticipated.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable economic and market conditions may have serious adverse consequences on our business, financial condition, and stock price.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global economic and business activities continue to face widespread uncertainties, and global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, rising inflation and monetary supply shifts, rising interest rates, bank failures, labor shortages, declines in consumer confidence, declines in economic growth, increases in unemployment rates, recession risks, and uncertainty about economic and geopolitical stability (for example, related to the ongoing Russia-Ukraine and Israel-Hamas conflicts). The financial institutions in which we hold our cash and cash equivalents are subject to risk of failure. For example, recent events surrounding certain banks, including Silicon Valley Bank, First Republic Bank, and Signature Bank, created temporary uncertainty on their customers&#8217; cash deposits in excess of Federal Deposit Insurance Corporation limits prior to actions taken by governmental entities. While we do not expect any developments with any such banks to have a material impact on our cash and cash equivalents balance, expected results of operations, or financial performance for the foreseeable future, if further failures in financial institutions occur where we hold deposits, we could experience additional risk. Any such loss or limitation on our cash and cash equivalents would adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The extent of the impact of these conditions on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected timeframe, as well as that of third parties upon whom we rely, will depend on future developments which are uncertain and cannot be predicted. There can be no assurance that further deterioration in economic or market conditions will not occur, or how long these challenges will persist. If the current equity and credit markets further deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we may process, as defined above, proprietary, confidential, and sensitive data, including personal data (such as health-related patient data), intellectual property, and trade secrets (collectively, sensitive information). We may rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, employee email, CROs, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive information with or from third parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of a security breach or disruption, particularly through cyber-attacks, cyber-intrusion, malicious internet-based activity, and online and offline fraud, are prevalent and have generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. These threats are becoming increasingly difficult to detect and come from a variety of sources, including traditional computer hackers, threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, natural disasters, terrorism, war, and telecommunication and electrical failures. Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our remote workforce poses increased risks to our information technology systems and data, as most of our employees work from home, utilizing network connections outside our premises.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the previously identified or similar threats could cause a security breach or disruption. While we have not experienced any such security breach or other disruption to date, if such an event were to occur, it could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information and cause interruptions in our operations, including material disruptions of our development programs and business operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security breaches and disruptions. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security breach or disruption has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant parties of certain security breaches and disruptions. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security breach or other disruption, or are perceived to have experienced such events, we may experience adverse consequences, including: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. In particular, since we sponsor clinical trials, any breach or disruption that compromises patient data and identities could generate significant reputational damage, which may affect trust in us and our ability to recruit for future clinical trials. Additionally, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. Furthermore, we cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cybersecurity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems, and those of our current and future CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Although we have not suffered any material incidents to date, the risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusion, including by computer hackers, foreign governments, and cyber-terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. In addition, since we sponsor clinical trials, any breach that compromises patient data and identities causing a breach of privacy could generate significant reputational damage and legal liabilities and costs to recover and repair, including affecting trust in us to recruit for future clinical trials. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications or inappropriate disclosure of confidential or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proprietary information, we could incur liability and the further development and commercialization of our products and product candidates could be delayed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="unresolved_staff_comment_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolved Staff Comments.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3d263bf-295a-4075-9be6-3b4f5c8dfe41" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we may process proprietary, confidential, and sensitive data, including personal data (such as health-related patient data), intellectual property, and trade secrets (collectively, "sensitive information"). We rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, employee email, CROs, and other functions. The secure maintenance of this sensitive information and our information technology systems is important to our operations. To this end, we have processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by our third-party information technology consultants and include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5e5c658-26cc-45f3-b2c7-b0c2df49f99a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are planning to establish an appropriate confidentiality framework and document management system in order to safeguard sensitive information in addition to the safeguards provided by our third-party service providers</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bfc5121e-76dd-444d-90e8-c60f5db89151" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such confidentiality framework may include the use of third-party information technology experts to manage and oversee our sensitive information and to work directly with our management in overseeing cybersecurity risks</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and appropriate responses thereto. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we plan to consult with outside advisors and experts, when appropriate, to assist with assessing and identifying cybersecurity risks, including to anticipate future threats and trends, and their impact on our risk environment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the last fiscal year, we have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1172081-615b-4dd4-ba69-03184e49fce0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not identified risks from known cybersecurity threats</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks faced by us are discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the headings &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a33d724-3692-4b4c-b820-d7866e17934a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><ix:nonNumeric id="F_3b3a8c39-9e35-483f-9280-e4ef8323c3f4" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88ec83e0-c574-4a75-893c-1869e265121e" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65e47340-c120-4bed-9a6d-90dced339d50" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="properties_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease office space for our corporate headquarters under a non-cancelable facility operating lease for 2,747 square feet located in Carlsbad, California. The initial contractual term is for 39-months commencing on June 1, 2022 and expiring on August 31, 2025. We have the option to renew the lease for an additional 36-month period at the prevailing market rent upon completion of the initial lease term. We do not expect to renew the lease upon its expiration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information regarding our lease agreements, see Note 8, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of the consolidated financial statements included in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="legal_proceedings_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not a party to any material legal proceedings at this time. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are a party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mine_safety_disclosures_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="market_for_registrant_common_equity_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock trades on the Nasdaq Capital Market under the symbol "PALI." On March 20, 2025, the last reported sale price our common stock on the Nasdaq Capital Market was $0.78 per share.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Holders</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 20, 2025 there were 137 holders of record of our common stock, which does not include stockholders who hold shares in street name or stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our Board of Directors and will depend on, among other factors, our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our Board of Directors may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 1, 2024, we issued 3,000 restricted common shares to a consultant. The common stock shares were fully vested on the grant date and valued at $3.45 per share on the date of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offers, sales and issuances of the securities described herein were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Rule 506 of D promulgated under the Securities Act as transactions by an issuer not involving a public offering. The recipients of securities in the above transaction(s) acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule 501 of Regulation D under the Securities Act and had adequate access, through employment, business or other relationships, to information about the Company.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="selected_financial_data_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. [R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">served.]</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="financial_condition_results_operations_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Fin</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ancial Condition and Results of Operations.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Statements in this Annual Report on Form 10-K that are not strictly historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. Some of these factors are more fully discussed in the section of this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and elsewhere herein. We do not undertake to update any of these forward-looking statements or announce the results of any revisions to these forward-looking statements except as required by law.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We recommend investors read this entire Annual Report on Form 10-K, including the &#8220;Risk Factors&#8221; section, the consolidated financial statements, and related notes thereto. As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, &#8220;Palisade,&#8221; &#8220;Palisade Bio,&#8221; the "Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; or similar designations in this report refer to Palisade Bio, Inc., a Delaware Corporation, and its subsidiaries. Any reference to &#8220;common shares&#8221; or &#8220;common stock,&#8221; refers to our $0.01 par value common stock. Any reference to &#8220;Leading Biosciences, Inc.&#8221; or &#8220;LBS&#8221; refers to our operations prior to the completion of our merger with Seneca Biopharma, Inc. ("Seneca") on April 27, 2021 (the "Merger"). Any technology that we currently own or may acquire the rights to in the future is referred to by us as either a &#8220;product candidate&#8221; or "product candidates." Additionally, any reference herein that refers to preclinical studies also refers to nonclinical studies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OVERVIEW</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease ("IBD"), including ulcerative colitis ("UC") and Fibrostenotic Crohn's disease ("FSCD").</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting a Phase 1 human clinical trial of our lead product candidate, PALI-2108, for the treatment of UC. The Phase 1 clinical trial is being conducted in Canada. We anticipate announcing topline data from this study during the second quarter of 2025. Assuming the trial meets its primary objectives, we plan to initiate a Phase 1b/2a clinical study in UC patients in the first quarter of 2026.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to conducting clinical studies in Canada, we anticipate filing an Investigational New Drug Application (&#8220;IND&#8221;) with the United States Food and Drug Administration (&#8220;FDA&#8221;) during 2025. If our IND is approved, we anticipate commencing clinical trials of PALI-2108 in the United States ("U.S.") during the first quarter of 2026.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Results</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating loss for the year ended December 31, 2024 was approximately $14.9 million, which consisted of research and development expense and general and administrative expense of approximately $9.1 million and $5.8 million, respectively. Net cash used in operating activities was approximately $12.2 million for the year ended December 31, 2024, which includes a $14.4 million net loss adjusted for $1.4 million of net cash inflows related to changes in operating assets and liabilities and certain non-cash items impacting the net loss. Net cash provided by financing activities was approximately $9.6 million for the year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Financings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we completed an underwritten public offering for net cash proceeds of $4.1 million consisting of gross cash proceeds of $5.0 million less cash equity issuance costs of approximately $0.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we completed a private placement for net cash proceeds of approximately $3.5 million consisting of gross cash proceeds of $4.0 million, less cash equity issuance costs of approximately $0.5 million.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we completed a warrant inducement transaction for net cash proceeds of approximately $2.2 million consisting of gross cash proceeds of $2.5 million, less cash equity issuance costs of approximately $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to use the net proceeds from these recent financings for working capital and general corporate purposes, including the development of PALI-2108 for the treatment of IBD. Based on our cash and cash equivalents balance of $9.8 million as of December 31, 2024, we believe we have sufficient cash to fund our currently planned operations through the fourth quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Giiant License Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, we entered into a research collaboration and license agreement (the "Giiant License Agreement") with Giiant Pharma Inc. (&#8220;Giiant&#8221;). Under the terms of the Giiant License Agreement, we obtained the rights to develop, manufacture, and commercialize all compounds from Giiant, existing now and in the future, and any product containing or delivering any licensed compound, in any formulation or dosage for all human and non-human therapeutic uses for any and all indications worldwide, including those technologies that are the basis of PALI-2108. Pursuant to the terms of the Giiant License Agreement, preclinical development of PALI-2108 was jointly undertaken by us and representatives of Giiant. Pursuant to the Giiant License Agreement, we paid, or reimbursed or advanced to Giiant, a portion of the joint development costs. Additionally, per the terms of the Giiant License Agreement, we will pay (i) certain milestone payments (in cash or stock at our sole election) (the "Giiant Milestone Payments") and (ii) royalty payments upon sales or sublicenses to third parties, with such milestone and royalty payments (the "Giiant License Payments") subject to a payment cap (the "Payment Cap").</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 2, 2024, we entered into an amendment to the Giiant License Agreement with Giiant (the "Giiant License Agreement Amendment"). Pursuant to the Giiant License Agreement Amendment, we agreed to increase the amount of joint development costs we would reimburse or advance to Giiant pursuant to the Giiant License Agreement. As consideration for the increase, Giiant agreed to (i) a reduction in the Giiant Milestone Payments that would be due to them upon the achievement of certain development milestones, and (ii) a decrease to the Payment Cap applied to future Giiant License Payments, as set forth in the original Giiant License Agreement. There were no other changes to the terms of the original Giiant License Agreement as a result of the Giiant License Agreement Amendment that would have a material impact on our results of operations, financial position or future cash flows.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FINANCIAL OVERVIEW</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We generated no revenues from the sale of our product candidates for any of the periods presented. For the year ended December 31, 2023, we recognized license revenue of approximately $0.3 million from the co-development and distribution agreement with Newsoara, a joint venture established with Biolead Medical Technology Limited, as amended, (the &#8220;Newsoara Co-Development Agreement&#8221;). For the year ended December 31, 2024, we recognized no license revenue.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research and development expenses include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries and employee-related costs, including stock-based compensation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses under agreements with third-party contract research organizations ("CROs"), investigative clinical trial sites that conduct research and development activities on our behalf, and consultants;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to develop and manufacture preclinical study and clinical trial material; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory expenses.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses recognized in the year ended December 31, 2023 consisted primarily of costs directly incurred for the clinical development of our legacy product candidate, LB1148. On August 9, 2023, based on the results of the efficacy and safety data of the U.S. Phase 2 PROFILE study of LB 1148, we terminated the development of LB1148. Through the first nine months of 2024, the nature of our research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurred related primarily to the preclinical activities associated with our joint development of PALI-2108 with our collaboration partner, Giiant. With the approval to commence the Phase 1 clinical trial of PALI-2108, which we received from Health Canada on October 9, 2024, pursuant to the Giiant License Agreement we have assumed all development, manufacturing, regulatory and commercialization activities and costs of PALI-2108. Therefore, we expect our clinical research and development costs directly attributable to the clinical trials of PALI-2108 to continue to increase in 2025, offset by a decrease in joint development costs associated with the Giiant License Agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our direct research and development expenses are tracked by product candidate and consist primarily of external costs, such as fees paid under third-party license agreements and to outside consultants, CROs, clinical site, contract manufacturing organizations (&#8220;CMOs&#8221;) and research laboratories in connection with our preclinical development, process development, manufacturing, clinical development, and regulatory activities. We do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. As needed, we manage third parties that are engaged to conduct our (i) research activities, (ii) preclinical, clinical and translational science development activities, and (iii) process development. When we perform any research and development or manufacturing activities under a co-development agreement, we record the expense reimbursement from the co-development partner as a reduction to research and development expense once the reimbursement amount is approved for payment by the co-development partner. Pursuant to agreements where we perform research and development activities under a joint development plan, such as our research and collaboration with Giiant, qualifying development costs are expensed as research and development costs as incurred. We recognize expense payments from Giiant, if any, as a reduction to research and development expense once the expense payments are realized or realizable, which is when we receive the cash or we have an undisputed claim to the cash that is probable of collection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salary and employee-related costs and benefits, professional fees for legal, intellectual property, investor and public relations, accounting and audit services, insurance costs, director and committee fees, and general corporate expenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring Costs</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to better utilize our resources on the implementation of our refocused business plans and corporate strategy, we committed to a reduction-in-workforce on October 27, 2023 (the "2023 RIF"). The 2023 RIF consisted of a 25% reduction in our employee workforce, specifically research and development employees that were no longer deemed critical for our development of PALI-2108. We have outsourced to a third-party CRO many of the clinical trial activities related to our Phase 1 clinical trial of PALI-2108, which commenced in November of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has evaluated all conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that these financial statements are issued, including: (i) our available cash as of the date of this filing will not be sufficient to fund our anticipated level of operations for the next 12 months; (ii) we will require additional financing by the end of 2025 to continue at our expected level of operations; and (iii) if we fail to obtain the needed capital, we will be forced to delay, scale back, or eliminate some or all of our development activities or perhaps cease operations. In the opinion of management, these factors, among others, raise substantial doubt about our ability to continue as a going concern as of the filing date of this Annual Report on Form 10-K and for one year from the issuance of the consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 5, 2024, we effected a 1-for-15 reverse stock split of our issued and outstanding common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, our stockholders received one share of our common stock for every 15 shares each stockholder held immediately prior to the effective time of the Reverse Stock Split. Unless otherwise noted, all common stock shares, common stock per share data and shares of common stock underlying convertible preferred stock, stock-based awards and common stock warrants included in this Annual Report on Form 10-K, including the exercise or conversion price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the Reverse Stock Split.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the year ended December 31, 2024 and 2023 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.942%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.662%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">n/a</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,063</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,893</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,170</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,796</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,202</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(406</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(225</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">n/a</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,859</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,320</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,539</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,859</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,070</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,789</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">785</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(352</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(45</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">421</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">770</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(349</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(45</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,438</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,300</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,138</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, we recognized license revenue of approximately $0.3 million earned upon the achievement of a milestone under the Newsoara Co-Development Agreement. During the year ended December 31, 2024, we recognized no license revenue.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by approximately $2.2 million, or 31%, from approximately $6.9 million for the year ended December 31, 2023 to approximately $9.1 million for the year ended December 31, 2024, primarily due to (i) an increase in joint development expenses directly related to PALI-2108 of approximately $3.6 million, from approximately $0.7 million for the year ended December 31, 2023 to approximately $4.3 million for the year ended December 31, 2024, and (ii) an approximately $1.0 million increase in drug manufacturing costs for the preclinical and clinical trials of PALI-2108. Partially offsetting these increases in joint development expenses and drug manufacturing costs was a decrease in clinical trial-related expenses of approximately $1.3 million for the year ended December 31, 2024, compared to the year ended December 31, 2023. Associated with our clinical trials of LB1148, which we ceased developing in August of 2023, we recognized clinical vendor costs, translational research costs, investigator site fees and regulatory activity costs of approximately $2.5 million for the year ended December 31, 2023, compared to costs specific to the clinical trials of PALI-2108 of approximately $1.2 million for the year ended December 31, 2024. With the commencement of our clinical trials of PALI-2108 in November of 2024, in 2025 we expect an increase in costs directly associated with the clinical trials of PALI-2108.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, for the year ended December 31, 2024 compared to the year ended December 31, 2023, employee-related costs decreased by approximately $0.6 million as a result of a 25% reduction in our employee workforce in October 2023 and a decrease in fees associated with the hiring of our CMO in September of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, associated with the Giiant License Agreement entered into on September 1, 2023, the year ended December 31, 2023 included transaction costs of approximately $0.2 million and non-cash expense of approximately $0.2 million for the initial recording of the fair value of the contingent consideration obligation, compared to a small non-cash gain recognized for a decrease in the fair value of the contingent consideration obligation in the year ended December 31, 2024, resulting in a net favorable impact year-over-year of approximately $0.4 million. The non-cash gain of less than $0.1 million for the year ended December 31, 2024 was due to a decrease in the fair value of the Giiant Milestone Payment primarily as a result of the Giiant License Agreement Amendment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses decreased by approximately $0.4 million, or 7%, from approximately $6.2 million for the year ended December 31, 2023 to approximately $5.8 million for the year ended December 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">primarily driven by (i) a decrease insurance costs of approximately $0.2 million, due to lower insurance premiums, (ii) a decrease in our Board and Board committee fees of approximately $0.2 million, due to reduction in the size of our Board and Board committee membership in the first quarter of 2024, (iii) a decrease of approximately $0.2 million related to patent costs, license and maintenance fees, and subscription fees recognized in 2023 that did not repeat in 2024, and (iii) a decrease in professional fees, primarily accounting fees, of approximately $0.5 million for the year ended December 31, 2024, compared to the for the year ended December 31, 2023. These increases were partially offset by an approximately $0.6 million increase in consultants and contract labor in the year ended December 31, 2024, compared to the year ended December 31, 2023, and a $0.1 million increase in shareholders services fees due to the special meeting of our shareholders held on March 25, 2024 to approve the Reverse Stock Split.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Associated with the 2023 RIF, we recognized restructuring expenses of approximately $0.2 million and for the year ended December 31, 2023, consisting of severance and benefits payments pursuant to employment agreements and the execution of severance and release agreements. We recognized no restructuring expenses for the year ended December 31, 2024. We do not expect to incur any other significant costs associated with the 2023 RIF.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income (expense)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net, of approximately $0.4 million for the year ended December 31, 2024 includes dividend income of approximately $0.5 million from our short-term investments of excess cash in money market funds with maturities of three months or less, partially offset by other non-cash losses of less than $0.1 million associated primarily with the write-off of certain other receivable balances.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net, of approximately $0.8 million for the year ended December 31, 2023 includes dividend income of approximately $0.7 million from our short-term investments, and a non-cash gain of approximately $0.1 million associated with the revaluation of our liability-classified warrants in the year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have financed our operations through the sales of our securities, issuance of debt, the exercise of common stock warrants, and to a lesser degree, grants and research contracts as well as the licensing of our intellectual property to third parties. Refer to the paragraph under the heading "Going Concern" in the Financial Overview section above for management's assessment of our ability to continue as a going concern.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur substantial operating losses for the foreseeable future. We will need to raise additional capital through a combination of equity offerings, debt financings, collaborations, and other similar arrangements. Our ability to raise additional capital may be adversely impacted by: (i) general political or economic conditions, (ii) inflation, (iii) rising interest rates, (iv) ongoing supply chain disruptions, (v) the ongoing global conflicts, including those in the Ukraine and the Middle East, and (vi) limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry. In the event that we are unable to access additional capital, we may need to curtail or greatly reduce our operations, which could have a materially adverse impact on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Equity Offerings</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 13, 2024, we completed an underwritten public offering of common stock, prefunded warrants to purchase common stock and warrants to purchase common stock (the "December 2024 Offering"). Gross cash proceeds from the December 2024 Offering were approximately $5.0 million and net cash proceeds were $4.1 million after deducting cash equity issuance costs of approximately $0.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 6, 2024, we completed a private placement of common stock, prefunded warrants to purchase common stock and warrants to purchase common stock (the "May 2024 Offering"). Gross cash proceeds from the May 2024 Offering were $4.0 million and net cash proceeds were approximately $3.5 million after deducting cash equity issuance costs of approximately $0.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 11, 2023, we completed a registered direct offering of common stock (the "September 2023 Offering"). Gross cash proceeds from the September 2023 Offering were approximately $2.0 million and net cash proceeds were approximately $1.7 million after deducting cash equity issuance costs of approximately $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 3, 2023, we completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "April 2023 Offering"). Gross cash proceeds from the April 2023 Offering were approximately $6.0 million and net cash proceeds were approximately $5.3 million after deducting cash equity issuance costs of approximately $0.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 4, 2023, we completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "January 2023 Offering"). Gross cash proceeds from the January 2023 Offering were approximately $2.5 million and net cash proceeds were approximately $2.2 million after deducting cash equity issuance costs of approximately $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders' Equity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Part II Item 8 of this Annual Report on Form 10-K for further details of our recent equity transactions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Exercises</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we received gross cash proceeds of approximately $2.5 million for the exercise of outstanding common stock warrants. During the year ended December 31, 2023, we received gross cash proceeds of approximately $2.8 million from common stock warrant exercises, approximately $1.4 million of which related to common stock warrant exercises on December 30, 2022 for which the related cash was received by us in January 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 30, 2024, we entered into warrant inducement agreements (the &#8220;Warrant Inducement Agreements&#8221;) with certain accredited and institutional holders (collectively, the &#8220;Warrant Holders&#8221;) of certain of our remaining outstanding common stock purchase warrants issued pursuant to: (i) the May 2022 Offering, (ii) the January 2023 Offering, and (iii) the April 2023 Offering, as well as certain outstanding common stock purchase warrants outstanding from the August 2022 Offering (the "August 2022 Warrants") (collectively, the &#8220;Existing Warrants&#8221;). Pursuant to the Warrant Inducement Agreements, the exercise price of each Existing Warrant was reduced to $10.97 per share. Each of the Warrant Holders that exercised their Existing Warrants pursuant to the Warrant Inducement Agreements received one replacement warrant for each Existing Warrant exercised with each such replacement warrant having a term of five years from issuance and an exercise price per share of $10.97 (in its entirety, the "February 2024 Warrant Inducement").</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrant Holders collectively exercised an aggregate of 228,162 Existing Warrants. As a result of the exercises of the Existing Warrants, we issued an aggregate of 228,162 shares of our common stock and 228,162 Replacement Warrants. The February 2024 Warrant Inducement closed on February 1, 2024 for net cash proceeds of approximately $2.2 million consisting of gross cash proceeds of approximately $2.5 million, less cash equity issuance costs of approximately $0.3 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had $9.8 million in cash, cash equivalents and restricted cash. The following table shows a summary of our cash flows for the years ended December 31, 2024 and 2023 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,193</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,133</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,582</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,186</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Operating Activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operations increased by approximately $1.1 million for the year ended December 31, 2024 compared to the year ended December 31, 2023 primarily due to an increase in net loss, partially offset by favorable changes in operating assets and liabilities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities was approximately $12.2 million for the year ended December 31, 2024, which reflects a $14.4 million net loss adjusted for (i) approximately $1.4 million of net cash inflows related to changes in operating assets and liabilities, and (ii) certain non-cash items impacting the net loss, consisting primarily of (a) an approximately $0.7 million non-cash expense recognized for stock-based compensation and related charges, (b) an approximately $0.1 million non-cash expense associated with the issuance of our common stock as payment for vendor services provided, (c) an approximately $0.1 million non-cash expense related to the amortization of our operating lease right of use asset, and (d) an approximately $0.2 million non-cash gain recognized for the remeasurement of the contingent consideration liability associated with the Giiant Milestone Payments. The net cash inflow from operating assets and liabilities was primarily attributable to an approximately $0.1 million cash outflow related to payments of our operating lease that was more than offset by approximately $1.6 million cash inflow from (i) an approximately $0.8 million decrease in prepaids and other current assets and other noncurrent assets, which was primarily attributable to the amortization of the current and non-current portions of our prepaid insurance policies, and (ii) an approximately $0.8 million increase in accounts payable and accrued liabilities, which was primarily due to additional drug manufacturing accruals associated with the clinical trials of PALI-2108 and an increase in accrued joint development expenses associated with the Giiant License Agreement. These increases in accounts payable and accrued liabilities were partially offset by a decrease in accrued severance payments and lower accrued Board and Board committee fees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities was approximately $11.1 million or the year ended December 31, 2023, which reflects an approximately $12.3 million net loss adjusted for (i) approximately $0.4 million of net cash inflows related to changes in operating assets and liabilities, and (ii) certain non-cash items impacting the net loss, consisting primarily of (a) a $0.6 million non-cash expense recognized for stock-based compensation and related charges, (b) a $0.1 million non-cash expense related to the amortization of our operating lease right of use asset, and (c) a non-cash expense of $0.2 million related to the remeasurement of certain liabilities recorded at fair value. The net cash inflow from operating assets and liabilities was primarily attributable to (i) a $0.7 million cash inflow from the decrease in prepaids and other current assets and other noncurrent assets, which was primarily attributable to the amortization of the current and non-current portions of our prepaid insurance policies, and (ii) a $0.3 million cash inflow from an increase in accrued compensation and benefits, partially offset by (i) a $0.5 million cash outflow for accounts payable and accrued liabilities due to the timing of payments, and (ii) a $0.1 million cash outflow related to payments of our operating lease.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Investing Activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2023 consists of payments for leasehold improvements. There was no cash used in or provided by investing activities for the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Provided by Financing Activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, cash provided by financing activities of approximately $9.6 million was attributable to net cash proceeds of approximately $2.2 million from the exercise of common stock warrants in conjunction with the February 2024 Warrant Inducement and net cash proceeds of approximately $7.9 million from the May 2024 Offering and December 2024 Offering, partially offset by payments made on our insurance financing arrangements of approximately $0.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, cash provided by financing activities of approximately $11.2 million was primarily attributable to net cash proceeds of approximately $8.8 million from the January 2023 Offering, the April 2023 Offering, and the September 2023 Offering. Also contributing to the cash provided by financing activities in the year was approximately $2.8 million from the exercise of common stock purchase warrants, which includes the receipt in early January 2023 of an approximately $1.4 million other receivable from warrant exercises on December 30, 2022, partially offset by payments of approximately $0.4 million for our insurance financing arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Office Lease</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party a to non-cancelable facility operating lease (the "Corporate Office Lease") of office space for our corporate headquarters. The initial contractual term is for 39-months commencing on June 1, 2022 and expiring on August 31, 2025. We have the option to renew the Corporate Office Lease for an additional 36-month period at the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevailing market rent upon completion of the initial lease term. We have determined that it is not likely we will exercise this renewal option.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commencing on June 1, 2022, we are subject to contractual monthly lease payments of $10,850, plus certain utilities, for the first 12 months with 3 percent escalations at the first, second and third lease commencement anniversaries. As of December 31, 2024, the total remaining future minimum lease payments associated with the Corporate Office Lease of approximately $93,000, including imputed interest of $3,000 calculated using a discount rate of 10.75%, will be paid over the remaining lease term of approximately 0.7 years.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insurance Financing Arrangement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we entered into an agreement to finance an insurance policy that renewed in May 2024. The insurance financing arrangement is payable over a 9-month period with the first payment having been payable on June 30, 2024. As of December 31, 2024, the aggregate remaining balance under our insurance financing arrangement was $79,000.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the remaining insurance financing arrangement payments due in 2025, as of December 31, 2024 we have no other minimum debt payments required in 2025 or thereafter.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Liquidity Needs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses and negative cash flows from operations since our inception. To date, we have not been able to generate significant revenues nor achieve operating profitability. Based upon our cash and cash equivalents balance of $9.8 million as of December 31, 2024, we believe we have sufficient cash to fund our currently planned operations through the fourth quarter of 2025. Notwithstanding, should our anticipated level of operations significantly change, we may require additional financing sooner than anticipated. Further, beyond the fourth quarter of 2025 we will require additional financing to continue at our expected level of operations. If we fail to obtain the needed capital, we will be forced to delay, scale back, or eliminate some or all of our development activities, or potentially cease our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;U.S. GAAP&#8221;). The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet and the reported amounts of expenses during the reporting period. Our estimates are based on historical experience, known trends, events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our significant accounting policies used in the preparation of the consolidated financial statements are described in more detail in Note 2 in Part II, "Item 8. Financial Statement and Supplemental Data" of this Annual Report on Form 10-K. We believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs as incurred pursuant to Accounting Standards Codification ("ASC") 730, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are required to make estimates of our accrued expenses resulting from our obligations under contracts or agreements with, as applicable, research and development collaboration partners, CROs, clinical sites, manufacturers, vendors, and consultants in connection with conducting research and development activities, including those related to our ongoing clinical operations. The financial terms of these contract arrangements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows that do not match the periods over which services are provided or milestones are met under the associated research and development contract. Payments under some of these contracts depend on factors such as the successful enrollment of patients, site initiation and the completion of clinical milestones. We make estimates of our accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period. If the actual timing of the performance of services or the level of effort varies from its estimate, we adjust the accrual or prepaid expense balance accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our process around estimating accrued research and development expenses involves reviewing open contracts and purchase requisitions, communicating with our personnel, consultants, and research and development collaboration partners to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accrue for research and development expenses, including manufacturing and clinical trial costs, for which the estimated services have been provided but we have not yet been invoiced as of the balance sheet date. There may be instances in which payments made to our service providers will temporarily exceed the level of services provided and result in a prepayment of the research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expense payments made to Giiant pursuant to the terms of the Giiant License Agreement for qualifying development costs are expensed only as the associated research and development costs are incurred or other aspects of the drug development or related activities are achieved. In instances where the expense determined to be recognized exceeds the payments made to the Giiant, we recognize an accrual of joint development expenses. In addition, there may be instances in which payments made to Giiant will temporarily exceed the level of services provided, which results in a prepayment of the joint development expenses. We record expense payments from Giiant, if any, as a reduction to research and development expense once the expense payments are realized or realizable, which is when Company receives the cash or has an undisputed claim to the cash that is probable of collection, pursuant to the terms of the Giiant License Agreement and the principles of ASC 450, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not expect our estimates of research and development expenses to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Giiant License Agreement, we incurred a contingent consideration obligation consisting of milestone payments. Because the contingent consideration associated with the milestone payments may be settled in shares of our common stock solely at the election of the Company, we have determined it should be accounted for under ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and accordingly we have recognized it as a liability measured at its estimated fair value. As of September 1, 2023, the date the contingent consideration obligation was incurred, the initial fair value of the liability was determined to be approximately $0.2 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the end of each reporting period, we re-measure the contingent consideration obligation to its estimated fair value and any resulting change is recognized in research and development expenses in the consolidated statements of operations. The fair value of the contingent consideration obligation is determined using a probability-based model that estimates the likelihood of success in achieving each of the defined milestones, which is then discounted to present value using our incremental borrowing rate. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The significant assumptions used in the calculation of the fair value as of December 31, 2024 included a discount rate of 9.29% and management's updated projections of the likelihood of success in achieving each of the defined milestones based on empirical, published industry data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the entire amount of contingent consideration obligation was classified as a noncurrent liability in the consolidated balance sheet as none of it is expected to be settled within one-year of the balance sheet date. As of December 31, 2023, approximately $143,000 of the contingent consideration obligation was classified in accrued liabilities in the consolidated balance sheets as it was expected to be settled within one-year of the balance sheet date and the remaining obligation of approximately $61,000 was classified as a noncurrent liability in the consolidated balance sheet.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in the fair value of the contingent consideration obligation of approximately $54,000 for the year ended December 31, 2024 was primarily due to the reduction in the milestone payments that would be due to Giiant upon the achievement of certain development milestones pursuant to the amendment to the Giiant License Agreement, partially offset by an increase in management's projected likelihood of success in achieving each of the defined milestones as a result of our commencement of a Phase 1 trial in November of 2024. The change in the revaluation of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the liability in the years ended December 31, 2024 and December 31, 2023 is recognized in research and development expenses in the consolidated statements of operations. In addition, the initial fair value of the contingent consideration liability of $0.2 million and transaction-related costs of approximately $0.1 million for the year ended December 31, 2023 is recognized in research and development expenses in the consolidated statements of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="quantitative_and_qualitative_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Disclosures About Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a smaller reporting company, we are not required to provide the information required by this Item.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="financial_statements_supplementary_data_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statements and </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplementary Data.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:18pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;box-sizing:content-box;"/>
    <td style="width:7.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cy_auditor_opinion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (Baker Tilly US, LLP; New York, New York; PCAOB ID #</span><span><ix:nonNumeric id="F_340890f8-65a0-4cbb-bcd2-4c94fbf2d5e7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">23</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#preferred_stock_stockholder_equity_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_financial_statements_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cy_auditor_opinion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT RE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the stockholders and board of directors of Palisade Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <div><ix:nonNumeric id="F_8baab0c4-0305-4db1-b140-4812ed861c91" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Palisade Bio, Inc. (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern Uncertainty</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 1 to the consolidated financial statements, the Company has suffered losses and negative cash flows from operations, and has an accumulated deficit as of December 31, 2024, that raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regards to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgements. We determined that there are no critical audit matters.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a68927e-2862-439d-bb63-2d970b6b8085" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Baker Tilly US, LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company's auditor since 2022.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_984e6062-4d8c-4cc4-9ce0-970016ec9f28" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Bala</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nce Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ASSETS</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab97b15-1ce9-4e52-8c9e-7c7c81ec4fae" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,821</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_621c7479-74dc-4344-8512-1b2fbc7b5f81" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,432</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3934918b-4718-43df-bc8e-e833f463e128" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">673</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7cb5eec-6726-42f1-a22c-68d5c2d5d6e1" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">896</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ec24756-eff0-43bc-8601-1539d7b7e619" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,494</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca539a83-5364-4646-ab25-16b3fd1b6df3" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,328</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4fb2f02-ade3-4caa-97ed-ab57dfc7b9ae" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27ae678a-6b4a-4746-a137-2d2c66037ad0" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b941c89-62d6-44ff-a17c-f0d3ac525147" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6b72aa9-bb5b-4557-a4c9-1be71fb85751" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3eb35cf-3625-4678-a5ee-671531df136b" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccf838e6-e50d-4f43-abe2-4f582402ee88" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other noncurrent assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0953df7e-fa39-4194-8ccf-447f934bbc42" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b9de1ea-1e5c-4ae7-a7a8-4a00eb93b50f" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dad86e35-a29e-4341-bdfa-6d0cf08f506f" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,880</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4d7afb9-140d-4068-97fd-db57317381d5" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,052</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fb629a0-5ea2-410e-98fc-5ff1f57a4300" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,105</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4747d17f-f4a9-449a-8366-53444d5c19ae" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">698</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7edb23f0-7437-4b95-ae4e-4e1939682e88" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,240</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1522b827-c2d4-42b0-9715-82fad570ccd2" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edb69110-f6b4-4675-815a-cddb7a750e0d" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f25888-94ee-4920-b497-7d9003c54da3" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">778</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of operating lease liability</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78d8d338-e858-4448-a38f-338cd1689ad9" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_910a6735-4dfe-4ec3-9959-55cb192d2732" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance financing debt</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e58bce1d-0907-4163-8d97-77494dad9699" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:AccruedInsuranceCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e36d2417-38f4-4755-81ad-a96e4e4ccb10" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:AccruedInsuranceCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_283fa600-c634-479c-9db0-7fa48f349d46" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,236</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3427f157-1d6f-486b-ab49-2808064801ee" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,586</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d266df3c-8da6-44de-be97-452e3f7b87c8" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce6e71b0-36a6-4f29-a674-d0822ce82f37" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contingent consideration obligation, net of current portion</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3123c5f0-5e8a-424b-a8a8-091aa484833f" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e346ae51-392b-4541-8b65-4761adfce3b2" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff763af-ae84-410b-a87d-15f4be44786e" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_065d7c9d-5e34-4fce-a81d-98fe3939eef1" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0981c04f-9af9-4d36-8d58-096301de2189" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,388</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7f5be41-c354-4e72-846a-942b93a3f040" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,739</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_41a02ef9-ef41-402f-a4a8-05fe4612c034;"><span style="-sec-ix-hidden:F_1ef91e9f-cd0d-43f4-90e4-9dfe50bab27e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 8)</span></span></span></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Convertible Preferred Stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ca3a71a-8761-499c-859e-e94bd021cc79" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4965c34a-9ef6-4729-b623-cd888bac8a87" contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, <br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49e381e8-17f2-411b-b278-7d0a55c2edae" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1ac6391e-0c49-4b16-88a5-df15c6f7f705" contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23e2bd00-ce2c-4930-874d-9080b15c3357" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9128f495-63ce-4c11-b02f-b888f932ce58" contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_41cc03e5-a6bc-4213-8eb2-35fb439a9cdf" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0d468110-78d0-44fa-9a9a-fb461b3240d4" contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;issued and <br/>outstanding at December 31, 2024 and December 31, 2023</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95c81f85-a4a2-447a-8a7a-3107bbdbf05a" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7af99c5e-069d-479a-bba3-3a5b056572a3" contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e497643-ec10-4932-81f7-637deddcd2cc" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f8f53c02-35e2-4783-b06f-f7ff344db3b9" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ec52d6a-89c4-4faf-8c7e-06656a7dd576" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_339ba632-8a01-40d7-8561-0571920d80a0" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">280,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized;<br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91f57b55-6c59-4025-b189-8d5f1d6ca3d2" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e43455ae-61f9-4bd6-98bf-b11d459cdcac" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,768,646</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfa9805e-3f6f-4f7e-bf66-468741566564" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_81f7c44b-9c37-42ea-98f7-a976fa7623f0" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">618,056</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding <br/>at December 31, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86102321-745a-4a9f-a767-3b4bbc94ede0" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3358f4e0-b6f3-4332-8301-e71ad4ef3650" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81c26ca4-87f1-4839-9e39-6b72007cf11d" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,407</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_317d609d-5a1d-46be-8d4c-36b4920fb07f" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,811</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18e330f3-4d50-45f4-8b85-4fb56067b44e" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:RetainedEarningsAccumulatedIncomeDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,944</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b81d8e06-b061-4d3a-bf81-cc126a364ef7" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:RetainedEarningsAccumulatedIncomeDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,506</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a8193d6-6512-4019-ba64-23c55b0ad4cd" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,492</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb1d47b2-0603-4c72-b230-d8ee824ed834" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,313</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50ab1f42-1f1b-469a-b89e-221efaf7e68f" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,880</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13094e7e-11c4-45fa-874a-e6a5f7d67c18" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,052</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ts of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.72%;box-sizing:content-box;"/>
    <td style="width:1.64%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.64%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d891136-1f89-4f61-a542-ac567f637fe4" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c29f43b-9227-486c-a0b2-96e7053b572c" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1086025e-f7cb-4c4e-b309-af420dd0e680" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,063</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2458fb54-1fba-4bdb-90b5-93212b1849bc" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,893</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8531ec98-e13b-41c8-bd66-c8be609c1020" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,796</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee2e60a5-2b70-4810-a87c-e74634a33c03" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,202</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring costs (Note 8)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09de3416-eca8-4aac-b7d9-2a56e7c79f78" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f4cb9ea-2f23-4b31-8ad0-3b463e8ea1ea" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e7a6927-0883-41ff-892e-75ececda7133" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,859</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_101b6a2f-00fa-461b-91c0-9bc50868098f" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,320</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a267f00f-fb98-45d5-95aa-ac3b988609ac" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,859</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4cb13d5-39c0-4f62-8668-34394e0edcda" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e533d2c5-c047-4bd5-8f32-b20e597f4df2" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de925185-c70d-43da-b004-c1d9ecd8701b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_354db0d1-b380-4b6b-a7ad-392430b9aa37" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">433</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec58f525-a24e-4d3a-8b9d-9dbe6300ced5" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">785</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3181c1c6-ba48-42e1-9553-ab93bb2e5afa" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d10bd205-e8a6-4524-ac55-646b0abf9d6f" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">770</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_133ea55e-5f0f-4bdf-9b39-f512a6653553" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f036d5b-30a9-48c7-9a3b-85d36263a364" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss available to common stockholders</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5683f02-c99c-4352-af9e-3d47271d4ac0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2e26012-c904-4ba6-a480-ec2385c0fc0b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,316</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted weighted average shares used in computing <br/>basic and diluted net loss per common share*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f258028-16ee-47ec-b30a-a72e7909933d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f295b006-8721-42a1-9ac3-52f7a33c05b0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,416,471</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d214d75-f0d4-46b6-a346-1086df1e7442" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ccbb254a-2085-465e-8ec8-ae210579281a" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">456,014</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3befa2c4-75ca-4fc6-ae21-d8d6d7a77d6d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_52f8c5ac-0778-4aeb-b48d-5ca369d4f1c9" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">10.19</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb5c5b37-1ce9-43b5-b2e5-323e82bd6b35" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dd2d9c2e-d568-4109-9a93-3600a95d4bb8" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">27.01</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_1cae901f-db24-4481-ad3f-2ed437509eae" xml:lang="en-US"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Basic and diluted loss per common share and basic and diluted weighted average share used in computing basic and diluted loss per common share for the year ended December 31, 2023 has been adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</span></p></ix:footnote>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="preferred_stock_stockholder_equity_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.725%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.0809999999999995%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.461%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.742%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.461%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.321%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.882%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="26" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in<br/>Capital*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders'<br/>Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d235f4ef-de95-455f-8655-3d689d2865b5" contextRef="C_51618521-fa5c-465f-afce-888db78121fc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae0358d7-f0a6-4a2e-a9c7-02a47e0b1588" contextRef="C_51618521-fa5c-465f-afce-888db78121fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d36e42da-1750-4bfd-8ccc-25d155d540fb" contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">618,056</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d752654-4a66-4b6d-98c9-36e92bc3213d" contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5efb6687-ed6e-45e6-9dfd-e297f64b1113" contextRef="C_b4194f6e-7d8f-4de8-9fdb-21da6a505d2a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,811</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f9c0fd8-2f97-472e-8ecb-fdd099c59940" contextRef="C_5ad66f61-3eb3-4d36-903d-7bac0116fcc6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,506</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ce5ecd7-b7a7-41b0-9b85-607c055451bc" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,313</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15b636a9-51c8-4f2f-91b9-9158ef424787" contextRef="C_de9ce026-379c-4626-83e2-28087fada0ba" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc622baa-97ee-4cf1-a1a0-36d9715d675a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense and related charges</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9fb2141-4746-4cf1-a213-25ff041b13d7" contextRef="C_09342590-da6c-45b7-8387-a049a00b0407" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">652</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55e61c39-8c24-40b6-be6a-30e8360930fd" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">652</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock to vendors</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_913a4536-6c4b-4315-bf67-d5c1533e34fb" contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">32,632</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_598beaea-107c-4159-af0f-159afd92aecb" contextRef="C_09342590-da6c-45b7-8387-a049a00b0407" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_212dd2ef-0df3-4aa8-8dae-fb266695c9ba" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdd775a9-38c9-4488-93ee-6a859c8265b1" contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,046</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9745b3d0-2782-465e-b09b-34f7e43e40e7" contextRef="C_09342590-da6c-45b7-8387-a049a00b0407" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a7a84ff-01e2-4b45-97f4-a9be081de18e" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in connection with exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9aaa239-ef30-4d3b-a071-c1561afdc27d" contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550" name="pali:StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,626,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2c67c24-ea99-467d-b763-290b87654180" contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550" name="pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f3be1d1-75d4-43bb-ba1c-fefea07a2041" contextRef="C_09342590-da6c-45b7-8387-a049a00b0407" name="pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0168a34-86e3-4e41-ba65-4af4a89bba6a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b466cb16-964d-49e3-96e0-9a33a892309c" contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,256</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58475b22-3533-4cb1-afde-56be185c8979" contextRef="C_09342590-da6c-45b7-8387-a049a00b0407" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7097f060-8b45-429e-8f8a-8a7d7c688d4c" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in connection with warrant inducement, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22a896a6-1ed1-4884-8c8c-3ccc6f3eded1" contextRef="C_5506b90a-1f64-4934-8403-8f83e8522373" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,412</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;(Note 5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7cc059f-57cd-4370-8109-52aebcece734" contextRef="C_5506b90a-1f64-4934-8403-8f83e8522373" name="pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">228,162</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25fe3de5-adc1-472b-9089-7ffa1ad3b53b" contextRef="C_5506b90a-1f64-4934-8403-8f83e8522373" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1dac30b-227b-4798-a021-13173d491f7b" contextRef="C_94a47a15-71e6-4ad0-8919-73628f2b0419" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,158</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afc2c3a2-e6e9-4e5d-bfef-af591fe43ebd" contextRef="C_8adee270-45e0-4d2c-a675-0eb8595fa4df" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,160</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and warrants in May 2024 Offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c92fbdeb-4398-4ce0-a1db-98586bf8e596" contextRef="C_0769ff66-ee84-425c-88ee-5721d253b14e" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;(Note 5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89a5ab14-b2e0-4738-a557-61eb27d9e8b7" contextRef="C_0769ff66-ee84-425c-88ee-5721d253b14e" name="pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32d51079-3301-4b4a-876e-bfb122660164" contextRef="C_0769ff66-ee84-425c-88ee-5721d253b14e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_223c3c04-379a-4125-84e0-9d7da2e2a28a" contextRef="C_8f0ecb26-e051-44ad-94f8-a05944e7fc18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,543</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7a3fddb-5c66-459b-adf2-160b894ea37c" contextRef="C_215542bf-2dd7-470b-b7be-f61e7050c227" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,544</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and warrants in December 2024 Offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56c61d87-0860-471e-be8a-14648727b385" contextRef="C_76e3614d-9c9a-46c6-a850-919f190aaaca" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;(Note 5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc72025c-7121-4942-ac82-720a8dcaf5c6" contextRef="C_76e3614d-9c9a-46c6-a850-919f190aaaca" name="pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">158,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_199eb8a0-6b97-4beb-b1bb-be7bf186d9a0" contextRef="C_76e3614d-9c9a-46c6-a850-919f190aaaca" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cc691d2-c99f-43b3-b37d-ba6cb755b8af" contextRef="C_05d7c843-a34b-479a-88d4-a12a886a60f7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,135</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15f75e40-073c-43e8-ac2a-0e987d922024" contextRef="C_418106b0-0eb9-4bd1-a9d8-1a674eb12eaa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,137</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reverse stock split fractional share settlement</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9511cfd1-2c72-40fd-82a4-ff06fe15d67d" contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c9e916a-4a75-4606-a0db-0f45cfc09a92" contextRef="C_4166f110-68a3-43b8-9e9a-a8db08091181" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b30db9c-8c44-4e5f-b265-8c71a5c06e24" contextRef="C_4166f110-68a3-43b8-9e9a-a8db08091181" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_319d8403-72a4-41d4-af2c-c72e7618880c" contextRef="C_8f070788-1b85-4e49-a494-ec7bbbbb19f8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,768,646</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f57a0064-dc8e-4fa8-a52f-54517bbe3c18" contextRef="C_8f070788-1b85-4e49-a494-ec7bbbbb19f8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bddb3b34-6a85-4acb-b78f-4f2ccd352734" contextRef="C_871f11a5-0df3-4821-9459-e430d23f2e22" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,407</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_986a83d7-f777-4197-ac11-38391551576a" contextRef="C_00c99cd4-9ed2-49c9-94cb-b920b598790f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,944</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e6d5dba-c387-4319-8679-046889420d4a" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,492</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd" xml:lang="en-US"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</span></p></ix:footnote>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.895%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.799%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.439%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.838%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.439%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.439%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.299%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.858%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="26" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in<br/>Capital*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders'<br/>Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff6663fb-f032-4018-bf72-cf68eb091678" contextRef="C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e73ef0d6-ff3a-4733-9224-45c5d4df0187" contextRef="C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481c1e2d-9068-4ae3-9ba7-c8d2ae60a338" contextRef="C_f507e9fa-1c64-4a5c-b79d-ad17dd341e37" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">196,287</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59ca71c2-b250-44d8-8b8a-4e88355311e3" contextRef="C_f507e9fa-1c64-4a5c-b79d-ad17dd341e37" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d411c7b8-b584-4e13-97b4-511b622f1b23" contextRef="C_56df2920-b057-4c20-af0b-3fb60d22d643" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,665</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a551830-ee16-47bf-9760-dd3edcc35254" contextRef="C_348f4f92-6daf-4dc1-aff7-04ba4780b100" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,190</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_364e98e2-a369-426d-8dfb-3c711eb6bc00" contextRef="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,479</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e459828-b84f-4fe4-acb4-e99c5fe2e7e5" contextRef="C_9ebb78c1-151a-4750-8ce8-05e1baf42364" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eea159b5-c530-4b11-93a2-2388e71563e6" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense and related charges</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2467db4a-5cce-40b8-8e36-9c08cd303c89" contextRef="C_ee931db3-063b-4b61-9205-fc476769857a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">624</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6b6ecdc-c50d-4252-b4a2-8da49d25460d" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">624</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebfb9068-25fc-4457-81e6-4ab7d1e6695f" contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,074</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d0c4430-3d06-42b8-b111-3e61fdac3cd0" contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68f6333-1c2a-4508-ada0-e03960169271" contextRef="C_ee931db3-063b-4b61-9205-fc476769857a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_949baaf0-2365-4cf3-9669-d14f9c7d34f9" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in connection with exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd270e0c-1614-4dab-8b8e-e5417adf32f7" contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6" name="pali:StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">146,932</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d939f84e-22a7-443b-8c7d-9877fdf3af00" contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6" name="pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65e1e41b-e592-45d0-9e65-6d7e4f5027a5" contextRef="C_ee931db3-063b-4b61-9205-fc476769857a" name="pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ca90bc-b6d0-4847-b5b5-a5ece0e77a2e" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,350</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and warrants in January 2023 Offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6df39e20-2e59-4ce5-9a84-0371ddda8d88" contextRef="C_07bbc911-5220-457e-b6ff-5ac9e1cf7eb7" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97d2faa5-3929-43e4-9b99-b2b09b8e728b" contextRef="C_07bbc911-5220-457e-b6ff-5ac9e1cf7eb7" name="pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">31,789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7228d524-4406-4b0c-8431-766f31a3570e" contextRef="C_06862901-f3a4-4bd2-bd72-90b6eae2c329" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c6210d1-c5c9-4266-bcab-a119e73787ea" contextRef="C_f73a25a6-b329-46fd-a117-c2bcc90c783a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,166</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and warrants in April 2023 Offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f42302e-15fc-4095-9d13-177e3f9c0216" contextRef="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">854</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_417255a2-0c2e-47c2-964a-37873d64eabb" contextRef="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447" name="pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">80,770</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f68d14e1-3be6-4e28-bab4-237421dd1b76" contextRef="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bce6c0dd-8418-4daf-adfd-5db44bf2a01a" contextRef="C_46b8f935-7e06-4909-98e0-8a09b69ca511" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8802d0e8-5f9f-4b98-8c5b-c997df350469" contextRef="C_6a4f9f7a-6ab6-414e-a396-2c7f3c0ae7ab" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,301</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock and warrants in September 2023 Offering, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f94206c8-b17a-4f57-abd2-3f8f1bb4cbfb" contextRef="C_25e9e99e-093d-49a0-982e-33f5812e37b8" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d8986ce-d38e-4bda-ab78-06023757e6ab" contextRef="C_25e9e99e-093d-49a0-982e-33f5812e37b8" name="pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">155,959</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7397b9f-06bf-42db-afdc-18d7fcca3a92" contextRef="C_25e9e99e-093d-49a0-982e-33f5812e37b8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c976ce42-1091-4cc0-944a-f361caf66be6" contextRef="C_f40fb1ae-32d9-4be3-b219-d5d71698de2b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,674</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55e5a70b-f665-410c-840d-98152958fefe" contextRef="C_a4cf7202-92fd-4462-bf25-87c0570b5099" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,676</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dee46229-4244-4ad9-b50c-f0b17e03436a" contextRef="C_ee931db3-063b-4b61-9205-fc476769857a" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ce8729d-b72a-4e6b-9d3f-32b7f104fc52" contextRef="C_9ebb78c1-151a-4750-8ce8-05e1baf42364" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3317ddf-3179-4840-bc94-8873d720e442" contextRef="C_51618521-fa5c-465f-afce-888db78121fc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_856b76a8-d2d5-4912-a4ac-444c7fe3a4ae" contextRef="C_51618521-fa5c-465f-afce-888db78121fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf86ad15-f481-43bc-95fd-ed93392090db" contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">618,056</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfea37a1-9005-48a7-8355-3aa202c9ac1b" contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fa2496c-4ca6-423d-a620-e2e7efcb12e5" contextRef="C_b4194f6e-7d8f-4de8-9fdb-21da6a505d2a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,811</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_310f5930-439d-438a-adea-b14f66456953" contextRef="C_5ad66f61-3eb3-4d36-903d-7bac0116fcc6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,506</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4431e4dd-eab6-41cd-b2f8-575c8c9b4675" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,313</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ts of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01f2b651-281f-452a-944a-7e1696672495" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdb419a7-4a85-42c1-b2db-e3cced07068d" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,300</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a86e5d59-1291-4def-8745-9500dda6b879" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a53ea558-17dc-4747-8de8-dc1a84b6ef19" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e148ffa-28f6-4171-82d8-21c2bc8cd694" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d315b20f-7893-4935-9867-1eaf69b1b1f2" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:NoncashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recurring fair value measurements of liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f92548c8-7de4-4e84-bb9b-6de33641d47a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:RecurringFairValueMeasurementsOfLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb14cbd3-f03f-4cae-bf89-55e846e499ac" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:RecurringFairValueMeasurementsOfLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock to vendors</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c8624d6-b40a-4095-9645-4f3dc8d618e2" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06d13e7a-cf42-4244-9788-03104e49e98f" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea30e00f-d0a2-409b-80bc-0f5329b827b0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:GainLossOnDispositionOfAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215e3df2-4415-4e30-9111-fdecd2e96bb2" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:GainLossOnDispositionOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation and related charges</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77088481-b723-4582-9a79-5e0ac377a8c0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">652</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9edd486d-26ff-425e-8661-369557ba953b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">624</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00ca5db8-8003-45db-b32b-c10bd7e001f6" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_785da57a-2985-474d-947b-96cb9063bc48" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets and other noncurrent assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57d2d8f7-e67b-4964-8ee2-e5cc65af1096" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">750</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_039e667d-a0e9-414c-a68e-5fdf1e758aec" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73dab088-f1a3-4491-bf82-5af4bcf024d7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">818</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_345a3549-b3f2-45ef-b180-6ce586864cf9" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">492</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41a5248d-35b5-40c5-837c-cd3784f17538" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e66d7bf-8b11-4155-b530-57bf4fa4730c" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc46a8e9-84cc-4af2-a116-d761490b5e2f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f80715c-a936-4646-902d-6089509c2349" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61db4d36-43de-48e7-8ee1-0a873ce1c1f1" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,193</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_116988a2-2a93-4931-8d2f-334af9f280cc" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,133</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bd3762f-038c-45f1-bd07-a2646e6db407" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4188521-b4c2-4d99-9389-4152443bfc1b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a12ee8c5-5afc-4687-89ce-d6fabb9b4d3c" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d5dc061-a33d-4714-be4c-acef58b59e1c" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on insurance financing debt</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc3d3ac5-79d7-48f4-887b-7d5f89e230fb" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">426</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cccc2507-ef63-45b1-b00f-ea56f35faf1f" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock and warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2aa03c7f-69c9-4241-99a5-2f1795805735" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d422fecd-cc79-4640-9876-f14d043605b2" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,419</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0f05dd0-9e74-48e3-a364-6971ed767476" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,506</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fc263b3-a537-4b2e-8cfe-41114ecd060b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,758</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of warrant inducement issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a598fe82-798a-486a-aaea-61bfecb4e4c8" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:PaymentOfWarrantInducementIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8b9447f-9564-4b4c-89e8-e0138a461554" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:PaymentOfWarrantInducementIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of equity issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beb13d2e-380a-42bd-88b2-076de2c64885" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">576</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c024f0d8-0760-4e20-9129-27f8527bbd0f" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d83d2b81-165e-46f1-8beb-e32b9b2861dd" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8400fbaa-f497-4b4d-ba68-3a1cbe855277" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares withheld for payment of employee withholding tax liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc864d6d-aa9b-4869-85e5-3743de7ccab1" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf23aa24-e000-465d-b0c2-dba656883ac4" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a13dbad-e01f-455f-bc90-4e473be0eba2" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,582</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdbc51da-ce5e-4d7d-8fe7-f44d465af567" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,186</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a795206c-261d-4a56-a1b6-01fbc7cc9cec" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,611</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92174de5-d9df-4879-9351-9b2f7e22e4d3" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b9cc41-c404-4757-9e03-c1827ab13895" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffbbb4e1-14e2-41ee-9848-ce087e8b1381" contextRef="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,409</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f504a6b3-2f08-4c9c-966e-22263271f064" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,847</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc40b64e-3958-4b60-b827-88eafcfd8214" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5fa7361-d788-4553-9eb3-f026f4680667" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,821</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83255ffd-1523-4324-ab84-007f7c258be2" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,432</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96dbe452-df01-4857-9db1-3fee8e16c92f" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ee585c6-0fa6-4961-b9be-cdf1eb8d9cf7" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42472918-b6c2-4437-b068-398fcae32c52" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,847</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa247662-0ad9-4395-946e-9f4e493f8501" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,458</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures of cash flow information:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest paid</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2931552-88af-4f60-a735-6e936e98f196" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59aa336b-a289-4d5e-a2a5-8c840a904c80" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures of non-cash investing and financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18ea44e6-6086-4429-95f7-ab3392abd485" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7814e577-677b-4669-a52d-2acf97342628" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash impact of exercise price reset on outstanding warrants related to down round provisions</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d0a7f5-de15-4d5e-bde1-6f24f4c0c578" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e58b69ba-fc8d-48d5-b965-e1ad7e6c84d7" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of warrants issued to solicitation agent</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69e96883-9dfc-4102-8e78-4ee3e62c740a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:FairValueOfWarrantsIssuedToSolicitationAgent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50faad6b-2c95-4bae-8102-cbd2e570e7b2" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:FairValueOfWarrantsIssuedToSolicitationAgent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of warrants issued to placement agents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7194a42d-ec72-4f31-b6ee-1fdc84aaed53" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:FairValueOfWarrantsIssuedToPlacementAgents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_190f985d-a438-4913-baa1-e7fa507237fe" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:FairValueOfWarrantsIssuedToPlacementAgents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of warrants issued to representatives of underwriter</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_825f5826-5f6f-42ae-843c-c0680bd47b80" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f588a02-692e-4c9f-82e2-47a5a0a01ae5" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3df2767b-bb0a-4cb7-9f69-6e505d24ec07" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74371af1-0552-462e-adb6-74bb52e8bfb0" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance financing debt included in prepaid and other current assets and other noncurrent assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae35c277-3afa-44a9-9f07-c80de39306f3" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">347</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7daa70c-5913-4043-a1ab-ecfe8435c83e" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incremental fair value of modified warrants (Note 5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee5d00fa-ae2a-4ede-b285-4fcbe0a37cd9" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:IncrementalFairValueOfModifiedOrExchangedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,237</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5385c097-2333-46ae-bf54-e0055ded5164" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:IncrementalFairValueOfModifiedOrExchangedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_financial_statements_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes To C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nsolidated Financial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbbf94d8-3733-47b4-bd0c-947b8bf9ffc8" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization and Business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the context indicates or otherwise requires, &#8220;Palisade,&#8221; &#8220;Palisade Bio,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; or similar designations in this Annual Report on Form 10-K refer to Palisade Bio, Inc., a Delaware Corporation, and its subsidiaries. Any reference to &#8220;common shares&#8221; or &#8220;common stock,&#8221; refers to the Company's $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ee55816-00b1-40ba-ac07-3e8cb06f08d5" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock. Any reference to &#8220;Leading Biosciences, Inc.&#8221; or &#8220;LBS&#8221; refers to the Company&#8217;s operations prior to the completion of its merger with Seneca Biopharma, Inc. ("Seneca") on April 27, 2021 (the "Merger"). Any reference herein that refers to preclinical studies also refers to nonclinical studies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company's lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease, or IBD, including ulcerative colitis and fibrostenotic Crohn's disease.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a limited operating history, and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operations since its inception. As of December 31, 2024, the Company had an accumulated deficit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0d6fba3-6082-4bd4-bf9c-1ab1600b2bd5" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">135.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash and cash equivalents of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91116e31-3797-4dbd-997d-78d85d7082b8" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company expects to continue to incur losses into the foreseeable future. The successful transition to achieving profitability is dependent upon achieving a level of revenues adequate to support the Company&#8217;s costs. There can be no assurances that such profitability will ever be achieved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Company&#8217;s current working capital, anticipated operating expenses, and anticipated net operating losses, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, the Company has funded its operations primarily through equity financings. The Company plans to continue to fund its operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. Refer to Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for discussion of the recent financings undertaken by the Company. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company is successful in raising additional capital, it may also be required to modify, delay or abandon some of its plans, which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div><ix:nonNumeric id="F_6698a66d-2631-43c4-8280-f133e07ae46a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_6698a66d-2631-43c4-8280-f133e07ae46a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Dollar amounts contained in these consolidated financial statements are in whole numbers, unless otherwise indicated.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_1" continuedAt="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6698a66d-2631-43c4-8280-f133e07ae46a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, LBS and Suzhou Neuralstem Biopharmaceutical Co., Ltd. All the entities are consolidated in the Company's consolidated financial statements and all intercompany activity and transactions, if any, have been eliminated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3677f763-9c47-46b8-85a5-182c2ffdcc06" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ReverseStockSplitPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 5, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cf82529-34d2-4e2a-8aa2-060c11dd5085" contextRef="C_4c38a0f6-0e17-4097-a741-e8528d218109" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1-for-15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> "Reverse Stock S</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plit"). As a result of the Reverse Stock Split, the Company&#8217;s stockholders received one share of common stock for every </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3756abdf-ed90-4227-bcf9-3acf649a7c2a" contextRef="C_4c38a0f6-0e17-4097-a741-e8528d218109" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#8217;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected the Company&#8217;s outstanding stock-based awards, common stock warrants, and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data and shares of common stock underlying convertible preferred stock, stock-based award and common stock warrants included in these consolidated financial statements, including the exercise price or conversion price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb76f54c-4753-48ab-ace9-51ae4e53d023" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f11979b-ce0c-4df5-a32d-e254785fb07f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" escape="true" continuedAt="F_2f11979b-ce0c-4df5-a32d-e254785fb07f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_2f11979b-ce0c-4df5-a32d-e254785fb07f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents represent cash in readily available checking and money market accounts. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d483bd0-1db9-47b3-be39-59654ea0685b" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company held restricted cash of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7edcbfd7-2994-4460-9d40-27891e1327e3" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_64cc3a5f-b350-466c-a136-3b01c711133f" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">26,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a separate restricted bank account as collateral for the Company&#8217;s corporate credit card program. The Company has classified these deposits as long-term restricted cash on its consolidated balance sheets.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_35f9c7eb-64f3-4766-9113-6b87461bf175" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true" continuedAt="F_35f9c7eb-64f3-4766-9113-6b87461bf175_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Equity Issuance Costs</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_35f9c7eb-64f3-4766-9113-6b87461bf175_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred equity issuance costs consist of the legal, accounting and other direct and incremental costs incurred by the Company related to its equity offerings, if not yet finalized as of the balance sheet date, or shelf registration statement. As of December 31, 2024 and December 31, 2023, deferred equity issuance costs of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5226bfe-79ea-4945-b6c0-3c20fc24fe2c" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredCostsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ac9bda9-682e-43fa-b712-6678c20e49ef" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredCostsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">112,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, were included in prepaid expenses and other current assets in the consolidated balance sheets. These costs will be netted against additional paid-in capital as a cost of the future equity issuances to which they relate. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company netted previously deferred equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73043d06-3cf2-4ef0-87c8-ae4b162d6065" contextRef="C_db7afb64-6e06-473b-8d9a-ceeac08c60c0" name="pali:DeferredEquityIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">37,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> against the additional paid-in capital recognized in conjunction with the February 2024 Warrant Inducement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company netted previously deferred equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc173782-ca93-446e-8d09-1db61c62ff7d" contextRef="C_ee931db3-063b-4b61-9205-fc476769857a" name="pali:DeferredEquityIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> associated with its shelf registration statement against the additional paid-in capital recognized in conjunction with the September 2023 Offering (see Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders' Equity)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_ace29a3d-98d4-40e6-8b32-c5b86dce2b81" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_ace29a3d-98d4-40e6-8b32-c5b86dce2b81_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_2" continuedAt="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ace29a3d-98d4-40e6-8b32-c5b86dce2b81_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accounts, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and historically the Company has not experienced any losses in such accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b1072f4-5340-47a0-9e6d-e0cc6a85588d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows Accounting Standards Codification ("ASC") 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.148%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further information on the fair value of the Company's financial assets and liabilities can be found at Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03f09fae-05f1-47e2-9a3c-9a51a9f54038" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:DerivativesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including common stock warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option pricing model or other acceptable valuation models, including the Monte-Carlo simulation model. Derivative instruments, if any, are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at the end of each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and common stock warrants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its common stock warrants in accordance with ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASC 480") and ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 815&#8221;). Based upon the provisions of ASC 480 and ASC 815, the Company accounts for common stock warrants as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement, or if it fails the equity classification criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified as equity. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at fair value at each balance sheet date with the offsetting adjustments recorded in change in fair value of warrant liability within the consolidated statements of operations. If the terms of a common stock warrant previously classified as a liability are amended and pursuant to such amendment meet the requirements to be classified as equity, the common stock warrants are reclassified to equity at the fair value on the date of the amendment and are not subsequently remeasured. Common stock warrants classified as equity are recorded on a relative fair value basis when they are issued with other equity-classified financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_3" continuedAt="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39a40624-decf-491b-939b-a983ac32be99" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_39a40624-decf-491b-939b-a983ac32be99_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_39a40624-decf-491b-939b-a983ac32be99_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company assesses contracts for lease arrangements at inception. Operating right-of-use (&#8220;ROU&#8221;) assets and liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit, if readily available, or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b47044a5-d5f3-4d6b-8381-5d699ce24981" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:RevenueRecognitionSoftware" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97727ae7-5bb0-4db6-8dba-0dcbc1816b5b" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ContingentConsiderationObligationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, the Company and Giiant Pharma, Inc. ("Giiant") entered into a research collaboration and license agreement (the &#8220;Giiant License Agreement&#8221;)(see Note 7, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborations and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation consisting of milestone payments, which are recognized as a liability measured at fair value, and ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses third parties of any products developed from the assets licensed under the Giiant License Agreement. Because the contingent consideration associated with the milestone payments may be settled in shares of the Company's common stock solely at the election of the Company, the Company has determined it should be accounted for under ASC 480 and accordingly the Company has recognized it as a liability measured at its estimated fair value. At the end of each reporting period, the Company re-measures the contingent consideration obligation to its estimated fair value and any resulting change is recognized in research and development expenses in the consolidated statements of operations. The Company has determined that the contingent consideration associated with the royalty payments should be recognized as a liability when they are probable and estimable, in accordance with ASC 450, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_0e0e9d33-bd74-4cfa-9bbc-01a4b9ab9c09" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_0e0e9d33-bd74-4cfa-9bbc-01a4b9ab9c09_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of salaries and other personnel related expenses including stock-based compensation costs, and, to the extent applicable, may include preclinical costs, clinical trial costs, costs related to acquiring and manufacturing clinical trial materials, and contract services. All research and development costs are expensed as incurred pursuant to ASC 730, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pursuant to situations whereby the Company performs any research and development or manufacturing activities under a co-development agreement, and the co-development partner is not considered a customer under ASC 606, the Company records the expense reimbursements from the co-development partner as a reduction to research and development expense once the reimbursement amount is approved for payment by the co-development partner. Expense payments made to Giiant pursuant to the terms of the Giiant License Agreement for qualifying development costs are expensed only as the associated research and development costs are incurred or other aspects of the drug development or related activities are achieved. In instances where the expense determined to be recognized exceeds the payments made to the Giiant, the Company recognizes an accrual of joint development expenses. In addition, there may be instances in which payments made to Giiant will temporarily exceed the level of services provided, which results in a prepayment of the joint development expenses. The Company records expense payments from Giiant, if any, as a reduction to research and development expense once the expense payments are realized or realizable, which is when Company receives the cash or has an undisputed claim to the cash that is probable of collection, pursuant to the terms of the Giiant License</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_4" continuedAt="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0e0e9d33-bd74-4cfa-9bbc-01a4b9ab9c09_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement and the principles of ASC 450, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 450"). The Company has determined that Giiant is not considered a customer under ASC 606.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_050646f3-bbfd-40ba-a160-f5c2cdd6f912" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClinicalTrialExpensesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses related to clinical studies are based on estimates of the services received and efforts expended pursuant to the Company&#8217;s contract arrangements. The financial terms of these contract arrangements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients, site initiation and the completion of clinical milestones. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense balance accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accrues for clinical trial expenses for which the estimated services have been provided but the Company has not yet been invoiced as of the balance sheet date. There may be instances in which payments made to the Company&#8217;s service providers will temporarily exceed the level of services provided and result in a prepayment of the clinical trial expenses. Clinical trial expenses are included in research and development expenses in the consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a190c39-95dc-4683-943d-8d3a47f4f3cb" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 740&#8221;) in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some of or all the deferred tax assets will not be realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e6fdc468-635f-4b33-ba2c-ba53a384e3db" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_e6fdc468-635f-4b33-ba2c-ba53a384e3db_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s stock-based compensation generally includes service-based restricted stock units (&#8220;RSUs&#8221;), stock options, and market-based performance RSUs (&#8220;PSUs&#8221;). The Company accounts for forfeitures as they occur for each type of award as a reduction of expense. Stock-based compensation expense related to service-based RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period, which is usually the vesting period. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model. The determination of the fair value of stock-based payment awards on the date of grant using the Black-Scholes option pricing model is affected by the Company's stock price as well as assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate, and expected dividends over the expected term of the award. Stock-based compensation expense represents the cost of the estimated grant date fair value of employee and non-employee stock option grants recognized ratably over the requisite service period of the awards, which is usually the vesting period. For PSUs with vesting subject to market conditions, the fair value of the award is determined at grant date using the Monte Carlo simulation model, and expense is recognized ratably over the derived service period regardless of whether the market condition is satisfied. The Monte Carlo simulation model considers a variety of potential future scenarios under the market condition vesting criteria, including but not limited to share prices for the Company and its peer companies in a selected market index.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not recognize any share-based compensation expense related to conditional RSUs, stock options, or PSUs that are subject to shareholder approval. When and if approval is obtained, the Company recognizes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e6fdc468-635f-4b33-ba2c-ba53a384e3db_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share-based compensation expense related to the conditional equity grants ratably to the vesting of shares over the remaining requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company offers to its employees an opportunity to participate in its shareholder approved Palisade Bio, Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP"). The Company estimates the fair value of 2021 ESPP awards on the first day of the offering period using the Black-Scholes option pricing model. The estimated fair value of 2021 ESPP awards is amortized on a straight-line basis over the requisite service period of the award. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of 2021 ESPP awards.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c649637f-752d-41a7-88e4-a1b6ea796146" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for all years presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60c29014-c74e-428b-983b-c1fdda2fb97b" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ("ASU 2023-07"), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The disclosure requirements included in ASU No. 2023-07 are required for all public entities, including those with a single reportable segment. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 31, 2024 on a retrospective basis, with early adoption permitted. The Company adopted ASU 2023-07 in the fourth quarter of 2024. The adoption of this guidance resulted in additional financial statement disclosures and had no impact on the Company's results of operations and financial condition. See Note 12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for disclosures resulting from the adoption of ASU 2023-07.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 720): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASU 2023-09"), which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASC 2023-09 on its consolidated financial statement disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASU 2024-03"), which is intended to improve disclosures about a public business entity&#8217;s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_2b476b0d-456f-4d9c-8283-d0bb0a3070a6" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Balance Sheet Details</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_4e12c78f-02f4-4adc-85d4-8be0f7339ae5" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c07addaa-9901-4f63-8c17-0a032d847922" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46de5fd3-fada-4bb2-8dcd-e6ce184bd4ad" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e248cd60-35ed-4545-84fb-95c8a74a6759" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cfcde5a-ec90-459b-a8a4-d8153297665c" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid subscriptions and fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee6c4033-7231-47c7-8916-1c0feb5f5d95" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:PrepaidSubscriptionsAndFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58153d06-d010-4a8d-8744-7e355e5850d3" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:PrepaidSubscriptionsAndFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid software licenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e4189a-2232-419f-8fc7-161f5e7793d0" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:PrepaidSoftwareLicenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f45d53b-0d94-4de0-a4bb-fbc35ed2ebba" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:PrepaidSoftwareLicenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8296eba2-fd91-4f5c-8bd4-19c0a272c21c" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DepositAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40272a8a-620c-49bf-b5be-bdb14d72d75b" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DepositAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred equity issuance costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8e80e18-aebc-49d3-9f88-f284868f2a04" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredFinanceCostsCurrentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a72a7846-ef68-40ba-a74f-83f02c76c9a5" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredFinanceCostsCurrentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bde7cfba-3042-48e3-babf-c107fd884f1a" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fa76709-b1d7-4e36-9253-b33014668136" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1ae7f5a-6996-4162-8df1-ce134687ece1" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">673</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0acbe27e-5b05-4dba-81aa-1903108f030f" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">896</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_c7d639b9-0466-4e1a-86ca-ad65c11e55a3" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other noncurrent assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance, less current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5043290-5896-4325-a454-6febe2dd424b" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7565576-2d35-48c6-97b0-f2fe2237be03" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">478</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other noncurrent assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f509dc2-834f-4ebc-86f4-d4024935d092" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:OtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f523ca8-c9b5-4012-a21f-6b9fcc251776" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:OtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5af0f01c-628c-468b-aacb-88afdc343a1e" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_507496f5-0a33-49f2-a11d-343105203fdc" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_2382cbcc-b063-4432-b181-9a9eb6155650" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_2382cbcc-b063-4432-b181-9a9eb6155650_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued accounts payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4499a250-8814-4ab3-9c7c-95d2a9b58867" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:AccruedAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_902db2fa-c39c-4b42-8d22-73db71e7e6c6" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:AccruedAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd8abcf-dba6-4fe4-b08b-9ef0b459a951" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:AccruedClinicalTrialCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdab3b25-34f7-46f7-a144-39bef40b487a" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:AccruedClinicalTrialCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued chemistry, manufacturing and controls ("CMC") expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0adcc0e9-2f5e-4f0f-a94f-a1a3d649a8c0" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:AccruedCMCExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5adcfbaa-4700-4349-b1bc-9d219f0f4e96" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:AccruedCMCExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued director stipends</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc8e04fa-4662-4dec-bccf-91af38273362" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:AccruedDirectorStipends" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_befba055-eab4-4c0e-a86f-5386f6e660e8" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:AccruedDirectorStipends" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued severance and benefits (Note 8)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa763c77-69d9-4e60-8612-2f66d382bc61" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_190d6314-da91-4b1e-9502-5b882063d69c" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued joint development expenses (Note 7)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a60b336e-f894-4a5a-b990-ea8fb92e9c02" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:AccruedJointDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_813ef374-5681-4331-9a29-c1d492497596" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:AccruedJointDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of contingent consideration obligation (Note 4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dc03c6f-0a5e-4df7-a62c-6a27c88c726c" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7c01244-d349-438f-94a9-741d850ee1db" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f9bb2c-fe73-4b4b-b1c7-e72310c19ec1" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_894bcec4-4235-4031-8103-e4b31c81c715" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60a65301-1df7-4588-bcd0-d9e8f5759a3d" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,240</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8256b7f7-a91b-416b-8fb8-779f33332502" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_2382cbcc-b063-4432-b181-9a9eb6155650_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_d24532b7-a57b-4c1b-8bc9-e8f0aeab3fff" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_d24532b7-a57b-4c1b-8bc9-e8f0aeab3fff_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments consist principally of cash and cash equivalents, restricted cash, other current receivables, accounts payable, accrued liabilities, insurance financing debt, liability-classified warrants and a contingent consideration obligation. The carrying amounts of financial instruments such as restricted cash, other current receivables, accounts payable, and accrued liabilities approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s insurance financing debt approximates its fair value as of December 31, 2024 and December 31, 2023 due to the market rate of interest, which is based on level 2 inputs. The Company&#8217;s liability-classified warrants and its contingent consideration obligation are carried at fair value based on level 3 inputs. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a nonrecurring basis.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_d24532b7-a57b-4c1b-8bc9-e8f0aeab3fff_1" continuedAt="F_d24532b7-a57b-4c1b-8bc9-e8f0aeab3fff_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash in money market funds that are classified as level 1 in the fair value hierarchy due to their short-term maturity, and measured the fair value based on quoted prices in active markets for identical assets. The fair value of the Company's cash and cash equivalents invested in money market funds was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f94bb1c9-5cdd-4656-88f1-15cbf13ffda4" contextRef="C_9360a9a6-4319-458b-a705-b8de13df423c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52610c4d-fdb9-4c6b-9e94-1baa1c55c7be" contextRef="C_4a7340ec-c1ef-4e8f-b685-40b983c0d414" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation related to future milestone payments. The Company has an obligation to make contingent consideration payments to Giiant, in either cash or shares of the Company&#8217;s common stock solely at the Company&#8217;s election, upon the achievement of development milestones. On August 2, 2024, the Company and Giiant entered into an amendment to the Giiant License Agreement, which among other things, reduced the milestone payments due to Giiant upon the achievement of certain development milestones (see Note 7, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborations and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for further details).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the contingent consideration obligation is determined using a probability-based model that estimates the likelihood of success in achieving each of the defined milestones that is then discounted to present value using the Company's incremental borrowing rate. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The significant assumptions used in the calculation of the fair value as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included a discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_191866bb-3b9b-47ff-9c0c-5bc3ebcf9c0c" contextRef="C_070fbbd6-0133-4fd9-a92e-3a59027648e0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.29</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and management's updated projections of the likelihood of success in achieving each of the defined milestones based on empirical, published industry data.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0484eb84-6846-4b71-9a24-e91d63412b96" contextRef="C_671d8ff9-d06e-44e8-8753-0d285732a4c2" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">summarizes the activity of the Company&#8217;s Level 3 contingent consideration obligations, which are fair valued on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_083d5bbc-e9b1-48ba-adc8-1fbc42cb8b1c" contextRef="C_e7194555-4ab8-40fd-b397-92bd0b1f7bb9" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf521a29-2177-4263-87b3-07fd56c2cca0" contextRef="C_4f54001b-6421-4019-8e41-db056882bcd4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial fair value at the original issuance date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e21bbe46-29af-412f-874a-b5e242fd6cf3" contextRef="C_671d8ff9-d06e-44e8-8753-0d285732a4c2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64967128-e6aa-4a46-92f4-8e85e5393a6f" contextRef="C_7d3732a3-912c-4fce-90de-1cf88fb0bb7c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b81a96b9-98d1-4e97-b424-68267bbbff2c" contextRef="C_671d8ff9-d06e-44e8-8753-0d285732a4c2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d74bc72-7cb4-41ce-a11b-88d9c2e02b75" contextRef="C_7d3732a3-912c-4fce-90de-1cf88fb0bb7c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3babe8c2-4288-4ac0-9c4c-65c43ebb7c3b" contextRef="C_e5488fc7-f4ab-4fdb-a268-96c258ed7b00" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4170d778-5f12-4776-940d-cfb07c412b9d" contextRef="C_e7194555-4ab8-40fd-b397-92bd0b1f7bb9" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the entire amount of contingent consideration obligation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cdab90e-922c-4f96-a4fe-584be9823f48" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was classified as a noncurrent liability in the consolidated balance sheet as none of it is expected to be settled within one-year of the balance sheet date. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0b5fd5c-3979-435e-ac3b-a4d0da1cd951" contextRef="C_01126dbc-d04a-4b1c-9f6b-d2a1bf5c9e96" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">143,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the contingent consideration obligation was classified in accrued liabilities in the consolidated balance sheets as it was expected to be settled within one-year of the balance sheet date and the remaining obligation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca4965dc-0b2a-43d7-91b8-2eeba5d9120c" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was classified as a noncurrent liability in the consolidated balance sheet.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in the fair value of the contingent consideration obligation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0deee5a4-ee11-4945-822e-2130579d67a0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ChangesInFairValueOfContingentConsideration" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">54,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was primarily due to the reduction in the milestone payments that would be due to Giiant upon the achievement of certain development milestones pursuant to the amendment to the Giiant License Agreement, partially offset by an increase in management's projected likelihood of success in achieving each of the defined milestones as a result of the Company's commencement of a Phase 1 trial in November of 2024. The change in the revaluation of the liability in the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is recognized in research and development expenses in the consolidated statements of operations. In addition, the initial fair value of the contingent consideration obligation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_504e3831-68a0-48b5-a050-e568bc9534f1" contextRef="C_0ac0e42c-71fc-4569-afd4-fccf25d6e52e" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and transaction-related costs of approxi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88f535f6-91ce-4b9e-bea4-a37955050411" contextRef="C_0ac0e42c-71fc-4569-afd4-fccf25d6e52e" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the year ended December 31, 2023 is recognized in research and development expenses in the consolidated statements of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liability-Classified Warrants</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has issued warrants that are accounted for as liabilities based upon the guidance of with ASC 480 and ASC 815. Estimating fair values of liability-classified financial instruments requires the development of estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d24532b7-a57b-4c1b-8bc9-e8f0aeab3fff_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">factors. Changes in fair value of the liability-classified warrants are recognized as a component of other income, net in the consolidated statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the fair value of the Company's liability-classified warrants outstanding was determined using a Black-Scholes option pricing model valuation model to be insignificant due to the low market price of the Company's stock at the date of valuation relative to the exercise price of the underlying warrants outstanding.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e8a53f2-7acc-41ad-bc05-da13cce0a819" contextRef="C_f3aab31d-1085-44a6-848c-14e1390b99a0" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity of the Company&#8217;s Level 3 liability-classified warrants during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.093%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.903%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.763%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_159087a5-f387-4827-8996-5ea92f60256a" contextRef="C_1b2b7036-6d4a-4dda-b9b5-3fef242b5750" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ced32ea-bb7d-4f90-8df8-d5416b574049" contextRef="C_f4816ad5-6544-4cc3-8edc-993c725f05ae" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9ed4c70-8a90-4d17-9146-43ebd9f94319" contextRef="C_feec2dcc-5780-4073-a999-74c92a2f28c7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d131b78-46ae-413d-acaf-b94b40065832" contextRef="C_790040b9-b57e-4116-8804-a4572f9ba17c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32916db6-0ecb-4b86-ab4d-58ff95ac3416" contextRef="C_9f691187-dbba-46aa-957f-8451263e8080" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9163f382-fc85-40f2-8e1e-aef2f6a8b954" contextRef="C_1b2b7036-6d4a-4dda-b9b5-3fef242b5750" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Classes of Stock</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company was authorized to issue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59519464-92fc-4892-8f05-4cf71d1c707e" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">280,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ae5201a-e226-4703-bc50-132111b6cccc" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock. Each share of common stock entitles the holder thereof to one vote on each matter submitted to a vote at a meeting of stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 5, 2024, the Company effected the Reverse Stock Split. Accordingly, the Company&#8217;s stockholders received one share of the Company's common stock for every </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_addcf986-1b62-43d8-8e3f-b45cee5468ba" contextRef="C_e786d4a3-2e6a-4337-8144-697692254d24" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock that each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all of the Company&#8217;s issued and outstanding shares of the Company's common stock equally. The Reverse Stock Split also affected the Company&#8217;s outstanding stock-based awards, warrants and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately by the Reverse Stock Split ratio. No fractional shares were issued as a result of the Reverse Stock Split with any fractional shares that would have otherwise resulted from the Reverse Stock Split paid in cash, at an amount equal to the resulting fractional interest in one share of the Company's common stock that the stockholder would otherwise be entitled, multiplied by the closing trading price of the Company's common stock on April 5, 2024. The amount of cash paid for fractional shares was immaterial to the Company's financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Reverse Stock Split, on April 5, 2024 the number of issued and outstanding shares of the Company's common stock was adjusted from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e9edd90-0835-4974-80a1-e80ec5db5112" contextRef="C_d5ec44e5-acfe-425d-94c1-cba3b6c5a935" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,771,015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e52580a-4297-4af7-9131-442e3a8dde27" contextRef="C_795c51ad-a42a-4991-8de6-80e768ef9af0" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">851,302</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company was authorized to issue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2b7a7f2-5d47-42bc-8eed-ab0081d85cee" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_521e4455-2234-4d69-8fb7-f17ba7c28c6c" contextRef="C_53120144-37f7-483b-a872-d0f02ddccfbf" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value preferred stock of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8882c8ce-3562-4162-b026-dd365ae0a229" contextRef="C_53120144-37f7-483b-a872-d0f02ddccfbf" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been designated as Series A 4.5% Convertible Preferred Stock ("Series A Convertible Preferred Stock") and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26246b3a-a5e0-4adb-97d0-222610ecae88" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_13197b82-1763-4f3c-a811-a83cc0716c0d" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which are issued and outstanding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company's Series A Convertible Preferred Stock issued in the amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d350595-bd04-4603-b351-493804b81ffe" contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> preferred stock shares is convertible into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b7ce4b0-108d-426e-ae69-6d51c5a14fc6" contextRef="C_53120144-37f7-483b-a872-d0f02ddccfbf" name="pali:ConvertiblePreferredStockIssuableUponConversionOfAllShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Equity Offerings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">December 2024 Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) pursuant to which the Company agreed to issue and sell, in an underwritten public offering by the Company (the &#8220;December 2024 Offering&#8221;), (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95aaad5e-ce2d-4608-9a05-942afa1b7444" contextRef="C_99e41a4e-a74b-43bc-991a-d6f51c9aeaa2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">158,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class A Units at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eac46836-476a-4669-bad9-5acaf53182d6" contextRef="C_73bb4959-69c7-4db1-8a36-8a4200ea4201" name="pali:UnderwritingCommitmentsPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">1.525</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Class A Unit (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_1" continuedAt="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Class </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Units&#8221;), with each Class A Unit consisting of (i) one share of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d5f012-da94-42e8-b7aa-ddbb416659b0" contextRef="C_73bb4959-69c7-4db1-8a36-8a4200ea4201" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and (ii) one warrant to purchase one share of the Company's common stock at an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_633a99bc-1f63-48cc-a105-c9d561d79123" contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad84bb19-e661-461d-9cfa-131d4f76dd2c" contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;December 2024 Offering Common Stock Warrant&#8221;) and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f55af14e-93ad-4678-81eb-f5cb76b0be85" contextRef="C_e55e3216-27d9-421d-a685-8982258e7fbb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,120,688</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class B Units at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09c008b8-c6fc-414f-bd3c-4557146c9ac0" contextRef="C_a6268737-830c-4d22-b51b-e3c071317b8f" name="pali:UnderwritingCommitmentsPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">1.5249</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Class B Unit (the &#8220;Class B Units&#8221;, and collectively with the Class A Units, the &#8220;Units&#8221;), with each Class B Unit consisting of (i) one pre-funded warrant to purchase one share of the Company's common stock </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being immediately exercisable, having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48b79baf-c14d-49e9-b613-772030e39969" contextRef="C_0cf6a60b-d394-429d-82ae-cbe7825fb226" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a perpetual term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;December 2024 Offering Pre-funded Common Stock Warrant&#8221;) and (ii) one December 2024 Offering Common Stock Warrant. In addition, pursuant to the Underwriting Agreement, the Company granted the sole underwriter a 45-day option (the &#8220;Overallotment Option&#8221;) to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24bcd83e-ec20-4085-8bb9-2d8bacbd925d" contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc" name="us-gaap:OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">491,803</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares of the Company's common stock and/or December 2024 Offering Common Stock Warrants. The Overallotment Option expired and was not exercised by the underwriter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued warrants to representatives of the sole underwriter in the December 2024 Offering to purchase an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eee3af78-242a-40ca-88ec-129453860c6e" contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">196,721</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;December 2024 Representative Warrants&#8221;). The December 2024 Representative Warrants have substantially the same terms as the December 2024 Offering Common Stock Warrants, except that the exercise price of each of the December 2024 Representative Warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32f11677-b86f-4d7c-b31f-a8f1ecc4bb45" contextRef="C_bd03d751-b219-4043-84ae-de9c81d5698b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:num-dot-decimal">2.51625</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The fair value of the December 2024 Offering Common Stock Warrants was recognized by the Company as an equity issuance cost which reduced the additional paid-in capital recognized from the December 2024 Offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The December 2024 Offering closed on December 13, 2024 for net cash proceeds to the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df619007-3097-47fe-b517-7081145e5f58" contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c" name="pali:NetProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, consisting of gross cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_627dcbd8-2148-478e-a6da-2c7f459e8b03" contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million less cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88526896-564d-47aa-8958-1c99632cf508" contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which excludes the grant date fair value of the December 2024 Representative Warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0575f091-de41-44bc-acba-e5f5c565853e" contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c" name="pali:GrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the incremental fair value of the Repriced Warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6ee885b-bcd9-4da6-9a53-6ae957346a92" contextRef="C_3ec4089f-24f1-40c5-a1ee-41580353eddb" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, described below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company entered into a warrant amendment agreement (the &#8220;Warrant Amendment Agreement&#8221;) whereby the Company, contemporaneously with and contingent with the closing of the December 2024 Offering, reduced the exercise price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af9763e3-bf9a-4b6a-a63c-6e41fa0166cb" contextRef="C_12a10425-82c0-439c-a876-125097f2fbf7" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,040,217</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding common stock warrants (the &#8220;Repriced Warrants&#8221;) held by an investor that participated in the December 2024 Offering which expire between July 31, 2027 and May 6, 2031. The Repriced Warrants had their exercise price reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ffc1606-fe43-4a6e-8005-3db960a76caa" contextRef="C_12a10425-82c0-439c-a876-125097f2fbf7" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Other than the reduction in exercise price, the terms of the Repriced Warrants remain the same and unchanged.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrant Amendment Agreement is considered a modification of the Repriced Warrants under the guidance of ASC 815-40. The modification is consistent with the Equity Issuance classification under that guidance as the reason for the Company's repricing of the warrants was to meet a condition of the holder's participation in the December 2024 Offering, which raised equity capital and generated gross cash proceeds for the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2668e041-3139-4854-a9da-4db3dff9f298" contextRef="C_dca63de9-3d4a-4b50-a74f-1090217fcb16" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As pursuant to the guidance of ASC 480 and ASC 815 the Repriced Warrants were classified as equity instruments before and after the modification, and as the modification is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2026b67d-9267-4adc-b25b-5df3b43b8933" contextRef="C_dca63de9-3d4a-4b50-a74f-1090217fcb16" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as an equity issuance cost netted against the additional paid-in capital recognized in the December 2024 Offering. The amount of the equity issuance cost recognized for the modification of the Repriced Warrants was determined using the Black-Scholes option pricing model as the incremental fair value of the Repriced Warrants as compared to the fair value of the warrants immediately prior to their modification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May 2024 Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 1, 2024, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company sold in a private placement, (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94cb2b5c-d0c8-4ed4-aeec-26a651cd683d" contextRef="C_b74d1b57-b99f-46a7-91d3-48efac8c1858" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a purchase price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d35e12af-b6d0-4c10-abc1-634eee5c51d4" contextRef="C_bd447e9d-307f-412a-8859-7e1a2091a009" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">6.5015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ba99dab-c6f1-46f0-a15e-eb43202c17c1" contextRef="C_70ce8c11-9f45-440b-9b1d-6046060ca1af" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">530,142</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants to purchase shares common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86dbef33-94d6-4b70-a1c2-675659a5c911" contextRef="C_70ce8c11-9f45-440b-9b1d-6046060ca1af" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" scale="0" decimals="4" format="ixt:num-dot-decimal">6.5014</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, with such pre-funded warrants being immediately exercisable, having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fd6f657-3fae-4995-ba77-46fbdf311d46" contextRef="C_70ce8c11-9f45-440b-9b1d-6046060ca1af" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a perpetual term, and (iii) common stock warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d754505-6049-4739-ba2d-11cc6bab7901" contextRef="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">922,863</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddca2c95-a231-405f-8b4d-7d5bbbf90456" contextRef="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">6.314</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ecc043f-21a6-4d4d-b4f7-39dbc629c3a8" contextRef="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance (the "May 2024 Warrants") (collectively, the &#8220;May 2024 Offering&#8221;).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued warrants to the placement agent in the May 2024 Offering to purchase an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1002229d-fa7b-4b1d-bcc6-331f4ead75ed" contextRef="C_6ffb0979-629b-4688-a29a-73f1f89ce426" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">36,914</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;May 2024 Placement Agent Warrants&#8221;). The May 2024 Placement Agent Warrants have substantially the same terms as the May 2024 Warrants, except that the exercise price of each of the May 2024 Placement Agent Warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5515117b-42bf-4092-8ce2-02f3e2781d26" contextRef="C_6ffb0979-629b-4688-a29a-73f1f89ce426" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">10.727</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the term is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe08b489-48e6-4a59-aef8-14c99e9f7407" contextRef="C_6ffb0979-629b-4688-a29a-73f1f89ce426" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from issuance. The fair value of the May 2024 Placement Agent Warrants was recognized by the Company as an equity issuance cost which reduced the additional paid-in capital recognized from the May 2024 Offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_2" continuedAt="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The May 2024 Offering closed on May 6, 2024 for net cash proceeds to the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0257e0ed-65ec-49f2-bed1-699243310fe0" contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7" name="pali:NetProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, consisting of gross cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a73486e-801d-4d1c-9a99-9f657f496212" contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million less cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56a133fe-9756-48ce-80c0-4e7fb5ee7363" contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which excludes the grant date fair value of the May 2024 Placement Agent Warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f36e300b-cab6-4725-ac1b-5dda33f3fc6d" contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7" name="pali:GrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Recent Equity Offerings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 11, 2023, the Company completed a registered direct offering of common stock (the "September 2023 Offering"). Gross cash proceeds from the September 2023 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84df41a9-8a51-42b0-8832-f9b72e56846c" contextRef="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and net cash proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd559c8-a862-4289-93fe-a0755a339936" contextRef="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316" name="pali:NetProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_271f3b0d-e609-4abd-a265-8fdaf7bfabb2" contextRef="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 3, 2023, the Company completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "April 2023 Offering"). Gross cash proceeds from the April 2023 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a31780ec-e11a-4018-9532-7c861c480c4b" contextRef="C_b957477c-5568-4340-967f-f75d2478e99a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and net cash proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1c19ae0-7535-4ced-9e86-434ac1f9f634" contextRef="C_b957477c-5568-4340-967f-f75d2478e99a" name="pali:NetProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acf35c24-c5ee-4488-98e1-06f5a514b63c" contextRef="C_b957477c-5568-4340-967f-f75d2478e99a" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 4, 2023, the Company completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "January 2023 Offering"). Gross cash proceeds from the January 2023 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d399a4f0-0dec-4b97-9387-95cfe2a6d08e" contextRef="C_989d323e-90bd-4bc1-84ab-7e972e39245f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and net cash proceeds were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c96e0fb-2e34-445c-aa5b-b94b0994a65f" contextRef="C_989d323e-90bd-4bc1-84ab-7e972e39245f" name="pali:NetProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea1a0a05-afea-41ca-b705-a932e2da310c" contextRef="C_989d323e-90bd-4bc1-84ab-7e972e39245f" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Warrants and Warrant Exercises</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">February 2024 Warrant Inducement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 30, 2024, the Company entered into warrant inducement agreements (the &#8220;Warrant Inducement Agreements&#8221;) with certain accredited and institutional holders (collectively, the &#8220;Warrant Holders&#8221;) of certain of the Company&#8217;s remaining outstanding common stock warrants issued on May 10, 2022 (the "May 2022 Warrants"), January 4, 2023 (the &#8220;January 2023 Warrants&#8221;), and April 5, 2023 (the &#8220;April 2023 Warrants&#8221;), as well as certain outstanding Series 2 warrants issued on August 16, 2022 (the "Series 2 Warrants") (collectively, the &#8220;Existing Warrant(s)&#8221;). Pursuant to the Warrant Inducement Agreements, the exercise price of each of the Existing Warrants exercised was reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7aaa184-c4e2-40fd-b8b0-952525464c73" contextRef="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.97</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Each of the Warrant Holders that exercised its Existing Warrants pursuant to the Warrant Inducement Agreements, received one replacement warrant to purchase one share of the Company's common stock (the &#8220;Replacement Warrants&#8221;) for each Existing Warrant exercised (in its entirety, the "February 2024 Warrant Inducement").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Replacement Warrants are exercisable immediately, have an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb1864cf-6166-44ba-830d-25e5699854d4" contextRef="C_73c82250-26a7-4e8c-bbde-5150f68a53ca" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.97</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bd635da-391d-444b-a3dd-17e9710d2f97" contextRef="C_73c82250-26a7-4e8c-bbde-5150f68a53ca" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance, which was February 1, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrant Holders collectively exercised an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8940bc5b-418e-4c58-8ed4-b8a2cde35bbd" contextRef="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">228,162</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Existing Warrants consisting of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3828a93-9fca-448f-b929-ef2d7663d749" contextRef="C_d8e2d363-b0b1-4013-b25f-43acf427f165" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,865</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> May 2022 Warrants, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94867da9-80f1-47a1-8b77-37b6cca61f81" contextRef="C_f15cfeb5-6c1f-45a8-9c16-b9c0acc83ad6" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,267</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 2 Warrants, (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0faf7322-b831-4523-acb4-b884d5666607" contextRef="C_96ce46ae-4e1d-4e12-9e91-5be0b6992fac" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">67,511</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> January 2023 Warrants, and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18c6df85-9eb0-46fa-a37b-22e59cf0aa74" contextRef="C_691877b9-f2f5-489e-a81b-02e81e212a3a" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">151,519</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> April 2023 Warrants. As a result of the exercises of the Existing Warrants, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8b13515-fede-4a91-b21c-a87ac6e6176a" contextRef="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">228,162</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b6dfeb1-3aca-42c7-9139-c7f8dbad6988" contextRef="C_5b7ce63d-492e-48d6-b155-482c37907109" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">228,162</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Replacement Warrants. The February 2024 Warrant Inducement closed on February 1, 2024 with the Company receiving net cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e45e5f54-6db2-4e82-970e-5e04f5ad6624" contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe" name="pali:NetProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million consisting of gross cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_439f37e3-c375-4b7c-8101-7ecd290803c5" contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_222827bc-bf27-457d-86ca-94e9f7d7e0c3" contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe" name="pali:CashTransactionRelatedExpensesAndPlacementAgentFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The February 2024 Warrant Inducement, which resulted in the lowering of the exercise price of the Existing Warrants and the issuance of the Replacement Warrants, is considered a modification of the Existing Warrants under the guidance of ASC 815-40. The modification is consistent with the Equity Issuance classification under that guidance as the reason for the modification was to induce the holders of the Existing Warrants to cash exercise their Existing Warrants, resulting in the imminent exercise of the Existing Warrants, which raised equity capital and generated gross cash proceeds for the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac34b450-0544-428e-b02c-cf1c2279e437" contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As pursuant to the guidance of ASC 480 and ASC 815 the Existing Warrants and Replacement Warrants were classified as equity instruments before and after the modification, and as the modification is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b69d22-57d8-4546-9ac4-45fd5c7a4d16" contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as an equity issuance cost netted against the additional paid-in capital recognized from the associated warrant exercises. The amount of the equity issuance cost recognized for the warrant modification was determined using the Black-Scholes option pricing model as the incremental fair value of the modified Existing Warrants and additional Replacement Warrants issued as compared to the fair value of the original Existing Warrants immediately prior to their modification.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_3" continuedAt="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_4"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The solicitation agent fees associated with the February 2024 Warrant Inducement consisted of: (i) a cash fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_160aca49-3ee4-41bd-ad53-4a2e100282b8" contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368" name="pali:PercentageOfGrossProceeds" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds received by the Company, (ii) a common stock purchase warrant to purchase such number of shares of common stock equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1a6a76d-309d-4176-880f-d75e85ca01c4" contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368" name="pali:PercentageOfShareIssued" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number shares issued pursuant to the exercise of the Existing Warrants, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e17f7f-ab62-4946-91c6-ab2f7bc07d7a" contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.97</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a238553-7104-4bdd-aa52-0e9ac15f4e45" contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from issuance (the "Solicitation Agent Warrants"), and (iii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f037a281-113f-4ae9-848f-c61be9abd05a" contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368" name="pali:OutOfPocketExpenses" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of out-of-pocket expenses. The fair value of the Solicitation Agent Warrants was recognized by the Company as an equity issuance cost, which reduced the additional paid-in capital recognized from the issuance of common stock in connection with the exercise of the Existing Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total equity issuance costs recognized in the February 2024 Warrant Inducement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c56ffc7c-0267-4ca2-9fcc-b2cc9e2fd58e" contextRef="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4" name="pali:WarrantsIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million include cash equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dab8dcd-6265-4311-b329-97a837b0c629" contextRef="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, non-cash warrant modification costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fe505ea-7339-4817-99f0-35e53d84b273" contextRef="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4" name="pali:NonCashWarrantModificationCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and non-cash issuance costs associated with the Solicitation Agent Warrants of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3054accd-27f5-48bf-a46f-12504eb2fd5a" contextRef="C_bb50a5e7-6ed1-4053-bfca-ab15e7b28b4a" name="pali:NonCashWarrantIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Warrants Outstanding and Warrant Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the majority of its warrants as equity-classified in accordance with ASC 480 and ASC 815. The Company&#8217;s outstanding common stock warrants that are classified as equity warrants are included as a component of stockholders' equity based on their relative fair value on their date of issuance. Common stock warrants accounted for as liabilities in accordance with the authoritative accounting guidance are included in noncurrent liabilities. The Company had exercisable common stock warrants outstanding of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f118624-032d-4aed-bc63-5e27c54b1ef9" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">6,745,213</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96960af5-d08d-4d5f-ba57-0402cc61f68a" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">272,211</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01_4"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_cc453878-97a5-47fe-8420-3bd3affec9a2" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" escape="true" continuedAt="F_cc453878-97a5-47fe-8420-3bd3affec9a2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company's outstanding and exercisable common stock warrants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.952%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:17.996%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.678%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.378%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.858%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.98%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classification</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Warrants Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024 Offering Pre-Funded Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd0c4b53-7a85-4a53-a366-d9108cc44e1f" contextRef="C_582ecc46-b417-4c17-b3ac-7494c5aa8bda" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,027,000</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf0ed02d-55a5-4395-82d6-5b7becba0452" contextRef="C_582ecc46-b417-4c17-b3ac-7494c5aa8bda" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Perpetual</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024 Offering Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41e9dac7-cc54-4dad-abf3-297d037f97d8" contextRef="C_33afec80-d974-4667-ab99-82569d37d0b0" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,278,688</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dcdc856-bb6d-4f26-b7ec-c563ad5630e5" contextRef="C_33afec80-d974-4667-ab99-82569d37d0b0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9e837514-6b53-4df4-bb85-723e1ee50a09" contextRef="C_a0bdf278-32cb-4874-b9d5-b39d0aa6c3f9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.95</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2024 Offering Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e614b42-396a-4f33-937d-ee665b64fbd0" contextRef="C_25437a64-b804-49d4-a583-6149701ed82e" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">922,863</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_042ee2e4-56b4-4586-bec7-c10c06c7444f" contextRef="C_25437a64-b804-49d4-a583-6149701ed82e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ff14bc21-ab4c-416c-a645-d88ebdec895c" contextRef="C_d36c00ce-2fa2-47f1-a66c-21a67e4857fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.34</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 2024 Warrant Inducement Replacement Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c1e494b-e318-4250-bf30-24c2bec1e739" contextRef="C_32effecb-dcdb-418d-b9ab-602e1ecc9121" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">228,158</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81acae0b-163b-40d6-98b5-ade6b938c3bd" contextRef="C_32effecb-dcdb-418d-b9ab-602e1ecc9121" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.17</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1b7a59b4-b791-4c2d-8599-0843d1196d35" contextRef="C_e3a8e347-dc37-40b0-851c-4ceba3d07be3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.09</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 2024 Offering Series 2 Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a98d7d-ea7c-4cb0-bc99-4bab828674cf" contextRef="C_f4c47b93-0a6c-459a-94b1-6b86830d25bc" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,748</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0ce1c17-0f14-48ef-9864-b68ddcf996f9" contextRef="C_f4c47b93-0a6c-459a-94b1-6b86830d25bc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.40</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6de3b4a4-5d07-4eee-9d4d-3a29cec9e4fb" contextRef="C_ad71c156-c72e-4679-bf89-118f467d7baf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.61</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bridge, January 2021, and July 2021 Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liability-Classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2f40080-58f3-45e9-84cb-6b944bceb420" contextRef="C_66aae2c0-5abe-49b9-befa-ef1108555742" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c9a58de-0f64-4067-8862-5cf4f10424d4" contextRef="C_66aae2c0-5abe-49b9-befa-ef1108555742" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">58.20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c81d39cd-c6d7-4eac-b95b-6f1c846d523c" contextRef="C_f399e54c-6ccd-4ae9-97a2-1db3bdc4468e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Placement Agent, Solicitor and Representative Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400ba99e-c1c8-4878-a46b-10bf1c493420" contextRef="C_9c81c8a6-3ae0-4c51-b74d-11500c011143" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">274,693</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f8fcfa5-2324-4316-a697-b383f3628396" contextRef="C_9c81c8a6-3ae0-4c51-b74d-11500c011143" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.98</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_12ecdb56-2a73-446b-aef4-cc06566edc03" contextRef="C_ffa661a6-473a-4c79-8a7f-48832923f5d9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.66</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03aaceff-407c-4b3d-8d56-1541f5d99b65" contextRef="C_dd1ca615-f781-4979-a8ac-e2d5b4aab50b" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,919</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e16f367-7179-4a42-85db-83e310217400" contextRef="C_dd1ca615-f781-4979-a8ac-e2d5b4aab50b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3,418.56</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_674693eb-13dd-4467-a338-f954f18ba1b4" contextRef="C_24d8c3be-2445-4bb1-aa0d-5f552876a8bb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.50</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Warrants Outstanding, December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0190b23d-8df3-4c80-9a8d-d863afd3dc7c" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,745,213</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17dc50e-fb87-4771-bb28-42b133ce3025" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.53</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9ec4bd57-f51b-4896-87de-7ea6b3c54805" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_cc453878-97a5-47fe-8420-3bd3affec9a2_1"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the outstanding common stock warrants, only the Series 2 Warrants include a down round feature whereby they are subject to price reset provisions in the event future sales of the Company's securities are sold at a price per share less than the exercise price of such warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_09379391-a5e1-4afb-b622-6440ed5dd9ed" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes all common stock warrant activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.951%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.922%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.342%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.922%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.501%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e662b12e-ee2a-447f-8987-696ca8e9900e" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:ClassOfWarrantOrRightNumberOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">272,211</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2588f178-5583-45af-a6b8-509d42a461d9" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">144.78</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7fefb8c8-215f-48d8-84bb-41f1fd07427e" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de0ee860-249f-4ea5-a15f-2253e20d2e60" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightIssuedDuringPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,327,864</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af472992-0b5c-4fd7-8629-5a80bacda3e1" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.68</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5632091e-04bc-4913-8599-b692f8c15eb4" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcfc352c-cade-499c-ae94-a59c64e51ef8" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightExercisedDuringPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,854,658</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a529532-6700-47e2-9b18-4637c31fa2ae" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.35</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, expired or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd6baa0f-1351-4e11-842f-84053a5bfe74" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">204</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ca973bd-2de5-417e-ba0c-fa1bac70a96d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17,438.12</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93846c07-d6b2-4f83-a4ae-e0b232e0b38d" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:ClassOfWarrantOrRightNumberOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,745,213</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_578d8f4a-3f98-4fcb-b04c-47dfd425f18e" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.53</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fce4d946-4eaa-49bf-bf56-389a9c946b62" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
      </table><ix:footnote id="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430" xml:lang="en-US"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p></ix:footnote></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company received gross cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9667c40-20bf-4a9c-ac7b-33986e331e02" contextRef="C_39580d8d-37fd-4134-8e15-fc3336a39dd1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d91f189-398c-4f2d-8218-e38f1c91ffc8" contextRef="C_04026d27-31da-458f-9340-63004096eee6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, from exercises of common stock warrants. Of the gross cash proceeds received for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1707ec6-6c77-4203-a85f-3a8e4e5c67de" contextRef="C_04026d27-31da-458f-9340-63004096eee6" name="pali:NetProceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to common stock warrants exercised on December 30, 2022 for which the related cash exercise price was receivable to the Company as of December 31, 2022. The related cash payment was received by the Company in January 2023.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_a9738ce2-b1f0-4e42-87a7-6995179bb3f9" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_a9738ce2-b1f0-4e42-87a7-6995179bb3f9_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2013, LBS adopted the 2013 Employee, Director, and Consultant Equity Incentive Plan, (as amended and restated, the &#8220;2013 Plan&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45f3b02f-facb-41c5-ba43-753b56e9a9ef" contextRef="C_cee46443-8d64-412f-b41e-41a2367bf1f3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> further awards will be made under the 2013 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2021, the Company&#8217;s shareholders approved the Palisade Bio, Inc. 2021 Equity Incentive Plan (the &#8220;2021 EIP&#8221;). As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcb30b57-5050-42d4-a1dd-a451bca5a37a" contextRef="C_b898e598-304f-4ea7-864c-b785cdbc5739" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,586</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s of the Company's common stock reserved for future issuance as equity-based awards under the 2021 EIP, which excludes the subsequent evergreen share increase in the number of shares of common stock reserved for issuance under the 2021 EIP that occurred on January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also in April 2021, the Company's shareholder approved the ESPP. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All employees are eligible to participate in the 2021 ESPP while employed by the Company. The 2021 ESPP permits eligible employees to purchase common stock through payroll deductions, which may not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_937c0d00-bb1b-49c4-9799-19bd2e22b057" contextRef="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="INF" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a calendar year or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea71ff99-1451-4f72-8991-c7a5c2a657cd" contextRef="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's shares of common stock each offering period, as defined in the 2021 ESPP, at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fbeea50-79ba-4624-83dc-b1b9af3b2a20" contextRef="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair value of the Company's common stock at the beginning or end of the offering period, whichever is lower. The 2021 ESPP is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> intended to qualify under Section 423 of the Internal Revenue Code. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d1c98ad-5e8d-488b-9768-bf0e27cc53cb" contextRef="C_800199c1-afa8-43b6-9911-358e1907566a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,501</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock issued under the 2021 ESPP. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d143dac6-b80d-4f58-98a7-c39ebd57e2b5" contextRef="C_0ce6c868-1e07-4b9e-ac58-05460a42652b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">19,086</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock reserved for future issuance under the 2021 ESPP, which excludes the subsequent evergreen share increases in the number of shares of common stock reserved for future issuance under the 2021 ESPP that occurred on January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation expense associated with the 2021 ESPP for the year ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f1edbb4-45e0-4f7a-9dad-c2b6f782d6eb" contextRef="C_800199c1-afa8-43b6-9911-358e1907566a" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15efd55f-2ce2-4553-92e5-81ad143a70d4" contextRef="C_98ae9a8f-1e7d-4c2d-ba28-e6b7c8ca5a22" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, the Company's compensation committee of the Company's Board of Directors ("Board") adopted the Palisade Bio, Inc. 2021 Inducement Award Plan (the "2021 Inducement Plan"). The 2021 Inducement Plan was adopted in order to grant equity-based awards to individuals not previously employed by the Company, as an inducement to join the Company. On August 7, 2023, the Company's compensation committee of the Board approved an increase in the shares of the Company's common stock authorized and available for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5115c726-8bb5-43ff-b68d-2dcc65d08948" contextRef="C_9a5cce76-d0fc-4cb9-bb7b-be35e5885dd3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,666</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb327f4-761c-4e28-ba28-c56e89460059" contextRef="C_6b08194e-e220-4a67-9b3b-b24bf7d2dc89" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">52,941</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock reserved for future issuance as equity-based awards under the 2021 Inducement Plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes that stock options align the interests of its employees and directors with the interests of its stockholders. Stock option awards are generally granted with an exercise price equal to the market price of Company&#8217;s stock at the date the grants are awarded and a term as determined by the Company's Board but generally not to exceed ten-years. Stock option awards to employees vest in equal proportions each quarter over three years and stock option awards to directors of the Company's Board cliff vest after a period of one year. Vesting could be accelerated in the event of retirement, disability, or death of a participant, or change in control of the Company, as defined in the individual stock option agreements or employment agreements. Stock-based awards are valued as of the measurement date, which is the grant date, and are generally amortized on a straight-line basis over the requisite vesting period for all awards. The Company's equity incentive plans allow for the issuance of both incentive stock options and non-statutory stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9784eb55-14f8-4d60-8064-2efcd8a21a4d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 is estimated as of the grant date using the Black-Scholes option pricing model using the assumptions in the following table:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.882%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average exercise price per share</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ee1027a-0b05-41fe-aa13-c39f0bd7f26d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.54</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fef615c-114b-415d-a8bb-3267134fa1e1" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.85</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average expected term (years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3a6ea49e-50da-4f35-ac48-6f9f98267dde" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.65</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_44525c56-8c82-466d-b4a4-3b0430126ecc" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7be465a9-d3aa-4d40-ac89-1cd361a1c2c1" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.03</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93fe61b6-5193-47cb-be07-1d80665a4ce2" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.08</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f89c6d84-2538-4481-b7d2-64bcd67997d5" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aff0d27-c77d-4903-b7ad-96a4caa2a1ac" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b076f003-ca31-4150-bae6-10fd7fb18339" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">111.74</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_597c5443-4288-4444-863b-9a7979273704" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">78.35</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a9738ce2-b1f0-4e42-87a7-6995179bb3f9_1" continuedAt="F_a9738ce2-b1f0-4e42-87a7-6995179bb3f9_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk-free interest rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected volatility. Due to the Company&#8217;s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biopharmaceutical industry.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected term. The expected term represents the period of time that options are expected to be outstanding. As the Company does not have sufficient historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9b82888-659c-4bb7-9f49-95b857a11751" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity and related information under the 2013 Plan, the 2021 EIP and the 2021 Inducement Plan for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.662%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.942%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.662%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Options</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25f930e6-5aea-456f-8327-67d7baa76097" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_311ffa6e-0a2f-4cdf-a628-9314e6ac2461" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">233.09</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ccea63ef-0442-456b-9f40-1a5b23ee0881" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c165d07e-cbc0-4131-a7be-7e05944ae3d0" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5d6cca5-e6ce-4225-b88b-4d7c77dcc55d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3af02d65-1f42-4aaa-9d26-6f88217d0b73" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.54</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb84b657-f82c-4942-ad81-b385e8776bfe" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, expired or cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bbb2e6f-845c-4c57-bdb6-0ed929b54cb6" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,902</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1ce8015-6fc4-4916-bd8b-06370f8a70d5" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">335.18</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2461fab6-5b9c-4de5-87d1-e7aaf3843d20" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_540126a6-f376-4f8c-affc-8628e4da85db" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">166.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1f692d69-0f53-489f-858a-bac8f04d4f5e" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.75</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03a2b54e-84ee-4d12-80b1-085b5593cad2" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a376aa1a-405b-4494-93b9-773ada73cc06" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a94918c9-5f2f-4ce2-89fc-1a2956995336" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">166.48</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_32a8cabf-db86-4568-adde-5530f471db71" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.75</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cb399f2-76ed-480f-a436-8018c69001e6" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ad108d9-70a2-4d25-b638-e230d271879f" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,825</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de78ad50-656a-4652-b4a2-384496ccf42e" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">349.89</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0485a5e9-f5c6-471a-9fda-69a0291e388f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.44</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ed20538-e4cd-42a0-a27c-8550ca7bb242" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted during the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b371ce1e-92ac-45e5-b426-4f38bf28d2d5" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56845edd-114d-4ea4-8057-0cef1bea202e" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, re</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">spectively. The grant date fair value of the options vested during each the years ended December 31, 2024 and December 31, 2023 was approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39bf1e1a-8fd4-4fed-a2f6-81127e3719f0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b646d00-1fb0-48e3-8d20-ddbf7f72b29b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company granted no RSUs. As of December 31, 2024, there were no RSUs that remained outstanding.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_214f272c-c0b6-448a-b339-26a9e4044a9a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following table summarizes RSU activity and related information under the 2021 EIP and the 2021 Inducement Plan for the year ended December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.700000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Restricted<br/>Stock Units</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddd82bbf-bb36-4d05-b55c-704cef9af499" contextRef="C_8645eaec-898b-48e4-befe-b013c00071ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">24,195</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eae4294-d36f-4141-a479-e5c3b492b308" contextRef="C_8645eaec-898b-48e4-befe-b013c00071ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_34d0167a-a96a-4677-adfb-27e63a6e8ccc" contextRef="C_1e5799eb-2dde-4495-859d-82b3ce5341eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.17</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8612c889-ffb6-4c23-90c1-78b83e51b253" contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b81b094-df24-4364-8d82-4f01cebf88c8" contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13cb5498-996c-4519-93f3-1ed85343c232" contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,067</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7df9a70a-7f55-4192-b4e5-eb0746fea843" contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.23</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af43076f-aa25-449c-8ac8-b50f41210674" contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,128</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e62d44d9-2bca-49da-8baa-5630709e6e04" contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.84</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_378a933c-fbcd-4740-b3c2-943386544c8c" contextRef="C_22d62b69-795d-4d94-914a-263cdadcd8a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66b6cf63-009f-47ce-957b-3a82e313aee0" contextRef="C_22d62b69-795d-4d94-914a-263cdadcd8a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant date fair value of the RSUs vested during the years ended December 31, 2024 and December 31, 2023 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bff12f3-899b-4ca5-b8c9-bdffc053b454" contextRef="C_57444f7a-2496-4f31-9eac-285e8dbbc2a7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_52974fb4-8255-49dc-bdfd-1d8c64bc8509" contextRef="C_12dc02fb-eac4-4610-bad8-fe8e9ad4d610" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in each year.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a9738ce2-b1f0-4e42-87a7-6995179bb3f9_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Based Stock Units</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 6, 2023, the Company granted to certain members of management a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dee227d5-845b-41dd-97f8-c03e944724dc" contextRef="C_2007472e-785f-4e66-8b90-31974e6c2d75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,580</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> market-based PSUs, which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4a55480-c460-4958-91e2-4b7d94fdf1a7" contextRef="C_7b587e1b-52d0-4b29-b97d-1630d7f21d83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% when the volume weighted average price of the Company&#8217;s common stock over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c607b7f-1bfc-4f84-b26a-332993f65c95" contextRef="C_7b587e1b-52d0-4b29-b97d-1630d7f21d83" name="pali:NumberOfTradingDays" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57faa40d-6bc8-4e77-924e-b0b86fd98c67" contextRef="C_11a397d8-f76e-4123-8ffc-90b0d4bba3ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">48.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or greater ("vesting Tranche 1"), and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc121055-8aba-4e0c-8afc-f9b10eaf1ac8" contextRef="C_7bdff01b-c6cb-4014-8bf2-6623ec18a56e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% when such volume weighted average price of the Company&#8217;s common stock over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_368fed1f-eae7-44e6-a6b4-8d80b1b755ae" contextRef="C_7bdff01b-c6cb-4014-8bf2-6623ec18a56e" name="pali:NumberOfTradingDays" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5c5a70a-f84e-4fa4-ba7d-698c0d022919" contextRef="C_5be85942-60b4-4ca7-b41c-6a7af1aea32f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">63.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or greater ("vesting Tranche 2").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The PSUs were conditional subject to shareholder approval, which such approval was received at the Company's annual shareholder meeting held on June 8, 2023. The fair value of each of the market-based vesting tranches of the PSUs was determined using a Monte Carlo simulation model that considered a variety of potential share prices for the Company's common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of vesting Tranche 1 and vesting Tranche 2 of the PSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15cb966f-8627-41bd-b3e0-b2000508c560" contextRef="C_89ee88e7-ca37-400a-8b0f-b936d897aea2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per award share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb453445-6f29-4bb7-8f72-2660ff29ea6d" contextRef="C_2a44715d-6d67-4a8c-9146-cda1c95f1181" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per award share, respectively, and was determined using the following key assumptions: (i) a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1e8946e-c81e-4fc0-839b-2e03525db794" contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, (ii) expected stock price volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3804927-baa5-44d1-b5a9-f13fa21fd370" contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">76.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, (iii) a cost of equity of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94400bb7-fb56-4487-9e13-530e6b5a869e" contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2" name="pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">27.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and (iv) an expected contractual life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1674dd2d-a5c2-4351-8642-fc99cfd62536" contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.66</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As shareholder approval of the PSUs was received, the Company is recognizing the share-based compensation expense associated with the PSUs ratably over the derived service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_471efafe-b7fa-4fad-98eb-b68bac8569e7" contextRef="C_89ee88e7-ca37-400a-8b0f-b936d897aea2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.75</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years for vesting Tranche 1 and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b749601d-1063-43db-8a95-95cf64699f90" contextRef="C_2a44715d-6d67-4a8c-9146-cda1c95f1181" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.48</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years for vesting Tranche 2, regardless of whether the market condition for vesting is satisfied. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe31b0f8-2c19-4e45-90fb-ca7d7719918c" contextRef="C_0e9b1aec-3b94-4255-8d2d-686c1a773637" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,144</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs remained unvested and outstanding. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ecf61cd-cdcf-4b6a-a843-6edc62b0c32c" contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the PSUs vested during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">year ended December 31, 2024 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b71d9a2c-b43e-4d73-a7be-54b9b33e1d5b" contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs were forfeited during the year. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd92dde5-b2f3-46dd-a7dc-6b8ab12f467d" contextRef="C_9c3eea55-6dac-475a-8dd9-570c44c3ad63" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,952</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs remain unvested and outstanding.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b109db76-19b6-414c-b28f-b8d01b461cd7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The allocation of stock-based compensation for all stock option, RSU and PSU awards is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03d4685-4516-462a-b6ae-69f400d61f05" contextRef="C_39cecd10-468f-4aba-9f46-454343174b91" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_336c842e-ddc4-4966-bdc2-da078d19fc70" contextRef="C_4d65b8a8-159b-4e62-9b59-1b4091249817" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc4e04c-9fe1-4d5e-8114-5e04a12fd3f8" contextRef="C_da789c28-414e-4ccd-947d-5e1f11d5ee32" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efd3a784-7851-4296-a94b-8f2b032c4a41" contextRef="C_5c1b7f20-1f1a-46c6-b1ce-e72714e8e6c0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">366</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_418c6e4d-3080-4693-9d88-06af3d2c8262" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">633</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_316d9936-7839-4077-86a4-fefdbf633f11" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To reduce the ongoing administrative burden and expense associated with the quarterly vesting of the Company's time-based RSUs, on May 28, 2024, the Company's Board approved the immediate accelerated vesting of all unvested time-based RSUs issued to employees that were outstanding as of that date. The accelerated vesting was accounted for as a Type I modification under ASC 718 and accordingly, in the second quarter of 2024 the Company recognized share-based compensation expense associated with the time-based RSUs subject to immediate vesting of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1583e3c-ff07-48b4-b407-3e85bf2ce3da" contextRef="C_a24647e4-47f9-4d57-a123-b33e432c6857" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">129,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in general and administrative expenses and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd04c02-c815-4e83-9204-a1f30d4dd2f5" contextRef="C_8b845079-c037-4485-9046-bc648460b149" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrecognized compensation expense related to outstanding options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d47d3949-18bd-4ccb-8dcc-b35e2ed2122b" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a67da61f-4a18-4bf1-98db-891cb6dfb90a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.49</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> there is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcdce0a9-9a91-4b96-80cf-3456e4d311d8" contextRef="C_b326ac9a-3edc-4669-a12a-a44223068a1d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrecognized compensation expense related to outstanding service-based RSUs as there are no outstanding non-vested service-based RSUs as of that date and the unrecognized compensation expense related to outstanding PSUs is immaterial.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:LicenseAgreementsTextBlock" escape="true" continuedAt="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Collaborations and License Agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research Collaboration and License Agreement with Giiant</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, the Company entered into the Giiant License Agreement whereby the Company received an exclusive, worldwide license (with the right to sublicense in multiple tiers) to develop, manufacture, and commercialize substantially all of the assets of Giiant, including: (i) the PALI-2108 compound, and (ii) the PALI-1908 compound and the associated intellectual property around each of the foregoing (the &#8220;Giiant Licensed Assets&#8221;). The Giiant License Agreement has a perpetual term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Giiant License Agreement, the Company and Giiant established a joint development committee (&#8220;JDC&#8221;), consisting of one Giiant appointee and two Company appointees. The JDC will be responsible for: (i)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_1" continuedAt="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing the day-to-day development of the Giiant Licensed Assets through Proof of Concept (as defined below), and (ii) creation and implementation of the development plan and development budget for such development (the &#8220;Giiant Development Plan&#8221;) and any amendments or updates thereto.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to receiving regulatory approval to commence a Phase 1 clinical trial (as such term is defined in the Giiant License Agreement) (the &#8220;Proof of Concept&#8221;), each of the Company and Giiant was solely responsible for all costs and expenses incurred by such party for the joint development of the Giiant Licensed Assets, except as set forth in the Giiant Development Plan. Prior to reaching the Proof of Concept, the Company reimbursed or advanced Giiant up to an amount in the low seven-digit range for costs and expenses incurred by them. Upon reaching the Proof of Concept, which occurred in October of 2024, the Company became solely responsible for all costs and expenses incurred for the development, manufacturing, regulatory and commercialization of the Giiant Licensed Assets. For the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized expenses related to the joint development plan with Giiant in the amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd1037bd-4717-4258-8b5b-68ea99e11280" contextRef="C_39cecd10-468f-4aba-9f46-454343174b91" name="pali:JointDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36c3fc6e-6267-4ce4-9e1d-60958e022e5c" contextRef="C_4d65b8a8-159b-4e62-9b59-1b4091249817" name="pali:JointDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which are included in research and development expenses in the consolidated statements of operations. The Company recognized no reductions to its joint development expenses for payments from Giiant for either the years ended December 31, 2024 or December 31, 2023. At December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company accrued joint development expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9569355f-bba7-4d2e-b127-74193974dd24" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:AccruedJointDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cb97864-03e9-40fd-86a4-db0531fc2b52" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:AccruedJointDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in Accrued liabilities in the consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Giiant License Agreement, as amended (see below), the Company will (i) make certain payments between the mid six-digit range and low seven-digit range upon the achievement of development milestones, as defined in the Giiant License Agreement, in either cash or shares of the Company&#8217;s common stock, at the Company&#8217;s election (&#8220; Giiant Milestone Payments&#8221;), and (ii) pay ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses of any products developed from the Giiant Licensed Assets to third parties (&#8220;Giiant Royalty Payments&#8221;) (collectively, the Giiant Milestone Payments and the Giiant Royalty Payments are referred to as the &#8220;Giiant License Payments&#8221;). The Giiant License Payments are subject to a maximum payment cap in the very low eight-digit range, which will be increased or decreased on a dollar-for-dollar basis based on a formula related to the aggregate of development costs incurred by the parties (&#8220;Payment Cap&#8221;). The Company has made no Giiant License Payments since the commencement of the Giiant License Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 2, 2024, the Company and Giiant entered into an amendment to the Giiant License Agreement (the "Giiant License Agreement Amendment"). Pursuant to the Giiant License Agreement Amendment, the Company agreed to increase the amount it would reimburse or advance to Giiant prior to Proof of Concept under the Giiant Development Plan by an amount in the mid six-digit range. After taking into account such increase, the amount that Company will reimburse or advance Giiant for costs and expenses incurred by them will remain in the low seven-digit range. As consideration for the increase, Giiant agreed to (i) a reduction in the Giiant Milestone Payments that would be due to them upon the achievement of certain development milestones, and (ii) a decrease to the Payment Cap applied to future Giiant License Payments, as set forth in the original Giiant License Agreement. The amount of the reduction in the Giiant Milestone Payment as a result of the Giiant License Agreement Amendment is in the high six-digit range and the decrease in the Payment Cap is in the mid-six digit range. There were no other changes to the terms of the original Giiant License Agreement as a result of the Giiant License Agreement Amendment that would have a material impact on the Company's results of operations, financial position or future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that Giiant desires to sell or assign any rights to receive the Giiant License Payments, they will be required to notify the Company of such offer or proposal (&#8220;Offer Notice&#8221;). The Company will then have a right of first refusal for thirty days from the receipt of such Offer Notice, to acquire the rights and obligations contained in such Offer Notice on the same terms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may unilaterally terminate the Giiant License Agreement for: (i) convenience, or (ii) a material breach by Giiant, that is not cured within the applicable notice period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Giiant may unilaterally terminate the Giiant License Agreement only for a material breach by Company that is not cured within the applicable notice period provided however that upon the Payment Cap being achieved, that right will terminate and the Giiant License Agreement will become perpetual.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-Development and Distribution Agreement with Newsoara</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LBS entered into a co-development and distribution agreement with Newsoara, a joint venture established with Biolead Medical Technology Limited, as amended, (the &#8220;Newsoara Co-Development Agreement&#8221;). Pursuant to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_2" continuedAt="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Newsoara Co-Development Agreement (and subsequent assignment agreement), LBS granted or licensed Newsoara an exclusive right under certain patents to develop, use, sell, offer to sell, import, and otherwise commercialize licensed products (the &#8220;Newsoara Licensed Products&#8221;) for any and all indications in the People&#8217;s Republic of China, including the regions of Hong Kong and Macao, but excluding Taiwan (the &#8220;Territory&#8221;). The Newsoara Licensed Products only include the drug asset referred to as LB1148. The right includes the right to grant sublicenses to third parties, subject to LBS&#8217; written consent, provided that both parties agreed that Newsoara would be permitted to use a certain partner for development purposes. The Newsoara Co-Development Agreement obligates Newsoara to initially use LBS as the exclusive supplier for all Newsoara&#8217;s requirements for Newsoara Licensed Products in the Territory. During the term of the Newsoara Co-Development Agreement, Newsoara may request to manufacture the Newsoara Licensed Products in the Territory, subject to satisfying certain conditions to LBS' reasonable satisfaction. LBS is obligated to approve Newsoara manufacturing rights without undue refusal or delay. The Company records the expense reimbursements from Newsoara for any research and development or manufacturing activities it performs under the Newsoara Co-Development Agreement as a reduction to research and development expenses once the reimbursement amount is approved for payment by Newsoara.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of the rights granted to Newsoara under the Newsoara Co-Development Agreement, Newsoara paid LBS a one-time upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_936beec2-5d07-4423-bf8c-1d66b2099a5b" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:CollaborationsAndLicenseAgreementsUpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In addition, Newsoara is obligated to make (i) payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7769262c-2d65-48f7-ae91-3cac9d77dd2b" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">6.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate upon achievement of certain regulatory and commercial milestones, (ii) payments in the low six-digit range per licensed product upon achievement of a regulatory milestone, and (iii) tiered royalty payments ranging from the mid-single-digit to low-double-digit percentage range on annual net sales of Licensed Products, subject to adjustment to the royalty percentage in certain events, including a change of control, the expiration of certain patents rights, and royalties paid by Newsoara third parties. To date, Newsoara has met all of its payment obligations under the Newsoara Co-Development Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company recognized license revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_549ab71c-8024-48ad-a63b-dea3976b47b5" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million earned upon Newsoara's achievement of a development milestone under the Newsoara Co-Development Agreement during the first quarter of 2023. During the year ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> December 31, 2024, the Company recognized no license revenue from Newsoara under the Newsoara Co-Development Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Newsoara Co-Development Agreement will expire upon the expiration date of the last valid claim of any licensed patent covering the Newsoara Licensed Products in the Territory. In addition, the Newsoara Co-Development Agreement can be terminated (i) by either party for the other party&#8217;s material breach that remains uncured for a specified time period after written notice or for events related to the other party&#8217;s insolvency, (ii) by LBS if Newsoara challenges or attempts to interfere with any licensed patent rights and, (iii) by Newsoara for any reason upon specified prior written notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements with the Regents of the University of California</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e442f8de-e8fb-43bc-97d0-c0bd9f798d69" contextRef="C_339a2504-3ac9-410d-8ca6-961361ccd1aa" name="pali:NumberOfLicenseAgreements" unitRef="U_Agreement" decimals="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> license agreements, as amended, with the Regents of the University of California (&#8220;Regents&#8221;) for exclusive commercial rights to certain patents, technology and know-how related to LB1148. Concurrent with the Company's decision to terminate the development of LB1148, on October 20, 2023 the Company terminated </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b8504d9-0c05-450b-a1c7-43e599e9cf55" contextRef="C_16734ac9-5f7d-4564-bb8b-aff2052903ed" name="pali:NumberOfTerminatedLicenseAgreements" unitRef="U_Agreement" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of its license agreements with Regents. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the only license agreement remaining with Regents is that entered into with LBS in August 2015, as amended in December 2019 and September 2022 (the &#8220;2015 UC License&#8221;). The 2015 UC License was retained for the sole purpose of maintaining the Newsoara Co-Development Agreement under which the Company may receive future milestone or royalty payments through the term of the license. Accordingly, pursuant to the 2015 UC License, the Company is obligated to pay a percentage of non-royalty licensing revenue it receives from Newsoara under the Newsoara Co-Development Agreement to Regents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3f1eff-1068-48eb-ba63-e2639ce017e7" contextRef="C_e42cccf2-0558-4a1d-8434-967432a7ef50" name="pali:RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab17b162-bbe6-4d5a-ab13-f75f304f2d36" contextRef="C_a049a491-7334-498c-b8d3-99fbfcde6601" name="pali:RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent of one-third of the upfront payment and milestone payments received from Newsoara. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9193d1b6-ae7f-411c-9755-0c1e715774f6" contextRef="C_386963f7-adcd-4589-ad1e-18c92d7f72e4" name="pali:SublicenseFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in sublicense f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ees and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9229e331-fc53-45e5-a0ba-e8ebfeec5076" contextRef="C_1daf9a02-8b5d-48fd-8804-9977e84acb12" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">21,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in license maintenance fees due to Regents in research and development expenses in the consolidated statements of operations. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83769c52-5263-4d95-abf3-317ae83a4206" contextRef="C_065287e3-70be-4640-bc93-2e29518133d5" name="pali:SublicenseFees" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sublicense fees and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d79c9a6-2209-42fb-8eec-17f79cbb31b5" contextRef="C_d0f8faa6-225c-4d7d-8f77-da0c5084bd1b" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">16,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in license maintenance fees due to Regents recognized in research and development expenses in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:nonNumeric id="F_aeb5b586-47c1-4a33-a266-ffa2dc30a990" contextRef="C_e678878a-0c3f-4ca9-be27-f1041b0e7025" name="pali:PeriodOfExpirationOfLicenseAgreementDescription" continuedAt="F_aeb5b586-47c1-4a33-a266-ffa2dc30a990_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2015 UC License will expire upon the expiration date of the longest-lived patent right licensed under the 2015 UC License. The Regents may terminate the 2015 UC License if: (i) a material breach by the Company is not cured within 60 days, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable, </span></ix:nonNumeric></span><span style=""></span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_3" continuedAt="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_aeb5b586-47c1-4a33-a266-ffa2dc30a990_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) the Company files for bankruptcy. The Company also has the right to terminate the 2015 UC License at any time upon at least 90 days&#8217; written notice.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Value Right</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to the closing of the Merger, Seneca issued each share of its common stock held by Seneca stockholders of record, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa7e605b-85cf-4e2b-ba33-4d67aa7d7c71" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:ClassOfWarrantOrRightNumberOfRightsIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> contingent value right (&#8220;CVR&#8221;). The CVR entitled the holder (the &#8220;CVR Holder&#8221;) to receive, pro rata with the other CVR Holders, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7933ed09-2ba2-4c4e-90dd-060a6a45304d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:ContingentValueRightProRataNetProceedsFromSaleOrLicensing" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net proceeds, if any and subject to certain minimum distribution limitations (&#8220;CVR Payment Amount&#8221;), received from the sale or licensing of the intellectual property owned, licensed or controlled by Seneca immediately prior to the closing of the Merger (the &#8220;Legacy Technology&#8221;); provided however that the CVR Holders are only entitled to receive such CVR Payment Amount if the sale or licensing of such Legacy Technology occurred on or before October 27, 2022 (&#8220;Legacy Monetization&#8221;). Pursuant to the terms of the CVR agreement (&#8220;CVR Agreement&#8221;), CVR Holders are only entitled to receive CVR Payment Amounts received within 48-months following the closing of the Merger. The CVR Agreement also provides that no distributions will be made to the CVR Holders in the event such distribution is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e394543c-2483-4091-b41f-583c31ce762c" contextRef="C_ad8d582e-2dde-4db3-8d6f-4a779f360888" name="pali:CvrAgreementDistributionMinimumAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NSI-189 &#8211; Exclusive License and Subsequent Exercise of Purchase Option</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Merger, Seneca exclusively licensed certain patents and technologies, including a sublicense covering a synthetic intermediate, of the Company's NSI-189 assets (&#8220;189 License&#8221;), along with a purchase option through December 16, 2023 (&#8220;Purchase Option&#8221;). On October 22, 2021, Alto Neuroscience ("Alto") agreed to terms of an early exercise of the Purchase Option under the 189 License and entered into an asset transfer agreement ("ATA"). Alto is a U.S. based public, clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the CVR Agreement, no distribution was required to be made to the CVR Holders as the CVR Payment Amount after deducting costs and expenses required to maintain the 189 License was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4b523ca-7730-463b-aac0-0e089d407779" contextRef="C_b1540c36-2dc4-4c82-81de-598e5062281b" name="pali:CvrAgreementDistributionMinimumAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In accordance with the terms of the CVR Agreement, the net proceeds from the sale of the NSI-189 assets, less any applicable transaction costs and expenses, were deposited into the CVR escrow to be used to pay costs and expenses associated with the monetization of the Company's other Legacy Technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Alto will be required to pay the Company up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c3a55f1-e87d-4f1d-a307-d54ce66e5ebc" contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development and regulatory approval milestones for NSI-189 (or a product containing or otherwise derived from NSI-189), which is now known as ALTO-100. If Alto sells or grants to a third party a license to the patents and other rights specific to ALTO-100 prior to the achievement of a specified clinical development milestone, Alto will be required to pay to the Company a low-double digit percentage of any consideration received by Alto from such license or sale, provided that the maximum aggregate consideration Alto will be required to pay to the Company under the ATA, including the upfront payment and all potential milestones and transaction-related payments, will not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5b0b785-beed-4c48-a985-a8061064aeab" contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6" name="pali:MaximumAggregateConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 22, 2024, Alto announced that its Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint. Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in 2026. Upon the enrollment of a patient in a Phase 3 clinical trial of ALTO-100, if it occurs, a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e78ea50a-a86e-4a52-9841-5fdfea616625" contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6" name="pali:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be due from Alto under the ATA. If this occurs within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01594f2f-a77e-43db-a3d7-caf6a36e766e" contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6" name="pali:ClosingPeriodOfMergerAgreement" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-months of the closing of the Merger, the CVR Holders will be entitled to a CVR Payment Amount, with the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aa642d2-b234-4664-997f-f352ef169444" contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6" name="pali:ProceedsDepositedIntoTheCvrEscrow" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net proceeds deposited into the CVR escrow. If the milestone is met after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b96497a0-30fc-4be6-97ed-eaf21014a63f" contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6" name="pali:ClosingPeriodOfMergerAgreement" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-months of the closing of the Merger, all the net proceeds will be paid to the Company. There can be no assurance that CVR holders will receive CVR Payment Amounts from the sale of the NSI-189 assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NSI-532.IGF-1</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2022, the Company entered an agreement to license NSI-532.IGF-1 to the Regents of the University of Michigan ("University of Michigan") for maintaining NSI-532.IGF-1 cell lines, continued development, maintaining patent protection, and seeking licensees. The Company received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ab67cf0-d0b9-4808-a40b-77e7b46027ac" contextRef="C_1ea433f0-bf37-4d98-8e23-9f24084ab798" name="pali:CollaborationsAndLicenseAgreementsUpfrontFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upfront fees for the license. NSI-532.IGF-1 is a preclinical cell therapy being investigated as a potential therapy for prevention and treatment of Alzheimer&#8217;s disease. The University of Michigan shall bear </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b23b213-cd0f-4902-9d4f-ed786a2ac6a5" contextRef="C_1ea433f0-bf37-4d98-8e23-9f24084ab798" name="pali:PercentageCostInPatentRight" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the costs for patent filing, prosecution, maintenance, and enforcement of the patent rights. The Company will receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b5cc97f-338d-448a-8566-1f5424fe8eaf" contextRef="C_1ea433f0-bf37-4d98-8e23-9f24084ab798" name="pali:PercentageOfNetRevenue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of net revenues received by the University of Michigan from the licensing of patent rights through the last-to-expire patent in patent rights, unless otherwise earlier terminated, less all reasonable and actual out-of-pocket costs incurred in the litigation of patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc_4"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">can be no assurance that NSI-532.IGF-1 will ever be successfully monetized or that CVR holders will receive CVR Payment Amounts from the sale of the NSI-532.IGF-1 assets.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_e4b9dcd4-edff-44af-9d87-d9bddd22826c" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_e4b9dcd4-edff-44af-9d87-d9bddd22826c_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Office Lease</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is party to a non-cancelable facility operating lease (the "Corporate Office Lease") of office space for its corporate headquarters in Carlsbad, California. The initial contractual term is for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1096e106-1661-4cb7-a389-e5df2c16b65c" contextRef="C_c88b6c40-1467-497e-aa09-abf945fe9976" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39-months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commencing on June 1, 2022 and expiring on August 31, 2025. The Company has the option to renew the Corporate Office Lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1f85430-4252-473c-84bb-aee462114d35" contextRef="C_c88b6c40-1467-497e-aa09-abf945fe9976" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period at the prevailing market rent upon completion of the initial lease term. The Company has determined it is not likely that it will exercise this renewal option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Corporate Office Lease is also subject to additional variable charges for common area maintenance, insurance, taxes and other operating costs. This additional variable rent expense is not estimable at lease inception. Therefore, it is excluded from the Company&#8217;s straight-line expense calculation at lease inception and is expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized an operating right-of-use asset related to the Corporate Office Lease in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f012a590-4066-456b-85ad-fa5b4b076c7f" contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">84,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which included in Operating lease right-of-use asset in the consolidated balance sheets, and an operating lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbb9c689-99c8-4121-b48f-595f20e69718" contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">90,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all of which is included in Current portion of operating lease liability in the consolidated balance sheets. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the total remaining future minimum lease payments associated with the Corporate Office Lease of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6c75990-4b20-4160-a2ab-6c4e52d3feb5" contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6" name="pali:OperatingLeasesFutureMinimumPayments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">93,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including imputed interest of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2be73ea4-6b68-4ad0-a7a5-366faaf99e61" contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> calculated using a discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb8b02b2-412b-4f42-962a-db1808e346a7" contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, will be paid over the remaining lease term of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee20d146-e551-4254-b2a8-29899865715c" contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Other than the remaining maturities of the operating lease liability due in 2025 related to Corporate Office Lease, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 the Company has no maturities of operating lease liabilities in 2025 or thereafter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized operating lease expense associated with its Corporate Office Lease of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd3715fe-9c7a-4317-bf20-6c1133209cba" contextRef="C_1647ede8-9b3a-4985-acc0-f4909695082f" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_75981048-eca7-49c8-b4d9-b40187d816b1" contextRef="C_1ab29fa5-66c6-45ad-818c-b0bfb6693551" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">130,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insurance Financing Arrangement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Company entered an agreement to finance insurance policies that renewed in May 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financing arrangement entered in June 2024 has a stated annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8452ac77-593e-47ee-8fe0-3499800cdd17" contextRef="C_0396c3a7-c3c7-4970-b67a-c7d717b609c7" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and is payable over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5aa41ff-09a2-46fa-aaa8-5975a00cf98a" contextRef="C_0396c3a7-c3c7-4970-b67a-c7d717b609c7" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with the first payment payable on June 30, 2024. The insurance financing arrangement is secured by the associated insurance policy. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the aggregate remaining balance under the Company's insurance financing arrangement was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12c23808-8d39-42d2-a904-7f74fdf298fe" contextRef="C_9e634a16-0f0c-47a0-b175-926c827758d4" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa425be0-3122-4263-b9ed-541324bdc04e" contextRef="C_81df8d1c-b732-4f34-b1db-4b541732537e" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and is included in Insurance financing debt in the consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the remaining insurance financing arrangement payments due in 2025, as of December 31, 2024 the Company has no other minimum debt payments required in 2025 or thereafter.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to better utilize the Company&#8217;s resources on the implementation of its refocused business plans and corporate strategy, the Company committed to a cost-reduction plan on September 9, 2022 (the "2022 Cost-Reduction Plan") and a reduction-in-workforce on October 27, 2023 (the "2023 RIF"). The 2022 Cost-Reduction Plan consisted primarily of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbf64205-79b8-432e-8c7d-72bd503f046f" contextRef="C_659e2af0-b6fd-4530-954e-5b638bb46b1b" name="pali:PercentageOfReductionInWorkForce" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% reduction in the Company's employee workforce to better align the Company&#8217;s resources with its proposed business plan. The 2023 RIF </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consisted of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1401972d-7d2c-4509-bf17-d5c1dd498e5d" contextRef="C_272eb503-8300-45b6-8c62-5bd2086f945b" name="pali:PercentageOfReductionInWorkForce" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% reduction in the Company's employee workforce, specifically research and development employees that were no longer deemed critical for the Company&#8217;s development of its lead drug candidate, PALI-2108.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00fd9403-cc29-48ab-8095-2962a351dcd1" contextRef="C_5b914c39-e156-49cc-b150-f585bc3b48b9" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restructuring expenses related to either the 2022 Cost-Reduction Plan or the 2023 RIF for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. For the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized restructuring costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4782e65-0629-469a-9dd3-66f5a9bf6715" contextRef="C_456ae310-d956-4c7f-aca2-b537a393db0d" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the 2023 RIF, consisting of severance and benefits payments pursuant to employment agreements and the execution of severance and release agreements. Total expenses related to the 2022 Cost-Reduction Plan and the 2023 RIF through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4243943e-ae08-486b-b6f2-29d488a17e5e" contextRef="C_5affaffb-555c-4738-91d1-a014135e69c5" name="us-gaap:DefinedBenefitPlanAdministrationExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f099eaae-28d4-4c9e-af13-8fb8e2b7a973" contextRef="C_5b914c39-e156-49cc-b150-f585bc3b48b9" name="us-gaap:DefinedBenefitPlanAdministrationExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively The Company does not expect to incur any other significant costs associated with either the 2022 Cost-Reduction Plan or the 2023 RIF.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_e4b9dcd4-edff-44af-9d87-d9bddd22826c_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the change in the Company's accrued restructuring liabilities under both the 2022 Cost-Reduction Plan and the 2023 RIF, which consisted solely of employee compensation and benefits and is classified within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ed9ab60-2265-466c-875c-341057ab5340" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" escape="true" continuedAt="F_4ed9ab60-2265-466c-875c-341057ab5340_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities in the consolidated balance sheets as of each year shown (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_4ed9ab60-2265-466c-875c-341057ab5340_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of the beginning of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f195dede-dea4-46fb-83cc-2fef47ea0054" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7f1c25e-0041-40b9-8877-cfc3c1ddb1fd" contextRef="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net accrual adjustments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b55bba93-f567-4ca4-8c4c-6457e860e764" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:RestructuringReserveAccrualAdjustment1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e6eddbb-3f63-458e-b198-a95129e3fe5e" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:RestructuringReserveAccrualAdjustment1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21080e41-be5b-4ab4-88bd-12288ec7e7ee" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3604d0a-a916-4472-8172-3b429c592406" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of the end of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5bef77a-bc3f-4150-940f-d265247647d1" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c39ae85-e542-4236-9763-7f0ef59f7287" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company through December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#8217;s business.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_d64bd9df-c0c6-4ddc-9c8c-d5c113fa4adb" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_d64bd9df-c0c6-4ddc-9c8c-d5c113fa4adb_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basic and Diluted Net Loss Per Common Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period, plus any potentially dilutive common shares, consisting of stock-based awards and equivalents, and common stock warrants. For purposes of this calculation, stock-based awards and equivalents and common stock warrants are considered to be potential common shares and are only included in the calculation of diluted net loss per common share when their effect is dilutive.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's Series A Convertible Preferred Stock and certain of the Company's outstanding common stock warrants contain non-forfeitable rights to dividends with the common stockholders, and therefore are considered to be participating securities. The Series A Convertible Preferred Stock and the common stock warrants do not have a contractual obligation to fund the losses of the Company; therefore, the application of the two-class method is not required when the Company is in a net loss position but is required if the Company is in a net income position. When in a net income position, diluted net earnings per common share is computed using the more dilutive of the two-class method or the if-converted and treasury stock methods.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the December 2024 Offering the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a3722e9-651d-4916-a9ce-8524d32187d4" contextRef="C_9b87aaa7-9c2f-4572-baaa-95cb98ab911a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,120,688</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prefunded warrants with such prefu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nded warrants being immediately exercisable, having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_319d0bdc-6922-4a4c-bb36-3923d1a69cac" contextRef="C_9b87aaa7-9c2f-4572-baaa-95cb98ab911a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a perpetual term (See Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The prefunded warrants were determined to be equity-classified in accordance with ASC 480 and ASC 815. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e6fcdc2-b0b2-4e2b-91bf-9693c79ef632" contextRef="C_d3c9c2d7-95dc-49bb-98bf-59ffcaac2dcb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,027,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of these prefunded warrants remained unexercised. Pursuant to the guid</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ance of ASC 260-10, the Company concluded that because the equity-classified prefunded warrants were immediately exercisable for little or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dfc4621-cae7-4b3b-8aff-3f4d1841eb5b" contextRef="C_d3c9c2d7-95dc-49bb-98bf-59ffcaac2dcb" name="pali:CashConsideration" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash consideration due to the non-substantive stated exercise price, all the necessary conditions for issuance of the underlying common shares had been met when the prefunded warrants were issued. Therefore, the underlying common shares have been included in the denominator for both the calculation of basic and dilutive net loss per common share for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company was in a net loss position for all periods presented, basic and diluted net loss per common share for both the years ended December 31, 2024 and December 31, 2023 was calculated under the if-converted and treasury stock methods. For both the years ended December 31, 2024 and December 31, 2023, basic and diluted net loss per common share were the same as all common stock equivalents other than the prefunded warrants discussed above were anti-dilutive for both years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In computing the basic and diluted net loss available to common stockholders for the year December 31, 2023, the Company has deducted the value of the effect of the down round feature on equity classified warrants that was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_d64bd9df-c0c6-4ddc-9c8c-d5c113fa4adb_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">triggered in each year as each was determined to be anti-dilutive. The value of the down round feature on equity classified warrants for the year ended December 31, 2024 was determined to be immaterial.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79a43597-0621-405a-99e8-1ae832bd5b5b" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the calculation of weighted average shares used to calculate basic and diluted net loss per common share (in thousands, except share and per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c9ce210-385f-426c-b72c-745314d366e4" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,438</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b752c87e-29f5-4cbb-b5e1-5910d8eb6395" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47eabbd1-91a1-46e3-8830-025fc974b3c6" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7fa7e6d-d8ec-4d66-9ae0-bbaa6a808b41" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss available to common stockholders - basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad949fbe-353c-4474-93a5-4889e2c01c1f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c3f25a5e-85b2-4904-a064-7cb61633ea5f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,438</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3942e842-ba49-409a-a30b-9d56e138d9e9" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_44b21ed6-6e79-4495-be31-e48187518460" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,316</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating basic and diluted net loss per common share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd17d92-6517-4691-aaff-44bc73fd8761" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dc860a40-b925-4255-9c9c-4500e8234f1d" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,416,471</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cebe6505-85a8-495f-8151-6537af3c5edc" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7b449db8-7688-480b-9af8-8bf21d989d62" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">456,014</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6ed2350-e321-4a7e-9d4b-fe76b2130c7e" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0ca0f4c3-a63c-40a2-a601-0131dfa7f5c7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">10.19</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0651e22d-e90b-454b-8b8c-fef9c45dd8ec" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8e34ecad-ab13-4883-9c57-26db838a9a65" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">27.01</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45a8d613-df0a-4e98-bbbb-e519264730b0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_45a8d613-df0a-4e98-bbbb-e519264730b0_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effects would be anti-dilutive:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afd6667c-862d-4146-94f6-3d8ff4717df3" contextRef="C_e4f02a44-93b6-4104-9ffb-23aeab786d9d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c655152a-bde7-46c0-b530-d0386ef2f0e5" contextRef="C_ff902a0c-401a-4796-873a-f487d5f3927d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units and performance stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9639f0c4-11ca-4ffd-83e2-6ef9a835a26a" contextRef="C_0e805a01-b80a-43a2-b2d3-6b7c1b32fbd6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2428db4d-595d-4741-8ed8-71fe22962183" contextRef="C_818ca5b3-48b6-4160-92ed-c3b213c95caf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,339</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants for common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57880153-db53-42d6-b380-ee59a1936408" contextRef="C_8eff58aa-d87c-40ad-9ed7-ea2c72cee31b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,718,213</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25e95639-2b5f-4f57-a39a-3eb7115e908f" contextRef="C_15b1b95a-f0a8-45cc-8b88-bb5a5b75d92d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">272,211</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Convertible Preferred Stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1210629-fa6c-4925-8fee-6ecb7baf8fd3" contextRef="C_281c192c-92de-47d8-8a46-d3ac8f6e44b9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0df7f399-b01c-4250-8686-05d84add1aa0" contextRef="C_bfdab209-cc24-443e-af8d-5930cc4c3149" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_534e33c1-87b9-4bee-90ea-08758a0e8417" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,771,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93c4d312-1b79-424c-8dd1-2e43c76a71d2" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">344,834</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_45a8d613-df0a-4e98-bbbb-e519264730b0_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1832fc3a-622b-4874-9b5a-ee8244a2a07f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Employee Benefits</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company participates in a defined contribution 401(k) plan adopted by LBS effective June 20, 2016. All employees are eligible to participate in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> plan beginning on the first day of employment. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation. No matching contributions have been made by the Company since the adoption of the 401(k) plan.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_16740a3c-9f8d-4e08-bd52-c819bd3eea89" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_16740a3c-9f8d-4e08-bd52-c819bd3eea89_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has no current or deferred income taxes as of December 31, 2024 and December 31, 2023.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_c499d0f7-23c3-48a1-aa40-3c318618fc77" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes vary from the statutory federal income tax rate applied to loss before income taxes as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory federal income tax rate of 21 percent applied to loss before income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06cb0210-9d0c-445b-9f02-792d6844a5f9" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,032</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c58a7f37-3608-41f8-9d4a-bb822ae94695" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,583</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes - net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffb0b75a-0252-40cb-9c1a-de60bf4ab8fd" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">660</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f6ac84d-06ea-4f06-bb8e-b63665dd1132" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">810</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Meals and entertainment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8636d52-7f63-47e8-9d5f-97ca7ff06197" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32ccf782-6ff5-41a0-af36-30590472f804" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc800055-0db8-4698-befe-dfac2b80a94a" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:IncomeTaxReconciliationNondeductibleExpenseWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f337bd58-512d-40f3-bf05-a29772d44f7a" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:IncomeTaxReconciliationNondeductibleExpenseWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a38496f8-d399-4059-b3fd-58e7f005d6b9" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">371</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83afc96a-c0eb-419a-b783-f7c24f7340a8" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-deductible expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed54b743-0c73-45ae-85fe-65b9ed10bf43" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:IncomeTaxReconciliationOtherNonDeductibleExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_407c5298-2ac1-44f6-b055-0d7f5e5d0a7b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:IncomeTaxReconciliationOtherNonDeductibleExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expiration of tax attributes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d3f3978-c52a-46e0-80ec-98ced9efa3d7" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc1621e8-7607-417f-9d4b-49c8f4e556ce" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">484</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39aa5f2e-6b5f-4797-bcf3-662cbaca9e11" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c0107de-c772-4bbc-b5c1-88020bbded9b" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27aa32e4-cf90-45c9-aaa1-366d59c216a1" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7b33955-72f4-46a8-b77d-e896307afc49" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73ace2f0-b80e-448a-b1c8-1c8cbdcd2d6e" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a970a23b-c3c6-4e06-88a4-4adc61eeb1f8" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,278</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d95d7a34-a124-40f2-a22d-091783274b2e" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8522747f-8b44-438b-8927-77e7a8205f62" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_7884fca5-39cd-4230-b07d-cc6d0e9171f0" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income tax assets and liabilities arising from differences between accounting for financial statement purposes and tax purposes, less valuation reserves at year end are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a68c2051-4808-41d2-8aff-d7609f76af10" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:DeferredTaxAssetsAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5386040-c3cc-471a-b267-c94a76441df4" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:DeferredTaxAssetsAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0dcaf0c-0c31-4e3e-a102-8b03f5dba40f" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:DeferredTaxAssetsDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_519aef29-fa1a-41b1-8b80-095dff0a4eb1" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:DeferredTaxAssetsDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_023df9ae-3255-4197-843e-f5e73ab3f56a" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23223515-64de-450e-b222-ae8630a25273" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b97e49e-9f16-4286-8e6f-3c2b221cea7a" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,383</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15661f01-8d14-49fc-ae71-a5bfc2219051" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,703</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc77f194-c527-4136-a46d-149616dd4a58" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,216</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f19b2771-0f14-4d56-b956-600591bebae5" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,470</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_427cff55-9523-45f5-9288-a61baf98d4d0" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,771</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b372f70-50da-4a54-b462-9f82b4a8d484" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9cea35d-3002-4c0b-8bcc-867433df8f3d" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,599</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed775b3d-c4f6-4576-9f2b-6bbb8e3c0170" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,116</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3bff432-d51a-4ff9-ae7b-c96a282d8315" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="pali:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b15ad6eb-aff1-4c95-9ee9-2d9eaae818f5" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="pali:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60b2d78c-748b-4b6d-9d91-d7be99b32b88" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1e31fa8-c703-4cbf-9cf8-3379b49c1b13" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_548002ca-80db-48ae-895c-366924e54e75" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4466a6f2-136f-4c1d-8313-4a7fffa9f0f6" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c55c4f7-6aaa-40a9-86cf-ea9cba888680" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,468</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96408d55-fefb-4a8d-a03b-2b9be64378f8" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6015a4b9-97a2-406c-8f7b-175afebc4a53" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,468</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ef941da-ae0f-4fcb-beb4-1255a6a70268" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6495e50d-3516-46a5-8bc7-c0bef9db28d5" contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f1a2801-3d58-4f11-af14-3d096d7f030a" contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are recognized for temporary differences and unused tax losses to the extent that realization of the related tax benefits is more-likely-than-not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods when the deferred tax assets become deductible. After considering the history of operating losses and uncertainty regarding its ability to generate positive pre-tax income in 2025 and beyond, the Company has concluded that it is not-more-likely-than-not that its deferred tax assets will be realized, and therefore maintains a full valuation allowance on all deferred tax assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation allowance increased $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e35e71de-4a91-4751-8bff-fec03f57bf7f" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_449d57c9-afbc-46f0-9661-01c91a1493de" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_16740a3c-9f8d-4e08-bd52-c819bd3eea89_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal net operating loss ("NOL") carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a41f1888-09b4-4170-b048-2fe9fa42b009" contextRef="C_01f7368c-fa1b-4d5d-a9c9-07ba03a45b8e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">109.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llion and state NOL carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91ffff21-6830-4b90-ab8b-4fb66c0f207e" contextRef="C_f9f17689-3835-44ab-86c4-7ce94e9a6825" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Of the total amount of federal NOL carryforwards, approx</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07626587-27ab-4945-8346-8d8cbfcbf7aa" contextRef="C_9a79efb8-eb68-42c2-a8fa-55c0d8aa5fda" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">77.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million arose in tax years beginning after December 31, 2017 and will carry forward indefinitely. The federal NOL carryforwards arising in tax years beginning before January 1, 2018 of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_526e6a26-85a6-412d-b566-13a34f438ac6" contextRef="C_ee8693bb-92aa-44a4-880d-83926ceee699" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will begin to expire in 2025 unless previously utilized. The Company&#8217;s state NOL carryforwards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 may be carried forward for 20 years, and will expire at various dates between 2027 and 2044.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the provisions of the Internal Revenue Code ("IRC"), the Company&#8217;s NOL and tax credit carryforwards and certain other attributes are subject to review and possible adjustment by the Internal Revenue Service ("IRS") and state tax authorities. NOL and tax credit carryforwards may be subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the IRC, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Including the recently completed Merger, the Company has completed several equity offerings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the IRC, or could result in a change in control in the future. The Company has not completed an IRC Section 382 and 383 analysis for all relevant tax years regarding the limitation of net operating losses. The NOL deferred tax asset does reflect the limitation resulting from the Merger; however, there could be further limitations due to prior changes in control. Due to the existence of a full valuation allowance, however, changes in the NOLs included as deferred tax assets on the Company&#8217;s consolidated balance sheets would have no impact on the Company's effective tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and California. Because of the NOLs, the Company is subject to U.S. federal examinations for tax years 2006 and forward, and for examinations from state taxing authorities for tax years 2008 and forward.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for taxation under ASC 740, which clarifies the accounting for uncertain tax positions. ASC 740 requires that the Company recognize the impact of a tax position in its consolidated financial statements if the position is more-likely-than-not to be sustained upon examination based on the technical merits of the position. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_163ff97c-1021-4f60-8bc8-4f7b9ee4d571" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="pali:UncertainIncomeTaxPositions" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6de43d9f-83c4-4a5e-b2ca-c9840bb62d09" contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311" name="pali:UncertainIncomeTaxPositions" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any uncertain income tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 740 requires the Company to accrue interest and penalties where there is an underpayment of taxes based on the Company's best estimate of the amount to ultimately be paid. The Company identified no unrecorded material uncertain tax positions as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, consequently no interest or penalties have been accrued by the Company in either period. The Company does not anticipate a significant change to its unrecognized tax benefits within the next 12 months.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_7a14279a-3afb-4079-9f5e-612d7d171fea" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_7a14279a-3afb-4079-9f5e-612d7d171fea_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Segment Information</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_260fcbe6-2cbf-4963-95f4-ebe466d636ce" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2d902210-8537-4796-b9e4-3f85c8a66cfa" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, focused on the research and development of novel therapeutics for patients, including the advancement of PALI-2108 through clinical trials. The Company did not aggregate multiple operating segments into its one operating segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0ffa1e3a-3c65-4853-b3c6-1a6c686c9e2d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief operating decision maker</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;CODM&#8221;) is its chief execut</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d5e2c29-76d7-4253-a01e-bc61cd012e8b" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription" continuedAt="F_4d5e2c29-76d7-4253-a01e-bc61cd012e8b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's CODM uses Net loss that is reported on the consolidated statements of operations and comprehensive loss for the purposes of assessing performance, allocating resources and planning, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">monitoring budget versus actual results, and forecasting future periods. The Company&#8217;s CODM views specific program spend within research and development expenses, research and development spend that is not allocated to specific programs, as well as general and administrative expenses as significant segment expenses. As a pre-product revenue company, the CODM considers budget versus actual results for expenses that are deemed significant and cash forecast models for assessing performance and to decide the level of investment in the Company&#8217;s operating and capital allocation activities. </span></ix:nonNumeric></span><span style=""></span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_7a14279a-3afb-4079-9f5e-612d7d171fea_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span><ix:continuation id="F_4d5e2c29-76d7-4253-a01e-bc61cd012e8b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to significant expense categories included in Net loss, the Company regularly provides disaggregated significant expense amounts that comprise operating expenses to the CODM to assist when managing the Company's single reporting segment.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbf28b9a-076a-4b0c-8507-897f4203f316" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" escape="true" continuedAt="F_bbf28b9a-076a-4b0c-8507-897f4203f316_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation to consolidated operating expenses as our single segment operating loss for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 is included in the table below (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_bbf28b9a-076a-4b0c-8507-897f4203f316_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.76%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PALI-2108 program expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c23ee955-573c-4304-b81c-d78d024ba51d" contextRef="C_4fedbd90-4e26-4897-b395-ac4b7cdb1342" name="pali:ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,070</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cef9748-76e4-4676-b99f-f2893b2f5cab" contextRef="C_f9ff4d32-3399-4339-9015-2a14b777cd9a" name="pali:ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">736</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legacy program expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdd1e31e-e7fa-4f88-acf5-5a3114453efb" contextRef="C_9845b157-d40c-4027-97c2-a0fd4385089a" name="pali:ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34e822a8-294f-420f-af1f-105e5a1badec" contextRef="C_16f011be-773b-4769-92b0-515dab2809dc" name="pali:ProgramExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,303</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07239f91-0bbf-4816-9e65-9f2620061ca3" contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,156</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9230d02e-4798-4e0d-9ae4-5657c7324fb4" contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,987</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39242558-b0a9-4b82-bd8c-350cc90fe5f9" contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,478</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a9297c3-662f-4471-9cb3-f01be65320cc" contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,069</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86645a48-f53f-4f86-8ca5-717206a2fa06" contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ece89f-c2ab-45e9-89fd-8b25e098ab18" contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17dde6cf-b771-4316-a8f6-51590586a14f" contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,859</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ebb77db-009c-4b64-acf1-7162730be34d" contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,320</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108 program expenses are those expenses directly related with the development of the Company's only asset currently under development, PALI-2108. Legacy program expenses are those expenses directly related to its legacy assets, primarily LB1148, which the Company ceased developing in August of 2023. Other research and development expenses includes primarily employee-related expenses and research and development facility expenses, which are not allocated to specific programs, and non-cash losses associated with changes in the fair value of the Company's contingent consideration obligation. For the year ended December 31, 2023, Other research and development expenses also includes the initial fair value of the contingent consideration obligation and transaction-related costs related to the Giiant License Agreement (See Note 4, Fair Value Measurements). Other general and administrative expenses consist primarily of salary and employee-related costs and benefits, professional fees for legal, investor and public relations, accounting and audit services, insurance costs, director and committee fees, and general corporate expenses. Excluded from other general and administrative expenses are intellectual property expenses and business development expenses that are allocated to program expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the other segment items that the Company used to aggregate Total operating expenses to arrive at Net Loss as shown on the consolidated statement of operations include, if applicable, License Revenue, Interest expense and Other income, net.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not provide separate segment asset information to the CODM because the CODM does not review segment assets at a different asset level or category than those shown on the consolidated balance sheets. All of the Company&#8217;s assets are located in the U.S.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="changes_in_disagreements_financial_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="controls_and_procedures_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls an</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Procedures.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer, who is also our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. Based upon the evaluation, our Chief Executive Officer concluded that, as of December 31, 2024, our disclosure controls and procedures were not effective at a reasonable assurance level as a result of the material weakness that existed in our internal control over financial reporting, as described below.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, our management, including our Chief Executive Officer, has concluded that, notwithstanding the identified material weakness in our internal control over financial reporting, the consolidated financial statements in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management's Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term as defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer, who is also our principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. GAAP.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Weakness in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim consolidated financial statements would not be prevented or detected on a timely basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously disclosed, during the quarter ended June 30, 2021, we identified a material weakness in our internal controls over financial reporting due to a lack of controls in the financial closing and reporting process, including a lack of segregation of duties and the documentation and design of formalized processes and procedures surrounding the creation and posting of journal entries and account reconciliations. This material weakness contributed to a material weakness in our control activities based on the criteria set forth in the Committee of Sponsoring Organizations 2013 Framework. If not remediated, or if we identify further material weaknesses in its internal controls, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our consolidated financial statements and a failure to meet its reporting and financial obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described below, management has begun to execute remediation actions to address the material weakness and further actions are ongoing as of December 31, 2024. The material weakness continues to be present as of December 31, 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Remediation Efforts related to the Material Weakness</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management, with oversight from our Audit Committee of the Board, is actively engaged in remediation efforts to address the material weaknesses identified in the management&#8217;s evaluation of internal controls and procedures. The remediation efforts summarized below, which have been or are in the process of being implemented, are intended to address the identified material weakness.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to hire additional finance and accounting employees with appropriate experience, certification, education and training.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented new accounting and finance management software effective July 1, 2022, which is intended to eliminate some of the existing deficiencies in the Company's internal control environment. The information technology general controls implemented with the new accounting and finance management software will be tested for operating effectiveness.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are in the process of updating our formal accounting policies, procedures and controls, including preparation and review of account reconciliations, review of journal entries, and controls over period end financial reporting.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have identified and remediated all segregation of duties deficiencies in its current control environment. The controls established to remediate all segregation of duties deficiencies identified will be documented and tested for operating effectiveness.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are in the process of implementing additional key internal controls designed to address the potential risks identified in its key business processes. Once fully implemented, these controls will be tested for operating effectiveness.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that the implementation and testing of the above steps will allow us to make progress on addressing a number of the deficient controls within our internal control environment, which will help facilitate the remediation of the material weakness identified above. As we continue to evaluate and work to improve our internal control over financial reporting, we will take additional measures to address control deficiencies, or we may modify certain of the remediation measures described above. However, we require additional time to complete the design and implementation of our remediation plans and demonstrate the operating effectiveness of our remediation efforts. The material weakness cannot be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in the Company's internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="other_information_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Information.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed1512d3-a82a-423f-88df-a26ff4a6fb30" contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_a5279440-32f1-4032-b294-0837fa4e2761" contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_fe4baedf-6fba-4f71-a1f8-cf183eee4bba" contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_2c33737c-40d7-4d10-a169-d3a4b4103ec8" contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="disclosure_foreign_jurisdictions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_iii_item_10"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The names of our directors and executive officers and their ages, positions, and biographies as of March 21, 2025 are set forth below. There are no family relationships among any of our directors or executive officers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.72%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:33.72%;box-sizing:content-box;"/>
    <td style="width:1.3%;box-sizing:content-box;"/>
    <td style="width:10.42%;box-sizing:content-box;"/>
    <td style="width:1.6%;box-sizing:content-box;"/>
    <td style="width:17.94%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position Since</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Named Executive Officers</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, Chief Financial Officer, and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mitchell Jones, MD</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Independent Directors</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Donald Williams</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director, Chair</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Margery Fischbein</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Binxian Wei</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director (Series A Preferred)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">J.D. Finley</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Chief Financial Officer since April 2021, and Chief Executive Officer since October 2022. He was appointed to our Board in February 2023. Previously, Mr. Finley served as Leading Biosciences, Inc&#8217;s (the Company&#8217;s wholly owned subsidiary and predecessor company) Chief Financial Officer since January 2017 and as a member of the board of directors of Leading Biosciences, Inc. (the &#8220;LBS Board&#8221;) since December 2014. Prior to joining Leading Biosciences, Inc., Mr. Finley was Chief Executive Officer of PointAcross, Inc., a marketing company, from January 2016 to January 2017. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was Chief Financial Officer at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. From March 2011 to June 2012 Mr. Finley was Executive Vice President, and from June 2012 to April 2014, Mr. Finley was President of Goldmail, Inc. Mr. Finley received a B.A. in business administration from Boise State University and an M.S. in Taxation from the University of Denver. Our Board of Directors (the "Board") believes Mr. Finley&#8217;s experience and familiarity with the Company, its operations, and the life science industry qualify him to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mitchell Jones, M.D., Ph.D</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., has served as the our Chief Medical Officer since September 2023. Dr. Jones has over 17 years of medical and pharmaceutical experience directing translational and clinical activities for therapeutic product candidates in inflammatory bowel disease, metabolic disease, hepatic infectious disease, and oncology. During his career, Dr. Jones has served in a number of positions related to the strategy and development of novel therapies. From November 2022 until joining the Company, Dr. Jones served as VP, Corporate Development and Strategy for Chemomab, Inc. (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases. Additionally, from November 2022 to September 2023, Dr. Jones served as a consultant for Novome Biotechnologies, Inc. and xBiome, Inc., both with development programs in inflammatory bowel disease. Additionally, from August 2020 through November 2022, Dr. Jones served as VP, Clinical Discovery and Development for Finch Therapeutics Group, Inc. (Nasdaq: FNCH), a company focused on developing immune modulating therapies including for serious GI infection and inflammatory bowel disease. From May 2015 through July 2020, Dr. Jones served as VP, Translational and Clinical Development for Biora Therapeutics, Inc. (Nasdaq: BIOR), a company focused on the development of targeted and local acting immune modulating therapies for the treatment of inflammatory bowel disease, where he assisted in securing over $100 million in investor capital. Dr. Jones holds a BS in Physiology, a Master of Biomedical Engineering, a Doctor of Medicine, and a Doctor of Biomedical Philosophy, all from McGill University in Canada.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Donald Williams</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, has served as a member of our Board since April 2021, and became chairman of our Board in February 2024. Previously, Mr. Williams served on the LBS Board since May 2019. Mr. Williams has also served as a member of the board of directors of Akari Therapeutics PLC from 2016 until 2024, a member of the board of directors of Forte Biosciences, Inc. from 2020 until 2024, and a member of the board of directors of ImpediMed, Inc. from 2017 until 2023. From 2014 to 2019, Mr. Williams was a member of the board of directors of Adhera Therapeutics, Inc. From 2015 to 2021, Mr. Williams served as a member of the board of directors of Alphatec Spine, Inc. From 2007 to 2014, Mr. Williams was a Partner and the National Life Sciences Leader for Grant Thornton LLP, and spent over 20 years as a partner at Ernst &amp; Young LLP. From 2001 to 2014, Mr. Williams served on the board of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">directors of the San Diego Venture Group, during which time he also served as the group&#8217;s president and chairman. Mr. Williams was also a founding member of the Young VCs of Southern California. Mr. Williams received a B.A. in accountancy from Southern Illinois University and completed the director education and certification program at the University of California, Los Angeles Anderson School of Business. Our Board believes Mr. Williams&#8217; experience as a board member and public accountant in the life sciences industry qualifies him to serve on the Board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Margery Fischbein</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, has served as a member of our Board since May 2024. Ms. Fischbein has been a Managing Director, Healthcare, at Cassel Salpeter &amp; Co., an independent investment banking firm, since January 2020. Previously, from 2017 through 2019, Ms. Fischbein was Managing Director, Healthcare Investment Banking, at Seaport Global. She also serves on the Board of CytoDel Inc., a private biotechnology company. Ms. Fischbein received a BA degree in economics from Harvard University and an MBA from Harvard Business School. She is a Board Member Emeritus of the Harvard Business School Club of New York. Our Board believes that Ms. Fischbein&#8217;s experience in investment banking and the healthcare industry qualifies her to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Binxian Wei</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, has served as a member of our Board since February 2019. Mr. Wei has been the V.P. of Darsheng Trade &amp; Tech. Development Co, Ltd. (a subsidiary to Tianjin Tiayo Pharmaceutical Co., Ltd.) since 2015. Mr. Wei is responsible for the active pharmaceutical ingredient and finished dosage marketing for Chinese pharmaceutical companies. From 2008 through 2010, he worked as a business development manager for Sakai Trading. Mr. Wei received a master&#8217;s degree in mathematical and computer sciences from Colorado School of Mines, and a master&#8217;s degree and B.S. in chemical engineering from Tianjin University in China. Mr. Wei was appointed as the director representative of the Series A 4.5% Convertible Preferred Stock by Tianjin Pharmaceuticals Group International Holdings Co., LTD, the sole holder of our outstanding Series A 4.5% Convertible Preferred Stock. Our Board believes Mr. Wei&#8217;s experience as a board member and pharmaceutical experience qualify him to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Meetings</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2024, the Board held seven meetings (including regularly scheduled and special meetings) and acted through unanimous written consent nine times. All of our directors, attended at least 75% of all meetings of the general Board and each respective committee on which such director serves during the year ended December 31, 2024. The Board currently holds regularly scheduled meetings and calls for special meetings or acts through unanimous written consents as necessary. Meetings of the Board may be held in-person, virtually or telephonically. Directors are expected to attend all board meetings and meetings of the committees of the board on which they serve and to spend the time needed and meet as frequently as necessary to properly discharge their duties. As required under applicable Nasdaq listing standards, in 2024, our independent directors met four times in scheduled executive sessions at which only independent directors were present. Information with regard to committee meetings and written consent is provided for below in the section of this Annual Report on Form 10-K entitled &#8220;Committees.&#8221; Although attendance of meetings is encouraged, we do not have a formal policy regarding attendance by directors at board and committee meetings.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attendance at 2024 Annual Meeting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not have a formal policy regarding attendance by members of our Board at annual meetings of stockholders, we encourage, but do not require, directors and nominees for director to attend. All of our directors attended the annual meeting of stockholders in 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#8217;s successor is duly elected and qualified. The holder of our Series A 4.5% Convertible Preferred Stock has the right to appoint one member of the Board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board presently has four members. Effective February 29, 2024, we amended our bylaws to remove the classified board structure. Accordingly, all of our directors&#8217; terms, except for the director appointed by the Series A Preferred Stock, expire on an annual basis. Our business, property and affairs are managed under the direction of the Board. Members of the Board are kept informed of our business through discussions with the Chief Executive Officer and other officers, by reviewing materials provided to them and by participating in meetings of the Board and its committees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board is responsible for establishing broad corporate policies and for overseeing our overall management. In addition to considering various matters which require its approval, the Board provides advice and counsel to, and ultimately monitors the performance of, our senior management.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independent Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required under the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. Our Board consults with our counsel to ensure that the Board&#8217;s determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of their family members, and the Company, its senior management and its independent auditors, the Board has affirmatively determined that each of (i) Mr. Williams, (ii) Ms. Fischbein and (iii) Mr. Wei are independent directors within the meaning of the applicable Nasdaq listing standards. In making this determination, the Board found that none of these directors had a material or other disqualifying relationship with the Company.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Leadership Structure</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has an independent chair, Mr. Williams, who has authority, among other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. Accordingly, the Board Chair has substantial ability to shape the work of the Board. The Company believes that separation of the positions of Board Chair and Chief Executive Officer reinforces the independence of the Board in its oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Board Chair creates an environment that is more conducive to objective evaluation and oversight of management&#8217;s performance, increasing management accountability and improving the ability of the Board to monitor whether management&#8217;s actions are in the best interests of the Company and its shareholders. As a result, the Company believes that having an independent Board Chair can enhance the effectiveness of the Board as a whole.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Role of the Board in Risk Oversight</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the Board&#8217;s key functions is informed oversight of our risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements. Audit Committee responsibilities also include oversight of cybersecurity risk management. Our Governance and Nominating Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as possible. The Board has delegated to the Board Chair the responsibility of coordinating between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delinquent Section 16(a) Reports</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.606%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:31.766%;box-sizing:content-box;"/>
    <td style="width:2.861%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:31.766%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Reporting Person</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Report and Number Filed Late</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No. of Transactions Reported Late</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephanie C. Diaz</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form 4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cristina Csimma, PharmD, MHP</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form 4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert Trenschel, D.O.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form 4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filed Form 4 on February 13, 2024.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) Beneficial Ownership Reporting Compliance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) of the Exchange Act requires the Company&#8217;s directors and executive officers, and persons who own more than ten percent of a registered class of the Company&#8217;s equity securities, to file with the SEC initial reports of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent shareholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that during the fiscal year ended December 31, 2024, our directors, executive officers, and greater than 10% stockholders complied with all applicable Section 16(a) filing requirements. In making these statements, we have relied upon a review of the copies of Section 16(a) reports furnished to us and the written representations of our directors, executive officers, and greater than 10% stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Ethics</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted the Palisade Bio, Inc. Code of Business Conduct and Ethics (the "Ethics Code") that applies to all of our officers, directors and employees. The Ethics Code is available on our website at www.palisadebio.com by clicking on &#8220;Investors &amp; News,&#8221; then clicking &#8220;Corporate Governance&#8221; then &#8220;Governance Documents.&#8221; The information on our website is not incorporated by reference into this Annual Report on Form 10-K. If we make any substantive amendments to the Ethics Code or grant any waiver from a provision of the Ethics Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff05127f-d773-4134-8b79-bcb7ee6b5544" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an Insider Trading Policy governing the purchase, sale, and/or other dispositions of our securities by directors, officers, employees, and the Company itself that is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any listing standards applicable to the Company. A copy of the policy can be found as Exhibit 19.1 to this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholder Communications with the Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a formal process for stockholder communications with our independent directors. Individuals wanting to communicate with our directors are invited to communicate with the non-management members of the Board by sending correspondence to the Board, c/o Corporate Secretary, Palisade Bio, Inc., 7750 El Camino Real, Suite 2A, Carlsbad, CA 92009. These communications will be reviewed by the Secretary of Palisade, who will determine whether the communication is appropriate for presentation to the Board or the relevant director. The purpose of this screening is to allow the Board to avoid having to consider irrelevant or inappropriate communications (such as advertisements, solicitations and hostile communications). The screening procedures have been approved by a majority of the independent directors. All communications directed to the Audit Committee in accordance with our Code of Business Conduct and Ethics policy or reported or on our Ethics Point whistleblower hotline that relate to questionable accounting or auditing matters will be promptly and directly forwarded to the Audit Committee, at the discretion of our compliance officer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Regarding Committees of the Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has three standing committees: an Audit Committee, a Compensation Committee, and a Governance and Nominating Committee. The following table provides, as of March 21, 2025, membership for each of the Board committees:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.531%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:17.277%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:17.097%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:17.097%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Audit Committee</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Compensation Committee</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Governance and Nominating Committee</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Donald A. Williams</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Margery Fischbein</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">C</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Binxian Wei</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley (not Independent)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">X = Current member of committee</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C = Current member and chairperson of the committee</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Committee</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of the Board was established by the Board in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), to oversee the Company's accounting and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent auditors; determines and approves the engagement of the independent auditors; determines whether to retain or terminate the existing independent auditors or to appoint and engage new independent auditors; reviews and approves the retention of the independent auditors to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent auditors on the Company's audit engagement team as required by law; reviews and approves or rejects transactions between the Company and any related persons; confers with management and the independent auditors regarding the effectiveness of internal control over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; reviews and assesses the Company's cyber security risks and assessments; and meets to review the Company's annual audited financial statements and quarterly financial statements with management and the independent auditor, including a review of the Company's disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee is currently composed of three directors: Mr. Williams (Chair), Ms. Fischbein, and Mr. Wei. The Audit Committee met five times and acted through unanimous written consent one time during the year ended December 31, 2024. The Board has adopted a written Audit Committee charter that is available to stockholders on our website at www.palisadebio.com by clicking on "Investors &amp; News", the clicking "Corporate Governance", then &#8220;Governance Documents.&#8221; The information on our website is not incorporated by reference into this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of the Company's Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing standards).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has also determined that Mr. Williams qualifies as an &#8220;audit committee financial expert,&#8221; as defined in applicable SEC rules. The Board made a qualitative assessment of Mr. Williams&#8217; level of knowledge and experience based on a number of factors, including his formal education and his tenure as a partner at Grant Thornton LLP and his tenure as a partner at Ernst &amp; Young LLP.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Committee</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee is currently composed of two directors: Ms. Fischbein (Chair) and Mr. Williams. The Board has determined that each member of the Compensation Committee is independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing standards), a &#8220;non-employee director&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act, and an &#8220;outside director&#8221; as that term is defined in Section 162(m) of the Internal Revenue Code of 1986, as amended. The Compensation Committee met two times and acted through unanimous written consent five times during the year ended December 31, 2024. The Board has adopted a written Compensation Committee charter that is available to stockholders on our website at www.palisadebio.com by clicking on "Investors &amp; News," the clicking "Corporate Governance," then &#8220;Governance Documents.&#8221; The information on our website is not incorporated by reference into this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee of the Board acts on behalf of the Board to review, modify (as needed) or approve (or, if it deems appropriate, making recommendations to the Board regarding) the overall compensation strategy and policies for the Company, including, among other things:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">reviewing and approving (or, if it deems appropriate, making recommendations to the Board regarding) corporate performance goals and objectives, which shall support and reinforce the Company's long-term strategic goals, relevant to the Company's compensation plans and programs;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">evaluating and approving (or, if it deems appropriate, making recommendations to the Board regarding) the Company's compensation plans and programs, as well as the modification or termination of existing plans and programs;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">evaluating (including, if it deems appropriate, with the input of some or all of the other members of the Board) risks associated with and potential consequences of the Company's compensation policies and practices, as applicable, to all the Company's employees, and assessing whether risks and consequences arising from the</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Company's compensation policies and practices for the Company's employees, as may be mitigated by any other compensation policies and practices, are reasonably likely to have a material adverse effect on the Company;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">establishing policies with respect to equity compensation arrangements, with the objective of appropriately balancing the perceived value of equity compensation and the dilutive and other costs of that compensation to the Company; and</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">evaluating the efficacy of the Company's compensation policy and strategy in achieving expected benefits to the Company and otherwise furthering the Committee&#8217;s policies.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Committee Processes and Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Typically, the Company's Compensation Committee meets at least once annually and with greater frequency if necessary. The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with management. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer does not participate in and is not present during any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under its charter, the Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Compensation Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. Under its charter, to the extent required by the SEC and Nasdaq rules, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the compensation committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence; however, there is no requirement that any adviser be independent.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, after taking into consideration the guidance from the SEC and Nasdaq described above, the Compensation Committee engaged Compensia Inc. (&#8220;Compensia&#8221;) as its compensation consultant. The Compensation Committee identified Compensia based on its general reputation in the industry and experience providing similar services to companies similar to us. The Compensation Committee requested that Compensia:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">evaluate the efficacy of the Company's existing compensation strategy and practices in supporting and reinforcing our long-term strategic goals (including through a peer group analysis); and</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">assist in refining the Company's compensation strategy and in developing and implementing executive and non-employee director compensation programs to execute that strategy.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under its charter, the Compensation Committee may form and delegate authority to subcommittees as appropriate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee holds one or more meetings during the fourth quarter of the year and the first quarter of the following year to discuss and make recommendations to the Board for annual base salary compensation adjustments, annual bonuses, annual equity awards, and current year corporate performance objectives. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#8217;s process comprises two related elements: the determination of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compensation levels and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee by our Chief Executive Officer. In the case of our Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee, which determines recommendations to the Board regarding any adjustments to his compensation as well as equity awards to be granted. For all executives and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels, compensation data from comparative companies, compensation surveys, and recommendations of any compensation consultant, if applicable. The Compensation Committee considered the peer-group analysis from Compensia when making compensation decisions. Based on this analysis, the overall average of the 2024 cash compensation for our named executive officers approximated the 25</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percentile of the peer group.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance and Nominating Committee</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Governance and Nominating Committee of the Board is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors, selecting or recommending to the Board for selection candidates for election to the Board, making recommendations to the Board regarding the membership of the committees of the Board, assessing the performance of the Board, and developing a set of corporate governance principles for the Company.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Governance and Nominating Committee is currently composed of three directors: Mr. Williams (Chair), Ms. Fischbein, and Mr. Wei. Each member of the Governance and Nominating Committee is independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards), a non-employee director and free from any relationship that would interfere with the exercise of his or her independent judgment. The Governance and Nominating Committee met one time and acted through unanimous written consent two times during the year ended December 31, 2024. The Board has adopted a written Governance and Nominating Committee charter that is available to stockholders on our website at www.palisadebio.com by clicking on "Investors &amp; News," then clicking "Corporate Governance," then &#8220;Governance Documents.&#8221; The information on our website is not incorporated by reference into this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The responsibilities of the Governance and Nominating Committee include, among other things:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on the Board;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">considering and making recommendations to the Board regarding the composition and chairmanship of the committees of the Board;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">considering the need for and, if necessary, developing and instituting plans or programs for the continuing education of the Board; and</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">developing corporate governance principles to be applicable to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Governance and Nominating Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The Governance and Nominating Committee also intends to consider such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of the Company's stockholders. However, the Governance and Nominating Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Governance and Nominating Committee typically considers diversity (including gender, racial and ethnic diversity), age, skills and such other factors as it deems appropriate, given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Governance and Nominating Committee appreciates the value of thoughtful Board refreshment, and regularly identifies and considers qualities, skills and other director attributes that would enhance the composition of the Board. In the case of incumbent directors whose terms of office are set to expire, the Governance and Nominating Committee reviews these directors&#8217; overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors&#8217; independence. The Governance and Nominating Committee also takes into account the results of the Board&#8217;s self-evaluation, conducted annually on a group and individual basis. In the case of new director candidates, the Governance and Nominating Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Governance and Nominating Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Governance and Nominating Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Governance and Nominating Committee meets to discuss and consider the candidates&#8217; qualifications and then selects candidates for recommendation to the Board by majority vote.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Governance and Nominating Committee does not have a formal policy regarding Board diversity. Diversity is one of a number of factors, however, that the committee takes into account in identifying nominees, and the Governance and Nominating Committee believes that it is essential that the Board members represent diverse viewpoints.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Governance and Nominating Committee will consider director candidates recommended by the Company's stockholders. The Governance and Nominating Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Governance and Nominating Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Governance and Nominating Committee at the following address: Palisade Bio, Inc., Attn: Corporate Secretary, 7750 El Camino Suite 2A, Carlsbad, California 92009, no later than the close of business on the 90</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day nor earlier than the close of business on the 120</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">day prior to the first anniversary of the preceding year&#8217;s annual meeting of stockholders. Submissions must include, among other things, the name and address of the stockholder on whose behalf the submission is made; the number of the Company's common stock shares that are owned beneficially by such stockholder as of the date of the submission; the full name of the proposed candidate; a description of the proposed candidate&#8217;s business experience for at least the previous five years; complete biographical information for the proposed candidate; and a description of the proposed candidate&#8217;s qualifications as a director. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_iii_item_11"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executive Compensation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE COMPENSATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our named executive officers for the fiscal year ended December 31, 2024, were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley, our Chief Executive Officer and Chief Financial Officer; and</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mitchell Jones, M.D., Ph.D., our Chief Medical Officer.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents all of the compensation awarded to or earned by or paid to our named executive officers during the fiscal years ended December 31, 2024 and 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary Compensation Table</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.724%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.041%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.921%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.001000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.843%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.002%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.522%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Principal Position</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Salary ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock  Awards </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Equity Incentive Plan Compensation </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other Compensation ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">542,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">813,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">520,333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,541</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221,226</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,277,100</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mitchell Jones, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">415,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">581,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,189</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,247</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,563</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,025</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,024</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with SEC rules, reflects the aggregate grant date fair value of stock awards and option awards granted to our named executive officers in the applicable fiscal years, as determined in accordance with the provisions of FASB ASC Topic 718. See Note 6 of the notes to our audited consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 26, 2024 with respect to grants in 2023. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts in this column reflect annual cash bonuses paid with respect to the applicable fiscal year, based on corporate and individual performance. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU and option awards granted to each named executive officer in November 2023 were intended to provide retention and compensation for service in 2024; however, because the grants were approved in November 2023, no amounts are disclosed for 2024 RSU or option awards for the named executive officers. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts reflect payment made to Dr. Jones as a consultant of the Company prior to becoming the Chief Medical Officer on September 5, 2023.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Program Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compensation program for executive officers is designed to encourage our management team to continually achieve our short-term and long-term corporate objectives while effectively managing business risks and challenges. We provide what we believe is a competitive total compensation package to our management team through a combination of base salary, an annual performance-based bonus and long-term equity-based incentives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee shall review, determine and approve (or, if it deems appropriate, recommend to our Board for determination and approval, except as provided below), at their discretion, in light of relevant performance goals and objectives, taking into account such other items as the Compensation Committee deems relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The base salaries of our named executive officers are reviewed from time to time and adjusted when our Board or compensation committee determines an adjustment is appropriate. The base salaries of Mr. Finley and Dr. Jones were $542,000 per annum and $415,000 annum, respectively, in 2024.  Prior to 2024, Mr. Finley's base salary in 2023 was $490,000 per annum, and increased to $542,000 per annum effective June 1, 2023 with his appointment to our Chief</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Officer. Dr. Jones was appointed Chief Medical Officer effective September 5, 2023 with a base salary of $415,000.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bonus Opportunity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our named executive officers are eligible to be considered for an annual discretionary cash incentive bonus of up to a percentage of their respective base salary, based on achievement of individual and/or corporate performance targets, metrics and/or objectives to be determined and approved by our Board or the Compensation Committee, including pursuant to an annual incentive plan or similar plan adopted by our Board, if any. Any such bonus would be paid after the close of the fiscal year and after determination by our Board or the Compensation Committee. All annual incentive compensation is discretionary and not guaranteed and, in addition to the other conditions for earning such compensation, each officer must remain an employee in good standing of the Company on the annual incentive compensation payment date in order to be eligible for any annual incentive compensation. Our Board (or the Compensation Committee thereof) may review an executive officer&#8217;s annual performance bonus amount for adjustment from time to time. The 2024 annual discretionary cash incentive bonus targets were 50% of base salary for Mr. Finley and 40% of base salary for Dr. Jones.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the annual cash incentive bonuses paid to Mr. Finley and Dr. Jones were calculated based on achievement of 100% of the corporate performance targets for the year multiplied by their respective bonus target percentages at the time. The corporate performance targets related to clinical and medical development, financial position, and corporate operations and infrastructure during 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer stock options and RSUs to our employees, including our named executive officers, as the long-term equity-based incentive component of our compensation program. Our stock options allow our employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant. Our Board or the Compensation Committee determines the fair market value of our common stock based on the closing price of our common stock. Generally, our stock options and RSUs granted to our named executive officers vest in equal amounts on a quarterly basis over three years from the date of grant, subject to continuous service.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grants to our current named executive officers also provide for accelerated vesting of all unvested option shares and RSUs in the event we undergo a change in control and the named executive officer is subject to an involuntary termination without cause within 12 months thereafter.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Previously, we granted to Mr. Finley market-based PSUs, which vest (a) 50% when the volume weighted average price of the Company&#8217;s common stock over 20 consecutive trading days is $48.00 or greater, and (b) 50% when such volume weighted average price of the Company&#8217;s common stock over 20 consecutive trading days is $63.75 or greater. The market-based PSUs remain unvested.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information regarding the equity awards currently held by our named executive officers, please see below under &#8220;Outstanding Equity Awards at Fiscal Year-End.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements with Our Named Executive Officers</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to (i) an employment agreement with Mr. Finley, our Chief Executive Officer and Chief Financial Officer and (ii) an employment agreement with Mitchell Jones, M.D., Ph.D., our Chief Medical Officer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Descriptions of each of the foregoing employment agreements are described below.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finley Employment Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Finley was appointed as our Chief Financial Officer in January 2021 pursuant to his amended and restated employment agreement dated January 22, 2021 (&#8220;Finley Employment Agreement&#8221;). Pursuant to the Finley Employment Agreement, Mr. Finley originally  received an annual base salary of $400,000, with an annual target cash bonus of 40% of his base salary. Mr. Finley&#8217;s base salary and annual target cash bonus have been increased several times since Mr. Finley was original appointed as our Chief Financial Officer, including in connection with his promotion to Chief Executive Officer, including most recently in June 2023, when his base salary was increased to $542,000 per annum and his annual target cash bonus was increased to 50% of his base salary. On September 25, 2024, we entered into an executive employment agreement (the &#8220;Amended Finley Employment Agreement&#8221;), which amended and restated the terms of the Finley Employment Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Finley Employment Agreement provides that if we terminate Mr. Finley without &#8220;Cause&#8221; or if Mr. Finley resigns for &#8220;Good Reason&#8221;, each as defined in the Amended Finley Employment Agreement, except during the Change in Control Period (as defined below) Mr. Finley will be entitled to receive the following, subject to Mr. Finley signing and not revoking a general release of claims against us: (i) salary continuation and COBRA reimbursement for 12 months each and (ii) 12 months of vesting acceleration of equity grants subject to time based vesting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that we terminate Mr. Finley without &#8220;Cause&#8221; or if Mr. Finley resigns for &#8220;Good Reason&#8221; during the period beginning three months before and ending 12 months after a &#8220;Change in Control&#8221;, as defined in the Amended Finley Employment Agreement (such period, the &#8220;Change in Control Period&#8221;), Mr. Finley will be entitled to receive the following, subject to Mr. Finley signing and not revoking a general release of claims against us: (i) salary continuation and COBRA reimbursement for 18 months each , (ii) full acceleration of all time-based equity awards, and (iii)an additional severance payment equal to his target bonus.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Jones Employment Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 5, 2023, we entered into an at-will employment agreement with Dr. Jones (the &#8220;Jones Employment Agreement&#8221;). Pursuant to the terms of the Jones Employment Agreement, Dr. Jones (i) receives a base salary of $415,000 per annum and is eligible to receive an annual cash bonus based on the achievement of certain performance goals with a target of 40% of his base salary, and (ii) is eligible to receive an annual market-based stock option grant as determined by the Board or a committee thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the Jones Employment Agreement, if we terminate Dr. Jones&#8217; employment without &#8220;Cause&#8221; or Dr. Jones resigns for &#8220;Good Reason,&#8221; as each term is defined in the Jones Employment Agreement, Dr. Jones will be eligible for the continued payment of his base salary (in accordance with regular payroll practices) and COBRA benefits for nine months following the termination date.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that we terminate Dr. Jones&#8217; employment without &#8220;Cause&#8221; or Dr. Jones resigns for &#8220;Good Reason&#8221; within the Change in Control Period, then Dr. Jones will be eligible to receive the following: (i) a lump sum payment equal to the sum of (x) 12 months of base salary plus (y) 100% of the target bonus in effect at the time of termination, (ii) the continued payment of COBRA benefits for 12 months, and (iii) full acceleration of 100% of outstanding equity awards that are subject to time-based vesting. The foregoing benefits are contingent on Dr. Jones entering into a release of claims satisfactory to the Company.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Perquisites, Health, Welfare and Retirement Benefits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. Current named executive officers are eligible to participate in our defined contribution 401(k) plan, on the same basis as all of our other employees, under which they may make voluntary contributions as a percentage of compensation. No matching contributions have been made by us since the adoption of the 401(k) plan.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Grant Policy</span></p>
  <div><ix:nonNumeric id="F_7380a179-dd07-4de1-a082-768152624e25" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="ecd:AwardTmgMnpiDiscTextBlock" escape="true" continuedAt="F_7380a179-dd07-4de1-a082-768152624e25_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity awards are discretionary and are generally granted to our named executive officers the second month of the applicable fiscal year. In certain circumstances, our Compensation Committee may  approve grants to be effective at other times. The Compensation Committee </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_757c4d6e-0c71-4ccb-8d9a-5f67a5ea27e9" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="ecd:AwardTmgMnpiCnsdrdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does not grant equity awards in anticipation</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the release of material nonpublic information and we </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee10d2bd-82c2-4143-b27b-8603cdbe26a5" contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb" name="ecd:MnpiDiscTimedForCompValFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do not time</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">release of material nonpublic information based on equity award grant dates. No equity awards were granted to our named executive officers in 2024, as the equity awards granted in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7380a179-dd07-4de1-a082-768152624e25_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 to our named executive officers were intended to provide retention and compensation for service in 2024.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective October 2023, we adopted a clawback policy (the &#8220;Clawback Policy&#8221;), that is administered by our Compensation Committee. Pursuant to the Clawback Policy, our current and former executive officers are required to reimburse us in the event that any Incentive Compensation (as defined in the Clawback Policy) is awarded to such executive and is determined to be awarded in error subsequent to an accounting restatement resulting from material noncompliance with financial reporting requirements under federal securities laws. Notwithstanding, we have not historically granted Incentive Compensation based on financial metrics that would be subject to a restatement. A copy of the Clawback Policy is included as Exhibit 97.1 to this our Annual Report on Form 10-K filed with the SEC on March 26, 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards at Fiscal Year-End</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.762%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.762%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.302%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.602%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.343%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.443%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.622%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.1%;box-sizing:content-box;"/>
    <td style="width:6.182%;box-sizing:content-box;"/>
    <td style="width:1.261%;box-sizing:content-box;"/>
    <td style="width:6.102%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.261%;box-sizing:content-box;"/>
    <td style="width:5.722%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.323%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.023%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.18%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="16" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock Awards </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Award Type </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities underlying unexercised options - exercisable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities underlying unexercised options &#8211; unexercisable </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity incentive plan awards:  Number of securities underlying unexercised unearned options</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option exercise price </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option expiration date</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of shares or units of stock that have not vested</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Market value of shares of units of stock that have not vested</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity incentive plan award: Number of unearned shares, units or other rights that have not vested </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity incentive plan awards:  Market or payout value of unearned shares, units or other rights that have not vested </span><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-weight:bold;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(b)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(c)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(d)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(e)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(f)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(g)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(h)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(i)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(j)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(k)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(l)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/12/2015</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/12/2025</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/10/2017</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/10/2027</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/18/2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/18/2031</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.85</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2019</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2029</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/17/2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715.65</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/17/2032</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/11/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,328</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/11/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/6/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,588</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/6/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2019</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2029</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/19/2020</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/19/2030</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2019</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2029</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2019</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2029</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/27/2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/27/2031</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/18/2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/18/2031</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/6/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,224</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/6/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/11/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,950</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">621</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/11/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2019</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2029</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/10/2017</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/10/2027</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/19/2020</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/19/2030</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1000</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.85</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/12/2015</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/12/2025</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2019</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1740.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/2029</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/17/2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715.65</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/17/2032</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#caeefb;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRSU</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/6/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,083</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,787</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;top:-3.283pt;white-space:pre-wrap;font-size:4.69pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mitchell Jones M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,474</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.85</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NQ</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/5/2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,083</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,917</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/5/2033</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option awards were granted under the 2013 Plan, the 2021 EIP and the 2021 Inducement Plan.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock awards were granted under the 2021 EIP and the 2021 Inducement Plan.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The acronym ISO refers to Incentive Stock Options, NQ refers to non&#8212;statutory stock options, PRSU to Performance Restricted Stock Units, and RSU to Restricted Stock Units.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vest in equal proportions each quarter over three years of continuous service, generally from the date of grant.</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All of the option awards granted under the 2013 Plan were granted with a per share exercise price equal to fair market value of one share of LBS common stock on the date of grant, as determined in good faith by the Board. All of the option awards granted under the 2021 EIP and the 2021 Inducement Plan were granted with a per share exercise price equal to the closing price of our common stock on the grant date.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The values shown are based on $1.65 per share, which was the closing price of our common stock on December 31, 2024, the last day of our most recent fiscal year.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Performance restricted stock units vest (a) 50% when the volume weighted average price of our common stock over 20 consecutive trading days is $48.00, and (b) 50% when such volume weighted average price of our common stock over 20 consecutive trading days is $6.75, subject to the named executive&#8217;s continuous service.  In accordance with SEC rules, the number of performance restricted stock units in column (k) and the value of those PRSUs in column (l) reflects threshold performance assuming the volume weighted average price of our common stock achieves the $48.00 requirement over 20 consecutive trading days.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Benefit Plans</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal features of our equity plans are summarized below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Equity Incentive Plan</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board and stockholders approved the 2021 EIP, which became effective in April 2021. On June 8, 2023, our stockholders approved amendments to the 2021 EIP increasing the numbers of shares of common stock issuable under the plan and increasing the annual evergreen share amount. The number of shares of common stock reserved for issuance under the 2021 EIP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 3031, in an amount equal to the lesser of (1) 7.5% of the total number of shares of our common stock outstanding on December 31 of the preceding year, or (2) a lesser number of shares of our common stock determined by the Board prior to the date of the increase. As of December 31, 2024, 37,586 shares of our common stock were authorized for future grants under the 2021 EIP and there were an aggregate of 43,107 outstanding awards issued under the 2021 EIP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2021 EIP provides for the grant of incentive stock options (&#8220;ISOs&#8221;), within the meaning of Section 422 of the Code to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of our affiliates. Our compensation committee has the authority, concurrent with our Board, to administer our 2021 EIP. The Board may also delegate to one or more of our officers certain authority under the terms of the 2021 EIP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options under the 2021 EIP are generally granted with an exercise price equal to the fair market value of our common stock on the date of grant. Options granted under the 2021 EIP vest at the rate specified in the stock option agreement as determined by the plan administrator. Options may have a term up to a maximum of 10 years. Unless the terms of an optionee&#8217;s stock option agreement provides otherwise, if an optionee&#8217;s service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionee may generally exercise any vested options for a period of three months following the cessation of service. If an optionee&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or an optionee dies within a certain period following cessation of service, the optionee or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual. In no event may an option be exercised beyond the expiration of its term.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2021 EIP provides that in the event of certain specified significant corporate transactions (or a change in control, as defined below), unless otherwise provided in an award agreement or other written agreement between us and the award holder, the administrator may take one or more of the following actions with respect to such stock awards:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">arrange for the assumption, continuation, or substitution of a stock award by a successor corporation;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not exercised (if applicable) at or before the effective time of the transaction;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">cancel or arrange for the cancellation of the stock award, without the approval of stockholders but with the consent of any materially adversely affected participant, in exchange for other awards, cash, or other consideration, if any, as determined by our Board; or</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">make a payment, in the form determined by our Board, equal to the excess, if any, of (i) the per share amount payable to holders of our common stock in connection with the corporate transaction, over (ii) any per share exercise price payable by such holder, if applicable.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2021 EIP, a corporate transaction is generally the consummation of: (i) a sale of all or substantially all of our assets, (ii) the sale or disposition of more than 50% of our outstanding securities, (ii) a merger or consolidation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">where we do not survive the transaction, or (iv) a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i) with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction), and (ii) any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, our Board may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i) the per share amount payable to holders of common stock in connection with the corporate transaction, over (ii) any per share exercise price payable by such holder, if applicable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional long-term equity incentives are provided through the ESPP. On June 8, 2023 our stockholders approved amendments to the ESPP increasing the number of shares of common stock authorized under the ESPP and increasing the annual evergreen share amount. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Code. Our compensation committee has the authority, concurrent with our Board, to administer the ESPP. Under the ESPP, all of our regular employees (including our named executive officers during their employment with us) may participate and may contribute, normally through payroll deductions, The 2021 ESPP permits eligible employees (including our named executive officers) while employed by the Company to purchase common stock through payroll deductions, which may not exceed $25,000 in a calendar year or 5,000 shares of the Company's shares of common stock each offering period, as defined in the 2021 ESPP, at a price equal to 85% of the fair value of the Company's common stock at the beginning or end of the offering period, whichever is lower. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 3031, in an amount equal to the lesser of (1) 2.5% of the total number of shares of our common stock outstanding on December 31 of the preceding year, (2) 28,909 shares of our common stock, or (3) such lesser number of shares of our common stock as the Board may designate prior to the date of increase. As of December 31, 2024, 19,086 shares of our common stock were authorized for future grants under the ESPP. A total of 2,256 shares of our common stock were purchased by employees under participation in the ESPP during the year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Inducement Plan</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board adopted the 2021 Inducement Plan in November 2021. The 2021 Inducement Plan was adopted without stockholder approval pursuant to Rule 5635(c) of the Nasdaq Listing Rules. On August 7, 2023, our Board amended the 2021 Inducement Plan to increase the number of common shares authorized under the plan from 1,000 to 66,666. The 2021 Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other forms of stock awards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock awards granted under our 2021 Inducement Plan may only be made to individuals who did not previously serve as employees or non-employee directors of the Company or an affiliate of the Company (or following such individuals&#8217; bona fide period of non-employment with the Company or an affiliate of the Company), as an inducement material to the individuals&#8217; entering into employment with the Company or an affiliate of the Company or in a manner otherwise permitted by Rule 5635(c) of the Nasdaq Listing Rules. In addition, stock awards must be approved by either a majority of our &#8220;independent directors&#8221; (as such term is defined in Rule 5605(a)(2) of the Nasdaq Listing Rules) or the Compensation Committee, provided such committee comprises solely independent directors. The terms of the 2021 Inducement Plan are otherwise substantially similar to our 2021 EIP (including with respect to the treatment of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock awards upon corporate transactions involving us or certain changes in our capitalization), except stock awards granted under the 2021 Inducement Plan may not be repriced without stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares of our common stock that may be issued under the 2021 Inducement Plan is 66,666 shares. Shares subject to stock awards granted under the 2021 Inducement Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under the 2021 Inducement Plan. Additionally, shares become available for future grant under the 2021 Inducement Plan if they were issued under stock awards granted under the 2021 Inducement Plan and we repurchase or reacquire them or they are forfeited. This includes shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award. As of December 31, 2024, there were 52,941 shares of our common stock authorized and available for issuance as equity-based awards under the 2021 Inducement Plan and there were an aggregate of 10,079 outstanding awards issued under the 2021 Inducement Plan.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DIRECTOR COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Compensation Arrangements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-employee Director Compensation Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a compensation policy that is applicable to each member of our Board who is not also serving as an employee or consultant to the Company (the &#8220;Director Compensation Policy&#8221;).  It was most recently amended in June 2024 with respect to the equity compensation payable to our non-employee directors, as further described below. Pursuant to our Director Compensation Policy, our non-employee directors will receive the following compensation for service on our Board:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Compensation</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">an annual cash retainer of $40,000;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">an additional annual cash retainer of $35,000 for service as chair of the Board;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">an additional annual cash retainer of $20,000, $15,000, $10,000 and $20,000 for service as chair of the Audit Committee, Compensation Committee, Governance and Nominating Committee and Strategy and Finance Committee, respectively (the Strategy and Finance Committee was removed as a committee of our Board in February 2024); and</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">an additional annual cash retainer of $10,000, $7,500, $5,000 and $10,000 for service as a member of the Audit Committee, Compensation Committee, Governance and Nominating Committee and Strategy and Finance Committee, respectively (the Strategy and Finance Committee was removed as a committee of our Board in February 2024).</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to June 2024, the equity compensation component of our Director Compensation Policy was not formalized and grants were made on an ad hoc policy. Based upon this policy, each non-employee director was also issued equity grants. In determining the size of such grants, the Compensation Committee would review the Company&#8217;s market capitalization, equity compensation paid to directors of its peer group companies, and such other factors as the committee deemed appropriate. The goal of such ad hoc policy was to incentivize and retain directors while not causing the excessive dilution that a value-based policy would result in. Ad hoc grants could be made in the form of options, Restricted stock units, or a combination thereof.  During the 2024 fiscal year, the Compensation Committee utilized this ad hoc policy to make an option grant to Ms. Fischbein on May 7, 2024 for 1,000 shares of the Company&#8217;s common stock.  This option vests in equal quarterly installments over a three year period from the date of grant, subject to Ms. Fischbein&#8217;s continued service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Compensation Committee approved a formal equity compensation program for our non-employee directors, pursuant to which they receive the following initial and annual equity awards:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Equity Award &#8212; Each non-employee director joining our Board receives an option grant to purchase such number of shares of the Company&#8217;s common stock equal to 200% of the Black-Scholes </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">value used to determine the most recent Annual Grant (as defined below) for non-employee directors, or such other amount as determined by the Compensation Committee at its sole discretion (the &#8220;Initial Grant&#8221;). The Initial Grant will (i) be issued on the date such director joins the Board, vest in equal quarterly installments over a three- year period of continued service, (iii) have a term of 10 years, and (iv) an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date (or the most recent closing price if not a trading day).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Equity Award&#8212; Following the conclusion of each regular annual meeting of shareholders, each continuing non-employee director receives an option grant to purchase such number of shares of the Company&#8217;s common stock as determined by: (i) the Black-Scholes value of the 75th percentile of equity compensation granted to the non-employee directors of the Company&#8217;s peer group most recently approved by the Compensation Committee or (ii) such lesser amount as determined by the Compensation Committee at its sole discretion (the &#8220;Annual Grant&#8221;). The Annual Grant will (i) be issued three days after the Company&#8217;s annual meeting of shareholders, (ii) vest fully on the one year anniversary of the grant date, subject to continued service, (iii) have a term of 10 years, and (iv) an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date (or the most recent closing price if not a trading day). </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the equity awards granted to our non-employee directors are granted pursuant to our 2021 EIP.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have reimbursed and will continue to reimburse all of our non-employee directors for their reasonable out-of-pocket expenses incurred in attending Board and committee meetings. Mr. Finley does not participate in any of the foregoing director compensation given his service as an executive officer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation During 2024</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the total compensation of each person who served as a director during the year ended December 31, 2024, other than a director who also served as a named executive officer.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:16.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:17.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:16.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fees Earned or Paid in Cash ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Donald A. Williams </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,875</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,842</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,717</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Margery Fischbein </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,918</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,474</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,392</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Binxian Wei</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,393</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,842</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,235</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James R. Neal </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,466</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,466</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephanie C. Diaz </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,379</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,379</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mary Ann Gray, Ph.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,645</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,645</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cristina Csimma, PharmD, MHP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,050</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,050</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert Trenschel, D.O. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,316</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,316</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts in this column represent the aggregate grant date fair value of option awards granted to the non-employee director in 2024, computed in accordance with FASB ASC Topic 718. See Note 6 of the notes to our audited consolidated financial statements included in this Annual Report on Form 10-K for the fiscal year ended December 31, 2024.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our non-employee directors serving on our Board in 2024 held the following options to purchase shares of the Company&#8217;s common stock: Mr. Williams -3,432 options; Ms. Fischbein - 3,100 options; and Mr. Wei - 3,260 options.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Williams was appointed chairman of the Board in February 2024.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ms. Fischbein was appointed to the Board in May of 2024. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective February 9, 2024, James R. Neal resigned as a member of our Board. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective February 8, 2024, Stephanie C. Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel resigned as members of our Board.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective March 4, 2024, Dr. Mary Ann Gray resigned as a member of our Board.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_iii_item_12"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EQUITY COMPENSATION PLAN INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information with respect to our equity compensation plans which have outstanding securities as of December 31, 2024. For the description of these plans, please see below under &#8220;Equity Benefit Plans.&#8221;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.435%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19.956%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:21.896%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:22.396%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Category</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities to be Issued upon Exercise of Outstanding Options and Rights (a)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted- Average Exercise</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price for Outstanding Options and Rights (b) ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities Remaining Available for Future Issuance under Equity compensation Plans (Excluding Securities Reflected in Column (a)) (c)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">2021 EIP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,107</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.95</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,586</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">2013 Plan </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">440</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,835.89</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">ESPP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,086</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by security holders</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Palisade 2021 Inducement Plan </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;font-style:italic;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,079</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.26</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,941</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,626</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.48</span></p></td>
    <td style="background-color:#caeefb;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,613</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On January 1 of each calendar year, the number of shares of common stock authorized under the 2021 EIP increases by an amount equal to (i) 7.5% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) a lesser number of shares of common stock determined by our Board prior to the date of the increase.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Although certain awards under the plan are outstanding, no additional grants will be made pursuant to the 2013 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On January 1 of each calendar year, the number of shares of common stock authorized under the ESPP increases by (i) 2.5% of the total number of shares of our common stock outstanding on December 31 of the preceding year, (ii) 28,909 shares of common stock, or (3) such lesser number of shares of common stock as our Board may designate prior to the date of increase.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The 2021 Inducement Plan is a non-shareholder approved plan which was adopted by our Board on November 18, 2021 and amended on August 7, 2023. It is intended to satisfy the requirements of Nasdaq Listing Rule 5635(c)(4) or any successor thereto. Nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance-based awards and other forms of awards valued on common stock may be granted under the 2021 Plan to new employees of the Company. The maximum number of shares of common stock that may be granted under the 2021 Inducement Plan is 66,000 shares of common stock. All option grants made pursuant to the 2021 Inducement Plan must have an exercise price per share of no less than 100% of the fair market value per share of our common stock on the grant date. Our Board may impose vesting conditions on each option or other equity incentive award granted pursuant to the 2021 Inducement Plan. Awards under the 2021 Plan that are forfeited, redeemed or repurchased by the Company generally are returned to the pool of shares of common stock available for issuance under the 2021 Inducement Plan.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information regarding beneficial ownership of our capital stock as of March 15, 2025 by:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">each of our directors;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">each of our named executive officers; and</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">all of our current executive officers and directors as a group.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in the following table is calculated based on 4,396,646 shares of our common stock outstanding as of March 17, 2025. Beneficial ownership is determined according to the rules of the SEC. Beneficial ownership means that a person has or shares voting or investment power of a security and includes any securities that person or group has the right to acquire within 60 days after the measurement date, including upon the exercise of common stock purchase options or warrants or the conversion of preferred stock.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19.7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.04%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Beneficial Owner </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares Beneficially Owned</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage of Shares Beneficially Owned</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than 5% Stockholders</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Armistice Capital, LLC </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,417</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Directors and Named Executive Officers</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Donald Williams </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,078</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Binxian Wei </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,015</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Margery Fischbein </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,980</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mitchell Jones, M.D., Ph.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,690</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All directors and executive officers as a group (5 persons) </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,096</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.02</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Represents less than one percent</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Except as otherwise indicated in the footnotes to this table, this table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G, and Forms 4, filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Shares of our common stock underlying options, warrants, restricted stock units, and convertible securities that are currently exercisable or exercisable within 60 days of March 15, 2025 are deemed to be outstanding for the purpose of computing the number of shares held and the percent of total ownership of the person holding those options, warrants, restricted stock units, or convertible securities, but are not treated as outstanding for the purpose of computing the percent of total ownership of any other person. Applicable percentages are based on 1,514,292 shares of common stock outstanding on March 15, 2025, adjusted as required by rules promulgated by the SEC. Unless otherwise indicated, the address of the beneficial owner is c/o Palisade Bio, Inc. 7750 El Camino Real, Suite 2A, Carlsbad, CA 92009.</span></p></td>
   </tr>
   <tr style="height:15.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes 285,417 shares of common stock as reported by Armistice Capital, LLC on Schedule 13G, filed with the SEC on November 14, 2024. The address of beneficial owner is 510 Madison Avenue, 7</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Floor, New York, NY 10022. Excludes common stock purchase warrants and pre-funded warrants held by Armistice Capital, LLC that are subject to beneficial ownership limitations.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes (i) 3,728 shares of common stock and (ii) 1,350 shares of common stock underlying stock options.</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes (i) 855 shares of common stock and (ii) 1,160 shares of common stock underlying stock options.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Margery Fischbein was appointed to the Board on May 7, 2024. Includes 333 shares of common stock underlying options.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consists of (i)(a) 13,472 shares of common stock held by Mr. Finley, (b) 134 shares of common stock that may be acquired pursuant to the exercise of outstanding warrants held by Mr. Finley, (c) 14,321 shares of common stock underlying options held by Mr. Finley, (ii)(a) 51 shares of common stock held by FCW Investments LLC, and (b) 2 shares of common stock underlying warrants held by FCW Investments, LLC. The address for FCW Investments LLC is 19 Cherrymoor Dr, Englewood, CO 80113. Does not include 2,166 performance stock units (PSUs), which vest based on volume weighted average trading price of the Company&#8217;s common stock.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes (i) 3,852 shares of common stock, and (ii) 5,838 shares of common stock underlying options.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Includes the securities described in footnotes (3)-(7) above.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_iii_item_13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party Transactions Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2021, we adopted a written Related-Person Transactions Policy that sets forth our policies and procedures regarding the identification, review, consideration and approval or ratification of &#8220;related persons transactions.&#8221; For purposes of our policy only, a &#8220;related person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are participants involving an amount that exceed the lesser of (a) $120,000 or (b) 1% of the average of our total assets for the fiscal years ended December 31, 2024 and 2023. Transactions involving compensation for services provided to the us as an employee, director, consultant or similar capacity by a related person are not covered by this policy. A related person is any of our executive officers, directors, or more than 5% stockholder, including any of their immediate family members, and any entity owned or controlled by such persons.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the policy, where a transaction has been identified as a related person transaction, management must present information regarding the proposed related person transaction to the Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent body of the Board) for consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether any alternative transactions were available. To identify related person transactions in advance, we rely on information supplied by its executive officers, directors and certain significant stockholders. In considering related person transactions, the Audit Committee takes into account the relevant available facts and circumstances including, but not limited to (a) the risks, costs and benefits to us, (b) the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated, (c) the terms of the transaction, (d) the availability of other sources for comparable services or products and (e) the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain Related Party Transactions</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than compensation arrangements for our directors and executive officers, which are described above under the heading &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; and except as set forth below, there were no transactions since January 1, 2023 to which we were a party or will be a party, in which:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:98%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;vertical-align:top;padding-bottom:0in;text-align:right;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amounts involved exceeded or will exceed the lesser of (a) $120,000 or (b) 1% of the average of our total assets for the fiscal years ended December 31, 2024 and 2023; and</span></div></div></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:98%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:48.95pt;vertical-align:top;padding-bottom:0in;text-align:right;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.</span></div></div></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The proposed or undertaken transactions are:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.999%;box-sizing:content-box;"/>
    <td style="width:95.001%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On January 3, 2023, we granted J.D. Finley, our Chief Executive Officer and Chief Financial Officer, 349 restricted stock units valued at $20,000. The restricted stock units vest in 4 equal quarterly installments over the grant year. The restricted stock units were issued from the Company&#8217;s 2021 EIP.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On February 6, 2023, we granted J.D. Finley, our Chief Executive Officer and Chief Financial Officer: (i) an option to purchase 3,813 shares of our common stock valued at approximately $87,853, having an exercise price of $36.00 per share, a term of 10 years, and which vests quarterly over a three year period (ii) 2,780 restricted stock units valued at approximately $100,080 which vests in 12 equal installments quarterly over a three year period, and (iii) 2,166 performance restricted stock units valued at approximately $78,000, which vest (a) 50% when the volume weighted average price of our common stock over 20 consecutive trading days is $48.00, and (b) 50% when such volume weighted average price of our common stock over 20 consecutive trading days is $63.75. All of the grants issued to Mr. Finley were issued on a conditional basis, and were subject to the receipt of shareholder approval of the grants, which was received at our annual shareholder meeting held on June 8, 2023.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On February 6, 2023, we granted Robert McRae, our former Chief Operating Officer (&#8220;COO&#8221;): (i) an option to purchase 800 shares of common stock valued at approximately $18,431, having an exercise price of $36.00 per share, a term of 10 years, and which vests quarterly over three years (ii) 533 restricted stock units valued at approximately $21,120 which vests in 12 equal installments quarterly over a three year period, and (iii) 1,193 performance restricted stock units valued at approximately $42,960, which vest (a) 50% when the volume weighted average price of our common stock over 20 consecutive trading days is $48.00 and (b) 50% when such volume weighted average price of our common stock over 20 consecutive trading days is $63.75. All of the grants issued to Mr. McRae were issued on a conditional basis, and were subject to the receipt of shareholder approval of the grants, which was received at our annual shareholder meeting held on June 8, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On February 22, 2023, the Compensation Committee amended the Company&#8217;s non-employee director compensation policy. For a full discussion of this policy, see the section of this Proxy Statement entitled &#8220;Director Compensation.&#8221;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pursuant to a registered offering in April 2023, we sold an aggregate of 50,421 shares of our common stock at a purchase price per share of $39.60 to certain institutional and accredited investors. In a concurrent private placement, we also sold (i) 30,349 unregistered shares of common stock, (ii) 70,744 prefunded warrants to purchase common stock with a perpetual term and exercise price of $0.0015 per share, and (iii) 151,514 unregistered shares of common stock purchase warrants with a term of five (5) years and an exercise price of $39.60 per share. Armistice Capital LLC, a then holder of greater than 5% of our outstanding common stock pursuant to the ownership of outstanding common stock purchase warrants, purchased (i) 25,210 shares in the registered offering and (ii) in the concurrent private placement: (a) 5,076 unregistered shares of our common stock, (b) 45,470 prefunded warrants, and (c) 75,757 warrants to purchase common stock in exchange for an aggregate of $2,999,930.11.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective May 15, 2023, Robert McRae, our then COO transitioned to an executive strategic consultant. Upon the transition, Mr. McRae ceased his duties and responsibilities as COO. For his services, Mr. McRae received ongoing monthly compensation of $4,000 per month until January 15, 2024, when he ceased providing services to the Company and his outstanding equity awards ceased vesting.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective June 1, 2023, we increased J.D. Finley&#8217;s base salary from $490,000 to $542,000 contemporaneous with his appointment from interim CEO to CEO. Additionally, Mr. Finley&#8217;s target cash bonus was increased from 45% to 50% of his base salary. Additionally, on June 11, 2023, we granted Mr. Finley: (i) options to purchase 9,900 shares of our common stock with a term of 10 years and an exercise price of $24.00 per share,</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.999%;box-sizing:content-box;"/>
    <td style="width:95.001%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">valued at $151,978 on the grant date and (ii) 4,446 restricted stock units valued at $106,720. Each of the options and restricted stock units granted to Mr. Finley vest in 12 equal installments on a quarterly basis over three (3) years. The equity grants were issued from our 2021 EIP.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On June 11, 2023, we granted to our non-employee members of the Board of Directors, as supplemental grants, an aggregate of: (i) options to purchase 5,158 shares of common stock with a term of 10 years and an exercise price of $24.00 per share and (ii) 2,756 restricted stock units. Each of the grants vests fully on the one year anniversary of the grant date. The aggregate options were valued at $78,136 and the aggregate restricted stock units were valued at $66,120. The equity grants were issued from the 2021 EIP.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On September 5, 2023, pursuant to his appointment as Chief Medical Officer, the Company issued Mitchell Jones, M.D., Ph.D. (i) options to purchase 5,000 shares of common stock with a term of 10 years and an exercise price of $10.35 per share and (ii) 3,646 restricted stock units. The options vest quarterly over three years from the grant date and the restricted stock units vest as follows: (a) 303 shares on November 6, 2023, and (b) the remaining 3,343 shares vest over 11 equal quarterly periods after the initial vesting date. The options were valued at $33,267 and the restricted stock units were valued at $37,727, respectively from the grant date. The equity grants were issued from the 2021 Inducement Plan.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On November 21, 2023, we granted J.D. Finley, our CEO and CFO, on a conditional basis until such time as there are sufficient shares available under the 2021 EIP, which occurred upon the annual evergreen share increase on January 1, 2024: (i) options to purchase 3,000 shares of common stock with a term of 10 years and an exercise price of $8.85 per share, valued at $22,114 on the grant date and (ii) 2,533 restricted stock units valued at $22,420. Each of the options and restricted stock units granted to Mr. Finley vest in 12 equal installments on a quarterly basis over three years.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On November 21, 2023, we granted Mitchell Jones, M.D., Ph.D., our Chief Medical Officer, on a conditional basis until such time as there are sufficient shares available under the 2021 EIP, which occurred upon the annual evergreen share increase on January 1, 2024: (i) options to purchase 2,210 shares of common stock with a term of 10 years and an exercise price of $8.85 per share, valued at $16,296 on the grant date and (ii) 1,866 restricted stock units valued at $16,520. Each of the options and restricted stock units granted to Dr. Jones vest in 12 equal installments on a quarterly basis over three years.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On November 21, 2023, we granted to each of the non-employee members of the Board of Directors, as supplemental grants: (i) options to purchase 458 shares of common stock with a term of 10 years and an exercise price of $8.85 per share and (ii) 388 restricted stock units. Each of the grants vests fully on the one year anniversary of the grant date. The aggregate of all options were valued at $23,494 and the aggregate of all restricted stock units were valued at $24,037. The equity grants were issued from the 2021 EIP.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Between February 8, 2024 and February 9, 2024, James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel resigned as members of our Board. Pursuant to their resignation, we agreed to fully vest all of their outstanding equity awards issued on June 11, 2023 and November 21, 2023 and to extend the exercise period of their outstanding options until the expiration of each option. Accordingly, as a result of the vesting, we issued to the former directors, an aggregate of 3,162 of our common stock shares upon vesting of outstanding restricted stock units and extended the exercise period for an aggregate of (i) 2,896 options issued on June 11, 2023 having an exercise price of $24.00 per share and a term of 10 years and (ii) 1,832 options issued on November 21, 2023, having an exercise price of $8.85 per share and a term of 10 years.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On May 7, 2024, we granted Margery Fischbein, upon her appointment to serve on the Board, options to purchase 1,000 shares of common stock with a term of ten years and an exercise price of $7.90 per share. The options vest in twelve quarterly installments over a three (3) year period. The options were valued at $6,632 on the date of issuance and were issued from our 2021 EIP.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On July 11, 2024, we granted each of our three non-employee Board members, pursuant to our non-employee director compensation plan, options to purchase 2,100 shares of common stock with a term of ten years and an exercise price of $4.49 per share. The options vest fully on the one year anniversary of the grant date. The options were valued at $23,527.23 in the aggregate on the date of issuance and were issued from our 2021 EIP.</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.999%;box-sizing:content-box;"/>
    <td style="width:95.001%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On May 28, 2024, we fully accelerated the vesting of an aggregate of (i) 7,068 restricted stock units held by J.D. Finley, our Chief Executive Officer and Chief Financial Officer and (ii) 4,290 restricted stock units held by Dr. Mitchell Jones, our Chief Medical Officer.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On September 25, 2024, we entered into a revised employment agreement with J.D. Finley, our chief executive and chief financial officer. Pursuant to the terms of the employment agreement, Mr. Finley (i) receives a base salary of $542,000 per year, (ii) is eligible to receive an annual cash bonus based on the achievement of certain performance goals with a target of up to 50% of his base salary and (iii) is eligible to receive an annual market-based stock option grant as determined by the Board</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On February 11, 2025, we granted J.D. Finley, our Chief Executive Officer and Chief Financial Officer, (i) options to purchase 47,000 shares of our common stock with a term of 10 years and an exercise price of $1.13 per share, valued at approximately $47,400 on the grant date and (ii) 40,000 restricted stock units valued at approximately $45,200. The options to purchase our common stock granted to Mr. Finley vest in 12 equal installments on a quarterly basis over three years. The restricted stock units granted to Mr. Finley vest in 3 equal installments on a yearly basis over three years. The equity grants were issued from our 2021 EIP.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9679;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">On February 11, 2025, we granted Mitchell Jones, our Chief Medical Officer, (i) options to purchase 29,000 shares of our common stock with a term of 10 years and an exercise price of $1.13 per share, valued at approximately $29,200 on the grant date and (ii) 24,000 restricted stock units valued at approximately $27,120. The options to purchase our common stock granted to Dr. Jones vest in 12 equal installments on a quarterly basis over three years. The restricted stock units granted to Dr. Jones vest in 3 equal installments on a yearly basis over three years. The equity grants were issued from our 2021 EIP.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_iii_item_14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accounting Fees and Services.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table represents aggregate fees billed to us for services performed by our independent registered public accounting firm, Baker Tilly US, LLP, New York, NY, PCAOB ID #23 (&#8220;Baker Tilly&#8221;).</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.4%;box-sizing:content-box;"/>
    <td style="width:1.8%;box-sizing:content-box;"/>
    <td style="width:2.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.8%;box-sizing:content-box;"/>
    <td style="width:2.72%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.98%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Fees </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454,213</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-related Fees</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Fees</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Fees</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">454,213</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit fees consist of fees billed for professional services performed by Baker Tilly for the audit of our annual financial statements, reviews of our financial statements included in our quarterly reports on Form 10-Q and annual report on Form 10-K, reviews of our current reports on Form 8-K, services rendered in connection with SEC registration statements, and related services that are normally provided in connection with regulatory filings or engagements.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All fees described above were pre-approved by our Audit Committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approval Policies and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by the Company&#8217;s independent registered public accounting firm, Baker Tilly. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of our Audit Committee&#8217;s approval of the scope of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of our Audit Committee&#8217;s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee has determined that the rendering of services other than audit services by Baker Tilly is compatible with maintaining the principal accountant&#8217;s independence.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT IV</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibits_financial_statement_schedules_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financial State</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ment Schedules.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(1) Financial Statements.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements and supplementary data required by this item are set forth under Item 8 above.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(2) Financial Statement Schedules.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All schedules have been omitted because they are not required or because the required information is given in the consolidated financial statements or notes thereto.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(3) Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exhibits listed in the Exhibit Index below are filed or incorporated by reference as part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit Index</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Number</span></p></td>
    <td style="padding-top:0in;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Document</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated as of December 16, 2020, by and among Seneca Biopharma, Inc., Leading BioSciences, Inc. and Townsgate Acquisition Sub 1, Inc. (Incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321002819/exh_31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 27, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184316013585/f8k_121216.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series A 4.5% Convertible Preferred Stock (Incorporated by reference to Exhibit 3.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 12, 2016).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1357459/000149315224009042/form8-k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 6, 2024).</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022017505/pali-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on August 16, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315222032591/ex3-01i.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Amended and Restated Certificate of Incorporation of Palisade Bio, Inc., effective November 15, 2022 (Incorporated by reference to Exhibit 3.01(i) to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 16, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to the Amended and Restated Certificate of Incorporation of Palisade Bio, Inc. effective April 5, 2024 (Incorporated by reference to Exhibit 3.01(i) to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 5, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reference is made to Exhibits </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022004093/pali-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Form 10-K, filed with the SEC on March 17, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001357459/000095017022004093/pali-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Common Stock Certificate. (Incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 17, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184316012120/exh_401.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Series A Preferred Stock Certificate (Incorporated by reference to Exhibit 4.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 12, 2016).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184317004432/exh_401.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Purchase Warrant from August 2017 Public Offering (Incorporated by reference to Exhibit 4.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on July 28, 2017).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184318007287/exh_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Purchase Warrant from October 2018 Offering (Incorporated by reference to Exhibit 4.01 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on October 29, 2018)</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184318007287/exh_42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Common Stock Purchase Warrant from October 2018 Offering (Incorporated by reference to Exhibit 4.02 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on October 29, 2018)</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184319003354/exh_440.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consultant Warrant for Hibiscus BioVentures, LLC issued January 2019 (Incorporated by reference to Exhibit 4.40 to the Registrant's Form 10-Q, originally filed with the SEC on May 14, 2019)</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184319004802/exh_445.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Series M and Series N warrant from July 2019 Offering (Incorporated by reference to Exhibit 4.45 to the Registrant's Registration Statement on Form S-1/A (File No. 333-232273), filed with the SEC on July 24, 2019)</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320000374/exh_1001.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement from January 2020 Offering (Incorporated by reference to Exhibit 10.01 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on January 22, 2020)</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.11</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184319004802/exh_446.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Series O Pre-Funded Warrant from July 2019 Offering (Incorporated by reference to Exhibit 4.45 to the Registrant's Registration Statement on Form S-1/A (File No. 333-232273), filed with the SEC on July 24, 2019)</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320000374/exh_402.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Series Q Replacement Warrant issued in January 2020 Offering (Incorporated by reference to Exhibit 4.02 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on January 22, 2020)</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.13</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320000374/exh_1002.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Agreement from January 2020 Offering (Incorporated by reference to Exhibit 10.02 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on January 22, 2020)</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320000374/exh_403.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant issued in January 2020 Offering (Incorporated by reference to Exhibit 4.03 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on January 22, 2020)</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.15</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320004007/exh_401.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant issued in May 2020 Offering (Incorporated by reference to Exhibit 4.01 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on May 27, 2020)</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.16</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320004007/exh_1001.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement with Investors from May 2020 Offering (Incorporated by reference to Exhibit 10.01 to the Registrant's Current Report on Form 8-K, originally filed with the SEC on May 27, 2020)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_430.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant to Purchase Shares of Common Stock of Leading BioSciences, Inc. (Incorporated by reference to Exhibit 4.30 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Bridge Warrant of Leading BioSciences, Inc. (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.19</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Equity Warrant of Leading BioSciences, Inc. (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.20</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, by and between Seneca Biopharma, Inc. and the investor party thereto, dated December 16, 2020 (Incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321004994/exh_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Waiver Agreement, dated as of July 21, 2021, by and between Palisade Bio, Inc. and Altium Growth Fund, LP (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321004994/exh_42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant, dated as of July 21, 2021, issued to Altium Growth Fund, LP (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on July 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022000621/pali-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Waiver Agreement, dated as of January 31, 2022, by and between Palisade Bio, Inc. and Altium Growth Fund, LP (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on February 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022000621/pali-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant, dated as of January 31, 2022, issued to Altium Growth Fund, LP (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on February 21, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.25</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321006119/exh_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, dated as of August 19, 2021, by and between Palisade Bio, Inc. and Yuma Regional Medical Center (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.26</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321006119/exh_42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant, dated as of August 19, 2021, issued to Yuma Regional Medical Center (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.27</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001357459/000119312522143077/d292710dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Purchase Warrant (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 6, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.28</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001357459/000119312522143832/d339827dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 6, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.29</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022017505/pali-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Series 2 Common Stock Warrant (Incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K, filed with the SEC on August 16, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.30</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022017505/pali-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant Agency Agreement dated August 16, 2022, by and between Palisade Bio, Inc. and American Stock Transfer and Trust Company, LLC. (Incorporated by reference to Exhibit 4.3 to the Registrant's Current Report on Form 8-K, filed with the SEC on August 16, 2022).</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.31</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022024748/pali-ex4_33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Underwriter Warrant issued August 16, 2022 (Incorporated by reference to Exhibit 4.33 to the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.32</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex4-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registered Prefunded Warrant issued in January 2023 Registered Offering (Incorporated by reference to Exhibit 4.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.33</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex4-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Prefunded Warrant issued in January 2023 Private Placement (Incorporated by reference to Exhibit 4.02 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.34</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex4-03.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant issued in January 2023 Private Placement (Incorporated by reference to Exhibit 4.03 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.35</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex4-04.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant issued in January 2023 Private Placement (Incorporated by reference to Exhibit 4.04 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.36</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex4-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Prefunded Warrant issued in April 2023 Private Placement (Incorporated by Reference to Exhibit 4.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.37</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex4-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant issued in April 2023 Private Placement (Incorporated by Reference to Exhibit 4.02 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.38</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex4-03.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant issued in April 2023 Private Placement (Incorporated by reference to Exhibit 4.03 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on April 5, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.39</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032245/ex4-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant issued in September 2023 Private Placement (Incorporated by reference to Exhibit 4.01 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.40</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315224004539/ex4-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Replacement Warrant issued in February 2024 Warrant Inducement Transaction (Incorporated by reference to Exhibit 4.01 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on February 1, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.41</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315224004539/ex4-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant issued in February 2024 Warrant Inducement Transaction (Incorporated by reference to Exhibit 4.02 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on February 1, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.42</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Prefunded Common Stock Warrant issued in May 2024 Private Placement (Incorporated by reference to Exhibit 4.01 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 3, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.43</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Warrant issued in May 2024 Private Placement (Incorporated by reference to Exhibit 4.02 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 3, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.44</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant issued in May 2024 Private Placement (Incorporated by reference to Exhibit 4.03 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 3, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.45</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000149315224050203/form8-k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Prefunded Common Stock Warrant issued in December 2024 Underwritten Public Offering (Incorporated by reference to Exhibit 1.01 to the Registrant's Current Report on Form 8-K filed with the SEC on December 16, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.46</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000149315224050203/form8-k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Five-Year Common Stock Purchase Warrant issued in December 2024 Underwritten Public Offering (Incorporated by reference to Exhibit 1.01 to the Registrant's Current Report on Form 8-K filed with the SEC on December 16, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.47</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000149315224050203/form8-k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant Agency Agreement by and between Palisade Bio, Inc. and Equiniti Trust Company LLC  (Incorporated by reference to Exhibit 1.01 to the Registrant's Current Report on Form 8-K filed with the SEC on December 16, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184319002717/def14a_042919.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Seneca Biopharma 2019 Equity Incentive Plan (Incorporated by reference to Appendix A to the Registrant&#8217;s Definitive Proxy Statement, originally filed with the SEC on April 29, 2019).</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184319004112/exh_443.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Option Grant from 2019 Equity Incentive Plan (Incorporated by reference to Exhibit 4.43 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232273), originally filed with the SEC on June 21, 2019, originally filed with the SEC on June 21, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, by and between Leading BioSciences, Inc. and The Regents of the University of California, dated August 19, 2015, as amended on December 20, 2019 (Incorporated by reference to</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, by and between Leading BioSciences, Inc. and The Regents of the University of California, dated April 1, 2020 (Incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022004093/pali-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, by and between Palisade Bio, Inc. and The Regents of the University of California, dated July 30, 2021 (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Form 10-K, filed with the SEC on March 17, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Co-Development and Distribution Agreement, by and between Leading BioSciences, Inc. and Newsoara Biopharma Co., Ltd. (as successor-in-interest to Biolead Medical Technology Limited), dated February 17, 2018, as amended on November 27, 2018 (Incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Seneca Biopharma, Inc. Support Agreement, dated as of December 16, 2020, by and between Leading BioSciences, Inc. and each of the parties named in each agreement therein (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Leading BioSciences, Inc. Support Agreement, dated as of December 16, 2020, by and between Seneca Biopharma, Inc. and each of the parties named in each agreement therein(Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, by and between Leading BioSciences, Inc. and the investor party thereto, dated December 16, 2020 (Incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008660/exh_106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, by and among Seneca Biopharma, Inc., Leading BioSciences, Inc. and the investor party thereto, dated December 16, 2020 (Incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321003532/exh_1003.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment Agreement to Securities Purchase Agreement by and among, the Company, Leading BioSciences, Inc. and Altium Growth Fund, LP, dated May 3, 2021 (Incorporated by reference to Exhibit 10.03 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321001886/exh_1001.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Separation Agreement with Seneca Biopharma, Inc. Executives (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321002819/exh_101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Contingent Value Rights Agreement, dated as of April 27, 2021, by and among the Company, American Stock Transfer &amp; Trust Company, LLC and Raul Silvestre (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 27, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184318008473/exh_1003.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement (incorporated by reference from Exhibit 10.03 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on December 18, 2018).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1024.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Leading BioSciences, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise of Stock Option thereunder (Incorporated by reference to Exhibit 10.24 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223020669/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc. 2021 Equity Incentive Plan, as amended (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 9, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017021004851/pali-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Palisade Bio, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 23, 2021).</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017021004851/pali-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Non-Employee Director Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Palisade Bio, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 23, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223020669/ex10-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc. Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.02 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017023041459/pali-ex10_20.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Palisade Bio, Inc. 2021 Inducement Incentive Plan, as Amended August 7, 2023 (Incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095012321015721/pali-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Grant Notice and Award Agreement under the Palisade Bio, Inc. 2021 Inducement Incentive Plan (Incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-261196), filed with the SEC on November 19, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095012321015721/pali-ex99_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Grant Notice and Award Agreement under the Palisade Bio, Inc. 2021 Inducement Incentive Plan (Incorporated by reference to Exhibit 99.2 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-261196), filed with the SEC on November 19, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017023009226/pali-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Policy (Incorporated by reference to Exhibit 10.35 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 22, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184321000505/exh_1023.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Executive Employment Agreement, by and between Leading BioSciences, Inc. and JD Finley, dated January 22, 2021(Incorporated by reference to Exhibit 10.23 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, by and between Leading BioSciences, Inc. and Thomas Hallam, Ph.D., dated December 16, 2020 (Incorporated by reference to Exhibit 10.22 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000117184320008771/exh_1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, by and between Leading BioSciences, Inc. and Michael Dawson, M.D., dated December 16, 2020 (Incorporated by reference to Exhibit 10.21 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-251659), originally filed with the SEC on December 23, 2020, as amended).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#134;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022004093/pali-ex10_27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Asset Transfer Agreement, by and between Alto Neuroscience, Inc. and Palisade Bio, Inc., dated October 18, 2021 (incorporated by reference to Exhibit 10.27 to the Registrant&#8217;s Form 10-K, filed with the SEC on March 17, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022009812/pali-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease Between AP Beacon Carlsbad, LP, and Palisade Bio, Inc., dated May 12, 2022 (Incorporate by reference to Exhibit 10.1 to the Registrant&#8217;s Form 10-Q filed with the SEC on May 13, 2022).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017022017248/pali-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment dated July 14, 2022 to the Office Lease Between AP Beacon Carlsbad, LP, and Palisade Bio, Inc., dated May 12, 2022 (Incorporated by reference to Exhibit 10.2 to the Registrants Form 10-Q filed with the SEC on August 15, 2022)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000119312522143077/d292710dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement, dated May 6, 2022, by and among the Company and the purchasers named therein (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 6, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315222028453/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement and Release with former Chief Executive Officer (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 14, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement dated December 30, 2022, by and among the Company and the purchasers named therein (Incorporated by Reference to Exhibit 10.01 to the Registrant&#8217;s Current report on Form 8-K, filed with the SEC on January 4, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex10-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement by and among the Company and signatories named therein (Incorporated by reference to Exhibit 10.02 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/ex10-03.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agency Agreement, dated December 30, 2022, by and between the Company and Ladenburg Thalmann &amp; Co Inc. (Incorporated by reference to Exhibit 10.03 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 4, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017023009226/pali-ex10_35.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of First Amendment Consulting Agreement dated January 25, 2023 by and between Dr. Herbert Slade and the Company (Incorporated by reference to Exhibit 10.35 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 22, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017023009226/pali-ex10_36.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Consulting Agreement dated April 7, 2023 by and between Dr. Herbert Slade and the Company. (Incorporated by reference to Exhibit 10.36 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 22, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.37</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement dated April 3, 2023, by and among the Company and the purchasers named therein (Incorporated by Reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex10-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement dated by and among the Company and the signatories named therein (Incorporated by Reference to Exhibit 10.02 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.39</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223011066/ex10-03.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agency Agreement by and among the Company and Ladenburg Thalmann &amp; Co Inc. (Incorporated by Reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on April 5, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.40</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032118/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Research, Collaboration, and License Agreement with Giiant Pharma (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 8, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.41</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032245/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement dated September 7, 2023, by and among the Company and the signatories named therein (Incorporated by Reference to Exhibit 10.01 to the Registrant&#8217;s Current report on Form 8-K, filed with the SEC on September 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.42</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032245/ex10-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agency Agreement dated September 7, 2023, by and among the Company and Ladenburg Thalmann &amp; Co Inc. (Incorporated by reference to Exhibit 10.02 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.43</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315223032278/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Employment Agreement with Mitchell Jones, dated September 5, 2023 (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 11, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.44</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315224004539/ex10-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant Inducement Agreement entered into pursuant to February 2024 Warrant Inducement Transaction (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on February 1, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.45</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement entered into pursuant to the May 2024 Private Placement (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 3, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.46</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Right Agreement entered into Pursuant to the May 2024 Private Placement (Incorporated by reference to Exhibit 10.02 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 3, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.47</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agency Agreement entered into Pursuant to the May 2024 Private Placement (Incorporated by reference to Exhibit 10.03 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 3, 2024.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.48</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Research Collaboration and License Agreement with Giiant Pharma, Inc. dated August 2, 2024 (Incorporated by reference to Exhibit 10.48 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.49</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024124664/pali-20240930.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Employment Agreement with J.D. Finley, dated September 25, 2024 (Incorporated by reference to Exhibit 10.01 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 27, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.50</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000149315224050203/form8-k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Underwriting Agreement by and between Palisade Bio, Inc. and Ladenburg Thalmann &amp; Co. Inc. (Incorporated by reference to Exhibit 1.01 to the Registrant's Current Report on Form 8-K filed with the SEC on December 16, 2024).</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.51</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000149315224050203/form8-k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant Amendment Agreement entered into Pursuant to the December 2024 Underwritten Public Offering (Incorporated by reference to Exhibit 1.01 to the Registrant's Current Report on Form 8-K filed with the SEC on December 16, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000149315224042973/ex19-01.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Insider Trading Policy (Incorporated by reference to Exhibit 19.1 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on October 30, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1357459/000095017023009226/pali-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of Registrant (Incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 22, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pali-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Baker Tilly US, LLP, Independent Registered Public Accounting Firm</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pali-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pali-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pali-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Exchange Act, and 18 U.S.C. Section 1350.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357459/000095017024036402/pali-20231231.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clawback Policy of the Registrant (Incorporated by reference to Exhibit 97.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 26, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101).</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Furnished herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Schedules and exhibits to the Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="form_summary_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form 10</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.38%;box-sizing:content-box;"/>
    <td style="width:2.7%;box-sizing:content-box;"/>
    <td style="width:5.54%;box-sizing:content-box;"/>
    <td style="width:46.38%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PALISADE BIO, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 24, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ J.D. Finley</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">J.D. Finley</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Director</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints J.D. Finley, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:43.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:21.64%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ J.D. Finley</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer,</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 24, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">J.D. Finley</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Principal Executive and Financial Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mitchell Jones, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mitchell Jones, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Donald A. Williams</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Chairman of the Board of Directors</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 24, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Donald A. Williams</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Binxian Wei</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 24, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Binxian Wei</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Margery Fischbein</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Margery Fischbein</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>pali-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 23.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-269234, 333-265769, 333-265570, 333-271393, 333-276315, 333-282883), Form S-3 (Nos. 333-263709, 333-263705, 333-259747, 333-258318, 333-278389, 333-279222), and Form S-8 (Nos. 333-263706, 333-261196, 333-259553, 333-274522, 333-278387) of our report dated March 24, 2025, relating to the consolidated financial statements of Palisade Bio, Inc., appearing in this Annual Report on Form 10-K. Our report includes an explanatory paragraph relating to the Company&#x2019;s ability to continue as a going concern.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">/s/ Baker Tilly US, LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">New York, New York</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">March 24, 2025</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>pali-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, J.D. Finley, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Palisade Bio, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;box-sizing:content-box;"></td>
    <td style="width:5.04%;box-sizing:content-box;"></td>
    <td style="width:3.04%;box-sizing:content-box;"></td>
    <td style="width:46.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 24, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ J.D. Finley</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>pali-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, J.D. Finley, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Palisade Bio, Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;box-sizing:content-box;"></td>
    <td style="width:5.04%;box-sizing:content-box;"></td>
    <td style="width:3.04%;box-sizing:content-box;"></td>
    <td style="width:46.46%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 24, 2025</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ J.D. Finley</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>pali-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), J.D. Finley, Chief Executive Officer and Chief Financial Officer of Palisade Bio, Inc. (the &#34;Company&#34;), hereby certifies that, to the best of his knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s Annual Report on Form 10-K for the period ended December 31, 2024, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Periodic Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dated: March 24, 2025</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the undersigned have set their hands hereto as of the date indicated above.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:48.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ J.D. Finley</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">J.D. Finley</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Executive Officer and Principal Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This certification accompanies the Periodic Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Periodic Report), irrespective of any general incorporation language contained in such filing.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img61919486_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61919486_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'C!3$# 2(  A$! Q$!_\0
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M;_\ #8>"?_E'2?\ #.?[/?\ T0CX-?\ AL/!'_RCJE],;AI)+_4W/=$E_O\
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MG]37]E7_  S!^S2>O[/'P,/_ '27P#_\S])_PR_^S0>O[._P+/\ W23P!_\
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MF7_R1_ [4+_>/X?R%?WT?\,=?LB_]&L?LX_^&/\ AE_\S%)_PQS^R)_T:O\
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MB[,NR7\WD_ZV_P _Y_NG\/YBH:_T!O\ AC3]D#_HU/\ 9M_\,9\,/_F7I/\
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MS'Z_ ?X6?_,K2?\ #%7[&_\ T:7^S-_X8?X6?_,K6D?VEW R5O\ B&?%>_\
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M_0_RK_1,_P"&)OV,O^C1_P!F+_PPGPJ_^92C_AB7]C+_ *-&_9B_\,'\*O\
MYE*T7[3;@5)+_B&/%NB2_P"1OD_E_=]?Z>@OH3<4I)?Z[Y!HE_S+\Q_^2/\
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M -&9_LI?^([_  A_^8^M%^U5\/TDO^(4\8_^'K)/_D!KZ&O$R:?^N>1:._\
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M&#OV'/\ HS+]E'_Q';X0_P#S'T?\55O#_P#Z-3QC_P"'K)/_ ) /^)->)O\
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M-?J$HQE@K1_9>BBBOZ</XO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _/3_AK/XC?\/ _^&4O[%\$_\*[_ +!_M3^V?[.UW_A-/M'_  K3_A,M
MG]H_\))_8?D_VI^XV_\ ".;_ +!^Z\S[1_I5>!^,?^"EWB7X7_MC>(O@K\0]
M!\#VGP9T3Q;;^&+KQ78V'B&'Q;HUOJ&G:?+;:_JMY)XAO])N[#3;V],VK0V?
MAVWG;3$D>U_TF$)<<U_SF>_[D_\ ]X/7DUK\!_"G[1__  4'_;4^%_BP&WCU
M'X9Z_?Z!K4<2RW7AKQ39:[\'UT;7[6-BHE-I)<2P7EMOB-]I=U?V'G0?:O.C
M_C[..,/$6O1QM#AO/:O]M+Z0W$_#65TL9*F\)7RC+,HGC\%P]B+PM'+JM:C[
M%WE&4/:N3K02YH_Z </\ >$>&Q67XGB_AFC_ *N/Z)O!7&6=U\OC56/PN?9U
MGU#+,RXLPEJC<LVH8?$O$*T9PJ>Q5.-";ER2_0']NG]K/QW^S3HWP>U;X:Z;
MX&\0P_$;Q+?:5?S^*+/6-6M!ID-KI=S:7>C2Z!XDT%=\ZW[N)YI+ZWEB\IHH
MP,L_(?MU?MA?&7]G+X@_"#P+\)?#7P[\0W7Q-MKV(IXWT_7[J4:O_;>FZ/I=
MO9W.D>+O#-K:V\\FH 7#WJSA6VR>=#&K@_B]\9OB/\3+#PS\.?V5/C%I]W'X
MS_9V^*-]I^E:K/(9EN_"&I0Z;!IFGB:14DN[+3_LL5SX<U-2\.H>&M4TV&)8
M8M-B:Y_1'_@I_P#\G.?L<?\ 89M/_5@^%JX,U\5N(<_R3Q4SC*,USC(_[/QW
MA1@<'@)<M'&\-8_,<7/+N*LNA&M1;A6^O4<3AZTZE.4:OLXU8PC&:B>MD?@9
MPGPKQ%X'Y#G^1Y!Q-_:V6^.N9X_-(J6(R[C'*\HP%+-^!LWJNAB$IX?^S,3A
M,5AZ=*K&5#VTZ$ZDYTW([7QC^VS^W+^SO<:=XA_:8_9F\#1_#>ZU"TL+K7OA
MUJ-T&MGN]V%.J1^./'NG6MX=L@M++6K71UU">$V\-VBS1W ^F/VH/VP;SX<_
MLK^&_P!H[X(Q>&/%%MXLUCPM!I \7V&JW>G'3-=BU(WD=W9:-KFB7EOJ^G7-
MBUC<PG4FCM+R"[MY8YF0%9_^"CGC_P !^%/V4_BCH'BS5=*76/&>C6FB>$_#
MMQ=QKJFL:W)K%A<V=U86*;[F6+19+-M9GNC&MI"-.V2SI))$C_F7\1-"U_0/
M^"0?PJM_$#7"R7_Q(MM;TJSN87AEL-!UCQ5XVO\ 2HQY@#RPWT$QUJVE(VM;
M:I$L9,2(3])Q3Q%Q5P1CO$/A3 \99OQ%AL'X6XWC' YEFCRVMGO#&<4,QA@:
M>&JX[ 8/!4ZM'&4*JQ5"EB</+$4_9TW3@J+J5JWQO!/"7 _B1EGA+QQF7AYD
M/".,S#QMRSP^S/*,FCG%#AGC7A_%93+,ZV,H99FF89C5H8C+\31>"Q5;!XN.
M%J^UJQJ5'B%2H8?]0_B!^V?H'P;_ &5OA3\?/B'I<.I^*_B9X#\!ZSI7@KPY
M)+ID&M>+/%/A'3O$FI6.GSW[ZQ/H_A_3FN;B2:^O&U:>QLUMH&_M&_G@CN?D
MU_VNO^"D47@F3XQ2_LI_#Y/A7'IK>(FA=M63Q?'X:2W^VOJDFF-\1/[?%LMD
M&NFNCX'7;:_Z<;3[&#*?F_\ ;ET^\A_9<_X)L^+[JPGOO!_AWX;>%[/Q(B*T
MEN]QJOP^^$NH:=9S1MB!I+W3O#GB&.#SF7A)HU.V23'[H:E\8/A=%\*K_P"+
M\OBS0-2^&*>&[GQ!)X@@O;*?3=0TH6;SFUA^T2Q1SW]VO^@Q:1/Y=[+J$BZ;
M);I=L81ZV S3B/C7B+B/*<5Q]FG!F#X/X1X.S'!?V4LIHULTQ.></PS7,>(,
MVK9G@L5/%Y=@<3;"5L-AW0PZ:;G6P]6;E5\/,\EX0\.>$>#\^P/A;DGB)F/B
M#Q]X@Y3F/]N//<1A\DP?#7%<\CRCA3(</DV98&G@<VS3!WQ^'QF+6)Q;4DJ6
M'Q5"FHT.#_9;_:4\*?M2_"ZW^(WAG3[G0;FWU.YT'Q-X9O;N&^N_#^O6<%K=
M2V@O88K87]E/:7MI=Z?J/V.R-U!-B2TMKB&>WB_/9?\ @ISXL'[5O_"NG\,>
M"6_9Y/Q6D^%@\<I8>)4\1"[P=&35SKQUU] ^S+X@9-7:W_X1@-)X:5X4G2<_
MVJGK4_[9_P 'V_8]^-GQR^"?@'6/AE9Z3<7G@;PXFJ^&O"/@ZXUKXC:SING6
M.D:AI=KX4U?7;?4UT%]<L=3NY9VAF-OIM["A2.VFFA_(1K+QX?V,1\,A^R5\
M:#<#Q:/CG_POK_A%?$Z^'OLQTW8VK&8>#3$WA8> R2-1;Q,=-,@7Q!N6$!5^
M9\0?%+/L#EO!6$R'B^EF&:8/A^MQIG&<Y-DN.E@N*8X'%1P6595+"83"XO\
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ME\/M<:E]H-HCM(!I>NQ7OV^6TM[B6/0/%&GZ_IS?:)+V:>W_ *4?V>_^2!_
M_P#[)!\-/_4+T6OT3PR\0<VXTX]XDPF/6+RW^R.%<DH9MPU735/)>*J&:9K@
M\ZA2;3=2%5T*%3#UU4J1JX.>&FW&HZD8_DGC-X49%X=>%_!^.RR6 SC^W^..
M)<5D7&.%:=;B/@?$Y+D68<.5:ZBXJC4H?6<32Q6&E1I3H9A3Q=-*5)4Y2]?H
MHHK^@#^50HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS6M7L/#
M^C:MK^JS?9]+T/3+_5]2N C2&"PTVUEO;R;RT#._E6\$C[$!9MNU020*TZPO
M%.IZ%HGAGQ%K/B@PKX9TC0M7U/Q$UQ93:G NA6&GW%WJYGTVVM[RXU"$:?%<
M&2R@M+J:[3=!%;SO(L38XB?LL/7J>UI4?9T:L_;5W:A2Y(2E[6LW*%J5.W/4
M?/"T%+WH[KHPE-5L5AJ+HU\0JN(HTWA\*KXFNIU(Q]CATH5&Z]6_)17LYWJ2
MC[DOA?Y">!_VXOVW?VAX_&'C#]FS]GOX8:I\.?"FKSZ6Z^+=8N;GQ/<RQ6B:
MC'9QN/'?@V&XU2;3Y+>=K>RT:YMX)[ZWM8[F[=&=_6_ O[7?[3OQY^"MSK?P
M1^!?A_3_ (X>$O'>C:%XY\)_$9]1LO"$WA'4]"\271\2^&;S4/$7@B\:[.M:
M9IMA+IEQJ-]+I\<ESN&H)+%>VWS)X$_8_P#!OQ#F\4?%K_@G1^UIK_@ZWAUF
M73M0\+WT7C'1-/L+YK<WT>DWM[+;:/XE_L)4N81I2Z]X/\1Q30K<;-4U"ZL9
M\?2G_!.7]JKXJ_'"?XJ_#3XQW>F^(?%7PKN-*6T\8Z3:Z?!'K%G-=ZKHU_;Z
ME)I7V?3+R>"]TJ&YTW4]/L84U.UN[J2Y(>WADN?Y.X.S?C&OGF0Y'Q?QKQ70
MK<9X;B"C@<YR3&\(9]PEQ'4P5*>+I8WA'-\MPL,1PU6P5*GS+#XS 9A2Q4>:
MA4^KSE"W]U>(.0>'V%X;XHXEX \.>!L5AO#K&<*8C,N'N),NX_X7X\X0I9A6
MI8"MEO'N09SC*F$XRPV95ZW(\7EV:Y37P4U'%4GBJ4*AX#X%_;<_X*&_$CXH
M>.O@YX1^#O[/6H_$#X;_ -I_\)=I$J>(+"#3_P"Q]7MM"U#RM4OOC#!IE]Y.
MIW<$ ^Q74_FJYFBWPJSCZ[_:3_:I^*_[.7[-7P^\8>)/"O@H?M#^-]3T'PW_
M ,(2(]3U/PG!K\XFO/$)M+;2?$DE_>V%E96ZVMKY7BE\:CJ6GL]W<INMI?EK
M]BO_ )22_MI?]U'_ /5J^'Z\\_;'^+NM^.OV\/ &B>$_A?XT^.?A_P#9=MK#
M7M5\ >!-/U'7;C4/%4]Q8:WJFHW*Z5HFNFPT[3]1F\#Z)JSW.G7D O=(GTV2
M2*:^6.'BPG%6?Y)X;YSGV+XWXGQN?9YQ=F?A_DCQ\Z.88?+(TL^J86>=87 Y
M?E2Q]7,,OR3!8[&U)TGB(U*M/EI82,JD(KT\=P/PMQ+XO\.\+8'PVX+RWA?A
MK@+)?%7B-973Q.4XK.9XCA:AC:?#F-S/-,[>5T<IS7B3,<MR^E"NL)*E0K.=
M?'SA2J2E]U?LV_M5?%3]H_\ 9H\>^,?#/A/P8/VB/!&HZ]X;D\%.NIZ9X3N?
M$4)2]\.M<VFK>((-1T[3[S3KD65W'<>*2QU32]3D2]M8W2RMOD'QC^V[_P %
M#? 7Q<\&? WQ/\'?V>['XD^/[+3-0\+Z+&GB"\MK^UUC4]7T>P>75[/XPSZ5
M9&:_T/4H62\NX7B$*RRA(IHG?D_V-OB[K?@3]N_X@Z'XM^%OC/X&>'_VHX+_
M ,0:1X"\=V.J:)=:?XIAN-0US3-1MUU;1-"^VZ;J.IQ^.=$TAK;3;6 7>JVV
MFP2O+9/#+Z!^UK_RE/\ V1?^Q2^'/_JQOBE1B.*L_P ]\/N',[PO&_$^"SW*
M>-,I\.\]>7RH9=0S*G7SR&'AG>)P.894\=2S+,,EQ6!QE.I6]C&%2K*-;"3G
M"I%F"X&X5X:\5^+N&\;X;<%YCPSGWASGGBWPPLUIXC-L3D]6APW+%SX<P>9Y
M7G:RVOE&5<1X'-,NJTJ'UF=2C04Z&/A3JTI+U/XW?M8_MA?L[_LSZ?\ $WXK
M_#CX.Z!\5=4^.EIX$LM M8M:UOPI+\/KWP!JWB"WUAET;XD7UW'XA?Q'HFHV
M1:37UMDTV%0^CB66*]?[RU+XCZY9_LZZA\7(K72F\26OP5NOB/'92079T-M<
M@\#2>)DM7MEOEOSI1OU$+0+J2W9M,QB^$W^D#X-_X+$6ES<_LO\ A&:"%Y8M
M/^-WA:[O77&+>V?P5\1;!)I,D'8UY>VEN, GS)TXQDCZ'U?QUX/G_8"U'Q3'
MXDT=M N?V8;G3HM3%_;/;'5+GX:/I$6D,\<C@:O_ &O(NDOIG-['JFZP>!;I
M6B'Z5E^;YMDW&GB'PYBN),SQV!X?\/<FS3*ZN<XG"SQ2Q$J6:O&YI.K2P^$I
M3J>TIT(XBM"C"C!PIQE&+W_',UR#(N(?#KPEXOP7!^399F7%7BQQ%DN=4.'L
M'C*>!>%C7R&.6Y+3HUL7CJ].C[*KBI87#U,14KU%4JRC.:MR^ ?!C_@H1XDU
MK]CKXI?M-?%CPOX6?6? _P 1KKP+H7AGP1%K.A:?KT\VC>!;C1K:XFUO5?%E
MU;7,FI>*KR34+])&MX=*L@T-@US$QNO-+;]M'_@H++\-++X_)^SC\)]3^#%]
M#!JMN=(OM6N/%DFASZA_9L=T+>W^(%]J8#70V&X'@UFBB=+N6P6U5Y:\W_8J
M/P2TC_@G?\4+;]IB\FT?X3>._C=K6G2ZE#I?B/4;J*ZE\,?#VWT74-/7PUI&
ML:C;WUAX@\.RW-C?"RGL(;ZPCBOO-CDEM):E[^S=\7_V>/@]>_M%_L??M?WN
MM?!RQ\-R?$2V\.^(FDTRPU#1+??<RQ+I6I&^\*:KKXCWV=QH^L>&?#6LOJ\=
MQH$EE#K6S3S^4QXF\1LPX=X0S:'$V=XS!4O#J.=YYA>%,UX7AQAEV8O&XN<>
M)\XR+.Z7UC/<BJ8.-"E3PN$Q&"C5J4JR56E)NI6_=)\&^$64\7<?9#/@SAK
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M5YEB<%@N(L##+,[P]&453S+ 4\12Q<,+B5*,G*E'$T:59*+B^>$7>V@5\O\
M[-G[)GPY_9;_ .$\_P"%?ZUXVUC_ (6'J6EZIK7_  F.HZ%J'V6XTC^UOLR:
M7_8GAOP]Y$+_ -LW7GK=_;7;RX/+DBVR>;]0448K)<KQV995G&+P5&OF>1_7
MO[)QDU)UL!_:=".%Q_L&I)+ZUAX1I5>92O&*M9ZA@>(L[RW)\\R# YEB<+DW
M$O\ 9G]NY?2E%8?,_P"Q\5/&Y7]9BXN4OJ6+G.O1Y91M.3;NM#Y9\%_LC?#G
MP#^T-XT_:2\-:_X[M/&/C^VU2T\2>''U307\$74>L-IEQ?,FFKX9CUQ))-3T
MFTUA6?Q%*%U+S7 ^RN+5?#_BA_P2\_9@^)OBO4O&,4/CGX=:GK%S->ZG:_#?
M7='TC1[B\NA+]LGATK7/#?B.TTT7AE9KBVTE+"R+9,=M'YLXE_1:BOG<;X<<
M"YC@)Y9C^%LHQ> GFF+SKZO7PRJ1IYICY*>-QM"4G[3#5<5)*5?ZO.E"H_BB
MSZW+?%[Q-RC-*>=97QMGV S.GDN7\._6\-C'2G6R3*J;I9;EV+A&*I8VA@J;
MY<-];IUZE)?#-'RY^SM^QY\#_P!F&/4)_AMH-]/XAU: 6FI^,?%%^FL^)[JP
M5TE&G1W45K8V&G6#31I//;:1INGI>3)#)??:6M;7R#]HG]CSX'_M/1Z?/\2=
M!OH/$.DP&TTSQCX7OTT;Q/:V#.\ITZ2ZEM;ZPU&P6:1YX+;5]-U!+.9YI+'[
M,UU=>?\ 4=%=W^I7"7^K_P#JI_JYDW^K=K?V+]0P_P!0YO:>U]K[#DY?K'MO
MWWUG^/[;][[3VGO'F?\ $1N//]:_]>?];^(?];^:_P#K%_:F+_M7D]E[#V'U
MKVG/]5]A_L_U3_=?J_[CV/L?</SQ^%/_  3%_9C^%GBS3O&C0>./B+K.C7-I
M?:.OQ(U_2]6TW3KVP,)L+I=,T+P]X;L[]K(P1FVAU>+4;6(JI%OF* Q>V?M%
M?LE_#G]IO5OAEK/CS6O&VD77PIU'6=3\/1^$=2T*P@O)]<N?#5U=IK2ZSX;U
M^2XACD\+:>MNMC+ISHDUX)9)FD@:W^HJ*XL+X=<#8+),9PYA.%\HPV29C7P^
M)Q^ HX94Z>-Q&$Q%'%X6MBZD6J^(J8?$8>C4I2JU9N#IQC&T+Q?HXSQ<\2\P
MXDR_B_'<:Y]C.),HPV+P>59IB,9*K6RW"X_"8C XW#X&E-/#82EBL)BL11KP
MH48*JJLI2O.TEX-^T7^SMX%_:=^'T?PW^(-YXCT[18/$&F^);:_\*WFEV.LV
MNIZ7!?VD+07&KZ/KMDL4MKJ5[;7"OI[NT4[".2)OFKROP/\ L/?"_P $_&+P
M;\<#XN^)OBSQCX"\%Z/X$\,P>+-6\)W6B6.C:'X,3P+8SFTT?P5HEY+J0T?[
M5<373ZCLFU74+V^:#=)%'#]FT5VX_@SA;,\VHY[C\DP6*S>A6RW$4L=4C/VJ
MKY/4K5LKK249JG.I@*N(K3PTZD).E*I)Q>UO.RSQ$XVR7(<1PQE?$>88+(<5
MA\XPE;+:,J2HRPO$%'#X?.\/&4J4JU*EFE'"8:EC(4JD(UH4HJ2WO\^_M(?L
MU_#[]J/P+8^ ?B)<^(=.TW3/$-GXFT_5/"EUI-CKEGJ-G9ZA8;(;O6-%UZU6
MTNK34KF*[A-B6EQ"RR(\*,.'N?V,_AQ??%CX+_&;4?%?Q'U#QC\#? WASP#X
M:-UJOA@Z;KFF>&5U];/4?%EO#X0ANK[6KH^([Y]0N=)OM$LYGCMFAL+<K/Y_
MUU13QW!O"^99A4S7'9+@\3F-:IE5:KBYQFJM6KD>(EBLHJ5.6<8SJ9?7E*IA
MIRBY0<G&[@W$G+/$+C7)LIHY'EG$>88/*</2SRA0P-*=-T:-#B7"PP6?4:7/
M3E.G2S7#4X4L93C)0J*,964TI!7S-^S=^RK\//V7;7QM9^ -9\9ZQ%X\UJTU
MW6&\8:CH>H26UW9QW<44>FG1?#OA]8;9EO93(ETMY*2L969 &#_3-%>IBLGR
MS&YCE>;XK!4:^99*L='*L9--UL"LRHPP^/5!II+ZU1I4Z=7F4KQBK6>IXN"X
M@SK+LHSK(<%F.(PV3\1O+99YE].45A\R>3XBIB\L>)3BY2^I8FK4K4>64;3F
MV[K0****](\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y?_X9
M,^'/_#3?_#5O]M>-O^%B?V;_ &7_ &-_:.A?\(7]G_X1+_A#=_\ 9W_"-_VY
MYW]E_O\ =_PD>S[?^]\O[/\ Z+5GP/\ LK?#WP#^T'\0_P!I/1]9\9W/CGXE
MZ)>:#KNE:GJ&B3>$[2SOKWPQ?RR:38VOAVSUB"Y6;PIIRQO>:[?Q".:]#0NT
MD#VWTO17S-/@WA>E6CB*>2X*-:/$.)XLC449\RXCQE%X?$YNKS_WNM1DZ<Y6
MY>5V4$?95?$+C2M0GA:O$>8SP]3A/!\"SI2G3Y)<(8#$0Q6#R!KV=_J&'Q$(
M5:<+\ZE%7J-:'QS^T3^PW\%/VE_%OAGQUXU?Q9X>\5^&K=;/^V?!&H:+IESK
MUC;W4=WIUGXA76?#WB"&]CTJ87/V":VBL;Q(KZYMY[JX@CLH[23]IK]B?X6?
MM5ZUX2U[X@^(OB)H5]X,T_4-.TD>"-7\.Z9%)%J-W;WDLMY_;?A3Q%,]Q%-;
M1^1);36JHI;<CMM=?L*BN;'< \&YE'/88WAW+:\.)Z^ Q6?Q=)PCFN(RN3G@
M*^+5.4%.KAYMSC-*,IU)2G4<YR;?;EOBGXAY1/ABIEW%V<8:?!>&S3!\*S6(
MC4ED>$SJ"IYIAL ZT*CIT,73C&E.E+FA"E&-.DJ<(QBOS0\(?\$HOV6_#7B*
MW\1:U<?$WXCR6TT-P-+\?>*M)N])N);<+Y(OH?#GAGPS=W\*[(P]I=WLUI-&
M@@G@EMV>)OK+X_?LY> OVB?AE!\)O%UUK_ASPK::IHVJ6@\#SZ-I%[:-H,-Q
M;Z?8VHU/0];TV#3HX;AHOLT6FJ42.)()(40JWOM%9Y=X=\#Y3E>:9+EO"^48
M++,[I.CF^&H8:,/[2HR4X^RQE>[Q%>G%5*BA"I5E&G[2?LU%SE?7-O%OQ+SW
M.\DXBSCC7/LQSCANM'$Y!B\5C)5%D^(A*$E6R_#-+"86K*5*DZDZ5",JOLJ:
MJ.:IPY?'I/@3\-=1^#&@? 3Q1H8\:?#OP_X.\,^"8;'Q+(LM_>Z9X3TJQTC2
M;^ZO]*BTE[;7$AT^"Y.J:-'I4T%Z7GL%L@4C3X5_X=#?LM_VE]L_MWXQ_P!G
M?:?M/_".?\)?X>_L7IM\K?\ \(7_ &WLV_)YG]L_:=O'VBOU+HHSOP[X&XC>
M >>\+9-F<\LP]/!X&IBL'"=6AA**2I8155:K4PM.UX8>K.=&+<I*'-.;D<-^
M+?B9P@LTCPSQOQ#DM/.<76S#,Z.!Q]2E0Q6/KMNMCG0?-1I8VK=*>+H4Z6(E
M&,(NIRTZ:C\=?%/]AWX+_%'X3>!_@@L_B_X??#7P%JS:YI?A[X>:EHFG)J.J
M&UN[5+W7KKQ%X=\3W6IW,:ZAJ<YNC+#=7-WJ-U<WL]S+Y#0?49\)^'3X3/@4
MZ7 ?"1\.GPF=$+SFV/ATZ;_8YTLN9?M)@.F?Z(7,_GF/GS?,^>NBHKU\#PUD
M&6XG&8S 91@<)B,?@<!EF*G1H0A&IEV649X? 8"-)+V-+!X6C4G3IX:C3IT>
M63YH2=F>!F7&/%.<8++\OS3/\SQV$RO,LSSC T\3BJE2='-LYKTL5FF9RKM_
M6*^88W$4:56MC,15JXCF@N6I%73^0?A+^Q?\-_@Y\&_BE\"_#GB[XEZIX&^+
M&G^(K#6E\1ZOX8O-4T0^*O#,GA/6KSPS<Z=X/TJTL[NZTPVSYU*PU>V6\L+6
M;[,4-U%<^D_L[_L^>#/V9_AXOPT\":GXGU;0EUS4]?%WXMO=*O\ 5_MFJK:K
M<1&?1M%T&S^S(+2/R4^P>:I9_,FDRH7W6BN;+.#^&<FJY77RS)\)@ZV2Y=B,
MIRJI2]HY8'+<7B(XK$8*@YU)6H5*\8U'!\W*XQC!QBE%=F<^(/&?$-#.L-G/
M$..S##\1YMA,]SRC6=%0S/.,#A98+"YCB8TZ4%+$T<-*5)5(\O,I2E-2G)R?
MR_\ ##]DSX<_";XW?$_X]^'-:\;7OC#XL?VW_P )%INMZCH5SX:LO[>\06?B
M.\_L6SL?#>FZI;>7?6445M]NUC4MEHTB2^=,5G3S7XZ_\$[?V<OCWXNNO'NN
MV/BKP7XPU)TGUC7/AWK&GZ)+K5Y&R,NHZC8ZKHNOZ2VJ,$VW&I6VGVU[>,QF
MO9KBY$<Z?=5%<N*X X+QN43R'&<-95BLHJ9AB,U>!Q&&C6I1S+%U:E;$XZDZ
MCE4H8JM4JU7.M1G3FU4J0NH3E%]V"\5/$7+<^I\49?QCGF"S^GE6$R-9GA<9
M*A7GD^ H4L/@\LKQIJ-+$X+#T:%"-/#XBG5IIT:4VG4IQDOC#]GO]@O]GS]F
M[7F\6^#M)U[Q'XS6&6WLO%OCO5+36]7TF&Y1X[L:1#I^EZ+HVGSW<3M#/?P:
M2NI-;M+:I>):W%S#-W&J_LK?#W6/VEO#7[5%SK/C./XA>%=$GT'3]'@U#1%\
M&S6=QX>\0>&GDO=/D\.RZW)<BQ\27TJ/!XAMXA=Q6DAA:&.:"?Z7HK3"<#<'
MX#+LORC!<.Y7@\MRK-L+GN P>&PT:%+#YS@JBJX7,_W?+*KC*-11E&O6E4F^
M6,9.48Q2QQWB9Q_FF;YKGV9<6YWC\XSO(L;PQFF/QF,GB:^*X>S&DZ&-R:];
MGA1R_$4I2C+#8>-*G'GG*"C*<Y/Y=_:9_9#^$?[5FF>';+XCIX@TO4O"UY/<
M:-XG\'WNEZ9XC@L[R(I?:++<ZOHVO6-QH]Y,MM>26\VG//#=V<,ME=6JRWJ7
M?OW@[POI_@CPAX5\%Z3->7&E^$/#>A^%]-N-1DAEU"?3] TRUTFSFOI;:WM+
M>6\EM[2-[F2WM;:%YV=HK>&,K&O245Z>&X?R7!YQF&?X7+,)A\YS:CAL/F68
MTJ2AB<=1PBY<-'$SC9571C:$)R3FH1C!R<8Q2\;&<5<1YAD&4\+8[.<=B^'L
MBQ&,Q>3917K.I@\MKX^7/C)X.$DW16(G>I4IPDJ;J2G44%.<Y2****]@^?"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN+>WN[>>TNX(;JUNH
M9;>YMKB))K>XMYD:.:">&16CEAFC9HY8I%9)$9D=2I(,U%)I---)IIIIJZ:>
MC33T::T:>XTW%J46XRBTXR3:::=TTUJFGJFM4S\SO%'_  2A_9?\0:]J.MZ/
MJ'Q4\ 0:I--+<^'_  1XLT>TT ).RM):06VO>%?$-]!9;M^RTCU 00K*\4*1
MQ)#'%]<_ #]FWX3_ +-/A:[\*_"W0Y["+5;J.^U_6]4O'U/Q#XBO+=98[2;5
MM1=(8VCL8)I8;&QL;:RTZT$MQ-!9I=7E[/<^\45\;DWAUP+P]FD\ZR/A7),K
MS22K16-PF"I4JM&.(NJ\<+9<F$C6BY0J+"QHJ<)2A).$I1?Z'Q#XM^)G%F2T
M^'>)...(\ZR2$L/*678_,J]>AB)82SPLL:W+VF/EAY1C.C+&SQ#IU(PJQ:J0
MC)?+_P ,/V3/AS\)OC=\3_CWX<UKQM>^,/BQ_;?_  D6FZWJ.A7/AJR_M[Q!
M9^([S^Q;.Q\-Z;JEMY=]9116WV[6-2V6C2)+YTQ6=$^"'[)?PZ^!'C_XG_$_
M0-<\<>*O&WQ:O9+[Q-K/C?5-$U"2W>YU>_US48=(BT+PYX=BMH-3U*]CGNUO
M$OW4:=I\5G):QQW"W/U#179AN#.%L'4RZMALDP5&IE.8YEFV7.,9M83,\XC4
MCF6.I0E.4/K.*C5J*=2492@YS=+D<FSSL9XA\;9A1S:AC.),QKTL]RG)LAS>
M,ITT\?DW#\J4\GRVO.%.,WA,#*A1=.E&48S]E!5O:**1\N?&_P#9*^'/QV^(
M/PP^*.OZYXX\*>-OA->1WGAK6? ^J:'I\ET]KK%AKNFPZQ'KOAOQ%'<P:5J5
ME-/9)9C3V(U34H[Q[M)+86J_$3]DOX<_$SX_?#G]HS7M:\;6GC?X8Z=HNF:#
MI>D:EH4'A6[@T+6M?UVT?5[&\\-W^KW$TEWXBO8[EK+7-/1[:*U2*.&5)II_
MJ*BC$\&<+8NMCL1B,DP56MF>9Y9G./FXS2Q.:Y-&$,MQ]2$9J'UG"QITU"I&
M,7/DBZOM&DQX/Q$XWP&'RS"8/B3,:%#)LFSGA[*X1G3;P>1\03J5,XRNE.5.
M53ZGCIU:CG1E.4:?M)JC[*,FCB_B'\//!OQ6\&ZYX \?Z%:^(_"?B.U%IJNE
M7;31K*L<L=Q;SP7%O)#=6=[9W4,-W97MI-#=6EU#%<6\L<L:L/SF'_!(;]EX
M7QN/^$D^-!TTW?VL>'3XP\-_V,&VA/+!'@@:OMV IYIU8W>PE?M.,8_4VBL.
M(N N#.+<1AL7Q+PUE.<XK"4_8X?$XW"PJ5X4.=U/J[JKEJ5,.JDIS5"I*=%3
MG4DH)SFY=/"/BEXB<!83&8#@[C'/>'L#CZWUC%8/+L;.EA:F)]G&E]:5"7/2
MI8MTH4Z3Q5&-/$2ITZ<'4<:<%'QD_L]_!T_![_A09\#:4?A1_9@TK_A%2UT8
M?*%V-1%[]N\_^TO[7&J :J-8^V?VD-3 OA<_:/GKX='_  2,_9C%T7'B?XUC
M23<_:CX9'C/P]_89;(^0K_PA7]JE< +YIU3[3M _TC(S7ZD45CG7AUP+Q#]0
M_MGA3),?_9>%IX'+_:X&E#ZI@:7\+ TO8JG;!4M?981WP]/FER4H\TK]'#OB
MYXF\)_VI_J[QSQ)E?]M8ZKF>:^QS*O4^O9G7_CYG7^L2K<V95M/;8]6Q=7EA
M[2M+DA;B_AY\//!OPI\&Z'X \ :%:^'/"?ARU:TTK2K1II%B6262XN)Y[BXD
MFNKR]O+J::[O;V[FFNKNZFEN+B6261F/:445]=AL-A\'AZ&$PE"CA<+A:-+#
MX;#8>E"CA\/AZ,(TZ-"A1IQC3I4J5.,84Z<(QA"$5&*221\%B\7B\PQ>)Q^/
MQ.(QN.QN(K8K&8S%UJF(Q6*Q6(J2JU\3B<16E.K7KUJLY5*M6I.52I4E*<Y.
M3;91116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?+OP[_9+^'/PS^/WQ&_:,T'6O&UWXW^)VG:UIFO:7J^I:%/X5M(
M-=UK0-=NWTBQL_#=AJ]O-'=^';*.V:]US4$2VENDECFE>&:#ZBHKS,PR7*\U
MKY9BLQP-#%XC)L:LQRNK53<\%C52J4%B:+32514JM2G=IKEF]#VLJXBSO),+
MG."RG,L3@<+Q#ESRG.J%"45#,<M=>EB7@\0I1DY477H4JMHN+YJ<7>RL?+_[
M2?[)GPY_:D_X0/\ X6!K7C;1_P#A7FI:IJFB_P#"':CH6G_:KC5_[)^TIJG]
MM^&_$/GPI_8UKY"VGV)U\R?S))=T?E5OCQ^R%\-?VA?'7PT^(/C37/'&F:S\
M++F.[\/6OA?4M LM,O)(]8L-;5=9AU;PSK=W<(;O3H(R+&]TYOL[RH&$C)*G
MU317E8[@OA7,YYQ4Q^28+%5.(*V4U\YE5C-O,:V0\JR>IB+37-+ <D?8<O*E
MRKF4CV\L\1N-\FI</T<KXES+!4N%:&?8;AZ%&=-1RFAQ/S?V_2PBE3ERQS7G
ME]:YN9RYGRN)X1\>_P!FSX1_M)^&[7PY\4_#AU,:9++<:%KNG7+Z9XC\/W$X
M1;B32=5A5F2*Z2.-;NPO(;S3+LQ02W-E+/;6LL/R'X/_ ."3O[+'A?7;'6M4
MG^)GCZWTYT:U\/>-O%.DS^'U$<LL\<,MMX;\,>&KZXM5FE:1[.?4)+2<[EN8
M9HY9TE_3.BN3./#K@7B'-*>=YWPID>9YK35)?7<9@*-6M55"WL8XF\>3%QI*
M,8TXXJ-91A&,$E"*BN_A[Q;\3>%,DJ\.<-\=<2Y+DE5UI++L!FF(H4*$L3=X
MB6"Y9<^ E7<I3JRP4\/*I4E.I)N<I2?S#^TC^R9\-/VG_"?A/P7XWU'Q9X;T
M3P9JAU718O 5WH&CO&_]FOI4=G(FK^&_$%HNGP6C[8+>TM;4Q%(PLGE+Y9]Q
MOO!FEZAX$O/A[-/?KHM[X2N/!DMU%+;KJBZ7<Z,^B23QS/:O:"_%HYD25K)[
M<7 #FU:/,)ZVBO:I</Y+0S#-,THY=AJ>89UA<+@LUQ4(M5<;A<%2J4,)0K6E
MRNG0I5:E.FHQC:,FM3YNMQ7Q%B,KR3)*^;XRKE7#F-QV8Y'@9SBZ.6X[,J]+
M$X[$X=./,JN*KT*56K*<IWG!-):W^3?A/^QQ\,?@[\"OB5^S[X9UWQY?>#/B
MG_PF7_"0:GKNI^'[KQ/9_P#";^#].\$ZM_8U[I_A?2]*M_L^E:7;W&G?;=%U
M'RM0>:6Y^UVS):1_)G_#G#]F/_H>OCO_ .%/\/\ _P"=A7ZRT5\QF'A7X>9K
MA<JP68\)Y5B\)DF$E@<IH5J=5PP.$E4=65"@E535-U&YM2<G=O6VA]ME/CCX
MM9'C<[S'*..\]P&.XDQT<SSW$T*M%5,SQ\*2H0Q6)<J$E*K&C%4TXJ*Y5L?#
M_CC]@7X.^/O"/P#\&:QXD^)=MI?[.EK?6G@F?3-8\+PW^J1ZA<>'+F9O%,MU
MX-O+>^=9/#%@(CI-KH:JDUX'5S)"UO[I\=?V>?A3^T;X4B\)?%3PXNLVEC<2
M7NBZI:7$FG>(/#U]-&(9;O1=6M_W]L9XUC6[LYEN=,O_ "+;^T+&Z^S6_E>V
M45[%/@KA.E1S;#1X?RR6&SW"Y;@LXP];#QKT,QPN3X*GE^5T,51K^TIU(8'!
MTJ=##^ZG"-.$K\\5)?/5?$?CNMB,BQDN*LYAB^&,;G&8\/XNABYX7%91CN(,
MQJYMG6)P6(PWLJU*IF>85JV)Q;4VJDZM2+2ISE!_F-X7_P""2_[+'A[6['5M
M3O/BEXVL]/F$MOX:\6^+=(;P^5$TEP+>2+PWX6\-ZI):F:0R26YU41SG<+@3
M++,)?JG]HC]ESX<?M*?#CP]\+/%]UXC\+^%?"_B/2?$FC0_#^?0=$GM9]$T'
M6_#NG:9''JGA[7=-@T:#3==N52RM=.MWB>WLE@GB@BD@F^D**X,!X;<!Y7E>
M:9+E_"N3X/+,ZIPI9MAJ&%C#^T*--WIT<56O[>K2I.[I4I5>2DY3=.,7.=_4
MS3QA\4,ZSO).(LVXXX@Q^<\-U:E?(<;B<;*H\IQ%5)5L1@J#C]5H5ZZ457K1
MH>UKJ%-59S]G#EY*Q\&:7I_@2S^'L,]^VBV7A*W\&174LMNVJ-I=MHR:)'/)
M,EJEH;\VB"1Y5LDMS<$N+58\0CQ7]F7]E;X>_LI^'/$GACX>:SXSUFP\4:W#
MKVH3>--0T34;R&\@L(M/2.SDT/P[X=ACMC#"K,DUO<2F4LPF"$(/I>BO?J9!
MDU7,<JS:IE^'GF.1X;%8/*<6U+VN PV-I4Z.*HT'S64*]*E3A/F4FXP5FCY:
MEQ5Q#0RG/,BI9MBJ>4<2XS!8_/<!&4/89GC,NK5<1@L1B5R<TJF&KUZU2FXR
MBE*I*Z:=CY6\*_LA?#7PA^T;XJ_:=TW7/'$_CWQ?;:C::EI%]J6@2^$((]3M
M=-M)VL;"W\,VVLQ.D>EV[0FXU^Y57>8NLBLBQS_M&_L??!3]J*'29?B5I&J6
M^O:%$UII/B[POJ$6D>);739))II-)>YN;/4M/OM--S.]W%;:CIMX+2Y>:6Q:
MV-W>BY^HJ*\^?!7"=3*LRR.KD&65LHSC'XG-,SR^OAXU\-C,QQ=6-?$8VK3J
M\Z^LSKPA656'+*%2,9TW"23/5I^(W'5'/,GXEH<59SA\_P"'\KP>29-FN&Q<
M\/C,!E& H3PN$RVC5H>S;P=+#5*E!T*BG"K2G.G552,FG^>7PO\ ^"9/[-?P
MS\9Z1X[FD^(/Q&US0;N'4-&3XE>(]+UG3;&_M'26QNSIVB^'?#MO?/8SH;BU
MAU,7UHEPWG-;N\<!B_0VBBNCAWA3AOA+"UL'PWDN R;#XBK[?$0P-"-*6(K*
M/(JN(JN]6O.,%RPE5G-PC[L;+0Y>+>.>+^.\9A\PXPXBS7B'%X2A]5PE3,L3
M.M'"8=S<Y4<)1]VAAJ<YOGJ1H4Z:J3]Z?-))A1117T!\H%%%% !1110 4444
M %%%% !117GGQ6^*WP_^"/P_\2_%#XH>)=.\)>"?"6G3:EK.LZG,L44442DI
M;VZ$A[N^NW @LK* //=3ND<:$DD=6"P6,S+&87+LNPN(QV/QV(HX/!8+"4:F
M(Q6+Q6)J1HX?#8:A2C.K6KUZLX4Z5*G&4ZDY1C&+DTC'$8BAA:%;%8JM2P^&
MP]*I7KUZ]2-*C1HTHN=2K5J3<84Z=.$7*<Y-1C%-MI(/BM\5OA_\$?A_XE^*
M'Q0\2Z=X2\$^$M.FU+6=9U.98HHHHE)2WMT)#W=]=N!!964 >>ZG=(XT))(_
M@E_X*;?\%-OB!^WC\0)-(TB34?"7[/WA+49O^$&\#><T4NLRQ,T:>+O%R1L$
MN]8NT&^RLGWP:/ XBB!N#)(#_@IM_P %-OB!^WC\0)-(TB34?"7[/WA+49O^
M$&\#><T4NLRQ,T:>+O%R1L$N]8NT&^RLGWP:/ XBB!N#)(/RLK_>SZ%OT+<'
MX08/!>)7B5@L/CO%#'8=5<KRNJJ>(PO F%Q--7ITW[]*MQ+6IR<,;CH.4,NA
M*>!P,VWB<3B/\W/'WQ]K\<5\1PGPGB*N'X0P]5PQF,@Y4JW$=:E+XI?#.GE-
M.<>;#X>24L5)1Q&(BDJ5*F4445_HT?RP%%%% !1110 4444 %%%% ']>%1R=
MOQ_I4E1R=OQ_I7^+,/B7S_)GYS#XE\_R9'37^Z?P_F*=37^Z?P_F*V-)_"_E
M^:(:1NA^A_E2TC=#]#_*G'=>J_,4-GZ_HB"OZ!/V2/'6E^./@-X"-C<I+>^%
M=&L_!NLVF]6GL+SPY;QZ?;),@)*K=Z9%8W]L>C07*+D.DBI_/W7IWPE^-'C[
MX+:Z^N>!]42W^U>2FK:1?1-=:+K<$'F^3#J=DLD+R>3Y\I@N+>>VO+=I',%Q
M'O<-^8^+WA[6\0^&J> P&(HX;-LMQBS#+I8ARCAJ\_95*-?"5YPC.5*->G44
MH55"7)6I4E)*G*I)?O?T>_%S#>$/&M;-<TPF(QF09SE\LISB&$4)XS"T_K%'
M$X;,,-2G.G"O/"UJ3A4H2J0]IAJ]=TVZT:47_2517Y/V'_!2_4H;>--5^#UC
M>W@1?-GT_P <7&F6SOC#&.TN?"NKRQJ3RJM>RE1P78\U<_X>:?\ 5$__ #)'
M_P" 5?Q]+P#\6(R:CPM&I%-I3AGG#JC-=)153-H32>ZYH1EW29_HE#Z5?@/*
M$92XXG2E**DZ=3ACB]S@VK\LG2R"I3<EL^2I.-]I-:GZJ45^51_X*:X!/_"D
MNG_52?\ \ :9_P /./\ JB7_ )DG_P# &DO /Q9>W"?_ )G>&O\ Y\E/Z5/@
M*M^.]U?_ ))?C+;_ ,1T_5BBORF;_@ISM&?^%(YYQ_R4K_\  &HS_P %/, G
M_A2'3_JI7_X 4_\ B /BW_T2?_F>X9_^?(_^)J/ 9_\ -=];?\DOQEO_ .(Z
M?J[17Y/_ /#S_P#ZH?\ ^9+_ /Q?T'_@I_@$_P#"C^@S_P E+_\ Q?TUX >+
MCVX2_P#,]PS_ //D?_$T_@/_ -%W_P":QQE_]#Q^L%%?DW_P]#_ZH=_YDS_\
M7]'_  ]#_P"J'?\ F3/_ ,7]/_B7_P 7/^B2_P#,]PS_ //H/^)I_ ?_ *+O
M_P UCC+_ .AX_62BOR8/_!4;!(_X4;T./^2F_P#XOJ3_ (>C?]4,_P#,F_\
MXOJK_B7WQ>?_ #2/_F?X8_\ GT5_Q-)X$/\ YKK_ ,UCC'_Z'C]:**_)0_\
M!4G!(_X47T_ZJ;_^+ZF-_P %3-IQ_P **SQG_DIW_P"+VFOH]^+[VX1_\S_#
M'_SZ#_B:3P)_Z+K_ ,UCC'_Z'C];J*_(\_\ !4[ )_X45T&?^2G?_B]J/_AZ
MC_U0G_S)_P#^+RJ7T>?&%NRX0_\ ,_PO_P#/L?\ Q-'X%.W_ !G.][?\8SQC
MTW_YI\_72BOR+_X>H_\ 5"?_ #)__P"+RD/_  52P"?^%$=/^JG_ /XO*?\
MQ+OXQ?\ 1'_^;!PM_P#/L']*+P*6_'.[M_R3/&&__B/GZZT5^0Y_X*JX!/\
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M]X&O_FN.MO\ DFN+]_\ PP'[)T5^-?\ P]N_ZM^_\RM_^+:C_A[=_P!6_?\
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M^::;33X4XV333LTU_JWHT]&?OY17X '_ (+H8)'_  RYT./^2V__ (HZC/\
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MS_YM_ ?_ -%!7_$UG@'_ -%Y_P":OQG_ /0Z?T2T5_.L?^"^N 3_ ,,G]/\
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M=[?]4QQE_P#0\?TBT5_-L?\ @X2P"?\ AD7I_P!5\_\ Q*TS_B(5_P"K1/\
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M2[<?\8?9S_U<#_\ B2IO_$1/_P!6??\ FP/_ .)&J7T(_I//5>&7_FZ>'O\
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MT6G_ )KG%G_SA/ZN**_E'_XB=_\ JR+_ ,V4_P#Q T?\1.__ %9%_P";*?\
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M )O?AI_]&0?\3*^"G_1:?^:YQ9_\X3^KBBOY1_\ B)W_ .K(O_-E/_Q T?\
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M*@?H/K_0UJ:$50O]X_A_(5-4+_>/X?R%:PV?K^B+CLO\:_(;1115FDMGZ/\
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MNA^A_E51W7JOS @HHHK<?1>K_*)7J!NI^I_G4]0-U/U/\ZZ#<2OT8_X))_\
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M?H/K_0U^I_\ P5&_YQU_]HL_V1O_ 'H-?E@_0?7^AK\H\!O^34<*_P#=<_\
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M1?D5W^\?P_D*8W0_0_RI[_>/X?R%,;H?H?Y5M'=>J_,9^HO_  5&_P"<=?\
MVBS_ &1O_>@U^6#]!]?Z&OKS]K;]I'1OVC_^&9?['\,ZGX:_X4-^R-\&/V;M
M5_M.]M;W_A(-9^%W_"2?;O$VG_98X_LFF:K_ &Y%]DLKG?=0>1)YTC;UQ\AO
MT'U_H:_/?"'),TX<\.^'LFSK"3P&9X/^UOK.$J3I5)TOK&>9GBJ-YT*E6E+G
MP]>E47+4E932E:2<5]AQWF."S;BW-,PRZO'$X/$/ >QKQC4A&?LLNP="I:-2
M$)KEJTYP?-%7<6U=--UWZ#Z_T-15*_0?7^AJ*OTZ&S]?T1\LMY>OZ(:_W3^'
M\Q4-3/\ =/X?S%0UT0V?K^B&5ZA?[Q_#^0J:H7^\?P_D*L!M0O\ >/X?R%35
M"_WC^'\A6\=EZ+\C>.R]%^1#)V_'^E1-T/T/\JED[?C_ $J)NA^A_E6\/A7S
M_-E1W7JOS(****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?U"EV21'1BKH5964X*LIR"".A!&0:]-T?55U.U7>0+J !;A
M!QN[+,H_NOCG^Z^5Z;2?,'ZCZ?U-3V5]-IUU%<Q'.TD2)G"R1M@.C?4=#_"P
M##I7^16.PD<52T256G=TY>;6L&_Y9?@TGLFG_-V39G++<5&4FWAZK4:\-[+9
M5(K^>G=O^]%RCNTUZ]37^Z?P_F*BM;F&\MXKF!MT4J[E/<'HR,.S(V58>HST
M(J5_NG\/YBOE6G%N,DTTVFGHTT[--=&GHS]-YXSIJ<)*4)QC*,HNZE&5FFFM
MTT[ID-(W0_0_RI:1NA^A_E1'=>J_,<-GZ_HB"J]6*KUN61/U'T_J:93WZCZ?
MU-,K>.R]%^0WO\H_DAK_ '3^'\Q4-3/]T_A_,5#6D-WZ?JAR^S_A7ZC'Z#Z_
MT-0/]T_A_,5._0?7^AJ!_NG\/YBM1QV7^-?D0TC=#]#_ "I:1NA^A_E6L-GZ
M_HC4@HHHJP(&ZGZG^=)2MU/U/\Z2MX[+T7Y&\=EZ+\B%_O'\/Y"H'ZCZ?U-3
MO]X_A_(5 _4?3^IK2&[]/U0R-NA^A_E4%3MT/T/\J@K>'Q+Y_DS2/V/^W@IK
M_=/X?S%.IK_=/X?S%;%2^S_B7ZD#=#]#_*H*G;H?H?Y5!3CNO5?F.6S]'^17
MHHHK<9 W4_4_SI*5NI^I_G25O'9>B_(")^H^G]33*>_4?3^IIE:0W?I^J-(_
M%_VZORB1R=OQ_I4#]!]?Z&IY.WX_TJ!^@^O]#6IH15"_WC^'\A4U0O\ >/X?
MR%:PV?K^B+CLO\:_(;1115FDMGZ/\B!NI^I_G4#_ 'C^'\A4[=3]3_.H'^\?
MP_D*WCLO1?D$=EZ+\AM1/U'T_J:EJ)^H^G]36D-WZ?JAD$G;\?Z5 _0?7^AJ
M>3M^/]*@?H/K_0UM'=>J_,<=UZK\R*BBBMS26\/7]4(W0_0_RJ"IVZ'Z'^50
M4%E>BBBN@WEL_1_D0-U/U/\ .H'^\?P_D*G;J?J?YU _WC^'\A6\=EZ+\@CL
MO1?D4;^QM]1M)[.Y3=%.A4_WD;JLB'LZ-AE/J,'@D5\_:OI=QH]]+93C.P[H
MI0,+-"Q.R1>N,CAAU5@5/2OHVN8\4Z$FM66(U47UN'>TD.!N. 7MV/'R2X !
M.0D@5L8W ^YDN9/!5_957_LU:24K_P#+N;TC47ETJ+^6TM7%)^/F^7+&4E5I
MQ_VFBFX6WJ0W=-]WUI]I76BDV>!2=OQ_I4#]!]?Z&K,Z/&YCD5D=&9'1@0RL
MIPRL#R""""#T-5GZ#Z_T-?H<&G%-.Z>J:V:ON?$;;D5(W0_0_P J6D;H?H?Y
M5O#9^OZ(I?9_Q/\ ]M*[=#]#_*H*G;H?H?Y5!6L/B7S_ "9I/X7\OS17HKL;
M#X=_$#5?!VK_ !$TSP+XQU'X?^'[]-*U[QS8>&-;O/!VB:G+]B,6G:OXFM[&
M31=-OY!J>FE+.\O8;A_[0LML9^UP>9QU*CBL-B95XX?$4*\L+6>&Q,:-6G5E
MA\1&$*DL/74)2=&M&G5IU'2J*-10J0DX\LXM]%7#8C#QHRKT*U&.)HK$8>56
ME.G&O0E.=.->BYQBJM%U*=2"J0YH.<)Q4KQDE"_WC^'\A4,G;\?Z5,_WC^'\
MA4,G;\?Z5W1V7HOR,X?$OG^3(Z8_0?7^AI],?H/K_0UT1V7HOR-B!_NG\/YB
MH&Z'Z'^53O\ =/X?S%0-T/T/\JJ.Z]5^8$%%%%;CZ+U?Y1*]0-U/U/\ .IZ@
M;J?J?YUT&XE0O]X_A_(5-4+_ 'C^'\A5PW?I^J @?J/I_4U!)V_'^E3OU'T_
MJ:@D[?C_ $K>'Q+Y_DRH?$OG^3(Z:_W3^'\Q3J:_W3^'\Q6QJMY>OZ(KO]T_
MA_,5#4S_ '3^'\Q4-:PV?K^B*Z+U?Y1"J]6*KUO3Z_+]1KX9?]N_F0-U/U/\
MZKMU/U/\ZL-U/U/\ZKMU/U/\ZUCNO5?F:QV7HOR$J)^H^G]34M1/U'T_J:W-
M(;OT_5$$G;\?Z5'4DG;\?Z5'6T/A7S_-BA\2^?Y,CD[?C_2H7^Z?P_F*FD[?
MC_2H7^Z?P_F*WAL_7]$:K>7K^B(:KU8JO6D=UZK\RH[KU7YA4#=3]3_.IZ@;
MJ?J?YUN:S^%_+\T0/]X_A_(4QNA^A_E3W^\?P_D*8W0_0_RK>.R]%^0X[+T7
MY$%1R=OQ_I4E1R=OQ_I5P^)?/\F7#XE\_P F0/T'U_H:BJ5^@^O]#45;QW7J
MOS-(_:_Q/]".3M^/]*B;H?H?Y5+)V_'^E1-T/T/\JW&MY>OZ(@JO5BJ]:4^O
MR_485"_WC^'\A4U0O]X_A_(5O#=^GZHWCLO1?D5W^\?P_D*8W0_0_P J>_WC
M^'\A3&Z'Z'^5;1W7JOS&04Q^@^O]#3Z]Q_9L_9]\9_M3_&[P)\ _A]J?AC1_
M&'Q"NM9M=%U+QE>ZKI_AJUDT/PUK7BB[;5+S1-%\0ZI"DFGZ'=PVYM-&O6>\
MDMXY5A@>6XAYLWS7+LARK,\\SC%T<ORG)LOQN:YIC\0W&A@LNR[#5<9C<77<
M5*2HX;#4:M:HU%M0A)I-Z'7E^!Q>9X_!9;@*$\5CLPQ>&P."PU))U,1B\76A
M0PU"FFTG.M6J0IP3:7-)7:6IX&_0?7^AJ*O9M1^"7BNP^/UW^SC-J'AYO'%E
M\8Y_@E+JL5WJ3>%&\5VWC1_ CZA'?/I*:N?#QU=#<I=MH::D=-Q,=)6ZS9CU
M3XI?L1_';X9_M9ZC^Q99Z5I'Q/\ CC9ZEX8TJSTWX97>I:GHNMW?BKP1HOQ
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M6[L-!TVUO[^]GFGC@LE>VT[4I+(737XTS4A:FQN,,;F.'P65XO-^3$XW"X3
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M,D2\F+/=X@"5]8\#JF3XV:8)RB\726L=*T4MTK6J+T6D_))]&S['AS-'&/\
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M_P#!%O\ ; M[B*2">#]HOP[#-#,C12PRQ>(?V84DBEC<*\<D;JR.CJ&1@58
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M?Q+U/Q%JVI:+JOB'4/%7Q-CTBVU+Q;KD>KVTO]K-/?Z)%I%S<W4MQ^8>K_\
M!2S]I/Q'^US\/?VRO$\G@?Q!\0_A3 FF_#WP9>>']1L/A3X5\/0Z5K&DVWAC
M2?"^@Z]H^J6VBVZZ]J5\ OB/^T[C4)EFO=2NHHU@'S-XC^/?C_Q!^T3KW[4-
MO+I7AOXI:W\:=4^/<$V@6,G]AZ!X_P!2\<S_ !#BET73=;NM;E_LK2_$4ROI
MMCJ][J\GV."&WU"ZOV\V67+A7Z,.<UJM./B!D_">?QPW@7FO!&11S.M_K#@.
M&.(\VXUX^SC+LJP,,SP4JM7!<*<*\4Y9PQ@<\C@J==X+!XBE@Z-"C7G1GIG'
MB]@:<)/AG'9UECK>(F#X@S)X.']EXG-\JP60<-8'%8S$2PE>,(8C.LYR?%YO
MB,N]O*FL17I3KSJ3IQJ+[S_X+'_'OXO_ !5_;6^+WPW^(?C"Z\0^#/@9\1?&
M?AWX4Z%<:3H5@GA+0M>&@W.HV5O>:9I5AJ6J17K:3IDBSZW>:G/&ENGV::-)
M91)]+_&C^W_^(?S]C[_A!_[0_P"$=_X:.^(?_"Z?^$>^T?9?MG_">?&K_A%/
M^$[^P\?8L_\ ")_8O[7_ - _M+_A$,?\3'^Q*_,_]L/]L_QE^VIXKT+QY\0_
MA3\"/ 7C?38M27Q#XM^#W@75/"&O_$FZU"VT*R@U'XD:AJGBGQ++XDU#1;/0
M+>TT*=/L"Z?;7FH0".2*:%;??_9&_P""A'[0W[&6G>,O"WPWN/!GC#X8_$$F
M;QG\'OBSX9_X37X9:]J36]M8MK,^AIJ&D7]GJ<^FVL.EZC+IFKV-OK6GPV5O
MKEMJ0TC16T[[B7A-Q=A_![P'RO(N%>%LIXK\&N)N%>+<5P.\QPV!X>S_ !N1
MY/Q#P_G='#YUEF65\+@L;G%7B#%\7X',JV55KYY&@\SA3Q%;$XRC\]'C7)*G
M'/B/C,QSG.,;DW'F49QDE'B'ZK5Q&9Y9A\QQ^5YGE\ZN7XO%TZV(P^ AEE#)
M,1A*>,IVR]U/J<ITJ=&A/]&O^"!$_B'_ (65^UY;^(&E;]G3_AE7Q=+\:$U0
M1GP9'?'4;!/#,FNF;]S'>2^%$^)R6P<B.;1(_$AF5U@5H_8?V?\ X]>-OV:O
M^"%MK\6_AK9^$C\0]$_:NUNP\&^(O%?A31O&)\#:OKD+Z5-XP\-:5XAM;_18
M_%-CI-SJ6G:;?:CIVHVMO;ZK?++8W"3%*_-+XU_\%5?VA_BY\%=2_9X\*^"/
M@#^S3\&]?EE;Q3X&_9>^&+_"O2O%-M<R_:+W3=8W^(/$%Q'IFIW/[W6;/2)M
M+37(S+9:R;_3;FZLY_"O^&T?BC_PQM_PP_\ V#X!_P"%3_\ "RO^%I_\)#_9
M?B+_ (6'_P )!OW_ &/^UO\ A*O^$;_L;/'V?_A$OMN/^8CGFOC^(? CCCQ"
MXES+C#BSAGAC+L-Q7XN>#V=9UP-_;%+.\/'@7PVR?B3*LSQV?8YX#!8#-\ZX
MA6?RP^*R?#8?$82.2X++LNK8W'<E=1]S*_$?A[A?*<+D62YOF^*K9-P3QS@,
M!Q$\#/+ZLN(N*\=E&-PF'RW#?6<1B<#E^5O+%4HXZK5I5GC\1BL5##X;FIM_
MN)^UBMC^TO\ #?\ X(D_M+?&WPK;?$GXE?%GXH^&_ WQH3P_X/T>'4_C!X1/
MCWP9]MT74M!T*QL8-1NI[+3-:ATS1=-CL-(BN/%FOP6-A96MY!!:_57Q5_:8
M\2_ GXA?MXM\<OVX?V<->_9K'PK^*_P]^ '[-OP.\=^%M+^//@?QO</9Z/X!
M\,:+X6\%Z?!XW^'?B/PG;6^I^'_$6MW?B%=/CUZ6#Q'/8Z7I]J%T#\,_@-^W
ME:>._$O_  3_ /@7^U!9^&?"O[-G[)GQ,L]>L?&7@&U\<:/\0H=\\E[INL^*
M-<L?%U_(]IHWB./2=0O+GP;H>@ZO;:9;7<MB)[Q(4;]Q-!_:S^(>A_M&_$OQ
M[^TQ_P %(OV$/BQ^P+/-\3[W_A2&@>)?A9\1O'?B/P#JNG:Z/ 7A+3/AQX?\
M'MX\F\0:6DNC6VL0W^N:^]_]FO[*X3Q$VI">OYS\2/#?B7@V.1\)YWPI@,UR
M;AS+/$[-\CR&E3Q4Y5\CS?QFQG%'"_"WA/F&#X$XVP>6<?QR'"9=EM+ 4:/#
M]3+<MS# 8*.9/"*G++/U/A3BO*L^>89UE^=8G!8_-,9PC@<PS&<Z,53S' \!
MX;*,XSCC7#5^(^'ZV,X:>95L5BIXFI/-(XO%X;$XB6$59R6+^$/'_P =_B7_
M ,$\O^"<7[#7C7]E+4;'PY\3_P!KF\^(WQ-^.W[0<GA;POXQ\6ZQK>A7FCW=
MAX$U74_&/AKQ%921F;Q9>6B1W+)?*W@756@%R^K^)+B;ZF7PSX4\1_MY?\$7
M?VKH/!_A_P $?%3]J_X5:UXS^,VF^$M,MM"\.ZUXJTCX5VM];^,K;1(&D:TN
M_$*>,+V.2XEN)Y+K3-,T=)II[NUN[JX_%'X;_P#!2SQY\(O!OBCX(:/\&?V?
M_C1^S4?B7XC\??"WX.?M0_#9OBSI/PL&K:WJVHV<'ARXMO$/AZZBNDM=4EBO
MWN[O4;>6YN=5FM8[<:SJPON7U?\ X*5_M)^(_P!KGX>_ME>)I/ _B#XB?"F!
M--^'O@R\\/ZC8_"KPKX>ATG6-)MO#&D^%]!U[2-4MM%MUU[4KY0GB,:G<:A,
ML][J5U&BP5^U8KZ//B+CJG%$\/D'#V6YSFF ^D%4S7CUYU2AQ!XDY=XHY'Q#
M@^ ."^(<%A\'SX/"\'U<XR2A6HXS,,5DF2/@_!_ZNQKTLPJU:/P%'Q/X6P\<
MGC5S/-,7@,'B?#*.#X;67S>5\*8K@_,<KK\2Y_E>(J8AQKUL\A@,PJ0J4,+1
MS#,%GE;^U'">&A&?[:?LG>,)/A[\3_\ @XJ\>P>'_#'BNY\%>*/BWXLM/#?C
M72?[>\(:W>>'OB#^T]JUGIWB;1#/:C5]#N;JTBCU/36N(%OK0RVS2HLA8> ^
M._CM\1OVY/\ @BI^T#\8_P!I:]T#QW\3?@1^TUX*T/X:>+[3P?X5\(ZAH&BZ
MI/\ "K3;C2X;?P?I&AZ8+3^S?B!K^GM$EA&+FW&G/?\ VN\TVTNX_P N?"O_
M  4.^-7A"?\ ;CN--\,?"Z=_V_?^$M_X7&+[1?%DJ^&O^$RU'Q_J>J?\*S%O
MXVMCHWD7'Q&UM+#_ (2EO&7E0VNE+<?:G@NY+[S[PA^V-\3?!?[(7Q5_8LTO
M0O EQ\+?B_\ $'1?B3XEU_4-,\02^/['7-!N/!5Q9VFAZI;^)[7P[;:3(_@3
M2!<P7_A74[QTN=2$5_"9K5K/U\/]&_B>GQ4N,9Y+P_\ ZR8/Q*^CIG64Y_\
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MZ/\ DEY>?K_3TM\3T;.^$J[/:I#M_A/;,'T/Y&C!]#^1KPW^U=3_ .@A>_\
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MIOL]I;V]K '$5M!#"B1K]A>'/^"EW[<?A'PW8>$]%^/^OG1].LTL+1M9\->
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MAJ5'$*EBZM:E7A*DHS_K[PQX@?#G@/4QJX\SGP_C/QAK49YIDF3RSO$XZ/\
MJ;EM9Y;5P:QN!IJA45+ZPZE>I5HNIAJ=*I1E&HW'V?XW_ CX6_"7_@KE^Q'X
MR^'.@:5X+U#XP6_B[Q'XX\':+;VMA86_B+2] \2V[>)UTNV\N/3[KQ(FH26V
MI"WL[.SO]3T&\U39+JM[J\\GCG[67_!.;X>?&_\ ;/\ BGJ_Q*_;.^$/P/\
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MX3TGP-X@L/#'B#4;6"U>*3Q S:UJ>FV>D0V<\%OJ(O[>]>^M-,$]_#],S?\
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M7?J/I_4U8?J/I_4U7?J/I_4UO'9>B_(U(VZ'Z'^505.W0_0_RJ"MX?"OG^;
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MM+O[(^=;Q7.Q^VQH6H_&G]DK]EGXT^!+>76_#W@?PI=:;XMMM*C;5)=!;6-
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MOPS>>%[2XC\GQ9>:W:7-SI=IIJ65S9R7[1W5R8=0F_L>T%[J3VUM<>_^)O\
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M;+5M,NO*@G^S:AIUS#>65QY%S'-;3>3<PQR>5<0RP2;=DL<D9932J.3M^/\
M2O1R?A7AC(57IY'PYD.34\9@\MR_%T\JR?+\NABL!DV7PRK)\#B(X/#T8U\'
ME65TZ>6Y;AJJE1P. IPP>%A2P\8TUAC<]SS-:E">:9SFN93P^(QN+P\L?F.+
MQDJ&+S+%3Q^8XJC+$5JCI8C'XZ<\;C:T'&IBL7*6(KRJ5I.;_12'_@K;_P %
M#[3Q1J?C*#]I+6EUK6-+TO1[^)_ WPKF\/O::/+J,ME/;^#YO LGA&QU8G4[
MB*^UZPT.VUS5;6+3K+5-1O+31])@LOC/XR_&_P"+'[0GCF]^)/QG\=:W\0/&
MM_:VMA)K6M26Z_9M-L1)]CTO2M.L(+/2=%TJWDFN+B+2]'L+'3UN[N]O!;?:
M[VZFF\P?H/K_ $-15P</^&_AWPIF/]J\+\!<%\-YI+!T\MEF60<+9'D^/>74
MU2C3P#QF78'#8AX*$:-&,,*ZGL(JE24::5.%O2S/C'B[/<*\#GG%7$><X%8J
M>,6#S7/,SS'"K%S<Y3Q2P^+Q5:BL1)U*CE74/:R=2;<FY2O')V_'^E1-T/T/
M\JED[?C_ $J)NA^A_E7W9\ZMY>OZ(@JO5BJ]:4^OR_485"_WC^'\A4U0O]X_
MA_(5O#=^GZHWCLO1?D5W^\?P_D*8W0_0_P J>_WC^'\A3&Z'Z'^5;1W7JOS&
M04Q^@^O]#3Z^C/V<OVM_VA/V1M>\1>*/V>?B!_PK[7?%FD6^@>(+[_A%/!'B
MS[?I-M>KJ,%I]F\;^&O$MG:[+R-)O/LK>VN6QY;S-$2AXLZK9W0RO&5N'<OR
MO-<ZA"#P&7YUG&+R#*\34=6"G#&9Q@<CXEQ>!A&BZM2%2CD>82G5A"BZ5.%2
M5>EW9;3RZKCL/3S;%8W!9?*;6)Q678"AFF-HP4).,J& Q.9910Q,G44(RC4S
M'"J,)2J*<I05.?S0_0?7^AJ*OZXO^"CO[5O[:2>+_P!AS]G[X$?%.'P]=?M?
M_ _P3H?C:RNO WP[U>S\1^*OBA>:?X4U#5+^]U?P3K>H^'M/>'6IY-0/AI],
MMM-LA/=VMO \".GPH_\ P3U_X)SW/[2-S^P5IWQZ_:=7]JF.PFT"#XGW6@?#
M*?\ 9WD^*5MX5?Q'-X;?P[;6J_$!(E$;VS6Q\0B*+4$DT9O$37R++)_-/!OT
MHL)C^%L!Q-QOPE+A^GF^2Y]Q7@\MX,S'/_$;'Y7P?PIFU?(^)>*.+(T^">%Z
M619;@,PI4EA8X.IG>)S&A4KU*-&G4P>(HQ_9L\\&J^%SG%Y/PYGBS26!S++,
MDKXOB#"99PGAL9G^=X"CF.49-D;EQ%G,\RQ>)PLYNLZ\<NI86K&G"<Y0KTJD
MOP&?[I_#^8J&OVF_9=_X)O\ P1\9?"']MWQK^U/\2/B'\,]<_8U^):>"O$][
M\.1H7B#06@\,:O>V/CFT30=5\-/J^O:QJ,VCWVB>$+JVUS0+2VU._P!.U#5K
M&]M(+FQF\\^-W[&_[+?B;]BO4/VU_P!B_P <?'"\\+?#KXFV?PS^,7P__:'A
M\$#Q;H]QK+:/;Z-KF@W_ ,/]*L-$DMY+OQ%X;W6'GZPEQ9ZY+(=5L+_0+S3+
MW]*H?2!\/:O$U3A>E/B"I.EQ5D/!E7/Z?#^85>%:?$7%63Y=G7#. EG]*$\'
MS9YALTP5#!3BY1AC,1AZ&,>%6,P4\3\M/POXIIY/#.9QRR$:F2YEQ!3RR>:8
M6&=3RK)L=BLOS?%++)RCB$LNK8/$5,1&24I4*56I059T,1&C^9'PZ^'7CCXM
M^-_#?PW^&WAG5/&/CGQ?J2:3X;\-:-"LVHZI?O'),8H0[QPQ10V\,]U=W5S+
M#:65G!/>7<\%M!+*F1XS\(>)_A_XL\1^!_&NA:CX9\7>$M9U#P]XE\/:O;M:
MZGHVM:3<R66H:=>V[\QSVUS#)&V"R-M#QN\;*[?TT?MM?#.+XQ?\%KOV6/AM
M-XW^(GPV3Q1\&_AO /'/PF\2KX/^(OAN6PT#XFZM!?\ A3Q,]AJ@T?4?/L(X
M&NA87#?9)KB)%1Y%D3Y!^"W_  3Z^ GQQ^,'_!5@_''XT?&;PYHG['7CKQW>
MZ;\49K[2_&GB/5=.TOQS\8K;Q!XT^*UG+X1OM:^(FOS:?X$MM9U*+PS/X3U#
M7M:O-49)8GOK=;3X?)?I.Y%7R+*N,.),)/),GS#PPX*X]Q.097E^:\2Y]@:W
M&O'%3@G+J5#,,)2PM+-\.\QEAL/'!83(Z69NHZN)2G3E2PY])F'@]F5/,L9D
M.4UXYAC\-QAQ!PU1S/&8K!91EN)I\/\ #D.(<7.KA:\ZT\#5CA56JO$5\QG@
M^7DHOEG&=4_#"H7^\?P_D*_8?XT?L8_L>>*?V%?%G[:?[&?CG]HFYT[X4_%C
M1?AG\3/"G[15K\/8;^Y&LC0+.+5?#"?#W2X;6T47_B[PQ=017NLZMYVF7E_%
M<_8-0T]8;OZ$MO\ @EA^S5\);7X"^ /VD$_;D\6?&CXT^%?"_BCQ)XB_9N^&
M_AO6O@?\$5\:WYLM)T[QUK6N>%-<U+6+C0R7D\3'P[J;W5M9Z==:G_9UK::A
MHRWGU^(^DKX;8++:>+Q4>)Z&9/B#B#ABMPQ5X<QE+B;"9GPKEF SG/\ ZWEM
M1PA1PN7Y5FV48R6(^LRAB%FV6X;"+$8W%TL,_,H>$W%E?$NA1>3U,*LJRO-Z
M><0S6A/**^#SG%XC 98Z&+@I2J5<5C,'C<.J7L5*D\%BZM?V6'HSK+^>Z3M^
M/]*B;H?H?Y5]+?M@_LXZW^R1^TC\5/V=_$&M6OB2^^&^MV5I;^(+.VDLHM;T
M/7]!TCQ9X9U5[&22=M/N[[PWKVDW-_IXN;N.POI+BTBO;V*%+J;]$=;_ &'_
M -AK]FOX"_LW>)_VU?BK^TII7QF_:C\%V?Q&\/:-\$O#W@2\\*?"/P1K]KIU
MQHFL_$?1?&6GCQ+KYL(M5L[C7=.\-ZM8:Y)<0:SHVFZ,\^E1W^I?;YOXO\&9
M1D_ V<8>IG'$5+Q(I4L5P5@N%\DS'.\US[+ZN2SXDGF6%R[#T5B88'#9'%9A
MB:V(A1E3C4H8>-.>,Q%##U/$R[@;/L;C^(,#5C@<KGPI4G1X@KYQF&%R_!Y;
MB89C'*HX2MBJLW2EB:V8/ZM1ITG-2E&I4<HT*=2K'\4:*_I7_P""I/P3^'?Q
MJ_X*>_LO?"3XE?&;PK\(/AAJ/[*'PP3Q7\7=>U'1M+TFPT#0=2^+5_&^E/XB
MU+2[275O%MQ8V?A_P["\ET]OJ.N6E_<:?>V5E>0-X1XM_P"";O[+OQ&_9S_:
MD^+O[-</[;/@+7OV9?#4/CZ"Z_:L\'^$]"\#?&7P);PZU?ZCJOP^_L3P9X5U
MVUF?1O#]_JMK'JAFN+-+S0+;5+"%]7FDTO\ .<@^E%P3CN&> <_XBRW.N'JG
M'.4\.YK.-# X[.,EX?CQ7Q!6X9R+#YEQ!]0RVE4K8W-J3I3HX?!2QF!H2AC<
MRPF"P%2CBJOU.9>#_$&'S;B3+<KQ>7YI'A[&YI@XNIB,/@<?F;R7+*>;YC5P
MF6?6,7.-.A@JBG&I5Q"H8BHI8?"5Z^)C.C#\'Z*_I/\ VAM)_8.@_P""-'[-
M6N:=X>_:3@T2_P#&OQCM?@KJKO\ !M?'<OQJC3XG($^,>I0:,EIJ'PA3Q?;W
M_EV?A-K?Q8GAF#2(Q/\ VG',Z_.7P*_83_88\2>!/V;$\:>-?VLOCQ\3_CQ;
M^'KCQO=?L@:;\./$'PS_ &:;KQ;-H\>F>'OC/J&L>'/%M_INOZ&FO6UQXHT\
M:A8ZIIUII6N7-SH]@JZ2FJ;95])?AW$</YSG^><(\:9'3ROCWC+@:A@XY14S
M.OC)\&XO-*6/S.I6H*A@LMIT\/E566,PV.Q--X;,:E/)\'B,TQDZ/MHQGA+F
ME/,\!EF7YYD&82QG#>0\15*\L=#!T\/'/J&"GAL)&G4=2OBYRJXV$</5PU*?
MML+">.KTL'0C4]G^'M%?57[;O[-9_9!_:G^+_P"SJOB*3Q9:?#K6M(32O$,]
MFEA=ZEH/BGPMH/C;P])?VD4DL,6I1:'XDT^VU(V[BVDOX;B6V2*!XXD_23X>
M_P#!-C]GSP#^SO\ L]_%W]J"S_;3^(_BW]I?1D\=>&O#7[&WP^\/>)M%^&/P
MYU&WTNZT'6/B+JGBCPQK\E_J>I:=JEIK T[2/[/N9%FN]+L+2]_L:35]1^YS
M_P :^ \@X7X*XMJXS'YEEWB+0P.*X+P^4Y;B<5F>?8;'Y'4XEI8BA@JJP\L-
M1I9'2GC\34Q\\)&BO9X:3^N5\/AZOSF6\ <29GG&?Y)"AAL)BN%ZF(HY_5QN
M+I4<)EM7#9C'*9TJN(@ZJJU)YA..&I1PT:[J/FJQ7L*=2K#\,:*_<(_\$QO@
M+\/?V[O$'[$WQM^+_CC1X_BW\.-.\5?LA?%S2I/#^@:5?>)?%D.IKX)\._&+
MPGK/AK6[R9M1UC3M1\->3H&N^%+S4M:T6WM[3[)-XPL+;0>%^*W_  3N^%/[
M-FA_LF_"?X]^*/':?ME?M%?&+PW9>,/AUX-\6>"6\&_"7X&ZSXY@\'6^KZK'
M)X3U[6-1\<>)")IO#5XNMVWAX2C5TGTR]/A2:/Q!X6&^D;X88[&9)E^7X[-L
M=B^)LFRKB7AVCA\FQBJ9SPSF>49QG-;B+!PKJC..59'1R+,\'Q'5Q4</7R3-
MJ>%RO&X>GC<SRNEC?2J^%?%^'P^88K$X?!8:AE./QF4YI4JX^ARX#-L)C<#@
M(977=-U$\9F-3,L)7RJ%)U:>88*5;&8>K+#X3&5*'X[T5_1)\1_^">O_  2R
M^$W[9]K^Q)XN^.O[7MU\2O'/B+P9X<\):OHMC\*6\'?#36_B!X:T"Y\&>&?B
M?K5YX4BU7Q7K/BC6]6M;ZTOO!WAC1-&TG1O%/AK3M9N()['7->C^=/@1_P $
MIO[6^-O[9WACX]>)/'Z_"W]B"1K?QH?@IX5CUWXJ_%R^UYM:E^'>F?#'0[Z#
M7-)L[[Q7HVDQZ_<0ZH=4FT9=2T?2+ZWA6_N]:T?SL!])_P +,9D=;B#$5>)\
MGP'^JF0<:95'.^%LWRW%<2</\39K@L@R?%\.8>K1<LU>*S_,LKR>,*;A_M.:
M9=B8REEF-P^/J=6)\(.,:&8T\LI0RC'8G^V<RR#&/+\XP6*HY5F>4X*OF6.H
M9K5A44<&J.6X7%XYRGS?NL'BJ+2Q>'JX:/XS45^P'[5/_!/?X9>&_P!EO2_V
MM_V9K+]J'P_X6TKXF6OPK^)7PA_:N\%:+X;^*OA_4M9BM_\ A'/%6A7/AS2/
M#^D^(?#>KWU[I>E11:5INI3?;M8AB-\EUI>LV5I[AXS_ ."?_P#P3B_9G^)'
MPD_9>_:X_: _:&T?]HWXA>&/#>J^,O'GP^'PKTO]G3X/:SXS>XAT*Q\:W?C#
M2+OQ6-'M;J)8]1U]+VVLH=*>V\3ZT?"VD7<_]F=?_$R'AS5R[ 8O 0XISC,<
M;C.*<%/AG)N&,RS3B;+Y\$T,!B>*JV897@X5?987*</FV35GB*->O#,(9SE2
MREYA+&T8O#_B%/%4,5B:&)EDV!PN'H9-B(YOC\WPN#RG$QXAJ8BEDT,-C*[@
MYUL;5P6.A[.=.G+"RP&,^N_5EAYM?@?17])7_!-?X3_LH?#KP[_P51^'WCWQ
M!XI^,FJ?#CX$?'.Q\2?$[X/ZE\*_$'PZ\4_LUV'A8-:>*O@QJ%X?$+6/QFU9
MD\1:A:SZEK6H^#=)5_#VFW?GZAI^KRO\H?LW_L$_LU?'7P?^TA^U:;K]J^X_
M9&^%/B[1_A[\,_AMX"\/>#/&?[6/Q \8ZCI?AC4-0M=1_LK0KWX?Z?9:*/$%
MK<S7-GH\\$VG:A]JN[G2AH5P=9\^7TE.$L)FW'6%S?)>(\NR;A#$<%83+L_6
M7UL12XJQO'>#RK$9#E^6Y?[*CC<-F..J9M06$PV*CRRP5+%9CCZV6T,/6C3Z
MEX3YW6P7#M; YAE6+Q^>4\_K8O+?K5.E/)</PY7Q=+,L5B\3SU*%;"X:.#J.
MO5H-M8B=+"X:&+J5:;E^,E%?L)^U#_P30T+P]X7_ &6/BK^S%=_&*V\#?M1_
M%'3O@-8?#O\ :B\.6/@OXN_#OXNZQK$NEZ#I_B=M!TFPTW4/#_B 6^H7-OJ.
MFZ#&+*STV&\BFUB/68([#[Z^ G[)_P#P3R_9A_X*._ S]GG0OC5^TAKG[6'P
MP\8^#-6U7Q-KOA[P!'^SQK_C5=%@\2:CX"L[*SM++Q_H>JZKH-VYT6\?5/$6
MBV.KW-CI-YK&HWBW, SSOZ4'A]@>&*N>Y'A.(^*,QCP_QSG[X=RS(\SEF&5T
M/#[$K+.(I<42HX3%_P"KV!P6=U<-E=7,:E'&0J>W^O9=1S+!4Y57>7^$'$^)
MS>&79C7RK)\(\SX=RU9KB\QPBPN,J<3TOK>5K)U4KT%FF(KY?&KC(86-2A*'
MLGA\54PM>2@OY@:*^KOV\?\ D^/]LW_LZ[]HG_U;WC"OZ"OVN_\ @GA^TQ^W
M!^R;_P $MM8^ >@^&-7L/A[^Q7\,=,\22>(O%NE^&GAN_$'PU^%EUIR6D5^=
M]VK0Z7=--)&H2(^6I)9R%];BWQ]X:X$I^$&/XO>5<.9!XI4L;4QF?YUQ!0R[
M+N%)X?A&?$V%I5JV)P4*.9RQV*5')J3E6RMJK7AB(QJRMA9<.2>&N;<1RXXP
MV1K&9KF7!\\/"AEF RRIBL5G,:N=QRFM.G"EB)3PBPU'GQ\[4\8G"G*DW!7K
M+^4>BOZ>?VG_ -EWXM_L@_\ !#F?X._&K3=(TKQM;_M4Z/XC>UT/6[/Q!8'2
M]<FN&T^5=0L283*_V:820G$D14;AAE)]!_X)0?&S]G#Q-\"?VE/@_P# G]G:
M/X<>)O"?[$=_XA^-_P 8O$&NRZ[XS^*GQ07PC)H?B*/3(IY=0;PY\/X-9_M?
M6=%T>WU9+29]2A=/#N@3V=PVI?GV8?2NP[\.>+/$KA7@2MQKD/#7B1F? ]/,
MLCXLRA9#BLGR_'9'@Z/&&+SBOA8UJ&%S.6>489?E>3Y5Q%B*F)A&%7$TL'*O
MC\+]/A?!BI_K5DO"><\1T^'\RS;A3!\0SPN8Y+C?[2I8[%8?,*\\BH8"G6=.
MI6PBR^<L3C,=C,KI1I.4H4IUU3PU;^46BBOZ3?V4_P#@H)XRU;XC?L,_L9_\
M$Y/A==^'/AQIVG>![#]IVW\<_#CP#<:[\6O$$U]%%\:/%_B+4K;5/%CZ9X*L
M]"CN?$UKXBAUSP_X@EU&[_L0:;;Z9INC:+J?[3XJ\><1\!9/1S/A[@["\4QI
MX?.\SSO&YQQ/3X.X;X<R3(,IQ&:8O'9MGKR;B"K2Q&,E2I8#*<'3RFI2Q.*J
MSGC,;EV$P];$KX'@WAO*N)<=/!YIGM;)W.KE^#R_#X'*)9[FN:YAF>.I8*AA
ML%EJQ^60G2H*<\3C:\L;&=*C",:&'Q5:K"D_YLJ*_JP^%_@#]F_P'^W!_P %
M??VI?A'X%\ >*='_ &,/A5)XJ^#7A)M,L;KX>:/\7+[X=ZO?^-]1LM)M4%I
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M^$O!7QX^ WPXT/X]WGA/XA7_ (8OY;K5O%'P]U;X3ZW'H/AO5/%EO=ZCI_\
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M_P"$?_X0S[O/V#_A(O[3[?8L\4?\$H?VH/@9^S5_PV'_ ,+L\<?\(7_PM/\
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MQ4-3/]T_A_,5#71#9^OZ(97J%_O'\/Y"IJA?[Q_#^0JP&U"_WC^'\A4U0O\
M>/X?R%;QV7HOR-X[+T7Y$,G;\?Z5$W0_0_RJ63M^/]*B;H?H?Y5O#X5\_P V
M5'=>J_,@HHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4KV62S!L=)2QDCO_ $_&[Q;\1N'H<49+X?\ "68X5<.8##9EG7B%F.&H3R7
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MEM9)+=S+ 9DM[CR?Q+_;Y^% ^%7[2?C-;.V%OH/CPQ_$30PHE,8'B.:Y;78
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M(54=E,DCO@?Q.QZDUY3_ ,$RI]4A_;.^&$>GK,;2ZTOX@0:V8K83HNEK\/\
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M (V3QKLO^8#PZ_\ H!/+CQ+DW,O^-?<(=?\ F-X][/\ ZK<^NO\ A37[)_\
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M).WX_P!*A?[I_#^8K>'!_$-O^3J<>[_]"[PP\O\ JW!JN(\GN_\ C N$]_\
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M -!G&_9?]5D?;/\ PHC]C#_H_/\ \U<^*W_RXJ'_ (4/^Q=_T?M_YJW\5_\
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M_P!6O*6?Y3=?\81PONO^8OC3O_V5Y]U_\,_?L/\ _20?_P U/^+O_P NJ/\
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M ,U/^+O_ ,NJ/^&?OV'_ /I(/_YJ?\7?_EU7P;11_J5Q+_T=[Q$_\-GA-_\
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MHH_U*XE_Z.]XB?\ AL\)O_I7A_;^4_\ 1#\+_P#A7QI_]%Y]Y?\ #/W[#_\
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M4LSS'!8S T\37I8^C+ 3AB<#BI253"5%4RO U/<YH\^'4E%.=3G_ &_^#/\
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MHK]*/DPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@?[I_#^8K-U"^M]-LY[VY;;% A8C^)WZ)$@[O(V%4>^3P#6BY 1B2  ,DDX
M Y))/  '))X YKP[Q;X@.KW)M[9S_9]J6$6#Q<2@%6N"/0\K$#G"9;@N17L9
M3@)X^NJ>JHP:G7FM+0T]U/;GGM%=-96:BSCS3'0P-%3NG6FW&C!_:EI>37\D
M-Y=W:-[R1S>K:E<:M>3WMP?GER$0$E8HESY<29_A0'KU9B6/)-8]3MT/T/\
M*H*_2J,(4U"G3BH0A%1C&*LHQ2LDEY(^"JSE4<YSDY3G)RE)[N3E=M^K*]%%
M%= $+_>/X?R%0R=OQ_I4S_>/X?R%0R=OQ_I6\=EZ+\BH?$OG^3(Z8_0?7^AI
M],?H/K_0UT1V7HOR-B!_NG\/YBH&Z'Z'^53O]T_A_,5 W0_0_P JJ.Z]5^8$
M%%%%;CZ+U?Y1*]0-U/U/\ZGJ!NI^I_G70;B5"_WC^'\A4U0O]X_A_(5<-WZ?
MJ@('ZCZ?U-02=OQ_I4[]1]/ZFH).WX_TK>'Q+Y_DRH?$OG^3(Z:_W3^'\Q3J
M:_W3^'\Q6QJMY>OZ(KO]T_A_,5#4S_=/X?S%0UK#9^OZ(KHO5_E$*KU8JO6]
M/K\OU&OAE_V[^9 W4_4_SJNW4_4_SJPW4_4_SJNW4_4_SK6.Z]5^9K'9>B_(
M2HGZCZ?U-2U$_4?3^IK<TAN_3]402=OQ_I4=22=OQ_I4=;0^%?/\V*'Q+Y_D
MR.3M^/\ 2H7^Z?P_F*FD[?C_ $J%_NG\/YBMX;/U_1&JWEZ_HB&J]6*KUI'=
M>J_,J.Z]5^85 W4_4_SJ>H&ZGZG^=;FL_A?R_-$#_>/X?R%,;H?H?Y4]_O'\
M/Y"F-T/T/\JWCLO1?D..R]%^1!4<G;\?Z5)4<G;\?Z5</B7S_)EP^)?/\F0/
MT'U_H:BJ5^@^O]#45;QW7JOS-(_:_P 3_0CD[?C_ $J)NA^A_E4LG;\?Z5$W
M0_0_RK<:WEZ_HB"J]6*KUI3Z_+]1A4+_ 'C^'\A4U0O]X_A_(5O#=^GZHWCL
MO1?D5W^\?P_D*8W0_0_RI[_>/X?R%,;H?H?Y5M'=>J_,9!7Z&?\ !*3QMX,^
M'7_!0']G7QG\0?%WACP)X/T35O'4FM>*_&6OZ5X8\-:1'>?"KQWIUI)JFNZW
M=V.EV"76H7EI8V[7=U$L]Y=6]K$6GGB1OSSIC]!]?Z&O XUX9H<:\&\6\&XK
M%5L%AN+>&<^X9Q.-P\(5*^$H9]E6+RJMBJ%.I^[G6P]/%RJTX5/<E.$8R]UL
M]GAS.*G#W$.0Y_1HPQ-;(\YRO.*6'JRE"G7J99CJ&-IT:DX>]&%65!0G*/O1
MC)M:I'[A?M._\$^O@[XT^(/[0?QRT+_@I/\ L)WL/BOQI\5_BQHW@NU^,?A:
M]\1WD>NZWK_B_3_"]JMGK\ZWFN7"W4.DPK:Q2K<7[J((Y ZJ?K3PA^UCXE^.
M7[('[(6@_LT_MJ?LG_LN>/O@7\.-.^#?QM^'W[4]K\)=+NM57P?H^@:!X;\8
M^"]9^)WPX\<MJ]G=Z;HTVIS6'AE8()6UL6VHW1UO2KJT3^8%^@^O]#45?A^8
M_1UQ?$N2<-99QEQ^^+\1P3F-'&<)5L\X!X+QF5X'"_V#C>'L;EF:\/5\!5RS
M/</B\'BZ&)HXC%QIX_+\RR[!8S"8J'+7I5_T_ ^*U#*,QSC&9!PNLBI<0X:I
M0SRGEO$_$.'QN)K?VEA<UP^,P6:T\3#&995H5Z%2C.E0<L-BL)BL10KT9-TY
MT_Z"[S]MSPS\./\ @K3\'/B(_P"TQ>_M)_#73?"/AO\ 9U^+/Q<UWPU\+_ /
M@^_\*^+KK7++Q%!I0\$>%O"'A>X^&O@'7O$>E>+QX@FL5N[Z3P_J,"ZWJ>@1
M:?//R?\ P4%_:%^!_P  /%O["W[/'[*OBOPC\4_@A^R/X@@^/>I77@/QQI'C
M#POXN^(6M_%&Y\6)H5]XDTV]\0PW&L:#IFEW\;7=Q>WLMK;>.9;>6VQ;I"OX
M//\ =/X?S%0UZ>6?1FX-P/$?!.?RS#'5\/P?P?1X5KY%3P>595DW$6*P66<3
M9/E7$>8Y=D6#RO+<+FN4Y9QMQ=@\O66X#"4<+2SEK#QH_4\+R88KQ>S_ !.4
M\19:L+AJ=7/L]GG-+,IXC'8W,,JH8C%Y-C\;E.%Q>98C&XNM@L;B^'<CKXIX
MS$UZE:> O5E4^L5N;^OWQ[^TWK?Q5_:#TWX[_"K_ (*F_LB?!_\ 9'\36'A_
MQ5J7A37O#/[/J?M2_#F;3_"MM#K?AS2?!WQ ^$7BCQEXBUR[\06"WEEJ.L:S
M]HLEUB\L;#2KZ#0=,BUG\^?A%^T%\(]3_8M_X+&0ZS\;O#.H>+OC=\6-1\6_
M#N+X@:WX)\$_$WXO6>L^*M0U<^)K'X?6?_"/K<:QJL5VNJ:UI/A#PY;Z5I%[
M<W%G9Z=86D$5M%^ %0O]X_A_(5\[D7T2.%<@RFED^$SV-/#X+%>',LOQ& X,
MX*R3,IX'PWXMP/%>70S_ #7)<GP&9<2YKF=7+L)@<TS?,<5:K3I/&PP,,QK8
MG$U_7S'QQSK,L=/'U\M<ZN(H\5K%4L3Q!Q!F&$CB.+,DKY+BY99@LPQ^)PF4
MX+!PQ-?$X+ X2C[DZBP\L3+"TZ-&G_0+^Q7XB^$VD_L#Z?'^SE\:/V+_ -GK
M]MW_ (6WK:_%WXC?M87G@K3_ !0OPRDBU=]+M/A5>?$'PIXVMIK*\T]?"=C>
M6.A>'[N!)E\5W#+9Z_/:74_V;\6OB9X,^//[6/\ P17T'X7?'#3/VC?&O@7_
M (3M/B1XC^ WB+P#X6\4_P!I:%HO@#4M=\4:UX36_MK+X?\ A[6+/PMXE\2Z
MOX.U>QT74-5\"6/B'0M'TM-3DBL8_P"2NO5_@3\<?B-^S9\7O!/QO^$VKP:'
MX_\  &I7&H:%?7=A;:G9/'J&EWVAZSIFH6%VCQ76FZWH.J:IHNI1J8;G[#J%
MPUE=6=X(+N&>+_HM_P!IYUQ3QOE'%,\?Q7BZ/BEF'#N%XARO+7!YIXA\"\0<
M)X?(\ZXKPV%GQ//A'(ZN<PEDF5X2M3P^3X&G4H4L+BJ\H8F'3D'C%]3RW)>'
ML=DZPV2T)<&X;-*V5XS%J7U/A?B+*\ZJYCE^2U:T<HCGF8PP$HYAC*T)5<=B
M9QJ3K4:2E2E_4-XIO_AY^V+>_M5_LX_L2?M4_LC>'/C/\9M/\?:I\0]*^'G[
M$WQ0^$7BCXUZ)H6L7USK?AW6OCUXA^*_C?PSKRZI=:I.-:UWPKX-2Y\36VJZ
MYXEL+!M-FU)XOA.Q^,WP?3_@G/\ \$C?!#_%;X;)XT^&O[:5]XJ^(OA!O'7A
M=?%'@'PP_P =/BKJZ>(_&N@'5!JWA706TG4=/U1=8UVTL-/;3KZSO1<&VNH)
M7^4=1_X*T?&2R'Q U?X7_L__ +'WP$^)'Q.T?6]#\6_&CX,?!C5/#GQ7N;+Q
M-<P7GB4V7B+6_'/B6PTVXUZ[@6\U*XL]%B=[\1ZE;_9]2MK*[MORK;H?H?Y5
MX?AO]&OB.&"67<68_%Y+D>2<5\-<8<.T,3/@W..*L9GN"\/>,N >(8YYG/"O
M#7#.!Q612R_B3*(<-4\52QN;8&&1UJ-:O1P>)H86CZW%/BOE4L0L5DF'H9AF
M.8Y/FN1YK4HPS[ 9-0RZOQ/D'$F6/+L!G.;9OB:.8K%95CI9M.C/#X+$2S&%
M2G3J5Z52M/\ HL\;_'#X+7?_  <-67QKM?B_\+[GX-IXN^']RWQ:M_'_ (3F
M^&2VUE^REX:\.WEPWCR/5F\*B"T\003Z%<RG51'!K,,NF2LE[&\"^Y?LW>,_
MA+H]K_P64^,_Q)\8^"+;]G/XB_MCZCH>F_$'XC^!)/VF/V:_'!N/C/XK\3:5
M::5\(?A[XT\(>,O&7BB^TWQ%H&N:/XQ\/>)AX?LM'U'1/$B7.- #S_RM5]L_
MLT_MX?%?]F?X=?$+X-6'@KX-?&/X+_$[5M/\0^*_A)\>/ L_CGP/<>)=,6Q2
MT\1VEKINN>&=5L]71-*TC$R:NT"2Z1IEW%;QWME#<KZW'WT9,94X-X?ROA'-
M\9F>/X>\/_!CPOJ4*U?+<HQV+X9\+.-,!Q-5SK*,?C<#FN4X7BO%4\-)X.CF
MV78S(H5Z<%7I-24H\7#7BY0CGV9XS.\#0P>'S3B;CWB^-6%/%X[#T,WXQR'$
M93# 8W#8?$X/&ULFH2J_OYX'%4<QE3G+V<TTT_T#_P""F7A#5OC3^S-\$_VI
M?A%\??@M\8?V5/A3XJU;X!>%_A[\%_@'XE_9RT7X)>)=>M+;Q#JL)\ >+O%_
MCWQ'N\0+I&AG5KK6O$D4VRX\(ZCI.FW&GZ]<:E6Y_P $R?VKM-_9A_X)]?M^
MZQX6^-'@'X9?']M3\%:Q\']'\0:YX#;Q?KVHVMC]CNKGPIX%\9_;AXO^S07%
MQ%<0PZ!J\$)8M)$LB*R_F_\ M(_MW_%7]I'X;^!O@M=>"/@Q\&/@I\/->O/%
MOA[X1_ 3P%+X%\$GQ?>V]_9S>*M1M]2UOQ-K%_K8M-6U:W6XFUD0D:I?S26\
MES<-/7Q/7TO#_@1F'$7@MA_"SQ(J8.EEV%X]PW$F"R^G@.&\PK5N&LGXXPW%
MV R7BV&49+DG#&<9IGM3#XF/%.,P&34,-C7FF(G6^OXQXG&XOR<S\1\-E?'U
M7C'A6%>>*K<-5<IQ&)GB<UPT*>;8[AZKDF)Q^22QN/S#-\#@\NC5I/)Z&)Q]
M2K06#I*'U:A[+#T/LG]H[_@H+^V+^UKH&F>%/V@/CAKWCOPMI.H+JMIX:M]#
M\&^#/#\FIQQF*"_U'1O 7AOPOIVL7EHC2"PN-7MKZ6P,]RUDT#7-P9/TL_X*
M>_&/X0^/_BM_P3.U'P)\5/AOXUT_P'\$_A'I7CF^\)>./#'B2S\&:IIOB3P_
M/J.F^++K1M4O8/#M_800S37MGK#V=Q:Q12R3QQI&Y'X%45^BXOP1X-CG/ 68
M\-Y?EO!F7< TN.:>7\.\+9'E63Y+B9\=9+3R7,*\\'@*&%H8>K0A36*A*A13
MQ%9M5VUJ?+4/$'/G@.),+FN)Q>?XOB6?#LL5FF<9AC,=CZ4>',PEF&%IQKXF
MI6J585)2]C)5*EJ5-?NTF?UB?$3XM_L*_$7_ (+#_%?QQ\1_B-^SMX\\,W7[
M,6@67P&\?>./$_A#QI^SG8_'/2M.T632Y/&>OVEUJ?A:&XTNWM]3%M/JNH0V
M%A<)=VY"^([CP\8\[Q9^T):V7_!/G]O7X3_M _MO_LB?&KXX^)/"?A74?!/A
M+X#:I\--'\+6F@7VMW5E8>&/!6J^&/#'P_L/B5XB23P_J.H:WH?A_2_$&I^#
M=(?P[<ZO?X\46>_^4RBOQV'T/>'X4^"\/4XUSG%X?@G+_"O!Y:LPR7(<PQ.'
MJ>%F9X7,,*\FQ^+PU;&<-8+B3ZK%<1X+)*N&EF&*C2Q%;%U*%.>!K?=2\=,S
M<\_JQX?P%"KG^*XRKXMX;'YEAJ-6/&.#JX6LL?AJ%6%#-J^4^U;RK$9A"LL-
M1=2E3HPJ3CB(?U1?LC?&Z]\&_#']F;2/AQ_P4)_9/\9?LLW/A'P?8?M"_LW?
MMW^*?!6F^/\ X77T>HR?\+,\,_#'3;WP]I/B7Q%X=LM'EO\ 1_AY8W.J7OA\
M7%M8O!;7/AS48%L_-_V5/VN_V3/A?^UC_P %)/A;\"/B)X(_9U^&7[3>BZ-:
M_LT_%WQ9X8TJ?X1>"OB#\/\ 2?$J0C5-#\3:1J&A:/X#U[Q1XQ\0:UX?CU_2
MX?#5IH>E6.E26<-Q<Z-IS_S2T5Z6)^B1PICWQ_',>),RK4>.\%3P^+H8+(N&
M,JP]7'83C++N.,JS_B3+\#E=/)^,<_RS-LHP&#CF6;Y9">.R5YA@,SAC)YGB
ML3+EI>-F<X9<,O"Y3A83X<Q$JM&IB,QS?&588>MD.*X=QN6Y3BL1C)8[(LMQ
M>"QN)KO"X+%RCAL?]6Q.$E0CA*-%?T%?MG?&?XA:9^Q)XY^''QS_ ."BWP)_
M:#^)OQ(\?^%8=#^"?[)'A[]G?Q%\-;GPKX9UG0/$<GB?XD>// /P?\&^)=#U
M+3[W3)I=+L]/UBQ:]NET:S>'5K"7Q!%IO\^M%%?M7A=X;9=X7Y%F&39?5R^L
M\VS[&\0XV64\,<.<(9;'&8O"X# JE@LDX8R_ 8*C1HX/+<)35;%2QV8UIQG+
M$8^I35"C0_/^,.*\5Q?F6%Q^*ABJ:P66X?*\.L;F^:YYBW0H5L3B'/$9AF^*
MQ->=2I7Q=>?)16&PM.,DJ6&A+VE2I^S7_!4CXH_#+X@_LZ_\$K]$\!?$7P)X
MWUKX>?L<>$O#'C_2/"'B[P_XEU3P-XEMO WPGM+CP]XPT_1M0O;OPSKEO=Z=
MJ%K-I.M0V5_%<6%[#);K):SK'^I&F_%+X'>!O$/[)?B']D']KG]@[]F_]C?0
M/#?PHU;XR^!M2M?AQJ/[5?CKQA9:WN\2:7XRT7Q)X/U?QNFIZAIT6D:!/XLO
MO%WA!] FU+Q/XLU?4KFRTK3+IOY':*_)\W^C#E&:\&\(\%OB[,XY=PKC/$#$
MNEC<FR3.<LS;_B(.;9AFV)Q&-R'-\/B\IGG'#M7'U8\+9M6P^)GE,YXC$1PU
M6MB'*G]K@?%['8+/L[S]9)@WBLYP_#-'GH8[,,!B\$^&<'A<'1IX?,L%5HXV
M.!S2&%@\XP-.K2CC8JE2=:%.E:?Z-_\ !6WQQX*^)'_!0[]H_P :_#OQAX7\
M>^#=<U;P%)HGBWP7X@TGQ3X8UB.S^$_@/3KN32]>T.[OM*U!+74+.[L+E[2[
MF6"]M;FUE*SP2QK]4_'9_A1^U%_P2Y_8NO/"O[0GP+\&_$[]C7PM\<=(^('P
M3^(OQ$TOPM\2_%%MXCUS1;JQ?X>>&[B*6_\ %FJZA:>"=+O=)T^RB2VNXO$2
MVK:C'J.GW-H/P[HK[I>#F'P_#G@KDF6<29AE^.\$:F1/(LX^I8+%2S;#Y7P1
MF7 &883-,#73P\:><Y#F^.]I4PTZ=? XR5&OAJMJ4J=3YS_7JK5S7C_,,7E.
M%Q.'\089DLQP/UC$48X*KC.(<)Q-AJV#Q%-JJY8#,L#A^6%52IXB@JE.K&\U
M*']*W[5?A/\ 9J_X*6_&;]G[]L#1_P!MC]FCX(^#I_AU\/?#WQU^&'Q;^)</
MPZ^-'@&_\&:SJ.I>)++P1X;EM5N/%-[+!J=YIFBWEG+I6GO?V%IJNDZIJ6F:
MG!)9?EK_ ,%2_P!I_P %_M=?MJ?%+XN_#;SYOAYY'AKP;X-U2[M+BPN_$&D>
M#]#L](F\12V5T1<6MOK6K1ZG?Z3!<06=Y'H<NF+J-C::D+R%?SSHKS/#?P'R
M_P .\WR#'QXJSKB# <$<+9UP3X?91F.%RO#4>%^&L_S;*\US'#UL3@,+0Q&=
MX]K(LDRZAF.-=.5/ 9<HSH5<5B<1BI]G%?B/B>*,#F6&>38#+,3Q#G&7\0<3
MX["UL96J9QFV68'%X+"U:='$UJE++\-?,<PQ=3"T%-2Q.*O&I"C2I48E%%%?
MO1^;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!_4&_4?3^IJ"3M^/]*G?J/I_4U!)V_'^E?Y+G\KD=1R=OQ_
MI4E1R=OQ_I6L-GZ_HC2/P_\ ;R_.)"_W3^'\Q4#=#]#_ "J=_NG\/YBH&Z'Z
M'^5=$-GZ_HC0@HHHJP(&ZGZG^=0/]X_A_(5.W4_4_P Z@?[Q_#^0K>.R]%^1
MI'XO^W5^42-_NG\/YBH:F?[I_#^8J&NB.R]%^1H,?H/K_0U _P!T_A_,5._0
M?7^AJ!_NG\/YBM(;OT_5%?8_[>_0AIC]!]?Z&GTQ^@^O]#6T=UZK\RH_#_V\
MOSB157JQ73>&-!&H2&\NU)LX6PB'@7$JGE3_ -,T_CQ]X_+_ 'J>(Q%/#4IU
MJKM&-M%K*3;LHQ6EVW]RNVTDVNS"X:KC*\*%%7G-ZM_#"*^*<GK:,5OU;LDF
MVD^>L]%U+4,M;6SM&2?WKD1Q'!Z!W(#?\!SCOBM7_A#M8_Z=1_VW/](ST_\
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M1$]O3O7L<G;\?Z5 _0?7^AK99]CTK?N?_!;_ /DO\R_]7<N_Z?\ _@U?_('
M:9X*MX'6;49A=,I#""-2L&001YA;YY #_#A%/\08'%=F0%.U0 J@  #
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M?Y,@?H/K_0U%4K]!]?Z&HJWCNO5?F:1^U_B?Z$<G;\?Z5$W0_0_RJ63M^/\
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M/X9?$'X.^%]830]8T.U\0VU_)IOB/2(8D7QCKB:9?))J4]Y]WA_I$\:5_%7
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MLSQK'9VT=RL-JGB_3&.F^)TA1%U[3L6.JBZM5$(^A?A%=^#[7_@H_P#\%GO
M.G^$KKQE\6/&_P (H+KX<_#[P[XOF^&_B_XAV-MX'BU#X@^#?"/Q$@MKBX\'
MZYXIUC6_"175[-C>6$X77(+:6/1II[/Y?#?2F\4L#P53XKSC(>"<TK\0>">5
M^*?#^7Y)EV<9;#(,7B..N'>!\PH<08S-^*Z^&SC)\'3XBI<3U\5"KPG# 8'
M8[+L9CO906?+UZO@[P?B.()9+@<RX@P=/+/$'%\'9GB<PQ6!Q<LRH4N'<TXA
MPU3+*&!R6%; XZO/*YY/3HRAG<L3B,3AL50PRG)Y:_YH?VB_V$?VLOV3M&T/
MQ)\?/@[JO@GPUXCU"32-)\36GB#P9XV\-3:O%%)<?V3<^(?A_P")/%.C:;JL
ML$%S-:Z;J=[9WMY%9WTEI!,EC=M#[?X;_P""0?\ P49\72:0OA[]FG6-0M]=
M\&^'_'VDZH?'_P )+30;SPSXH%VVB7">(K[Q_:Z%'JMS%9S7$_AJ;48_$VG6
MKVEUJ>CV=M?V,MQ^@OQ4N?$_A3_@EE^U1X3\+?\ !/CQE^R'\&]<^)GPFDOK
MKX\_M%>/=<\:-X^M/'G@.Z.H_##X7?$'X)^%]1UH7^E6$6B>([^Q\0Z#9Q:<
MNI7\4FKS^&]2TT=C_P %8/%GBBQ^)O\ P28T&R\1Z[9Z)8?"3X)>+++2;35;
MZVTZT\41>(/"UG#XCM[.&=+>'78+2"*V@U5(UOH($$44Z(2I]S+_ !^\8L[Q
MG#'#.!P_AKEF>YMQ3XHY%C,[QV70XBRZ>!X$X'X9XUR_&0X?X(\7>(,+E&8X
MIYWBLES#**_B!FU:D\-0S=5L-3KPRZIY^)\-.!<OH9OFV)J<68O+L%DW!V8T
M,OP^*>5XJ.(XCXBS;A_%4)9EQ#P1EM;&X6BLOI8_"XVEPS@H3]K4P3A4G3EB
M8?"7[!'_  2L^(_[3/[47Q&^!/QNT;QC\*-"^"4(L?C->Z=J7@JT\6^$/$NO
M:7K=[X"TZTTG7;V\F\0Z?XG;0-1NH]8\+Z5XATI=(CM=2DO[6PU;2KZZ_/OX
M^_LZ_&']F#QXOPS^.'A6V\'>-FT/3O$:Z/:^*O!OC&/^QM5EO(+"[.K^!O$'
MB71%>>2PNE-HVI"]A$:O<6\22PM)_6/)+H.A?\''\?F&QTV^\7_ 18E.U(9M
M=UZ'X-$H'8 &YOD\.^&=B-(2_P!ATF.%25AC2OY#OBC\)_B5\%/&6I_#_P"*
M_@?Q/\/_ !?I,DRW.A>*]$U+0KZ2WBN[JR34K*'4K:V>_P!(O)[*Y&GZM:+-
MI^H1Q-+9W$T8W5]/X#^*_''B5Q]6Q^>Y_P /X#A_B'P+\%?$#*N!:>38FGC\
M-F7%5+C.GQ%BLDS>MQ%.>)P>%S;*91S*M6R;&1JX#$\-X"/]E8S*\?C^(_'\
M1^"^'N$^&H8;+LMS/$YGE?B+Q_PSC.(I8^E+#5<)DT\@GE=',,#3RM1I5ZV"
MQR>%IPQ]!PQ-+-<2_KM#&8;#97Y[1117]@'X<%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?U!OU'T_J:@D[?C_2IW
MZCZ?U-02=OQ_I7^2Y_*Y'4<G;\?Z5)4<G;\?Z5K#9^OZ(TC\/_;R_.)"_P!T
M_A_,5 W0_0_RJ=_NG\/YBH&Z'Z'^5=$-GZ_HC0@HHHJP(&ZGZG^=0/\ >/X?
MR%3MU/U/\Z@?[Q_#^0K>.R]%^1I'XO\ MU?E$C?[I_#^8J&IG^Z?P_F*AKHC
MLO1?D:#'Z#Z_T-0/]T_A_,5._0?7^AJ!_NG\/YBM(;OT_5%?8_[>_0AIC]!]
M?Z&GTJPR3R1PPH7EE=41%&2S'( _J3T R3Q6MTM6TDM6WLDM6WY)%P3:22;;
MG%))7;;<4DDM6V]$EN6](TR75;M($RL:X>XEQD11 \GTWM]U!W8^@->O0016
MT,=O @CBB4(BCH /7U)ZD]222>35#1]+CTJS6 ;6GDP]S*/XY,?=!P"8XQ\J
M#ZMU8FM6ODLSQSQE;E@W["DVJ:_G>SJ-;Z[13VCV;9^AY/ERP-#FJ)?6:R3J
MO^2.\:2?:.\[;SOJU&) W4_4_P Z2E;J?J?YTE<<=EZ+\CWX[+T7Y$+_ 'C^
M'\A4#]1]/ZFIW^\?P_D*@?J/I_4UI#=^GZH9&W0_0_RJ"IVZ'Z'^505O#XE\
M_P F:1^Q_P!O!37^Z?P_F*=37^Z?P_F*V*E]G_$OU(&Z'Z'^505.W0_0_P J
M@IQW7JOS'+9^C_(KT445N,@;J?J?YTE*W4_4_P Z2MX[+T7Y 1/U'T_J:93W
MZCZ?U-,K2&[]/U1I'XO^W5^42.3M^/\ 2H'Z#Z_T-3R=OQ_I4#]!]?Z&M30B
MJ%_O'\/Y"IJA?[Q_#^0K6&S]?T1<=E_C7Y#:***LTEL_1_D0-U/U/\Z@?[Q_
M#^0J=NI^I_G4#_>/X?R%;QV7HOR".R]%^0VHGZCZ?U-2U$_4?3^IK2&[]/U0
MR"3M^/\ 2H'Z#Z_T-3R=OQ_I4#]!]?Z&MH[KU7YCCNO5?F14445N:2WAZ_JA
M&Z'Z'^505]:?L0^'?#_BS]J3X4>'O%6A:-XFT#4KWQ,FHZ'X@TNRUG1[](/!
M/B6[@6]TS48+FRNEANH(+F)9X)!'<0Q3(%DC1E^V_CS^TU\ _@K\7?&_PNB_
M8?\ @1XCC\(:E;6":U)HG@S2GOQ<Z78ZEYK:>OPVU!;8I]M\G:+R<-Y?F;EW
M[%_+^)/$/,\IXQI<%9%P9F/%6:SX:I\4UGA,XR7*J5#+YYI7REJ4LXQ.%A4J
M0Q-*FW&G4E-QK1:@U";7ZGPWX>99FO!U7C;/N,\NX4RJ/$U3A:BL7D^=9K5K
MYA3RO#YLG&&3X;%3ITY8:M4M*I3C%2H23GS3IQE^-%%?JW^S1XW^+/Q.^)7[
M2/CK]FKP#\ ?A;HFL^"_"Z>(_ GC"RU:70]$TBPT*XTDKX-'@WP_I=M]KU2\
MTS5-8U6UOM-M=*N[S4(FO;>_FA^TB3]C?X,:#\5?V0OVCUM?AQX6\9?$U]5U
M+1? FIZCX?\ #]YXDL-2N_"VD?V=;Z-X@U:W$^B*M_<-<"X34+&ULW>6\FF@
M02S#ES;Q;H\/T<XKY[D^'P+R3%\!X',,'3S_  >*QV68CC2E2E66<QCAJ> P
M%+)JM2:^L8?,<PH9EAZ-7%TJF'IJ,9>OE7A-6X@JY10R+-\1CO[:P?'>-P&*
MJ9#C,-@<QP_!M6K&B\GE+$5,=CZN<4X1?U>OE^ KY=B*U+"U:>(FY2C^3+=3
M]3_.H'^\?P_D*^^O&?\ P3K^//A/P3X@\<V&K?#+Q[:>%K>YN_$>A^ /%=]K
MGB/2(;&(W&HB>RN] TNSGN=.MTEGN;"RU&ZOW2&06EK<R;$?S'X(?L=?%K]H
M7P+XL\>_#JX\)W%MX3UA="F\/ZIJ>J67B+5]3DLK&]BAT>.+0[O1BDJ7\,?V
MC5=;TJ"%UE>YD@MHS<'ZZAXG>']?*,5GM+BW)9Y1@,;A<MQV.^MQC1P6-QDH
M0PE'%\RC/#_695(NC4K0A1J1;G&HX1E)?+U?#3CW#YIA,CK<*9S#-L;@<1F.
M"P*PKG6QF#P<)RQ=;"N#E#$?5U"2K4Z,YU:<TH2@IRC%_*-1R=OQ_I7UCXH_
M8V^,OAWXT:!\!=/B\->-?'VO^'[3Q*$\&ZO<WVBZ-I=Q=:A;7$GB#5M5TW1H
MM*.F?V;)-J#R1O;!+FPAM+B[O+VWM7]=U_\ X)F_M!Z9I.M7NBZ_\)/'6L>'
MK<SZMX-\&>,[^^\6VI5(Y6MGL-4\.:/9+>"-]Z6SZDDEQ@):B>62%)9Q7BGX
M=8)96\9QCD6&6<X2CC\N=?&PIJO@<16>'P^-FYI+#8.O64J5+$XKV-"I.,XP
MJ-PE;3#>&'B#C7F4<)PCG>)EE&*K8',%1P<ZCHXW#TE7KX*"BW]9QE&C*-6K
MA<+[:O3A*,ITTI1O^<=[>6]A:S7ERXC@@0N[=2>P51U9W8A44<EB![U\]Z[J
MT^LWLMY.2%+;((L_+#"N=D:XXS_$[=6<D^@'UG\+?V>/C!^U9XZUCX>_"W2;
M."#P;;2ZAXQU_P 47DN@^&O#*Q2S6JR>(=0:UN;BVEEN8+JVL=.@L;K49S:W
M]TEI]EL+ZXM>H^+7_!/+XT_#'X7ZS\8=(\6?!SXT^ /#%Y+:>+=:^!_CJ?QN
M/"WV:Y^Q7UQJ\%UH6ARF#2[QHX=8&FC4;C1T=[W5+>TTZTO[RT_1\#QKP)P_
MG&'R#..*<EP7$V/G@*%'*\1BX1KT9YM=Y5A:\M:6%QF:V3P6'Q-6E7QB=..&
MIU.=<_P6*X-XWS[)Z^>Y1PSG&,X;P,,=7K9G0PDY4*T,KLLSQ-&.E7$X3*^;
MEQN(P].K0PDE4EB*D%!\GP52-T/T/\J_?7PS_P $O/ .J?L5ZGJ5QXF^!<OQ
M_P!1U[3KW0_C4?BUXY3X9Z+H%WK?AZZ;0=7EBMET"+6O[#DU/2FA?P7>RKJ6
MH6BK?^88KRW_ #%^$W[$WQJ^-WQ3^)/PM^'?_"(ZNGPGUO7-$\;_ !(DU^2V
M^%VF_P!C:EJNE0ZK!XD?3C?7^F:]/H]Y<: ;/1)M0O=.5M2GT^TLK>^GM,^&
M/';PUXEPO&.,H9[#*\%P/FF*R_.L9G:HY?A71P\L)1IYKA*SKU85,NQV)Q=/
M!X"-=X;,<1BXRH_V?"4Z'MNWB'P2\1.',1PA@Z^2RS+&<:9?ALPR?"9,ZN/Q
M,:N(AB*M3+,71]C2G3S#!8;"SQ>.E06(R^AA91K+'SC"O['X\;H?H?Y5!7WI
M\<?^">/QV^"/P[N_BP^L?"_XK?#O2KD6GB+Q3\&_&,_B^Q\,222VT$+ZW#?Z
M+H%]';O/>00R7-C:W\%DTD;ZC)9Q3022S?!O_@G!^T+\>?@WX?\ C9\.+GX?
MZGX>\1>([GP[;Z%>^(-6TSQ-IZZ=K4VCZMKNK"[\.)X:LM!TE;:YU2\N/^$E
MEOI-/A\JPTZ]U>>UTNX^@7BWX:1R.CQ//C7(*>05<W60?VK5QL:6%H9U*A4Q
M"RW&2J*,L!B_JU.6(=+&QP[CA^2O*U*I3G+R'X6>(DLYJ\.0X.SRIGE/*GGG
M]F4L'*KB:V41K4\.\QPD:;E'&X7ZQ5AAU4P<JZEB.:A&]6$X1_/VBOT!_:$_
MX)M_'_\ 9S^%\OQA\1:S\+O''@2PO].T_7=5^&GBO4]=;P[)JM[#I=C/JL6L
M^&_#@>VFU>ZLM*:32I-3:&]OK59DC@=ITXK]FS]A+XZ_M0:!K?C3P:GA#PA\
M/?#]S/8ZA\0_B7K\WAGPE_:5LEM+=6%M<6>F:UJ=U+:PW<$EU<PZ4VFVID6"
MXOH[DK >JAXK>'&)X9Q'&5#C/(9\,87'O*L1G'UV$<-1S1.DEEDXS4:ZS&:K
MT)T\$J3Q56G6I5*=*=.I"4IK>&7B!0XBH<)5>$<[AQ'B<"LSH95]3G+$5<M:
MJ/\ M&,HN5'ZA%T:T:F,=58:G.E4IU*L9PE%?%K_ 'C^'\A4,G;\?Z5]N_M)
M_L#?'G]F/PMI'Q \6#P9XV^'6M7<=A#X_P#A?K]UXH\,6=[<;ELH-2GO-(T3
M4+*/4&BEBLK]]..ESW2"R^W+?36]M-^FVK?\$HO 9_8V\-BQ\5_ "S_:)_X2
MR==7^.=S\8/'H^$^J:'_ ,)'KS1Z+I]R]G-H+:I'H@TO3'2+P+:SB_TV]!O&
ME66[N?GL_P#I ^%O#V6<)9Q4XAIYME?&'$,^&\NQV1JECZ.$Q6&AS9CBLUO6
MH5,'A<JE+#4\PI*%;,Z<\9A?99=6A*I.E]+D'@;XD9[F7$V50R*IEF9<*9%#
M/\PP><.I@JN*PV)ERX##9:U1K4\5B<SC&O4P-1SI9=4AA,3[7'T9QA"I_/13
M'Z#Z_P!#7ZW?!S0/VFO"O["'[8_A[P5J'[.NJ_ SPY\1O$N@?$_4M7B\6ZM\
M1-2UC2;#P9I=[J'PQU&STQ?"U[X?N[0:+=:%>^(EAO;68W^I:?'IES-%+)\R
M_LU?L$?'S]J;P]K/C3P5#X0\(?#W0KB:RO/B'\3->N/#/A.74;987NK"QGL=
M*US5;V2TCN(WO+RWTE]*M&S;7.H17A2V?W\+XK\,T,+QAF?$6:\.Y!DG"G$6
M'X?CF<\_6*6*J8K+<NQ^%CC,-4R_ SR[-,0\PC3HY/1GF=>I3C"O"O+VKI4_
M.K^&G$%:OPKE^0Y;GN=YOQ+D-;/'E\<E>'^K4\-C\=@L1+"XBGCL9#'Y=0^I
M.=7-:L,OHPJ2G1E17LU4J?$C_=/X?S%0-T/T/\J^V/VFOV#/CO\ LM^'-#\;
M^,U\&^,?AWXBN8;#3OB)\,O$,WB?PD-3N%N);73[NXO=+T35+26[@M)I;.[F
MTI=+NRC6]M?RW:26Z?$[=#]#_*OMN&N*.'N,,KHYWPOG. SS*JU6K1AC<NQ$
M,115?#S]GB,/5Y7ST,30FN6MAZT:=>E*RJ4XW5_DL_X=SWA;,JF4<195C<GS
M*E3I59X/'T)4*KHUX*I0KT^9<M:A6@^:E7I2G2J*[A.5G:"BBBOI3Q^B]7^4
M2O4#=3]3_.IZ@;J?J?YUT&XE0O\ >/X?R%35"_WC^'\A5PW?I^J @?J/I_4U
M!)V_'^E3OU'T_J:@D[?C_2MX?$OG^3*A\2^?Y,CIK_=/X?S%.IK_ '3^'\Q6
MQJMY>OZ(KO\ =/X?S%0U,_W3^'\Q4-:PV?K^B*Z+U?Y1"J]6*KUO3Z_+]1KX
M9?\ ;OYD#=3]3_.J[=3]3_.K#=3]3_.J[=3]3_.M8[KU7YFL=EZ+\A*B?J/I
M_4U+43]1]/ZFMS2&[]/U1!)V_'^E1U))V_'^E1UM#X5\_P V*'Q+Y_DR.3M^
M/]*A?[I_#^8J:3M^/]*A?[I_#^8K>&S]?T1JMY>OZ(AJO5BJ]:1W7JOS*CNO
M5?F%0-U/U/\ .IZ@;J?J?YUN:S^%_+\T0/\ >/X?R%,;H?H?Y4]_O'\/Y"F-
MT/T/\JWCLO1?D..R]%^1!4<G;\?Z5)4<G;\?Z5</B7S_ "9</B7S_)D#]!]?
MZ&HJE?H/K_0U%6\=UZK\S2/VO\3_ $(Y.WX_TJ)NA^A_E4LG;\?Z5$W0_0_R
MK<:WEZ_HB"J]6*KUI3Z_+]1A4+_>/X?R%35"_P!X_A_(5O#=^GZHWCLO1?D5
MW^\?P_D*8W0_0_RI[_>/X?R%,;H?H?Y5M'=>J_,9!6MH/B/Q#X1UK2_$WA37
M=9\,>)-$O([_ $;Q!X>U2^T76])OH<F&]TS5=-GMK^PNXB3Y=S:W$4R9.UQF
MLFF/T'U_H:TJTJ5>E4HUJ=.M1K4YTJM*K"-2E5I5(N%2G4IS3A.G.#<9PDG&
M46XR33:+I3G3J4ZE.<J=2G.$X5(2<9PG"2E&<)1:E&49).,DTTTFFFCW'7OV
MJ/VGO$K:W+XC_:/^//B"3Q-X8U'P/XDDUOXO_$+57\0^"M9C,6K^$-<>_P#$
M4[:MX7U6/]WJ7A^_-QI-\GR75I*O%<I\-OCI\;?@U_:7_"H/C%\5/A3_ &R8
M6U?_ (5M\0O%O@;^U6M@ZV[:E_PC&KZ7]N,"R2+";KS3$'<)M#-GS%^@^O\
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MKQ[XKU%84U#Q/XT\0ZOXI\0WR6T2PVZWFM:Y>7VI7*V\*+#"LURXBB58T"H
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M%6:^LUXRFXUJ]FU[:HI5+-^]JPHHHKTSD"BBB@ HHHH **** "BBB@ HHHH
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MQ_: L+#4]#L+KPS9VTWBNYUS4X[/5KMHM3T2XNI/B/:W&CFP^QZW:1%;;4;
M6+0SV])\ ?LV?&W]F[]IKQ-^PA\0/C'\"[[P[X NO$/Q>^#7B/4;A_"'BC0X
M=(\5W=OHVMRZUJ.OVZC5=(TOQ3I^G:CI/CF>TL$GB_X2#3XH)(?*_*O]GO\
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MZ;>0/;7^FZC<:KX@\1-'::A;L+:_.G+87-W:H;.:X:SFN8)_&/\ AK[XE?\
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MPI_; ^)?P?\ @-\7/V>/#6A^!K[P5\9_[1_X2C5-=TS7[GQ18?VGHMIH4_\
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MF"Y^SI_P4'^-_P"S3\/=6^%'A[0_AC\0OAUJVJSZTOA+XL^%M1\4:5IE_="
MWS::FF>(?#TRVU[-;07<UA>S7MC'?))>VEO;75W>RW.>(\)/$:K@ZW%L<MR)
M<3XGQ[R'Q??!5'/YQR^AE>49)+A^65PS^>5PP\L[QM*7]HXS%K 1PDY1C2C*
MI4BN?IPOBAP%3Q=#A=YAG+X=P_@EG/A7'C"KDD7CJV8YIF\,\CF4\CCF4Z\<
MHP=2#P&$PKQLL5&,I5&H0E[OVM^R1_RB)_;>_P"QZU7_ -1OX45<_:->1/\
M@C1^RNGPZ_M ^%9/'^F#XC'1XF-H+X3_ !,?5O\ A)VLPZQ6(^(JVJPOJ#);
MR:Q_82OB_?3HZ_/;0?VV?B?X;^"_QT^!&D^%?AG:^"?C_P",M>\:^*WCT/Q#
M#JN@7^OMHQN--\&-;>*X-)TK1+)-#LH=-L]2T?69K:$S1O=S Q>3:_9L_;U^
M//[+OAS6_!'@U_!_C+X=:_<37E]\.OB?X?G\4>$H]0N1 MU?V5O9ZIHFJ6;W
M<=M&EY9P:JNE7;C[3<Z?+>!+E.O'>$/'SS;.>+<%@<FQ68X3QWRWQ5R?AS'9
MS]7P>=Y31X,PG#N)P=;,*6!Q<,NS;"XF>)Q&6XBOA*M&,\,I34%B(SIS@O%'
M@G^RLIX8Q>,S;#8'%>#./\-LUS[!Y5[?%91F=7BS$Y]A\53P-3&86>/RO$X>
M&'H9A0HXFG5E#$.,')T91G/I+_MJS_L->+5T_P"W_P##%5EXTMDUW^TD^&\5
MN/%3^)O#,D/]@-K2I\3[FP_X2J[T<3/X1,WAU=4.MQW+"2W\3K%\,-T/T/\
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M&ME^)J:UZM'V$>=UE)3A#X=D[?C_ $J%_NG\/YBOH+X#_LN_'[]J#6]3\/\
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MJ&>ULHS"ED]9U)^SIJEF<\/'!5'4G[D%"O+FG[L;O0\,J!NI^I_G7W=\*?\
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M^GZ5XBT*WT]O"&H^)=8\5:A)>V^J:_KSV]M>:=HMEIMU^65K^WO\'X/V-O\
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M,,IS#+,-A,>IXG.:5?+G[&IB?\$A/V=_@[^U%^VGX8^$OQU\'_\ "<_#[4?
M_C_6+SP__P )!XI\,^=J.B:+]KTRY_M7P?K?A_6X_LMQ^\\F+4D@F^Y<12I\
MM?<7P)_9Z_X)Q?MD>/?VC/V._A)^SQ\0_A%\4_AE\/?'NM_"?]I3Q!\9_%7B
M[5O&FO\ PXU:TT.\N?&WPTFFLO ^A6>KZG>V5X=)T.POI)O#ZZM'%JGA_5H[
M*XKP?_@@-_RD9\%?]DT^*G_J.&O5-/\ VYOV$_V/O''[4OQ2_9C^#?[1,7[6
MOQ+TWQ_\-[*V^)FO>!M2^!?PKO\ Q!XF,GBS4_!=_I&I#QMKVG?VQIUKK>GV
MGBW0KG4[F'2K+P_'J^@6>HZQ?3UXS8OQ%S;QH\1>&N!L7XI8G/L%X8>%68<
MX7A+BO,LIX/X>XOS'C'C&A6SKB[*X9]EN4XC*\7@<!"&:K-<MS7*\9EF7XG#
MXW"U<=#)H.> J/"V"X"X7S;B*AP=2RVOQ?QEA>):V=Y+A,=GF:9'A<BR&I#
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M/"^D>(+*75+74-+E2\\,BVUC2[+4-.LYC\/_  @_X*+^'M&_9RT+]EG]I?\
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M$]OI,_AR^\+:G;6GC[PQX?&HV]Y=ZQXOU&(:-=ZW#IL5_%;7-X$DLGN*,?\
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M !!5X0RFOEU%5LOC/A7 8VECJ->6'IT<%AI*I0^)W^\?P_D*_H7^)'_*O5\
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M>.^HPCC:N)SR.%R>I1S.L\@P^:-8*OA\1&,J=>C*?X3U"_WC^'\A7ZF> O\
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MK8O"U<YP^ I3P].=7G4(MK\I*A?[Q_#^0K]G+_\ 8C_8K\+?L8_'7]K#P?\
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M;6$U;P/K&NZSJ-OX3U:?4]9OX?#PO;R;6+9+O2-:TG3_ %C]O[]@GX/>+?\
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M!NA^A_E7[<^$?V3/^"47QJUNV^'?P?\ VO/C'I'Q&\0?Z%X5'Q"T>TM]#O\
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M'\/Y"KAN_3]4! _4?3^IJ"3M^/\ 2IWZCZ?U-02=OQ_I6\/B7S_)E0^)?/\
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M#.\9GF(S!NK.K.6)HU\9.C3A4J5%4A!3JU)5)2D_W$_X*?O\*/VEOA%^RO\
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MTZV(Y*V<8W$K#8>$:%"CA\/A:5%1I4HO$5,342J1****_9#X0**** "BBB@
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MJ*_P8_XB+^T9_P"DTO$?_P 6%QKY?]0_]?-G^KO^L'[/+_I#?A;_ ,07@?\
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M*-S_  T^)GQ'_9$\3^#-:^$GQO\ C'XOL+/P?\9M!^"_CS1M?TKQ7XHT>\\
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MHR?&G_!-'P1#I?B[]N[XOZAH/PT^&/Q7^%L&LZ)X5TOQAJ"Z/X'^">M:U/\
M$:\UR'6[PV^H6WA[PAH>H>&]-T.;6[9+VZM?#VB^(;2/_19ITO?+?#7[6_\
MP3R^&WQHU#]IWP!\&/VCU^,$DOB77=*\'ZEK7@JP^%VG>*_%-CK%IK=]:WEK
MXBU+Q%;0:FFMW\#Q3V.J:3IL-R6TKPW;?9;:$?.?P#_;UUGX8_';XU?$GX@^
M#K3QYX _:3N]>B^,7P_CFB1;G2]>U'5;J)-%GO8W2;^P;#7-7T>TTN^DAL=4
MTF^N+&[GM)6MM0L[R_PK\0*_!?B1D.1\+YCA,-F/"' >"P.(SW)>&N$N)\TE
MP_Q#3QN:\%XB'#N84LAXEP\>'J>*P4.)LPR_*J^9U\>\LQ.*Q& E4K1>-\3N
M Z'&/AWGF=\2Y?B\1E_%G'&-QU#),YXCXKX:RR.?9#+!Y7QCAYY_@:N><.UY
MY_/#8R?#> Q^9T<MH8%9CA\-A\<J=&?ZJ?LY>*/$MGJ7Q*\+_MF?M[_L9_'+
MX,_$CP1J^AW_ (9LOCWX6UC5;/7[Z]LQ#<:=%JF@>$['3-(?2IM:BN(+2[/V
M:^71KG3[*%[/S8_YK]?T^VTG6]:TJRU*#6+/3-4U+3[35[41BVU6VLKN:V@U
M*W$4]U$(+Z*-+F$17-Q'Y<J[)YEQ(WZR>&/VJ?\ @G5\"/\ A*?&/P"_9J^*
MOB;XE:UHE]HVBV7QPN_#.J> _#T>H75M=MY%LOBOQ?<745I-:VS)-=:5-K5Q
M;6GV"/6]/34M0N7_ ".O+F:]N;J\N#&9[N>>YG,4,-M$9IY&EE,=O;1Q6\$9
M=VV0P110Q+A(HT154?O?@3PMFF39[Q[G-7(<[X<RG/*7#%'#8+-<BX8X3PV+
MS#*\-F-+%XO <+\-8G'4L!*EA\1@\+B\PK8FG_:LJ=#DHS6"]JOQ3QJXERW-
M\DX%RBEGF3<0YIDM;B2KB,9EF><2<4XC"X',\1EU7#83'<2\18;!5<=&IB*&
M+Q6%P%*A465QG64ZL'C/9G[%?\%3+8>%_@C_ ,$^_A]ILUW_ &%X?^!]S-$D
ML@"7MT/#7PQT];V[CB2.&6_"6D\K2[=L3:A<BVCMTGF63ZRU;6_V:= _X)9_
MLEWG[5'@_P"(7C;X?2Z_H5MH^E?#:ZMK37;?QD^E?%*73]0NY+KQ3X1C;28M
M$A\0VTZ#4IW-Y=V#"QE56GMOCC]IJ>U_:'_X)L_LK_&C0?.O-9_9NO7^!?Q%
MLXKF&9M$L9]*T70=.U;559Q)B]/AKP)-:% 9L^,HTE641R30^)_&W]L'X:?$
MG]@KX _LMZ'H?CJT^('PJ\8:)X@\0ZQJVF:!!X.O+/3="^(VF3Q:-J%GXFO]
M;N+I[CQ?IKQ)?>'M.B:&"^9YHWBMX[G\GRC@G.>*."/"7A?#PSRGC>!_'GC;
M#<=9AD.,GE>;9)*GF?&^*JYLL?AZD:^$>+HYSE6,I8FC*4Y4,RH2IN5*I&;_
M %7->,<IX:XR\4>):\\EJ8/C+P0X-Q'!6 SO!PS+*LYC/+N#,-2RMX"O3=#%
M+"U<HS/"U</5C&,*^75HU%"K3E!<'^T+XG_8>\3Z#X1T[]CCX6?'OP=\4SXV
MTQI[SQK>PW\6H:0]EJ,%OIN@6^E?$+QC?MXCF\13:%+IXMM.@E989TANA,T<
M$WW?KW[<W[.WQJTSPYX#_P""CW[*/BK3/B+HNFZ=IT'Q"\/:3J6A:['IDTCR
M#6IK&ZU'PCXVT#2YKL3WMSI&F7_BG2KZX:\N+73?G_L]?P[\/Z]JWA;7M$\3
MZ!>OINN^'-7TW7M%U&)(99+#5M(O(=0TV]CCN(YH)'M;RWAG1)XI87:,+)&Z
M%E/[+^-/V[?V$?VHK+PIXG_:_P#V:OB5/\7- T*+0;_Q)\(]6M(M,U.V@N&G
M"![GQ]X)OCI\EQ+=7MEINKP:U<:";ZZL;/6+N.26[G_3O$G@%Y?'@K#OAGQ*
MX^R[)ZN?UJ/&_#O'&,J>*_"&9Y@L)*C_ &?B<=FF55,QR7,847A\52GC,12P
MGU:BYX*?[ES_ #[P]XX^O2XOKKB+P\X(Q^:T\CHU>#>(.#<)'PQXJR[ 2Q,:
MOU[#8/+<SA@,WR^=55\/5AA*%7%+$5E#&1_?*/$_M*?L,_ 'P7\,_AM^UQ^S
MO\2=7\>?LZ>)/'WAW3?%>D^*XBUYH&B:GXDNM,O[FWU!+#0=9_L_2[^S;PO?
M:'J>BR>)+.>2.ZEU.^Q/)'W7_!='_A)O^%[_  7\W[1_P@/_  IQO^$8V^1_
M9?\ PDW_  F/B#_A+OL/E_O/M']B_P#"!_:]W[C[/_9WD?-YU> _M9_MW> ?
MB1\$O"?[*_[-/PIO?A'\!/#-]::K>P^(+NWO?%'B*ZL[FZU*VLKB*&]UJ.SM
M?[:NY=?U74KG7M:UO7]86TFFO+""WO+?5._^'?\ P4.^"?Q%^"OAGX$_MY?!
M+7/C/I'@"&RM/!'Q"\'7T<7CN"PLHK6VMX=2GN_$?A348M4BL[.VM+[7=+\5
MVW_"2V,%K;>(-)N;N&ZU34?D\ER#QERS$>&WB7Q-D'$'&E3@K._$?*J?#F.Q
M/#M7Q%H^'_%M'+,/PYG&*5#%X+(,9Q9@%EU2GG.'H8^-?%9?C*-)SC6IXITO
MK<TSSPFS"AQ_X><.YWD7"5/B_)N ,SGG^"P^?4^ JW'/#%3,*^?Y5AG7PV+S
MO"<,8V6/A4RFO7P4J.&QV%JU.25*IAE4^ OV:/"_[2OBWQ_J&E_LKW/Q#M/B
M+'X5U"\U.7X:>+[KP5KQ\(1:GHT6I)=:O::UH+R:2=6GT(SV+WK1S7BV,IMY
M'MXWC_6O_@E'!K]K\//^"EEKXK>]E\4VW@SP_!XEDU.[:_U*37X=#_: CUE]
M0OFFN&O;U]16Y:[NVN)VN9S),9I2Y=O,8O\ @H5^RI^SA\/_ !GH'[!O[/?C
M+P-X_P#'NGMI6I_$OXIZC:WFK:-"+5HK?4+" >+/'L^HSV$[->:=HW]H:)X>
MAU3R]5O;#4O+DT^X\@_X)V_MH_!G]EO1_P!HO1/CCX<^)?B[3_C?IW@K257P
M'8Z#J-PUGI%K\1;3Q*NL7>O>,O"=S:S:A!XRM197-A+>SNZ7LLTEI)% UQ[?
MBA3\1_$KPV\3ZF'\+L5DE#$XGPXI<)97BL-EW_$1N(Z>2\:9%F^?XK-J."S;
M&X#"9=@Z&&J?V/@:N*^LRA2Q>)K2I0G2A+S_  YJ<!>'_'OAW3K^(N&SBMA\
M-QY4XGS'#8C'_P"H>0SS?A+.,LR3#Y94QF5X3&XG'8JMB(+-<;3P_P!7C.IA
M</2C4E"K./Y<VWVO[3;?8/M'V[[1!]B^R>;]K^U^:GV;[+Y/[[[1YVSR/*_>
M^;M\OYL5^[__  7+Q]L_9-_M+9_PEO\ P@'CC_A(O-V?VCCS? WV?[9M_@_M
M/^W?)Q\GG_;=G>N'\*_M7_\ !)[X-:U;?$+X2?L@_&#6OB'X?*W_ (53XC:M
M97>@6.M6DT5WINHJ=6^*OQ!M-/O[.]@@N+/68O"VH:CI,T2W6G>7<*&KX,^)
M_P 4?BW_ ,%"/VH_#M[KD-K!XK^)&O\ ACX=>$-"T:UN[G1_!OAV?5&MM/L;
M>,M+>SZ=I!U+4O$.NZC<RKYMQ/K.J2?8+-A;VGU#K<0\>>*? GB'F7!?$/AW
MP;X39-QUCL?F7&W]CX/,\YQ?$N3X;+9X/"99E.;9O4H9;E>$P]7,\5C\57A3
MK5*=.C2HJ=/GE\_&ED?!?AQQEP-@.+<BXZXK\3,VX-P>"P'"/]JXK+\IPW#^
M:ULPABL3F&9Y;E<*V/S+$XBGEV'P6&HSG2ISG5JU>6?)'[J_X*_B;5_!G[!W
MCG6K$6/C'Q7\ Y1XFADFM+F[@FM=*^'VL+8W%W8XM+D66J>)=<1)K51:22R7
M$MKF.0 ?B77ZT?\ !8GXJ:/XL_:4T#X3>%KA9O#7[/GP]T3P T<:(+>/Q1=C
M^U]=2V>.1E=+/2Y/#.BW,>R,VVIZ/?VQ#>6&/Y+U]K]&W XS+_!+@*&-P\L)
M4QF!S/.L/A9*<7ALMX@S[-<]R?#J-5RJ0C1RG,<%3A"<G*$(Q@V['R_CYC,+
MC?%OC*6$KQQ4,)C<!E-?$Q<)+$9ADF2Y7DV:5G*FE"4JN98#%SE.*2E*3DDK
MV*]0-U/U/\ZGJ!NI^I_G7[P?DXE0O]X_A_(5-4+_ 'C^'\A5PW?I^J @?J/I
M_4U!)V_'^E3OU'T_J:@D[?C_ $K>'Q+Y_DRH?$OG^3(Z:_W3^'\Q3J:_W3^'
M\Q6QJMY>OZ(KO]T_A_,5#4S_ '3^'\Q4-:PV?K^B*Z+U?Y1"J]6*KUO3Z_+]
M1KX9?]N_F0-U/U/\ZKMU/U/\ZL-U/U/\ZKMU/U/\ZUCNO5?F:QV7HOR$J)^H
M^G]34M1/U'T_J:W-(;OT_5$$G;\?Z5'4DG;\?Z5'6T/A7S_-BA\2^?Y,CD[?
MC_2H7^Z?P_F*FD[?C_2H7^Z?P_F*WAL_7]$:K>7K^B(:KU8JO6D=UZK\RH[K
MU7YA4#=3]3_.IZ@;J?J?YUN:S^%_+\T0/]X_A_(4QNA^A_E3W^\?P_D*8W0_
M0_RK>.R]%^0X[+T7Y$%1R=OQ_I4E1R=OQ_I5P^)?/\F7#XE\_P F0/T'U_H:
MBJ5^@^O]#45;QW7JOS-(_:_Q/]".3M^/]*B;H?H?Y5+)V_'^E1-T/T/\JW&M
MY>OZ(@JO5BJ]:4^OR_485"_WC^'\A4U0O]X_A_(5O#=^GZHWCLO1?D5W^\?P
M_D*8W0_0_P J>_WC^'\A3&Z'Z'^5;1W7JOS&04Q^@^O]#3Z8_0?7^AK<<=UZ
MK\RN_0?7^AJ*I7Z#Z_T-15K#9^OZ(V6\O7]$-?[I_#^8J&IG^Z?P_F*AKHAL
M_7]$,KU"_P!X_A_(5-4+_>/X?R%6 VH7^\?P_D*FJ%_O'\/Y"MX[+T7Y&\=E
MZ+\B&3M^/]*B;H?H?Y5+)V_'^E1-T/T/\JWA\*^?YLJ.Z]5^9!1115""BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT[X7?"[6_B;K:V-BKVNDVK
MH^L:PZ$P6<).?*BR-LU[,N1!"#QGS9<1CYF_##X8:W\3-<33[!'MM+MGC?6-
M7="8+&W)R40GY9;R501!"">?WDF(QS_2E_P3J_X)U3?&F:PO;VPO?"WP'\*W
MJIK>MHK6^J>.=5MV1KK0M"NF7=-<3, -=UT!X=)A?[-;[]1>**'_ "6_:+_M
M%(_1YI+P'\!_J/%OTG^,,#:A2BJ.-R?PDR7&T;KB[BN,E4PW]KO#U%BL@R+%
MQE3Y'2SG.:,LM> R_/O]*?H0?0CPGB[AZ_COX[UL5PC]&W@[%\]>M-U<)F_B
MEG&$JVCPGPJHNGBIX"IB(/"YQFV#:JRG[3*LJJPQRQV/R1W_  3L_P""=L_Q
MKFT^]O;"\\*_ 7PI>+'K.M1JUOJGCC5(&5[K0M"NG3=-<S-@:]KP#Q:5$_V>
MWWZ@\,4']67A?POX>\%>'M'\)^$]'L/#_AOP_80:9HVC:9 MM8Z?8VR[8H((
ME_%Y97+S3S/)//))-))(QX7\+^'O!7A[1_"?A/1[#P_X;\/V$&F:-HVF0+;6
M.GV-LNV*"")?Q>65R\T\SR3SR23222-O5_@QP/P//AJ>;Y]GV;X[B[Q!XNQV
M(SKC?C?.:];&YSQ!G..K3Q>,JU<9BIU,2\.\55J5(QJ5'4KU)/$8ARJR2A_H
M1XM^+>+\1\7E>4Y3E>%X1\..$,+2RC@+@+**5+"91P_D^$I1PN%OA<+&GAIX
M^>%ITZ=2I3IJEAZ26$PBA0@W5****_0#\>/Y$GZCZ?U-02=OQ_I4[]1]/ZFH
M).WX_P!*_P!J#_F'(ZCD[?C_ $J2HY.WX_TK6&S]?T1I'X?^WE^<2%_NG\/Y
MBH&Z'Z'^53O]T_A_,5 W0_0_RKHAL_7]$:$%3VUO+=SQV\"[I96"J.P]68]E
M499B>@!-05Z9X=TC[!!]IG7%W<J.".883AEC_P!]^&DZ8X3LQ//C<7'"47-V
M<Y>[2@_M2[O^['>7R5TVCTLKR^>8XE4E>-*%IUZB^S"^RO\ ;F_=BM>LFFHL
MT;'3X=-MH[:'G W2R8PTLISN<]\=D4_=4 >M6Z>_4?3^IIE?)N<JC<YMRE/W
MI-[MO5_UT/TR%.%*$*5.*A3A"$81BK*,5%))?YO5O5ML:_W3^'\Q4-3/]T_A
M_,5#50W?I^J-)?9_PK]1C]!]?Z&H'^Z?P_F*G?H/K_0U _W3^'\Q6HX[+_&O
MR(:1NA^A_E2TC=#]#_*M8;/U_1&I!1115@0-U/U/\Z2E;J?J?YTE;QV7HOR-
MX[+T7Y$+_>/X?R%0/U'T_J:G?[Q_#^0J!^H^G]36D-WZ?JAD;=#]#_*H*G;H
M?H?Y5!6\/B7S_)FD?L?]O!37^Z?P_F*=37^Z?P_F*V*E]G_$OU(&Z'Z'^505
M.W0_0_RJ"G'=>J_,<MGZ/\BO1116XR!NI^I_G24K=3]3_.DK>.R]%^0$3]1]
M/ZFF4]^H^G]33*TAN_3]4:1^+_MU?E$CD[?C_2H'Z#Z_T-3R=OQ_I4#]!]?Z
M&M30BJ%_O'\/Y"IJA?[Q_#^0K6&S]?T1<=E_C7Y#:***LTEL_1_D0-U/U/\
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MK#1K!]<UR1[6]T^QL["R;P[HFDQSVFBFYD_,<K\;O&/'<2<6RRIX_/LIR'Q
M\>N&\[P5?PPSK*^%^$^%O#^?&%#A3/L-XFU:6&X?SO.7F639)E^-X?P]?-\7
MC5C\;&O2RNKA?;'UV+\/N!,-E62K&+#9;C<RX9\-\UR_$4^+\!C,WSK.>)HY
M%4SK+:W",)ULSR_ ?5,?F.*P^9U*>!HX=X;#NG/&0K>S/PY_:0^ ?C#]E[XW
M?$#X">/]2\-:OXP^&^J6>DZYJ7@^\U34/#5U<WNCZ;K<3Z5>:UHWA_5)X%M-
M4MXY&O-'L9!<),BQO&J2R=/^S)^R'^T%^U[XXLO WP*^'>M^*I7U&PL=>\5O
M9WEKX$\#V]](1_:WC;Q9]FETW0K"WMDN+P0.T^LZG%:S6V@Z5J^I-!83?U0Z
M!^VC\9/$?_!;#Q;^PU?VWP['[,7BV[\>>&_&7PY3X<>%)#XQO[3]G[6OB3+X
MP\4>);K3[CQ3K/B:_P!4TRST2]2[UA_#3^%H(M+C\.1W,4>HK_/W\&/BY\6/
MV??VP=1_9E^$/Q(\7^!_@SKO[:GAOPSXG\):%JTM@OBK1?"WQ@7PGINF>(=6
M@"ZYJ>F2Z"'T_4])N-2?2]8@EE35;.\$C9^UX.\;O%3BW@S&98^&^#\B\1J'
M@KX=^+.59SC<[S'/.',VR/C"EG6'QN99CE. R+(\3E&=X7$<.YABJ'#&%Q^9
MY=5>*P>'GQ+2IPK5%X&>^'W!N29]0Q?]JY[F/"U3C[BC@K&X##Y?A,NS7!9A
MD4\OJX?"X7'8G,<QHX[ 5J6:8:C5S>MA<)BH>QKU8Y3.4J<'X-\6OV+_ (H_
M!O\ ;"@_8G\3Z]X!O_BI<>./A9X!37]!U3Q%=?#X:Q\7=+\':MX;N6U74/"V
ME^(QIEC;>-M*37)AX4:ZMI[?4%L+/4XXK:2[\^_:<_9X\:_LH_'3Q[^S]\1-
M4\+ZSXR^'5SHMIK>I^"[W5M1\,74FN^&=%\56C:7>ZYHGAS59TCT_7;2&Y-W
MHMBR7L=S'$LT"17$WZ\?MW_\K FF?]G*_L0_^H5^S[7Z#_%C]O'X_>'?^"T:
M?LB:%I'A&_\ V?/%OQ+^&WPZ^(?PQL/A[X0NI?B+8?$;X;>$I_$/CKQ_K^K:
M5?>(=9U'PO;:[_: ,&J6.EP^#O"5CHATNXA%\^H^-A?'[Q/HX#PKS;"9#P]Q
M93SSZ*<_&WC'+<;G*X-C+-<!1X+Q>98S*\SIY'Q$H3E3SG'X7 9)6PN$R^K7
MQ=&KC,XR^AA)59=];PTX0J8GC+ ULRS3)99=XS1\/LBQ=# //6L'B:F?4,+0
MQF$EF&5MQC+ 8>MB<PIUJ^)A3HU(4,#B:E=07\G?PW\ >(_BM\0_ OPP\'VT
M=YXK^(GB_P .>"/#=M,95@FUSQ3K%GHFEI</!#<S16WVV]A-S-';S/# ))1$
M^S:?T<MO^"4'Q@\7_M)?M"_ ?X6_$?X::YX0_9C_ +-@^+'[0OQ"U"X^&7PB
M\-:G>:3;7U[I.IZACQ=J%M?:7J"ZWI%U%%:W9AE\-ZM=WPT^U2%I?MW]FCX'
M_#3]G'_@HW_P4%_:(CTRW/P0_P"">%M\7_'?AG1;>:S6"+QQXIDU_0OA7\/+
M**:>&VD>W27Q5I.@BXNX98=;\/:)'.PN7=H_S?\ V=/$?[='[7-]\4/V1O@K
MK5WXBT;]I[X@+\5_CEIDGA_PM;:+/JT?B72=;U#XA>.?'<GAR[\3>$_"NCZS
M!IVH7\&DZQ;6E[/Y>E6&B:QJFKPZ5J7V.;>*?%_%V,XAS7@#B7A?@S@WA;@#
M@3-L_P ^XZPL'EV4YCQ[B,NXLS/'8F-.'M*F:\%^&5&CC<#E%;,LLRG,<VXU
MR_\ M;$_5L%3JP\+!<'9'DF'RO!\2Y1G&?9]G'$W$>"RW+>'*TEBL;A>&J>)
MR7"8:DYOEC@L^XMJ5*&)QU/"8O&X7!9!BOJ5+VM><7QG[6G[ _QL_8^TCX>>
M,?&NK_#/XD?"WXK6DMQ\/_C%\$_&+^/?ACXEF@B%U)867B"72M$N1=O8LNH6
M3RZ9'8:M9"XFTB]O_P"S]36R^):_;?\ ;@^(OPQMOA3^R1_P2J_9HUZ7X^V_
MP7^($E[\0?B#HDUGIUG\0?COX[UW6+"7P?\ #75[U;C3K71;36O'7BFQBU.>
M'4]*234- @-]JDNAZK=WW[C_  _^)FN:9^W'\+_V3O'/[0/[._PP\*OX/?P;
MJ'_!,[X2?"+6?B9X'LM!;X3ZIKJ67B7XXZC\-/"WAZ+Q+)'!_P );-IDEGI$
M-MX>L],\/BQOAJ[:OK_Q^)^DIQQP/X?Y-G7$W!U#BS.,;EGBCQ?";>=\'9KC
M?#;@;-:<>'N)\5P=E7#/'6=9)CN*LCQF"Q\YYSA<CX1R>H_^%_B7(*F,P>"E
M[E+PGX>XAXFQ^7Y3GM3)<#0Q?!V1R267Y[@\/Q7Q%@I/-,HHY[C,WX<R_,,-
MDV8T,1AHQP%?,<[QT?\ D793F4*%?$+^(&BOH3]H'P'X9\*_M6_&WX8Z)-9^
M%/!WAS]H3XD^ ](N+HS2V'AKPSH_Q(UKP_I\UP2[W$EGHVEV\+S$N\SPVS9=
MG.3_ %K_ !T^*_PI_8Y_:0^$G[-7AC]KOX9? ?X!>#/#7PYT/5_V*V_8Y^)'
MQ>;XN^'O$,TL>LW.L>//"W@/Q+<Z[XK\>I=SPZ?<Z?K%W=)K\%O?:W8:OJ5W
MK-OJ7ZAXG^/M;@=<"8;AS@C-.,\VXZX:X@XOP>748<31>%R/AS!Y#B<7"?\
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M^%2_#?XBZ5\,/$:W&KS1>*?^$EUF#P[<6CV&C"P>"ZTT+XHTI9KIM1AE1VG
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MB6C;^*S3/*]6I.E@ZCI4(7C[6&E2JUO)2WC"_P *C9M>])ZJ,=K_ (2G7?\
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M3XO\0G_E_P#_ "6M/ZP&N;;J?J?YTE;QP&!LG]3PNR_YAZ79?W/)%PQ^.O\
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M3Z#8B.Y(T;0_%NI:+IL<.AVMCI,1^R5^U[^UQ^UQ\;/V*_@7^R'X?\3?LW_
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M?P_F*AJ9_NG\/YBH:TAN_3]4.7V?\*_48_0?7^AJ!_NG\/YBIWZ#Z_T-0/\
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M7?J/I_4U8?J/I_4U7?J/I_4UO'9>B_(U(VZ'Z'^505.W0_0_RJ"MX?"OG^;
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KJE[:I4Q6)J3FY5ZKEO4445^LG\E!1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img61919486_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img61919486_1.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0X!X # 2(  A$! Q$!_\0
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MX _#'6/'?B'7/"EYI&EF$30Z9=W,D[>;,D*[5>W13AI 3EAP#UZ5ZU_P1O\
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M;<Q)GH2F)5QT,;GJ:]'\!^#IO^"</[*/Q$\4:T8#\0=<U*73-+;@[]C216C
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M1<XV1OZ'^Q/\==?U"&SM_AAX@@DD8*)+ZV^RQ+[L\A50/J:^T_CM'IG[$_[
MT7PEN]3M;WQ[XI5UGAMFR/WL@:XEP>?+6-1"&.-S8..H'R7??\%&/VB]1M9(
M)?B-,L;##-;Z381./HZ0!A^!KQ/7;[Q1\1=1N?$&MZE>:[J5R=TEYJ-TTL\V
M#CJQ)(&, =L8J.2I4:3_  #EG-KG:LC]#_\ @F=8W6L?LK?'*QL89+F]N?M$
M$$,0R\DC6+*JJ.Y)( KXT;]D'X\'_FF/BO\ \ 9*SO@W^U#\6/@!9ZAHO@'Q
M&V@PZA<":YMO[.M;DO*%V@YFB<CCL"!7H-]_P4>_:8TV3R[GQ^\+^C:%IO\
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M<[XPP8+B:-P.0#D &E*,I1:93IU*D'%V/M']DS]M[Q#X4_:<\1>#_B'XGO\
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MA2Q [98#\176:W\*/%?@[4+'3]:\/:AIU_??\>UM/;L))N<?(O4\G'%>Z_\
M!,V/;\6_$)_Z@,G_ *405]U>.+?PGX1U/_A8GB:6&V.D636L5U.NX0*[@ML
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M*JP]P37TC_P36_97TGXB7VH?$;Q;81ZCI6DW(M-,L+A T4UT%#O*ZGA@@9,
MY!9C_=K[8^/_ .UMX)_9WN+33=72\U36[F,31Z9IJ*72/) >1F8*JD@@=2<=
M,<TH4ER\TW9&N*S.I&M]7PT.:1^37C;]EGXK_#G3Y+_Q!X$U>RL(ANENHXA<
M0QCU=XRP4>Y(KS/[(>XK]M?@!^U?X,_:(DO+'1X[S3-9M8_.ETS4D4.T>0"Z
M%6(902 >A&1QR#7Q1_P40_9STGX:^+-,\8>&[*/3]'U]I([JS@7;%!=KAB5
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M3R-]5%?"'_!,-MW[5%A_V";S_P!!%#TD=5"K[7+Y)[Q31]P_\%+AG]E'6_\
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M375Q9\_WIK6:)!_WTZU^K7[>_A6Y\9?L@_$O3[2-I9X["._VJ,G;;3Q7#?\
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M7_74YZEGQ!"_]>ZSYT_9U9H_CSX+*DJ?MP&1Z%6!_2OLC]MT9_9?\:#VL_\
MTM@KX]_9YC_XOIX,/_3^O_H)K[&_;57?^S+XR7_KS_\ 2V"C#_P)_/\ (O./
M^1MA?6/_ *4?G'^SW^S7K/[1WC*YTVSNUTK2;!%EU#4G0R>2K$A%5<C<[8;
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M0?\ 8!D_]*(*]I_X*'ZI/;^!?"M@CE;>XU&2611_$4CPN?\ OLUXI_P31/\
MQ=[Q"/\ J R?^E$%>M_\%&Y/+\,>"O>\N/\ T!*Y4_\ 96>Q67_"Y!?ULSYE
M_9WG:/XY>!BC;2=6@7CT+@$?D:_0#]K49_9W\9_]>\7_ */CK\\_V=V+_'/P
M)Z?VQ;?^ABOT0_:M7S/V??&*^L$7_H^.HPW\&?\ 70TSC_D98;U7_I1\A?L$
MH5^.#G_J$W'_ *%'7OO[>D?F?#30!_U&%_\ 1,M>(_L*VWE?&EVQ_P PN?\
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M?2OJ;PWH.B^#=/73] TRVTJT4!=MNF&;'=FZL?<DU&*QGLVE1?O._-\];?\
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MQ;&\G^TSP_8;:XWR;0N[,L;$< # ('%>70\XJU&M2FUL3.$*BY9JZ\SZ /\
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MYRE\3N>7#"T,.[TH)>B,W5+/S(VXK;\ _'SX@?"B'[+X<\0W%M89)^PW"K/
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MUOJ>E7<^G:C:OYD-U;2&.2-AW##D5Z]#^W)\9=+L1;G7+.[95VBXN-.B,GZ
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M>:Y74M1W9YKOI0.&M4(M5U R,>:Q02[9ILTYD?K2HU=NR/*<KLM1U=M83,X
MJG;J9& %=?X<T7SI%+"LY2L5L:&@^'UDVEES7;Z?X;BVCY*T- \.IY:FNIAT
M?REXKEE(J$KLY-M#6,<#%1_9_*[5UMU (U-<YJ#!<XKGMJ>K3EH49&"]ZV?#
MOADZH!=7>Y;0'Y5Z&3_ZU9FBV']M:K' 2?*7YY3_ +([?CT_&O0+BX6",(@"
MHHP%'0#TKHIQ.7$UN7W41S316D(BA18HU& JC %8&H7V<\T^^O>O->D_"?\
M9A\5?%RQ;6II8/#/A2,,[ZSJ7"LB_>:-,C<!SEB57@_-D8KOBCY^M545>3/%
MKBZW$\U3>0M7T!K#?L?_  ]N&L=?^+NI>(M3CXD.BQO/;D^JO# Z?^1#69_P
MLW]B7_H:_%7_ ("7/_QBM+GG/$Q>R?W'A^ZGI7MG_"SOV)?^AK\5?^ ES_\
M&:>OQ0_8F_Z&OQ5_X!W/_P 9K-A]8CV9XQ'Q5N.0"O7Q\4_V)Q_S-?BK_P
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M4KZU'LSQZ(U:3I7KR?%3]BI>GBOQ1_X!W/\ \9J4?%C]BSMXK\3_ /@'<_\
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M76KQJI::4 Y^\YJ6UD6X171@RGN#FO$U2.5FA'*35B-JK1QD5:C&W&[@5$I
M31L:M(I-0V^QI=@8%NH J\L6VL7,8Q5*H6)P!R<TECJEO>3&.)\L.Q4C/TR.
M:M(H96!&X="*L16Z;5Q&HV]#CD?X5E*8PW%>F:8;E5^]Q]:NK#NJ3^PXM14H
M9O+?MG@5C*=BHG):SXDLH6(DO_*0#^$$\_E7,:K\3M(M]-EMK.^BFU<Y7R#C
M(4_QXK/\864EG?7%I<&XB*N<".5H\^^5(KE(_"^G-<-.MJC73')FD&]R?=CS
M7KX? <S4ZNQDZK5T8-Q9M?3/)(=[L<DGO6K9^%XK1;:[AN7CN0=R\#&>Q%>W
MZ'\*?#BV5M*RR7\LD2NQ9]J@D<@ 5T%G\,?"EM<)+<: AD ^65I'(_%<X/Y5
MV5LUI1]R*%&GS;GA.C_#/QA\399Y[KQ1J-AI^XCS&?"-[*!UKL_!_P #-:\
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MZ\US'@O4 WA2S(/WC(3_ -]L/Z5:N;LMFNZ$3PZU2\F>U_LS_";3_B=XLO\
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M-70;ZZ$CQZDKR9[7^U8W_&L/X<G_ *FL_P#H>H5^:Q:OTF_:K/\ QK!^'/\
MV-A_]#U"OS6S0>.MY>K FFFEI#04(:2BFU(#]U&:;FEI#%I*** %%.I *6F
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M,7Y+@GO5>20M3 2U.VU:1+9[9\-R?^$+T[_MI_Z,:NFKG?ANG_%%Z=_VT_\
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MY;Z$\=7(152&KT"]*S9VTRU$E6XX:9;Q]*OQQUFT>C$9'#4JQ5.D=/V5)NB
M1TC1U8*XJ-J8,B5:N6_WA59:LP=: 1K6M:</:LJV[5J6_:LY'7 NQU8C%01K
M5NWC:61$12SL=JJHY)/:L)'7$FBC,C!5&YB<  <UU6E_#S5;]5>1$M$/_/8X
M;\A_7%=AX/\ !\.@VZ3SJLE^PR6/(C]E_P :ZI:RL92K=(GGG_"J)2O.HH#[
M1'_&HI/A/)_T$E_[\_\ V5>O:/X8UCQ K'3-)OM1"G!-I;/+C_OD&M4?"[Q>
M?^94US_P73?_ !-3R^1SRQ3CO(\"E^$\G_027_OR?_BJW/!WA>+PHNH--,MW
M-,@$+>40(VY!/WNX->P-\)_%S#_D5-;_ /!=-_\ $UGW?PA\7\E?">N?^"V;
M_P")J94U)6:'2S*I0FJE.=I+T/G^^^&,]U<2S/JB%Y'+M^X[DY_O51D^$\A_
MYBB_]^#_ /%5[I=?"?QNAX\'Z^?IID__ ,35-OA7XX_Z$WQ!_P""N?\ ^(JU
M#R.5XK^\>(M\)9/^@HO_ 'X/_P 52K\)9/\ H*+_ -^#_P#%5[7_ ,*K\<?]
M";X@_P#!7/\ _$4X?"GQQ_T)OB#_ ,%<_P#\16G)Y$?6O[QXNOPFD'_,37_O
MP?\ XJI5^$\G_047_OP?_BJ]F'PJ\<?]";X@_P#!7/\ _$4\?"OQQ_T)OB#_
M ,%<_P#\14.GY%K%?WCQE?A/)_T%%_[\_P#V5/\ ^%3R?]!1?^_)_P#BJ]G7
MX5^-_P#H3?$'_@KG_P#B*?\ \*J\;_\ 0F^(/_!7/_\ $5'LWV-%BO[QXK_P
MJB3_ *":_P#?@_\ Q5+_ ,*FD_Z":_\ ?D__ !5>U?\ "J?''_0F^(/_  5S
M_P#Q%.7X4^./^A-\0?\ @KG_ /B*%!]@^L_WD>*K\)9/^@FO_?D__%5*OPED
M_P"@FO\ WY/_ ,57M*_"GQO_ -"=X@_\%<__ ,14B_"GQO\ ]";X@_\ !7/_
M /$57*^P+$_WCQF/X4R+_P Q-?\ OR?_ (JIE^%;_P#027_OS_\ 95[%_P *
MJ\<?]";X@_\ !7/_ /$4]?A7XX_Z$WQ!_P""N?\ ^(K*4'V-XXK^\OP/&V^%
M<G_027_OR?\ XJH6^$\G_027_OR?_BJ]M'PI\<'_ )DWQ!_X*Y__ (BE_P"%
M3^.#_P R;X@_\%<__P 163@^QJL5_>7X'AK?":3_ *":_P#?D_\ Q5-/PGD_
MZ":_]^?_ +*O=/\ A4OCC_H3?$'_ (*Y_P#XBF-\(_'/_0F>(/\ P53_ /Q%
M+D?8?UK^\OP.,\)Z+;>"] _T:_6[OY,EXIH#M4G(R/;&.]<%??#.?4+R:YDU
M*-7E<NP2WP 2<\#=7MC?"/QU_P!"9XA_\%4__P 12#X1>.O^A+\0_P#@JG_^
M(J512;DEJS>IF4ZD(4W-6CML>(K\)Y/^@FO_ 'Y/_P 55F+X3R?]!)?^_)_^
M*KVN/X0^.?\ H2_$/_@JG_\ B*L)\(O'/_0F>(/_  53_P#Q%7[-]CF^M?WE
M^!XQ#\*Y%_YB2_\ ?G_[*M.R^&DL,BM_:2\'_GB?_BJ];7X2>.?^A,\0_P#@
MKG_^(JQ'\)?'/_0F>(/_  5S_P#Q%/V;[%?6O[R_ X^S\$R^6/\ B8*1_P!<
MO_KU/)X&E9?^0@O_ 'Z_^O7>6GPO\<QC!\&^(/\ P5S_ /Q%7E^&/C=A_P B
M=K__ (*Y_P#XFAQ?8S]LK_$OP/&]4^',DJ,/[07_ +]?_7K#_P"%6R?]!%?^
M_/\ ]E7O4WPG\;R?\R=K_P#X*Y__ (FH/^%0>-_^A.U__P %<_\ \36+@WT.
MVGBN5?&OP/$HOAC(N/\ B8K_ -^?_KU?A^&L@Q_Q,%_[]'_&O8%^$/C<?\R=
MX@_\%<__ ,14T?PC\;C_ )D[Q!_X*Y__ (FI]GY&_P!=_OK\#RRU^'+@9^WK
M_P!^C_C5M?AW)_S_ *_]^O\ Z]>K6_PG\;+U\'Z\/^X9/_\ $U=A^%/C+OX1
MUT?]PV;_ .)H]GY$O&_WU^!Y OPWD;_E^7_OU_\ 7I?^%8OG_C^7_OU_]>O:
MH_A7XP7_ )E/6_\ P73?_$TO_"K?&&?^13US_P %TW_Q-3[/R'''?WU^!XHW
MPS?'_'\O_?K_ .O5.Y^&;L#_ *>O_?K_ .O7NK?"WQA_T*>N?^"Z;_XFJLWP
MI\9-T\(ZZ?\ N&S?_$U/L_(W6._OK\#Y_N/A;(Q_Y""_]^C_ (U2;X52?]!%
M?^_)_P :^@9/A)XT;_F4->/_ '#)O_B:@/PA\:Y_Y$_7O_!9/_\ $TO9^17]
MH?\ 3Q?@>#Q_"N1?^8@O_?G_ .O5^W^&<B8_XF"_]^O_ *]>T_\ "HO&O_0G
M:_\ ^"R?_P")IR_"7QL/^9.U_P#\%D__ ,31[/R%]?\ [Z_ \LL_AY(N/]/7
M_OU_]>MFT\!NN/\ 3E_[]?\ UZ]!C^%?C9?^9/U__P %D_\ \35R'X9^-%Z^
M$=>_\%D__P 32]EY!]>7_/Q?@<3:>"77_E^7_OW_ /7K07P.S#_C]7_OW_\
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MT..:=XHU32/"^GJ8-3\Z)UP$EG#D>^:Y#4OVC_#UMH/V"2XA>>--B",A^!Z
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M(/\ XW3A^W1\=O\ HHVH_P#?B#_XW7@@-.!HLNP<S[GO8_;H^.W_ $474/\
MOQ;_ /QNG#]N?XZ_]%%U#_OQ;_\ QNO! :>#5607?<]Z_P"&YOCK_P!%%U#_
M +\6_P#\;IP_;F^.G_11-0_[\6__ ,;KP4&G T678F[[GO0_;F^.G_11-0_[
M\6__ ,;IZ_MR?'3_ **'J'_@/;__ !NO! :>&HLNP<S[GO8_;D^.?_10[_\
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MSBV7(R?1=F\Y/ $H-=M\.O 7A[]GN,E_*U[X@O%F6X528; ,/NH?7'4_>(]
M>?5OC]XBTW]F'P?I4%OITU]?36OV:WNK:,,L*@+A&DZ(.!@=3MZ'%>+_ +,'
MQ1\.^,?%.IKXKF$.MR.)-/AE&8&&"6)8\L^>>>._T\G'5)T,/4J\K=NBW?\
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M27*T[-/H_P!47)KKKS6;<7.<TR28M525BU-'N-GZ1_%W5)[7X-_ !8Y70?\
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M5'\*>[D#[4USP_I?B;3VL=8TVTU6R9E<VU] DT993E3M8$9! (/8BN<'QF\
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M]AL?V*_!?C35+SPI\/OCSX?\9?$>WBE:/PZ-)N+2WO9(U+/%;7KDQRMA3C
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M7_V$Q_Z*2O1PW4^%SCXH'A=%%%=I\X+1244Q#O6EIM+0 M+244 .I<TVES3
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M\R2#S4CAPI3;SNS[8/2OT7.LAIYAET:.)E:%%-IMV2TM=^6BVU['T'!_$=;
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MIXY"IJLM3+7E'V)^HWCS5/LOP=^ @SC=X&T\_P#D)*\RUW7\:-?<_P#+!_\
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MF6*63U,N48C^[CZ5%R^:4$G(^2I?V._'4'QV_P"%1"?1Y_&*V1O9(H;IWBB
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M*R[9+N7YYI/JQ[>PP/:OD#XA?L^S^"_VA++XB^&X5^Q2:A)I^O62\86=<1W
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M'VKJ+O2RF?EK&N8"F<BALA&/)'5*9:T;D[:S9FS47-4BC,M>@_"Q?^)7??\
M78?^@BO/Y*]#^%G.EWO_ %V'_H(J4S&LO</6/A.O_%V/!7_8;LO_ $>E>.?M
MR_\ )V?Q+_["?_M)*]H^$H_XNQX+_P"PW9?^CTKQ?]N7_D[/XE_]A/\ ]I)7
MHX;J?!YU\4#PJBBBNT^:"EI*6@ HHHH *6DHH =124N:8A:6DHH =3A3*=3
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M_5>%\)^%LLHQ_M";G)]92Y%?R2M]S;/4KSQAX$\>>7$EY)H=UG"?VA$$7/\
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M,[:&#5^5OF?\J_5[+Y7/HU8_A]\-] OWF:U\<ZK;PLTGF+_Q*XL Y!SS,/\
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M_P!#MHO_ (#S?X4?\.L?%W_0[:+_ . \W^%'M(]Q>SEV/B2EK[:_X=9^+O\
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MUV]#"W@&(HMV&GD/W4'U]>P!/:L75OAVWBK5+Z^UN;R+2 -(\LAPJ*O)8GT
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MJN9*FNH67/%4&?#8-;I',V6U>ID:J*-5F-JEC3/8_ I_XI:R_P"!_P#H;5T
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M]_Z[#_T$5YW]GED@:=8G:%3M:0*=H/H37I/PG_Y!=[_UV'_H(IK<FM\!Z_\
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MH7FK\J;2O)]9-VO;[[))'T]X3\&Z9X%T&VT>Q^2TM%+SW,F%\Q\9>5SVZ?@
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M5Y+E?+U-Z&"]K7C*>RW\SZIO-3^(7C30K9[KQ+?P"U4F);%_LQSCJ3'C<?\
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M&(DA#Y:,@D$'^?TKHM8U1]2\-S32L7POR _WNU>QE7!67955A7I+GOLWJ_\
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MX8TS4Y((X9PZ0L^(YL<^6Q],GZ9 )KXSOK.XTVZEMKJ%[>XB;:\<@PRGTK]
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M-?1WPRTYETZ!8EVF3YGD[L3VS5SARNS(PN(^L04ELSS34+Z[MY79U=9B2QW
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M .-5=C_;9^,D/W/%JC_N&6G_ ,:KPNEICLCWZ/\ ;H^-<?W?&"#_ +A5G_\
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MT:;$O+A$Z;5E8#^=0M(TC%F8L>Y)R:^_J<8SE&T:6OK_ , ^:CD:3]Z?X?\
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MW,/^"=.@+_S..I?^ L?^-.7_ ()V: /^9PU+_P !8_\ &O-_UFRS_GX_N?\
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MH7D8#>1 Q+,>E/FZHM49./O'O=KJEA;:I<&<JI!PN:N77EAQ+$!^\XR*\_\
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MJQX<^'7[&GPAN?$%]:6\UU9Q 27TB*;N_N2/EBC)Y&X]%'"@$GH37P;\!_\
MDMG@+_L.V7_H]*_1+XW_ +-N@_'K7O"5[XAU"_\ L&@W+3OI,;C[->J0,JZ]
M0<JHW YV[E[Y'?A8-0DX:R/:P,>92J):['E/[''[94?QVO\ 4O#7BJ*ST[Q4
MLLMU8K"NR.ZMR2WEJ#_'$./5E&[DAC7UAY*?W%_(5^;/[&O[-.E?&CPRWBL:
MQ>^&]=\/^+GD2_TT#S)(!#$_E GA2'Y#8. 6&#GCZ)\6>/\ 6)/B?\3+*Y^*
M_P#P@]GH"6KZ;9R16;)*7M][\2H7?Y@. <_-]*VH5IJDG4UOL>C2J24$YGT[
MY*?W%_*CR4_N+^5?)UU^U)K'@^/P%K_BN5K:TU'PK<7]SI<4*K]KNQ(JPE<C
M<NX?-UP Q/:O8/!GB+7/"?PAU+QIXXUJ+4KF2UDUAH;81BWM(2A>.")E'S\8
M&XDDD\&NF->,W9&T:L9:(]1\E/[B_E5#6O#FE>([&2RU73;74;208:&ZA61#
M^!%>$?L[_$+QK-XL.@>/]1^W7>MZ);^(M*S"D7DQLS+)!\JC)7*'GG%?1%:0
MFJD;V+C)5(WL?FI^UG\#[3X-^.;9]'#)H&KQM/;0L2Q@=2 \>3R0,J1GLV.U
M>'BOMW_@H!I-WK]Y\--,L(3<7][=7=M;P@@%Y'-NJKD\#)('-<-XF_8OT#X.
MS6T/Q;^+ND^#[V:,3)I^FZ/>:C.Z^@.R-<]LY(![UXU?EA4<4?+8JFH5I**T
M/EU:>M?0PU+]F#P3S;Z-X\^)5XG4:A=0:192?3RPTP'UIX_;"C\*?)\.?A3X
M'\#%?]5?M8'4]0C],7%P3_Z#7/=]$<?*NK//?A[^SO\ $SXJ>6WA;P3K&JV\
MGW;Q;8Q6W_?Y]L8_[ZKTI?V3]#\#?O/BG\6O"WA!T_UFD:3(VLZDI_NM%#\J
M$],EB*\V^('[1OQ.^*?F)XH\<:SJEM)]ZS^TF*V/_;&/;'_X[7GBT]1>ZNA]
M(#XG? ;X8\>#/AOJ'Q!U6/[NK^/KD"V##N+*#"NI]';-<I\0/VL/B9\1-/\
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M0)B$@%1N!).W..:XCX*Z#X ^.7[37A;0;7PG<:!X3OH;A)]*;59;EVDCM9Y
MXFPK#+*G _N^]$'R--=15XJM&<*D=(]?17[GC%_&]A?7%M(R&2&1HV\MPRY!
M(."."..HJ$3^]>K_  7^&OAC4O#_ (V\>^.&O'\'^%3%"-/L'"3ZA=2N5BA#
MG[JC +$<X88Z&IM<U/X,_$3P)X@N=%T.X^&/BK2HUN+*TFU:74+;54W8:+,B
M[DDQR,<'^6=CLY];)-V/)5N/>K,-Q7/K=>]6([RI3-94SIH;CWJ['<CUKF8;
MSIS5N.^]ZU4CCG1+ U,NP53R:TK'3_M&&;GZUPN@ZI'=70^?FO1K2=5A3'>N
M^I"QK3J*3LBW#I\<?0<U:73T?H*BAE#=ZU+&9%Z]:XFCM3Y48FH6<4<;!JY&
M]M_+ERHP*[+Q-\RG8>3Z5RZ+Y@*OR14-'33[F4TI92"*S;[4FB7;72PZ/)(K
MG::Y[5=/,5T%92*E=F=41= OCO+.:WFO(Y&"D\FN62,V[?+5A9'Y8U+T9;C=
M&Q<*DC?+61J5B'C(]:EAD=F49X[TMU(=S'^$5+&D^I@I9FUD!/2K4A62/).*
M+JY79[]JHK,H;YS^%(+%6\B/;I3;:,<DU+<S+,V.@IK!4@R#S096.I^'?PA\
M6_&#4[S3_!VAS:Y=VD7GSQ0.BE$)"[CN8=R!79:A^Q/\;+&W:X?X>:HZ(,E8
M3%*_X*CEC^ KW7_@D^Q;XL>-\]/[%3_T>M=YX+_::^,>J?MH:CX(CO9M8\)0
M^)KS3WL&TV$)!9),Z[_-2,.-B#.XMSCG.:Z(QBTFSP<1B:T:LZ=-*T5?6Y^=
MFH:3=:;>3V=Y;36EW YCFM[A"DD;@X*LI&00>QKO/"/[)_Q6^)?ANU\0^&/!
M=[JVC71<0W<<D2+)M8HV-S@\,I'3L:^A_P#@I?X=LW_:3T6WT6V5]8UC2+8W
M$, &Z6<S2Q1D_P"T55%^@6OK_P 7?$;2_P!D'PO\"O :-"8]2U*WT2Y=A@&$
M1%)[CV_?RPN3_M&G&"YFGLC&KBY>RIRIQ]Z73T/QH\4>%]5\#^*-0T'7;*73
M=7T^4P75I-C=$XZ@X./Q'!KMOA]\ /B'\4_#.H>(/"GA>ZUG1K"5X;F[ADC5
M8W5%=@0S \*RG@=Z^B/^"JWPM/A7XYZ7XPMHMEEXIL!YK@<&ZMPL;_\ D,P?
MCFO;_P#@F7S^R?\ $H?]1:]_]((*I1][E(J8A_5U6BM['Y>22A@<'-=Y\-_V
M>?B+\7]'U#5?!WA>ZUW3["3RKF>"2-1&VW=@[F!Z'/%<G8^&[BYVD*<5^H/_
M  2_TEM+^"?Q"C88,FHD_P#DLHI17,[#Q-1T:;FC\GY.:K;6+8KO-.^'>JZI
M+(MG87-ZT8!86\+/MSTS@<5Z+^S[H^A?#_\ : \&:K\0;66Q\/Z=>K>7:W%K
M(Y4HK-$QC"EF'F!. #T-(TE9)LJ^%/V&?CKXPT.+5M.^'6I?894\R-KR6"T=
ME/((CFD1R".G'->6>-_ ?B'X<Z_<:%XFT:\T+5[?!DL[Z$QN >C 'JI[,,@]
MC7Z6?%3]M;QUXN_:1\*^&_@UK-MJ7A>X>UB,,>GJ_P!ND=LR^894\R-57@[=
MN I)/>L__@KIINDW7_"MI1''_;N;U"R@;S;CRB WL')QGU?'>M'%6;1Y\*M3
MGC&:7O?>O4_/_P *_LW_ !4\>74<6A?#[Q'J DQB9=-E2$9Z$RLH11[DBN,\
M2>%=2\)^(M5T'5;?[+JVEW<ME=V^]7\J:-RCKN4E3AE(R"0<<&OV/_8?_:L\
M5?M":YKVD:[I6DZ;8:-I]NUM_9Z2B1F+%#O9W8'@#H!7YR_$KP2WC+]KKQ=H
M08QG6/'5Y9"0#E?-OW3/_CU#M9-!3G*4Y0FK6.,^%O[*/Q7^-&FMJ7@[P5J&
MKZ:K%!?,T=O [#@A9)656(/7:3CO6+\4O@1X[^"^I06/C7PQ?^'YIP3"UP@:
M*;'79(I*/C(SM)QD9K]0?V\/CSKG[,/A/P)X%^&,L/AD2V[DS0P1NT%M#L2.
M- ZL!N)8EL9^0<\FG:;XBE_;,_X)^^)[[Q;#!=>)='@O&^V)$J9O+2/SHY5
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MS!YY23]:SH?$ MYFVL<^N:S@^5ZF]:/M(VBSZUT?Q796^US*OYUI:M\2+&1
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M&"XE1@.0.0,URGC#Q#J'CCQ!J>NZK<_:M3U*YDO+JXV*GF2R,6=MJ@*,L2<
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M_".';\0_"IQ_S%;7_P!'+7R+^W+_ ,G:?$O_ +"?_M)*^P?A(#_PL+PL,?\
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MC!8I-2AMTVHUW!/&DDH';>6'Y9Y)),\J:T.J.(J)I26Y\?3?LY_%'31+//\
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MBN5S9[M/#KJ>1V?P[*@.8^?3%>P_"WP>UOI-U\F!YH(X]A5FWAA+#A<"O1/
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MIVO+$I#<$@D89,\<+7N?PJ^,7AO6?^"HOQ%\B]A%KK6DOX=L[M&&)+J!+;>
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M@O\ L1^$_#-E\0O!4GQ3^*NLV2ZA=:;/?-;6>G1L2-GR@@_,&4$JY8HQ^0$
MX7C3P/\ !K]HK]GWQ7\1/ASX='PR\9>$6234O#[Z@9K:[@;)S&6Q\VU7(VJO
M,;*5.0U=!_P4F\)W6J?%'P=\8+#3Y/$OP]UG2;-UNH=WDG8S/Y3N ?+#QNI!
M/7+8Y4UUO@GX?_#/XU_LS_%GQU'\ +7X>+H^A7D^BZB^JW%RUW,EM*YDC#*@
MVQL(_F^8$L1_":.B86U<3\YJ_0[X_'X#?LUV?@"PU#X$67BRXUW0(-2FO%UJ
M>T96("M\N'R2<G.1UK\\J_37]L+XJ?#/X?1_"F#QQ\(H?B-J$OA:VEMKR76Y
MK$0( !Y>Q$8,"03D^N*N6Z,X;,\4_:#_ &>_A[H/B3X$^-/ ^GW5AX,^(DUN
M\V@7TS2FVS) 60.6+899B"-QP5)!P0!WO[27B+]G?]GSXP7W@.]_9\MM9M[:
M*WEEU*VUZ>!]LL8<[8\'D9Q]\9]17AOC3]IG5_VC/CA\+1-I%EX9\-^']2LK
M/1]!T[)BM(S/$#\V!N)"(O 4 (H '.?N3Q]XT^$&N?MR2?#[Q[\.=#NM7NK6
MU^P>)K_]Z9[HQ(T4$D3#;@C*J<G+!1CYN(U5KEJSO8^-_P!JO]D_2_!?Q]\$
M^%_AP)O[,\=6]M<:997TA9K1Y93&49CEM@^5LMD@%@2<9/>_$Z7]G7]D#7$\
M O\ #23XN^+[*&/^VM6U34FM8HY'0-L10KJ#A@=H4;00"[$'&)XN^*WC'P[_
M ,%$/#VK_%][6SFT+5H;!?LL9CLK>Q8L(Y8MQ)\O$IER23R<],#B?^"@'PH\
M1>!?VD/%>KW]A</HOB"[_M#3M2"$PS+(H)0/TW(V5*]> >A!-+6R;)=E=I'5
M_&3X(_#+XI?L]W'QM^#>GW?AJ/2+I;7Q#X5NIVF%L6*CS(V8DX!D0\':5;("
M%&6NJ\$:#\'_ (6?L1^!/B=XP^%EOXZUC5]9N-*F8ZA+:N?WMV4<D9'"VX7&
MT=<Y]5^%/AW4/@;_ ,$]_BQK7BZVDTE_&LT5CHVGWBF.6?*A1($/."&D89ZK
M#NZ$$]-H'Q<;X,_\$V?ACK:^%?#OB\W'B2YL_L/B:R^U6R;I;]_,5-PPX\O
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M?D,BKIO6QS5X\R3(9O%3^-->,=K%Y6CV3 !VZR,.Y-=G:QP^(@AFG\G2[/\
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M3]*\J\8365WJ36^B&632[-1!"SG)D(ZM]":^FM6^%]Q\5]4L[07S:=I:-OU
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M56SJ=:@ZTH?O.;DY>G-_D>/6?_!/OXPW>GBXDTO3;64C/V6;48_,^GRY7/\
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MMK8K$U<4\)A$DXI.4G=VOLDEU*/Q:_9I^(WP=MGU37_#S'1\@/J%E(L\*$G
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M5RD.6'J*K7VCRW,99R=W:M+2=(BT^$$@9K09E93BO8IT(PW/GJV)E)Z'G_\
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M,$*5!K6\*^&WU!A-*..M=]#I:6\85% I)7,*U94GRQW/*+[X?/M1L'/>G/\
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M&)C=D <_ZI__ (FD\5/I,Z:'#^%<;SH:^C/I?5/BXEHJ&'P#X'8$<[M&!_\
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MM=R-,5EM+G484[:=C7\0Z-X?TB\\F+PSHC#:&R]A&?Y"N=NKS2+?[OA;P_\
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MQG!_*EM[R-DZ[\=F% >S+S>3MY;]*B9(V&5?=5>:XMY%X5HV]4X%,XZJX/\
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MF0V,:[ !@MUHTFUEM;P$N06YYKGY7%:G;&;MH>KZ+>3:?!!B;:P*ACZUV?Q
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MHF):J_F5-'-W)JN5D<R9*H$>#3FN"[>PJO+-EO:H6FQWI\@N=;(M>:*CDDW
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MM7A/]M7XE^&8?LFIWMGXJT\C:UOK-L)"R]QO7:Q_X$6KPGR6B4@AEQZU')(
M .YJ94X5/B5S:GA:DO(^G5^+_P !_B<NWQC\-Y_"%_)UU#P[(/+![L479^J.
M:G7]ESP-\1O+_P"%;?%73;\$Y32=77R;D_4X#'_OT*^4YKA8UY-9=QJPCSA2
MY[<UC[%Q_AR:_'\SM]C2IKXM?O/;_B?^S?\ %;P+N63PA>W-A&/^/[3,7:;?
M4B/+*/\ > KQ2SMY1=.LZLDBL5*,"&![@UV_P_\ VGOBE\/I8H]&\5Z@EHO2
MTO)/M4 'H$DW!1_NXKW>P_:^T[Q]''!\3OA;HGBAF&W^T+!/(NE [C=N.?\
M==:.:M'XDGZ:?G_F<DW%2O)W/F"]M9+=AG&YNE=G\.? JZTK3W",0&^48XKZ
M3MOAC\!/B8J3Z/KFJ^!KQ^5LM<CW0K_P)B1^<M;%Q^RYXOT>UCFT"ZT[Q%I?
M5)M-G 8K]#@'_@)-2\3#9Z/S.2I6]RT8ZGC5KX.M+69?-5@ ?NYZUJR6:P+L
M"?)[5['\.?@'?^,/%1M-:BU#2;6S0271FB*.V3A43<.IP>>0 #[5[U??LV>
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MR=0010&AZ/\ #/7O$_B[P?;:AXU\'1^"==>219=%&IQ:D(E#$(WG1JJG<,'
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ML9/-4M)A_M;4H;&P"I-(^%DD. *]&U+X/ZGJ6Z2XOVD<]SBL(? _4EF!@O\
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M[-95MJ#7F$=%0'^]UK.5S=6Z'N/P]\9RZO;C?D=NM=Y;ZAM;K7AW@6]ATN3
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M,MP0,,K\BA0TNC=5-+/H:]K-=:+-$TT>8I3GU.*P_'LFE0PI>6,O[V0[9(\
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MNOF[_@F=HMCXD_89T+2-3M8[[3;^35+6ZM9EW)-$]Q*KHP[@J2#]:YO]KO\
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M0Y%?EM\=O%5Q=?%7QI;NY*Q:U>Q*/99W _E7ZC9K\D_C=)_Q>7QZ,\?V_?\
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MHRMW!%>=5@HRT.>[(=KM]:>D<BM4\=N<XJUY8+ < 5SE%>-7SSP*M>?\@ 4
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MR[Z5?]JH5DJUXIM6MM5?C[U9\:,>37N4Y<T$S\YQ%/V=:4'T9;61FZ581BP
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MX]HZU+N4B:'33)-';P1F6>0A551DDU]G?LY_L>026MMK_BE<LV'CMSVKS_\
M8L^$Z>-O$DGB/4HM]E9G$2L."?6OT&CFCAC2-%"QJ,!1T KP,=BW%^R@SZ#
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M@Y:79@?3(KP6X>^O-C7DLDNT87>V<5]+_%;XN?$+5O!,NC>)/#Z;T;#7:+G
M]:^7]6U*9E"\J?IBO1I-1CJ>/4:BG*1=5U6V:-AR>AK)D9K,$. Z'I26MY<,
MI7[PJ*16F8HYP:ZI34DFCAE+F6A%8ZM/I=ZEU:2R6TR'<DD;%2#[&OKG]D_]
MISQ?X>\1QVNN1ZIKFE2*52%<MU_BR>>*XCX4>(O@UH/AV$>);6XN-7W?, #M
MQZYZ5]S_  B@\$>-/!D5_P"'=+;18D4"*X:,?-]#7#4G;1H,/0YIKW_DCM/
M/B"#QEK$L^ERW-K+G,EG=QLO'XU[?9V\=C J(H5NK8]:\\\"Z2]E,LGG)-M'
M+; &(]SBNV:[&>M<J:W.S&*=22@^A>D;?TJ":-MN2A ^E117HCF5NH!Z5MW7
MBJTDM"AA!;&,=JM1C*]W8\N?MJ4HJG#F3_ Y*^L8IE.5%<OJ7A^)F+ !O9AF
MNHNKQ)"Q!P*R[B8'/-8<NNA[M.32U/+/'&B:M';M)HL5J)U&?*F7AOH:^1OB
M9XG\7ZG?R:7K>ZR13_Q[Q@JK?XU]Y:C(L@*UY1\4/ =EXPTUXG11>IS#-CY@
M?2N[#SY)IL<XJ4=4?#]YI)A4,5K%U"U/ELXZ"O7M7\/FS6>WN%_>0G:WU%>>
M:Q:B*.5.O/ KZE2YHZGG.FHO38Y"&/Y@3UK6L(RK!EZ>E4)(G5'*CD5I6"M)
M:@J/FQ6U-[,XJEN9Q:U+4T<2RAAD!NM-FC"C*C>IIS))-9R9Y91G-4;:]:/J
M<FNJ6A\+BH\M1ON+(_D$;@R U)&S2'*OM%.FNQ= +(H84QH85QL8I[&IN<8[
M<RY'F;JB;[X+-QZ5*B1KR?F--DD'9:=V TW'\*"F;F8_>IC-Z\4JY;IP*A#/
MLKXM;?VFOV0O#OQ&3_2/&7@,_P!D:Z1S)-;?*%E;N>L;YZ#?-Z5XQJWP5TNU
M^#=CXMM;YY;Z1=\L7\('I78?L+_$VS\&_%2?PGKVV;PGXVMSHNH03']V9'!6
M%C]2S1_24GM77:I\.[GP3;^/OA;?LTD^CS.UE(_6>V<;H7_%2N<=#D=JRA[L
MG#INC*HW%)H^1=S'@'BG-D*"3DU#&6CDD@?AXF*G\#BBZNU50J\M71?N;(N6
ML^Y=G4CI2S=FQR.M4+598RK,W/7%:T+1W$8)/S#TJXOF5F=5*#J^ZMRE(_IP
M*@>X55]3[5:F@C9B22#[57D"1X 5B2>2.M3RLOZK46Y+'%YJJT@V^@[FKZ!(
MER< 571=JY;(X_&JSNTS#.<#H*O2)M>E16FK-)=255PD9)]3TIRZA*2=SX_V
M5K.Z8YYIRY'8"H<CEEB:DNI>>Y\P<GCWJ%W9NW'UJNUP$&<$YJ/[5(W"@ >]
M1S)&-VR=@W<XIC-N8#VIGS-C+_@*8I5-W-',P0YH4;)W-36MTVYV9'N>:59>
MOK2,ID;)_6GH;K8EL9C;WD#( #O'(KI9+B.9067YNYZ5R\,C0S1N-A"N&QCT
M-=7)8[EWITZXJUMH>]ENJDA(]C8 RIK[4_X)P1B-OB)@Y_Y!W_MU7P_N:-N*
M^W/^";+;U^(9_P"P=_[=5RXC^$_ZZG5CDOJ\OE^:/M^+[M3CC%0PU)S7C'R)
M/'*4)(]*BD D4A@&#<$'N*=$N[</:F9YIC/C/]M#PEH5C\6OV9H[;1=/MX[C
MQU%',L5K&HD7"_*P Y'L:VO^"@FI3^"/@'I_AGPDL/ARX\>>);#PM/>6$2PM
M'%<>8TA^7'58BA_V785K_M>>"=?\5?%#]G:^T;1K[5+31_&L5WJ,UG;O*MI#
MA<RRE00B#'WC@5V7[7?P(NOVAO@MJ'AS2KU-,\26=S#JVB7LAPD-["28]Q .
M P+IGMOS@XP9 BU#1?@=^RE\+=-TG6K3P_X4\(N5TY6U&V1A=RE&8B5MI,CL
MJ,Q+9S@UPO[$UAX T;5/B?8_#'XA:;XK\&7&JQ:I9>'].B<+H/G*^^,,QY1V
MC.U0 %$9ZYK'L?VM/%!T&VT'XC_LW?$&_P#&UL DD&DZ%'J&DW-P!M\V*Y+[
M$0G))YVANK=V?L3?#WQ_X7^.GQS\1>//"Z^&9O$R:->VUO9Q?Z'" ES_ *+'
M* $E>%&B1RG&[/J"6MP/&/V4_P!H3X3?"W1_B1H_C?3KJZUE_'6KW"O#X<GO
MU\IG0*/,2)@.5;Y<Y'XU]N^#_BQ\/I_AEIWC*RU"P\+^$M0D=8)]6C&E(9 [
MQD,DH3:Q,;8R,D#(XKS7]@WP;KW@GP!\0[7Q#HM]HEQ=^/-7OK>*_MWA::W<
MQ;)5# 91L'##@XKW3QIX$\-_$321I/BG0-,\2:6)%F%EJUI'<P^8,A6V.",C
M)YQW-.V@CYE_X*&>*M&\8?L(_$74O#^L6.MZ<[:>BWFFW27$18:E:A@'0D9'
M<9KF?VN/%6IW'Q"\&Z-\1O#][X8^ ND:M8:G-XML46]2_ND53%#<!&#64 E<
MJS%6+%1@J#QT'_!03P3X?^'_ .P7\1-(\,:'IWA[2HWT^1;'2[5+:!6;4[4L
MP1 !DGJ<5@_&[XX>(OV@?@YK/PO\,_!CX@6GB[Q%;KILA\1:,;33M/!9=\\E
MT6*%5 +*5SN.*E@?:<4T<\22Q.LD;J&5T.0P/0@]Q2EJP_ OAL^#? _A[P^U
MP;MM*TZWL3<-UD,42IN_';G\:WX8&GD"K2+&*I8X'-?F;\3O@_\ VM\7/&U[
MJEYY,$FNWTB0IU*FX<C]*_4/R5@&%Z^M? 7Q(M[A_B=XJ)A>0'5;K;QV\YJ]
M7+U>35KG10;DVD>::?\ #7PW:1[H;+[1)'R?,YJ6/3]%B<K)I<++GE=HKKAX
M*UJXD\RSA8+(.0:?I?PEU:YU"..\!B1SR5KZ!TJLK1C'4]949NR41UI\./AI
MXPT7R[BR&FWN/]; =IS^%?/_ ,0OA?<>";R0V\WVZQR=LB_> ]Z^R%^">EV5
ML,2R>;C[V:\J^(W@N;0]Y&9[=N"K<UG_ &?5@G-ZHWE@:D8N9\H-*>I-*C+]
MXMS75>,O"1LE-[;J1"QRR^E<.9EW<'-<4DXNS/,DW!V9I;@12QR+&N[O45N%
M W$Y)JRN."0,5)I&7<(L2;B%.&IRV[33!=N *NV,)?@#.:[[PY\-;S688I(T
M5!*_EH\KA%+>F20*YZM2%)<U1V/7P>#K8Z7)1C<\LN+':TG&:C^Q,JC:.]=Y
MXE\'SZ,S>8!C.,J00WN".H]ZQ[#2)KS[B'CIQ3C4@X\R>A<L'5IU'2E'WET,
M'RPHY^]32I*GC%;E]HTUFQWQL![BL::4!B-I!Z52:EJ85*<Z3M)6*,BMNW8J
M%I&?Y=I!JRS;CR*8<AABJ]#!,FM;6VQS,0^.<CBI3.L"X#9_"J\<GEG! (H:
M3=]*GED]S12ML1W-X-P)!K*FN?/N JH,>IJY<!IY0JGCN:(=-DNIRD:;]HY/
MI3M;<.:3>A'/821QY1U?UVFJ?EIY?/$@[UIS:>]FA>20+_L@U!:V_P!JDX(
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MG +<4R9%#,IJE$Z><KQ,=ISZT2 *"<5<MU7RP2.*9-AB3VH%T,TH-Q-1LO.
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M/3J!4U*D*44MS)1G.5]KE[_A)Y+9"%*G(QG'-9;:H\[!0?F)XK)OF_?,(V+
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M-&LN8ZO>:T/*-6\3*V41LFL*-FNIP2<DFNG\2> )+7=)&#D=ZY;3XY(+SRY
M00:[U4BUH91B[ZGHOAJU"Q+D5UL,"[>E<OH<ZK&M=$MXJKUK)1NQRE8AU",1
M\BN?OM:6 %2:T-6U1!&WS5YCXDUC;,V&KIC"QFI<Q8\1:P)5;#9K@KBZ\R8\
MTNIZUN4Y:L*/4 \QYK1VV'L='8W[VS94XK2;67F7&237.I,K**Z/1;%)X\GF
ML>:QI:[N96HL\BDD5RFH3M'D&O3K[2T:,X%<'XCTOR\X%=E.6AP5HJ^ADZ7<
M[9 ?>NOL]5"(.:XFUMWC[5:>Z>(8/%=".3H=;>:R/+)S7.Z?JWVG6",UD7VH
M2>20IK.\,7#MK7S=355M:;1Y_MN3$TXKN>F:PHFTV0>U>.74>R\E7_:KV2[&
MZS<?[->0ZH#'J4H/K7FY>]T=O$4;\DRKMQ1TI^13#7L'Q ]6-2JY%01YJ9:I
M"+"R9I?,>-@T;,KCH5ZU&M?07[./P#D\=7T6I7\1^S Y1&''UK.K4C1BY2.B
MC1E7FH0W'_ _P[XS\2",A9%M>S2 Y(KZDTWX3Z@UBHN"?,QSFO3O"_A+3O"E
MC';VD**5&"P%=)!=1QL"W(KXZO6=:=TK'Z5@Z,\-346[M'C/_"IYK>WRZM^5
M>8>/O"<MC<F,9"GCI7V#K&M6DUD(T0;L5Y1XRTNUOLNRC<.:YM4[GJ4*TIZS
MC8^5=2^%\LEN\Z%BYZ&O,M:^'NL1W)$437"YYKZNU(;?]'C3/I3/^$:%G8M<
MRVOFMC(R:/:2BSJE!2U/E6;1Y]#TT^?8O$Y&-R]:\]UB"Z!>5YY8D/\ "7.:
M]D^+'BC48;IX8M+*1]-W:O"=<UB[N[@1RQ^2HZUTQ;EK8Y:G+8J0ZI';%E??
M)^M<WKETMU<9"E5]ZV+ZZ@ME 4@M[5CW"+?,,';6MNJ/*K:KE1Z3\&=)\*SR
M&37?)8Y_Y;M@8KZO^%_B3PUIC/:Z&(_LX'S&(?*/QKXFTWP0UY;*RW+HS?W:
M]Y^#/A_5]*TN2TLT>Y=OXV'3-9NS>YKA])).)]+/K<&H3.MK<*Q7JN:ADFFZ
M'->;:3\.O$>GR&X1WC+G<P/>NI\-Z!XPUG6DLH("8<_-,3D5$K=&>Q&3IQO+
M8V'WL>^:GM=-O;J4>7 Y7UQ7O/@WX.06-I&^I?O;C'(/)KLSX+L;6,&.W5!]
M*RA-QE<SGC%)62/E/5+6[TB%F-J[MCTKS'7+V]U"=OM"/$@/"L*^V-<T"U56
MS$K#Z5Y1XR\$Z?>1OB)48]"!7KT,0KZG').6K/F&ZAPAXKD-4!CD.1BO5?$V
MAG2;IXF&5[&O-?$D(5CBO:3NKG++R,6)M[XK5M8> #6/9']YS6[#(-N:W@<D
MMB6X7RXR!UQ63#&&NLGBM)IEVL6-8<EX%9F!XW8K><?=.&-6U2[-&X!"R*K=
M!7G6J7$DMU(KL3@UZ),H\H-V9:\]U3:+Z08[UA3>AY&;1U4D9RJ<U.NW'K2[
M5QUJ/<B]#FM=#YT<:3E>:1F#<YHZ_2@!ZD]:>LF&J)<[J&:@#0LKK[/<)(#R
MIS7JND7@U/3E/7<N#7C4;?-7IGP]NO,LVB/5:YZFUSZ3):UJCI/9G(^)+$V>
MI2#& 3D5FXQBNS\?68\Q90.:XS-;0=T>3C:7L:\HHFCZ9IDDC-0KCN:%V^M7
MH<(L1;/M5I?N\U%&1VI2V: )>6[U'/((EP.M-\TJ.E,5)+IUCCC:65C@*HR3
M4MC1]'?LN_%R/3HI?#]]+M!.8BQKZ/N-8.,[N*^(_!_P$^(.MR0WVEZ+=0[2
M&25AM(KZG^'_ (3\?0V<6G^(M(DW*,+.E?+9A1CS.I3?JC]!R/,'&*H5T[=&
M=1-KA4?>K,N==//S4[7?#6IZ23YMO(%]<5REQ(ZD@Y!KPXR74^]48R5XLT[G
M6GW;@W(K$UC6);IMSN6/N:ADF8<'FLZ^F2.-GE<1HHR2U:WZ(E\L=6>J>$_'
MNKS>#;NUMKJT-S"A"+(=K"OE76];^+NH>)KO^R[Z5@SG"!\@XK(^(?Q/22]%
MEI%S)$R'#2PL03[<5B^'?'VL^&]0M[F>YO(K=6SYC*2/QKJITN:+EU/-NKMI
M;D^K_%3QCX3N);+QAI;2+(#AI(^&_&O.M:U;2O%EC.4LEM[@$LN*^@/C]\3H
MOB%\-;6&RTM;^6)<R7\:#Y?<FOD16N;=F>-MN>M7!=;')*HY73$"_9MV!\P[
M57DN!(VXKC%*PW99GP3UYIEGI=_JEPT.GVD][(!DK!&7('KQ6_,TCS:LN70]
M^_9[^ _A/XD6;ZIXCUZVL8,E1"S -P<5^@WPF\#Z!X1\%IIGAZ^AU2TC.4_?
M9Q]*^'_@C8?">]\+0Z1XQTK5(-79\%K96SGWVU],>#/@_P"'?#6GC_A'O%>H
MV^F.=_DK$0R^W3K7!4U=V=^$M=.*5^_4]^\.ZC)I]\8;I3 \B[55C6W+J&US
MDUX'<7BZ1"/LFO76ISQN&7[1&05_'%=_X=\7IXGLPR,JW:#$D6>?K6#MLCMG
M3ES.<MCO/[4]ZCFU#CK7*-J+QG#?*:1M4/K2L-4SH)+[MFJ=Q?;<_-6/)JH5
M36=<:MN8\U2B6HFG<Z@%R2:YV_N/,D#+ZU/+()+1Y6E .<!*S@WS L?E')]J
MZH0ZDN2LSP_XCVT=KXBU !1AOF/UKPK5K?[5>3G.$4U['X]U8:GJU],&RC2$
M#Z"O)=281M,.@)KZ".D4F>>MCDA:YD=!T-6=+7['/Y3]&Z&K4-N6?..:EFLV
MCDBDQT/-;T9:V./%127.MT2-;BWBD=A\N":Y*-O,D.#@9K=\3:TMK:B!6S(_
M4>@KD5N7;[HQ7?*2V/@\8U*I9&W'$B\B0A_0]*5L%OF;-9L,DA^\>:L+(U*Y
MYQ:#87K@4R2<;2,U7DFR.214;R!5]:8$OFCZFGJ7X.:BAV\-^=2^=_=7-(">
M.ZEMI$D1VCD4AE93@@CH0?6OOKQEXP7XN?!GP'\<;<"35=* \-^+TC'.-P"3
M-Z#>ZM]+D?W:^"-/T>[U:]AM+2)[FZF8)'%&,LQ/85]3_L2^)5\+_$+7?A%X
MWMI;?P[X\LVTZ6WN!M\NZVL(F7/0L&9 1SN,?]VL:ETN==!-*2LSP?XS>$3X
M9\92W<'_ "#;\^=%(OW>>2*XC]WD,#D5]!ZQX8GL=<\0_"7Q@0-9T6Y>WM+U
MACS%',;C/9D*L/9A7A&N>&+SPSJT]A?H4EB.!Z,/45K?2Z)@_LOH4I;AI#MC
M''K1;WC6[C'*]Q41R%^3@YI\5BS9+-M'6A7W.B,G%J2/4OA)\)9_BM<:@RWZ
MV%K9Q;VF9=V6.=J >IP?R-<:]K'HFJWEO<@330NT2N#QP<9KUS]G75#I/@OQ
MJ]OS-"L4HS_LK*:\-NIC=74LC-EF8DDGOFNA+2YU0Q52O.HGLK?\$MS3>;(Q
M4?+GI4'F-N.U#D4SIP3S3&N2H.WFL).YR-W99@9I@2WRFG2(J=3NJFLCOPV0
M?8U/]G#+EBWXFE<0C3)P,$GZTN6.,#%'E+'C:.O>D>01J2!FEKU 5N1UIFP?
M6FJY8#(Q3PP'%/<9-'\L>,8&*1FPHI%;MFHVW;B*M,T0Y1NS75>&]0^T0FUD
M.9%&5/J/2N5C^4 5/;W<EI<QS1\.IR*N,K,Z\/6=&:D=->V_ER-W!K[2_P""
M;<?ECXB?]P[_ -NJ^/6>+5+%+F(CIEAW![@U]A?\$Y;N**\\=V;-B>:*RE5?
M54,X8_FZ_G7/BHVIL^CQDE/#2E'R_-'VY#4Q.:;#&.I..<"I7CV\5X=SY'E:
MU"%O+D!J1H1(<CBJYJQ!<;6 [UHNQ(?9_5J:T([&IFN%D;&W:::SA>O%5895
M92M ;'3FI&PS<]*3*Q\BE;41'GC)J)CN-.=]U,]J38CQ_P#:V^#6I_M!?L^^
M*O &C7UIIVI:O]D\JZOBWDIY5W#,V[:">5B(&!U(KUR&/RX40G)50*DV[>3W
MHVU!2&FK]H1# 3_$U4E7+ 598T"D3QKYS8KPOQ9X;L+?Q%J9DM4WRW4LGF'N
M6<G^M>Y6[@-R>:^4_B=XXGA\0:D8BTD9NI3&0>-N\XKZ?(:+J596Z(]/+Y^S
MFVSC?BIK&J>&+RVFT^14M4;]X%]*FTWQS>:QI\<UG(AFXSNKA?B)XUCOM+,#
M',[]1FN.\&^*'TJ;RV<JA[YKZMXJ-/$*C-^[8]>>*O4T>A]+76H7&K:?'&9]
MEQCDK7&>,K>>:SD2<[]J]:YNU\72),K1SAAVYK3NM=.H6,YD.YBIKU'"/*W'
M56.RGB+Z'C&I6/VI98I!NCY&*\2\3>&7T75BH4F%VW+_ (5] 6\8FN9<CC<:
MY7XC:$LVF/.H&Z/D5\-6BI['GUZ*E#G1X]'(8R5"XJ2-BSDYR/2AV7M^="L%
M!Q7%8\JYT&C8CN(BQ&"?6O:Y&L-9T>PT^X6ZBTJ.S:5[RWQ_K=V2F2< YQZG
M@5\^PW)7&T_-6[8:U+(T4$LYCA)&XYZ5Y6/P*QD5";T_,^XX=X@_L.4JBC=M
M:/L^YWFN7VGZE?QVMG"8+&(!8X2^[:/3-=K;:)9^$=(D_=;M5N+036<+PEQ*
MQ8 !?7COC'O7D^LZU;2ZI;Q:6H=(T +J.6/<UU%O\1UM;6&.[MXIIX0OEREF
M5UVDD#*D9&2>#D<UY^,PM;V*IX?3_+^MCZK(L^P4\9/%YA\3U[]?UZE_5M_B
M+1]6NKG3TM%M6C$3+'Y; ;I48..NXE%.#SCVYKQK4=L<S8 ZUV7BGXCWFN1^
M7+.QB!R$SQT _D /PK@KJX\QB<UWY=AZF'I*%25V>)Q3FF%S+%^UPL.6)7F;
M=TX-9TTDBMC&:N.P]1BH\Q[>F37JM7/AKE'[4WO3A=/WXJ3[TF0 /K4;,.AQ
M2L^XM1T;;0QSDFI+>^N8=ZQ':'ZGUJLS;3@&GL6Q\IX'6H<2U*W4FEC>\95=
MMHSR:@N(5M]RQ2$CUJO,\Q7 .13-\FT@YS4:7U+<KHCCM,MDL3]:N0QJO;M5
M)[IT& ,FG1W4ACY%7=$<R1N:=:K-)&CR+&CN Q/85H^(+#1X;A5MG-P<?,1T
M%<HMQ*W3-'GS*W0T71DX\SNS>L_*MHY(XD&&YRW44[(W$-\F/6L>WDFSR<<]
MZ[+5+&&^T.UN+4B2>, S8[4-LIS5.R2.5NBT%RKJO ^8&I+K5FNF,DIRYZFJ
M30RI(0S'KTJPMJ'7!%)WZ%QN]2:&Z5L'.,]*>\BM(V6[5%;Z->76%@MI9AVV
MJ2*Z?3_ VK7=JL?]F3))G.YA5J,I= YW'<PX9E6W()S3KN-85C*MO#C-:USX
M(U?35VSV,@'7*C-9AL)865)XG0 \;U(JN5K<KF<K<I4Y]*C8'DXJ_=*GF' V
MC'2JOEJQ.&Q3L%V5U4<YI?/=73=RB_PGH:D:(C'!/I44T3=U(HY4+FZ&U9:U
M)-&RR6VZW49VQ#&/QJ?_ (2VXL=/^SR:?;M$RD(S#YN>]8EM)<)&T4 <AOO!
M1FM2SB-]:M%]FEG XX'W?QK-HY)4X;LP&U*[C_U<QCYX*G%.BU;4&^[=RY]=
MYK=MO"L5Q.(Y9/LX[[L9%5Y-/MM/D=[>Y69HVP%(ZU2&JL(Z)F7)JM\P(DNI
M6_X&:I2,\IW.S.?]HYK;UBW^P*D[^1<"<;ML9Y2K_AE?#DT;MJ)F$JC(3. U
M-O2Y/MXVO8Y:WTYKR0*J]:L:AI*:>Z*7$C,,G:>E=UK/B;PU8V/EZ=IZR3'C
MYN,>YK@99A=2.Y4)N.0HZ"LTK]"X3<];61 MLC9Y-20VOH2*>F%[5(D@%5R(
MUNAT=J&ZL?SJP+,'& <FHUD&:E6=MW#4^5#30Z72)84WM&=OK525=HYK5F6Z
MCA_>;PC=-W2LJ8"08;@T<JZ"YK[,KEANZTTD'H:@FA9&)!XJI(SKT:B]C-R9
MHB/=_%4BP^]94<\PZBK<=U(,?+3NB.9GN'@"/'A.P[_ZS_T8U=%L[UROP_N'
M_P"$2L/E_P">G_HQJZ W#>E<[DKF3;ZGJ_[5B;O^"</P_'_4S'_T._K\Z5@]
MJ_1S]IQ3-_P3C^'^>O\ PDA_]&7]?GLMO[5PK=^IRK=^I06W]JFCM<]JOK;^
MU6(K7VJS1(HQ6>>U6X]/)[5HP6N>U:4%CG'%:*)JHE'0]*$VJVL;79L%=PK7
M*YR@/4\5]'^$]#D\&V%K9Q7K3NV[9+)A7?G)V@DY XKPI+#CI6A;ZA?6FJ6M
M^;B66>V8,AD<M@#MSVKT\)76&?-RW9-2C[16N?2$FL1:-H-W,) UY,#$8L'D
M'N>V.AQZUY+KM]*Q+/\ ,^.:[N>YCUK3+>[MSNBN$#K['N/J#6!?Z0EQ&0P(
M."/K7V=/WDIQZGAU(V;BSR#6[N3<PS@5SZK).VT9]J]1U7P'=<7"P>;']X #
MFHM>TW3+B"-M-L&A:, .O?..:B2J/XG8Y?91W1RMAX#U+4+%KN.!V@7[S*.*
MN>&_!(U36;2UFR!-*(^N,<]_:O4_!'B2^MO!^IZ%:6(N9KQE*2,X C Z\$>O
M/X5S[6M[HNI0W,$HBO;=]P; ;#=^#P::IIJ]A<MC.^-W@70O _BO^QM$NEOE
MMT FN(FRC/[>V:\^L$:SOHY_+$FTYV-TKT+6;6]\2:I<7]XYN;RX??+*5 R?
M8#@?05J^'?AV+B<27"!(5&YI)#@ #KD^E<DZ<MT:1BFSG]+\*:E\2/$"_9K&
M.U$@5?E^5 % &?TKUZ31O"_PE\*W4MU#%J-W'%N:23H6Z!0/K61J?Q>\/^ X
M6MK8QE578AMP'DD]3D< 5X'X]^)EYXUN"&!M[-6W+#NSD^K'N:YJF(I86#UY
MJGY'9&G=Z;?F:?C7QI'K6D6EK#Y0+-YLNT9;H,*3[<UQ7F#UJ@;CWIOVGWKY
M;$5I5Y<\]S:RCHC0::JDTU5I+KWJK-<9[UQB%N)NM9\LF:=+-FJS/30ANVEI
M^*3%:DV'*:D4U$*>M5<"9:EA3<XJ)35B-N15$GNGPE80V49QSBO1A??-UKQS
MX;:TL,*H6Y'%>@M?-NR#D5YE:#;/L,NJ1]FD=*;X8ZU&UX/6L%;J1O:F&^VG
MYVXKAE ]Y21JW%]MYS6)JFN1B-UW#<>E0ZA>EH_D!(]:PS )FW2'Y:R:Z%QF
MI?"<MXBNS>3$'&.Y]:@TNX$*[-W'K6EXCMX5C)0 -7,6,VV9@YSCH*Q>ITIV
M.FM;W[--O4Y%:<VL&Z540<GBN>@M9=0D AP!WKI=&\'ZE-<Q?N\H"#NIQNC*
M4M;'O?P@T&-+%)I0"<9R:]@M=NT!1@5YSX,C;2])2-N#@5V-C?;L<UI4;>YG
M2CI<[B/2XVL2^><9KE]0C5L@U:CU:3R=@?Y:HW,FY2<YKG?D;TXRC?F9RFL6
MJ2*RD<&O)_%FABSN/.1<8.:];U>0*&KAO$:BZM6'>NFG<NHE:YRFGZN(XQ\U
M6YO$!"\-7,"SD61P,@ U'+'-R,$UZ,))'-*/,6=5\0':<M^M<#KFL"1CS6KK
M$<BJ<@UP>JL_F'K70YI[&?+RE?4M0,F0#5>TF.[)-4IF);%3VJEF %3I8B[;
M.IL29(Q78>&;@1_*37-:'ILDT:D"NLTW26A.X\&N3G46=D:<I*QJWDP52:Y'
M6E6XDQUKJIK,SC&:S+C0V5\]:WCB(6L8U,)4O<P(-*39TK)U?2]G(KL&M6AX
MVUBZY\J\BNRF^;8\ZI'EW.2.GEE/%4+6T^Q:M&XXR<5TD<BLE95QB;5(43DY
MKI^P[GEXBFN:+6]T=PH,UD3_ +->1Z^-NK2@\5[5:6NVQ&?[M>-^+HS'K,A
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M6>E&4Y?"K'5Q_ _0;/Y;[QC:1SC[R1X./UI\?P6T*1@8O%-K,OHI4'^=>/\
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MB+4O.W '-1WFM%E(W5A32/<R&B35BU$U_#N-V378Q.OEX]JX;39/LK#-;?\
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M=5)^E--\V,")B?I1==2E<L26B-STJ%K5!SO.*C^TW$GW8ROX4L,,C-^\;/\
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M,)!+GEK<];"T4TYL9XB\?12W#!W53]:Y6]\0+,VY)@?QKRS7(;^._N&NI'0
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M53F:G>=GO4$K9JG$&SZQM?B+=?"?]GO]F[Q=:;B^E>(-6GDC4X,D7G[98_\
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MK,Q)/ Q^%9VVM(QLK 1;:-M2[:3;56&2QK5A5%0+Q4RO3,B8+3@M,5JD5JH
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MKE/A_J@_X16Q)7.?,_\ 1C5TO]J9&S=@&N=NTKHS=STK]K^Z6Z_X)_>!YE&
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MR2?^W>OT;N)O,<X^Z.E0T?7*I,8J+<NK/SBC_P"";WQ(3_F-^%3_ -O=S_\
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M7-+74!\*\G&R+4L?C]D_PKM]HXUX2?2_Y%*6J9\S_L-S _M2^ !OR3>2<?\
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MI@$ C=DG:*\V-1VBU*[?0D^3/V7/@KIOQ[^)S>&-5O[O3;46$UWYUF%W[D*
M#Y@1CYC7!?%;P7#X%^*'B?PO8RS7=OI6I3V,,DH'F2!'*@D 8R<=J]__ ."<
MK!OVAWQU_L:Y_P#0HJ?X,\.V?BW_ (*-7FGWJ++;IXHU"\*,,@M )IDX[_-&
MM;N3C.5]D@-7P5^PCHWAWP7;>*?C-XUC\$VEP 4TZ)XXYDR,A6DDR/,Q_P L
MU5B/7J!J1?L2_"3XL6%Y'\)?BLVH:U;QF3['JDD4V[_>")&Z+D@;]K 9Z&O/
MO^"AWCS4-?\ VB-2T.XE<Z?X?MK>WM8,G8#)"DSOCU)D )[A%]*\$^&?CS4O
MAS\0- \2:7*\-YI]Y',-A(WKN&]#ZJRDJ1W!-1&-24>?FU'8H^/? ^L?#CQ9
MJ7ASQ!9-8:MI\GE3PMSVR&!Z%2""".""#7H_[)?[.</[2/Q&N]%OKNYT[1K&
MR>[N[NT52X.X+&@W C)9L\CHK5[Q_P %4O"]K8^-O ^O0QJEWJ5C<6LY48+"
M!T9"??\ ?D9] /2M_P#9=M_^&=_V)?'/Q.E'D:WKRR&P<\-A2;>U&.O^N>1_
M=3GWI.HW24ENRNAXE^V#^Q[I'P \*^%_$WA;6KSQ!H>JS/;S7%UY9".4#PE&
M0 $,HD_[Y'K7/?L;_LV^$_VE/$GB+0M?US4]&U&QM8[VT73_ "R)H]Y27=O4
M\J6BQC^\:^D/@C;M^T?^P+XG\#2G[5XA\,F068;YI"4/VBWQ_O?/"/8&OE']
MDOXB'X4?M">#];EE\JPENQ87I)POD3CRV9O92P?_ ( *<>9PE&^J*Z'CWCOP
ME?\ @/QEKGAR^_X_=)O9K&;C&6C<H2/8XS^-?1GP?_9#\/\ BS]E?Q1\8/&&
MMZII*6 NWL+2R$82Y6)0J9+J3EY]T?'I6[_P4B^%<GAO]HK^UK*V9H/%5I%=
M(L:];A?W,B =R=L;'WDKUG]N*XC^!W[)_P -_@]92*EU>)%]N$9X=+=5>4D?
M[=PZL/\ =--S<E#EZ_TQW/@#X4_#R^^*WQ+\->$;/<L^L7\5H9%&?*1F^>3'
MHJ;F/LM?:G[0'_!-WPS\-?A#XM\4^$?%.K:YK'AU%FN+"Z\DJ(QL>4-L4%66
M%_,^F/6J?_!+OX81:A\2/$7C_4%5+#PW9&"":3A5GF!#.#_LQ+(#_P!=!7H_
M[%_Q\B^,'Q\^,6@ZV?M&D^-/-U"SMK@\>5&/(\G'J;=HP?:&HJRES/EV0FS\
MQ=Q]*^HOBE^R;H/@/]D?P9\6;36=2N=8UQ[59K&81_9X_-21CMPN[@H,9/<U
MY!\5_AK/\+OB5XE\)W:L9=(OI;5788,D8;]V_P!&0JWT:OM[]H2'=_P33^%B
M 9Q+IV!_VRGK6<G>-GNRKK2QX!^S!^R?H7QR^#_Q%\7ZKK&I:=>^&8Y'M[>S
M$?ER[;=I1OW*3U4#C'%?,K6N[GH:_1C_ ()_VKQ_LQ_'!2I4O!/C/_7E)7P5
M'H-Q(<;:JGS2E)/H5&,I-V1SJV[K[U]T_LP_\$_?#_Q=^#^C>,?%WB74]!NM
M9NI4L;6U\I5>)253[ZDEF*2$8ZKBOE'PM\-]4\7>*-(T'3X]][J=W%9P@CC?
M(X4$^V37WU^W!\2W^ [?!?P/X3W+%X6DM]9>%3C<EOB&W5L=0P$^[/6IJ\UU
M"&["49+2Q\-_'3X97/P0^+WB7P9-+)<1:;<[;:>4 -+;N \3G'&2C+G'&<UZ
MG^QG^SQHW[2GBS7M)UG5;[2X=.L5ND>Q";F8R!<'<#Q@U[/_ ,%,O MGKB>
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ML;W2*9XU9L<9(4$XI?AKX3@\<?$CPIX<NII+>VUC5K33Y9H<;T269(V9<\9
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MGM+]&QR#6K#=)BO-K'4E,8:.3/MFNAT_4O- RU=T*D*FQY\J;CN=I%,K=ZG
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ME:_ W> \FI11K5+,L-_,*>4XF/1'CRV[&K$=J!]X<5[3#\--&T2"5IKZ.XD
MXZ?XUP6N1V=NT@1%XZ$4I9IAHJZU-:.28JL]TCSW6K55D#+Q7HG[,N@IKOQ:
MTN.092$F8YZ<?_KKS_59=\C'M7I'[+>K)I_Q6M-QV[XV4'WR*^9K8IUI2G'2
MY]6L$J%)4V[V/T%EO1T!XJG-?@9YK!FU7J,\UF76L=?FKQ7$]6G'0W+K4AS\
MU8UYJ.,X-8]UJ_7FL:\UCKS4\IUQB=5I]J=968+(%91FO/\ Q S6]S+&QY4X
MJU:^*I=-D=HVP6&#7+ZUK1NKEW8_,U.27*:TXS51WV,35)LL<UFV/A^YNKR.
MY>VD%N_RI*4.W/UK:TJP&M:DD)Y7.6KWW1=;.B^&SI0M+>2VV_*70$K]#4P5
MW<C%8B5)*,%=GQQXW\#OIUV"TOVB:;+DGT':L6]T.SM+&WN;NW$\4RX95'W3
M7T+X^\-Q:PT<\0S-#NPJCK7D>CW20W4:7T.Z".X,<L;#MG%:R>FIT4+U$GU/
M.-/O#H.L6SB(2Z?:RK(-R]!Z5]?>$_$EM)_9]VH$^C7R@-M_Y9M7FWB+X1)X
M@@C7PW ;M;Q@-B_P9]?:O?/@S^S/-X+\-&SUW46N8Y/F6V4?ZOVS7&VY/1'1
M7K4:,5SO5DVH^*-/\,;-RS&V8C:8QG&:].L]02;3K9XSF-HPP_$5C:E\--$6
MR%NZRNB]-QS4\_EZ=##!&3Y:(%7-$+W=SR:U2G6Y>2_S-47FULYK?C\>7,=A
M]G.UQC:&-<-]L![TUKH>M;1<H[')4PU.M95(WL7]2NQ<,6( SS7/WT*2 Y J
M6XO.N36=<7@YYJ>6[.V"Y5H8.K:3&V2%KFY]+"L3BNNN)/.; /6JNK:?#:VP
MW3J\S?PKVKIIQ-'4<;)G*VMM^\(Z@\$5\^?$S08M+\:7EK I\H8<#TSVKZ7M
M8%MX7FDX1 6+'T%?/?BR^&M>(KN\/.Y\#Z"OJLIB^:3Z'R6?5(J,5U./M])=
ML$\"KJZ:BCGFM98N.!2/"?2OJ3XAW9E_95Z!:<MF.XJS(IAY(Q5"XOCR$'-,
M5B&\*QG&<5053))_LU(RF1\L<FIU7:O2F5L)E$'S4QKQ0<(,T31HW49/I1#8
MEOF*XH<BHP3W/I?_ ()_S&3XSZR#_P! ";_THMJ_0&O@#_@G_&L?QGUK^]_8
M$W_I1;5]_$U\MF'\=F%2REH+0*2EKS3,7=2YIM)NI@/I:9NIPH <JT\**:*>
MJYH$+3EBW4]4 I^,4A"+&%I^!3<TF30(=36HIK&@8UJ2E9A41;TH <33-U')
MI0M QC&DP:F\NE$= $06OR6AT5L#C]*_7#97YF1:"_&[D?2O9RZ7+S_+]2HI
M/<XG^P]W49J2/PN\A&V+CWKT.WT18\$IS[BM".RCC7[H)KV/:%>AYS!X-$?S
M,H9OI6K;QR:5I\L,:E&E_B KK]L,;8. :BF6&12"%J.9/1F52G[1<LMCD+W7
MM6;38[%M\T2C"[B< 5R7BBWU63PK)I5A&%CED\QV8?-GZUZO;V<$DF" <5J?
MV=:NN"BXI\T5LCRZ^74:CYK69\VP^$_$$UK%'(598UPN3G%=?\-?#-SH^I-=
MW]A]KE5@8Y?[GT%>S1:38[AD1KW.<5),L$; P(JQJ#\H'>B59R7*>=/*:.ED
M<]JOQ \1VMQ=1:?;?9[)H]C1M(3Q_6O&+CP+]LNF>X5F>X8NWH37O$UFMSYI
M?A^GU]*Q9-'B0A@/F7U[5$9**LCTJ.!IQNGN>=Z1X&M;$_NTP<<]JV[?PQ!
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MS01VT3RB62-UE=]H()SY<!\LD9'(&>1GQSQ%^U1\3KJ'S-.\;ZA;M_=58_\
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MB[^!=[\4TO+(:'::ZN@/:LS_ &DSM")@X&W;LVG&=V<]J\],U0ZAM&A?8O\
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MIY\=%Q\RL3]:Y'RA2[14/ 4/Y32.:8G^8[/3_%ANK@*B,/4UN2:Q(ZX$C_\
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MI?W+*2R-5WP;HM[XMUN*R@7*_>D;LJU26M@>UV7]%T.YU1BT:,(AU?%=G9Z
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MUT/QF_:.\*? FZTJ#Q);:Y</J22/!_8^D3WP 0J&WF)3M/S#&>O/I7F?AO\
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M_"&L>$/&FI/K<VE^*IKB%]*U&0 32H85/F1N0"5X/RJ!C&6^L^*^=/B)\?\
MQ_J_QJU7X6_"#POHFL:WH%C!?Z]K'B>]EM[&R\X;H8 L2L[R.GS9Z ?C@&<C
M\+?V3?B%\&?C5I'C[2?%FE^([SQ%;R0_$)]8$L9NY6G,RSV2("JE ?*5&(4(
MHXRQQ]<8KQO]F?X]:A\:M-\5Z?XCT"/PQXS\(ZO)HNLZ?;W'VBW\U0"LL,F!
ME'&< \C!Z\$^ST#&;:,4ZD+4P%HS3&>F[J0$NZC=46ZEW4Q$NZ@-4>ZC<*!$
MOF5^=;:_NZ"OT/W5^8W_  D4:KP:]7 J_-\OU Z234KB3@ BJ<K.W,DF/;-<
M_-XF';-4+C7Y). <5ZO*--G2R74,.3W]36?<:HLP('3UKGY+S=\TTG']W-4[
MK6HU7"MT]*=BTV;ZW4>?OFIUND/ D;\ZX636CNX.!4MOK>S)9B2>E*R-;2:.
MZ_M,1KM4X%-_M<=2:XQM<#?Q4W^UQV;-4HF+B^IV+:T%[U6DUI3T-<A/J 89
M#[367-K$T).6!^E5:PXQ;.[EU?=SN_,TRWUP-_%7GD^M2R#:&Q^=56UYK7[\
MBKWQFDVC3V4CU^VUE>F_]:N_VVJ_Q#%>+P^.K.+/F7)##_9;_"K]MX\T^3 %
MUS[JW^%9\\>YFZ3/5I-<ST.:2&_9F!=\9/"BO/U\860&&NH WIY@!_6K4/BW
M3]NXWT*D= 7'^-',NY#IL[^34MS8!J(ZD.0*X&;QK9;@!>PD^JR#_&H_^$KB
MY*R;AMW$CT]:SND[MFJHSDK15SN)M2#<9J&34., UP,GC&V7YO-4$_WCBID\
M50SJ2)EXZ[3FNJ\7LSF=*<79H[!M0 XS43:D.YXKD3XAM\_ZX,?3-5I_$D"@
M@SQK_LEQFJT0N1]CKIM3'8\5F7>J]<'-<?>>+[9,A9]^.R\UB7GC(-Q&"?=C
M@5E*I"/4UC3D==>:YMD*[JY[4->VMC<%^IKE[G7IYLG=L'HM9DUPTO4US2Q*
M^RCHC32.IDUKS& \Z/\ [[%,FO)%7+.F#TP<UR1J2.X95V9^7M4?6GV*Y4;3
M7S2$_O0!]*K-,FTDLQ/TQ6<93G@TGF'UJ'B)L?*7/W4C E<^NXU[E\#M#CL=
M%N;YE"S73X7Y0,*/0UX);R 2+DX&>:^I_ .CMI_A?3D9@Q\H-E3D<\UW8'FJ
M3<I/9')B-(V-QK52V<9J.32+=FW[!NJ[N4-MS\U6[)8_M"F497N*])W1YRE)
M&3]E&W[O2F0;[.8.O3N*Z;6+FVEVB"()Q6*MJ9Y51>K'%*FVI*2-*<W":<=S
M9TMKO4;4S0)M53MS[U;N&O[U)+?4PN$7Y& ZBNHT/P^]IIJ16D1EF89V^IJ>
M\T.XDB,=U!Y<N.5[U[5[M7M<^_I0YDG+<\)U32HX;IUV@\\'%85]IZNKAEW
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MC.HT_P 626^%8FMZV\7I)C)KSL4]69>0:[(8J<3!TTSV;2?$$<N-K9KK]-U
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M,UG@:W-02[&N94>3$.71D*S!FJ['(NVHTT=\U.FER5V.1YZB7+-@S#%=#I\
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M </U9U5[96B<6)QE.$7[.6I]4^&=-LK&.*!$0$\%F%7_ !+HEHJX8QR*1DX
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M*W1:D739?[M4DPYFA\=X>U6X;@M4$>GN/X35Z"S<?PUHD2YLMVN6(K9M8>A
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MG8^'X/,NIEB'9<\FO,?%GQ"N-9#6]L3;VN/N@\GZFN2U#5[G4IC)<2M*Q/\
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M-*OV+>K#;2^6>PI/MP[)Q2?;'/0 5RRS>DMD>S3X$QDOXDTB00-_=-'V=O7
MJ(W4C=\4QI';JQKDEG/\L3VJ/ ,/^7M4\FHHI:^D/P,6EI*6F 4ZDI: %I:2
MG4 %**04ZF 4M%+0 M%%+5 *IJ16J.EH G!IDD(>D5JD5J"XR<7=&9<Z>&Y
MYK/DMFC)R.*Z7 ;M4,EJK5G*"9ZM'&=)'-;*3;6M<:?W Q5&2W:/J*YY0:/6
MA.,UH0QRO$?E:KMOJ[)C=5,I2>74<THE2I1GNCI+75E?&36A'<K)CFN-3<C<
M'%7;>^>,C/2MHUNYPU,O4M8'5C!KMO ?Q.U/P'8WMM82*B7((;/TKS2VU+(
M)J_'=+)BNF%2VL6>/6PDXJTU=%K6+A]4O)+B4[G<Y)]:RY+,'M5WS!2<&F9Q
MG*.AD2Z>#VJG-I/?%=(%'I2F!7I<J9U0Q4D<<VFR \#-6=/TEGDY&*Z?["OI
M3X[<1*3C!HC35[G?&MS*[*_R6,&.^*PKG5'60[>:T]14R9&36(]FZL>,UG6D
M]HG7149;ENTUR2%N<UN6/B7:P*R%6]CBN5\G;2[2*XO:2B=KPM.:U1ZKI7Q
MO+3;LN"P]":ZNQ^*UPJ@2'/XUX''<20_=<BKL.M2Q_>Y^E=4,5*/4\^IE<9?
M"?2NF_$RWGP)3M-=)9^*K.X (F7FOE6#Q-MX8D8K5M/%3+C;,1]&KMCC.YYL
M\NG'8^IEU2&0?+(I_&G"\1OXA^=?.%IXWN8SD3GZ$UJ6_CZ\5LF7/XUT+%09
MRRPU2/0]]\Y&[TC,OK7D-G\2I44;^:W;/XC6\P&]L&M56A+J8\DH[G?MBH7X
MKGK?QA:38Q+^M3'Q!;-TF7\ZOF0&J^#5.ZA#+5<:DDGW9%(^M2JYDZFJN44&
MT]6;)I\6EHW 6M**U$G>KL,*14[LAM&#)H[#.!6-J6E/S7=R,NW%9EU:B8FK
MBR>8\\DTF3/6H7TEN]=U)IHYXJN^F>U:W&I'"2:,33(]#W-TS7<_V/YC8 K7
MTCPNI8,XJ78UYV<1I_A-YF!V''TK>3PJ88^%YKOX]-B@4!5 J5+-7_AXK%2U
M'*>AYI)HDBG&TTD>@R,?N&O36TE&_A%(NEJO\(KHYSGYC@H?#;]Q5E?#C>E=
MPNG#TJ:/3@.U92J]C2*.)C\-GN*G3PP&_AS79_8EZ"KUGIJY!(K/VC.A)(Y"
MQ\%K(P++75:?X7AMU'R"MRWM53&!5M8Q4.39+D9L=A%#_"*5S'&.U7)HPP]*
MH36XYR:FX)7*UQ=*,XK+N+AFSBKUQY<>>YJ!+5KAN!@4KG5"!B7"O(2*S[C2
MFN%*E<@UVL>C#C-3?V,M0]3LB^38\\TSP+:P7'G&,%B<]*[C3[<0*JJN *NG
M3UB4 "ECA*MZ5G&*CL:2FZGQ,T;(9Q6NDRPJ.YK(M\]!5Q8R>M;I'#.Q.UPT
MC4X25$L5/VD55CG?*.:7BJLTO6K"V\DIX%6X-",F"U.Q+E"/4YZ53)G K.N-
M,FFSA37HD.@QH.5J8Z3&O\-3H.-;L>8QZ+(G5:E_L^2,9"UZ#)IR?W:IS6*\
MX%2;^TYMSAFFEA]:9_:$C< 9-=1>:6K?PU#:Z-&#G;DT&W,HJY@QVMS>>J@U
MI6?AT* 7&3700V*H.%JR(0.U!Y]6JY&7#I4: ?+4DU@FW@5?V@=*CD/!IQ9Y
M\KLY75-/4*3BN \06@7/%>E:O)\K!1DUQ.IV;3,01DUT*5D:T8ML\QOM/,TA
M %85Q9M#,5Q7J,FAM#ERF:PM0T=96R%P:VC)=3MG%R.2L[8LPS76Z/:[0.*@
MMM#=6!Q6[9:>Z =J;D8\C+D2[5JK><C%:*6K8QUJ5-(>;^'\36?,4J;.7DMY
M)#\HXJQ::2S<L,"NBFL[?386EN9%C51GYC7G?BSXG10J]OI:_.#CSF''X5G.
MHH[FZ2@M37US6-/\/JOVA_F/ 1>37-3?%J.WC*VUAE^S.>*\\U#4)=0G:6:1
MI';J6.:ILU<,J\GL2ZC>QV]_\5=9NLB-DME(QA!DUS=]XCO]0;,]W+(<8Y8U
MDECZTPL:P<Y2W9FVWN3M+FF;ZBW4G-222;J;G/6H)[N*W7+N!6%?>*0I*P#/
MO42G&&[.NCA:M;X4=!),D()=@*R;WQ)%#E8OG:N9NM0GNVR[G'IVJ%:XY8E[
M1/=HY;".L]6:<^IW%X?F? ]!3$456C;I5B/+5QRFY;GO4J*BK11]H_\ !*S_
M )."\0_]BO<?^E=I7ZHU^7'_  2HTRYD^/'B&X6"0P?\(U/'YNT[=QNK4@9]
M< _E7ZKQZ>D>#/(%_P!D4D?(9PN7%->2**HS\*"?I5N'2Y6&Y_W:_P"U4_VZ
M*W7;!&/]XU5FN))OOL2/2JL>$Y$[1VMKW\UZ@DN';.WY%]!7G'QL^.7AGX!^
M$X=;\1M=W#W=RECI^EZ9!Y][J%R_W88(@1N8X/4@>_2O/?"'[8-I?^.M"\*>
M-?A]XM^&=_X@D,.C77B&VC%K>S8R(?,1SLE/9&'?&<D T9\S/=X]:TZ;5I=*
M2_M9-4AB$TEDLRF9(R<!RF=P4GN1BKM?#/C#XQ6'P=_X*">-+N?1M9\2ZIJ7
M@ZPLM-T30+0W-Y>3>;O(5<@*JHC,S,0  ?8'WKX'_M2:5\8_%^N>#;[PQKW@
M3QMH]NMY<:#XBMUCE>W8A1-&RL0R9903Q]X8SUH)/;**^?\ Q9^UY:6?C37?
M#/@GP!XK^)MYX>D\G6KKP[;QFULINI@\R1U\R8=T7..F<@@='H?[3WA#Q1\"
M=>^*FDK?W.CZ':W<^H:;)"(KZVEMD+36TD;'"RC'0G'(.<'- &-^W!\-/$OQ
MC_9B\8^#O".GKJFOZD;+[/;-/'"&$=Y!*YWR,JC"QL>37M]C"MK9P01HL211
MJBQH %4 8  '05\GS?\ !0_0(_#=GXPC^''CJ;X>2>2+KQ:NGH+2V9RJMQOW
M.J.WELZ\;E(7=QG1U;]OSPWHK1:W)X'\82?#1[Q;+_A/A8*-,)9_+$RY;>T.
M[CS-O/8$X!1II8^IJ*\T^.'[0/A?X#:#IM]K2WVJ7^KW L](T31;?[3?:E,<
M?)#&",]1DD@#(&<D \/X)_;$T[5O'NC^#O&O@;Q5\,-;UPE=';Q):HMMJ#C_
M )9),C$"7D?(<<D#.2 69GNJZUI[:PVDK?VQU18?M+6(F7SQ%G:)"F=VW/&[
M&,\5=KY<TV1(?^"E&O2.P1%^%\3,S'  &I#))KU#X1_'G1/C[>>*(O#6E:E<
M^%M+N&T]?$LRHECJ4HXD6U(;>ZKR"^T+Z$T >G6MW!?0B:VFCN(B2!)$P=20
M2",CT((_"I:^6_V<_'OPR^$W['^J^-_ V@:WI_@G2I-1OY-.O9EFO7:*5DDP
M3(5Y,?RC<. ,\YJIJ/\ P4(T.'05\5:9\,_'FM^ HD1[WQ59Z:GV.#IYFTEQ
MYBQL2K./ERK8)') /J^EKSCQY^T%X*^'OPGM/B+J.I/<>&[^&WETYK*(RSZ@
MTZAH(X(^"SN#P.,#). "1P7AG]L"UG\9:!X>\;?#SQ=\-'\1S"VT6_\ $5M&
M+:[G(RL#/&[>5*W9&')XSF@#Z#HKQGXJ?M,6W@'Q_;^!/#_@[7_B#XSDL/[4
MGTS0DB"VEJ7V"2:65U5=S<!>2>^,C.W\$/CUHOQPL=;6STW5/#VO:#=BRUC0
M-<@$-Y8RD;EW $@JPR58'! -,#TNOP0VD]Z_?"OP445UX?J;T^I'Y9]:-I%3
M 4;:ZS8@IVVI"@I *!C?+H\LU**7% $&WUI56I2M-XH'9B>6*/+IXQZBG9'J
M* LR'::4+4AQZU%]HB!YD7\Z3+4)/9$FP>E'ETT74/\ SU3_ +Z%'VRW_P">
MR?\ ?5%T/V<_Y62QL4(K0L[Z6UF26)S&Z]&4X-9!OK=?^6\?_?0IJZY9J<&=
M:?,H]32.'K2U4']Q]%_"O]I;5/"-S$M_+)(JG FCQD#'1AWKZ*_X7-X.^)ND
M[Y/)AU;& \9"ECCN*_/%=>L5Y-PM68?%-C"P9+P(W]Y2017=3Q_*TYZV^\M8
M6I+25-_<S[@:.*/)B*E3W!J"^OK:QC!GFCB4<[G8"OCJ'XM3V,*PQ:[.D:]%
M#,?Z5GZA\4AJ,G^EW]Q=8X^;.*[99M3W2U]1QRJFU?V<V_N/H#QY\5HU6;3]
M*D+R9VO< < >WOUKK[77&UCPS8S/G_4JO)SDA0,_C7R'_P )W89SND_[YKZ>
M^&>HV_B/X?V$]NY?"_,",8.<8_2ML#BGBIS3=] E1GA6IRARQ.H\%R1+KD#2
M'Y0U?3?AOQ?;::O[V-95*X%?*\$;VD@D4<J<UZ[X#_XJ;3Y/])6*>,?=8U[^
M%5'V<H57H;TL1&=TF>FW/B&*\D9LXC)X7TKA/&$\:S>=&,8]*Y[4M8NM-F>'
M=DH<9!XJS9ZO_;EF8Y4Q)C%>XL.H+W3H^L.7N6,6?Q88$+(/G%1W_P 09KK2
M6CE.,# %8>O:;<V-TP,;;6/!Q5K2?A[?ZY%YI!5#7G2KRDW!1U.*-6<Y\B6I
MYEJC?;+B60GDG-4(Y$MV4L^TYZ5Z]XF^%$6FZ:TX?$@&37E=QHJ23J'!)4\5
MY,L*HSO41Z#K2PZ]\M>,+%/$?@R52FZ6%<JWI7SM<J58@]0<&OJ_1]/6:PFA
M9-T9C.0>AXKXV\<>(IM%\5ZII\<47EP3LJ\'IU'?WKQLV4:5.%:770X84)8R
MJ_9>I>88-"KFN/D\77,G140_[(/]31'XLNU8'Y6'H0*^8^M4^YW?V1B+;H[/
M%*JUR0\97'>&+]?\:D3QG)QN@0CO@FJ^LTNYD\JQ/9?>=3MS1M]JYY?&4?\
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MO7??$;]H3X2WOBGX?>&7&E_$K6]:UJ!M*L-(^S:D]A(JL1J#9;$21#)\P'<
M6*YP<>Q:QH]AX@TRYTW5+*WU+3[E#'/:7D2RQ2J>JLC AA[$5RG@7X(?#WX8
MWT][X2\$Z#X<O9UV27.F:=%!*RDYV[U4';_LYQ[4KBY#Q#PC:V\O_!2GQ[=/
M$K3P^ [-8Y",E UPF['IG J36-L?_!3+070;6D^&,JN1QN U%R :^C8?"FB6
MWB2X\0Q:/I\6OW$"VLVJI:H+J6%3E8VE W% >0I.!1)X4T27Q+'XC?1[!_$,
M=J;)-6:U0W:VY;<81+C>$W<[<XSSBBX^4_/K]FO3]?\ "]Q\1O!U_P#M 2?"
M?Q%I/B>^N+[0[S3=-/VA96#+>I+<IND61<<Y. %Z KGKO"V@^'[;]DG]IS7O
M#OC74?'L6M1ZQ+>ZS>:='9P7-XEHRS2VXC 21&)'SJ,$@^E?6_COX)_#_P"*
M%W;W7B[P7H7B2[MUVQ7&IZ?%/(BYSM#,I.W/;.*WE\':"GA=O#2Z)IP\.-;M
M:-I M(_LAA((,1AQLV$$@KC&#2N-1/EOQM86]O\ \$NHX(XE2(?#FRDV@8&X
MVD3%OJ6Y^M,_:+LX(/\ @F7<V\<2)!'X0TD)&HP%V_9B,#VP*^J+CP?H5UX7
M_P"$:GT33YO#GV9;+^QY+2-K3R%4*L7DD;-@4 !<8  &*-2\&Z#K/AIO#FH:
M)IU]X>:%+<Z3<VD<EH8EQLC\H@IM&U<#&!@>E!7*?(OQ<URS^&O[07[-_P 1
M/%[>1X)BT2YT=M5G&;?3;Z:W7RY)&Z)Y@.W<> %8G 6K'[:'Q&\+?%Q?AA\/
M?!&M:=XH\<7WB[3]1LUT>Y2Z;3X82S2W3M&2(U5">I!(+$9"FOK?5O"VCZ_H
M,NAZGI-CJ.BRQB%].N[9);=D&,*8V!4@8'&,<5S_ (#^"O@+X73W$_A#P9H?
MANXN!MFGTS3XH))%SG:6502,]LXHN+D/C7]HWX1^)_CK^VYXC\'>'/%G_"'Q
M:A\,T74KM(B[SV_VQ]L Q@A6E,6_!!*!QSG!]\_8T^*-KKWP_?X>ZCHMKX1\
M<> @FCZSX=MT"1IM&([F$?Q12@;PWJ3R00S>W)X3T:/Q,_B-='L5\026HL7U
M9;5!=M;AMXA,N-QCW?-MSC/.*CC\$Z#'XJD\3)H.FKXDDM_LCZPMG&+QH 0?
M*,VW>4R =N<<"BX_9GPE\)V_XU3^.Q_TYZ]_Z535] V]E;6G_!/L6D,$<=N/
MAD1Y:K\O.EY/'N2<^N:]EM/AOX7L/"MQX7M?"^CVWAJX$BS:-%I\26<@D),@
M:$+L(8DDY'))S6C_ ,(SIO\ 8']A?V5:_P!B?9?L7]F_9U^S?9]FSR?+QMV;
M?EVXQCC&*+AR(_.GXEV&IP_L=_LI>*HM5NM#T/PY>Z;<ZGJ]K:)=MIBO'LBO
M#$ZLK"-O4'EQQS78_%30]+\9?\(-HOBC]J&[\>)JFOV4ND:1HFCZ7//+<J^Z
M.8?9E#I&O.Z3. &YK[BL_".DZ?X=CT"TT:RMM"C@^RII<-JB6JPXQY8B VA,
M<;<8Q7,^"_@#\._AUK,NK^%O /A_P_JD@*F\TW2X8)0IZJ&505![@8%%Q<A\
M\?&&U\+^(/VJ+V+1/B)K'P6^+%CH-NJ:Q<QVLFF:Y9.[,$6&9L3F-P0<[3P<
M;MN1T?[(/Q.U;QCX]^+N@Z\/#'B#6O#UY807'CGPO9K!'KH>!R@F*DAI80NP
MX8A<[1C&6]T\>_"'PA\4K6"W\8>$M)\316Y+0C5+&.X,1/4H6!*YQSC%7O!_
MP_T'X>Z*FC^%] T_P]I:,7%GIEJEO%N.,MM0 $G R>IHN/E1M>8:_GS_ .$@
MN<_P_E7]!<ZM;PR2R*PCC4NQQT &37X(-\)_%<:Y;0;X#WB-93K2IVL]SZW(
ML-1K>T]JEI;?YF)_PD-S_L_E2'Q#=_[/Y5O1_"3Q;-]S0;UO^V1ILGPI\5QG
M:VAW8/\ N5G]:GW/JOJ.$_EC^!@-X@NV_B ^@J$ZO==?.:MJ3X<^(D?8VDW*
MMZ;*)/AOXAA7<^ESH/=:7UJ;ZE+"8:.R7X&'_;5VO29A3#K5W_SW:MK_ (5W
MKNW(TZ8CV%5V\$ZLI(-C(#4_6)=R_JM#HE^!F_VS==YW_.H&OYV)/FMS[UI2
M>$]1CX:V9?K3&\,WR]8<?4TO;M]2EAX1V2,[[;-_ST?\S1]KE_OM^=7&T*Z7
MK'^M1MI<R]4_6CVK[C]BNQ6^V2=W8_C36G)J=K"1>HIIM6%'M&/V+Z$/G'M1
MY[5(;?':D\CVI>T8>R9&;AJ:9F-2>32>53YQ>S9'O;UI-S5)Y='ETN87LV1;
MC2;C4WETGETN87LV1[CZU]+?LG^,5:WO-"G?E&\R,'T/_P!?^=?-OEUM>#?$
MESX-\16NIVQ.8VPZC^)>XKU<LQGU/$QJ/;9^C/.Q^">+P\J77IZGWA=6\_VX
M;<>5WJ]9S36<FZWD:)O53BL+P;XHM_&&BV]];2!Q(H)Q71ZAH][#8?:8H69/
M4"OTZ=I-..W0_)*D:L)\C5FATE]-+DR/N)ZDUI:+XDCL?DECS_M5Q\>JL83O
M0JR]<U<CF5H5<D9-;<]>G]H7UBO1E=L[74_$ NV@98UDC!YS79:;XPL[:S14
M"IQT%>+&=E!VN0/0&K-GJ13 <Y'K7=1Q5.6E9:GKT,UZ3W/3==FD\2V<L4#
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M.9_\^?\ R:/^9^A']JR?W5_*D;59#T"C\*_/C_AZI_U3#_RX/_N6D_X>J_\
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MC274XXYMFE7X:9\/TM(*6OMS\!%HHIU !2TE+3 6EI *6@ IPI*6F M%%+3
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M"+B^[2_S%^*WPQ>9);N& QW\&?,CQ@L*\4^R,.JX/>OO*ZBB^(OAS[1%&O\
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M1^53K8PK_#6RP,NK..>?4%\*;.1%I(W 0TY=-G8_<Q77_9XQR%%.V+_=%;+
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M0XHQ4_DTUEQ0.Q'MI=M.Q2T#L-Q2XIV*DCA+4@L1 5/!%NJ5;4U;M[?;UZT
MR_X9\-S>(M:M-.@_UMQ($7->H7W[/M_9W\=LMQ&WS['*@\<>]97PPU?0M#U:
MSNKVWF>\AE#(Z'().0!C/O7TA<ZQ=:I&(HK3[%(I\T22+@D&M:<>8\#'8V6'
MDDCS'P;^S=)=1744UQLU(-_H[*>,#UK<\4?!$RZ.5EA$+0D*T\8_BKT*+Q)]
MGM8;6.,O?L>)D'-="=2DBTV2PO75!,P8[^N:VY>4\.6-J57S1=SQGPUX=N/"
MG@R]M[A=ZHQ:/;W'J:R/'GA73;_P'%J8@$%SE6=L8.,\BOH".WMVTJYLVB$B
M@=0.M>:>.[%KO0[K3VMBJ2)B$CCFM%%2]TPCB*D)^U?7<^3-5M8X-0F2')B4
M_+GZ5DW$7S5]':3^SNLWANXU;5[B2*X:(M%"HQ\V*\!U2T-I?30,,-&Q4CW%
M<DXN+9]I@\5#$*T7K8QBF*-M69(ZCVXXK$]5(CVTNVG[:7;0/E&;:-M2;:-M
M ^49MI=M/VTNVD/E&;:-M2;:7;[4#Y2/%+MI^VEQ1<?*,VFC;4FVC;2N/E&;
M:-M2;:7;1<?*1[:7;3]M+MHN'*,VT;:DVTNV@?*1[:-M2;:7;2'RD>VEVT_;
M2[:!\I'MI=M/VTNTT7#E&;:-M2;:7;0/E(]M&VI-M+MHN/E(]M+MJ0)3UAS2
M'RD&VEVU8\G':CRZ Y2#;2[34_E^U+LICY2OL-+Y=6-E&R@.4A\NG*F#4VS%
M& .I%0YQCNSHIX:M5=H0;^0*,5LZ/K3Z=;7"%L1XW5B--&@R6S].:S[Z^:6,
MQJI53U]Z\[$XJC[-QYKL^KR?)L>L3"K*#C%;WTT-G4/&"JQPQ-84_BZ.2;]Z
MI*_WO2LJX0&J$D8]*\&G6E3?-%GZ/BL#2KTW3J1NCL8]0MYHPRRJ0?>E-Y H
MR95_.N$<;:@=CZUZ\<Q;6J/AJG#5&,KJ;L=O)KUBH/[Y3^-5'\56_&Q6:N.)
M.:<I-1+'5'LBZ>0X2+]Z[^9TDOBB5LB- H[&J[:S<3,29",]<=*R$YJS"N:X
MYUZL]V>W0P.$H_!!%];AY.KL?J:LQ\U4ACJ]&M<4KO<]NGRK1(EC6K"*:9&*
ML)BL&CNC)"JIJ3;0"!1Y@%)%<QTWP]NDM?$<"RR%(FXZ\5] W6J:'I\=G;W.
MIJMK-( XW=,U\J_:"K94X([BJU_=2W2XDE=Q_M,37U&6YS4P-%T5&]SXK.L@
MCFE:-=S<;(^S?B1\&[:/2H=8\.7"WMLR!W1#DCW%<+ILMJOA^>"X.R5<\'K7
M _ ?]H"Z^'^J1:9K$SW6B2MM(D.?+_\ K5]9ZM\$="^*^C_V[X3NXO-D3>T4
M9&#^%?483,HU8IS9^99CETL#+V=3;HSC/V9[]KKQ4;,2*L9_A;OSU%=+^T]:
M7-MJD-M($"2'"LO0GUKQC4-)UOX4^(,MOM+N%N&'>JGC+XF:SXWF@_M&;<8^
MA_K7O4:DO;JI?0^8Q5%JDX+8;/>ZEH4'E1_O(F'##C\*XK4KJ6ZF9VZYKV*Z
MCL1X)61Y%>Y*]^HKRZZT]/)W[^:^DIU5'WG:Y\C6PDZONQO8YJ16<\G-)'"1
MBNNA\"WMTJ/'M,;#);TK%U#3)=,O'MY.64]17GUL>Y.T&52RQ4W[ZU-I=0N6
M\/\ E/:,(\8\S'%4/#[GS'MPA8MZ"NC74)9/"9@"*0%QNS7 'X@VO@Z^$CKY
MK'C YKSOK*HKFKNT3VZ6 JXJ:ITU>1D^.]=/A>X:$(1*V2JUYS?>+]4U"%XI
M9OW;?P@5H^/_ !8/&.L_:UC,:*#C/O7-A:^$S+,JN(JRC3G[BV/V')LGH8.A
M%SIKGZC%6I56E5>*D5:^>9]A%V%1:F5:11[5(M(T4ARBG8I*<*BQJIL6C-*J
M$]J=Y+'M2Y67S-C=WI2[B:D2V)J7[.!WJN0-60@$THB+592-%^\:D5T7H,TG
MRK=FD:4WT*H@/I3UMV]*L>9Z"D+,>]9NI%;(WCAI=6,6W7O2L$CZ#-+C\ZC<
M5FZKZ(ZHX:'5B-<;>@J%[I^U#5$]3[21M["FMD6=/UFXTZ;>N'!X*-T-=;I?
MBRSO"$D'D2>C5PC"HV'YUW4<7*GINCQ,=E-'%J[T?='KJNK*&4@J>A%!KS/3
M?$%WIC *Y=,\J?P_PKKM'\56VH*%D8138Y!X%>W2Q%.KMN? XS*<1A;RMS1-
MS%)3E^;D<BC970>-8913MII-M*Y7*)13MM&VE<.49_.CFG[:7;1<?*1\T8J3
M;1MHN/E(]M&VI=M+MI7'RD6VC;[5+MI=M%PY2+;1MJ7;1MH'RD>VC;4NVC;0
M/E(MM+MJ7;1MI#Y2+;1MJ7;2[: Y3YRI:**] _.A:6BBF M%%% "TZBBF 4M
M%% "TM%%, I:** %HHHH 6BBB@H=1110(*6BB@8M%%% !1110 M%%% Q:***
M "EHHI@%%%%( I:** "BBB@!VXTX2444P'>92^9110 [=2[J**8QWF'UIXF(
M'6BB@KF:V8J7#+WIWVI\]:**5D:JK46TA_VQL4^.]*BBBIY(]C>.,KQVFQZW
M_P W(XI6OAZ445'LH/H=,<SQ45I,D2\CQR/TH^V1;NE%%2Z%/L=4<XQB5N8E
M62!AD\4+) 3C/ZT45F\/3['?'.<79:HDVQ-R&J>&U$G ;%%%82P].^QZ4<VQ
M/*MON+']ASO]QE(I#X=O.H56^AHHJ?JM,]:CF-:25[%22SD@8JZD,.U1,I%%
M%<,J48RLCZ*,G*-V.6Z>/C=Q52[N"_>BBE**:'2BKF7*I9J8%*]:**PY4=5[
M,LPYZU>@D'K1142BAJI(N1S#UJ9;@>M%%9."'[:8];I?6G_:5_O445GRHU]K
M(9]K3^]2_:D_O444N5&GMI#ENT_OBG?:D_O"BBIY47[:8HNE_O"G_:D_O445
M/*BU6D*+I&Z-3OM"_P!X444N5&GMI#?MB_WQ3A=I_>%%%3RHMU9#OMB?WA1]
MMC'\8HHI.*'&M(5;Z/\ OBE^W1_WQ112Y46JLA_VQ#_$*/MB8^^***GE12JR
M#[:G]X4GVN/^^/SHHJ>5&WM)!]KC_OBG"ZC_ +X_.BBCE17M&/\ M*'HXI?M
M2_WJ**GE17M)#OM ]:?]L'K114\J*C4;'_;@OWF _&IDU")NK*/QHHJ7%&J=
MR9;J!OXU_.I?,@;^)1^-%%3RHCF=R0V\;CAE_.D_L]G V$.?8T45%B75E%#7
MTVY4<PM^559K9D^\,&BB@N%:4MRLT3+SG--V>O)^M%%.[1U7YMQLEJDG++S[
MU4DTR-FX ^@.#11773Q-:G\,FCS*^6X/%?QJ47\OU(9M'*KD,2?=34*61P<$
M$C\_RHHKUJ&8UW)1E9GQ^,X6R[V<JD$XM=G_ )W![4J!D<&J\L/6BBOIXOFB
MFS\AQ5*-&M*G'9,K%>:-M%%4<HY5W,!6I:VX:BBI%(]>\/\ [.^N>)/!\.O:
M8T-VLB[S;C[^*I>%_@MJFJ:UY.I1R:;;*>68#<WL***Z.1:'@5L54C&5CUS2
M?ACH6BWELB:<KS0,&$DG+,?6O?8]/LM1TR)YD'G;0#D=J**Z>51BFCXZM5GB
M:CA5=T%OH-NO[^VM1)Y0Y;;P*QO^$8,TEU?WTD<K.=L<>>5]Z**$SCE3C%V6
MVY?6W_LO2A/%&TO.T\=:Y.QCG\2:U.MQ;B.ULQO"OU)HHI]'(Z(7O&%]#D_&
M_P 0GM;2:$R+OC)5(QT KY^\6&PU6QN;MX%CN\Y#KQS1177.E!46[&V78BI+
M%I7MJ>=3QU69>:**\%GZM$,4N***184N***0Q<4NVBB@H,4N/:BB@8NVEVT4
M4 &VEVT44%6%Q1BBBD M+BBB@8NVC;110,7;2[:**0Q=M&***!BXI<444#L&
MVEQ112&+MI=M%% $L46:MQV^>U%%-#0Z2W"C)X^M49)HD8CS%)] :**\S$8J
M=)VC8^YRS),+BHJ51O9=?^ )YR8SS^5(+A3T4_C117BRS#$/K8^RI<.9;3?\
M._JV#W!V_(JC]:A-Q)GEMOL!117'+$UI[R9[='+,%17[NDE\B)W+9)D/YTU=
MG7.3117,Y.6[/3C",5[J$:1>FX57FD7NPHHH0I%5E5L\U7DMU(R#116T3SZL
MF4YH0*I2*N>M%%=4#QJS(6VTY0#1170CSI2)%7WJ>.15[T44F3"3N6X9E]:M
M1W*?WJ**PDCT:;)UNE_O5*ERIZ-11631V*3L*UT!WIOVD-WHHJ;&JDP\X>M1
MR2HPX:BBK2,)3;,ZX7<QP:]K_9M^)GBOPQX@%MI=^XLU&6B<DK^%%%>]ED>?
M$P@]FSY#.[?4ZDFD[([;XJ?%8^)O$++J4B+,O'%<OI\UMJDRQ0RJS'M117W$
M:SC5=-)63/SR6#IRH1GU:)O$]]+X>M!]IE;R1V)XJGX=U*R\40L+><%AV!HH
MKH]M/Z]&A]EHY7@Z2P$L0E[R9FZK\4;SPC<?V=*YPO"L?2G>%_'&G:[K6V\D
MWO(,Y)[T45XLL95CBY4D]+V/9_L_#3P:K./O6N=%XXUVRT+P_.L+8R#M_P#K
M5\UWMY+J%PTLK%F)_*BBN+/:DO;*G?1([>&Z,/J[JV]YLC5"W2G+'BBBOF3[
M.)(L=2K"2:**FQO$LQVCMVK7MO"]W-@[0%/-%%=E*E&6YR8JO*A&\2_%X+D(
MR[XJ];^$8(\;^3117;&A370^9J9EB9.W-8T(=#M8A@(*2X\.VUTN!F,]BM%%
M:>SC:UCECC<1&7.INYE77A*>/F%O,'ITK$NK":S;;*A0^]%%>?B,/",;H^RR
MG,:^)?+4L5&^7J:59D7O117D2BCZGF=A?M2?WJD6=/6BBL[()2:)!)&?XA3)
M)$_O"BBE8E5)7(69/[PJ&1D]:**5C55)$3;<9W"F,R^M%% <[&<48[JV/I11
M5Q;6J)FDUJ;VB^*;K3V"S$SP]/<5W6GZA!J<(D@;<.X]***]["5)35I'PN;X
M.C3C[6"LRT5INVBBNT^60;:-M%% "[:7;1104@VT8]J**!V%Q1BBB@!<48HH
<I &*7%%% PVT;:**0Q=M&VBB@8N*-M%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pali-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-24T15:04:39.9992+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.palisadebio.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:pali="http://www.palisadebio.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information" id="statement-document-and-entity-information">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2" id="DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2">
        <link:definition>100020 - Disclosure - Note 9 - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" id="StatementConsolidatedBalanceSheetsParentheticals">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" id="StatementConsolidatedStatementsOfCashFlows2">
        <link:definition>100040 - Statement - Consolidated Statements of Cash Flows 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100050 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1" id="StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1">
        <link:definition>100060 - Statement - Consolidated Statements Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical" id="StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995453 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusiness1" id="DisclosureNote1OrganizationAndBusiness1">
        <link:definition>995463 - Disclosure - Note 1 - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPolicies" id="DisclosureNote2SummaryOfSignificantAccountingPolicies">
        <link:definition>995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetails1" id="DisclosureNote3BalanceSheetDetails1">
        <link:definition>995483 - Disclosure - Note 3 - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurements" id="DisclosureNote4FairValueMeasurements">
        <link:definition>995493 - Disclosure - Note 4 - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquity" id="DisclosureNote5StockholdersEquity">
        <link:definition>995503 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt" id="statement-note-6-debt">
        <link:definition>995513 - Disclosure - Note 6 - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlans1" id="DisclosureNote6EquityIncentivePlans1">
        <link:definition>995523 - Disclosure - Note 6 - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1" id="DisclosureNote7CollaborationsAndLicenseAgreements1">
        <link:definition>995533 - Disclosure - Note 7 - Collaborations and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingencies" id="DisclosureNote8CommitmentsAndContingencies">
        <link:definition>995543 - Disclosure - Note 8 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShare1" id="DisclosureNote9NetLossPerShare1">
        <link:definition>995553 - Disclosure - Note 9 - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote10EmployeeBenefits" id="DisclosureNote10EmployeeBenefits">
        <link:definition>995563 - Disclosure - Note 10 - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxes1" id="DisclosureNote11IncomeTaxes1">
        <link:definition>995573 - Disclosure - Note 11 - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformation" id="DisclosureNote12SegmentInformation">
        <link:definition>995583 - Disclosure - Note 12 - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995593 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables" id="DisclosureNote3BalanceSheetDetailsTables">
        <link:definition>995603 - Disclosure - Note 3 - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4CommonStockWarrantsTables" id="DisclosureNote4CommonStockWarrantsTables">
        <link:definition>995613 - Disclosure - Note 4 - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables" id="DisclosureNote5FairValueMeasurementsTables">
        <link:definition>995623 - Disclosure - Note 5 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt-tables" id="statement-note-6-debt-tables">
        <link:definition>995633 - Disclosure - Note 6 - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables" id="DisclosureNote5StockholdersEquityTables">
        <link:definition>995643 - Disclosure - Note 5 - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables" id="DisclosureNote6EquityIncentivePlansTables">
        <link:definition>995653 - Disclosure - Note 6 - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables" id="DisclosureNote9NetLossPerShareTables">
        <link:definition>995663 - Disclosure - Note 9 - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables" id="DisclosureNote8CommitmentsAndContingenciesTables">
        <link:definition>995673 - Disclosure - Note 8 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables" id="DisclosureNote11IncomeTaxesTables">
        <link:definition>995683 - Disclosure - Note 11 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationTables" id="DisclosureNote12SegmentInformationTables">
        <link:definition>995693 - Disclosure - Note 12 -Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails" id="DisclosureNote1OrganizationAndBusinessDetails">
        <link:definition>995703 - Disclosure - Note 1 - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual" id="DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>995713 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>995723 - Disclosure - Note 3 - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails" id="DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails">
        <link:definition>995733 - Disclosure - Note 3 - Balance Sheet Details - Summary of Other Noncurrent Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" id="DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails">
        <link:definition>995743 - Disclosure - Note 3 - Balance Sheet Details - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails" id="DisclosureNote4FairValueMeasurementsDetails">
        <link:definition>995753 - Disclosure - Note 4 - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails" id="DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails">
        <link:definition>995763 - Disclosure - Note 4 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual" id="DisclosureNote5StockholdersEquityDetailsTextual">
        <link:definition>995773 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails" id="DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails">
        <link:definition>995783 - Disclosure - Note 5 - Stockholders' Equity - Schedule of Stockholders' Equity warrant outstanding and exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails" id="DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails">
        <link:definition>995793 - Disclosure - Note 5 - Stockholders' Equity - Summary of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual" id="DisclosureNote6EquityIncentivePlansDetailsTextual">
        <link:definition>995803 - Disclosure - Note 6 - Equity Incentive Plans (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails" id="DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails">
        <link:definition>995813 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails" id="DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails">
        <link:definition>995823 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Summarized Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails" id="DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails">
        <link:definition>995833 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Stock-based Compensation for all Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails" id="DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails">
        <link:definition>995843 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual" id="DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual">
        <link:definition>995853 - Disclosure - Note 7 - Collaborations and License Agreements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual" id="DisclosureNote8CommitmentsAndContingenciesDetailsTextual">
        <link:definition>995863 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails" id="DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails">
        <link:definition>995873 - Disclosure - Note 8 - Commitments and Contingencies - Accrued liabilities in the consolidated balance sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual" id="DisclosureNote9NetLossPerShareDetailsTextual">
        <link:definition>995883 - Disclosure - Note 9 - Net Loss Per Share - (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" id="DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails">
        <link:definition>995893 - Disclosure - Note 9 - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>995903 - Disclosure - Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual" id="DisclosureNote11IncomeTaxesDetailsTextual">
        <link:definition>995913 - Disclosure - Note 11 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails" id="DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails">
        <link:definition>995923 - Disclosure - Note 11 - Income Taxes - Schedule of Statutory Federal Income Tax Applied to Loss Before Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" id="DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
        <link:definition>995933 - Disclosure - Note 11 - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual" id="DisclosureNote12SegmentInformationDetailsTextual">
        <link:definition>995943 - Disclosure - Note 12 - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails" id="DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails">
        <link:definition>995953 - Disclosure - Note 12 - Segment Information - Schedule of Reconciliation of Loss from Operations Disclosure Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information" xlink:href="pali-20241231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="pali-20241231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:href="pali-20241231.xsd#StatementConsolidatedBalanceSheetsParentheticals" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="pali-20241231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1" xlink:href="pali-20241231.xsd#StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:href="pali-20241231.xsd#StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="pali-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="pali-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusiness1" xlink:href="pali-20241231.xsd#DisclosureNote1OrganizationAndBusiness1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPolicies" xlink:href="pali-20241231.xsd#DisclosureNote2SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetails1" xlink:href="pali-20241231.xsd#DisclosureNote3BalanceSheetDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurements" xlink:href="pali-20241231.xsd#DisclosureNote4FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquity" xlink:href="pali-20241231.xsd#DisclosureNote5StockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt" xlink:href="pali-20241231.xsd#statement-note-6-debt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlans1" xlink:href="pali-20241231.xsd#DisclosureNote6EquityIncentivePlans1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1" xlink:href="pali-20241231.xsd#DisclosureNote7CollaborationsAndLicenseAgreements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingencies" xlink:href="pali-20241231.xsd#DisclosureNote8CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShare1" xlink:href="pali-20241231.xsd#DisclosureNote9NetLossPerShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote10EmployeeBenefits" xlink:href="pali-20241231.xsd#DisclosureNote10EmployeeBenefits" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxes1" xlink:href="pali-20241231.xsd#DisclosureNote11IncomeTaxes1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformation" xlink:href="pali-20241231.xsd#DisclosureNote12SegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pali-20241231.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables" xlink:href="pali-20241231.xsd#DisclosureNote3BalanceSheetDetailsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4CommonStockWarrantsTables" xlink:href="pali-20241231.xsd#DisclosureNote4CommonStockWarrantsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables" xlink:href="pali-20241231.xsd#DisclosureNote5FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt-tables" xlink:href="pali-20241231.xsd#statement-note-6-debt-tables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables" xlink:href="pali-20241231.xsd#DisclosureNote5StockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables" xlink:href="pali-20241231.xsd#DisclosureNote6EquityIncentivePlansTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables" xlink:href="pali-20241231.xsd#DisclosureNote9NetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables" xlink:href="pali-20241231.xsd#DisclosureNote8CommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables" xlink:href="pali-20241231.xsd#DisclosureNote11IncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationTables" xlink:href="pali-20241231.xsd#DisclosureNote12SegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails" xlink:href="pali-20241231.xsd#DisclosureNote1OrganizationAndBusinessDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="pali-20241231.xsd#DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails" xlink:href="pali-20241231.xsd#DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:href="pali-20241231.xsd#DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails" xlink:href="pali-20241231.xsd#DisclosureNote4FairValueMeasurementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails" xlink:href="pali-20241231.xsd#DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote5StockholdersEquityDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails" xlink:href="pali-20241231.xsd#DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails" xlink:href="pali-20241231.xsd#DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote6EquityIncentivePlansDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails" xlink:href="pali-20241231.xsd#DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails" xlink:href="pali-20241231.xsd#DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails" xlink:href="pali-20241231.xsd#DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="pali-20241231.xsd#DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote8CommitmentsAndContingenciesDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails" xlink:href="pali-20241231.xsd#DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote9NetLossPerShareDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:href="pali-20241231.xsd#DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="pali-20241231.xsd#DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote11IncomeTaxesDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails" xlink:href="pali-20241231.xsd#DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:href="pali-20241231.xsd#DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual" xlink:href="pali-20241231.xsd#DisclosureNote12SegmentInformationDetailsTextual" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails" xlink:href="pali-20241231.xsd#DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2" xlink:href="pali-20241231.xsd#DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" xlink:href="pali-20241231.xsd#StatementConsolidatedStatementsOfCashFlows2" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JointDevelopmentExpenses" xlink:label="pali_JointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ChangesInFairValueOfContingentConsideration" xlink:label="pali_ChangesInFairValueOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClosingPeriodOfMergerAgreement" xlink:label="pali_ClosingPeriodOfMergerAgreement"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncrementalFairValueOfModifiedOrExchangedWarrants" xlink:label="pali_IncrementalFairValueOfModifiedOrExchangedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RepricedWarrantsMember" xlink:label="pali_RepricedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" xlink:label="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ProgramExpenses" xlink:label="pali_ProgramExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RecurringFairValueMeasurementsOfLiabilities" xlink:label="pali_RecurringFairValueMeasurementsOfLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeriesAConvertiblePreferredStockMember" xlink:label="pali_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RetainedEarningsAccumulatedIncomeDeficit" xlink:label="pali_RetainedEarningsAccumulatedIncomeDeficit"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsAccruedExpenses" xlink:label="pali_DeferredTaxAssetsAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UnregisteredSharesMember" xlink:label="pali_UnregisteredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CvrAgreementDistributionMinimumAmount" xlink:label="pali_CvrAgreementDistributionMinimumAmount"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" xlink:label="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024PlacementAgentWarrantsMember" xlink:label="pali_May2024PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="us-gaap_RestructuringReserveRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" xlink:label="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021EsppMember" xlink:label="pali_The2021EsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AprilTwoThousandTwentyThreeWarrantsMember" xlink:label="pali_AprilTwoThousandTwentyThreeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedClinicalTrialCosts" xlink:label="pali_AccruedClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsDepreciation" xlink:label="pali_DeferredTaxAssetsDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UncertainIncomeTaxPositions" xlink:label="pali_UncertainIncomeTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_InsuranceFinancingArrangementMember" xlink:label="pali_InsuranceFinancingArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing" xlink:label="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OutOfPocketExpenses" xlink:label="pali_OutOfPocketExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdditionalFinancingAgreementsTwoMember" xlink:label="pali_AdditionalFinancingAgreementsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfNetRevenue" xlink:label="pali_PercentageOfNetRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeriesA4Point5PercentConvertiblePreferredStockMember" xlink:label="pali_SeriesA4Point5PercentConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AprilTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_AprilTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FinancingAgreementsMember" xlink:label="pali_FinancingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdditionalFinancingAgreementsOneMember" xlink:label="pali_AdditionalFinancingAgreementsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" xlink:label="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:label="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_TheDecember2019NoteMember" xlink:label="pali_TheDecember2019NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionSoftware" xlink:label="us-gaap_RevenueRecognitionSoftware"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentConsiderationObligationsMember" xlink:label="pali_ContingentConsiderationObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidSoftwareLicenses" xlink:label="pali_PrepaidSoftwareLicenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_September2023OfferingMember" xlink:label="pali_September2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsLeaseLiability" xlink:label="pali_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OperatingLeasesFutureMinimumPayments" xlink:label="pali_OperatingLeasesFutureMinimumPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="pali_MayTwoThousandTwentyTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021PlanMember" xlink:label="pali_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementReplacementCommonStockWarrantsMember" xlink:label="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingPreFundedCommonStockWarrantsMember" xlink:label="pali_December2024OfferingPreFundedCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Nsi532Igf1Member" xlink:label="pali_Nsi532Igf1Member"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClinicalTrialExpensesPolicyPolicyTextBlock" xlink:label="pali_ClinicalTrialExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredEquityIssuanceCosts" xlink:label="pali_DeferredEquityIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PALITwoOneZeroEightMember" xlink:label="pali_PALITwoOneZeroEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FinancingCostDerivativeWarrantLiabilities" xlink:label="pali_FinancingCostDerivativeWarrantLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfReductionInWorkForce" xlink:label="pali_PercentageOfReductionInWorkForce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="pali_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationNondeductibleExpenseWarrants" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementMember" xlink:label="pali_February2024WarrantInducementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PaycheckProtectionProgramCARESActMember" xlink:label="pali_PaycheckProtectionProgramCARESActMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedAccountsPayable" xlink:label="pali_AccruedAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" xlink:label="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NoncashOperatingLeaseExpense" xlink:label="pali_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_August2024OfferingSeries2CommonStockWarrantsMember" xlink:label="pali_August2024OfferingSeries2CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" xlink:label="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" xlink:label="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Series2WarrantsMember" xlink:label="pali_Series2WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" xlink:label="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ReplacementWarrantsMember" xlink:label="pali_ReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAgreementsMember" xlink:label="pali_WarrantInducementAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedJointDevelopmentExpenses" xlink:label="pali_AccruedJointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfTerminatedLicenseAgreements" xlink:label="pali_NumberOfTerminatedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MilestonePayments" xlink:label="pali_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationOtherNonDeductibleExpenses" xlink:label="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" xlink:label="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PlacementAgentWarrantsMember" xlink:label="pali_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NotesToFinancialStatementsAbstract" xlink:label="pali_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UnderwritingCommitmentsPerShare" xlink:label="pali_UnderwritingCommitmentsPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" xlink:label="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024OfferingMember" xlink:label="pali_May2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingCommonStockWarrantsMember" xlink:label="pali_December2024OfferingCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAdministrationExpenses" xlink:label="us-gaap_DefinedBenefitPlanAdministrationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingMember" xlink:label="pali_December2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_DE" xlink:label="stpr_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JanuaryTwoThousandTwentyThreeWarrantsMember" xlink:label="pali_JanuaryTwoThousandTwentyThreeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MaximumAggregateConsideration" xlink:label="pali_MaximumAggregateConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfLicenseAgreements" xlink:label="pali_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNotesMember" xlink:label="pali_SeniorSecuredPromissoryNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CostReductionPlanMember" xlink:label="pali_CostReductionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfGrossProceeds" xlink:label="pali_PercentageOfGrossProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PaymentOfWarrantInducementIssuanceCosts" xlink:label="pali_PaymentOfWarrantInducementIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToSolicitationAgent" xlink:label="pali_FairValueOfWarrantsIssuedToSolicitationAgent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_April2023OfferingMember" xlink:label="pali_April2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pali_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfTradingDays" xlink:label="pali_NumberOfTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_InducementPlanMember" xlink:label="pali_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" xlink:label="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockPurchaseWarrantsMember" xlink:label="pali_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceeds" xlink:label="pali_NetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantsIssuanceCosts" xlink:label="pali_WarrantsIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2013PlanMember" xlink:label="pali_The2013PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CollaborationsAndLicenseAgreementsUpfrontFee" xlink:label="pali_CollaborationsAndLicenseAgreementsUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_GrantDateFairValue" xlink:label="pali_GrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_October2020NoteMember" xlink:label="pali_October2020NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares" xlink:label="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedCMCExpenses" xlink:label="pali_AccruedCMCExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PreFundedWarrantsMember" xlink:label="pali_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AltiumGrowthFundLPMember" xlink:label="pali_AltiumGrowthFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_TimeBasedRestrictedStockUnitsMember" xlink:label="pali_TimeBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OtherNoncurrentAssets" xlink:label="pali_OtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_July2020NoteMember" xlink:label="pali_July2020NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsTextBlock" xlink:label="pali_LicenseAgreementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OriginalFinancingAgreementsMember" xlink:label="pali_OriginalFinancingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LegacyMember" xlink:label="pali_LegacyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CashTransactionRelatedExpensesAndPlacementAgentFees" xlink:label="pali_CashTransactionRelatedExpensesAndPlacementAgentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024RepresentativeWarrantsMember" xlink:label="pali_December2024RepresentativeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyFourOfferingMember" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Series1PreferredStockOfLBSMember" xlink:label="pali_Series1PreferredStockOfLBSMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SublicenseFees" xlink:label="pali_SublicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ReverseStockSplitPolicyPolicyTextBlock" xlink:label="pali_ReverseStockSplitPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToPlacementAgents" xlink:label="pali_FairValueOfWarrantsIssuedToPlacementAgents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedDirectorStipends" xlink:label="pali_AccruedDirectorStipends"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CostReductionPlanTwentyTwentyThreeMember" xlink:label="pali_CostReductionPlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidSubscriptionsAndFees" xlink:label="pali_PrepaidSubscriptionsAndFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceedsFromIssuanceOfWarrants" xlink:label="pali_NetProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassBUnitsMember" xlink:label="pali_ClassBUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" xlink:label="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentConsiderationObligationsPolicyTextBlock" xlink:label="pali_ContingentConsiderationObligationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageCostInPatentRight" xlink:label="pali_PercentageCostInPatentRight"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CashConsideration" xlink:label="pali_CashConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeptemberTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pali_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAbstract" xlink:label="us-gaap_RestructuringReserveAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightNumberOfRightsIssued" xlink:label="pali_ClassOfWarrantOrRightNumberOfRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PeriodOfExpirationOfLicenseAgreementDescription" xlink:label="pali_PeriodOfExpirationOfLicenseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AllOtherCommonStockWarrantsMember" xlink:label="pali_AllOtherCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashWarrantIssuanceCosts" xlink:label="pali_NonCashWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JanuaryTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassAUnitsMember" xlink:label="pali_ClassAUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfShareIssued" xlink:label="pali_PercentageOfShareIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2022WarrantsMember" xlink:label="pali_December2022WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightNumberOutstanding" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashWarrantModificationCosts" xlink:label="pali_NonCashWarrantModificationCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_January2023OfferingMember" xlink:label="pali_January2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ProceedsDepositedIntoTheCvrEscrow" xlink:label="pali_ProceedsDepositedIntoTheCvrEscrow"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriod"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JointDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Joint development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JointDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Joint Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JointDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Joint development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal income tax rate of 21 percent applied to loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ChangesInFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ChangesInFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Fair Value Of Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ChangesInFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in fair value of contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClosingPeriodOfMergerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing period of merger agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClosingPeriodOfMergerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing period of merger agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClosingPeriodOfMergerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Period of Merger Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncrementalFairValueOfModifiedOrExchangedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental fair value of modified warrants (Note 5)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncrementalFairValueOfModifiedOrExchangedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Fair Value of Modified or Exchanged Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncrementalFairValueOfModifiedOrExchangedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental fair value of modified or exchanged warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RepricedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repriced Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RepricedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repriced warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to outstanding RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">It represents the amount of stock issued during period value of common stock upon warrant exercises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Of Common Stock Upon Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon warrant exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, Weighted Average Exercise Price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Program Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Program expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ProgramExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Program expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RecurringFairValueMeasurementsOfLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Recurring fair value measurements of liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RecurringFairValueMeasurementsOfLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recurring fair value measurements of liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RecurringFairValueMeasurementsOfLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recurring fair value measurements of liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RetainedEarningsAccumulatedIncomeDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retained earnings accumulated income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RetainedEarningsAccumulatedIncomeDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Income (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RetainedEarningsAccumulatedIncomeDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UnregisteredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unregistered Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UnregisteredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unregistered Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UnregisteredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unregistered Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CvrAgreementDistributionMinimumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Agreement, distribution minimum amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CvrAgreementDistributionMinimumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CVR agreement, distribution minimum amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CvrAgreementDistributionMinimumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CVR Agreement, Distribution Minimum Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Issued Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital warrant issued, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants related to promissory note (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Vesting Rights Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining balance under insurance financing arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants for common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_May2024PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May 2024 Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_May2024PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May 2024 Placement Agent Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Forfeited, expired or cancelled (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited, expired or cancelled (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants issued to representatives of underwriter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants Issued to Representatives of Underwriter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants issued to representatives of underwriter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other current assets and other noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2021EsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The 2021 ESPP member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2021EsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The 2021 ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AprilTwoThousandTwentyThreeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">April 2023 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AprilTwoThousandTwentyThreeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">April two thousand twenty three warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AprilTwoThousandTwentyThreeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">April Two Thousand Twenty Three Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum shares issued under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued clinical trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of accrued clinical trial costs as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedClinicalTrialCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets depreciation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UncertainIncomeTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">uncertain income tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UncertainIncomeTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain Income Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UncertainIncomeTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain income tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Secured Promissory Note Warrants, First Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding warrants associated with the first closing of the Senior Secured Promissory Notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_InsuranceFinancingArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance Financing Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_InsuranceFinancingArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Financing Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_InsuranceFinancingArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Insurance Financing Arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value right, pro rata, net proceeds from sale or licensing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Right, Pro Rata, Net Proceeds from Sale or Licensing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value right, pro rata, net proceeds from sale or licensing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OutOfPocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Out-of-pocket expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OutOfPocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Out-of-pocket expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OutOfPocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Out-of-Pocket Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained earnings (Accumulated deficit), ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements with the Regents of the University of California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding license agreements with the Regents of the University of California for exclusive commercial rights to certain patents, technology and know-how.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements with the Regents of the University of California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock capital shares reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AdditionalFinancingAgreementsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Financing Agreements Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AdditionalFinancingAgreementsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding the second additional financing agreement or second set of financing agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing arrangement expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, term of contract (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested, Weighted Average Contractual Life (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Remaining Contractual Life (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposit Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deposit Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued royalties, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Inducement and Equity Issuance Costs Included in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeriesA4Point5PercentConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A 4.5% Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeriesA4Point5PercentConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Series A 4.5% convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued severance and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Unemployment Benefits, Severance Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase shares of Company's common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AprilTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">April 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AprilTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">April Two Thousand And Twenty Three Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AprilTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">April two thousand And twenty three offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring costs (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Restricted Stock Units, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FinancingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FinancingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regard agreements to finance certain insurance policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AdditionalFinancingAgreementsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Financing Agreements One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AdditionalFinancingAgreementsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the first additional financing agreement or first set of financing agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non cash impact of exercise price reset on outstanding warrants related to down round provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Impact of Exercise Price Reset on Outstanding Warrants Related to Down Round Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash impact of exercise price reset on outstanding warrants related to down round provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Contract Indexed to Equity, Settlement, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to purchase shares of Company's common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_TheDecember2019NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The December 2019 Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_TheDecember2019NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding an unsecured promissory note to a consultant as payment for consulting services performed in 2019.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition, Software [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentConsiderationObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Obligations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentConsiderationObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentConsiderationObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Obligations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Restricted Stock Units, Non-vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidSoftwareLicenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid software licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidSoftwareLicenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Software Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidSoftwareLicenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid software licenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_September2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September 2023 Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_September2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_September2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OperatingLeasesFutureMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OperatingLeasesFutureMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OperatingLeasesFutureMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total remaining future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Loss from Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MayTwoThousandTwentyTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May two thousand twenty two warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MayTwoThousandTwentyTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May Two Thousand Twenty Two Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MayTwoThousandTwentyTwoWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2022 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Sold, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The 2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding the 2021 Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The 2021 EIP and Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February 2024 Warrant Inducement Replacement Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February 2024 warrant inducement replacement common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options, Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Core research and development operating expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024OfferingPreFundedCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2024 Offering PreFunded Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024OfferingPreFundedCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December 2024 offering prefunded common Stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Nsi532Igf1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NSI-532.IGF-1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Nsi532Igf1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NSI-532.IGF-1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Nsi532Igf1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NSI-532.IGF-1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClinicalTrialExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClinicalTrialExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClinicalTrialExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for clinical trial expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent consideration obligation, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred equity issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Equity Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredEquityIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred equity issuance costs againist additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PALITwoOneZeroEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PALI Two One Zero Eight [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PALITwoOneZeroEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PALI-2108.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PALITwoOneZeroEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PALI-2108 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Meals and entertainment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FinancingCostDerivativeWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on issuance of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FinancingCostDerivativeWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FinancingCostDerivativeWarrantLiabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FinancingCostDerivativeWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents amount recognized during the period for the financing cost associated with derivative warrant liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FinancingCostDerivativeWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on issuance of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfReductionInWorkForce_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in work force</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfReductionInWorkForce_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reduction In Work Force</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfReductionInWorkForce_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of reduction in work force</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares unvested and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants related to promissory note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for employee stock purchase plan (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued under the ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Current, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Current, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Forfeited, expired or cancelled, Weighted Average Exercise Price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve, Accrual Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net accrual additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Nondeductible Expense Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Basic and Diluted Net Loss Per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Others</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Expiration of Tax Attributes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expiration of tax attributes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration of tax attributes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_February2024WarrantInducementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February 2024 Warrant Inducement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_February2024WarrantInducementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February 2024 warrant inducement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_February2024WarrantInducementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2024 Warrant Inducement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of the Company's operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restricted Stock Units Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PaycheckProtectionProgramCARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program, CARES Act [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PaycheckProtectionProgramCARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents loan designed to provide funds for small businesses to keep their employees on the payroll.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost weighted-average period of recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of accrued accounts payable, included in accrued liabilities rather than in the Accounts Payable line item.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected contractual life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Equity Issuance Costs Recognized As a Reduction in Additional Paid in Capital From Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Equity Issuance Costs Recognized As a Reduction in Additional Paid in Capital From Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Restricted Stock Units, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Stock Units, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Restricted Stock Units, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NoncashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Cost inquired with exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment of equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Restricted Stock Units, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Restricted Stock Units, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_August2024OfferingSeries2CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August 2024 Offering Series 2 Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_August2024OfferingSeries2CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">August 2024 offering series 2 common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued during the period common stock upon warrant exercises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Of Common Stock Upon Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon warrant exercises (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bridge, January 2021, and July 2021 Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bridge, January 2021, and July 2021 common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Series2WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series Two Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Series2WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series 2 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Series2WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series 2 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Equity Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corpotate Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space Lease for Corporate Headquarters in Carlsbad, CA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Space Lease for Corporate Headquarters in Carlsbad, CA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding an office space lease for corporate headquarters in Carlsbad, CA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding, weighted average remaining contratual life (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants outstanding, December 31, 2020 (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the weighted average remaining contractual life of warrants or rights outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Replacement warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Replacement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ReplacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Replacement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right forfeited expired or cancelled during period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Forfeited Expired or Cancelled During Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, expired, or cancelled, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantInducementAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Inducement Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantInducementAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Inducement Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantInducementAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Inducement Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Stock and Warrants for Services or Claims</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to vendors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedJointDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Joint Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedJointDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Joint Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedJointDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued joint development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfTerminatedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Terminated License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfTerminatedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Terminated License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfTerminatedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of terminated license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, at carrying value, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right issued during period weighted average remaining contractual life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Issued During Period Weighted Average Remaining Contractual Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, weighted average remaining contractual life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares withheld for payment of employee withholding tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options, Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Dividend Rate, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Dividend Rate, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other non-deductible expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Non-Deductible Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-deductible expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes - net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercise price of common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price of common stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent, Solicitor and Representative Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent, solicitor and representative common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Statutory Federal Income Tax Rate Applied to Loss Before Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NotesToFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes To Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NotesToFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes To Financial Statements Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UnderwritingCommitmentsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Commitments Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UnderwritingCommitmentsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting agreement, per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_UnderwritingCommitmentsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting commitments, per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate on the portion of sublicense income to be paid, expressed as a percentage of one-third of the upfront payment and milestone payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate, portion of sublicense income to be paid, percentage of one-third of upfront payment and milestone payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_May2024OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2024 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_May2024OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May 2024 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_May2024OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May 2024 Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Reserve, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance as of the beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance as of the end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense and related charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024OfferingCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2024 Offering Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024OfferingCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December 2024 offering common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanAdministrationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Administration Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanAdministrationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2024 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December 2024 Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2024 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial fair value at the original issuance date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DELAWARE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Delaware [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation for all Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JanuaryTwoThousandTwentyThreeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2023 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JanuaryTwoThousandTwentyThreeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January Two Thousand Twenty Three Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JanuaryTwoThousandTwentyThreeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Two Thousand Twenty Three Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MaximumAggregateConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum Aggregate Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MaximumAggregateConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MaximumAggregateConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued liabilities in the consolidated balance sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pali_NumberOfLicenseAgreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of license agreements in place.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Insurance, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance financing debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeniorSecuredPromissoryNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Secured Promissory Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeniorSecuredPromissoryNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding the Senior Secured Promissory Notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to vendor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CostReductionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost Reduction Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CostReductionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reduction Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CostReductionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">cost reduction plan Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Gross Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PaymentOfWarrantInducementIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of warrant inducement issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PaymentOfWarrantInducementIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Warrant Inducement Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PaymentOfWarrantInducementIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of warrant inducement issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToSolicitationAgent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants Issued to Solicitation Agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToSolicitationAgent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants issued to solicitation agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToSolicitationAgent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants issued to solicitation agent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split fractional share settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_April2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">April 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_April2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">April 2023 Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_April2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">April 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consecutive trading day period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering shares (Per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of stock during period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Secured Promissory Note Warrants, Second Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding warrants associated with the second closing of the Senior Secured Promissory Notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common shares - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shares - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Short-term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Short-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on insurance financing debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation and related charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Inducement plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2021 Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of contingent consideration obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from insurance financing debt included in prepaid and other assets and other noncurrent assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds from Insurance Financing Debt Included in Prepaid and Other Assets and Oher Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance financing debt included in prepaid and other current assets and other noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to stock purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pali_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of warrants or rights exercised during period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Proceeds from the exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per common share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares used in calculating basic loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Basic weighted average shares used in computing net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used in calculating basic loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantsIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantsIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_WarrantsIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant date fair value of the options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted Average Remaining Contractual Life (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2013PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2013PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The 2013 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_The2013PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The 2013 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CollaborationsAndLicenseAgreementsUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations and license agreements upfront fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CollaborationsAndLicenseAgreementsUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations and License Agreements Upfront Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CollaborationsAndLicenseAgreementsUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations and license agreements upfront fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_GrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_GrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_GrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_October2020NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2020 Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_October2020NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October 2020 Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_October2020NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding an unsecured promissory note issued in October 2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock, Issuable Upon Conversion of All Shares (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issuable for all shares of a given class of convertible preferred stock that may be converted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedCMCExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued C M C Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedCMCExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of accrued CMC expenses as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedCMCExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued chemistry, manufacturing and controls ("CMC") expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants for additional gross cash proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from the exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Summarized Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Table Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Vested and expected to vest, Weighted Average Remaining Contractual Life (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental fair value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per common share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Date of issuance of warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and Rights Outstanding, Term (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AltiumGrowthFundLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Altium Growth Fund, LP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AltiumGrowthFundLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Altium Growth Fund, LP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AltiumGrowthFundLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding Altium Growth Fund, LP (the "Investor").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time Based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Time based restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time-based RSU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sum of the carrying amounts as of the balance sheet date of other noncurrent assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_July2020NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July 2020 Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_July2020NoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding an unsecured promissory note issued in July 2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common shares - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in income available to common shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss available to common stockholders - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, Weighted Average Remaining Contractual Life (Year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing arrangement interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OriginalFinancingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Original Financing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_OriginalFinancingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding the original financing agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at December 31, 2024 and December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted-average expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted-average expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LegacyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legacy [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LegacyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_LegacyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CashTransactionRelatedExpensesAndPlacementAgentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash transaction-related expenses And placement agent fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CashTransactionRelatedExpensesAndPlacementAgentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash transaction-related expenses And placement agent fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CashTransactionRelatedExpensesAndPlacementAgentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash transaction-related expenses And placement agent fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes to Financial Statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds (payments) from the redemption of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024RepresentativeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2024 Representative Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2024RepresentativeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December 2024 Representative Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted, weighted average exercise price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average exercise price per share of warrants or rights issued during period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Income Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May Two Thousand Twenty Four Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May Two Thousand Twenty Four Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2024 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: current portion of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Series1PreferredStockOfLBSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series 1 Preferred Stock of LBS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_Series1PreferredStockOfLBSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information regarding Series 1 Preferred Stock of LBS.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants outstanding, weighted average exercise price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the weighted average exercise price of warrants or rights outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SublicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SublicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SublicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split, policy [Policy Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ReverseStockSplitPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToPlacementAgents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants Issued to Placement Agents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToPlacementAgents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants Issued to placement agents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_FairValueOfWarrantsIssuedToPlacementAgents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants issued to placement agents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of purchase price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedDirectorStipends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued director stipends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedDirectorStipends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued director stipends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AccruedDirectorStipends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of accrued director stipends as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CostReductionPlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost Reduction Plan Twenty Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CostReductionPlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reduction Plan Twenty Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CostReductionPlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 RIF [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Vested and expected to vest, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Forfeited, expired or cancelled (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of warrants or rights forfeited, expired or cancelled during period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Warrant Outstanding And Exercisable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of warrants outstanding and exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stockholders' Equity warrant outstanding and exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidSubscriptionsAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid subscriptions and fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidSubscriptionsAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Subscriptions and Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidSubscriptionsAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid subscriptions and fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other noncurrent assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net proceeds from issuance of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NetProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassBUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class B Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassBUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class B Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Incremental Value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value; 280,000,000 shares authorized; 2,768,646 and 618,056 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Employee Related Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Employee Related Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets, other receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentConsiderationObligationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentConsiderationObligationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Obligations [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ContingentConsiderationObligationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of the company's cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageCostInPatentRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage cost in patent right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageCostInPatentRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Cost in Patent Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageCostInPatentRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage cost in patent right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions Cost of equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Cost Of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_CashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average shares used in calculating diluted loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average shares used in calculating diluted loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used in calculating diluted loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, renewal term (Month)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Two Thousand And Twenty Three Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September two thousand And twenty three offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOfRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of rights issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOfRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Number of Rights Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOfRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value right issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares used in computing loss per common share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PeriodOfExpirationOfLicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of Expiration of License Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PeriodOfExpirationOfLicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of Expiration of License Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PeriodOfExpirationOfLicenseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period of Expiration of License Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AllOtherCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Other Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_AllOtherCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">All other common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Warrant Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash warrant issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash warrant issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercised during period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Exercised During Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January Two Thousand And Twenty Three Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January two thousand And twenty three offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to vendor (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassAUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassAUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfShareIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Share Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfShareIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Share Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_PercentageOfShareIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2022WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2022 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_December2022WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December 2022 warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Warrants outstanding, balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Warrants outstanding, balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pali_ClassOfWarrantOrRightNumberOutstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of warrants or rights outstanding as of the specified date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashWarrantModificationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash warrant modification costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashWarrantModificationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Warrant Modification Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_NonCashWarrantModificationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash warrant modification costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_January2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_January2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_January2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January 2023 Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares per employee (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ProceedsDepositedIntoTheCvrEscrow_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds deposited into the CVR escrow.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ProceedsDepositedIntoTheCvrEscrow_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds Deposited into the CVR Escrow</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ProceedsDepositedIntoTheCvrEscrow_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds deposited into the CVR escrow</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">pali_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of warrants or rights issued during period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant or right, issued during period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_JointDevelopmentExpenses" xlink:to="pali_JointDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ChangesInFairValueOfContingentConsideration" xlink:to="pali_ChangesInFairValueOfContingentConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClosingPeriodOfMergerAgreement" xlink:to="pali_ClosingPeriodOfMergerAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_IncrementalFairValueOfModifiedOrExchangedWarrants" xlink:to="pali_IncrementalFairValueOfModifiedOrExchangedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_RepricedWarrantsMember" xlink:to="pali_RepricedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" xlink:to="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ProgramExpenses" xlink:to="pali_ProgramExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_RecurringFairValueMeasurementsOfLiabilities" xlink:to="pali_RecurringFairValueMeasurementsOfLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SeriesAConvertiblePreferredStockMember" xlink:to="pali_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_RetainedEarningsAccumulatedIncomeDeficit" xlink:to="pali_RetainedEarningsAccumulatedIncomeDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_DeferredTaxAssetsAccruedExpenses" xlink:to="pali_DeferredTaxAssetsAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_UnregisteredSharesMember" xlink:to="pali_UnregisteredSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_CvrAgreementDistributionMinimumAmount" xlink:to="pali_CvrAgreementDistributionMinimumAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" xlink:to="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_May2024PlacementAgentWarrantsMember" xlink:to="pali_May2024PlacementAgentWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveRollForward" xlink:to="us-gaap_RestructuringReserveRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" xlink:to="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_The2021EsppMember" xlink:to="pali_The2021EsppMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AprilTwoThousandTwentyThreeWarrantsMember" xlink:to="pali_AprilTwoThousandTwentyThreeWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AccruedClinicalTrialCosts" xlink:to="pali_AccruedClinicalTrialCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_DeferredTaxAssetsDepreciation" xlink:to="pali_DeferredTaxAssetsDepreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_UncertainIncomeTaxPositions" xlink:to="pali_UncertainIncomeTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" xlink:to="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_InsuranceFinancingArrangementMember" xlink:to="pali_InsuranceFinancingArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing" xlink:to="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_OutOfPocketExpenses" xlink:to="pali_OutOfPocketExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:to="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AdditionalFinancingAgreementsTwoMember" xlink:to="pali_AdditionalFinancingAgreementsTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PercentageOfNetRevenue" xlink:to="pali_PercentageOfNetRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SeriesA4Point5PercentConvertiblePreferredStockMember" xlink:to="pali_SeriesA4Point5PercentConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AprilTwoThousandAndTwentyThreeOfferingMember" xlink:to="pali_AprilTwoThousandAndTwentyThreeOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_FinancingAgreementsMember" xlink:to="pali_FinancingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AdditionalFinancingAgreementsOneMember" xlink:to="pali_AdditionalFinancingAgreementsOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" xlink:to="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:to="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_TheDecember2019NoteMember" xlink:to="pali_TheDecember2019NoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionSoftware" xlink:to="us-gaap_RevenueRecognitionSoftware_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ContingentConsiderationObligationsMember" xlink:to="pali_ContingentConsiderationObligationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PrepaidSoftwareLicenses" xlink:to="pali_PrepaidSoftwareLicenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_September2023OfferingMember" xlink:to="pali_September2023OfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_DeferredTaxAssetsLeaseLiability" xlink:to="pali_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_OperatingLeasesFutureMinimumPayments" xlink:to="pali_OperatingLeasesFutureMinimumPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_MayTwoThousandTwentyTwoWarrantsMember" xlink:to="pali_MayTwoThousandTwentyTwoWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_The2021PlanMember" xlink:to="pali_The2021PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember" xlink:to="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_December2024OfferingPreFundedCommonStockWarrantsMember" xlink:to="pali_December2024OfferingPreFundedCommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_Nsi532Igf1Member" xlink:to="pali_Nsi532Igf1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClinicalTrialExpensesPolicyPolicyTextBlock" xlink:to="pali_ClinicalTrialExpensesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_DeferredEquityIssuanceCosts" xlink:to="pali_DeferredEquityIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PALITwoOneZeroEightMember" xlink:to="pali_PALITwoOneZeroEightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_FinancingCostDerivativeWarrantLiabilities" xlink:to="pali_FinancingCostDerivativeWarrantLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PercentageOfReductionInWorkForce" xlink:to="pali_PercentageOfReductionInWorkForce_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="pali_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants" xlink:to="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" xlink:to="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_February2024WarrantInducementMember" xlink:to="pali_February2024WarrantInducementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PaycheckProtectionProgramCARESActMember" xlink:to="pali_PaycheckProtectionProgramCARESActMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AccruedAccountsPayable" xlink:to="pali_AccruedAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" xlink:to="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NoncashOperatingLeaseExpense" xlink:to="pali_NoncashOperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_August2024OfferingSeries2CommonStockWarrantsMember" xlink:to="pali_August2024OfferingSeries2CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" xlink:to="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" xlink:to="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_Series2WarrantsMember" xlink:to="pali_Series2WarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" xlink:to="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" xlink:to="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ReplacementWarrantsMember" xlink:to="pali_ReplacementWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice" xlink:to="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_WarrantInducementAgreementsMember" xlink:to="pali_WarrantInducementAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AccruedJointDevelopmentExpenses" xlink:to="pali_AccruedJointDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NumberOfTerminatedLicenseAgreements" xlink:to="pali_NumberOfTerminatedLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_MilestonePayments" xlink:to="pali_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife" xlink:to="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses" xlink:to="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" xlink:to="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PlacementAgentWarrantsMember" xlink:to="pali_PlacementAgentWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="pali_NotesToFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_UnderwritingCommitmentsPerShare" xlink:to="pali_UnderwritingCommitmentsPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" xlink:to="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_May2024OfferingMember" xlink:to="pali_May2024OfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_December2024OfferingCommonStockWarrantsMember" xlink:to="pali_December2024OfferingCommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAdministrationExpenses" xlink:to="us-gaap_DefinedBenefitPlanAdministrationExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_December2024OfferingMember" xlink:to="pali_December2024OfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_DE" xlink:to="stpr_DE_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_JanuaryTwoThousandTwentyThreeWarrantsMember" xlink:to="pali_JanuaryTwoThousandTwentyThreeWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_MaximumAggregateConsideration" xlink:to="pali_MaximumAggregateConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NumberOfLicenseAgreements" xlink:to="pali_NumberOfLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInsuranceCurrent" xlink:to="us-gaap_AccruedInsuranceCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SeniorSecuredPromissoryNotesMember" xlink:to="pali_SeniorSecuredPromissoryNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_CostReductionPlanMember" xlink:to="pali_CostReductionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PercentageOfGrossProceeds" xlink:to="pali_PercentageOfGrossProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PaymentOfWarrantInducementIssuanceCosts" xlink:to="pali_PaymentOfWarrantInducementIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_FairValueOfWarrantsIssuedToSolicitationAgent" xlink:to="pali_FairValueOfWarrantsIssuedToSolicitationAgent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_April2023OfferingMember" xlink:to="pali_April2023OfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pali_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NumberOfTradingDays" xlink:to="pali_NumberOfTradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" xlink:to="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_InducementPlanMember" xlink:to="pali_InducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" xlink:to="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_StockPurchaseWarrantsMember" xlink:to="pali_StockPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="pali_ClassOfWarrantOrRightExercisedDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NetProceeds" xlink:to="pali_NetProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_WarrantsIssuanceCosts" xlink:to="pali_WarrantsIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_The2013PlanMember" xlink:to="pali_The2013PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_CollaborationsAndLicenseAgreementsUpfrontFee" xlink:to="pali_CollaborationsAndLicenseAgreementsUpfrontFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_GrantDateFairValue" xlink:to="pali_GrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_October2020NoteMember" xlink:to="pali_October2020NoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares" xlink:to="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AccruedCMCExpenses" xlink:to="pali_AccruedCMCExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PreFundedWarrantsMember" xlink:to="pali_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AltiumGrowthFundLPMember" xlink:to="pali_AltiumGrowthFundLPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_TimeBasedRestrictedStockUnitsMember" xlink:to="pali_TimeBasedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_OtherNoncurrentAssets" xlink:to="pali_OtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_July2020NoteMember" xlink:to="pali_July2020NoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_LicenseAgreementsTextBlock" xlink:to="pali_LicenseAgreementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_OriginalFinancingAgreementsMember" xlink:to="pali_OriginalFinancingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_LegacyMember" xlink:to="pali_LegacyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_CashTransactionRelatedExpensesAndPlacementAgentFees" xlink:to="pali_CashTransactionRelatedExpensesAndPlacementAgentFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_December2024RepresentativeWarrantsMember" xlink:to="pali_December2024RepresentativeWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice" xlink:to="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_MayTwoThousandTwentyFourOfferingMember" xlink:to="pali_MayTwoThousandTwentyFourOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_Series1PreferredStockOfLBSMember" xlink:to="pali_Series1PreferredStockOfLBSMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SublicenseFees" xlink:to="pali_SublicenseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ReverseStockSplitPolicyPolicyTextBlock" xlink:to="pali_ReverseStockSplitPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_FairValueOfWarrantsIssuedToPlacementAgents" xlink:to="pali_FairValueOfWarrantsIssuedToPlacementAgents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AccruedDirectorStipends" xlink:to="pali_AccruedDirectorStipends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_CostReductionPlanTwentyTwentyThreeMember" xlink:to="pali_CostReductionPlanTwentyTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod" xlink:to="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:to="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PrepaidSubscriptionsAndFees" xlink:to="pali_PrepaidSubscriptionsAndFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NetProceedsFromIssuanceOfWarrants" xlink:to="pali_NetProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassBUnitsMember" xlink:to="pali_ClassBUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" xlink:to="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ContingentConsiderationObligationsPolicyTextBlock" xlink:to="pali_ContingentConsiderationObligationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PercentageCostInPatentRight" xlink:to="pali_PercentageCostInPatentRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_CashConsideration" xlink:to="pali_CashConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember" xlink:to="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pali_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveAbstract" xlink:to="us-gaap_RestructuringReserveAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightNumberOfRightsIssued" xlink:to="pali_ClassOfWarrantOrRightNumberOfRightsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PeriodOfExpirationOfLicenseAgreementDescription" xlink:to="pali_PeriodOfExpirationOfLicenseAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_AllOtherCommonStockWarrantsMember" xlink:to="pali_AllOtherCommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NonCashWarrantIssuanceCosts" xlink:to="pali_NonCashWarrantIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice" xlink:to="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember" xlink:to="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassAUnitsMember" xlink:to="pali_ClassAUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_PercentageOfShareIssued" xlink:to="pali_PercentageOfShareIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_December2022WarrantsMember" xlink:to="pali_December2022WarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightNumberOutstanding" xlink:to="pali_ClassOfWarrantOrRightNumberOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_NonCashWarrantModificationCosts" xlink:to="pali_NonCashWarrantModificationCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_January2023OfferingMember" xlink:to="pali_January2023OfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ProceedsDepositedIntoTheCvrEscrow" xlink:to="pali_ProceedsDepositedIntoTheCvrEscrow_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pali_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="pali_ClassOfWarrantOrRightIssuedDuringPeriod_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RetainedEarningsAccumulatedIncomeDeficit" xlink:label="pali_RetainedEarningsAccumulatedIncomeDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="pali_RetainedEarningsAccumulatedIncomeDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedInsuranceCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FinancingCostDerivativeWarrantLiabilities" xlink:label="pali_FinancingCostDerivativeWarrantLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="pali_FinancingCostDerivativeWarrantLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAgreementsMember" xlink:label="pali_WarrantInducementAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_September2023OfferingMember" xlink:label="pali_September2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_April2023OfferingMember" xlink:label="pali_April2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024OfferingMember" xlink:label="pali_May2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingMember" xlink:label="pali_December2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_January2023OfferingMember" xlink:label="pali_January2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" xlink:label="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" xlink:label="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" xlink:label="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_WarrantInducementAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_September2023OfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_April2023OfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_May2024OfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_January2023OfferingMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingMember" xlink:label="pali_December2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024OfferingMember" xlink:label="pali_May2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_January2023OfferingMember" xlink:label="pali_January2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_September2023OfferingMember" xlink:label="pali_September2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_April2023OfferingMember" xlink:label="pali_April2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAgreementsMember" xlink:label="pali_WarrantInducementAgreementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_May2024OfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_January2023OfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_September2023OfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_April2023OfferingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_WarrantInducementAgreementsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" xlink:label="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NoncashOperatingLeaseExpense" xlink:label="pali_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToSolicitationAgent" xlink:label="pali_FairValueOfWarrantsIssuedToSolicitationAgent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RecurringFairValueMeasurementsOfLiabilities" xlink:label="pali_RecurringFairValueMeasurementsOfLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToPlacementAgents" xlink:label="pali_FairValueOfWarrantsIssuedToPlacementAgents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PaymentOfWarrantInducementIssuanceCosts" xlink:label="pali_PaymentOfWarrantInducementIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" xlink:label="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" xlink:label="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" xlink:label="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncrementalFairValueOfModifiedOrExchangedWarrants" xlink:label="pali_IncrementalFairValueOfModifiedOrExchangedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_10"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pali_NoncashOperatingLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_FairValueOfWarrantsIssuedToSolicitationAgent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pali_RecurringFairValueMeasurementsOfLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_FairValueOfWarrantsIssuedToPlacementAgents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pali_PaymentOfWarrantInducementIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_IncrementalFairValueOfModifiedOrExchangedWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusiness1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NotesToFinancialStatementsAbstract" xlink:label="pali_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OriginalFinancingAgreementsMember" xlink:label="pali_OriginalFinancingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Series1PreferredStockOfLBSMember" xlink:label="pali_Series1PreferredStockOfLBSMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NotesToFinancialStatementsAbstract" xlink:label="pali_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AltiumGrowthFundLPMember" xlink:label="pali_AltiumGrowthFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdditionalFinancingAgreementsOneMember" xlink:label="pali_AdditionalFinancingAgreementsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdditionalFinancingAgreementsTwoMember" xlink:label="pali_AdditionalFinancingAgreementsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FinancingAgreementsMember" xlink:label="pali_FinancingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_TheDecember2019NoteMember" xlink:label="pali_TheDecember2019NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_July2020NoteMember" xlink:label="pali_July2020NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_October2020NoteMember" xlink:label="pali_October2020NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNotesMember" xlink:label="pali_SeniorSecuredPromissoryNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PaycheckProtectionProgramCARESActMember" xlink:label="pali_PaycheckProtectionProgramCARESActMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_OriginalFinancingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_Series1PreferredStockOfLBSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pali_AltiumGrowthFundLPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_AdditionalFinancingAgreementsOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_AdditionalFinancingAgreementsTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_FinancingAgreementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_TheDecember2019NoteMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_July2020NoteMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_October2020NoteMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_SeniorSecuredPromissoryNotesMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_PaycheckProtectionProgramCARESActMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlans1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NotesToFinancialStatementsAbstract" xlink:label="pali_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsTextBlock" xlink:label="pali_LicenseAgreementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="pali_LicenseAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote10EmployeeBenefits" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxes1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ReverseStockSplitPolicyPolicyTextBlock" xlink:label="pali_ReverseStockSplitPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionSoftware" xlink:label="us-gaap_RevenueRecognitionSoftware"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentConsiderationObligationsPolicyTextBlock" xlink:label="pali_ContingentConsiderationObligationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClinicalTrialExpensesPolicyPolicyTextBlock" xlink:label="pali_ClinicalTrialExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pali_ReverseStockSplitPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionSoftware" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pali_ContingentConsiderationObligationsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pali_ClinicalTrialExpensesPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4CommonStockWarrantsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentConsiderationObligationsMember" xlink:label="pali_ContingentConsiderationObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockPurchaseWarrantsMember" xlink:label="pali_StockPurchaseWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_ContingentConsiderationObligationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_StockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt-tables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementMember" xlink:label="pali_February2024WarrantInducementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pali_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pali_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredEquityIssuanceCosts" xlink:label="pali_DeferredEquityIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_February2024WarrantInducementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pali_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesTable" xlink:to="pali_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCostsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pali_DeferredEquityIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" xlink:label="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidSubscriptionsAndFees" xlink:label="pali_PrepaidSubscriptionsAndFees"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidSoftwareLicenses" xlink:label="pali_PrepaidSoftwareLicenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="pali_PrepaidSubscriptionsAndFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="pali_PrepaidSoftwareLicenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_DepositAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OtherNoncurrentAssets" xlink:label="pali_OtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="pali_OtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NotesToFinancialStatementsAbstract" xlink:label="pali_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedAccountsPayable" xlink:label="pali_AccruedAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedClinicalTrialCosts" xlink:label="pali_AccruedClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedCMCExpenses" xlink:label="pali_AccruedCMCExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedDirectorStipends" xlink:label="pali_AccruedDirectorStipends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedJointDevelopmentExpenses" xlink:label="pali_AccruedJointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="pali_AccruedAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="pali_AccruedClinicalTrialCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="pali_AccruedCMCExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="pali_AccruedDirectorStipends" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="pali_AccruedJointDevelopmentExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ChangesInFairValueOfContingentConsideration" xlink:label="pali_ChangesInFairValueOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="pali_ChangesInFairValueOfContingentConsideration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentConsiderationObligationsMember" xlink:label="pali_ContingentConsiderationObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockPurchaseWarrantsMember" xlink:label="pali_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_ContingentConsiderationObligationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_StockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeriesA4Point5PercentConvertiblePreferredStockMember" xlink:label="pali_SeriesA4Point5PercentConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_DE" xlink:label="stpr_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingCommonStockWarrantsMember" xlink:label="pali_December2024OfferingCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassAUnitsMember" xlink:label="pali_ClassAUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024RepresentativeWarrantsMember" xlink:label="pali_December2024RepresentativeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassBUnitsMember" xlink:label="pali_ClassBUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingMember" xlink:label="pali_December2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RepricedWarrantsMember" xlink:label="pali_RepricedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="pali_MayTwoThousandTwentyTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PreFundedWarrantsMember" xlink:label="pali_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeptemberTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares" xlink:label="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyFourOfferingMember" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Series2WarrantsMember" xlink:label="pali_Series2WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UnregisteredSharesMember" xlink:label="pali_UnregisteredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AprilTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_AprilTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024PlacementAgentWarrantsMember" xlink:label="pali_May2024PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JanuaryTwoThousandTwentyThreeWarrantsMember" xlink:label="pali_JanuaryTwoThousandTwentyThreeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ReplacementWarrantsMember" xlink:label="pali_ReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JanuaryTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UnderwritingCommitmentsPerShare" xlink:label="pali_UnderwritingCommitmentsPerShare"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementMember" xlink:label="pali_February2024WarrantInducementMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AprilTwoThousandTwentyThreeWarrantsMember" xlink:label="pali_AprilTwoThousandTwentyThreeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PlacementAgentWarrantsMember" xlink:label="pali_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2022WarrantsMember" xlink:label="pali_December2022WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceedsFromIssuanceOfWarrants" xlink:label="pali_NetProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CashTransactionRelatedExpensesAndPlacementAgentFees" xlink:label="pali_CashTransactionRelatedExpensesAndPlacementAgentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:label="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OutOfPocketExpenses" xlink:label="pali_OutOfPocketExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantsIssuanceCosts" xlink:label="pali_WarrantsIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashWarrantModificationCosts" xlink:label="pali_NonCashWarrantModificationCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashWarrantIssuanceCosts" xlink:label="pali_NonCashWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfGrossProceeds" xlink:label="pali_PercentageOfGrossProceeds"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfShareIssued" xlink:label="pali_PercentageOfShareIssued"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceeds" xlink:label="pali_NetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_GrantDateFairValue" xlink:label="pali_GrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_SeriesA4Point5PercentConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_DE" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingCommonStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_ClassAUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024RepresentativeWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_ClassBUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_December2024OfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_RepricedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_MayTwoThousandTwentyTwoWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_PreFundedWarrantsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_MayTwoThousandTwentyFourOfferingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_Series2WarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_UnregisteredSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_AprilTwoThousandAndTwentyThreeOfferingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_May2024PlacementAgentWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_JanuaryTwoThousandTwentyThreeWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_ReplacementWarrantsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_UnderwritingCommitmentsPerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_February2024WarrantInducementMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_AprilTwoThousandTwentyThreeWarrantsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_PlacementAgentWarrantsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2022WarrantsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NetProceedsFromIssuanceOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_CashTransactionRelatedExpensesAndPlacementAgentFees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_OutOfPocketExpenses" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_WarrantsIssuanceCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NonCashWarrantModificationCosts" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NonCashWarrantIssuanceCosts" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageOfGrossProceeds" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageOfShareIssued" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NetProceeds" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_GrantDateFairValue" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingPreFundedCommonStockWarrantsMember" xlink:label="pali_December2024OfferingPreFundedCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingCommonStockWarrantsMember" xlink:label="pali_December2024OfferingCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyFourOfferingMember" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementReplacementCommonStockWarrantsMember" xlink:label="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_August2024OfferingSeries2CommonStockWarrantsMember" xlink:label="pali_August2024OfferingSeries2CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" xlink:label="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" xlink:label="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AllOtherCommonStockWarrantsMember" xlink:label="pali_AllOtherCommonStockWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingPreFundedCommonStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingCommonStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_MayTwoThousandTwentyFourOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_August2024OfferingSeries2CommonStockWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_AllOtherCommonStockWarrantsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightNumberOutstanding" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NotesToFinancialStatementsAbstract" xlink:label="pali_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightNumberOutstanding" xlink:label="pali_ClassOfWarrantOrRightNumberOutstanding_4"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice" xlink:label="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" xlink:label="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife" xlink:label="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightNumberOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightIssuedDuringPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightExercisedDuringPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightNumberOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021PlanMember" xlink:label="pali_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2013PlanMember" xlink:label="pali_The2013PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021EsppMember" xlink:label="pali_The2021EsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_InducementPlanMember" xlink:label="pali_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_TimeBasedRestrictedStockUnitsMember" xlink:label="pali_TimeBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfTradingDays" xlink:label="pali_NumberOfTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2021PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2013PlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2021EsppMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_InducementPlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_TimeBasedRestrictedStockUnitsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NumberOfTradingDays" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021PlanMember" xlink:label="pali_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2021PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CollaborationsAndLicenseAgreementsUpfrontFee" xlink:label="pali_CollaborationsAndLicenseAgreementsUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NotesToFinancialStatementsAbstract" xlink:label="pali_NotesToFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Nsi532Igf1Member" xlink:label="pali_Nsi532Igf1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MaximumAggregateConsideration" xlink:label="pali_MaximumAggregateConsideration"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MilestonePayments" xlink:label="pali_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClosingPeriodOfMergerAgreement" xlink:label="pali_ClosingPeriodOfMergerAgreement"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ProceedsDepositedIntoTheCvrEscrow" xlink:label="pali_ProceedsDepositedIntoTheCvrEscrow"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfLicenseAgreements" xlink:label="pali_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfTerminatedLicenseAgreements" xlink:label="pali_NumberOfTerminatedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" xlink:label="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JointDevelopmentExpenses" xlink:label="pali_JointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedJointDevelopmentExpenses" xlink:label="pali_AccruedJointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SublicenseFees" xlink:label="pali_SublicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PeriodOfExpirationOfLicenseAgreementDescription" xlink:label="pali_PeriodOfExpirationOfLicenseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightNumberOfRightsIssued" xlink:label="pali_ClassOfWarrantOrRightNumberOfRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing" xlink:label="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CvrAgreementDistributionMinimumAmount" xlink:label="pali_CvrAgreementDistributionMinimumAmount"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageCostInPatentRight" xlink:label="pali_PercentageCostInPatentRight"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfNetRevenue" xlink:label="pali_PercentageOfNetRevenue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_CollaborationsAndLicenseAgreementsUpfrontFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pali_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pali_Nsi532Igf1Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_MaximumAggregateConsideration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_MilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClosingPeriodOfMergerAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ProceedsDepositedIntoTheCvrEscrow" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NumberOfLicenseAgreements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NumberOfTerminatedLicenseAgreements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_JointDevelopmentExpenses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_AccruedJointDevelopmentExpenses" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_SublicenseFees" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PeriodOfExpirationOfLicenseAgreementDescription" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightNumberOfRightsIssued" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_CvrAgreementDistributionMinimumAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageCostInPatentRight" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageOfNetRevenue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CostReductionPlanMember" xlink:label="pali_CostReductionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_InsuranceFinancingArrangementMember" xlink:label="pali_InsuranceFinancingArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" xlink:label="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CostReductionPlanTwentyTwentyThreeMember" xlink:label="pali_CostReductionPlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfReductionInWorkForce" xlink:label="pali_PercentageOfReductionInWorkForce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAdministrationExpenses" xlink:label="us-gaap_DefinedBenefitPlanAdministrationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OperatingLeasesFutureMinimumPayments" xlink:label="pali_OperatingLeasesFutureMinimumPayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="pali_CostReductionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="pali_InsuranceFinancingArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="pali_CostReductionPlanTwentyTwentyThreeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LossContingenciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pali_PercentageOfReductionInWorkForce" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RestructuringCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DefinedBenefitPlanAdministrationExpenses" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pali_OperatingLeasesFutureMinimumPayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="us-gaap_RestructuringReserveRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAbstract" xlink:label="us-gaap_RestructuringReserveAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="us-gaap_RestructuringReserveAccrualAdjustment1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveRollForward" xlink:to="us-gaap_RestructuringReserve" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveAbstract" xlink:to="us-gaap_RestructuringReserveRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveRollForward" xlink:to="us-gaap_RestructuringReserveAccrualAdjustment1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveRollForward" xlink:to="us-gaap_PaymentsForRestructuring" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringReserveRollForward" xlink:to="us-gaap_RestructuringReserve_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CashConsideration" xlink:label="pali_CashConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PreFundedWarrantsMember" xlink:label="pali_PreFundedWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="pali_CashConsideration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_PreFundedWarrantsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeriesAConvertiblePreferredStockMember" xlink:label="pali_SeriesAConvertiblePreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pali_SeriesAConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UncertainIncomeTaxPositions" xlink:label="pali_UncertainIncomeTaxPositions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pali_UncertainIncomeTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationNondeductibleExpenseWarrants" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationOtherNonDeductibleExpenses" xlink:label="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsAccruedExpenses" xlink:label="pali_DeferredTaxAssetsAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsDepreciation" xlink:label="pali_DeferredTaxAssetsDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsLeaseLiability" xlink:label="pali_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="pali_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pali_DeferredTaxAssetsAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pali_DeferredTaxAssetsDepreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pali_DeferredTaxAssetsLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pali_DeferredTaxLiabilitiesRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PALITwoOneZeroEightMember" xlink:label="pali_PALITwoOneZeroEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ProgramExpenses" xlink:label="pali_ProgramExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LegacyMember" xlink:label="pali_LegacyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pali_PALITwoOneZeroEightMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="pali_ProgramExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pali_LegacyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestructuringCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RetainedEarningsAccumulatedIncomeDeficit" xlink:label="pali_RetainedEarningsAccumulatedIncomeDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="pali_RetainedEarningsAccumulatedIncomeDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedInsuranceCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAgreementsMember" xlink:label="pali_WarrantInducementAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_September2023OfferingMember" xlink:label="pali_September2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_April2023OfferingMember" xlink:label="pali_April2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024OfferingMember" xlink:label="pali_May2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingMember" xlink:label="pali_December2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_January2023OfferingMember" xlink:label="pali_January2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" xlink:label="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" xlink:label="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" xlink:label="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_WarrantInducementAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_September2023OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_April2023OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_May2024OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_January2023OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingMember" xlink:label="pali_December2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024OfferingMember" xlink:label="pali_May2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_January2023OfferingMember" xlink:label="pali_January2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_September2023OfferingMember" xlink:label="pali_September2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_April2023OfferingMember" xlink:label="pali_April2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAgreementsMember" xlink:label="pali_WarrantInducementAgreementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_May2024OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_January2023OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_September2023OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_April2023OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_WarrantInducementAgreementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" xlink:label="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NoncashOperatingLeaseExpense" xlink:label="pali_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToSolicitationAgent" xlink:label="pali_FairValueOfWarrantsIssuedToSolicitationAgent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RecurringFairValueMeasurementsOfLiabilities" xlink:label="pali_RecurringFairValueMeasurementsOfLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToPlacementAgents" xlink:label="pali_FairValueOfWarrantsIssuedToPlacementAgents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PaymentOfWarrantInducementIssuanceCosts" xlink:label="pali_PaymentOfWarrantInducementIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" xlink:label="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" xlink:label="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" xlink:label="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncrementalFairValueOfModifiedOrExchangedWarrants" xlink:label="pali_IncrementalFairValueOfModifiedOrExchangedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pali_NoncashOperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_FairValueOfWarrantsIssuedToSolicitationAgent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pali_RecurringFairValueMeasurementsOfLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_FairValueOfWarrantsIssuedToPlacementAgents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pali_PaymentOfWarrantInducementIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="pali_IncrementalFairValueOfModifiedOrExchangedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OriginalFinancingAgreementsMember" xlink:label="pali_OriginalFinancingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Series1PreferredStockOfLBSMember" xlink:label="pali_Series1PreferredStockOfLBSMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AltiumGrowthFundLPMember" xlink:label="pali_AltiumGrowthFundLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdditionalFinancingAgreementsOneMember" xlink:label="pali_AdditionalFinancingAgreementsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" xlink:label="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AdditionalFinancingAgreementsTwoMember" xlink:label="pali_AdditionalFinancingAgreementsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FinancingAgreementsMember" xlink:label="pali_FinancingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_TheDecember2019NoteMember" xlink:label="pali_TheDecember2019NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_July2020NoteMember" xlink:label="pali_July2020NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_October2020NoteMember" xlink:label="pali_October2020NoteMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeniorSecuredPromissoryNotesMember" xlink:label="pali_SeniorSecuredPromissoryNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PaycheckProtectionProgramCARESActMember" xlink:label="pali_PaycheckProtectionProgramCARESActMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_OriginalFinancingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_Series1PreferredStockOfLBSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pali_AltiumGrowthFundLPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_AdditionalFinancingAgreementsOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_AdditionalFinancingAgreementsTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_FinancingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_TheDecember2019NoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_July2020NoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_October2020NoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_SeniorSecuredPromissoryNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="pali_PaycheckProtectionProgramCARESActMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsTextBlock" xlink:label="pali_LicenseAgreementsTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="pali_LicenseAgreementsTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentConsiderationObligationsMember" xlink:label="pali_ContingentConsiderationObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockPurchaseWarrantsMember" xlink:label="pali_StockPurchaseWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_ContingentConsiderationObligationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_StockPurchaseWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="pali_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SummaryOfSignificantAccountingPoliciesTable" xlink:label="pali_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementMember" xlink:label="pali_February2024WarrantInducementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredEquityIssuanceCosts" xlink:label="pali_DeferredEquityIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pali_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_February2024WarrantInducementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pali_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pali_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredCostsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pali_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="pali_DeferredEquityIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ChangesInFairValueOfContingentConsideration" xlink:label="pali_ChangesInFairValueOfContingentConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="pali_ChangesInFairValueOfContingentConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentConsiderationObligationsMember" xlink:label="pali_ContingentConsiderationObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_StockPurchaseWarrantsMember" xlink:label="pali_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_ContingentConsiderationObligationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="pali_StockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PreFundedWarrantsMember" xlink:label="pali_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeriesA4Point5PercentConvertiblePreferredStockMember" xlink:label="pali_SeriesA4Point5PercentConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_DE" xlink:label="stpr_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingCommonStockWarrantsMember" xlink:label="pali_December2024OfferingCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassAUnitsMember" xlink:label="pali_ClassAUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UnregisteredSharesMember" xlink:label="pali_UnregisteredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024RepresentativeWarrantsMember" xlink:label="pali_December2024RepresentativeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassBUnitsMember" xlink:label="pali_ClassBUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ReplacementWarrantsMember" xlink:label="pali_ReplacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingMember" xlink:label="pali_December2024OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RepricedWarrantsMember" xlink:label="pali_RepricedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="pali_MayTwoThousandTwentyTwoWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeptemberTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares" xlink:label="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyFourOfferingMember" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Series2WarrantsMember" xlink:label="pali_Series2WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AprilTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_AprilTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_May2024PlacementAgentWarrantsMember" xlink:label="pali_May2024PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JanuaryTwoThousandTwentyThreeWarrantsMember" xlink:label="pali_JanuaryTwoThousandTwentyThreeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JanuaryTwoThousandAndTwentyThreeOfferingMember" xlink:label="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UnderwritingCommitmentsPerShare" xlink:label="pali_UnderwritingCommitmentsPerShare"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementMember" xlink:label="pali_February2024WarrantInducementMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AprilTwoThousandTwentyThreeWarrantsMember" xlink:label="pali_AprilTwoThousandTwentyThreeWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PlacementAgentWarrantsMember" xlink:label="pali_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2022WarrantsMember" xlink:label="pali_December2022WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceedsFromIssuanceOfWarrants" xlink:label="pali_NetProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CashTransactionRelatedExpensesAndPlacementAgentFees" xlink:label="pali_CashTransactionRelatedExpensesAndPlacementAgentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:label="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OutOfPocketExpenses" xlink:label="pali_OutOfPocketExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_WarrantsIssuanceCosts" xlink:label="pali_WarrantsIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashWarrantModificationCosts" xlink:label="pali_NonCashWarrantModificationCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NonCashWarrantIssuanceCosts" xlink:label="pali_NonCashWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfGrossProceeds" xlink:label="pali_PercentageOfGrossProceeds"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfShareIssued" xlink:label="pali_PercentageOfShareIssued"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NetProceeds" xlink:label="pali_NetProceeds"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_GrantDateFairValue" xlink:label="pali_GrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_SeriesA4Point5PercentConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_DE" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingCommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_ClassAUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_UnregisteredSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024RepresentativeWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_ClassBUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_ReplacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_December2024OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_RepricedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_MayTwoThousandTwentyTwoWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_MayTwoThousandTwentyFourOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_Series2WarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_AprilTwoThousandAndTwentyThreeOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_May2024PlacementAgentWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_JanuaryTwoThousandTwentyThreeWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_UnderwritingCommitmentsPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_February2024WarrantInducementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pali_AprilTwoThousandTwentyThreeWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_PlacementAgentWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2022WarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NetProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_CashTransactionRelatedExpensesAndPlacementAgentFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_OutOfPocketExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_WarrantsIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NonCashWarrantModificationCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NonCashWarrantIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageOfGrossProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageOfShareIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NetProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_GrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingPreFundedCommonStockWarrantsMember" xlink:label="pali_December2024OfferingPreFundedCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_December2024OfferingCommonStockWarrantsMember" xlink:label="pali_December2024OfferingCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MayTwoThousandTwentyFourOfferingMember" xlink:label="pali_MayTwoThousandTwentyFourOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_February2024WarrantInducementReplacementCommonStockWarrantsMember" xlink:label="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_August2024OfferingSeries2CommonStockWarrantsMember" xlink:label="pali_August2024OfferingSeries2CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" xlink:label="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" xlink:label="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AllOtherCommonStockWarrantsMember" xlink:label="pali_AllOtherCommonStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingPreFundedCommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_December2024OfferingCommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_MayTwoThousandTwentyFourOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_August2024OfferingSeries2CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pali_AllOtherCommonStockWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021PlanMember" xlink:label="pali_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2013PlanMember" xlink:label="pali_The2013PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021EsppMember" xlink:label="pali_The2021EsppMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_TimeBasedRestrictedStockUnitsMember" xlink:label="pali_TimeBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_InducementPlanMember" xlink:label="pali_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfTradingDays" xlink:label="pali_NumberOfTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2021PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2013PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2021EsppMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_TimeBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_InducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NumberOfTradingDays" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" xlink:label="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_The2021PlanMember" xlink:label="pali_The2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pali_The2021PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CollaborationsAndLicenseAgreementsUpfrontFee" xlink:label="pali_CollaborationsAndLicenseAgreementsUpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" xlink:label="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_Nsi532Igf1Member" xlink:label="pali_Nsi532Igf1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MaximumAggregateConsideration" xlink:label="pali_MaximumAggregateConsideration"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_MilestonePayments" xlink:label="pali_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClosingPeriodOfMergerAgreement" xlink:label="pali_ClosingPeriodOfMergerAgreement"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ProceedsDepositedIntoTheCvrEscrow" xlink:label="pali_ProceedsDepositedIntoTheCvrEscrow"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfLicenseAgreements" xlink:label="pali_NumberOfLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NumberOfTerminatedLicenseAgreements" xlink:label="pali_NumberOfTerminatedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" xlink:label="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_JointDevelopmentExpenses" xlink:label="pali_JointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedJointDevelopmentExpenses" xlink:label="pali_AccruedJointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SublicenseFees" xlink:label="pali_SublicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PeriodOfExpirationOfLicenseAgreementDescription" xlink:label="pali_PeriodOfExpirationOfLicenseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ClassOfWarrantOrRightNumberOfRightsIssued" xlink:label="pali_ClassOfWarrantOrRightNumberOfRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing" xlink:label="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CvrAgreementDistributionMinimumAmount" xlink:label="pali_CvrAgreementDistributionMinimumAmount"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageCostInPatentRight" xlink:label="pali_PercentageCostInPatentRight"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfNetRevenue" xlink:label="pali_PercentageOfNetRevenue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_CollaborationsAndLicenseAgreementsUpfrontFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pali_Nsi532Igf1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_MaximumAggregateConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClosingPeriodOfMergerAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ProceedsDepositedIntoTheCvrEscrow" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NumberOfLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_NumberOfTerminatedLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_JointDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_AccruedJointDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_SublicenseFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PeriodOfExpirationOfLicenseAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ClassOfWarrantOrRightNumberOfRightsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_CvrAgreementDistributionMinimumAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageCostInPatentRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pali_PercentageOfNetRevenue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CostReductionPlanMember" xlink:label="pali_CostReductionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_InsuranceFinancingArrangementMember" xlink:label="pali_InsuranceFinancingArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" xlink:label="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CostReductionPlanTwentyTwentyThreeMember" xlink:label="pali_CostReductionPlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PercentageOfReductionInWorkForce" xlink:label="pali_PercentageOfReductionInWorkForce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAdministrationExpenses" xlink:label="us-gaap_DefinedBenefitPlanAdministrationExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OperatingLeasesFutureMinimumPayments" xlink:label="pali_OperatingLeasesFutureMinimumPayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="pali_CostReductionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="pali_InsuranceFinancingArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="pali_CostReductionPlanTwentyTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pali_PercentageOfReductionInWorkForce" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DefinedBenefitPlanAdministrationExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pali_OperatingLeasesFutureMinimumPayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PreFundedWarrantsMember" xlink:label="pali_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_CashConsideration" xlink:label="pali_CashConsideration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pali_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="pali_CashConsideration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_SeriesAConvertiblePreferredStockMember" xlink:label="pali_SeriesAConvertiblePreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pali_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_UncertainIncomeTaxPositions" xlink:label="pali_UncertainIncomeTaxPositions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pali_UncertainIncomeTaxPositions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PALITwoOneZeroEightMember" xlink:label="pali_PALITwoOneZeroEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_ProgramExpenses" xlink:label="pali_ProgramExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_LegacyMember" xlink:label="pali_LegacyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pali_PALITwoOneZeroEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="pali_ProgramExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pali_LegacyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="pali_RetainedEarningsAccumulatedIncomeDeficit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedInsuranceCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RetainedEarningsAccumulatedIncomeDeficit" xlink:label="pali_RetainedEarningsAccumulatedIncomeDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="us-gaap_AccruedInsuranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="pali_FinancingCostDerivativeWarrantLiabilities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_FinancingCostDerivativeWarrantLiabilities" xlink:label="pali_FinancingCostDerivativeWarrantLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pali_PaymentOfWarrantInducementIssuanceCosts" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pali_RecurringFairValueMeasurementsOfLiabilities" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pali_NoncashOperatingLeaseExpense" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="20" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="26" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PaymentOfWarrantInducementIssuanceCosts" xlink:label="pali_PaymentOfWarrantInducementIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_RecurringFairValueMeasurementsOfLiabilities" xlink:label="pali_RecurringFairValueMeasurementsOfLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_NoncashOperatingLeaseExpense" xlink:label="pali_NoncashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pali_PrepaidSubscriptionsAndFees" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="pali_PrepaidSoftwareLicenses" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" xlink:label="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidSubscriptionsAndFees" xlink:label="pali_PrepaidSubscriptionsAndFees"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_PrepaidSoftwareLicenses" xlink:label="pali_PrepaidSoftwareLicenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="pali_OtherNoncurrentAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_OtherNoncurrentAssets" xlink:label="pali_OtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pali_AccruedAccountsPayable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pali_AccruedClinicalTrialCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pali_AccruedCMCExpenses" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pali_AccruedDirectorStipends" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pali_AccruedJointDevelopmentExpenses" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedAccountsPayable" xlink:label="pali_AccruedAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedClinicalTrialCosts" xlink:label="pali_AccruedClinicalTrialCosts"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedCMCExpenses" xlink:label="pali_AccruedCMCExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedDirectorStipends" xlink:label="pali_AccruedDirectorStipends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_AccruedJointDevelopmentExpenses" xlink:label="pali_AccruedJointDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="13" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationNondeductibleExpenseWarrants" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" xlink:label="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_IncomeTaxReconciliationOtherNonDeductibleExpenses" xlink:label="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="pali_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pali_DeferredTaxAssetsAccruedExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pali_DeferredTaxAssetsDepreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pali_DeferredTaxAssetsLeaseLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="pali_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsAccruedExpenses" xlink:label="pali_DeferredTaxAssetsAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsDepreciation" xlink:label="pali_DeferredTaxAssetsDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="pali-20241231.xsd#pali_DeferredTaxAssetsLeaseLiability" xlink:label="pali_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pali_SeptemberTwoThousandAndTwentyThreeOfferingMember" name="SeptemberTwoThousandAndTwentyThreeOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_Nsi532Igf1Member" name="Nsi532Igf1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" name="StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_IncrementalFairValueOfModifiedOrExchangedWarrants" name="IncrementalFairValueOfModifiedOrExchangedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_PercentageOfNetRevenue" name="PercentageOfNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_StockPurchaseWarrantsMember" name="StockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife" name="ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_LicenseAgreementsTextBlock" name="LicenseAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" name="OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PaycheckProtectionProgramCARESActMember" name="PaycheckProtectionProgramCARESActMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ClassOfWarrantOrRightNumberOfRightsIssued" name="ClassOfWarrantOrRightNumberOfRightsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_DeferredTaxAssetsAccruedExpenses" name="DeferredTaxAssetsAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" name="LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_WarrantInducementAgreementsMember" name="WarrantInducementAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_NumberOfLicenseAgreements" name="NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_February2024WarrantInducementReplacementCommonStockWarrantsMember" name="February2024WarrantInducementReplacementCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_MaximumAggregateConsideration" name="MaximumAggregateConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" name="NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_LegacyMember" name="LegacyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PercentageCostInPatentRight" name="PercentageCostInPatentRight" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_October2020NoteMember" name="October2020NoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_OperatingLeasesFutureMinimumPayments" name="OperatingLeasesFutureMinimumPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" name="ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_Series2WarrantsMember" name="Series2WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_AccruedAccountsPayable" name="AccruedAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" name="SeniorSecuredPromissoryNoteWarrantsFirstClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_September2023OfferingMember" name="September2023OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_DeferredEquityIssuanceCosts" name="DeferredEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_InsuranceFinancingArrangementMember" name="InsuranceFinancingArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_OtherNoncurrentAssets" name="OtherNoncurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_December2024OfferingPreFundedCommonStockWarrantsMember" name="December2024OfferingPreFundedCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_CvrAgreementDistributionMinimumAmount" name="CvrAgreementDistributionMinimumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" name="PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_CostReductionPlanMember" name="CostReductionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" name="AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_AprilTwoThousandAndTwentyThreeOfferingMember" name="AprilTwoThousandAndTwentyThreeOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ClinicalTrialExpensesPolicyPolicyTextBlock" name="ClinicalTrialExpensesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_AccruedDirectorStipends" name="AccruedDirectorStipends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_ProceedsDepositedIntoTheCvrEscrow" name="ProceedsDepositedIntoTheCvrEscrow" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" name="DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_RecurringFairValueMeasurementsOfLiabilities" name="RecurringFairValueMeasurementsOfLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_FinancingCostDerivativeWarrantLiabilities" name="FinancingCostDerivativeWarrantLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_CostReductionPlanTwentyTwentyThreeMember" name="CostReductionPlanTwentyTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_TimeBasedRestrictedStockUnitsMember" name="TimeBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_Series1PreferredStockOfLBSMember" name="Series1PreferredStockOfLBSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod" name="ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_The2021EsppMember" name="The2021EsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" name="IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_JanuaryTwoThousandAndTwentyThreeOfferingMember" name="JanuaryTwoThousandAndTwentyThreeOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_SeniorSecuredPromissoryNotesMember" name="SeniorSecuredPromissoryNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_NetProceedsFromIssuanceOfWarrants" name="NetProceedsFromIssuanceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_JanuaryTwoThousandTwentyThreeWarrantsMember" name="JanuaryTwoThousandTwentyThreeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ClassOfWarrantOrRightNumberOutstanding" name="ClassOfWarrantOrRightNumberOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_ContingentConsiderationObligationsMember" name="ContingentConsiderationObligationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PrepaidSoftwareLicenses" name="PrepaidSoftwareLicenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_AllOtherCommonStockWarrantsMember" name="AllOtherCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_April2023OfferingMember" name="April2023OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" name="BridgeJanuary2021AndJuly2021CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_FinancingAgreementsMember" name="FinancingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ClassBUnitsMember" name="ClassBUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing" name="ContingentValueRightProRataNetProceedsFromSaleOrLicensing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_RetainedEarningsAccumulatedIncomeDeficit" name="RetainedEarningsAccumulatedIncomeDeficit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_AccruedJointDevelopmentExpenses" name="AccruedJointDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" name="SeniorSecuredPromissoryNoteWarrantsSecondClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_AdditionalFinancingAgreementsOneMember" name="AdditionalFinancingAgreementsOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" name="RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_February2024WarrantInducementMember" name="February2024WarrantInducementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PercentageOfShareIssued" name="PercentageOfShareIssued" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_NumberOfTerminatedLicenseAgreements" name="NumberOfTerminatedLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_AccruedCMCExpenses" name="AccruedCMCExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice" name="ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_OriginalFinancingAgreementsMember" name="OriginalFinancingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ReverseStockSplitPolicyPolicyTextBlock" name="ReverseStockSplitPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_NumberOfTradingDays" name="NumberOfTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_SeriesA4Point5PercentConvertiblePreferredStockMember" name="SeriesA4Point5PercentConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_UnderwritingCommitmentsPerShare" name="UnderwritingCommitmentsPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_AdditionalFinancingAgreementsTwoMember" name="AdditionalFinancingAgreementsTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_OutOfPocketExpenses" name="OutOfPocketExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_UnregisteredSharesMember" name="UnregisteredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_December2024OfferingMember" name="December2024OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_May2024OfferingMember" name="May2024OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_DeferredTaxAssetsDepreciation" name="DeferredTaxAssetsDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_ProgramExpenses" name="ProgramExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_RepricedWarrantsMember" name="RepricedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_AccruedClinicalTrialCosts" name="AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" name="StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_July2020NoteMember" name="July2020NoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_TheDecember2019NoteMember" name="TheDecember2019NoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PaymentOfWarrantInducementIssuanceCosts" name="PaymentOfWarrantInducementIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_May2024PlacementAgentWarrantsMember" name="May2024PlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PercentageOfGrossProceeds" name="PercentageOfGrossProceeds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_ReplacementWarrantsMember" name="ReplacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_GrantDateFairValue" name="GrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_December2022WarrantsMember" name="December2022WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_MayTwoThousandTwentyFourOfferingMember" name="MayTwoThousandTwentyFourOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ContingentConsiderationObligationsPolicyTextBlock" name="ContingentConsiderationObligationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_IncomeTaxReconciliationNondeductibleExpenseWarrants" name="IncomeTaxReconciliationNondeductibleExpenseWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_PrepaidSubscriptionsAndFees" name="PrepaidSubscriptionsAndFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_UncertainIncomeTaxPositions" name="UncertainIncomeTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_CashTransactionRelatedExpensesAndPlacementAgentFees" name="CashTransactionRelatedExpensesAndPlacementAgentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares" name="ConvertiblePreferredStockIssuableUponConversionOfAllShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_IncomeTaxReconciliationOtherNonDeductibleExpenses" name="IncomeTaxReconciliationOtherNonDeductibleExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_ClosingPeriodOfMergerAgreement" name="ClosingPeriodOfMergerAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_InducementPlanMember" name="InducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_NetProceeds" name="NetProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_PALITwoOneZeroEightMember" name="PALITwoOneZeroEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice" name="ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_MayTwoThousandTwentyTwoWarrantsMember" name="MayTwoThousandTwentyTwoWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_CollaborationsAndLicenseAgreementsUpfrontFee" name="CollaborationsAndLicenseAgreementsUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_SublicenseFees" name="SublicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_ClassAUnitsMember" name="ClassAUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_August2024OfferingSeries2CommonStockWarrantsMember" name="August2024OfferingSeries2CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PeriodOfExpirationOfLicenseAgreementDescription" name="PeriodOfExpirationOfLicenseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_AprilTwoThousandTwentyThreeWarrantsMember" name="AprilTwoThousandTwentyThreeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_AltiumGrowthFundLPMember" name="AltiumGrowthFundLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_FairValueOfWarrantsIssuedToSolicitationAgent" name="FairValueOfWarrantsIssuedToSolicitationAgent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_NonCashWarrantIssuanceCosts" name="NonCashWarrantIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" name="WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" name="PrepaidExpensesAndOtherCurrentAssetsOtherReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" name="NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_The2013PlanMember" name="The2013PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_ChangesInFairValueOfContingentConsideration" name="ChangesInFairValueOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pali_FairValueOfWarrantsIssuedToPlacementAgents" name="FairValueOfWarrantsIssuedToPlacementAgents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pali_CashConsideration" name="CashConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" name="FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_NonCashWarrantModificationCosts" name="NonCashWarrantModificationCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_December2024RepresentativeWarrantsMember" name="December2024RepresentativeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_PercentageOfReductionInWorkForce" name="PercentageOfReductionInWorkForce" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pali_The2021PlanMember" name="The2021PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_JointDevelopmentExpenses" name="JointDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pali_December2024OfferingCommonStockWarrantsMember" name="December2024OfferingCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_January2023OfferingMember" name="January2023OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pali_WarrantsIssuanceCosts" name="WarrantsIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 19, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001357459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PALISADE BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2007292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7750 El Camino Real, Suite 2A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">704-4900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PALI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,396,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text"> Baker Tilly US, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Palisade Bio, Inc. (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,821,000<span></span>
</td>
<td class="nump">$ 12,432,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">673,000<span></span>
</td>
<td class="nump">896,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,494,000<span></span>
</td>
<td class="nump">13,328,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">273,000<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,880,000<span></span>
</td>
<td class="nump">14,052,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,105,000<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,240,000<span></span>
</td>
<td class="nump">831,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">722,000<span></span>
</td>
<td class="nump">778,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance financing debt</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,236,000<span></span>
</td>
<td class="nump">2,586,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligation, net of current portion</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,388,000<span></span>
</td>
<td class="nump">2,739,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 280,000,000 shares authorized; 2,768,646 and 618,056 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">143,407,000<span></span>
</td>
<td class="nump">132,811,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_RetainedEarningsAccumulatedIncomeDeficit', window );">Accumulated deficit</a></td>
<td class="num">(135,944,000)<span></span>
</td>
<td class="num">(121,506,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">7,492,000<span></span>
</td>
<td class="nump">11,313,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">10,880,000<span></span>
</td>
<td class="nump">14,052,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_RetainedEarningsAccumulatedIncomeDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retained earnings accumulated income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_RetainedEarningsAccumulatedIncomeDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">280,000,000<span></span>
</td>
<td class="nump">280,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,768,646<span></span>
</td>
<td class="nump">618,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,768,646<span></span>
</td>
<td class="nump">618,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,063<span></span>
</td>
<td class="nump">6,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">6,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs (Note 8)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,859<span></span>
</td>
<td class="nump">13,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,859)<span></span>
</td>
<td class="num">(13,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">433<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">421<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,438)<span></span>
</td>
<td class="num">(12,300)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (12,316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per common share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (10.19)<span></span>
</td>
<td class="num">$ (27.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (10.19)<span></span>
</td>
<td class="num">$ (27.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares used in computing loss per common share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating basic loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,416,471<span></span>
</td>
<td class="nump">456,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating diluted loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,416,471<span></span>
</td>
<td class="nump">456,014<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Basic and diluted loss per common share and basic and diluted weighted average share used in computing basic and diluted loss per common share for the year ended December 31, 2023 has been adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Warrant Inducement Agreements [Member]</div></th>
<th class="th"><div>September 2023 Offering [Member]</div></th>
<th class="th"><div>April 2023 Offering [Member]</div></th>
<th class="th"><div>May 2024 Offering [Member]</div></th>
<th class="th"><div>December 2024 Offering [Member]</div></th>
<th class="th"><div>January 2023 Offering [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th" colspan="2">
<div>Common Stock [Member] </div>
<div>Warrant Inducement Agreements [Member]</div>
</th>
<th class="th" colspan="2">
<div>Common Stock [Member] </div>
<div>September 2023 Offering [Member]</div>
</th>
<th class="th" colspan="2">
<div>Common Stock [Member] </div>
<div>April 2023 Offering [Member]</div>
</th>
<th class="th" colspan="2">
<div>Common Stock [Member] </div>
<div>May 2024 Offering [Member]</div>
</th>
<th class="th" colspan="2">
<div>Common Stock [Member] </div>
<div>December 2024 Offering [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>January 2023 Offering [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Warrant Inducement Agreements [Member]</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>September 2023 Offering [Member]</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>April 2023 Offering [Member]</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>May 2024 Offering [Member]</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>December 2024 Offering [Member]</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>January 2023 Offering [Member]</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">196,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 121,665<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">$ (109,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(12,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">17<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense and related charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">624<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises', window );">Issuance of common stock upon warrant exercises (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises', window );">Issuance of common stock upon warrant exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">1,349<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,074<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares', window );">Issuance of common stock warrants related to promissory note (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">155,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">80,770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31,789<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants related to promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
<td class="nump">$ 5,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 1,674<span></span>
</td>
<td colspan="2" class="nump">$ 5,300<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 2,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">16<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">618,056<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">132,811<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(121,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">11<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to vendor (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,632<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to vendor</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">135<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense and related charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">652<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises', window );">Issuance of common stock upon warrant exercises (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,626,496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises', window );">Issuance of common stock upon warrant exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(13)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,046<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(25)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares', window );">Issuance of common stock warrants related to promissory note (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">228,162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">85,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">158,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants related to promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,544<span></span>
</td>
<td class="nump">$ 4,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 2,158<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 3,543<span></span>
</td>
<td colspan="2" class="nump">$ 4,135<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split fractional share settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">2,768,646<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 143,407<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">$ (135,944)<span></span>
</td>
</tr>
<tr><td colspan="37"></td></tr>
<tr><td colspan="37"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital warrant issued, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period common stock upon warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of stock issued during period value of common stock upon warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Convertible Preferred Stock and Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | December 2024 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | May 2024 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | January 2023 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | September 2023 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | April 2023 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant Inducement Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_May2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_May2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_January2023OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_January2023OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_September2023OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_September2023OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_April2023OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_April2023OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_WarrantInducementAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_WarrantInducementAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (12,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_RecurringFairValueMeasurementsOfLiabilities', window );">Recurring fair value measurements of liabilities</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock to vendors</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and related charges</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets and other noncurrent assets</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">818<span></span>
</td>
<td class="num">(492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,193)<span></span>
</td>
<td class="num">(11,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments on insurance financing debt</a></td>
<td class="num">(426)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">8,435<span></span>
</td>
<td class="nump">9,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">2,506<span></span>
</td>
<td class="nump">2,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PaymentOfWarrantInducementIssuanceCosts', window );">Payment of warrant inducement issuance costs</a></td>
<td class="num">(343)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="num">(576)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for payment of employee withholding tax liability</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,582<span></span>
</td>
<td class="nump">11,186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(2,611)<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">12,458<span></span>
</td>
<td class="nump">12,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">9,847<span></span>
</td>
<td class="nump">12,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">9,821<span></span>
</td>
<td class="nump">12,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">9,847<span></span>
</td>
<td class="nump">12,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities', window );">Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions', window );">Non cash impact of exercise price reset on outstanding warrants related to down round provisions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_FairValueOfWarrantsIssuedToSolicitationAgent', window );">Fair value of warrants issued to solicitation agent</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_FairValueOfWarrantsIssuedToPlacementAgents', window );">Fair value of warrants issued to placement agents</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter', window );">Fair value of warrants issued to representatives of underwriter</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities', window );">Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets', window );">Insurance financing debt included in prepaid and other current assets and other noncurrent assets</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_IncrementalFairValueOfModifiedOrExchangedWarrants', window );">Incremental fair value of modified warrants (Note 5)</a></td>
<td class="nump">$ 2,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Equity Issuance Costs Recognized As a Reduction in Additional Paid in Capital From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_FairValueOfWarrantsIssuedToPlacementAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants Issued to placement agents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_FairValueOfWarrantsIssuedToPlacementAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued to representatives of underwriter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_FairValueOfWarrantsIssuedToSolicitationAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued to solicitation agent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_FairValueOfWarrantsIssuedToSolicitationAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_IncrementalFairValueOfModifiedOrExchangedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental fair value of modified or exchanged warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_IncrementalFairValueOfModifiedOrExchangedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from insurance financing debt included in prepaid and other assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash impact of exercise price reset on outstanding warrants related to down round provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash operating lease expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PaymentOfWarrantInducementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of warrant inducement issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PaymentOfWarrantInducementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_RecurringFairValueMeasurementsOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recurring fair value measurements of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_RecurringFairValueMeasurementsOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (12,300)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity awards are discretionary and are generally granted to our named executive officers the second month of the applicable fiscal year. In certain circumstances, our Compensation Committee may  approve grants to be effective at other times. The Compensation Committee </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does not grant equity awards in anticipation</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the release of material nonpublic information and we </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do not time</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">release of material nonpublic information based on equity award grant dates. No equity awards were granted to our named executive officers in 2024, as the equity awards granted in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 to our named executive officers were intended to provide retention and compensation for service in 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we may process proprietary, confidential, and sensitive data, including personal data (such as health-related patient data), intellectual property, and trade secrets (collectively, "sensitive information"). We rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, employee email, CROs, and other functions. The secure maintenance of this sensitive information and our information technology systems is important to our operations. To this end, we have processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by our third-party information technology consultants and include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are planning to establish an appropriate confidentiality framework and document management system in order to safeguard sensitive information in addition to the safeguards provided by our third-party service providers</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such confidentiality framework may include the use of third-party information technology experts to manage and oversee our sensitive information and to work directly with our management in overseeing cybersecurity risks</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and appropriate responses thereto. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we plan to consult with outside advisors and experts, when appropriate, to assist with assessing and identifying cybersecurity risks, including to anticipate future threats and trends, and their impact on our risk environment.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the last fiscal year, we have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not identified risks from known cybersecurity threats</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks faced by us are discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the headings &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such confidentiality framework may include the use of third-party information technology experts to manage and oversee our sensitive information and to work directly with our management in overseeing cybersecurity risks</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization and Business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the context indicates or otherwise requires, &#8220;Palisade,&#8221; &#8220;Palisade Bio,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; or similar designations in this Annual Report on Form 10-K refer to Palisade Bio, Inc., a Delaware Corporation, and its subsidiaries. Any reference to &#8220;common shares&#8221; or &#8220;common stock,&#8221; refers to the Company's $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock. Any reference to &#8220;Leading Biosciences, Inc.&#8221; or &#8220;LBS&#8221; refers to the Company&#8217;s operations prior to the completion of its merger with Seneca Biopharma, Inc. ("Seneca") on April 27, 2021 (the "Merger"). Any reference herein that refers to preclinical studies also refers to nonclinical studies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company's lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease, or IBD, including ulcerative colitis and fibrostenotic Crohn's disease.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a limited operating history, and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operations since its inception. As of December 31, 2024, the Company had an accumulated deficit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash and cash equivalents of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company expects to continue to incur losses into the foreseeable future. The successful transition to achieving profitability is dependent upon achieving a level of revenues adequate to support the Company&#8217;s costs. There can be no assurances that such profitability will ever be achieved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Company&#8217;s current working capital, anticipated operating expenses, and anticipated net operating losses, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, the Company has funded its operations primarily through equity financings. The Company plans to continue to fund its operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. Refer to Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for discussion of the recent financings undertaken by the Company. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company is successful in raising additional capital, it may also be required to modify, delay or abandon some of its plans, which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Dollar amounts contained in these consolidated financial statements are in whole numbers, unless otherwise indicated.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, LBS and Suzhou Neuralstem Biopharmaceutical Co., Ltd. All the entities are consolidated in the Company's consolidated financial statements and all intercompany activity and transactions, if any, have been eliminated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 5, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1-for-15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> "Reverse Stock S</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plit"). As a result of the Reverse Stock Split, the Company&#8217;s stockholders received one share of common stock for every </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#8217;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected the Company&#8217;s outstanding stock-based awards, common stock warrants, and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data and shares of common stock underlying convertible preferred stock, stock-based award and common stock warrants included in these consolidated financial statements, including the exercise price or conversion price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents represent cash in readily available checking and money market accounts. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company held restricted cash of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a separate restricted bank account as collateral for the Company&#8217;s corporate credit card program. The Company has classified these deposits as long-term restricted cash on its consolidated balance sheets.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Equity Issuance Costs</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred equity issuance costs consist of the legal, accounting and other direct and incremental costs incurred by the Company related to its equity offerings, if not yet finalized as of the balance sheet date, or shelf registration statement. As of December 31, 2024 and December 31, 2023, deferred equity issuance costs of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, were included in prepaid expenses and other current assets in the consolidated balance sheets. These costs will be netted against additional paid-in capital as a cost of the future equity issuances to which they relate. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company netted previously deferred equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> against the additional paid-in capital recognized in conjunction with the February 2024 Warrant Inducement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company netted previously deferred equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> associated with its shelf registration statement against the additional paid-in capital recognized in conjunction with the September 2023 Offering (see Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders' Equity)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accounts, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and historically the Company has not experienced any losses in such accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows Accounting Standards Codification ("ASC") 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.148%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further information on the fair value of the Company's financial assets and liabilities can be found at Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including common stock warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option pricing model or other acceptable valuation models, including the Monte-Carlo simulation model. Derivative instruments, if any, are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at the end of each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and common stock warrants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its common stock warrants in accordance with ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASC 480") and ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 815&#8221;). Based upon the provisions of ASC 480 and ASC 815, the Company accounts for common stock warrants as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement, or if it fails the equity classification criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified as equity. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at fair value at each balance sheet date with the offsetting adjustments recorded in change in fair value of warrant liability within the consolidated statements of operations. If the terms of a common stock warrant previously classified as a liability are amended and pursuant to such amendment meet the requirements to be classified as equity, the common stock warrants are reclassified to equity at the fair value on the date of the amendment and are not subsequently remeasured. Common stock warrants classified as equity are recorded on a relative fair value basis when they are issued with other equity-classified financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company assesses contracts for lease arrangements at inception. Operating right-of-use (&#8220;ROU&#8221;) assets and liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit, if readily available, or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, the Company and Giiant Pharma, Inc. ("Giiant") entered into a research collaboration and license agreement (the &#8220;Giiant License Agreement&#8221;)(see Note 7, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborations and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation consisting of milestone payments, which are recognized as a liability measured at fair value, and ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses third parties of any products developed from the assets licensed under the Giiant License Agreement. Because the contingent consideration associated with the milestone payments may be settled in shares of the Company's common stock solely at the election of the Company, the Company has determined it should be accounted for under ASC 480 and accordingly the Company has recognized it as a liability measured at its estimated fair value. At the end of each reporting period, the Company re-measures the contingent consideration obligation to its estimated fair value and any resulting change is recognized in research and development expenses in the consolidated statements of operations. The Company has determined that the contingent consideration associated with the royalty payments should be recognized as a liability when they are probable and estimable, in accordance with ASC 450, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of salaries and other personnel related expenses including stock-based compensation costs, and, to the extent applicable, may include preclinical costs, clinical trial costs, costs related to acquiring and manufacturing clinical trial materials, and contract services. All research and development costs are expensed as incurred pursuant to ASC 730, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pursuant to situations whereby the Company performs any research and development or manufacturing activities under a co-development agreement, and the co-development partner is not considered a customer under ASC 606, the Company records the expense reimbursements from the co-development partner as a reduction to research and development expense once the reimbursement amount is approved for payment by the co-development partner. Expense payments made to Giiant pursuant to the terms of the Giiant License Agreement for qualifying development costs are expensed only as the associated research and development costs are incurred or other aspects of the drug development or related activities are achieved. In instances where the expense determined to be recognized exceeds the payments made to the Giiant, the Company recognizes an accrual of joint development expenses. In addition, there may be instances in which payments made to Giiant will temporarily exceed the level of services provided, which results in a prepayment of the joint development expenses. The Company records expense payments from Giiant, if any, as a reduction to research and development expense once the expense payments are realized or realizable, which is when Company receives the cash or has an undisputed claim to the cash that is probable of collection, pursuant to the terms of the Giiant License</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement and the principles of ASC 450, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 450"). The Company has determined that Giiant is not considered a customer under ASC 606.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses related to clinical studies are based on estimates of the services received and efforts expended pursuant to the Company&#8217;s contract arrangements. The financial terms of these contract arrangements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients, site initiation and the completion of clinical milestones. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense balance accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accrues for clinical trial expenses for which the estimated services have been provided but the Company has not yet been invoiced as of the balance sheet date. There may be instances in which payments made to the Company&#8217;s service providers will temporarily exceed the level of services provided and result in a prepayment of the clinical trial expenses. Clinical trial expenses are included in research and development expenses in the consolidated statements of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 740&#8221;) in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some of or all the deferred tax assets will not be realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s stock-based compensation generally includes service-based restricted stock units (&#8220;RSUs&#8221;), stock options, and market-based performance RSUs (&#8220;PSUs&#8221;). The Company accounts for forfeitures as they occur for each type of award as a reduction of expense. Stock-based compensation expense related to service-based RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period, which is usually the vesting period. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model. The determination of the fair value of stock-based payment awards on the date of grant using the Black-Scholes option pricing model is affected by the Company's stock price as well as assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate, and expected dividends over the expected term of the award. Stock-based compensation expense represents the cost of the estimated grant date fair value of employee and non-employee stock option grants recognized ratably over the requisite service period of the awards, which is usually the vesting period. For PSUs with vesting subject to market conditions, the fair value of the award is determined at grant date using the Monte Carlo simulation model, and expense is recognized ratably over the derived service period regardless of whether the market condition is satisfied. The Monte Carlo simulation model considers a variety of potential future scenarios under the market condition vesting criteria, including but not limited to share prices for the Company and its peer companies in a selected market index.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not recognize any share-based compensation expense related to conditional RSUs, stock options, or PSUs that are subject to shareholder approval. When and if approval is obtained, the Company recognizes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share-based compensation expense related to the conditional equity grants ratably to the vesting of shares over the remaining requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company offers to its employees an opportunity to participate in its shareholder approved Palisade Bio, Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP"). The Company estimates the fair value of 2021 ESPP awards on the first day of the offering period using the Black-Scholes option pricing model. The estimated fair value of 2021 ESPP awards is amortized on a straight-line basis over the requisite service period of the award. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of 2021 ESPP awards.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for all years presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ("ASU 2023-07"), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The disclosure requirements included in ASU No. 2023-07 are required for all public entities, including those with a single reportable segment. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 31, 2024 on a retrospective basis, with early adoption permitted. The Company adopted ASU 2023-07 in the fourth quarter of 2024. The adoption of this guidance resulted in additional financial statement disclosures and had no impact on the Company's results of operations and financial condition. See Note 12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for disclosures resulting from the adoption of ASU 2023-07.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 720): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASU 2023-09"), which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASC 2023-09 on its consolidated financial statement disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASU 2024-03"), which is intended to improve disclosures about a public business entity&#8217;s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Balance Sheet Details</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid subscriptions and fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid software licenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred equity issuance costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other noncurrent assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance, less current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other noncurrent assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">490</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued accounts payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued chemistry, manufacturing and controls ("CMC") expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued director stipends</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued severance and benefits (Note 8)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued joint development expenses (Note 7)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of contingent consideration obligation (Note 4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,240</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments consist principally of cash and cash equivalents, restricted cash, other current receivables, accounts payable, accrued liabilities, insurance financing debt, liability-classified warrants and a contingent consideration obligation. The carrying amounts of financial instruments such as restricted cash, other current receivables, accounts payable, and accrued liabilities approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s insurance financing debt approximates its fair value as of December 31, 2024 and December 31, 2023 due to the market rate of interest, which is based on level 2 inputs. The Company&#8217;s liability-classified warrants and its contingent consideration obligation are carried at fair value based on level 3 inputs. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a nonrecurring basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests its excess cash in money market funds that are classified as level 1 in the fair value hierarchy due to their short-term maturity, and measured the fair value based on quoted prices in active markets for identical assets. The fair value of the Company's cash and cash equivalents invested in money market funds was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation related to future milestone payments. The Company has an obligation to make contingent consideration payments to Giiant, in either cash or shares of the Company&#8217;s common stock solely at the Company&#8217;s election, upon the achievement of development milestones. On August 2, 2024, the Company and Giiant entered into an amendment to the Giiant License Agreement, which among other things, reduced the milestone payments due to Giiant upon the achievement of certain development milestones (see Note 7, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborations and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for further details).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the contingent consideration obligation is determined using a probability-based model that estimates the likelihood of success in achieving each of the defined milestones that is then discounted to present value using the Company's incremental borrowing rate. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The significant assumptions used in the calculation of the fair value as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included a discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and management's updated projections of the likelihood of success in achieving each of the defined milestones based on empirical, published industry data.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">summarizes the activity of the Company&#8217;s Level 3 contingent consideration obligations, which are fair valued on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial fair value at the original issuance date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the entire amount of contingent consideration obligation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was classified as a noncurrent liability in the consolidated balance sheet as none of it is expected to be settled within one-year of the balance sheet date. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the contingent consideration obligation was classified in accrued liabilities in the consolidated balance sheets as it was expected to be settled within one-year of the balance sheet date and the remaining obligation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was classified as a noncurrent liability in the consolidated balance sheet.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in the fair value of the contingent consideration obligation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was primarily due to the reduction in the milestone payments that would be due to Giiant upon the achievement of certain development milestones pursuant to the amendment to the Giiant License Agreement, partially offset by an increase in management's projected likelihood of success in achieving each of the defined milestones as a result of the Company's commencement of a Phase 1 trial in November of 2024. The change in the revaluation of the liability in the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is recognized in research and development expenses in the consolidated statements of operations. In addition, the initial fair value of the contingent consideration obligation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and transaction-related costs of approxi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the year ended December 31, 2023 is recognized in research and development expenses in the consolidated statements of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liability-Classified Warrants</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has issued warrants that are accounted for as liabilities based upon the guidance of with ASC 480 and ASC 815. Estimating fair values of liability-classified financial instruments requires the development of estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">factors. Changes in fair value of the liability-classified warrants are recognized as a component of other income, net in the consolidated statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the fair value of the Company's liability-classified warrants outstanding was determined using a Black-Scholes option pricing model valuation model to be insignificant due to the low market price of the Company's stock at the date of valuation relative to the exercise price of the underlying warrants outstanding.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity of the Company&#8217;s Level 3 liability-classified warrants during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.093%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.903%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Classes of Stock</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company was authorized to issue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock. Each share of common stock entitles the holder thereof to one vote on each matter submitted to a vote at a meeting of stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 5, 2024, the Company effected the Reverse Stock Split. Accordingly, the Company&#8217;s stockholders received one share of the Company's common stock for every </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock that each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all of the Company&#8217;s issued and outstanding shares of the Company's common stock equally. The Reverse Stock Split also affected the Company&#8217;s outstanding stock-based awards, warrants and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately by the Reverse Stock Split ratio. No fractional shares were issued as a result of the Reverse Stock Split with any fractional shares that would have otherwise resulted from the Reverse Stock Split paid in cash, at an amount equal to the resulting fractional interest in one share of the Company's common stock that the stockholder would otherwise be entitled, multiplied by the closing trading price of the Company's common stock on April 5, 2024. The amount of cash paid for fractional shares was immaterial to the Company's financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Reverse Stock Split, on April 5, 2024 the number of issued and outstanding shares of the Company's common stock was adjusted from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,771,015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,302</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company was authorized to issue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value preferred stock of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been designated as Series A 4.5% Convertible Preferred Stock ("Series A Convertible Preferred Stock") and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which are issued and outstanding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company's Series A Convertible Preferred Stock issued in the amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> preferred stock shares is convertible into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Equity Offerings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">December 2024 Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) pursuant to which the Company agreed to issue and sell, in an underwritten public offering by the Company (the &#8220;December 2024 Offering&#8221;), (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class A Units at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.525</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Class A Unit (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Class </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Units&#8221;), with each Class A Unit consisting of (i) one share of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and (ii) one warrant to purchase one share of the Company's common stock at an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;December 2024 Offering Common Stock Warrant&#8221;) and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,120,688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class B Units at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5249</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Class B Unit (the &#8220;Class B Units&#8221;, and collectively with the Class A Units, the &#8220;Units&#8221;), with each Class B Unit consisting of (i) one pre-funded warrant to purchase one share of the Company's common stock </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being immediately exercisable, having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a perpetual term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;December 2024 Offering Pre-funded Common Stock Warrant&#8221;) and (ii) one December 2024 Offering Common Stock Warrant. In addition, pursuant to the Underwriting Agreement, the Company granted the sole underwriter a 45-day option (the &#8220;Overallotment Option&#8221;) to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491,803</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares of the Company's common stock and/or December 2024 Offering Common Stock Warrants. The Overallotment Option expired and was not exercised by the underwriter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued warrants to representatives of the sole underwriter in the December 2024 Offering to purchase an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196,721</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;December 2024 Representative Warrants&#8221;). The December 2024 Representative Warrants have substantially the same terms as the December 2024 Offering Common Stock Warrants, except that the exercise price of each of the December 2024 Representative Warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.51625</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The fair value of the December 2024 Offering Common Stock Warrants was recognized by the Company as an equity issuance cost which reduced the additional paid-in capital recognized from the December 2024 Offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The December 2024 Offering closed on December 13, 2024 for net cash proceeds to the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, consisting of gross cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million less cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which excludes the grant date fair value of the December 2024 Representative Warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the incremental fair value of the Repriced Warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, described below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company entered into a warrant amendment agreement (the &#8220;Warrant Amendment Agreement&#8221;) whereby the Company, contemporaneously with and contingent with the closing of the December 2024 Offering, reduced the exercise price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,040,217</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding common stock warrants (the &#8220;Repriced Warrants&#8221;) held by an investor that participated in the December 2024 Offering which expire between July 31, 2027 and May 6, 2031. The Repriced Warrants had their exercise price reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Other than the reduction in exercise price, the terms of the Repriced Warrants remain the same and unchanged.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrant Amendment Agreement is considered a modification of the Repriced Warrants under the guidance of ASC 815-40. The modification is consistent with the Equity Issuance classification under that guidance as the reason for the Company's repricing of the warrants was to meet a condition of the holder's participation in the December 2024 Offering, which raised equity capital and generated gross cash proceeds for the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As pursuant to the guidance of ASC 480 and ASC 815 the Repriced Warrants were classified as equity instruments before and after the modification, and as the modification is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as an equity issuance cost netted against the additional paid-in capital recognized in the December 2024 Offering. The amount of the equity issuance cost recognized for the modification of the Repriced Warrants was determined using the Black-Scholes option pricing model as the incremental fair value of the Repriced Warrants as compared to the fair value of the warrants immediately prior to their modification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May 2024 Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 1, 2024, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company sold in a private placement, (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a purchase price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,142</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants to purchase shares common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5014</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, with such pre-funded warrants being immediately exercisable, having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a perpetual term, and (iii) common stock warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">922,863</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.314</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance (the "May 2024 Warrants") (collectively, the &#8220;May 2024 Offering&#8221;).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued warrants to the placement agent in the May 2024 Offering to purchase an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,914</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;May 2024 Placement Agent Warrants&#8221;). The May 2024 Placement Agent Warrants have substantially the same terms as the May 2024 Warrants, except that the exercise price of each of the May 2024 Placement Agent Warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.727</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the term is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from issuance. The fair value of the May 2024 Placement Agent Warrants was recognized by the Company as an equity issuance cost which reduced the additional paid-in capital recognized from the May 2024 Offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The May 2024 Offering closed on May 6, 2024 for net cash proceeds to the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, consisting of gross cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million less cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which excludes the grant date fair value of the May 2024 Placement Agent Warrants of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Recent Equity Offerings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 11, 2023, the Company completed a registered direct offering of common stock (the "September 2023 Offering"). Gross cash proceeds from the September 2023 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and net cash proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 3, 2023, the Company completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "April 2023 Offering"). Gross cash proceeds from the April 2023 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and net cash proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 4, 2023, the Company completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "January 2023 Offering"). Gross cash proceeds from the January 2023 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and net cash proceeds were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million after deducting cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Warrants and Warrant Exercises</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">February 2024 Warrant Inducement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 30, 2024, the Company entered into warrant inducement agreements (the &#8220;Warrant Inducement Agreements&#8221;) with certain accredited and institutional holders (collectively, the &#8220;Warrant Holders&#8221;) of certain of the Company&#8217;s remaining outstanding common stock warrants issued on May 10, 2022 (the "May 2022 Warrants"), January 4, 2023 (the &#8220;January 2023 Warrants&#8221;), and April 5, 2023 (the &#8220;April 2023 Warrants&#8221;), as well as certain outstanding Series 2 warrants issued on August 16, 2022 (the "Series 2 Warrants") (collectively, the &#8220;Existing Warrant(s)&#8221;). Pursuant to the Warrant Inducement Agreements, the exercise price of each of the Existing Warrants exercised was reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.97</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Each of the Warrant Holders that exercised its Existing Warrants pursuant to the Warrant Inducement Agreements, received one replacement warrant to purchase one share of the Company's common stock (the &#8220;Replacement Warrants&#8221;) for each Existing Warrant exercised (in its entirety, the "February 2024 Warrant Inducement").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Replacement Warrants are exercisable immediately, have an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.97</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance, which was February 1, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrant Holders collectively exercised an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,162</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Existing Warrants consisting of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,865</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> May 2022 Warrants, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,267</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series 2 Warrants, (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,511</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> January 2023 Warrants, and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151,519</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> April 2023 Warrants. As a result of the exercises of the Existing Warrants, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,162</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,162</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Replacement Warrants. The February 2024 Warrant Inducement closed on February 1, 2024 with the Company receiving net cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million consisting of gross cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less cash equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The February 2024 Warrant Inducement, which resulted in the lowering of the exercise price of the Existing Warrants and the issuance of the Replacement Warrants, is considered a modification of the Existing Warrants under the guidance of ASC 815-40. The modification is consistent with the Equity Issuance classification under that guidance as the reason for the modification was to induce the holders of the Existing Warrants to cash exercise their Existing Warrants, resulting in the imminent exercise of the Existing Warrants, which raised equity capital and generated gross cash proceeds for the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As pursuant to the guidance of ASC 480 and ASC 815 the Existing Warrants and Replacement Warrants were classified as equity instruments before and after the modification, and as the modification is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as an equity issuance cost netted against the additional paid-in capital recognized from the associated warrant exercises. The amount of the equity issuance cost recognized for the warrant modification was determined using the Black-Scholes option pricing model as the incremental fair value of the modified Existing Warrants and additional Replacement Warrants issued as compared to the fair value of the original Existing Warrants immediately prior to their modification.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The solicitation agent fees associated with the February 2024 Warrant Inducement consisted of: (i) a cash fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds received by the Company, (ii) a common stock purchase warrant to purchase such number of shares of common stock equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number shares issued pursuant to the exercise of the Existing Warrants, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.97</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from issuance (the "Solicitation Agent Warrants"), and (iii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of out-of-pocket expenses. The fair value of the Solicitation Agent Warrants was recognized by the Company as an equity issuance cost, which reduced the additional paid-in capital recognized from the issuance of common stock in connection with the exercise of the Existing Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total equity issuance costs recognized in the February 2024 Warrant Inducement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million include cash equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, non-cash warrant modification costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and non-cash issuance costs associated with the Solicitation Agent Warrants of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Warrants Outstanding and Warrant Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the majority of its warrants as equity-classified in accordance with ASC 480 and ASC 815. The Company&#8217;s outstanding common stock warrants that are classified as equity warrants are included as a component of stockholders' equity based on their relative fair value on their date of issuance. Common stock warrants accounted for as liabilities in accordance with the authoritative accounting guidance are included in noncurrent liabilities. The Company had exercisable common stock warrants outstanding of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,745,213</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,211</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company's outstanding and exercisable common stock warrants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.952%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.996%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.678%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.378%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.858%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classification</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Warrants Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024 Offering Pre-Funded Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,027,000</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Perpetual</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024 Offering Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,278,688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.95</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2024 Offering Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">922,863</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.34</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 2024 Warrant Inducement Replacement Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.17</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.09</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 2024 Offering Series 2 Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,748</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.61</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bridge, January 2021, and July 2021 Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liability-Classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Placement Agent, Solicitor and Representative Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,693</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.98</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.66</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,919</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,418.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.50</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Warrants Outstanding, December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,745,213</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.53</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the outstanding common stock warrants, only the Series 2 Warrants include a down round feature whereby they are subject to price reset provisions in the event future sales of the Company's securities are sold at a price per share less than the exercise price of such warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes all common stock warrant activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.951%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.342%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.501%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,211</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144.78</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,327,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.68</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,854,658</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.35</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, expired or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,438.12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,745,213</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.53</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company received gross cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, from exercises of common stock warrants. Of the gross cash proceeds received for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to common stock warrants exercised on December 30, 2022 for which the related cash exercise price was receivable to the Company as of December 31, 2022. The related cash payment was received by the Company in January 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2013, LBS adopted the 2013 Employee, Director, and Consultant Equity Incentive Plan, (as amended and restated, the &#8220;2013 Plan&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> further awards will be made under the 2013 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2021, the Company&#8217;s shareholders approved the Palisade Bio, Inc. 2021 Equity Incentive Plan (the &#8220;2021 EIP&#8221;). As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,586</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s of the Company's common stock reserved for future issuance as equity-based awards under the 2021 EIP, which excludes the subsequent evergreen share increase in the number of shares of common stock reserved for issuance under the 2021 EIP that occurred on January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also in April 2021, the Company's shareholder approved the ESPP. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All employees are eligible to participate in the 2021 ESPP while employed by the Company. The 2021 ESPP permits eligible employees to purchase common stock through payroll deductions, which may not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a calendar year or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's shares of common stock each offering period, as defined in the 2021 ESPP, at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair value of the Company's common stock at the beginning or end of the offering period, whichever is lower. The 2021 ESPP is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> intended to qualify under Section 423 of the Internal Revenue Code. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock issued under the 2021 ESPP. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,086</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock reserved for future issuance under the 2021 ESPP, which excludes the subsequent evergreen share increases in the number of shares of common stock reserved for future issuance under the 2021 ESPP that occurred on January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation expense associated with the 2021 ESPP for the year ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, the Company's compensation committee of the Company's Board of Directors ("Board") adopted the Palisade Bio, Inc. 2021 Inducement Award Plan (the "2021 Inducement Plan"). The 2021 Inducement Plan was adopted in order to grant equity-based awards to individuals not previously employed by the Company, as an inducement to join the Company. On August 7, 2023, the Company's compensation committee of the Board approved an increase in the shares of the Company's common stock authorized and available for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,666</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,941</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock reserved for future issuance as equity-based awards under the 2021 Inducement Plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes that stock options align the interests of its employees and directors with the interests of its stockholders. Stock option awards are generally granted with an exercise price equal to the market price of Company&#8217;s stock at the date the grants are awarded and a term as determined by the Company's Board but generally not to exceed ten-years. Stock option awards to employees vest in equal proportions each quarter over three years and stock option awards to directors of the Company's Board cliff vest after a period of one year. Vesting could be accelerated in the event of retirement, disability, or death of a participant, or change in control of the Company, as defined in the individual stock option agreements or employment agreements. Stock-based awards are valued as of the measurement date, which is the grant date, and are generally amortized on a straight-line basis over the requisite vesting period for all awards. The Company's equity incentive plans allow for the issuance of both incentive stock options and non-statutory stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 is estimated as of the grant date using the Black-Scholes option pricing model using the assumptions in the following table:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average exercise price per share</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.85</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average expected term (years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.65</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.08</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.35</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk-free interest rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected volatility. Due to the Company&#8217;s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biopharmaceutical industry.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected term. The expected term represents the period of time that options are expected to be outstanding. As the Company does not have sufficient historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity and related information under the 2013 Plan, the 2021 EIP and the 2021 Inducement Plan for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Options</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,276</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233.09</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, expired or cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,902</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">335.18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.48</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.75</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.48</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.75</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,825</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">349.89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.44</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted during the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, re</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">spectively. The grant date fair value of the options vested during each the years ended December 31, 2024 and December 31, 2023 was approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company granted no RSUs. As of December 31, 2024, there were no RSUs that remained outstanding.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following table summarizes RSU activity and related information under the 2021 EIP and the 2021 Inducement Plan for the year ended December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.700000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Restricted<br/>Stock Units</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,195</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.30</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.17</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,067</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.23</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,128</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.84</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant date fair value of the RSUs vested during the years ended December 31, 2024 and December 31, 2023 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in each year.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Based Stock Units</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 6, 2023, the Company granted to certain members of management a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,580</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> market-based PSUs, which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vest (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% when the volume weighted average price of the Company&#8217;s common stock over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or greater ("vesting Tranche 1"), and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% when such volume weighted average price of the Company&#8217;s common stock over </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or greater ("vesting Tranche 2").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The PSUs were conditional subject to shareholder approval, which such approval was received at the Company's annual shareholder meeting held on June 8, 2023. The fair value of each of the market-based vesting tranches of the PSUs was determined using a Monte Carlo simulation model that considered a variety of potential share prices for the Company's common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value per share of vesting Tranche 1 and vesting Tranche 2 of the PSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per award share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per award share, respectively, and was determined using the following key assumptions: (i) a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, (ii) expected stock price volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, (iii) a cost of equity of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, and (iv) an expected contractual life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.66</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As shareholder approval of the PSUs was received, the Company is recognizing the share-based compensation expense associated with the PSUs ratably over the derived service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.75</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years for vesting Tranche 1 and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.48</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years for vesting Tranche 2, regardless of whether the market condition for vesting is satisfied. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,144</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs remained unvested and outstanding. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the PSUs vested during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">year ended December 31, 2024 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs were forfeited during the year. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PSUs remain unvested and outstanding.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The allocation of stock-based compensation for all stock option, RSU and PSU awards is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">370</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">366</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">633</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To reduce the ongoing administrative burden and expense associated with the quarterly vesting of the Company's time-based RSUs, on May 28, 2024, the Company's Board approved the immediate accelerated vesting of all unvested time-based RSUs issued to employees that were outstanding as of that date. The accelerated vesting was accounted for as a Type I modification under ASC 718 and accordingly, in the second quarter of 2024 the Company recognized share-based compensation expense associated with the time-based RSUs subject to immediate vesting of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in general and administrative expenses and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the unrecognized compensation expense related to outstanding options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.49</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> there is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrecognized compensation expense related to outstanding service-based RSUs as there are no outstanding non-vested service-based RSUs as of that date and the unrecognized compensation expense related to outstanding PSUs is immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Collaborations and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_LicenseAgreementsTextBlock', window );">Collaborations and License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Collaborations and License Agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research Collaboration and License Agreement with Giiant</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, the Company entered into the Giiant License Agreement whereby the Company received an exclusive, worldwide license (with the right to sublicense in multiple tiers) to develop, manufacture, and commercialize substantially all of the assets of Giiant, including: (i) the PALI-2108 compound, and (ii) the PALI-1908 compound and the associated intellectual property around each of the foregoing (the &#8220;Giiant Licensed Assets&#8221;). The Giiant License Agreement has a perpetual term.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Giiant License Agreement, the Company and Giiant established a joint development committee (&#8220;JDC&#8221;), consisting of one Giiant appointee and two Company appointees. The JDC will be responsible for: (i)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing the day-to-day development of the Giiant Licensed Assets through Proof of Concept (as defined below), and (ii) creation and implementation of the development plan and development budget for such development (the &#8220;Giiant Development Plan&#8221;) and any amendments or updates thereto.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to receiving regulatory approval to commence a Phase 1 clinical trial (as such term is defined in the Giiant License Agreement) (the &#8220;Proof of Concept&#8221;), each of the Company and Giiant was solely responsible for all costs and expenses incurred by such party for the joint development of the Giiant Licensed Assets, except as set forth in the Giiant Development Plan. Prior to reaching the Proof of Concept, the Company reimbursed or advanced Giiant up to an amount in the low seven-digit range for costs and expenses incurred by them. Upon reaching the Proof of Concept, which occurred in October of 2024, the Company became solely responsible for all costs and expenses incurred for the development, manufacturing, regulatory and commercialization of the Giiant Licensed Assets. For the years ended December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized expenses related to the joint development plan with Giiant in the amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which are included in research and development expenses in the consolidated statements of operations. The Company recognized no reductions to its joint development expenses for payments from Giiant for either the years ended December 31, 2024 or December 31, 2023. At December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company accrued joint development expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in Accrued liabilities in the consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Giiant License Agreement, as amended (see below), the Company will (i) make certain payments between the mid six-digit range and low seven-digit range upon the achievement of development milestones, as defined in the Giiant License Agreement, in either cash or shares of the Company&#8217;s common stock, at the Company&#8217;s election (&#8220; Giiant Milestone Payments&#8221;), and (ii) pay ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses of any products developed from the Giiant Licensed Assets to third parties (&#8220;Giiant Royalty Payments&#8221;) (collectively, the Giiant Milestone Payments and the Giiant Royalty Payments are referred to as the &#8220;Giiant License Payments&#8221;). The Giiant License Payments are subject to a maximum payment cap in the very low eight-digit range, which will be increased or decreased on a dollar-for-dollar basis based on a formula related to the aggregate of development costs incurred by the parties (&#8220;Payment Cap&#8221;). The Company has made no Giiant License Payments since the commencement of the Giiant License Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 2, 2024, the Company and Giiant entered into an amendment to the Giiant License Agreement (the "Giiant License Agreement Amendment"). Pursuant to the Giiant License Agreement Amendment, the Company agreed to increase the amount it would reimburse or advance to Giiant prior to Proof of Concept under the Giiant Development Plan by an amount in the mid six-digit range. After taking into account such increase, the amount that Company will reimburse or advance Giiant for costs and expenses incurred by them will remain in the low seven-digit range. As consideration for the increase, Giiant agreed to (i) a reduction in the Giiant Milestone Payments that would be due to them upon the achievement of certain development milestones, and (ii) a decrease to the Payment Cap applied to future Giiant License Payments, as set forth in the original Giiant License Agreement. The amount of the reduction in the Giiant Milestone Payment as a result of the Giiant License Agreement Amendment is in the high six-digit range and the decrease in the Payment Cap is in the mid-six digit range. There were no other changes to the terms of the original Giiant License Agreement as a result of the Giiant License Agreement Amendment that would have a material impact on the Company's results of operations, financial position or future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that Giiant desires to sell or assign any rights to receive the Giiant License Payments, they will be required to notify the Company of such offer or proposal (&#8220;Offer Notice&#8221;). The Company will then have a right of first refusal for thirty days from the receipt of such Offer Notice, to acquire the rights and obligations contained in such Offer Notice on the same terms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may unilaterally terminate the Giiant License Agreement for: (i) convenience, or (ii) a material breach by Giiant, that is not cured within the applicable notice period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Giiant may unilaterally terminate the Giiant License Agreement only for a material breach by Company that is not cured within the applicable notice period provided however that upon the Payment Cap being achieved, that right will terminate and the Giiant License Agreement will become perpetual.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-Development and Distribution Agreement with Newsoara</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LBS entered into a co-development and distribution agreement with Newsoara, a joint venture established with Biolead Medical Technology Limited, as amended, (the &#8220;Newsoara Co-Development Agreement&#8221;). Pursuant to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Newsoara Co-Development Agreement (and subsequent assignment agreement), LBS granted or licensed Newsoara an exclusive right under certain patents to develop, use, sell, offer to sell, import, and otherwise commercialize licensed products (the &#8220;Newsoara Licensed Products&#8221;) for any and all indications in the People&#8217;s Republic of China, including the regions of Hong Kong and Macao, but excluding Taiwan (the &#8220;Territory&#8221;). The Newsoara Licensed Products only include the drug asset referred to as LB1148. The right includes the right to grant sublicenses to third parties, subject to LBS&#8217; written consent, provided that both parties agreed that Newsoara would be permitted to use a certain partner for development purposes. The Newsoara Co-Development Agreement obligates Newsoara to initially use LBS as the exclusive supplier for all Newsoara&#8217;s requirements for Newsoara Licensed Products in the Territory. During the term of the Newsoara Co-Development Agreement, Newsoara may request to manufacture the Newsoara Licensed Products in the Territory, subject to satisfying certain conditions to LBS' reasonable satisfaction. LBS is obligated to approve Newsoara manufacturing rights without undue refusal or delay. The Company records the expense reimbursements from Newsoara for any research and development or manufacturing activities it performs under the Newsoara Co-Development Agreement as a reduction to research and development expenses once the reimbursement amount is approved for payment by Newsoara.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of the rights granted to Newsoara under the Newsoara Co-Development Agreement, Newsoara paid LBS a one-time upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In addition, Newsoara is obligated to make (i) payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate upon achievement of certain regulatory and commercial milestones, (ii) payments in the low six-digit range per licensed product upon achievement of a regulatory milestone, and (iii) tiered royalty payments ranging from the mid-single-digit to low-double-digit percentage range on annual net sales of Licensed Products, subject to adjustment to the royalty percentage in certain events, including a change of control, the expiration of certain patents rights, and royalties paid by Newsoara third parties. To date, Newsoara has met all of its payment obligations under the Newsoara Co-Development Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company recognized license revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million earned upon Newsoara's achievement of a development milestone under the Newsoara Co-Development Agreement during the first quarter of 2023. During the year ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> December 31, 2024, the Company recognized no license revenue from Newsoara under the Newsoara Co-Development Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Newsoara Co-Development Agreement will expire upon the expiration date of the last valid claim of any licensed patent covering the Newsoara Licensed Products in the Territory. In addition, the Newsoara Co-Development Agreement can be terminated (i) by either party for the other party&#8217;s material breach that remains uncured for a specified time period after written notice or for events related to the other party&#8217;s insolvency, (ii) by LBS if Newsoara challenges or attempts to interfere with any licensed patent rights and, (iii) by Newsoara for any reason upon specified prior written notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements with the Regents of the University of California</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> license agreements, as amended, with the Regents of the University of California (&#8220;Regents&#8221;) for exclusive commercial rights to certain patents, technology and know-how related to LB1148. Concurrent with the Company's decision to terminate the development of LB1148, on October 20, 2023 the Company terminated </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of its license agreements with Regents. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the only license agreement remaining with Regents is that entered into with LBS in August 2015, as amended in December 2019 and September 2022 (the &#8220;2015 UC License&#8221;). The 2015 UC License was retained for the sole purpose of maintaining the Newsoara Co-Development Agreement under which the Company may receive future milestone or royalty payments through the term of the license. Accordingly, pursuant to the 2015 UC License, the Company is obligated to pay a percentage of non-royalty licensing revenue it receives from Newsoara under the Newsoara Co-Development Agreement to Regents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent of one-third of the upfront payment and milestone payments received from Newsoara. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in sublicense f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ees and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in license maintenance fees due to Regents in research and development expenses in the consolidated statements of operations. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sublicense fees and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in license maintenance fees due to Regents recognized in research and development expenses in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2015 UC License will expire upon the expiration date of the longest-lived patent right licensed under the 2015 UC License. The Regents may terminate the 2015 UC License if: (i) a material breach by the Company is not cured within 60 days, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable, </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) the Company files for bankruptcy. The Company also has the right to terminate the 2015 UC License at any time upon at least 90 days&#8217; written notice.</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Value Right</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to the closing of the Merger, Seneca issued each share of its common stock held by Seneca stockholders of record, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> contingent value right (&#8220;CVR&#8221;). The CVR entitled the holder (the &#8220;CVR Holder&#8221;) to receive, pro rata with the other CVR Holders, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net proceeds, if any and subject to certain minimum distribution limitations (&#8220;CVR Payment Amount&#8221;), received from the sale or licensing of the intellectual property owned, licensed or controlled by Seneca immediately prior to the closing of the Merger (the &#8220;Legacy Technology&#8221;); provided however that the CVR Holders are only entitled to receive such CVR Payment Amount if the sale or licensing of such Legacy Technology occurred on or before October 27, 2022 (&#8220;Legacy Monetization&#8221;). Pursuant to the terms of the CVR agreement (&#8220;CVR Agreement&#8221;), CVR Holders are only entitled to receive CVR Payment Amounts received within 48-months following the closing of the Merger. The CVR Agreement also provides that no distributions will be made to the CVR Holders in the event such distribution is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NSI-189 &#8211; Exclusive License and Subsequent Exercise of Purchase Option</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Merger, Seneca exclusively licensed certain patents and technologies, including a sublicense covering a synthetic intermediate, of the Company's NSI-189 assets (&#8220;189 License&#8221;), along with a purchase option through December 16, 2023 (&#8220;Purchase Option&#8221;). On October 22, 2021, Alto Neuroscience ("Alto") agreed to terms of an early exercise of the Purchase Option under the 189 License and entered into an asset transfer agreement ("ATA"). Alto is a U.S. based public, clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the CVR Agreement, no distribution was required to be made to the CVR Holders as the CVR Payment Amount after deducting costs and expenses required to maintain the 189 License was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In accordance with the terms of the CVR Agreement, the net proceeds from the sale of the NSI-189 assets, less any applicable transaction costs and expenses, were deposited into the CVR escrow to be used to pay costs and expenses associated with the monetization of the Company's other Legacy Technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Alto will be required to pay the Company up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development and regulatory approval milestones for NSI-189 (or a product containing or otherwise derived from NSI-189), which is now known as ALTO-100. If Alto sells or grants to a third party a license to the patents and other rights specific to ALTO-100 prior to the achievement of a specified clinical development milestone, Alto will be required to pay to the Company a low-double digit percentage of any consideration received by Alto from such license or sale, provided that the maximum aggregate consideration Alto will be required to pay to the Company under the ATA, including the upfront payment and all potential milestones and transaction-related payments, will not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 22, 2024, Alto announced that its Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint. Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in 2026. Upon the enrollment of a patient in a Phase 3 clinical trial of ALTO-100, if it occurs, a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be due from Alto under the ATA. If this occurs within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-months of the closing of the Merger, the CVR Holders will be entitled to a CVR Payment Amount, with the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net proceeds deposited into the CVR escrow. If the milestone is met after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-months of the closing of the Merger, all the net proceeds will be paid to the Company. There can be no assurance that CVR holders will receive CVR Payment Amounts from the sale of the NSI-189 assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NSI-532.IGF-1</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2022, the Company entered an agreement to license NSI-532.IGF-1 to the Regents of the University of Michigan ("University of Michigan") for maintaining NSI-532.IGF-1 cell lines, continued development, maintaining patent protection, and seeking licensees. The Company received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upfront fees for the license. NSI-532.IGF-1 is a preclinical cell therapy being investigated as a potential therapy for prevention and treatment of Alzheimer&#8217;s disease. The University of Michigan shall bear </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the costs for patent filing, prosecution, maintenance, and enforcement of the patent rights. The Company will receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of net revenues received by the University of Michigan from the licensing of patent rights through the last-to-expire patent in patent rights, unless otherwise earlier terminated, less all reasonable and actual out-of-pocket costs incurred in the litigation of patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">can be no assurance that NSI-532.IGF-1 will ever be successfully monetized or that CVR holders will receive CVR Payment Amounts from the sale of the NSI-532.IGF-1 assets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Office Lease</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is party to a non-cancelable facility operating lease (the "Corporate Office Lease") of office space for its corporate headquarters in Carlsbad, California. The initial contractual term is for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39-months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commencing on June 1, 2022 and expiring on August 31, 2025. The Company has the option to renew the Corporate Office Lease for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period at the prevailing market rent upon completion of the initial lease term. The Company has determined it is not likely that it will exercise this renewal option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Corporate Office Lease is also subject to additional variable charges for common area maintenance, insurance, taxes and other operating costs. This additional variable rent expense is not estimable at lease inception. Therefore, it is excluded from the Company&#8217;s straight-line expense calculation at lease inception and is expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized an operating right-of-use asset related to the Corporate Office Lease in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which included in Operating lease right-of-use asset in the consolidated balance sheets, and an operating lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all of which is included in Current portion of operating lease liability in the consolidated balance sheets. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the total remaining future minimum lease payments associated with the Corporate Office Lease of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including imputed interest of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> calculated using a discount rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, will be paid over the remaining lease term of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">0.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Other than the remaining maturities of the operating lease liability due in 2025 related to Corporate Office Lease, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 the Company has no maturities of operating lease liabilities in 2025 or thereafter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized operating lease expense associated with its Corporate Office Lease of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insurance Financing Arrangement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Company entered an agreement to finance insurance policies that renewed in May 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financing arrangement entered in June 2024 has a stated annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and is payable over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period with the first payment payable on June 30, 2024. The insurance financing arrangement is secured by the associated insurance policy. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the aggregate remaining balance under the Company's insurance financing arrangement was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and is included in Insurance financing debt in the consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the remaining insurance financing arrangement payments due in 2025, as of December 31, 2024 the Company has no other minimum debt payments required in 2025 or thereafter.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restructuring Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to better utilize the Company&#8217;s resources on the implementation of its refocused business plans and corporate strategy, the Company committed to a cost-reduction plan on September 9, 2022 (the "2022 Cost-Reduction Plan") and a reduction-in-workforce on October 27, 2023 (the "2023 RIF"). The 2022 Cost-Reduction Plan consisted primarily of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% reduction in the Company's employee workforce to better align the Company&#8217;s resources with its proposed business plan. The 2023 RIF </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consisted of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% reduction in the Company's employee workforce, specifically research and development employees that were no longer deemed critical for the Company&#8217;s development of its lead drug candidate, PALI-2108.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> restructuring expenses related to either the 2022 Cost-Reduction Plan or the 2023 RIF for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. For the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized restructuring costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the 2023 RIF, consisting of severance and benefits payments pursuant to employment agreements and the execution of severance and release agreements. Total expenses related to the 2022 Cost-Reduction Plan and the 2023 RIF through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively The Company does not expect to incur any other significant costs associated with either the 2022 Cost-Reduction Plan or the 2023 RIF.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the change in the Company's accrued restructuring liabilities under both the 2022 Cost-Reduction Plan and the 2023 RIF, which consisted solely of employee compensation and benefits and is classified within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities in the consolidated balance sheets as of each year shown (in thousands): </span></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of the beginning of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net accrual adjustments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of the end of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company through December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#8217;s business.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basic and Diluted Net Loss Per Common Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period, plus any potentially dilutive common shares, consisting of stock-based awards and equivalents, and common stock warrants. For purposes of this calculation, stock-based awards and equivalents and common stock warrants are considered to be potential common shares and are only included in the calculation of diluted net loss per common share when their effect is dilutive.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's Series A Convertible Preferred Stock and certain of the Company's outstanding common stock warrants contain non-forfeitable rights to dividends with the common stockholders, and therefore are considered to be participating securities. The Series A Convertible Preferred Stock and the common stock warrants do not have a contractual obligation to fund the losses of the Company; therefore, the application of the two-class method is not required when the Company is in a net loss position but is required if the Company is in a net income position. When in a net income position, diluted net earnings per common share is computed using the more dilutive of the two-class method or the if-converted and treasury stock methods.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the December 2024 Offering the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,120,688</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prefunded warrants with such prefu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nded warrants being immediately exercisable, having an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and a perpetual term (See Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The prefunded warrants were determined to be equity-classified in accordance with ASC 480 and ASC 815. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,027,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of these prefunded warrants remained unexercised. Pursuant to the guid</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ance of ASC 260-10, the Company concluded that because the equity-classified prefunded warrants were immediately exercisable for little or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash consideration due to the non-substantive stated exercise price, all the necessary conditions for issuance of the underlying common shares had been met when the prefunded warrants were issued. Therefore, the underlying common shares have been included in the denominator for both the calculation of basic and dilutive net loss per common share for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company was in a net loss position for all periods presented, basic and diluted net loss per common share for both the years ended December 31, 2024 and December 31, 2023 was calculated under the if-converted and treasury stock methods. For both the years ended December 31, 2024 and December 31, 2023, basic and diluted net loss per common share were the same as all common stock equivalents other than the prefunded warrants discussed above were anti-dilutive for both years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In computing the basic and diluted net loss available to common stockholders for the year December 31, 2023, the Company has deducted the value of the effect of the down round feature on equity classified warrants that was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">triggered in each year as each was determined to be anti-dilutive. The value of the down round feature on equity classified warrants for the year ended December 31, 2024 was determined to be immaterial.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the calculation of weighted average shares used to calculate basic and diluted net loss per common share (in thousands, except share and per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss available to common stockholders - basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,316</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating basic and diluted net loss per common share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,416,471</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">456,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effects would be anti-dilutive:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units and performance stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants for common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,718,213</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Convertible Preferred Stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,771,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344,834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Employee Benefits</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company participates in a defined contribution 401(k) plan adopted by LBS effective June 20, 2016. All employees are eligible to participate in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> plan beginning on the first day of employment. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation. No matching contributions have been made by the Company since the adoption of the 401(k) plan.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has no current or deferred income taxes as of December 31, 2024 and December 31, 2023.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes vary from the statutory federal income tax rate applied to loss before income taxes as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory federal income tax rate of 21 percent applied to loss before income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,032</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,583</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes - net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">810</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Meals and entertainment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">371</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-deductible expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expiration of tax attributes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">184</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income tax assets and liabilities arising from differences between accounting for financial statement purposes and tax purposes, less valuation reserves at year end are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,383</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,216</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,599</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are recognized for temporary differences and unused tax losses to the extent that realization of the related tax benefits is more-likely-than-not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods when the deferred tax assets become deductible. After considering the history of operating losses and uncertainty regarding its ability to generate positive pre-tax income in 2025 and beyond, the Company has concluded that it is not-more-likely-than-not that its deferred tax assets will be realized, and therefore maintains a full valuation allowance on all deferred tax assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The valuation allowance increased $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal net operating loss ("NOL") carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llion and state NOL carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Of the total amount of federal NOL carryforwards, approx</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million arose in tax years beginning after December 31, 2017 and will carry forward indefinitely. The federal NOL carryforwards arising in tax years beginning before January 1, 2018 of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will begin to expire in 2025 unless previously utilized. The Company&#8217;s state NOL carryforwards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 may be carried forward for 20 years, and will expire at various dates between 2027 and 2044.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the provisions of the Internal Revenue Code ("IRC"), the Company&#8217;s NOL and tax credit carryforwards and certain other attributes are subject to review and possible adjustment by the Internal Revenue Service ("IRS") and state tax authorities. NOL and tax credit carryforwards may be subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the IRC, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Including the recently completed Merger, the Company has completed several equity offerings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the IRC, or could result in a change in control in the future. The Company has not completed an IRC Section 382 and 383 analysis for all relevant tax years regarding the limitation of net operating losses. The NOL deferred tax asset does reflect the limitation resulting from the Merger; however, there could be further limitations due to prior changes in control. Due to the existence of a full valuation allowance, however, changes in the NOLs included as deferred tax assets on the Company&#8217;s consolidated balance sheets would have no impact on the Company's effective tax rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and California. Because of the NOLs, the Company is subject to U.S. federal examinations for tax years 2006 and forward, and for examinations from state taxing authorities for tax years 2008 and forward.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for taxation under ASC 740, which clarifies the accounting for uncertain tax positions. ASC 740 requires that the Company recognize the impact of a tax position in its consolidated financial statements if the position is more-likely-than-not to be sustained upon examination based on the technical merits of the position. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any uncertain income tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 740 requires the Company to accrue interest and penalties where there is an underpayment of taxes based on the Company's best estimate of the amount to ultimately be paid. The Company identified no unrecorded material uncertain tax positions as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, consequently no interest or penalties have been accrued by the Company in either period. The Company does not anticipate a significant change to its unrecognized tax benefits within the next 12 months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Segment Information</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, focused on the research and development of novel therapeutics for patients, including the advancement of PALI-2108 through clinical trials. The Company did not aggregate multiple operating segments into its one operating segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0ffa1e3a-3c65-4853-b3c6-1a6c686c9e2d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief operating decision maker</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;CODM&#8221;) is its chief execut</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's CODM uses Net loss that is reported on the consolidated statements of operations and comprehensive loss for the purposes of assessing performance, allocating resources and planning, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">monitoring budget versus actual results, and forecasting future periods. The Company&#8217;s CODM views specific program spend within research and development expenses, research and development spend that is not allocated to specific programs, as well as general and administrative expenses as significant segment expenses. As a pre-product revenue company, the CODM considers budget versus actual results for expenses that are deemed significant and cash forecast models for assessing performance and to decide the level of investment in the Company&#8217;s operating and capital allocation activities. </span></span><span style=""></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to significant expense categories included in Net loss, the Company regularly provides disaggregated significant expense amounts that comprise operating expenses to the CODM to assist when managing the Company's single reporting segment.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation to consolidated operating expenses as our single segment operating loss for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 is included in the table below (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.76%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PALI-2108 program expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legacy program expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">155</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,303</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,987</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,478</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,069</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,859</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PALI-2108 program expenses are those expenses directly related with the development of the Company's only asset currently under development, PALI-2108. Legacy program expenses are those expenses directly related to its legacy assets, primarily LB1148, which the Company ceased developing in August of 2023. Other research and development expenses includes primarily employee-related expenses and research and development facility expenses, which are not allocated to specific programs, and non-cash losses associated with changes in the fair value of the Company's contingent consideration obligation. For the year ended December 31, 2023, Other research and development expenses also includes the initial fair value of the contingent consideration obligation and transaction-related costs related to the Giiant License Agreement (See Note 4, Fair Value Measurements). Other general and administrative expenses consist primarily of salary and employee-related costs and benefits, professional fees for legal, investor and public relations, accounting and audit services, insurance costs, director and committee fees, and general corporate expenses. Excluded from other general and administrative expenses are intellectual property expenses and business development expenses that are allocated to program expenses.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the other segment items that the Company used to aggregate Total operating expenses to arrive at Net Loss as shown on the consolidated statement of operations include, if applicable, License Revenue, Interest expense and Other income, net.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not provide separate segment asset information to the CODM because the CODM does not review segment assets at a different asset level or category than those shown on the consolidated balance sheets. All of the Company&#8217;s assets are located in the U.S.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Dollar amounts contained in these consolidated financial statements are in whole numbers, unless otherwise indicated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, LBS and Suzhou Neuralstem Biopharmaceutical Co., Ltd. All the entities are consolidated in the Company's consolidated financial statements and all intercompany activity and transactions, if any, have been eliminated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ReverseStockSplitPolicyPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 5, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1-for-15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> "Reverse Stock S</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plit"). As a result of the Reverse Stock Split, the Company&#8217;s stockholders received one share of common stock for every </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#8217;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected the Company&#8217;s outstanding stock-based awards, common stock warrants, and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data and shares of common stock underlying convertible preferred stock, stock-based award and common stock warrants included in these consolidated financial statements, including the exercise price or conversion price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents represent cash in readily available checking and money market accounts. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company held restricted cash of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a separate restricted bank account as collateral for the Company&#8217;s corporate credit card program. The Company has classified these deposits as long-term restricted cash on its consolidated balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Equity Issuance Costs</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Equity Issuance Costs</span><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred equity issuance costs consist of the legal, accounting and other direct and incremental costs incurred by the Company related to its equity offerings, if not yet finalized as of the balance sheet date, or shelf registration statement. As of December 31, 2024 and December 31, 2023, deferred equity issuance costs of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, were included in prepaid expenses and other current assets in the consolidated balance sheets. These costs will be netted against additional paid-in capital as a cost of the future equity issuances to which they relate. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company netted previously deferred equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> against the additional paid-in capital recognized in conjunction with the February 2024 Warrant Inducement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company netted previously deferred equity issuance costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> associated with its shelf registration statement against the additional paid-in capital recognized in conjunction with the September 2023 Offering (see Note 5, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders' Equity)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accounts, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and historically the Company has not experienced any losses in such accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows Accounting Standards Codification ("ASC") 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.148%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further information on the fair value of the Company's financial assets and liabilities can be found at Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including common stock warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option pricing model or other acceptable valuation models, including the Monte-Carlo simulation model. Derivative instruments, if any, are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at the end of each reporting period.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and common stock warrants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its common stock warrants in accordance with ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASC 480") and ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 815&#8221;). Based upon the provisions of ASC 480 and ASC 815, the Company accounts for common stock warrants as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement, or if it fails the equity classification criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified as equity. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at fair value at each balance sheet date with the offsetting adjustments recorded in change in fair value of warrant liability within the consolidated statements of operations. If the terms of a common stock warrant previously classified as a liability are amended and pursuant to such amendment meet the requirements to be classified as equity, the common stock warrants are reclassified to equity at the fair value on the date of the amendment and are not subsequently remeasured. Common stock warrants classified as equity are recorded on a relative fair value basis when they are issued with other equity-classified financial instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company assesses contracts for lease arrangements at inception. Operating right-of-use (&#8220;ROU&#8221;) assets and liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit, if readily available, or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionSoftware', window );">License Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ContingentConsiderationObligationsPolicyTextBlock', window );">Contingent Consideration Obligation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 1, 2023, the Company and Giiant Pharma, Inc. ("Giiant") entered into a research collaboration and license agreement (the &#8220;Giiant License Agreement&#8221;)(see Note 7, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborations and License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation consisting of milestone payments, which are recognized as a liability measured at fair value, and ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses third parties of any products developed from the assets licensed under the Giiant License Agreement. Because the contingent consideration associated with the milestone payments may be settled in shares of the Company's common stock solely at the election of the Company, the Company has determined it should be accounted for under ASC 480 and accordingly the Company has recognized it as a liability measured at its estimated fair value. At the end of each reporting period, the Company re-measures the contingent consideration obligation to its estimated fair value and any resulting change is recognized in research and development expenses in the consolidated statements of operations. The Company has determined that the contingent consideration associated with the royalty payments should be recognized as a liability when they are probable and estimable, in accordance with ASC 450, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist primarily of salaries and other personnel related expenses including stock-based compensation costs, and, to the extent applicable, may include preclinical costs, clinical trial costs, costs related to acquiring and manufacturing clinical trial materials, and contract services. All research and development costs are expensed as incurred pursuant to ASC 730, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pursuant to situations whereby the Company performs any research and development or manufacturing activities under a co-development agreement, and the co-development partner is not considered a customer under ASC 606, the Company records the expense reimbursements from the co-development partner as a reduction to research and development expense once the reimbursement amount is approved for payment by the co-development partner. Expense payments made to Giiant pursuant to the terms of the Giiant License Agreement for qualifying development costs are expensed only as the associated research and development costs are incurred or other aspects of the drug development or related activities are achieved. In instances where the expense determined to be recognized exceeds the payments made to the Giiant, the Company recognizes an accrual of joint development expenses. In addition, there may be instances in which payments made to Giiant will temporarily exceed the level of services provided, which results in a prepayment of the joint development expenses. The Company records expense payments from Giiant, if any, as a reduction to research and development expense once the expense payments are realized or realizable, which is when Company receives the cash or has an undisputed claim to the cash that is probable of collection, pursuant to the terms of the Giiant License</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement and the principles of ASC 450, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain Contingencies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">("ASC 450"). The Company has determined that Giiant is not considered a customer under ASC 606.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClinicalTrialExpensesPolicyPolicyTextBlock', window );">Clinical Trial Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses related to clinical studies are based on estimates of the services received and efforts expended pursuant to the Company&#8217;s contract arrangements. The financial terms of these contract arrangements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients, site initiation and the completion of clinical milestones. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense balance accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accrues for clinical trial expenses for which the estimated services have been provided but the Company has not yet been invoiced as of the balance sheet date. There may be instances in which payments made to the Company&#8217;s service providers will temporarily exceed the level of services provided and result in a prepayment of the clinical trial expenses. Clinical trial expenses are included in research and development expenses in the consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company follows ASC 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 740&#8221;) in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some of or all the deferred tax assets will not be realized.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s stock-based compensation generally includes service-based restricted stock units (&#8220;RSUs&#8221;), stock options, and market-based performance RSUs (&#8220;PSUs&#8221;). The Company accounts for forfeitures as they occur for each type of award as a reduction of expense. Stock-based compensation expense related to service-based RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period, which is usually the vesting period. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model. The determination of the fair value of stock-based payment awards on the date of grant using the Black-Scholes option pricing model is affected by the Company's stock price as well as assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate, and expected dividends over the expected term of the award. Stock-based compensation expense represents the cost of the estimated grant date fair value of employee and non-employee stock option grants recognized ratably over the requisite service period of the awards, which is usually the vesting period. For PSUs with vesting subject to market conditions, the fair value of the award is determined at grant date using the Monte Carlo simulation model, and expense is recognized ratably over the derived service period regardless of whether the market condition is satisfied. The Monte Carlo simulation model considers a variety of potential future scenarios under the market condition vesting criteria, including but not limited to share prices for the Company and its peer companies in a selected market index.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not recognize any share-based compensation expense related to conditional RSUs, stock options, or PSUs that are subject to shareholder approval. When and if approval is obtained, the Company recognizes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share-based compensation expense related to the conditional equity grants ratably to the vesting of shares over the remaining requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company offers to its employees an opportunity to participate in its shareholder approved Palisade Bio, Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP"). The Company estimates the fair value of 2021 ESPP awards on the first day of the offering period using the Black-Scholes option pricing model. The estimated fair value of 2021 ESPP awards is amortized on a straight-line basis over the requisite service period of the award. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of 2021 ESPP awards.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was the same as its reported net loss for all years presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ("ASU 2023-07"), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The disclosure requirements included in ASU No. 2023-07 are required for all public entities, including those with a single reportable segment. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 31, 2024 on a retrospective basis, with early adoption permitted. The Company adopted ASU 2023-07 in the fourth quarter of 2024. The adoption of this guidance resulted in additional financial statement disclosures and had no impact on the Company's results of operations and financial condition. See Note 12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for disclosures resulting from the adoption of ASU 2023-07.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 720): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASU 2023-09"), which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASC 2023-09 on its consolidated financial statement disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("ASU 2024-03"), which is intended to improve disclosures about a public business entity&#8217;s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClinicalTrialExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClinicalTrialExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ContingentConsiderationObligationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ContingentConsiderationObligationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ReverseStockSplitPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split, policy [Policy Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ReverseStockSplitPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for software arrangements relating to the licensing, selling, leasing, or marketing of computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Table Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">384</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid subscriptions and fees</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid software licenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred equity issuance costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">896</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Noncurrent Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other noncurrent assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance, less current portion</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">478</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other noncurrent assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">490</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued accounts payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued chemistry, manufacturing and controls ("CMC") expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">606</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued director stipends</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued severance and benefits (Note 8)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued joint development expenses (Note 7)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of contingent consideration obligation (Note 4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,240</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Table Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes all common stock warrant activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.951%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.342%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.501%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,211</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144.78</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,327,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.68</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,854,658</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.35</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, expired or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,438.12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,745,213</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.53</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pali_ContingentConsiderationObligationsMember', window );">Contingent Consideration Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value of Options Granted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">summarizes the activity of the Company&#8217;s Level 3 contingent consideration obligations, which are fair valued on a recurring basis (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contingent Consideration Obligation</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Initial fair value at the original issuance date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pali_StockPurchaseWarrantsMember', window );">Warrant Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value of Options Granted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the activity of the Company&#8217;s Level 3 liability-classified warrants during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.093%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.903%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.763%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrant Liabilities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at beginning of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value during the period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pali_ContingentConsiderationObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pali_ContingentConsiderationObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pali_StockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pali_StockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Table Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock', window );">Schedule of Stockholders' Equity warrant outstanding and exercisable.</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company's outstanding and exercisable common stock warrants as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.952%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:17.996%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.678%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.378%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.858%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.98%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classification</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Warrants Outstanding</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024 Offering Pre-Funded Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,027,000</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Perpetual</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024 Offering Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,278,688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.95</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2024 Offering Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">922,863</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.34</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 2024 Warrant Inducement Replacement Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228,158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.17</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.09</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 2024 Offering Series 2 Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,748</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.61</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bridge, January 2021, and July 2021 Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liability-Classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Placement Agent, Solicitor and Representative Common Stock Warrants</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274,693</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.98</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.66</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Common Stock Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-classified</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,919</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,418.56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.50</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Warrants Outstanding, December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,745,213</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.53</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
      </table><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes all common stock warrant activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.951%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.342%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.501%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Warrants</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining <br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2023</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,211</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144.78</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,327,864</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.68</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.27</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,854,658</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.35</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, expired or cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,438.12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:11pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding, December 31, 2024</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,745,213</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.53</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Table Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options Granted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 is estimated as of the grant date using the Black-Scholes option pricing model using the assumptions in the following table:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.882%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average exercise price per share</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.85</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average expected term (years)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.65</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.66</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.03</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.08</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average expected dividend yield</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average volatility</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111.74</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.35</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Summarized Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity and related information under the 2013 Plan, the 2021 EIP and the 2021 Inducement Plan for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.662%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Options</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise Price</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,276</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233.09</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,300</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited, expired or cancelled</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,902</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">335.18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.48</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.75</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,674</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.48</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.75</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,825</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">349.89</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.44</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">following table summarizes RSU activity and related information under the 2021 EIP and the 2021 Inducement Plan for the year ended December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.700000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>Restricted<br/>Stock Units</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Remaining Contractual<br/>Life (Years)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2023</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,195</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.30</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.17</span></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,067</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.23</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,128</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.84</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-vested at December 31, 2024</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation for all Stock Awards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The allocation of stock-based compensation for all stock option, RSU and PSU awards is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">263</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">370</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">366</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">633</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">606</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the calculation of weighted average shares used to calculate basic and diluted net loss per common share (in thousands, except share and per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss available to common stockholders - basic and diluted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,316</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares used in calculating basic and diluted net loss per common share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,416,471</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">456,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effects would be anti-dilutive:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units and performance stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants for common stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,718,213</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A Convertible Preferred Stock</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,771,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344,834</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Accrued liabilities in the consolidated balance sheet</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities in the consolidated balance sheets as of each year shown (in thousands): </span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of the beginning of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net accrual adjustments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">274</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of the end of year</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Statutory Federal Income Tax Rate Applied to Loss Before Income Tax</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes vary from the statutory federal income tax rate applied to loss before income taxes as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Statutory federal income tax rate of 21 percent applied to loss before income taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,032</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,583</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes - net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">660</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">810</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Meals and entertainment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">371</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-deductible expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expiration of tax attributes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">184</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">484</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,278</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income tax assets and liabilities arising from differences between accounting for financial statement purposes and tax purposes, less valuation reserves at year end are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,383</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,216</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,771</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,599</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 -Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Loss from Operations</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation to consolidated operating expenses as our single segment operating loss for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 is included in the table below (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.76%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PALI-2108 program expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,070</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legacy program expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">155</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,303</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,156</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,987</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,478</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,069</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restructuring costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,859</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,320</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (Accumulated deficit), ending balance</a></td>
<td class="nump">$ 135,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,821<span></span>
</td>
<td class="nump">$ 12,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split fractional share settlement</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred equity issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_DeferredEquityIssuanceCosts', window );">Deferred equity issuance costs againist additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember', window );">February 2024 Warrant Inducement [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_DeferredEquityIssuanceCosts', window );">Deferred equity issuance costs againist additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_DeferredEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred equity issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_DeferredEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables', window );">Other receivables</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PrepaidSubscriptionsAndFees', window );">Prepaid subscriptions and fees</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PrepaidSoftwareLicenses', window );">Prepaid software licenses</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred equity issuance costs</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets, other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PrepaidSoftwareLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid software licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PrepaidSoftwareLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PrepaidSubscriptionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid subscriptions and fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PrepaidSubscriptionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Balance Sheet Details - Summary of Other Noncurrent Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid insurance, less current portion</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_OtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets, Total</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Balance Sheet Details - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NotesToFinancialStatementsAbstract', window );"><strong>Notes To Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AccruedAccountsPayable', window );">Accrued accounts payable</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AccruedClinicalTrialCosts', window );">Accrued clinical trial expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AccruedCMCExpenses', window );">Accrued chemistry, manufacturing and controls ("CMC") expenses</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AccruedDirectorStipends', window );">Accrued director stipends</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Accrued severance and benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AccruedJointDevelopmentExpenses', window );">Accrued joint development expenses</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, current, Total</a></td>
<td class="nump">$ 1,240<span></span>
</td>
<td class="nump">$ 831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_AccruedAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued accounts payable, included in accrued liabilities rather than in the Accounts Payable line item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_AccruedAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_AccruedCMCExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued CMC expenses as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_AccruedCMCExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued clinical trial costs as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_AccruedDirectorStipends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued director stipends as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_AccruedDirectorStipends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_AccruedJointDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Joint Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_AccruedJointDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes To Financial Statements Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Fair Value Measurements (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligation</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ChangesInFairValueOfContingentConsideration', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value of the company's cash and cash equivalents</a></td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="nump">12,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">0.0929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts', window );">Transaction related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ChangesInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ChangesInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pali_ContingentConsiderationObligationsMember', window );">Contingent Consideration Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, Beginning</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value at the original issuance date</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value during the period</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, Ending</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, Beginning</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, Ending</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pali_ContingentConsiderationObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pali_ContingentConsiderationObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>May 06, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
<th class="th"><div>Apr. 05, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Sep. 11, 2023</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000,000<span></span>
</td>
<td class="nump">280,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split fractional share settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,745,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768,646<span></span>
</td>
<td class="nump">618,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768,646<span></span>
</td>
<td class="nump">618,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,435,000<span></span>
</td>
<td class="nump">$ 9,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,000<span></span>
</td>
<td class="nump">617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,745,213<span></span>
</td>
<td class="nump">272,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pali_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pali_ReplacementWarrantsMember', window );">Replacement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Date of issuance of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares (Per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split fractional share settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split fractional share settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,771,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split fractional share settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Date of issuance of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Pre Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingCommonStockWarrantsMember', window );">December 2024 Offering Common Stock Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,278,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_MayTwoThousandTwentyFourOfferingMember', window );">May Two Thousand Twenty Four Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceeds', window );">Net Proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_GrantDateFairValue', window );">Grant date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock during period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_MayTwoThousandTwentyFourOfferingMember', window );">May Two Thousand Twenty Four Offering [Member] | Unregistered Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares Sold, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_May2024PlacementAgentWarrantsMember', window );">May 2024 Placement Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Date of issuance of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember', window );">February 2024 Warrant Inducement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceedsFromIssuanceOfWarrants', window );">Net proceeds from exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from the exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_CashTransactionRelatedExpensesAndPlacementAgentFees', window );">Cash transaction-related expenses And placement agent fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_WarrantsIssuanceCosts', window );">Total equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NonCashWarrantModificationCosts', window );">Non-cash warrant modification costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember', window );">February 2024 Warrant Inducement [Member] | Replacement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember', window );">February 2024 Warrant Inducement [Member] | May 2022 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember', window );">February 2024 Warrant Inducement [Member] | Series 2 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember', window );">February 2024 Warrant Inducement [Member] | January 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember', window );">February 2024 Warrant Inducement [Member] | April 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Date of issuance of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_OutOfPocketExpenses', window );">Out-of-pocket expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NonCashWarrantIssuanceCosts', window );">Non-cash warrant issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PercentageOfGrossProceeds', window );">Percentage of gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PercentageOfShareIssued', window );">Percentage of share issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2022WarrantsMember', window );">December 2022 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceeds', window );">Net Proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_SeriesA4Point5PercentConvertiblePreferredStockMember', window );">Series A 4.5% Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares', window );">Convertible Preferred Stock, Issuable Upon Conversion of All Shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock issued and outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember', window );">December 2024 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Option to purchase shares of Company's common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Date of issuance of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceeds', window );">Net Proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_GrantDateFairValue', window );">Grant date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember', window );">December 2024 Offering [Member] | Pre Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember', window );">December 2024 Offering [Member] | Class A Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares (Per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_UnderwritingCommitmentsPerShare', window );">Underwriting agreement, per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember', window );">December 2024 Offering [Member] | Class B Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares (Per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_UnderwritingCommitmentsPerShare', window );">Underwriting agreement, per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember', window );">December 2024 Offering [Member] | December 2024 Representative Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.51625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember', window );">December 2024 Offering [Member] | Repriced Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,040,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Incremental fair value of Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_SeptemberTwoThousandAndTwentyThreeOfferingMember', window );">September 2023 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceeds', window );">Net Proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_AprilTwoThousandAndTwentyThreeOfferingMember', window );">April 2023 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceeds', window );">Net Proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pali_JanuaryTwoThousandAndTwentyThreeOfferingMember', window );">January 2023 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NetProceeds', window );">Net Proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</span></p></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_CashTransactionRelatedExpensesAndPlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash transaction-related expenses And placement agent fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_CashTransactionRelatedExpensesAndPlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for all shares of a given class of convertible preferred stock that may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_GrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_GrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NetProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NetProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NonCashWarrantIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash warrant issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NonCashWarrantIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NonCashWarrantModificationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash warrant modification costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NonCashWarrantModificationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_OutOfPocketExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Out-of-pocket expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_OutOfPocketExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PercentageOfShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Share Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PercentageOfShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_UnderwritingCommitmentsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting commitments, per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_UnderwritingCommitmentsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_WarrantsIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_WarrantsIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares as a settlement alternative for each freestanding option contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pali_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pali_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pali_ReplacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pali_ReplacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_MayTwoThousandTwentyFourOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_MayTwoThousandTwentyFourOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pali_UnregisteredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pali_UnregisteredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_May2024PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_May2024PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pali_MayTwoThousandTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pali_MayTwoThousandTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pali_Series2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pali_Series2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pali_JanuaryTwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pali_JanuaryTwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pali_AprilTwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pali_AprilTwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_December2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pali_SeriesA4Point5PercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pali_SeriesA4Point5PercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pali_December2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pali_ClassAUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pali_ClassAUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pali_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pali_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_December2024RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_RepricedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_RepricedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pali_SeptemberTwoThousandAndTwentyThreeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pali_SeptemberTwoThousandAndTwentyThreeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pali_AprilTwoThousandAndTwentyThreeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pali_AprilTwoThousandAndTwentyThreeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pali_JanuaryTwoThousandAndTwentyThreeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pali_JanuaryTwoThousandAndTwentyThreeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity - Schedule of Stockholders' Equity warrant outstanding and exercisable (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">6,745,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingPreFundedCommonStockWarrantsMember', window );">December 2024 Offering PreFunded Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">2,027,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingCommonStockWarrantsMember', window );">December 2024 Offering Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">3,278,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_MayTwoThousandTwentyFourOfferingMember', window );">May Two Thousand Twenty Four Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">922,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementReplacementCommonStockWarrantsMember', window );">February 2024 Warrant Inducement Replacement Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">228,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 6.17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 1 month 2 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_August2024OfferingSeries2CommonStockWarrantsMember', window );">August 2024 Offering Series 2 Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">6,748<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 7 months 9 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember', window );">Bridge, January 2021, and July 2021 Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 58.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember', window );">Placement Agent, Solicitor and Representative Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">274,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 10.98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 7 months 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pali_AllOtherCommonStockWarrantsMember', window );">All Other Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">5,919<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 3,418.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingPreFundedCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingPreFundedCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_December2024OfferingCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_MayTwoThousandTwentyFourOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_MayTwoThousandTwentyFourOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementReplacementCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_February2024WarrantInducementReplacementCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_August2024OfferingSeries2CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_August2024OfferingSeries2CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pali_AllOtherCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pali_AllOtherCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightNumberOutstanding', window );">Warrants outstanding, balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">272,211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,327,864<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Exercised (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,854,658)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod', window );">Forfeited, expired or cancelled (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(204)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightNumberOutstanding', window );">Warrants outstanding, balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,745,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">272,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Warrants outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 144.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1.68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice', window );">Forfeited, expired, or cancelled, weighted average exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,438.12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife', window );">Warrants outstanding, weighted average remaining contratual life (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife', window );">Granted, weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised during period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights forfeited, expired or cancelled during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right forfeited expired or cancelled during period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued during period weighted average remaining contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightNumberOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights outstanding as of the specified date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightNumberOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average remaining contractual life of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plans (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2023 </div>
<div>Days </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Maximum shares issued under ESPP | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 12.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to outstanding options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Grant date fair value of the options vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,000<span></span>
</td>
<td class="nump">606,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Grant date fair value of the options vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to outstanding RSUs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Based Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Restricted Stock Units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Stock Units, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity', window );">Cost of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares unvested and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,952<span></span>
</td>
<td class="nump">4,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Based Stock Units [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award Vesting Rights Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NumberOfTradingDays', window );">Consecutive trading day period | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Based Stock Units [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award Vesting Rights Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NumberOfTradingDays', window );">Consecutive trading day period | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pali_TimeBasedRestrictedStockUnitsMember', window );">Time-based RSU [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pali_TimeBasedRestrictedStockUnitsMember', window );">Time-based RSU [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pali_The2021PlanMember', window );">The 2021 EIP and Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pali_The2021PlanMember', window );">The 2021 EIP and Inducement Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Restricted Stock Units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Stock Units, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pali_The2013PlanMember', window );">2013 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pali_The2021EsppMember', window );">The 2021 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Maximum shares issued under ESPP | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Share based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pali_InducementPlanMember', window );">2021 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted (in shares)</a></td>
<td class="nump">66,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions Cost of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pali_TimeBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pali_TimeBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pali_The2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pali_The2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pali_The2013PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pali_The2013PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pali_The2021EsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pali_The2021EsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pali_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pali_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plans - Schedule of Fair Value of Options Granted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share</a></td>
<td class="nump">$ 4.54<span></span>
</td>
<td class="nump">$ 20.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm', window );">Weighted-average expected term (years)</a></td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">4.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Weighted-average expected dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="nump">111.74%<span></span>
</td>
<td class="nump">78.35%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted-average expected term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plans - Schedule of Summarized Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding (in shares)</a></td>
<td class="nump">44,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted (in shares)</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited, expired or cancelled (in shares)</a></td>
<td class="num">(5,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding (in shares)</a></td>
<td class="nump">50,674<span></span>
</td>
<td class="nump">44,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">50,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable (in shares)</a></td>
<td class="nump">22,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 233.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options Granted, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">4.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options Forfeited, expired or cancelled, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">335.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">166.48<span></span>
</td>
<td class="nump">$ 233.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">166.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 349.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Year)</a></td>
<td class="text">8 years 9 months<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options Vested and expected to vest, Weighted Average Remaining Contractual Life (Year)</a></td>
<td class="text">8 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (Year)</a></td>
<td class="text">8 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plans - Schedule of Stock-based Compensation for all Stock Awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 633<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plans - Schedule of Restricted Stock Units Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested, Weighted Average Contractual Life (Years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pali_The2021PlanMember', window );">The 2021 Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Restricted Stock Units, Non-vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Restricted Stock Units, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Restricted Stock Units, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,067)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Restricted Stock Units, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested, Weighted Average Contractual Life (Years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 1 day<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pali_The2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pali_The2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Collaborations and License Agreements (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Agreement </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 20, 2023 </div>
<div>Agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_CollaborationsAndLicenseAgreementsUpfrontFee', window );">Collaborations and license agreements upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_MaximumAggregateConsideration', window );">Maximum Aggregate Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClosingPeriodOfMergerAgreement', window );">Closing period of merger agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ProceedsDepositedIntoTheCvrEscrow', window );">Proceeds Deposited into the CVR Escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_AccruedJointDevelopmentExpenses', window );">Accrued joint development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ClassOfWarrantOrRightNumberOfRightsIssued', window );">Contingent value right issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing', window );">Contingent value right, pro rata, net proceeds from sale or licensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_CvrAgreementDistributionMinimumAmount', window );">CVR Agreement, distribution minimum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_JointDevelopmentExpenses', window );">Joint development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember', window );">License Agreements with the Regents of the University of California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NumberOfLicenseAgreements', window );">Number of license agreements | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_NumberOfTerminatedLicenseAgreements', window );">Number of terminated license agreements | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_SublicenseFees', window );">Sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PeriodOfExpirationOfLicenseAgreementDescription', window );">Period of Expiration of License Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2015 UC License will expire upon the expiration date of the longest-lived patent right licensed under the 2015 UC License. The Regents may terminate the 2015 UC License if: (i) a material breach by the Company is not cured within 60 days, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable, or (iii) the Company files for bankruptcy. The Company also has the right to terminate the 2015 UC License at any time upon at least 90 days&#8217; written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember', window );">License Agreements with the Regents of the University of California [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived', window );">Royalty rate, portion of sublicense income to be paid, percentage of one-third of upfront payment and milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember', window );">License Agreements with the Regents of the University of California [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived', window );">Royalty rate, portion of sublicense income to be paid, percentage of one-third of upfront payment and milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember', window );">License Agreements with the Regents of the University of California [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_SublicenseFees', window );">Sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pali_Nsi532Igf1Member', window );">NSI-532.IGF-1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_CollaborationsAndLicenseAgreementsUpfrontFee', window );">Collaborations and license agreements upfront fee</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PercentageCostInPatentRight', window );">Percentage cost in patent right</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PercentageOfNetRevenue', window );">Percentage of net revenue</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_AccruedJointDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Joint Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_AccruedJointDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClassOfWarrantOrRightNumberOfRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClassOfWarrantOrRightNumberOfRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ClosingPeriodOfMergerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing period of merger agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ClosingPeriodOfMergerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_CollaborationsAndLicenseAgreementsUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations and license agreements upfront fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_CollaborationsAndLicenseAgreementsUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value right, pro rata, net proceeds from sale or licensing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_CvrAgreementDistributionMinimumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CVR agreement, distribution minimum amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_CvrAgreementDistributionMinimumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_JointDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_JointDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_MaximumAggregateConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_MaximumAggregateConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of license agreements in place.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_NumberOfTerminatedLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Terminated License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_NumberOfTerminatedLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PercentageCostInPatentRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage cost in patent right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PercentageCostInPatentRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PeriodOfExpirationOfLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of Expiration of License Agreement Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PeriodOfExpirationOfLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ProceedsDepositedIntoTheCvrEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds deposited into the CVR escrow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ProceedsDepositedIntoTheCvrEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate on the portion of sublicense income to be paid, expressed as a percentage of one-third of the upfront payment and milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_SublicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_SublicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pali_Nsi532Igf1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pali_Nsi532Igf1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 09, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="nump">$ 198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pali_CostReductionPlanMember', window );">Cost Reduction Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PercentageOfReductionInWorkForce', window );">Reduction in work force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAdministrationExpenses', window );">Total expenses</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pali_CostReductionPlanTwentyTwentyThreeMember', window );">2023 RIF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_PercentageOfReductionInWorkForce', window );">Reduction in work force</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAdministrationExpenses', window );">Total expenses</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=pali_InsuranceFinancingArrangementMember', window );">Insurance Financing Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line of Credit Facility, Interest Rate During Period</a></td>
<td class="nump">8.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of Credit Facility, Expiration Period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining balance under insurance financing arrangements</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember', window );">Corpotate Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_OperatingLeasesFutureMinimumPayments', window );">Total remaining future minimum lease payments</a></td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_OperatingLeasesFutureMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_OperatingLeasesFutureMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_PercentageOfReductionInWorkForce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reduction in work force</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_PercentageOfReductionInWorkForce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAdministrationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of administration expense of defined benefit plan which decreases plan assets. Excludes plan administration expense paid by employer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAdministrationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pali_CostReductionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pali_CostReductionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pali_CostReductionPlanTwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pali_CostReductionPlanTwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=pali_InsuranceFinancingArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=pali_InsuranceFinancingArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies - Accrued liabilities in the consolidated balance sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance as of the beginning of year</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Net accrual additions</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash paid</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance as of the end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Net Loss Per Share - (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pali_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,027,000<span></span>
</td>
<td class="nump">3,120,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price of common stock Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_CashConsideration', window );">Cash consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_CashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_CashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pali_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pali_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Basic and diluted net loss per common share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (12,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (12,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating basic loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,416,471<span></span>
</td>
<td class="nump">456,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (10.19)<span></span>
</td>
<td class="num">$ (27.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted net loss per common share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shares - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (12,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating diluted loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,416,471<span></span>
</td>
<td class="nump">456,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (10.19)<span></span>
</td>
<td class="num">$ (27.01)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Basic and diluted loss per common share and basic and diluted weighted average share used in computing basic and diluted loss per common share for the year ended December 31, 2023 has been adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">4,771,847<span></span>
</td>
<td class="nump">344,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">50,674<span></span>
</td>
<td class="nump">44,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="nump">28,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">4,718,213<span></span>
</td>
<td class="nump">272,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pali_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pali_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pali_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase of valuation allowance</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_UncertainIncomeTaxPositions', window );">Uncertain income tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">109,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="nump">$ 77,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_UncertainIncomeTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>uncertain income tax positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_UncertainIncomeTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes - Schedule of Statutory Federal Income Tax Applied to Loss Before Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate of 21 percent applied to loss before income taxes</a></td>
<td class="num">$ (3,032)<span></span>
</td>
<td class="num">$ (2,583)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes - net of federal benefit</a></td>
<td class="num">(660)<span></span>
</td>
<td class="num">(810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_IncomeTaxReconciliationNondeductibleExpenseWarrants', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_IncomeTaxReconciliationOtherNonDeductibleExpenses', window );">Other non-deductible expenses</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes', window );">Expiration of tax attributes</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="num">(346)<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Others</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">3,515<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration of tax attributes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_IncomeTaxReconciliationNondeductibleExpenseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Nondeductible Expense Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_IncomeTaxReconciliationNondeductibleExpenseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_IncomeTaxReconciliationOtherNonDeductibleExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non-deductible expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_IncomeTaxReconciliationOtherNonDeductibleExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_DeferredTaxAssetsAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">27,383<span></span>
</td>
<td class="nump">24,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">32,599<span></span>
</td>
<td class="nump">29,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_DeferredTaxLiabilitiesRightOfUseAsset', window );">Operating right-of-use asset</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expense</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">32,468<span></span>
</td>
<td class="nump">28,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(32,468)<span></span>
</td>
<td class="num">(28,952)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_DeferredTaxAssetsAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_DeferredTaxAssetsAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right-of-use asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segment Information (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The Company's CODM uses Net loss that is reported on the consolidated statements of operations and comprehensive loss for the purposes of assessing performance, allocating resources and planning, monitoring budget versus actual results, and forecasting future periods. The Company&#8217;s CODM views specific program spend within research and development expenses, research and development spend that is not allocated to specific programs, as well as general and administrative expenses as significant segment expenses. As a pre-product revenue company, the CODM considers budget versus actual results for expenses that are deemed significant and cash forecast models for assessing performance and to decide the level of investment in the Company&#8217;s operating and capital allocation activities. In addition to significant expense categories included in Net loss, the Company regularly provides disaggregated significant expense amounts that comprise operating expenses to the CODM to assist when managing the Company's single reporting segment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segment Information - Schedule of Reconciliation of Loss from Operations Disclosure Disclosure (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,859<span></span>
</td>
<td class="nump">13,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expenses</a></td>
<td class="nump">2,156<span></span>
</td>
<td class="nump">2,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative expenses</a></td>
<td class="nump">5,478<span></span>
</td>
<td class="nump">6,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,859<span></span>
</td>
<td class="nump">13,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | PALI-2108 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ProgramExpenses', window );">Program expenses</a></td>
<td class="nump">7,070<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Legacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pali_ProgramExpenses', window );">Program expenses</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 3,303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pali_ProgramExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Program expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pali_ProgramExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pali_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pali_PALITwoOneZeroEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pali_PALITwoOneZeroEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pali_LegacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pali_LegacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (.">%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( (.">%HFP!8+\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( (.">%K#2N 65PD  )(W   8
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M,,ZM2_D0I]4*Z%*KTBO-@*G.WPMZ0\\#]:2]_8#NX3ST&,G;G%KR_+QOH'&
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M^PZY<I@D,=D7/ ";[, F0;!WDJTH+Q#[#ON28LH"%WK))"3__IKYP*]-#_=
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MM\W\E9 6L%@@\6(WW$;^V>N 2VUC7]0]#$@"46\)$(<9\$.M&FD;VP6OX=?
M+MC<NV%CE^5&8P]65PP/ [%NZ1"'^?"PK3B6T!XZ)+&'NCV"9)AULS=N61&'
M:?$+E1!:?20!7(+SY>\1J4.$+0OB, W"A&,2U80SAV&'%S9S31K/2_Y@#VV[
M8=(Z/\QTKR\N">*A+YM=N;0[F4G+E23,E2_[D%W@7^,$<6GR)7Z/2(#K24NC
M),A8FP0_DM@;&P>)'6>9&V6/('0NXVZ<>Q-CF/EFHJJX-LWH>BC)MVF4 V;T
M]@^A&<J\DW'8L)^RD7>*_'%#A\ZWA$KB8*]SKT7^=2E*J!7UBVW+];-_:@X2
M\ZO'YC-9._2Z96<29F>SY+ O*.-\'[V)+B,,?8]$,#\W[!V"6:P/B67^D%I2
M::;51B^%Y/^Q F[W1VG63Y/4IDN*LWXT3+>"7"G#^W:Z;;32<&!*F&ITRW)6
MS:%1W[XML4(OK\9]!&96S+[T*KV;+''IGXP\%>.9FKO+I>T12+A'N"D*;G8;
MJ&TST%_P&J;-%8=:]V+U4'T2)Y$/KV\N)AD.[*5M8T#"C0&T8TW5E/;=5P']
M5\Z]/0%QR?X"Q\-QXAGEO+($&"(0Y+8Y(*<T!\I3G%[8+NF/DK&'>#V"&,<X
M[D;<M@<DW!XXN[W-[I,]\ S&_KG/)QF<^TC;/Y!P_W#/I,%]@^XD6S"@U@+9
M[1']\]&6Z+]>Y$&;K]X7SV3M\'UBVW+$T7G8( ZV+J_U^ES6#KUN&Y4XW*CL
MUAT:R$<&K12,OR]SP&&)/AH%.6)SZX?IP!M][+RD]13[,:EUM 9[7Q3,YYR/
M5#[P6D'/N0"UZ'($E2;77TC6)UJL[$>&N=!:5/9PR2ADC!& ^PL!#=/FQ'RW
MV'VGFOX/4$L#!!0    ( (.">%I&_A%0( ,  #0,   8    >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&ULM9==;]HP%(;_BI5-4RMUY ,(:0>16JIINZB$BM9=
M3+LPR8%8=>+,-M#MU\]VTI24E 2T<0&V<S[>Q\ZQS7C+^*-( "1Z2FDF)E8B
M97YEVR)*(,6BQW+(U),EXRF6JLM7ML@YX-@XI=3V',>W4TPR*QR;L1D/QVPM
M*<E@QI%8IRGFOV^ LNW$<JWG@7NR2J0>L,-QCE<P!_DMGW'5LZLH,4DA$X1E
MB,-R8EV[5U/7TP[&XH' 5NRTD499,/:H.U_CB>5H14 ADCH$5C\;F *E.I+2
M\:L,:E4YM>-N^SGZ9P.O8!98P)31[R26R<0*+!3#$J^IO&?;+U "#76\B%%A
MOM&VL/5'%HK60K*T=%8*4I(5O_BIG(@=!W?PAH-7.GA='?JE0]^ %LH,UBV6
M.!QSMD5<6ZMHNF'FQG@K&I+I99Q+KIX2Y2?#*<L$HR3&$F)T@RG.(D!S'4Z@
MLQGFD,D$)(DP%>?H(WJ/;"02-2S&ME3I=1 [*E/=%*F\-U+=0M1#??<">8XW
M:'"?=G?OU]UM!5V1>Q6Y9^(-WB1/4_4>S26+'B^00D6,JYZ9B =,UX!FH 8T
M+#HC&8H9I9@+E*M1,P7G35-0Y Q,3EU"F]#I.>[8WNR"MAC5</H53O\('"-;
MH.NU3!@G?Q221BA6KE%W$7RX(\D+G.+S2GP7RQK!H"(8="$0!4&A%1$AUNWJ
M!_N:1G[@#_Q7VO?M?#=PAGZS\&$E?'B\<+5E"HFSF&2K-O7#CNKW[0ZI]ROU
M_D'U<^!$ORIHIC90X%S-MGF)T(\[2!? ?S9)/AA2'SU7(L<13"QUM@C@&[#"
M#^]<W_G45/?_*%B-?E31CP[2OT#7EP]WKIS1WJJ,&NNFW:X&$%0 P7$ N=K)
M-F;_ZKYK!5UVK1:CFOK+2OWE2=/?K>PO]PNG:>9;S6K27>?EZ'1.$G]$Z9<9
M6A':[>H,.\>_^[\VW3)RN_:#"DZL;_?EF'<[G?.G+Y'7$?.@C&,Q[9TKG;Y/
MWV&^(IE %)8JO-,;*3V\N*(6'<ER<\M;,*GNC*:9J&L]<&V@GB\9D\\=?7&L
M_BB$?P%02P,$%     @ @X)X6N4X-,A !0  _!0  !@   !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6RM6&UOVS80_BN$5PS)T$8B)<MVYAAH[+T46+LB:=</
MPS[0$FUID42/I.STW^\HR9(M44P"Y(LM47</GSL>[XZ<'[AXD#%C"CUF:2YO
M1K%2NVO'D6',,BJO^([E\&7#1485O(JM(W>"T:A4RE*'N&[@9#3)1XMY.?99
M+.:\4&F2L\\"R2++J/A^RU)^N!GAT7'@+MG&2@\XB_F.;MD]4U]WGP6\.0U*
ME&0LEPG/D6";F]%[?+TBGE8H)?Y*V$&>/"-MRIKS!_WR(;H9N9H12UFH- 2%
MOSU;LC352,#COQITU,RI%4^?C^B_EL:#,6LJV9*GWY)(Q3>CZ0A%;$.+5-WQ
MP^^L-FBL\4*>RO(7'6I9=X3"0BJ>U<K ($ORZI\^UHXX4<#>@ *I%4A7(1A0
M\&H%KZO@#RCXM8)?>J8RI?3#BBJZF M^0$)+ YI^*)U9:H/Y2:[7_5X)^)J
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M2JR82:S^2!^+*U&,4\^FV_Q%HCB9D";3+&^G^ZE?A+"$E3]%0I,'06DVE.9
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M[2(ML'3<TA<#>C:@YY5S\2!P@/X;9/4=4$L#!!0    ( (.">%HL=6B^0P(
M (H&   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)V56V^;,!2 _XK%
MI#VUX9;+E@%2TFY:'CI%:;<].W  J\9FM@GMOZ]M",NFA$IY =N<\_D[1ARB
MEHMG60(H]%)1)F.G5*I>NJY,2ZBPG/ :F'Z2<U%AI:>B<&4M &<VJ:)NX'ES
MM\*$.4EDU[8BB7BC*&&P%4@V587%ZQHH;V/'=XX+.U*4RBRX253C AY!_:RW
M0L_<@9*1"I@DG"$!>>RL_.5Z8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/
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MX^YH.Y@_CJ"N;N*<A:06TE5'W))H#[>LAH,!TW,=_/9=/$KR& ;NDB6IW/;
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M1(2GD!U@B#=GB#!HY]NB79"$#P$L6A+_CKYFXL",9.8+:8IUQ9P,#?&)=(S
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MLV%PH8_.POC,F\A'8# 0[NM^WHDG/#N9G4,M1D\3OGM[AW9YT T ^54_N._
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M$6)X!TM6L[9 >+*E<(^:\5K-?$TVC*1?[/"6#B_Z#EX8P8-H]4;!A[;$\J\
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MR_D,'&.^!-N.%FC7%^^;D35X^S(&1X0P=06KIK&<AH?1JXL/1;EF>*P4V.=
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MV\&^J\XR3I#5;)9:4^LCTR(,*#V:TF*5/7G,W XU*]80J-.["C<GX!1=N2V
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M#=58/.[H"M)*+=WZ6IM"R5Q\4#D5[;ZH;%>9PFSWP&BI6Q1-3 2GO:)<H'C
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MUZ&2"/+Z!Y:JK:DH</ #DH#LG*0)T<8+GNV2^APJ)3VI(WL4@%[4=.14.A6
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M,)D8)PLJ6\.M1[P6958'2[C3@D<^70MQ"AVFGD[I#C+LV$Y9+!_WNKYP*1
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M>P7&6PE^-<#QD!M@\'6I+4)>9M,PFQXP!]@"R(.Q6Q@;ZPLF6O'')(?BH2Y
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MKF\,G"WW 3<(/QGTZO\!4$L#!!0    ( (.">%JS?9"XI D  #@:   9
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M;D*^?!)[@CNY'#W7)O'./#=HEV%K.7;.[+O1'FZ'Q7C:[8._ZMU6O126L^E
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M5BJ(M60W%E=KL"E0B4$2!-QHVVC'S0 [[]9'&\@D<#!*R:I;U HMH*@T!8;
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M,!9ULX3G-/![NU%K7>DF+\L]_J)WN$X>SF'7&%AQ5\))P+LM[/BQ,OC,%>Y
M4)YM=0,<JQ[\ZQ\OYO/3GSY.KZ;JU[.S2_H\^^GA5+VNRS)O5+[%92T"W8+6
M8GA@37M7/.#QFTU=:E5UVX5N;*:Z"D #,&"5YL98?&0)P, J4Z(/HK+=Y=4>
MD;E]$T"V[)::$!4J$([X^8(7HH,P\#5" E2K;Q 1VRVL69J\ 9[-U/OS*WKL
MJONRJ3OU']T!A2ULHLY-O=ODH-,*W;4 : G+3N&%%N ]*TO:"" Q+?(^HIS
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MR#- V@V=Q;T60%\2D()P6V/8XT-N(FG_V\<J=7S)[6O"@H0P*JX=F.[/Q)I
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M!-A]C]RQTZ5\ =A#;,$G]2DM@)S\P48/U*>B3[B(M P--&Z^A>8!J 5Z[X)
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M9)2-GTQ.'WLVOO(+3B)CEGH_\NC$-X*]#N>(&"3,?=4M6K:$\]/)$Q2+WM.
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MI:'NZH8E/6>HK 'M%Y**:3^Q#H8'<OD#4$L#!!0    ( (.">%KL"'O_N ,
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MK"I;,"HHN6S>]+[-PQ8@'KP 2%I \EI V@)2;[11YFW-J*792*L-T2X:V=S
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M!3V7_Y!@WD!@+3&O:S&OO]5F=SVDP$.">0.!M02VK>-YS_H/2Q7(3MT5J)!
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M]E;@^WSYJ2H&O'_L!EI?_-%*(*KYJ!:@FD UB6HAJD6HIE!-HUJ,:@FEF=-
M4PGTSJP$_K&/^-CUWO,"V@:LM?9+]=SS9I.#3V4&Z*@"U22JA:@6H9I"-8UJ
M,:HEE&8FOJD#>O8B&E$"M@_1._9H1[#67+>5^\G%T!T=QAYM_Z&:1+40U2)4
M4ZBF42U&M832S-@WC4#/W@CLV0*V:[T3CO8"3_RDTR>;M@&Z'P+5)*J%J!:A
MFD(UC6HQJB649MXTJND #D\MD/?4.;[SN_.^YRH?]K'ZS@BHYJ-:@&H"U22J
MA:@6H9I"-8UJ,:HEE&;.$DV7<&AO^GWE)0"[WGM>0!N!PXZ5U88#=W1PM3Y
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M00):QD,U']4"5!.H)E$M1+4(U12J:52+42VA-'/*:!I[$VL[Z/PW[^U.[QF
MU'Q4"U!-H)JLM?;AP&@V&1\>#)!C1JBF4$VC6HQJ":69R6YZ>1-[+Z_/P<"'
M+%^69P7G'@R@'3U4\U$M0#6!:A+50E2+4$VAFD:U&-422C.GC*;)-X&:?':G
M]PR -OE0+4 U@6IR<MSD&WF3PT8/.F:$:@K5-*K%J)90FIGLIL<WL??X^AP,
M1.GZX:'#,P\(T(8?JOFH%J":0#6):B&J1:BF4$VC6HQJ":69TT93!)Q M\:U
M.[UG +0"B&H!J@E4DY/C90<GT['K'AX1H 5 5%.HIE$M1K6$TLQH-P7 B;T
MV.>(X.U=OESU.1Y BX*HYJ-:@&H"U22JA:@6H9I"-8UJ,:HEE&9,&M.F<SBU
M=P[//AZP.WUG %3S42U -8%JLM;:QP/NN/S?_."  !TU0C6%:AK58E1+*,W,
M=E,RG)ZX=^X?69S?;O;..5H>1+4 U02J250+42U"-85J&M5B5$LHS9P-FO+@
M],SRX%=\\-<^1._) 6T0HEJ :@+59*V=^N O.FB$:@K5-*K%J)90FIGZID X
MM1<(>Z[4;==Z!QQM!:):@&H"U>2)Y_3I-<E#=#\B5%.HIE$M1K6$TLS,-PW
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M#:K$)TUYI=YO>(:[7HM7Q'A%?D1UVV/%6Y>WJK[).[*CP#V.P1 FMA/6%7U
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MOS\D2?[VI@CPG*3?R\N^^!]02P,$%     @ @X)X6DC7PJ+V @  (0@  !D
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M,*,>CMH9T/Y"45VO)^X#S5_!["]02P,$%     @ @X)X6HH<K6#;!   N18
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MZ1F\6#!EGV13VWH.B4NE15X[(X,\X]6;/M=YV'+HA <<_-K!WW?H'G (:H?
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MIF.+6IA!P]'!%!F-+5,D0@K:$6*\%6+L%&*3R)_8"\M+JQ!.P*E"8,*"\<$
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M:%U]=GP#[XW%6JXA;QI!7FA:,B*-AT.X4D:U/X\O=C^YP2=KY!V,O;<O#V;
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MF,* M0>5F!MU3;V0BGS!E#Y/H6Q(2 &_P '6]E@S@1-2Y@FD)WT8Z8)\V:E
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M!!8!+QNHWU=Y+M\NR@[:\_Z+?P%02P,$%     @ @X)X6GC=S3+Q @  W0<
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MA"US5=U_3>_.RCJC:>5EC[]<CJ:7;?WNZ*JRJD\!*N=\P\0JR26DN*1@3F=
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M:.#L<(T>&Z0)P/=+@;:KGI@-&M<^^0=02P,$%     @ @X)X6G^%<T": P
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M7J*:>*N%XGDY-&ZYPA&TO#S@5P((+8#/=QP'QWJA7]!\=X3_ E!+ P04
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M\YZLH:1,I$7<VYVO=](<W0K(^5]#R6NP)\/8JCY<\I*$L#!D ># MF $/_Z
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MX93_C3XP"W+>(?]0.PDV(2:FG#R%<JI?T7>.*2=/H9R8OLF1CXDI)T^AG)C
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M_D]97ZQ=_?7?'MT];TS5'O-9_TO-[ U02P$"% ,4    " "#@GA:1L=-2)4
M  #-    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( (.">%HFP!8+\@   "L"   1              "  <,   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( (.">%J97)PC$ 8  )PG   3
M          "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M@X)X6L-*X!97"0  DC<  !@              ("!)0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (.">%H*8RAB!@8  +,:   8
M          " @;(1  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " "#@GA:1OX14" #   T#   &               @('N%P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ @X)X6N4X-,A !0  _!0
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M965T."YX;6Q02P$"% ,4    " "#@GA:C@E)?5 #  "/"   &
M    @($,1@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M@X)X6BQU:+Y# @  B@8  !D              ("!DDD  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " "#@GA:/*4S.!$"  #=!   &0
M            @($,3   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( (.">%KK8V=O\ @  %(?   9              " @51.  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ @X)X6KY, W I"
M=!,  !D              ("!>U<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " "#@GA:@DP[">0=  "C8   &0              @(';
M7P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (.">%I_
M7(:UQ@,  +0(   9              " @?9]  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ @X)X6DBGPG=M"0  -!T  !D
M     ("!\X$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (.">%H!6BE'O0<  %D6   9              "
M@6+-  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ @X)X
M6L"0'1[2 @  .@8  !D              ("!5M4  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " "#@GA:R6"'#9@*   =&P  &0
M        @(%?V   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( (.">%KZ:!.EG@<  (<3   9              " @2[C  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ @X)X6KS+1[D4'P  &FH
M !D              ("! ^L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " "#@GA:]8PZ5P@$   ,"@  &0              @(%."@$
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (.">%JW8?@>
M7P,  "P'   9              " @8T. 0!X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ @X)X6NP(>_^X P  3@L  !D
M ("!(Q(! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "#
M@GA:,/A(Z*H$   O#   &0              @($2%@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (.">%H^&"97*04  /(-   9
M          " @?,: 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ @X)X6MKL4U(M!   T@D  !D              ("!4R ! 'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "#@GA:YN^F+L("   @
M!@  &0              @(&W) $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( (.">%K6"Z,>L 0  .4*   9              " @; G
M 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ @X)X6L]1
MOFLA P  L 8  !D              ("!ERP! 'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " "#@GA:N/*:1;$"  #1!@  &0
M    @('O+P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M (.">%H(!&4KU0,  %<2   9              " @=<R 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ @X)X6L<KMQ<> P  M D  !D
M             ("!XS8! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " "#@GA:]].<XX@"  "*!@  &0              @($X.@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( (.">%I8Y:=T<0,
M *H*   9              " @?<\ 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ @X)X6AN]TI4"!   ;!,  !D              ("!
MGT ! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "#@GA:
M4QNW9%(#  #3"@  &0              @('81 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( (.">%H?&3!Q?AX  /?^ 0 9
M      " @6%( 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ @X)X6A.U0.WL!0  )!T  !D              ("!%F<! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "#@GA:YAI[7'$$  !($0
M&0              @($Y;0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( (.">%K3TR@"I@P  .N#   9              " @>%Q 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ @X)X6DC7PJ+V
M @  (0@  !D              ("!OGX! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " "#@GA:BARM8-L$  "Y%@  &0
M@('K@0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (."
M>%I>XX\#X0(  %\(   9              " @?V& 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ @X)X6AYTPCNF!   ;Q(  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( (.">%HC0V+Q@00  $T/   9
M  " @:JE 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M@X)X6E<?H<%' P  P0L  !D              ("!8JH! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " "#@GA:?X5S0)H#   !$@  &0
M            @('@K0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( (.">%ISY+U?[P,  (,,   9              " @;&Q 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ @X)X6LMM"$70 P
M]0P  !D              ("!U[4! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " "#@GA:"<@"8X\$  #T"@  &0              @('>
MN0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( (.">%K?
M?)\O\@,  -$0   9              " @:2^ 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ @X)X6KIUM(=< P  VA8   T
M     ( !S<(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "#@GA:EXJ[',
M   3 @  "P              @ %4Q@$ 7W)E;',O+G)E;'-02P$"% ,4
M" "#@GA:C]^\W-4$  ""*   #P              @ $]QP$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ @X)X6I@;6I[[ 0  RR,  !H
M ( !/\P! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M@X)X6G32QF+> 0  6B,  !,              ( !<LX! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     $0 1 "3$@  @= !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>192</ContextCount>
  <ElementCount>379</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1</Role>
      <ShortName>Consolidated Statements Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995453 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995463 - Disclosure - Note 1 - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusiness1</Role>
      <ShortName>Note 1 - Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Note 3 - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetails1</Role>
      <ShortName>Note 3 - Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995493 - Disclosure - Note 4 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurements</Role>
      <ShortName>Note 4 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995503 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Note 6 - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlans1</Role>
      <ShortName>Note 6 - Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Note 7 - Collaborations and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1</Role>
      <ShortName>Note 7 - Collaborations and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995543 - Disclosure - Note 8 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingencies</Role>
      <ShortName>Note 8 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Note 9 - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShare1</Role>
      <ShortName>Note 9 - Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Note 10 - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote10EmployeeBenefits</Role>
      <ShortName>Note 10 - Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Note 11 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxes1</Role>
      <ShortName>Note 11 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Note 12 - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformation</Role>
      <ShortName>Note 12 - Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Note 3 - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables</Role>
      <ShortName>Note 3 - Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetails1</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995613 - Disclosure - Note 4 - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4CommonStockWarrantsTables</Role>
      <ShortName>Note 4 - Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995623 - Disclosure - Note 5 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables</Role>
      <ShortName>Note 5 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995643 - Disclosure - Note 5 - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables</Role>
      <ShortName>Note 5 - Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995653 - Disclosure - Note 6 - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables</Role>
      <ShortName>Note 6 - Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlans1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995663 - Disclosure - Note 9 - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables</Role>
      <ShortName>Note 9 - Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShare1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995673 - Disclosure - Note 8 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables</Role>
      <ShortName>Note 8 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995683 - Disclosure - Note 11 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables</Role>
      <ShortName>Note 11 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxes1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995693 - Disclosure - Note 12 -Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationTables</Role>
      <ShortName>Note 12 -Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995703 - Disclosure - Note 1 - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails</Role>
      <ShortName>Note 1 - Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusiness1</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995713 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995723 - Disclosure - Note 3 - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Note 3 - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995733 - Disclosure - Note 3 - Balance Sheet Details - Summary of Other Noncurrent Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails</Role>
      <ShortName>Note 3 - Balance Sheet Details - Summary of Other Noncurrent Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995743 - Disclosure - Note 3 - Balance Sheet Details - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Note 3 - Balance Sheet Details - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995753 - Disclosure - Note 4 - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails</Role>
      <ShortName>Note 4 - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995763 - Disclosure - Note 4 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails</Role>
      <ShortName>Note 4 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995773 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995783 - Disclosure - Note 5 - Stockholders' Equity - Schedule of Stockholders' Equity warrant outstanding and exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails</Role>
      <ShortName>Note 5 - Stockholders' Equity - Schedule of Stockholders' Equity warrant outstanding and exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995793 - Disclosure - Note 5 - Stockholders' Equity - Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails</Role>
      <ShortName>Note 5 - Stockholders' Equity - Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995803 - Disclosure - Note 6 - Equity Incentive Plans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual</Role>
      <ShortName>Note 6 - Equity Incentive Plans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995813 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Note 6 - Equity Incentive Plans - Schedule of Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995823 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Summarized Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails</Role>
      <ShortName>Note 6 - Equity Incentive Plans - Schedule of Summarized Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995833 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Stock-based Compensation for all Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails</Role>
      <ShortName>Note 6 - Equity Incentive Plans - Schedule of Stock-based Compensation for all Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995843 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Note 6 - Equity Incentive Plans - Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995853 - Disclosure - Note 7 - Collaborations and License Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual</Role>
      <ShortName>Note 7 - Collaborations and License Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995863 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Note 8 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995873 - Disclosure - Note 8 - Commitments and Contingencies - Accrued liabilities in the consolidated balance sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails</Role>
      <ShortName>Note 8 - Commitments and Contingencies - Accrued liabilities in the consolidated balance sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995883 - Disclosure - Note 9 - Net Loss Per Share - (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual</Role>
      <ShortName>Note 9 - Net Loss Per Share - (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995893 - Disclosure - Note 9 - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Note 9 - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995903 - Disclosure - Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995913 - Disclosure - Note 11 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual</Role>
      <ShortName>Note 11 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995923 - Disclosure - Note 11 - Income Taxes - Schedule of Statutory Federal Income Tax Applied to Loss Before Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails</Role>
      <ShortName>Note 11 - Income Taxes - Schedule of Statutory Federal Income Tax Applied to Loss Before Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995933 - Disclosure - Note 11 - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Note 11 - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995943 - Disclosure - Note 12 - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual</Role>
      <ShortName>Note 12 - Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformation</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="pali-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995953 - Disclosure - Note 12 - Segment Information - Schedule of Reconciliation of Loss from Operations Disclosure Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails</Role>
      <ShortName>Note 12 - Segment Information - Schedule of Reconciliation of Loss from Operations Disclosure Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="pali-20241231.htm">pali-20241231.htm</File>
    <File>pali-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img61919486_0.jpg</File>
    <File>img61919486_1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="603">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pali-20241231.htm": {
   "nsprefix": "pali",
   "nsuri": "http://www.palisadebio.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "pali-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "pali-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 294,
   "keyCustom": 85,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 49,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://fasb.org/us-gaap/2024": 3
   },
   "contextCount": 192,
   "entityCount": 1,
   "segmentCount": 74,
   "elementCount": 678,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 603,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/ecd/2024": 8,
    "http://xbrl.sec.gov/cyd/2024": 8
   },
   "report": {
    "R1": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b47952f8-e25d-4791-a542-4d8bd701e282",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "longName": "100050 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
     "longName": "100060 - Statement - Consolidated Statements Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Consolidated Statements Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical",
     "longName": "100070 - Statement - Consolidated Statements Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_76e3614d-9c9a-46c6-a850-919f190aaaca",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_494b0e96-ca6c-4dd0-aada-9c385796b28c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_494b0e96-ca6c-4dd0-aada-9c385796b28c",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995453 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusiness1",
     "longName": "995463 - Disclosure - Note 1 - Organization and Business",
     "shortName": "Note 1 - Organization and Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPolicies",
     "longName": "995473 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetails1",
     "longName": "995483 - Disclosure - Note 3 - Balance Sheet Details",
     "shortName": "Note 3 - Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurements",
     "longName": "995493 - Disclosure - Note 4 - Fair Value Measurements",
     "shortName": "Note 4 - Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquity",
     "longName": "995503 - Disclosure - Note 5 - Stockholders' Equity",
     "shortName": "Note 5 - Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlans1",
     "longName": "995523 - Disclosure - Note 6 - Equity Incentive Plans",
     "shortName": "Note 6 - Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1",
     "longName": "995533 - Disclosure - Note 7 - Collaborations and License Agreements",
     "shortName": "Note 7 - Collaborations and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingencies",
     "longName": "995543 - Disclosure - Note 8 - Commitments and Contingencies",
     "shortName": "Note 8 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShare1",
     "longName": "995553 - Disclosure - Note 9 - Net Loss Per Share",
     "shortName": "Note 9 - Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote10EmployeeBenefits",
     "longName": "995563 - Disclosure - Note 10 - Employee Benefits",
     "shortName": "Note 10 - Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxes1",
     "longName": "995573 - Disclosure - Note 11 - Income Taxes",
     "shortName": "Note 11 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformation",
     "longName": "995583 - Disclosure - Note 12 - Segment Information",
     "shortName": "Note 12 - Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995593 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables",
     "longName": "995603 - Disclosure - Note 3 - Balance Sheet Details (Tables)",
     "shortName": "Note 3 - Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4CommonStockWarrantsTables",
     "longName": "995613 - Disclosure - Note 4 - Common Stock Warrants (Tables)",
     "shortName": "Note 4 - Common Stock Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables",
     "longName": "995623 - Disclosure - Note 5 - Fair Value Measurements (Tables)",
     "shortName": "Note 5 - Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_671d8ff9-d06e-44e8-8753-0d285732a4c2",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_671d8ff9-d06e-44e8-8753-0d285732a4c2",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables",
     "longName": "995643 - Disclosure - Note 5 - Stockholders' Equity (Tables)",
     "shortName": "Note 5 - Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables",
     "longName": "995653 - Disclosure - Note 6 - Equity Incentive Plans (Tables)",
     "shortName": "Note 6 - Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables",
     "longName": "995663 - Disclosure - Note 9 - Net Loss Per Share (Tables)",
     "shortName": "Note 9 - Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables",
     "longName": "995673 - Disclosure - Note 8 - Commitments and Contingencies (Tables)",
     "shortName": "Note 8 - Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables",
     "longName": "995683 - Disclosure - Note 11 - Income Taxes (Tables)",
     "shortName": "Note 11 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationTables",
     "longName": "995693 - Disclosure - Note 12 -Segment Information (Tables)",
     "shortName": "Note 12 -Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails",
     "longName": "995703 - Disclosure - Note 1 - Organization and Business (Details)",
     "shortName": "Note 1 - Organization and Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
     "longName": "995713 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_4c38a0f6-0e17-4097-a741-e8528d218109",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "pali:ReverseStockSplitPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4c38a0f6-0e17-4097-a741-e8528d218109",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "pali:ReverseStockSplitPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "995723 - Disclosure - Note 3 - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Note 3 - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails",
     "longName": "995733 - Disclosure - Note 3 - Balance Sheet Details - Summary of Other Noncurrent Assets (Details)",
     "shortName": "Note 3 - Balance Sheet Details - Summary of Other Noncurrent Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:PrepaidExpenseNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:PrepaidExpenseNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails",
     "longName": "995743 - Disclosure - Note 3 - Balance Sheet Details - Summary of Accrued Liabilities (Details)",
     "shortName": "Note 3 - Balance Sheet Details - Summary of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "pali:AccruedAccountsPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "pali:AccruedAccountsPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails",
     "longName": "995753 - Disclosure - Note 4 - Fair Value Measurements (Details)",
     "shortName": "Note 4 - Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:ChangesInFairValueOfContingentConsideration",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
     "longName": "995763 - Disclosure - Note 4 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Note 4 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_e7194555-4ab8-40fd-b397-92bd0b1f7bb9",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4f54001b-6421-4019-8e41-db056882bcd4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
     "longName": "995773 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)",
     "shortName": "Note 5 - Stockholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails",
     "longName": "995783 - Disclosure - Note 5 - Stockholders' Equity - Schedule of Stockholders' Equity warrant outstanding and exercisable (Details)",
     "shortName": "Note 5 - Stockholders' Equity - Schedule of Stockholders' Equity warrant outstanding and exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_582ecc46-b417-4c17-b3ac-7494c5aa8bda",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails",
     "longName": "995793 - Disclosure - Note 5 - Stockholders' Equity - Summary of Warrant Activity (Details)",
     "shortName": "Note 5 - Stockholders' Equity - Summary of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78",
      "name": "pali:ClassOfWarrantOrRightNumberOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:ClassOfWarrantOrRightIssuedDuringPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
     "longName": "995803 - Disclosure - Note 6 - Equity Incentive Plans (Details Textual)",
     "shortName": "Note 6 - Equity Incentive Plans (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails",
     "longName": "995813 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Fair Value of Options Granted (Details)",
     "shortName": "Note 6 - Equity Incentive Plans - Schedule of Fair Value of Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails",
     "longName": "995823 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Summarized Stock Option Activity (Details)",
     "shortName": "Note 6 - Equity Incentive Plans - Schedule of Summarized Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails",
     "longName": "995833 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Stock-based Compensation for all Stock Awards (Details)",
     "shortName": "Note 6 - Equity Incentive Plans - Schedule of Stock-based Compensation for all Stock Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails",
     "longName": "995843 - Disclosure - Note 6 - Equity Incentive Plans - Schedule of Restricted Stock Units Activity (Details)",
     "shortName": "Note 6 - Equity Incentive Plans - Schedule of Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_22d62b69-795d-4d94-914a-263cdadcd8a8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual",
     "longName": "995853 - Disclosure - Note 7 - Collaborations and License Agreements (Details Textual)",
     "shortName": "Note 7 - Collaborations and License Agreements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:CollaborationsAndLicenseAgreementsUpfrontFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "pali:CollaborationsAndLicenseAgreementsUpfrontFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual",
     "longName": "995863 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 8 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_659e2af0-b6fd-4530-954e-5b638bb46b1b",
      "name": "pali:PercentageOfReductionInWorkForce",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails",
     "longName": "995873 - Disclosure - Note 8 - Commitments and Contingencies - Accrued liabilities in the consolidated balance sheet (Details)",
     "shortName": "Note 8 - Commitments and Contingencies - Accrued liabilities in the consolidated balance sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual",
     "longName": "995883 - Disclosure - Note 9 - Net Loss Per Share - (Details Textual)",
     "shortName": "Note 9 - Net Loss Per Share - (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d3c9c2d7-95dc-49bb-98bf-59ffcaac2dcb",
      "name": "pali:CashConsideration",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
     "longName": "995893 - Disclosure - Note 9 - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)",
     "shortName": "Note 9 - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "995903 - Disclosure - Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual",
     "longName": "995913 - Disclosure - Note 11 - Income Taxes (Details Textual)",
     "shortName": "Note 11 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails",
     "longName": "995923 - Disclosure - Note 11 - Income Taxes - Schedule of Statutory Federal Income Tax Applied to Loss Before Income Tax (Details)",
     "shortName": "Note 11 - Income Taxes - Schedule of Statutory Federal Income Tax Applied to Loss Before Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails",
     "longName": "995933 - Disclosure - Note 11 - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "shortName": "Note 11 - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "pali:DeferredTaxAssetsAccruedExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4efa6da-edbc-4b10-9455-f745bdeb2312",
      "name": "pali:DeferredTaxAssetsAccruedExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual",
     "longName": "995943 - Disclosure - Note 12 - Segment Information (Details Textual)",
     "shortName": "Note 12 - Segment Information (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails",
     "longName": "995953 - Disclosure - Note 12 - Segment Information - Schedule of Reconciliation of Loss from Operations Disclosure Disclosure (Details)",
     "shortName": "Note 12 - Segment Information - Schedule of Reconciliation of Loss from Operations Disclosure Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aba08c8a-3298-4ff6-87c6-223993191a45",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pali-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r762"
     ]
    },
    "pali_AccruedAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AccruedAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued accounts payable",
        "label": "Accrued accounts payable",
        "documentation": "Represents the amount of accrued accounts payable, included in accrued liabilities rather than in the Accounts Payable line item."
       }
      }
     },
     "auth_ref": []
    },
    "pali_AccruedCMCExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AccruedCMCExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued C M C Expenses",
        "documentation": "Represents the amount of accrued CMC expenses as of the balance sheet date.",
        "terseLabel": "Accrued chemistry, manufacturing and controls (\"CMC\") expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pali_AccruedClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AccruedClinicalTrialCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical trial costs",
        "documentation": "Represents the amount of accrued clinical trial costs as of the balance sheet date.",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pali_AccruedDirectorStipends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AccruedDirectorStipends",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued director stipends",
        "label": "Accrued director stipends",
        "documentation": "Represents the amount of accrued director stipends as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedInsuranceCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Insurance, Current",
        "terseLabel": "Insurance financing debt",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "pali_AccruedJointDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AccruedJointDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Joint Development Expenses",
        "label": "Accrued Joint Development Expenses",
        "terseLabel": "Accrued joint development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued Liabilities, current, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities [Member]",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties, current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r715"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "pali_AdditionalFinancingAgreementsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AdditionalFinancingAgreementsOneMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financing Agreements One [Member]",
        "documentation": "Represents information pertaining to the first additional financing agreement or first set of financing agreements."
       }
      }
     },
     "auth_ref": []
    },
    "pali_AdditionalFinancingAgreementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AdditionalFinancingAgreementsTwoMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financing Agreements Two [Member]",
        "documentation": "Represents information regarding the second additional financing agreement or second set of financing agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Additional Paid in Capital, Total",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r762",
      "r1062"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r927",
      "r928",
      "r929",
      "r930",
      "r998",
      "r1064"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense and related charges",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r357"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrants related to promissory note",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r30",
      "r85"
     ]
    },
    "pali_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Warrant Issued Shares",
        "documentation": "Adjustments to additional paid in capital warrant issued, shares.",
        "terseLabel": "Issuance of common stock warrants related to promissory note (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r820",
      "r830",
      "r863"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r866"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r858",
      "r867",
      "r871",
      "r879"
     ]
    },
    "pali_AllOtherCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AllOtherCommonStockWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Other Common Stock Warrants [Member]",
        "documentation": "All other common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r398"
     ]
    },
    "pali_AltiumGrowthFundLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AltiumGrowthFundLPMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Altium Growth Fund, LP [Member]",
        "label": "Altium Growth Fund, LP [Member]",
        "documentation": "Represents information regarding Altium Growth Fund, LP (the \"Investor\")."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "pali_April2023OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "April2023OfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2023 Offering [Member]",
        "documentation": "April 2023 Offering.",
        "label": "April 2023 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_AprilTwoThousandAndTwentyThreeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AprilTwoThousandAndTwentyThreeOfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2023 Offering [Member]",
        "label": "April Two Thousand And Twenty Three Offering [Member]",
        "documentation": "April two thousand And twenty three offering."
       }
      }
     },
     "auth_ref": []
    },
    "pali_AprilTwoThousandTwentyThreeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "AprilTwoThousandTwentyThreeWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2023 Warrants [Member]",
        "documentation": "April two thousand twenty three warrants.",
        "label": "April Two Thousand Twenty Three Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r104",
      "r120",
      "r144",
      "r183",
      "r192",
      "r204",
      "r208",
      "r247",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r442",
      "r444",
      "r476",
      "r564",
      "r642",
      "r727",
      "r728",
      "r762",
      "r787",
      "r958",
      "r959",
      "r1023"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r124",
      "r144",
      "r247",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r442",
      "r444",
      "r476",
      "r762",
      "r958",
      "r959",
      "r1023"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Opinion",
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "pali_August2024OfferingSeries2CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "August2024OfferingSeries2CommonStockWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2024 Offering Series 2 Common Stock Warrants [Member]",
        "documentation": "August 2024 offering series 2 common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "pali_BridgeJanuary2021AndJuly2021CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "BridgeJanuary2021AndJuly2021CommonStockWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge, January 2021, and July 2021 Common Stock Warrants [Member]",
        "documentation": "Bridge, January 2021, and July 2021 common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of contingent consideration obligation",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r90"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, measurement input",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration obligation",
        "verboseLabel": "Contingent consideration obligation, net of current portion",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r90"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs",
        "terseLabel": "Transaction related costs",
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "verboseLabel": "Cash and cash equivalents",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents, at carrying value, ending balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r118",
      "r713"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value of the company's cash and cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r93"
     ]
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total cash, cash equivalents and restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r140"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r74"
     ]
    },
    "pali_CashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "CashConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Consideration",
        "documentation": "Cash consideration.",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "auth_ref": []
    },
    "pali_CashTransactionRelatedExpensesAndPlacementAgentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "CashTransactionRelatedExpensesAndPlacementAgentFees",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash transaction-related expenses And placement agent fees",
        "label": "Cash transaction-related expenses And placement agent fees",
        "documentation": "Cash transaction-related expenses And placement agent fees."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "pali_ChangesInFairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ChangesInFairValueOfContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value of contingent consideration",
        "label": "Changes In Fair Value Of Contingent Consideration",
        "documentation": "Changes in fair value of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassAUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassAUnitsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Units [Member]",
        "documentation": "Class A Units"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassBUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassBUnitsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Units [Member]",
        "documentation": "Class B Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r121",
      "r122",
      "r123",
      "r144",
      "r168",
      "r169",
      "r176",
      "r178",
      "r185",
      "r186",
      "r247",
      "r281",
      "r284",
      "r285",
      "r286",
      "r290",
      "r291",
      "r320",
      "r321",
      "r324",
      "r327",
      "r335",
      "r476",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r630",
      "r651",
      "r669",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r902",
      "r924",
      "r931"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrants exercise price of common stock warrants",
        "terseLabel": "Warrants exercise price of common stock Warrants",
        "netLabel": "Weighted average exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "pali_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "pali_ClassOfWarrantOrRightExercisedDuringPeriod",
        "documentation": "The number of warrants or rights exercised during period."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right exercised during period weighted average exercise price.",
        "label": "Class of Warrant or Right Exercised During Period Weighted Average Exercise Price",
        "terseLabel": "Exercised, weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited, expired or cancelled (in shares)",
        "label": "pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod",
        "documentation": "The number of warrants or rights forfeited, expired or cancelled during period."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right forfeited expired or cancelled during period weighted average exercise price.",
        "label": "Class of Warrant or Right Forfeited Expired or Cancelled During Period Weighted Average Exercise Price",
        "terseLabel": "Forfeited, expired, or cancelled, weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "pali_ClassOfWarrantOrRightIssuedDuringPeriod",
        "documentation": "The number of warrants or rights issued during period.",
        "terseLabel": "Class of warrant or right, issued during period (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average exercise price per share of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right issued during period weighted average remaining contractual life.",
        "label": "Class of Warrant or Right Issued During Period Weighted Average Remaining Contractual Life",
        "terseLabel": "Granted, weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightNumberOfRightsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightNumberOfRightsIssued",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right number of rights issued.",
        "label": "Class of Warrant or Right Number of Rights Issued",
        "terseLabel": "Contingent value right issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrants to purchase shares of Company's common stock",
        "terseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "pali_ClassOfWarrantOrRightNumberOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightNumberOutstanding",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "periodStartLabel": "Warrants outstanding, balance (in shares)",
        "periodEndLabel": "Warrants outstanding, balance (in shares)",
        "label": "pali_ClassOfWarrantOrRightNumberOutstanding",
        "documentation": "Represents the number of warrants or rights outstanding as of the specified date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Number of warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Represents the weighted average exercise price of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding, weighted average remaining contratual life (years)",
        "label": "Warrants outstanding, December 31, 2020 (Year)",
        "documentation": "Represents the weighted average remaining contractual life of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClinicalTrialExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClinicalTrialExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Trial Expenses",
        "label": "Clinical Trial Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for clinical trial expenses."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ClosingPeriodOfMergerAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ClosingPeriodOfMergerAgreement",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing period of merger agreement",
        "documentation": "Closing period of merger agreement.",
        "label": "Closing Period of Merger Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "pali_CollaborationsAndLicenseAgreementsUpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "CollaborationsAndLicenseAgreementsUpfrontFee",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations and license agreements upfront fee.",
        "label": "Collaborations and License Agreements Upfront Fee",
        "terseLabel": "Collaborations and license agreements upfront fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r98",
      "r565",
      "r629"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r271",
      "r272",
      "r698",
      "r946",
      "r951"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock capital shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r927",
      "r928",
      "r930",
      "r998",
      "r1061",
      "r1064"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par or stated value per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares Authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r630"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r61",
      "r630",
      "r648",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 280,000,000 shares authorized; 2,768,646 and 618,056 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r568",
      "r762"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r109"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r149",
      "r183",
      "r194",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r727",
      "r728",
      "r958",
      "r959"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r149",
      "r183",
      "r194",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r727",
      "r728",
      "r958",
      "r959"
     ]
    },
    "pali_ContingentConsiderationObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ContingentConsiderationObligationsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Obligations [Member]",
        "documentation": "Contingent consideration obligations.",
        "label": "Contingent Consideration Obligations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ContingentConsiderationObligationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ContingentConsiderationObligationsPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contingent consideration obligations.",
        "label": "Contingent Consideration Obligations [Policy Text Block]",
        "terseLabel": "Contingent Consideration Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ContingentValueRightProRataNetProceedsFromSaleOrLicensing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ContingentValueRightProRataNetProceedsFromSaleOrLicensing",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value right, pro rata, net proceeds from sale or licensing",
        "label": "Contingent Value Right, Pro Rata, Net Proceeds from Sale or Licensing",
        "terseLabel": "Contingent value right, pro rata, net proceeds from sale or licensing"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ConvertiblePreferredStockIssuableUponConversionOfAllShares",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, Issuable Upon Conversion of All Shares (in shares)",
        "label": "pali_ConvertiblePreferredStockIssuableUponConversionOfAllShares",
        "documentation": "Number of shares issuable for all shares of a given class of convertible preferred stock that may be converted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible Preferred Stock issued and outstanding",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r31",
      "r60",
      "r84",
      "r330"
     ]
    },
    "pali_CostReductionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "CostReductionPlanMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost Reduction Plan [Member]",
        "label": "Cost Reduction Plan [Member]",
        "documentation": "cost reduction plan Member."
       }
      }
     },
     "auth_ref": []
    },
    "pali_CostReductionPlanTwentyTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "CostReductionPlanTwentyTwentyThreeMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Reduction Plan Twenty Twenty Three [Member]",
        "label": "Cost Reduction Plan Twenty Twenty Three [Member]",
        "terseLabel": "2023 RIF [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r296",
      "r322",
      "r495",
      "r512",
      "r563",
      "r716",
      "r718"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r956"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r956",
      "r957"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "pali_CvrAgreementDistributionMinimumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "CvrAgreementDistributionMinimumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVR Agreement, distribution minimum amount",
        "documentation": "CVR agreement, distribution minimum amount",
        "label": "CVR Agreement, Distribution Minimum Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r890"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r890"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r892"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r892"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r894"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r892"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r885"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r886"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r886"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r887"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r889"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r889"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r890"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r893"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r891"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r888"
     ]
    },
    "stpr_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "DE",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DELAWARE",
        "terseLabel": "Delaware [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r142",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r279",
      "r280",
      "r292",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r308",
      "r315",
      "r316",
      "r318",
      "r484"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r95",
      "r97",
      "r149",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r760",
      "r925",
      "r947",
      "r948",
      "r949",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r149",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r760",
      "r925",
      "r947",
      "r948",
      "r949",
      "r1017",
      "r1018"
     ]
    },
    "pali_December2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "December2022WarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2022 Warrants [Member]",
        "documentation": "December 2022 warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pali_December2024OfferingCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "December2024OfferingCommonStockWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Offering Common Stock Warrants [Member]",
        "documentation": "December 2024 offering common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "pali_December2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "December2024OfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Offering [Member]",
        "documentation": "December 2024 Offering.",
        "terseLabel": "December 2024 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_December2024OfferingPreFundedCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "December2024OfferingPreFundedCommonStockWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Offering PreFunded Common Stock Warrants [Member]",
        "documentation": "December 2024 offering prefunded common Stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "pali_December2024RepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "December2024RepresentativeWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Representative Warrants [Member]",
        "documentation": "December 2024 Representative Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Equity Issuance Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred equity issuance costs",
        "label": "Deferred Costs, Current",
        "totalLabel": "Deferred Costs, Current, Total",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "pali_DeferredEquityIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "DeferredEquityIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred equity issuance costs.",
        "label": "Deferred Equity Issuance Costs",
        "terseLabel": "Deferred equity issuance costs againist additional paid-in capital"
       }
      }
     },
     "auth_ref": []
    },
    "pali_DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities",
        "documentation": "Deferred Equity Issuance Costs Recognized As a Reduction in Additional Paid in Capital From Financing Activities",
        "label": "Deferred Equity Issuance Costs Recognized As a Reduction in Additional Paid in Capital From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred equity issuance costs",
        "totalLabel": "Debt Issuance Costs, Current, Net, Total",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "terseLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r96",
      "r419"
     ]
    },
    "pali_DeferredTaxAssetsAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "DeferredTaxAssetsAccruedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets accrued expenses",
        "label": "Deferred Tax Assets Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pali_DeferredTaxAssetsDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "DeferredTaxAssetsDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets depreciation.",
        "label": "Deferred Tax Assets Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "pali_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability.",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred tax asset",
        "totalLabel": "Net deferred tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Net deferred taxes",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "terseLabel": "Prepaid expense",
        "negatedLabel": "Prepaid expense",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "pali_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right-of-use asset",
        "label": "Deferred Tax Liabilities Right-of-Use Asset",
        "terseLabel": "Operating right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAdministrationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAdministrationExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Administration Expense",
        "terseLabel": "Total expenses",
        "documentation": "Amount of administration expense of defined benefit plan which decreases plan assets. Excludes plan administration expense paid by employer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Assets",
        "totalLabel": "Deposit Assets, Total",
        "terseLabel": "Deposits",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r28"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r621",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r645",
      "r646",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666",
      "r684",
      "r685",
      "r686",
      "r687",
      "r778",
      "r780",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r92",
      "r619",
      "r621",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r645",
      "r646",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666",
      "r684",
      "r685",
      "r686",
      "r687",
      "r718",
      "r778",
      "r780",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liability, noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r40",
      "r41",
      "r45",
      "r148",
      "r163"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlans1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r359",
      "r390",
      "r391",
      "r393",
      "r748"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1",
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes to Financial Statements",
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816",
      "r859"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per common share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r168",
      "r176",
      "r177",
      "r178",
      "r182",
      "r437",
      "r440",
      "r455",
      "r456",
      "r561",
      "r575",
      "r719"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r176"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r168",
      "r176",
      "r177",
      "r178",
      "r182",
      "r437",
      "r440",
      "r455",
      "r456",
      "r561",
      "r575",
      "r719"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r179",
      "r180",
      "r181"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost weighted-average period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to outstanding RSUs",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to outstanding options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r114",
      "r129",
      "r130",
      "r131",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r184",
      "r248",
      "r249",
      "r258",
      "r338",
      "r427",
      "r428",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r494",
      "r573",
      "r588",
      "r589",
      "r590",
      "r604",
      "r669"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r820",
      "r830",
      "r863"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r817",
      "r827",
      "r860"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Incremental fair value of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r753"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r753"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r560",
      "r750",
      "r754"
     ]
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r469"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options Granted",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r465",
      "r469"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value during the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r469"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial fair value at the original issuance date",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r469"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodStartLabel": "Balance, Beginning",
        "periodEndLabel": "Balance, Ending",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r469"
     ]
    },
    "pali_FairValueOfWarrantsIssuedToPlacementAgents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "FairValueOfWarrantsIssuedToPlacementAgents",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Warrants Issued to Placement Agents",
        "documentation": "Fair value of warrants Issued to placement agents",
        "terseLabel": "Fair value of warrants issued to placement agents"
       }
      }
     },
     "auth_ref": []
    },
    "pali_FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants issued to representatives of underwriter",
        "label": "Fair Value of Warrants Issued to Representatives of Underwriter",
        "documentation": "Fair value of warrants issued to representatives of underwriter."
       }
      }
     },
     "auth_ref": []
    },
    "pali_FairValueOfWarrantsIssuedToSolicitationAgent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "FairValueOfWarrantsIssuedToSolicitationAgent",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Warrants Issued to Solicitation Agent",
        "documentation": "Fair value of warrants issued to solicitation agent",
        "terseLabel": "Fair value of warrants issued to solicitation agent"
       }
      }
     },
     "auth_ref": []
    },
    "pali_February2024WarrantInducementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "February2024WarrantInducementMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2024 Warrant Inducement [Member]",
        "documentation": "February 2024 warrant inducement.",
        "terseLabel": "February 2024 Warrant Inducement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_February2024WarrantInducementReplacementCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "February2024WarrantInducementReplacementCommonStockWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2024 Warrant Inducement Replacement Common Stock Warrants [Member]",
        "documentation": "February 2024 warrant inducement replacement common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r317",
      "r333",
      "r452",
      "r475",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r574",
      "r735",
      "r750",
      "r751",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r763",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r938",
      "r939",
      "r940",
      "r941",
      "r999",
      "r1002",
      "r1003",
      "r1004",
      "r1011",
      "r1014"
     ]
    },
    "pali_FinancingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "FinancingAgreementsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Agreements [Member]",
        "documentation": "Represents information regard agreements to finance certain insurance policies."
       }
      }
     },
     "auth_ref": []
    },
    "pali_FinancingCostDerivativeWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "FinancingCostDerivativeWarrantLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on issuance of warrants",
        "label": "FinancingCostDerivativeWarrantLiabilities",
        "documentation": "Represents amount recognized during the period for the financing cost associated with derivative warrant liabilities.",
        "negatedLabel": "Loss on issuance of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r944",
      "r945"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r653"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "pali_GrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "GrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date fair value.",
        "label": "Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "verboseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r265",
      "r268",
      "r461",
      "r465",
      "r469",
      "r585",
      "r587",
      "r654",
      "r710",
      "r752",
      "r1032"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r268",
      "r461",
      "r465",
      "r469",
      "r585",
      "r587",
      "r654",
      "r710",
      "r752",
      "r1032"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r406",
      "r407",
      "r415",
      "r424",
      "r749",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r406",
      "r407",
      "r415",
      "r424",
      "r749",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxes1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r401",
      "r406",
      "r412",
      "r413",
      "r414",
      "r416",
      "r423",
      "r429",
      "r431",
      "r432",
      "r433",
      "r603",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r112",
      "r162",
      "r163",
      "r183",
      "r196",
      "r208",
      "r405",
      "r406",
      "r430",
      "r576",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r403",
      "r404",
      "r416",
      "r417",
      "r422",
      "r426",
      "r597"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r749",
      "r992"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in tax rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r406",
      "r410",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Statutory federal income tax rate of 21 percent applied to loss before income taxes",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r749"
     ]
    },
    "pali_IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Nondeductible Expense Expiration of Tax Attributes",
        "documentation": "Expiration of tax attributes",
        "terseLabel": "Expiration of tax attributes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "terseLabel": "Meals and entertainment",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r994"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r992",
      "r994"
     ]
    },
    "pali_IncomeTaxReconciliationNondeductibleExpenseWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation Nondeductible Expense Warrants",
        "label": "Income Tax Reconciliation Nondeductible Expense Warrants",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Others",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r992",
      "r993"
     ]
    },
    "pali_IncomeTaxReconciliationOtherNonDeductibleExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "IncomeTaxReconciliationOtherNonDeductibleExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non-deductible expenses",
        "label": "Income Tax Reconciliation Other Non-Deductible Expenses",
        "terseLabel": "Other non-deductible expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesScheduleOfStatutoryFederalIncomeTaxAppliedToLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes - net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r749",
      "r992"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r921"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets and other noncurrent assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "pali_IncrementalFairValueOfModifiedOrExchangedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "IncrementalFairValueOfModifiedOrExchangedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental fair value of modified warrants (Note 5)",
        "label": "Incremental Fair Value of Modified or Exchanged Warrants",
        "documentation": "Incremental fair value of modified or exchanged warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r858",
      "r867",
      "r871",
      "r879"
     ]
    },
    "pali_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Inducement plan [Member]",
        "label": "2021 Inducement Plan [Member]",
        "terseLabel": "2021 Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "pali_InsuranceFinancingArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "InsuranceFinancingArrangementMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Financing Arrangement [Member]",
        "label": "Insurance Financing Arrangement [Member]",
        "documentation": "Insurance Financing Arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r192",
      "r195",
      "r197",
      "r208",
      "r483",
      "r727",
      "r728"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest paid",
        "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r137",
      "r138"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of common stock to vendors",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "pali_January2023OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "January2023OfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2023 Offering [Member]",
        "documentation": "January 2023 Offering [Member]",
        "label": "January 2023 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_JanuaryTwoThousandAndTwentyThreeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "JanuaryTwoThousandAndTwentyThreeOfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Two Thousand And Twenty Three Offering [Member]",
        "documentation": "January two thousand And twenty three offering.",
        "terseLabel": "January 2023 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_JanuaryTwoThousandTwentyThreeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "JanuaryTwoThousandTwentyThreeWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2023 Warrants [Member]",
        "documentation": "January Two Thousand Twenty Three Warrants.",
        "label": "January Two Thousand Twenty Three Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_JointDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "JointDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint development expenses.",
        "label": "Joint Development Expenses",
        "terseLabel": "Joint development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pali_July2020NoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "July2020NoteMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2020 Note [Member]",
        "documentation": "Represents information regarding an unsecured promissory note issued in July 2020."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r903"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r903"
     ]
    },
    "pali_LegacyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "LegacyMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy [Member]",
        "documentation": "Legacy.",
        "terseLabel": "Legacy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r493"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of the Company's operating lease liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r1020"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term (Month)",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract (Year)",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r52",
      "r54",
      "r55",
      "r56",
      "r59",
      "r144",
      "r247",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r443",
      "r444",
      "r445",
      "r476",
      "r628",
      "r720",
      "r787",
      "r958",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r99",
      "r570",
      "r762",
      "r926",
      "r942",
      "r1015"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r117",
      "r144",
      "r247",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r443",
      "r444",
      "r445",
      "r476",
      "r762",
      "r958",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "pali_LicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "LicenseAgreementsTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Text Block]",
        "documentation": "The entire disclosure for license agreements.",
        "terseLabel": "Collaborations and License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "pali_LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements with the Regents of the University of California [Member]",
        "documentation": "Represents information regarding license agreements with the Regents of the University of California for exclusive commercial rights to certain patents, technology and know-how.",
        "terseLabel": "License Agreements with the Regents of the University of California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing arrangement expiration period",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing arrangement interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r53"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining balance under insurance financing arrangements",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r53",
      "r280"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r278",
      "r399",
      "r737",
      "r952",
      "r953"
     ]
    },
    "pali_MaximumAggregateConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "MaximumAggregateConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum Aggregate Consideration",
        "documentation": "Maximum aggregate consideration.",
        "label": "Maximum Aggregate Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r354",
      "r399",
      "r459",
      "r528",
      "r584",
      "r586",
      "r593",
      "r620",
      "r621",
      "r674",
      "r677",
      "r681",
      "r682",
      "r688",
      "r708",
      "r709",
      "r734",
      "r743",
      "r747",
      "r753",
      "r754",
      "r758",
      "r759",
      "r773",
      "r960",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "pali_May2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "May2024OfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2024 Offering [Member]",
        "label": "May 2024 Offering [Member]",
        "documentation": "May 2024 Offering."
       }
      }
     },
     "auth_ref": []
    },
    "pali_May2024PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "May2024PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2024 Placement Agent Warrants [Member]",
        "documentation": "May 2024 Placement Agent Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "pali_MayTwoThousandTwentyFourOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "MayTwoThousandTwentyFourOfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Two Thousand Twenty Four Offering [Member]",
        "documentation": "May Two Thousand Twenty Four Offering.",
        "terseLabel": "May 2024 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_MayTwoThousandTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "MayTwoThousandTwentyTwoWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May two thousand twenty two warrants [Member]",
        "label": "May Two Thousand Twenty Two Warrants [Member]",
        "terseLabel": "May 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r753"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r753"
     ]
    },
    "pali_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r354",
      "r399",
      "r459",
      "r528",
      "r584",
      "r586",
      "r593",
      "r620",
      "r621",
      "r674",
      "r677",
      "r681",
      "r682",
      "r688",
      "r708",
      "r709",
      "r734",
      "r743",
      "r747",
      "r753",
      "r754",
      "r758",
      "r773",
      "r960",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r76",
      "r100",
      "r115",
      "r126",
      "r127",
      "r131",
      "r144",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r174",
      "r247",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r437",
      "r440",
      "r456",
      "r476",
      "r572",
      "r650",
      "r667",
      "r668",
      "r786",
      "r958"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss attributable to common shares - basic",
        "terseLabel": "Reduction in income available to common shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss available to common stockholders - basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r155",
      "r156",
      "r157",
      "r158",
      "r165",
      "r166",
      "r175",
      "r178",
      "r440"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Basic and diluted net loss per common share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common shares - diluted",
        "totalLabel": "Net loss attributable to common shares - diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r167",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r178"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Diluted net loss per common share"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NetProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Proceeds",
        "documentation": "Net Proceeds",
        "terseLabel": "Net Proceeds from the exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from insurance financing debt included in prepaid and other assets and other noncurrent assets.",
        "label": "Net Proceeds from Insurance Financing Debt Included in Prepaid and Other Assets and Oher Noncurrent Assets",
        "terseLabel": "Insurance financing debt included in prepaid and other current assets and other noncurrent assets"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NetProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NetProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of warrants",
        "label": "Net proceeds from issuance of warrants",
        "terseLabel": "Net proceeds from exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "pali_NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non cash impact of exercise price reset on outstanding warrants related to down round provisions",
        "label": "Non Cash Impact of Exercise Price Reset on Outstanding Warrants Related to Down Round Provisions",
        "documentation": "Non cash impact of exercise price reset on outstanding warrants related to down round provisions"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NonCashWarrantIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NonCashWarrantIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Warrant Issuance Costs",
        "documentation": "Non cash warrant issuance costs.",
        "terseLabel": "Non-cash warrant issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NonCashWarrantModificationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NonCashWarrantModificationCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash warrant modification costs",
        "label": "Non Cash Warrant Modification Costs",
        "documentation": "Non cash warrant modification costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r858",
      "r867"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NoncashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NoncashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash operating lease expense",
        "label": "Noncash operating lease expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]",
        "documentation": "Notes To Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "pali_Nsi532Igf1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "Nsi532Igf1Member",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NSI-532.IGF-1 [Member]",
        "label": "NSI-532.IGF-1 [Member]",
        "documentation": "NSI-532.IGF-1."
       }
      }
     },
     "auth_ref": []
    },
    "pali_NumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NumberOfLicenseAgreements",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "pali_NumberOfLicenseAgreements",
        "documentation": "Represents the number of license agreements in place.",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r933"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r732",
      "r933"
     ]
    },
    "pali_NumberOfTerminatedLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NumberOfTerminatedLicenseAgreements",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Terminated License Agreements",
        "label": "Number of Terminated License Agreements",
        "terseLabel": "Number of terminated license agreements"
       }
      }
     },
     "auth_ref": []
    },
    "pali_NumberOfTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "NumberOfTradingDays",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading day period",
        "label": "Number Of Trading Days",
        "documentation": "Number Of Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "pali_October2020NoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "October2020NoteMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2020 Note [Member]",
        "label": "October 2020 Note [Member]",
        "documentation": "Represents information regarding an unsecured promissory note issued in October 2020."
       }
      }
     },
     "auth_ref": []
    },
    "pali_OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corpotate Office [Member]",
        "terseLabel": "Office Space Lease for Corporate Headquarters in Carlsbad, CA [Member]",
        "label": "Office Space Lease for Corporate Headquarters in Carlsbad, CA [Member]",
        "documentation": "Represents information regarding an office space lease for corporate headquarters in Carlsbad, CA."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r721",
      "r932",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Less: current portion of lease liability",
        "terseLabel": "Current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Lease, Right-of-Use Asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "pali_OperatingLeasesFutureMinimumPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "OperatingLeasesFutureMinimumPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments",
        "terseLabel": "Total remaining future minimum lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r727",
      "r728"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Contract Indexed to Equity, Settlement, Number of Shares",
        "terseLabel": "Option to purchase shares of Company's common stock",
        "documentation": "Number of shares as a settlement alternative for each freestanding option contract."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusiness1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r91",
      "r594",
      "r595"
     ]
    },
    "pali_OriginalFinancingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "OriginalFinancingAgreementsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original Financing Agreements [Member]",
        "documentation": "Represents information regarding the original financing agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other noncurrent assets, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other general and administrative expenses",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r1063"
     ]
    },
    "pali_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Noncurrent Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r943"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "pali_OutOfPocketExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "OutOfPocketExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Out-of-pocket expenses",
        "documentation": "Out-of-pocket expenses",
        "label": "Out-of-Pocket Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r822",
      "r832",
      "r865"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r835",
      "r868"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r835",
      "r868"
     ]
    },
    "pali_PALITwoOneZeroEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PALITwoOneZeroEightMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PALI Two One Zero Eight [Member]",
        "documentation": "PALI-2108.",
        "terseLabel": "PALI-2108 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "pali_PaycheckProtectionProgramCARESActMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PaycheckProtectionProgramCARESActMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll."
       }
      }
     },
     "auth_ref": []
    },
    "pali_PaymentOfWarrantInducementIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PaymentOfWarrantInducementIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of warrant inducement issuance costs",
        "label": "Payment of Warrant Inducement Issuance Costs",
        "documentation": "Payment of warrant inducement issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Cash paid",
        "negatedLabel": "Cash paid",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r920"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Proceeds from issuance of debt",
        "negatedLabel": "Payment of equity issuance costs",
        "netLabel": "Cost inquired with exercise of warrants",
        "verboseLabel": "Payment of equity issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld for payment of employee withholding tax liability",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote10EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefits",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r746"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "pali_PercentageCostInPatentRight": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PercentageCostInPatentRight",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage cost in patent right",
        "label": "Percentage Cost in Patent Right",
        "documentation": "Percentage cost in patent right"
       }
      }
     },
     "auth_ref": []
    },
    "pali_PercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PercentageOfGrossProceeds",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross proceeds",
        "documentation": "Percentage of gross proceeds",
        "label": "Percentage of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "pali_PercentageOfNetRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PercentageOfNetRevenue",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net revenue",
        "label": "Percentage of net revenue",
        "documentation": "Percentage of net revenue"
       }
      }
     },
     "auth_ref": []
    },
    "pali_PercentageOfReductionInWorkForce": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PercentageOfReductionInWorkForce",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in work force",
        "label": "Percentage Of Reduction In Work Force",
        "documentation": "Percentage of reduction in work force"
       }
      }
     },
     "auth_ref": []
    },
    "pali_PercentageOfShareIssued": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PercentageOfShareIssued",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Share Issued",
        "label": "Percentage of Share Issued",
        "terseLabel": "Percentage of share issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Based Stock Units [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "pali_PeriodOfExpirationOfLicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PeriodOfExpirationOfLicenseAgreementDescription",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of Expiration of License Agreement Description",
        "documentation": "Period of Expiration of License Agreement Description",
        "label": "Period of Expiration of License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "pali_PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent, Solicitor and Representative Common Stock Warrants [Member]",
        "documentation": "Placement agent, solicitor and representative common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "pali_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants [Member]",
        "label": "Placement Agent Warrants [Member]",
        "documentation": "Placement agent warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "pali_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Funded Warrants [Member]",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Dividend Rate, Percentage",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r675",
      "r678",
      "r680",
      "r689"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r782",
      "r783",
      "r784",
      "r785",
      "r1061",
      "r1064"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r320"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r630"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r320"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r630",
      "r648",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r567",
      "r762"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance, less current portion",
        "label": "Prepaid Expense, Noncurrent",
        "totalLabel": "Prepaid Expense, Noncurrent, Total",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "pali_PrepaidExpensesAndOtherCurrentAssetsOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Prepaid Expenses and Other Current Assets Other Receivables",
        "documentation": "Prepaid expenses and other current assets, other receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r736",
      "r943"
     ]
    },
    "pali_PrepaidSoftwareLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PrepaidSoftwareLicenses",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid software licenses",
        "label": "Prepaid Software Licenses",
        "documentation": "Prepaid software licenses."
       }
      }
     },
     "auth_ref": []
    },
    "pali_PrepaidSubscriptionsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "PrepaidSubscriptionsAndFees",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid subscriptions and fees",
        "label": "Prepaid Subscriptions and Fees",
        "documentation": "Prepaid subscriptions and fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ProceedsDepositedIntoTheCvrEscrow": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ProceedsDepositedIntoTheCvrEscrow",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds deposited into the CVR escrow.",
        "label": "Proceeds Deposited into the CVR Escrow",
        "terseLabel": "Proceeds deposited into the CVR escrow"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from issuance of common stock and warrants",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants for additional gross cash proceeds",
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Gross proceeds from the exercise of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under Employee Stock Purchase Plan",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds (payments) from the redemption of warrants",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r529",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r711",
      "r744",
      "r772",
      "r773",
      "r774",
      "r776",
      "r777",
      "r954",
      "r955",
      "r962",
      "r1031",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r529",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r711",
      "r744",
      "r772",
      "r773",
      "r774",
      "r776",
      "r777",
      "r954",
      "r955",
      "r962",
      "r1031",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "pali_ProgramExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ProgramExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Program Expenses",
        "documentation": "Program expenses.",
        "terseLabel": "Program expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r492",
      "r562",
      "r571",
      "r762"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r342",
      "r354",
      "r385",
      "r386",
      "r387",
      "r399",
      "r459",
      "r502",
      "r511",
      "r528",
      "r584",
      "r586",
      "r593",
      "r620",
      "r621",
      "r674",
      "r677",
      "r681",
      "r682",
      "r688",
      "r708",
      "r709",
      "r734",
      "r743",
      "r747",
      "r753",
      "r754",
      "r758",
      "r759",
      "r773",
      "r780",
      "r950",
      "r960",
      "r1003",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r342",
      "r354",
      "r385",
      "r386",
      "r387",
      "r399",
      "r459",
      "r502",
      "r511",
      "r528",
      "r584",
      "r586",
      "r593",
      "r620",
      "r621",
      "r674",
      "r677",
      "r681",
      "r682",
      "r688",
      "r708",
      "r709",
      "r734",
      "r743",
      "r747",
      "r753",
      "r754",
      "r758",
      "r759",
      "r773",
      "r780",
      "r950",
      "r960",
      "r1003",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Loss from Operations",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r817",
      "r827",
      "r860"
     ]
    },
    "pali_RecurringFairValueMeasurementsOfLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "RecurringFairValueMeasurementsOfLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Recurring fair value measurements of liabilities",
        "label": "Recurring fair value measurements of liabilities",
        "documentation": "Recurring fair value measurements of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Repayments of Short-term Debt, Total",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Payments on insurance financing debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "pali_ReplacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ReplacementWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Replacement warrants.",
        "label": "Replacement Warrants [Member]",
        "terseLabel": "Replacement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_RepricedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "RepricedWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repriced Warrants [Member]",
        "documentation": "Repriced warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r296",
      "r322",
      "r495",
      "r512",
      "r563",
      "r717",
      "r718"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]",
        "verboseLabel": "Core research and development operating expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r818",
      "r828",
      "r861"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r819",
      "r829",
      "r862"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r826",
      "r836",
      "r869"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Total",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93",
      "r118",
      "r140",
      "r566"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "totalLabel": "Restricted cash, Total",
        "terseLabel": "Restricted cash, noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r913",
      "r923"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability (in shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Issuance of common stock for vesting of restricted stock units, net of employee withholding tax liability",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r269",
      "r270"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs",
        "label": "Restructuring Costs",
        "totalLabel": "Restructuring Costs, Total",
        "verboseLabel": "Restructuring costs (Note 8)",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restructuring Reserve, Total",
        "label": "Restructuring Reserve",
        "periodStartLabel": "Balance as of the beginning of year",
        "periodEndLabel": "Balance as of the end of year",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r270"
     ]
    },
    "us-gaap_RestructuringReserveAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAccrualAdjustment1",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Accrual Adjustment",
        "terseLabel": "Net accrual additions",
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r270"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesAccruedLiabilitiesInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote1OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (Accumulated deficit), ending balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r85",
      "r569",
      "r591",
      "r592",
      "r602",
      "r631",
      "r762"
     ]
    },
    "pali_RetainedEarningsAccumulatedIncomeDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "RetainedEarningsAccumulatedIncomeDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retained earnings accumulated income.",
        "label": "Retained Earnings Accumulated Income (Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r248",
      "r249",
      "r258",
      "r427",
      "r428",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r446",
      "r448",
      "r449",
      "r451",
      "r454",
      "r485",
      "r486",
      "r588",
      "r590",
      "r604",
      "r1064"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r183",
      "r193",
      "r194",
      "r202",
      "r208",
      "r211",
      "r213",
      "r215",
      "r339",
      "r340",
      "r529"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r183",
      "r193",
      "r194",
      "r202",
      "r208",
      "r211",
      "r213",
      "r215",
      "r339",
      "r340",
      "r529"
     ]
    },
    "us-gaap_RevenueRecognitionSoftware": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionSoftware",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Software [Policy Text Block]",
        "terseLabel": "License Revenue",
        "documentation": "Disclosure of accounting policy for revenue recognition for software arrangements relating to the licensing, selling, leasing, or marketing of computer software."
       }
      }
     },
     "auth_ref": []
    },
    "pali_ReverseStockSplitPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ReverseStockSplitPolicyPolicyTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split, policy [Policy Text Block].",
        "terseLabel": "Reverse Stock Split",
        "label": "Reverse Stock Split, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "pali_RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived",
        "documentation": "Represents the royalty rate on the portion of sublicense income to be paid, expressed as a percentage of one-third of the upfront payment and milestone payment received.",
        "terseLabel": "Royalty rate, portion of sublicense income to be paid, percentage of one-third of upfront payment and milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock during period",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares Sold, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Income Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19",
      "r168",
      "r169",
      "r176"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Statutory Federal Income Tax Rate Applied to Loss Before Income Tax",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r749",
      "r992"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation for all Stock Awards",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Noncurrent Assets",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Accrued liabilities in the consolidated balance sheet",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r79",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summarized Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4CommonStockWarrantsTables",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "pali_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Outstanding And Exercisable [Table Text Block]",
        "documentation": "Tabular disclosure of warrants outstanding and exercisable.",
        "terseLabel": "Schedule of Stockholders' Equity warrant outstanding and exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Number of Shares",
        "verboseLabel": "Schedule of Basic and Diluted Net Loss Per Common Share",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r616",
      "r617",
      "r618",
      "r676",
      "r679",
      "r683",
      "r690",
      "r697",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r712",
      "r745",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r775",
      "r780",
      "r962",
      "r1031",
      "r1033",
      "r1034",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r726",
      "r733"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r723",
      "r730"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r183",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r198",
      "r199",
      "r200",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r722",
      "r724",
      "r725",
      "r727",
      "r729",
      "r731",
      "r732"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote12SegmentInformationScheduleOfReconciliationOfLossFromOperationsDisclosureDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "pali_SeniorSecuredPromissoryNoteWarrantsFirstClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SeniorSecuredPromissoryNoteWarrantsFirstClosingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Promissory Note Warrants, First Closing [Member]",
        "documentation": "Represents information regarding warrants associated with the first closing of the Senior Secured Promissory Notes."
       }
      }
     },
     "auth_ref": []
    },
    "pali_SeniorSecuredPromissoryNoteWarrantsSecondClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SeniorSecuredPromissoryNoteWarrantsSecondClosingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Promissory Note Warrants, Second Closing [Member]",
        "documentation": "Represents information regarding warrants associated with the second closing of the Senior Secured Promissory Notes."
       }
      }
     },
     "auth_ref": []
    },
    "pali_SeniorSecuredPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SeniorSecuredPromissoryNotesMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Promissory Notes [Member]",
        "documentation": "Represents information regarding the Senior Secured Promissory Notes."
       }
      }
     },
     "auth_ref": []
    },
    "pali_September2023OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "September2023OfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September 2023 Offering.",
        "label": "September 2023 Offering [Member]",
        "terseLabel": "September 2023 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_SeptemberTwoThousandAndTwentyThreeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SeptemberTwoThousandAndTwentyThreeOfferingMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Two Thousand And Twenty Three Offering [Member]",
        "documentation": "September two thousand And twenty three offering.",
        "terseLabel": "September 2023 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_Series1PreferredStockOfLBSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "Series1PreferredStockOfLBSMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series 1 Preferred Stock of LBS [Member]",
        "documentation": "Represents information regarding Series 1 Preferred Stock of LBS."
       }
      }
     },
     "auth_ref": []
    },
    "pali_Series2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "Series2WarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Two Warrants [Member]",
        "terseLabel": "Series 2 Warrants [Member]",
        "documentation": "Series 2 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_SeriesA4Point5PercentConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SeriesA4Point5PercentConvertiblePreferredStockMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A 4.5% Convertible Preferred Stock [Member]",
        "documentation": "Represents information pertaining to Series A 4.5% convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "pali_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915",
      "r961"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915",
      "r961"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation and related charges",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Restricted Stock Units, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "verboseLabel": "Number of shares forfeited",
        "negatedLabel": "Number of Restricted Stock Units, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Restricted Stock Units, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of Restricted Stock Units, Non-vested",
        "verboseLabel": "Granted, Weighted Average Grant Date Fair Value",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Non-vested, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Exercise price",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested, Weighted Average Contractual Life (Years)",
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Number of Restricted Stock Units, Vested",
        "verboseLabel": "Number of Stock Units, Vested",
        "negatedLabel": "Number of Restricted Stock Units, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions Cost of equity.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Cost Of Equity",
        "terseLabel": "Cost of equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "terseLabel": "Weighted-average expected dividend yield",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted-average expected term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted-average expected term",
        "terseLabel": "Weighted-average expected term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "pali_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate",
        "terseLabel": "Weighted-average risk-free interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted-average volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per employee (in shares)",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable, Weighted Average Exercise Price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Forfeited, expired or cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited, expired or cancelled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of options, Granted (in shares)",
        "terseLabel": "Number of Options, Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Outstanding (in shares)",
        "periodStartLabel": "Number of Options, Outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Number of shares outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "periodEndLabel": "Options Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareDetailsTextual",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price per share",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Forfeited, expired or cancelled, Weighted Average Exercise Price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Granted, Weighted Average Exercise Price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two [Member]",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r363",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r394",
      "r395",
      "r396",
      "r397"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award Vesting Rights Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "verboseLabel": "Grant date fair value of the options vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected contractual life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable, Weighted Average Remaining Contractual Life (Year)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Number of shares unvested and outstanding",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life (Year)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Vested and expected to vest, Weighted Average Remaining Contractual Life (Year)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of purchase price of common stock",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "terseLabel": "Shares Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r141"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r121",
      "r122",
      "r123",
      "r144",
      "r168",
      "r169",
      "r176",
      "r178",
      "r185",
      "r186",
      "r247",
      "r281",
      "r284",
      "r285",
      "r286",
      "r290",
      "r291",
      "r320",
      "r321",
      "r324",
      "r327",
      "r335",
      "r476",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r630",
      "r651",
      "r669",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r902",
      "r924",
      "r931"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r61",
      "r64",
      "r65",
      "r114",
      "r129",
      "r130",
      "r131",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r184",
      "r248",
      "r249",
      "r258",
      "r338",
      "r427",
      "r428",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r494",
      "r573",
      "r588",
      "r589",
      "r590",
      "r604",
      "r669"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r616",
      "r617",
      "r618",
      "r676",
      "r679",
      "r683",
      "r690",
      "r697",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r712",
      "r745",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r775",
      "r780",
      "r962",
      "r1031",
      "r1033",
      "r1034",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquitySummaryOfWarrantActivityDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r184",
      "r486",
      "r529",
      "r596",
      "r615",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r630",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r781"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfFairValueOfOptionsGrantedDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfStockbasedCompensationForAllStockAwardsDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r184",
      "r216",
      "r486",
      "r529",
      "r596",
      "r615",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r630",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r781"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r821",
      "r831",
      "r864"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for employee stock purchase plan (shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Shares issued under the ESPP",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r85"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to vendor (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues (in shares)",
        "terseLabel": "Offering shares (Per share)",
        "verboseLabel": "Issuance of stock during period, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r85",
      "r598",
      "r669",
      "r692"
     ]
    },
    "pali_StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period common stock upon warrant exercises.",
        "label": "Stock Issued During Period Shares Of Common Stock Upon Warrant Exercises",
        "terseLabel": "Issuance of common stock upon warrant exercises (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split fractional share settlement",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfSummarizedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Options, Exercised (in shares)",
        "terseLabel": "Warrants exercised",
        "negatedLabel": "Options Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r85",
      "r369"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "verboseLabel": "Maximum shares issued under ESPP",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r60",
      "r61",
      "r85"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to vendor",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "pali_StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the amount of stock issued during period value of common stock upon warrant exercises.",
        "label": "Stock Issued During Period Value Of Common Stock Upon Warrant Exercises",
        "terseLabel": "Issuance of common stock upon warrant exercises"
       }
      }
     },
     "auth_ref": []
    },
    "pali_StockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "StockPurchaseWarrantsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Purchase Warrants [Member]",
        "documentation": "Represents information pertaining to stock purchase warrants.",
        "terseLabel": "Warrant Liabilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r78",
      "r632",
      "r648",
      "r670",
      "r671",
      "r762",
      "r787",
      "r926",
      "r942",
      "r1015",
      "r1064"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r143",
      "r319",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r338",
      "r453",
      "r672",
      "r673",
      "r696"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "pali_SublicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SublicenseFees",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense Fees",
        "documentation": "Sublicense fees",
        "terseLabel": "Sublicense fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityScheduleOfStockholdersEquityWarrantOutstandingAndExercisableDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "pali_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote3BalanceSheetDetailsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued severance and benefits",
        "label": "Supplemental Unemployment Benefits, Severance Benefits",
        "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "lang": {
      "en-us": {
       "role": {
        "label": "Table Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "pali_The2013PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "The2013PlanMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan [Member]",
        "label": "The 2013 Plan [Member]",
        "documentation": "The 2013 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_The2021EsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "The2021EsppMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2021 ESPP member",
        "label": "The 2021 ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_The2021PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "The2021PlanMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 Plan [Member]",
        "documentation": "Represents information regarding the 2021 Equity Incentive Plan.",
        "terseLabel": "The 2021 EIP and Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_TheDecember2019NoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "TheDecember2019NoteMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-note-6-debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The December 2019 Note [Member]",
        "documentation": "Represents information regarding an unsecured promissory note to a consultant as payment for consulting services performed in 2019."
       }
      }
     },
     "auth_ref": []
    },
    "pali_TimeBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "TimeBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time Based Restricted Stock Units [Member]",
        "documentation": "Time based restricted stock units.",
        "terseLabel": "Time-based RSU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r317",
      "r333",
      "r452",
      "r475",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r574",
      "r750",
      "r751",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r763",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r938",
      "r939",
      "r940",
      "r941",
      "r999",
      "r1002",
      "r1003",
      "r1004",
      "r1011",
      "r1014"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreements1",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote7CollaborationsAndLicenseAgreementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote8CommitmentsAndContingenciesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r269",
      "r270"
     ]
    },
    "pali_UncertainIncomeTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "UncertainIncomeTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "uncertain income tax positions",
        "label": "Uncertain Income Tax Positions",
        "terseLabel": "Uncertain income tax positions"
       }
      }
     },
     "auth_ref": []
    },
    "pali_UnderwritingCommitmentsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "UnderwritingCommitmentsPerShare",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Commitments Per Share",
        "terseLabel": "Underwriting agreement, per share",
        "documentation": "Underwriting commitments, per share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "pali_UnregisteredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "UnregisteredSharesMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unregistered Shares.",
        "label": "Unregistered Shares [Member]",
        "terseLabel": "Unregistered Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote2SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r107",
      "r108",
      "r110",
      "r111"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote11IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote6EquityIncentivePlansDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "calculation": {
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions diluted",
        "terseLabel": "Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions",
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r337"
     ]
    },
    "pali_WarrantInducementAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "WarrantInducementAgreementsMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Inducement Agreements [Member]",
        "label": "Warrant Inducement Agreements [Member]",
        "terseLabel": "Warrant Inducement Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pali_WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Inducement and Equity Issuance Costs Included in Accounts Payable and Accrued Liabilities",
        "documentation": "Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities",
        "negatedLabel": "Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities",
        "terseLabel": "Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote4FairValueMeasurementsActivityForItemsMeasuredAtFairValueOnARecurringBasisDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants for common stock",
        "verboseLabel": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r782",
      "r783",
      "r784",
      "r785"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and Rights Outstanding",
        "label": "Warrants and Rights Outstanding",
        "verboseLabel": "Incremental Value of Warrants",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Date of issuance of warrant",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "pali_WarrantsIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.palisadebio.com/20241231",
     "localname": "WarrantsIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote5StockholdersEquityDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issuance Costs",
        "documentation": "Warrants issuance costs",
        "terseLabel": "Total equity issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares used in calculating diluted loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares used in calculating diluted loss per share",
        "terseLabel": "Weighted average shares used in calculating diluted loss per common share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r178"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares used in computing loss per common share:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.palisadebio.com/20241231/taxonomy/role/DisclosureNote9NetLossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.palisadebio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares used in calculating basic loss per share",
        "negatedLabel": "Basic weighted average shares used in computing net loss per common share",
        "terseLabel": "Weighted average shares used in calculating basic loss per common share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r178"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "SubTopic": "40",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0000950170-25-043859-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-043859-xbrl.zip
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M;*DT7R[U [3Z .IRUFI.'/B/H?%O$>L@QM]PN #5LGBQ)K-Z7P)^$B-^L5B
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MI1%M5-@K0AYD2==!@)(0H "2%@+A5, O-X#Z[ %\O6%!A/D32!2E6A_06%J
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M*GB&>C^!'X'B 3X?/0VD N( TY5SA)]*97T(6UVT* -,D\7"\&41-7#61BL
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M^\,)6,=*P"B/$.\DAQ5WB"8402,O>.%?DY ]%748Q&/5#(CQB=CQ%BJ0-;/
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M-'@?,5A?8;*)[5]<W?-)(2]^R4'696UHK.GC5MFR% $J952_]WZ?$*/1NIY
MWZIL:=C*,PVN#1IAS"[.8FAOO80/-@3U<I[=\$RPU*F;[RUZK.S,C[>[FJ)T
MC#.=0S3:T0+LC[KWMSVI!(?[1%'@&>]:W"!)JQT$OLTCF1UP)6T45M"XH?V6
M41_T2:-PQTT9Y\Q94MQ.C[OOL#94#\H@V1H>)4N%Z;!3ZYP":3B%,)GRFAXC
MEZOLY[2_F[(G;+_W^\VY]/LZR,;G/_,UD:UYE;+3IL-O\&>*OD?*]VYF9931
ML9/\:LA/?4"N'CF ZYOE$%C4^V'K&*$]I8';PTY6I7=3.+LN/D@T'\&O'1^(
MR(7D4WH/P1'T,SWE<H;F-J.+]9IE*72]B&8GNZQ7+%T.PEI?A;VOBO5;P\#(
MJ]=;F;GVG,Z&F$4$?+V':Z?V\=).U0#MB;&>'&IG]9'\[VW/H8!)I\9D[96,
MOL_^9927U.%'0[JL@'RNGBM!SJIKX2>;'%WMS70UJ[\I39;U;?4N^N2NEE&2
M<5A%>^!JS\S&E(KV%P\56R.=/NVV*"26WB50'E0VNLFQ\CP;^Z:?9EU)#/8*
M?NR=YGF0*ESOF*>T[\ODSSX3V0+\SM2S-(:62^F6Y#"&^]SRV>+I7)^S>3T'
M\H44@M2)-9AC#8C!)YYN\Y65;X;U1L*T99RHM]V\2^#F"Y4F?S!>F/@_9L?)
M'W;,L&GTF#,:DQW"_)&BI1-WT( BJ6Q=F'L[IS\"E+;"[#[O.MO[#/^) '61
M&OV*]P?<?RG1/-?9R?QJE5@-9^5&MV<GH[Q++?#7P4#%CD>+_KLG13T<.\IG
MC"^$&O9Y.I];7,=YS*\RLA[&Q1[&E.9/3[ ZL,#YRJEMDPGQ\ZNH"A>BS0;_
MI7.R;'FFC)LA'#M5659!LNO^E=^C[:IRY.7%K#F.C]ND,?8G.G[@2Q3;$ME2
MS%K;Q AU]I--O?V4Y4F)7PP7<W9^9_J6U5/,Q$M.L;]]/V?TLGD?B>%<Y*]N
M_?;M8Y=CE\6(VL$UF2*!NM/<XG'R%NIP 53FE<$V",6)3488DQJO(1N[ROL9
M;]Y4)=9G[6;UQI;).5M.-<9O(CNQ6M_1\I.29 +^<MTFVNNP.6! S7A$"$PD
MMG1)*QL \_>K?Q3 W,UW4%^9Y6A?GIV1C!XE>"8)4(%55%;RH@!5%&KB56B&
M!C:UYE!JU!"F21K,+VN"C'9"\*VKO-6WL<T6O_5R#?GG4X+E,YG+4IJ.2RM%
MLFAN(%=]*JLW<<FV@2:,?.$K6?.KJ;[D_OD&-ZER_FNJ-U48=JY54'UG:8B7
MY.G5) S[T#3XA?87>9XCK>JVU9TY\R5JVOMU5"5LLKI%N\F96TQ[3:A<0D0?
M68+JO3EB70/KNBD<RB3#SG.$FL,9C8<-?N4$"%#]5L,Z+%[Z\16EF#"=[5OI
M4)W#Y5Y;-YT?EW?W5ZM>>M7BO>S'&8+GN9Z\C6PIRHT20NIP<2\M$VHR> :)
M&"E"?Q.\&Q34(?2+]$0?@\RAV/!GYMK!_3Z?."JM3C?N6;Y[5BIA:?SIV&>H
M]G0>^UH.@]ZW;<3:V4J]J6)%_=XHU?S2R*M7G=6N(1XL\U\I5B9RUV.^='0Z
MWEC7W^#+'J3)W#&\=E8\2^R/D:S=GPC.#0_RU9GQ>O5>\NK.D;Z><-;>SYI/
MI+=Z:L^?5FJ>F[8SN%&#MSO3JCS:M?-F);K8DW"@[&5BQ.(Y*[V;U4H,\N9@
MC!PLD37Z39)1(G=@Q%=AEW5K4-@N\MA;TI:Q\LLF6UJUPD2=^L7\CS ONYB>
MB#UW4R:GUOM&O$*-0?J2\ND,.V-\$U2!FZ%P#T_5B%7SGT>L"=/L#%O'##=_
M02TSVA!^8U_.;J>[X18J*@MPU(BJR4Z;GH$+U6]>=E^ZE&A],B]F:,+.^VTI
M7PL>8:>:P\=82DV0K'CQ[ N>X?!8[]7ME?'!/H63 R^N<2+$2]\^,"[N<)H<
M&,U]YMA&O,-45LN\;2Z]CC7/><V:G=DUW";#$^_%!I+$?2#IFLWH[5:H5_"1
MY^?@:W5-UAHO4GT*GH')N]K8N'LA1;R<41[ZYTI)HL]SGW3\O:N&]]74_EX1
M1K90V/NL("M8AJL?9MP9@I.P&HE]A[VG&R'/<GNR$I__@N#5X-51C<D?ES((
M*?_>\'D2]$"@J],1'R]VSL64R^L3M)6SHO',?1!-7SUVD?TV7\+AAJ@"II:5
M9]6X< @SE8?69XKL/&4B)Q[C>%IVAY&]8VR+RAG*[7QB04SA^%_!1NW9NDKX
MSZUA>QEN6DSU'$1.]9.>H;""<GVP/3:^,I9VR=2+9]@$E&:+QSB3_=AE>VF+
MZZD((?T/GN?"3LMI%L7FW/[[U8T4=,*YPK!8]"ST$C]3,3([X%R?9<)2:F@3
M(3C716A^-=)GD.5@K\ZZ@=/49[6%,-8Y>L R[N@O>KW"'^P-M8,*Y0QG_N')
M(8+_;-G,39D$S><)K0T1WX'W:<#U>XR0(FLP\+&ZK#5LZ2B=0.* 4%SY&[98
M)E._VK3M!I.^X^)*;E[J<Y\(Y8Z%03WJZVK] ,YEU_&JVV^J4YC,X>_.E\I)
M3/_K(V_>@S@X-; H]T]?>BF^GM1?5/NFRNTV*Z.>8Z+;P3,32RLA!/1\&:%M
M<_-92E\BANG*IYKL9$4-)=DT2B=%L1K3KFA)A49G3& 'Z+0!]5AH.%^ *C6+
MJC;+KRTB0/70IJM\M'/'K[#:C=FYOE5-C<TJ7'TGI7@[RUC'G_>J-<T.!-"W
MW]]=1-((7I+T4I ?T30JC64G,J?)]0$[&>EAULX;8CYX:/1C);S$"Y*\SK5L
M=+]#.U_06;!ED66WWZZVSFY7RF?K,5O;U#+>P>&PHH9IH6UC1FM2:;<J(^L4
M#HX8/)$DM@0Y9JT[R!03_9P);('R!Z\;]AX/:GN*+$KD1!]W4,PP-ML+O0\]
MX#\I^/S$A ,W<%U@(4;O] ?(9^>6R4&73B/SOR?F>/J= 8.?_:$&DS\JDL8'
M)!>N=9;6'LXTDBZ%TWOD2&5]3A>KNH+?OBVW,[$3H-9S^2^0O1'=-?)P<E&8
MV5>>9/800<OM:UFQ 6:C3SHG3>3EY#7=)5VE,R17MM*]W 3"S_(3]VH5"Y^F
M.NYY=,]S67V8RI,8')%ZQ*8?8T$-EF_+J?VXX8I8GO7(;-3$]6)"Q"_,]LFJ
M]U]239+SOXU+55PW:$CQ+"M[SY9W>I/AEV=^.*/(V>=T^U2'BU67 %6+@7X(
M<4]"_2>^0@N);I07G_2:ZI_TUM/1$VP%89FZ&R:>=YE/R)(TNP(N=N;4(%%3
M5N]%IW% \.6"Y-X6]M><1Y\E%;=4GA+JZ<J5M_O)>F+.6(KLQT2:J-@QY)O5
M1TIV?6)72];O4-.@=7.H?6EH:?8)%S%+VF;;]*B#LZ*)GN4:\E9;DK)MH@UU
M5N[FR/Q5C.F_"8:;?#23]31&&?7_<*V;[T1DVYBZ/",T(F/)E:[%LDH$J)=0
M.?8-5%I.AZU,VD$K=B(2JN0!+"L!<E_&#I K!P6H3:/@MHBI%J[9BAT!\P :
MSAU2A/%<#T+L,*7>6.@#A[SQ*DYJ$#X_U7#ML,(N8D.53DUVOL_<H-]*\8^L
M7=2.@&GMP<'.P\6B9*+_F+_&WE#\PN.C+E?P\VFSW$0!:BFR-]&))\3*G\$
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MPIEQ+(B("(@4R0C2FU($%<E8  $! 0&I&4"D"8B ! 5BH;<H51'(T*49I8-
M@%!&6NA52H)TT(0:(+GS[3#O>][G/._YRN_[G3_/'PG)3?:ZUU[7M=:^=LJ]
MAC>(X]Q;TU3.1N)+^"%(*>#$9PHZH@P?N1LM/EKKF;/L]T8[RX;VU-V>(ZF&
M+T*9K5CEGL0UMT">;3^=WSX3/1S6N3OAGF["2H/*3-BKE+QFR3\_N;MVD-)^
M1I/+DV1"^\;O5E#*:KX]TCEJ(S;Z2=59%)6T*<]1+2F?=/LV@HT)\^#D1>';
M$)_0*Y@9^)FQD5$4MKE>8D@E:D2Y2[C_6C_4%FA'YB_3*=J(.OUG6>G+Y>ON
M%Y=47I[3N3GEO)-BW/7C:=N*PMY-RP"A074+U54&-7-=LX+F](PL%0"7%5:#
M.FKZ2,"!A'2!U_C6"'>-QJN9:7(=+H^M&&D1%SF%W8E!AYL]U' MJ79"A:)=
M-)Q\ %<C?RN<_08\[OYYTNYH_37S,^&MM<)>;Z][I<L73>B0SH^D^MY6IW2G
M+AE0T@P5%"EA!&O5 ZA V?6(Q\*'NK+(AA'6B*A6^\?UY\B1J19A?Z,*.9/L
M%&??/H),C!/R_Y0TN>OB\!FE7I(D?7ID*$\WQ=2E;U=TRYWQ&9((L&=@@C2"
M>FS%>VH/.\P@0K"4,B:,!.]7EE-J/E5_NA9(,5'2DY 9=XF]!QUWJ%KY!=\"
MLTP'Y>4VX9_=+/W>YV5?L J,F[7]8?B $89P1O!#_? #_61D[ ;QF,OE9=27
M9H%?RBB)285VV8$87?VKQ;,GW"X/U?EO):L^]B=N,6%2+_.2CZ'LIU*G/N'H
M6:);K4S8EV F;"B($A*HPX3]!B1SO%X4U&X>S81M&$39V I0_4[.C1)#U (Z
MU%H=).=M3SOYM[H9E&7.Q'92=EI/A@BY/[OF;9:GY9UWJBCA_H:G27RK_"_3
MW\+" KQ;[M.O)L_28H6H6:$TM&AQ6(BF>J5X"P52Y8WH^-1M>BXKK#@\[VAI
M=$+V/,] 7,\2X MZK)^LNO*5C!QEPK0HPE'3:;;#Y(IJ<II2LR+JB_ZPYWSI
MJQMX"F]QUD)Q%BK^C]A)%U&JP5_#'(&G,F,IHV^S0AS2/"XC >M[2Q@I.13L
MBP QDB F B&@<=9?GX0X],>PT?@U1]]GXHF.^4M(^]!G>_,#Y:CO_67N?/HW
M:P8ERO&<@7ER9?K>U#8Z;QNDC1\A0JU3X<A=%.V*-1.VRHO.I<LQ82^+ @1H
M452U&X[3' Z:/;%OBI;,1:Z*?/U.&0ZGGW$+]/+YWIC7!G:*_-:62]L=,MIG
MBCB.YSRVK_S"+7Q<8692IAT5WTPO/9!F^$L(YC1-GZ F1.3631)E;QSUX_G^
MJ#!UGB??+$^:?;OC70=/CJX*]42^AW.30M\T)SN*[^HTV'"5%G6$2<V]7:2A
M9_#\<_X7C]>+LL50#ZM.QXJE'1<F[6Y2-ATBT2L_XRXT/C9/%V0W3MP1,W;#
M4PU7L7N! 1S]RL1P=!GGRI=I/61(,M\IO0(;U WCZLHA'V=?]NSR\BBSVE=M
MZ5>B-&O?_9 3K;1QN_:YLKHN7>Y"7@4^[I9<X/P6CE'ABPQ%E!XF<(Y)3+LG
MAP9H.E$E6FW/]*Z0J'.)18:>GEENPKS4]%)_H:'+\' ?F??NSPP&U56.OW^,
M*/NXDN$S('*S9L+3#_XN: +/BW:#A\B0%<*#V*CHQD+/T9TR+ ?:83%=JIPR
M5XVC84QK]7BK*GLWBF_HU\8CE9!=9Q@E5EWJ=URH.OE_]UA8=J@CY:#A=&5J
M6+,A31RQ0IKQ%+9R24J7 #ZA5 2K? (%.@B[=I\"$3/13X\-/=5*.W;*[,T$
M*NBJ_/>W(J95_NF+4>HKJ[/S=#LLI0[.H^9]L*76,Z;E>RV?R=4.+W63A%D>
MZEMK+3ZUQMGXKA*0('+I\&7_!TY"AA<YV:.^DK\Y#^!N<!\42%A^IBX'D&?W
M*D;_1ONB.(W@>+QRF(L6HQVJ%"#QFU,UP_J0*EL,:>6)][$H!.DA.5UIZ5*W
MOBQ<WBZV@?I;7[I(DB!W<+Y4;_&-K?5;U/3\#P%"?=!9_8,OE\WQQU9JG>2*
MC*SEDVIRB"&90]]?JMDN_FAY_L5;X.8P[I%<PPV?O@<..X0]#6@$64Y</4OA
M:ZM7H7E1?DYOE5--FL"F9P/!L3C&/KY<(Q$J3JF;#/<]8PEM+".Y5O/B[U96
MQTU>,3GTQ9,K8D0E>.58U+R -JL V]"%^N@6G*P"3-2LICDYDB5KX3RL ES>
M-T<ILTP($HC.:PTOUF@\F,4A=W31:YR1=NT4F[!<ZT\Z%P;2X6QAPO:D!/R@
MK%,J&\AE<R&OPV=0@03_W /A5=P*1#6'2,?PPAM72/0G$JK%-Z0;!S/>D7*2
M![K.!C?_*=TQUK>[R?.-*CW@*GDW.DB/H4WI#U&_0#6/5KS='UQ[IZO*+49-
M1,WR]$<!<FWEX=<DZJ4YC5@9L5:3KOS[Y5ZTVWW19XXR8:-5$6*&A_J;C7VE
M= -L7^P]1C=>5]>G8I$,[ ;Z%1-6.D%L43AF-6F]+,#=0I9Y9H4J^OUS=8U4
ML2'UY57AZ;;C6:Z-?]8]GAUU^/9WPS-TR\]QSZT(VMV@0_33R:3#+\H18Y7D
M^M2:6-Q?');W:G_)8,)<:5^0%&+(PZ+?;"6KW$;+$_HT!GV]?6>>6<G)6G4Z
M)4*#LRZ3,A0$9/R3V@8U3(*ZTB_Q:GD*X8X)FRHQ;$-&:?Q"LZ*RDS\64RJW
MHO4X-/H;GJ:_^XL6Z5/7[_M^KR.-SW  -]L[W%1Y<=[LU9U ,>V(#7W=J;OI
M;CY?3MKD%.%5$L@T,NZ05ZS[2RJW2I)_R,RW_I>/"X2TT[]?>L+'^[QCO8CG
M;%C'!?]0<R&YXS*=YWT*2>??IG3GGJD93)/ED:[QE6+$^K^D]&'"TX7O^R<'
MOQ-2<Q-D?2:LY1]!$CY-3ITZ\[)+R5:P4_INB].]8X57DI1X&T8--"K@<$PC
M:5#6VB&,L!?06LQKE@BJYS%H%%'N1\!$31ZFN>V9!1$GS_0J8\/-+YZR-(_2
MX*W/RQ]S#C,:/-MG/U!N6DF%8^3DBU8^3GD4WO?<B#$8ZG;>5+.KB;"KK&.8
MXQKP O0_&#C\=#KZ!'1Z0>,";=R1.D7"Q)3SE%7VUEZ3:X'J?0)%MKI;M\3T
M'^O]Y$(](,FIW(M]HX$EG]&[F3+'Y>YWIND>N_?>(K*(IHUU6&?SLM5.?:!N
MB%0E?2,HA"I(D5?D#66GSN6]^W,VG-#K/ZEMLL0/<9_*O]M,^HPV:S+/$78U
MR9,V")XB:5REM)HGWGB!2OZ]74V!XS75PR2%> #[Z)0J(O9:<^+C@*;3MVU%
M&59D2^18J@*FX?+&H[??.(<OT![>W'$S*32H]5+.--+DW9.BK_$8:<+^_<9+
M_XINM&/"IC&/Z#=>-6/+$2NEI*IBNK\[;^MGJA[I2<S#-S=FCIS52MEN">(M
M"3$5I0H9%>H7+#XJ^%@4.7QQ23[Q#1.6.[9.C)SBK8?3N6AH,C(2SJ.NEX?2
M:]0XV9\[4)[F9/+./E(RT]AX<H*-TR_PR?0U1T>8_X\\GUCE<W$(.XI2"^9$
M@#"579SL>=S5WHN_590;,$?HBD%:@!EW).5MD:::^BO!YX3)7#D':37MHPLM
M9,I(I1[7JX0+)Z+0'&2)@Y2V,X]:$9+DM\9Y+_)T/\JG.TF99"'%B[52LTME
M-<2+LZ[U1'I47KGKVC.?8Z.;D(U9&TYG*\Y-&9OC=_\A-QO'-IVN&NDL'M'Y
MF*!L?! U&S,8=VO"M'>@$':-ES<P:L^?'D1SV=,/ZL>?@.3I8C2['+H,Q2E<
MX;<G3PW22PC>Y"M1+A^#>F=LGOS=OF7YY OYK*SQY,BBD>4]PIFZ4G6.#U<W
MN]K:3)DPXX +[^8LB,>_^U=XOR&CG"YVEA0=5U4DK3P0Y8AJN5_US4 @S=K
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M+YGR<X@RTJ;K6W*[X'U.TNQ(E99TTL70H^]G"8$>:4\3D@G* =5[5X+:L =
M>$YOLD&"SJK]M#"SYY:N01>HFKMN&A(UG\QUM-+.#)A57!3P?:4O8'BUXDWN
MXJ*_X@VQ[3'+H>&_$<[8D?5I].I582RB.>W0+N>)Q?."^DJM&GQX?<'FK8IC
M/Z7ZLVN2AG8)1I\LLOVG*P8W)J[)SOEG?]Y3LK'Q9\*,>FVFELS9T(4@6?)V
MJ^/1A4\JMQ0&SC-A=^:VTH?']HX;((N>>4X%.M&@\>WZ_K%G;>^ MA+$((;P
MF_,,3S)\$Y_"A"WS;>4J[)G'CS[CM-O$N1 WD780<=-P&UD(S8SLP1_1J:QK
MU/S6PG@+G4*5&E"SKLU@PFNZ8[Q= K-PS3%HO<&RB<M;#4T/Y9-O]]1>)7VY
MLE5R7LL]8Y \X&XOG6TU)WG,=G1/,^@K^CC:I<Z*E%0ZT^76.J8YW)2F;3%
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MBT=GOP*) #+T/1K8V;@#_^\&-1/,UT'*<X(\+-0'2PM0#F17# T]S[#TA)P
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M! N'/8*N!;9\$:=W3? [Y5,[7U @$KV/AOO\&N:?>=5W3ZWI>P6!*/R)^
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MO5IF</SQ']VR?_8$HC,^P/<[80YXC:)C@FXJ[W<6S\GV"%M )[IQ8'$+,;<
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M.:_UEPD'N@T%%)\=NE'$J;K6*[=A@;U]GI@KO2%C$G\FIO76K&7B0GLCIW'
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M4670PP9-9Q)^B$L_,2^Y)6F3@3+.DD^T2;HN>4WGV 'R0-XS3_S/XR;,93K
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MY/EPGJ@8BC#>FP__!;H'W7'X$6Z9#A!Y^HVB@]WY*JH5F.R41*B7]?:#1EU
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MCM!/6UL5?+3!(8@MF?F7"B\BB0$=0YM'59O>+2602"E3U.(1M<,6J)%SBW3
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M?,B8D!ECN6%DJ!D=\#)\E;;/B+F-2Y'%79Y&FN"W"NN;% W&YXT\ &]P0>F
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M5)-;V^^+RZ5($Q%IH<2.]%Y$($M9@'3IG0A([T(D0$A4>E>17B)"Z+TWB9
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MO/\-5K6%1L@M5.N+BJ,Y \7E;RM;STDQ5GPB"BG=I]<XV4'F*PU_M:1TZ]<
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MZE";&UA7])'UO&355Q%*VTFV 4>.@IOH-[-.UJ7&"=537U6YQS=5!6C=*.:
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M!Q=_:?5EOX#M1?T9,0 390C13P %5(6WC%,,/&!'*U@$4ZOTE+9!!Z8>!JL
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M$DB<V_&5D@._#@*<_N6LN9L='@.XI:$?YQ-9NQW[81D(0FU=X6:XH;=!PIH
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M%'JHCY<52&WEMSVAWV 5G(P$B!P3S;(-\L1]F =STO<!%=0WSK2I2+HHR?P
M_'H7OOD4-20F&.-[;L,9:C9,OZQAPGENQ:GG7)^?IG/8]2>M3OY+MD[Q"W=J
M5BG0I_"!]FQ//-Q%X!]M-I7("!G*I:\Z$$&-MJOSY)7%>*Z"J'RGDVV%_9AS
MV7E.HI'6<PF15_1D._AMK14:C+.VB)^W06_%]K:E-Y\DF_.LZJ;['9[FB K]
MJB[30BF<KC*3:--VP[BN=//F>&MG5J1P[%,:++A79,*K=[X\R#T6;U!5V.S?
MO VZKSW_^$-CIO\26\''^7-Z'5[AU%Z*>45H+6_%&CORZ'S(D8Y97W/-H'>B
MKFJAI_^.Q2DUZR+8@.1-/7A3HR!-YF)<Y[J/1W-_L*^N9_-[O;,%:2L]Z_&%
MU:>6 OBLV#B[!076Z]9O1YJ\N:CW3T)N%16Z7K+UC'Z&%O_6L7%* '("R&4G
M"MU(U6V_1U81!!X01 S>%'AOU-2\*G -S/=.^Y[J+S4HR%-:\L5/6;$LP>Z4
M/U^?!/?P%*#@&?DMW'P]C(J+4S9]*3(5!9'\<FK#IKN\=23M5!@#5>HTWZ#Y
M<EDR\'R:DD>!]_>#!]*-&PZ%IGXZ5E]+_ZY,@0K0M6FG[\/5"2Y2[X I*<HV
MJ,3U%GQ1P/1AI^IK6TA"GK'>TQ6Z.)>F[)9;,P^_RPG^/%W^>>N'U%7\.^LM
M)_5I\SUT:VHT@4N/6O>PBL@=.,4941K?,3,:%9[82Q7N=7;AP4#"7N>>/JIK
MPRB-;N^-:R5RR[J=_/;%3"C=[=D7I$[-][K%Y]N@/5M [*;)EX;HN#5?%PK)
M_^\3=3;O&ZV* *^UT4:;P@QK(Z[H%\UUI"^>_:6N/)J3C2/W__DH=/,F#\-C
MD"NK:><?K \BKX?O)X!Y$4:;AFC0%DJ_CZX53-I+&\H.>ZO5NFF59A7.BU_>
M^RVSZ5M RU7BT=J,\,##*X2+N0$\$6\0?VS5ZTEL7J CAAC\])/ORYY3]T=&
M""\PI-,(&VW/!_QKFIS,:(;WJY5.*0E>= CQR@4_,!^N.7AP\ 7*LBG5Y.3-
MH*<53TYO@\S;EP7H!J3/ 08FI&W0P>O:-OATCE,>.?#(=%*AN=1;UV+7\OHI
M]Z>6[9=+[W4''D([1''=PB[-G"NHK?TS .:$_S%E2-S;J$P.I>:&D^U$9N!U
M;3I)*O+_-*IUTN!QH0R/^+SXMFE(1<[(6S?966$7)_/Y(=7JN>B-Z@"^K<A5
M^=O-[/S 'YL.$;UH:M<VB%\"\-JQ T67$=_9+*B=N.N+;#VS$VY[IY:<<HRG
M%F&CN/'<8\31;5#5]ZV")4K/:NV/(S_NHF>-MY@B)17;H'<#X]N@415J-",;
M8>1R=',?0KX">+-I@=!ZKYG%-ZAW^KDS##Y.$*B<QFNF12I^&@P"E-VN!=57
M-=(.?:X5K*WD5B;WSL.SE]RXY\6.=FC'1;!?8QRGV4K;+]IP'4(899./F[!'
M%B5@HMX.M@U;%[H6N5*?8MR<H1X&*2(:7S8=6E7O-Z$ZX>/X"25S\54B1SWT
MH-B;@S&4MM91<9'@"G@G7$2[I#6)ZR'&3=6F0KMS\&0QIM2E-&S->U,^\.GL
M4N!G\WM@JC$N'LG?J.I*X0;#J\P _?P%6]NZ#?&4N\\F '1;\NA'A:ZCPZ7/
MRXI("[Z<TG4^H4NE9<&A-9>,:?,B?EF29ST^ DQL;R*0/XWB@,&3274$3@5R
M4V^*_YF9N:@LO!;D,&WOQ])&%<7X9W]I$GE'Y\>BK&.^?<$&?2DS[+KQ7="4
M_R7:<AO48H/T0HO156NI^UO-HR85!O4D,/#BCLLTS_@U&/<\SY=<2=1?M6^<
M5?!CX;EYGHHA&[Y1I45."\DP\QOK(X*>%^[WGLZ[OI%3VI&-;)'?!NT\WIAF
M)=I('.,@79_F\H:B!)G#"T).4I,*R.%NJPY#&O%+XCL;LVHHR%ZE1O!U<Y;Y
MX&*PYJ!;W9/%\2^5GU>S[/GF[3B@.7*TN?[3PJ0MI-@M^EF\O9](OFVMIR%^
M[C%)NOC6NB!8D=-[8*?@$;B1'9YSQ5"^Y[AM+5=66S_FH'7^ ^3@FM[I#949
MAJ1K,PK(%267V/$-Y45W^@!/ZA\(F_:3KUQW%L-SGQ,V5?3I5%+Q,>3L7LE\
M6NCN;;C?,?&B56DB+$KKL*FOXOK(R2[_ '_)\BM.1-$V#=[S/6+E/7SWKL79
MYSA()@XY'S4NWW,$YA;1A2X?V7D:8X^5-8G<M1DD%9 ]#(*^2T$>B4_V"0@]
M)#'Q 4!>JDXL6^L:MTF5N(7HXCSUYZQPS<6O:8MS_3LE1"'TX#=<%*QZO:CX
MQBD5]Y?TR]1)-.W0Q1>U]D&?&_7#D<6?&5))/90H[<F[/8:&XL<''^<Z#*_"
M0C_)\0\U<(^H[%L80[=. =*0>#+Q8='>*-PS!M$"GMJZ8%Y;D[4))0@V! SI
M.6!_\."E2D8:_ I"RWQ"#.8/4NYV>3G.ZW2D8S<*8B9/S6DC.?5TR.)L>?=;
MYR"RLZ$0BS2W5?@F0I![N+O(?,&*H&QG7(,05PVW,2Z5KX]PA"=<*ARVIA@C
MD^&PZ5-&,31S0J\(C:OYM.!CP"3%,W38\\&[:U3@J^3SE)'H(8DH1&<I!^0T
MFTJ9L0;&DK!JC7=][A*/T1UD: Q"I^/#*KU6(!F;Y[U&PIXEI)<L-PM.?!GF
MEK4\9U0X#GRWKD]2/V:C5I:BL$>1S-,IX=\)0^V$"6P;>+2JG:T%S?L-KOC5
M;RES4W_X&R9Z4$^+[*PCO2+9U*<I?7_,R/;@WTGSG>O#'385:G^-C(57A]AB
M(5.M4R@<N%&'IM_:+$U-0R'N8N'M2%ZO@_[YDT"!\^!(V_>TAL2FAL\B34TS
MW]X5CR]4&FO\(#7P"&K]>?Y:SHD4J#=NNC+5\3P:%"'BK7[!+W@!%K]^Q_'F
M8HP?I5^%+DK^LE;__%'18Z79Q@$$Y/O%LB+)1X[JF&J+IY2W ;#X25$@_ZV>
M<$>C<S(\,AF(JU+4Y# 3//[VFO KHX2NPOXBW4=YJ99Y9F5'!@FNE"55B]*U
M. 6^+R6:E]37<W.U'NH)T4ZW^A\&*/A>3J*>5F^C1JY-+,$U *&?'B!@DSN]
MJCM0<"@0FSF$M4Q5M<2[>2R6/\E;\R8>*-8S5;1<1_;R\UG AN=6#O[_]JYO
MW-BX--:V,6Z8$GOKN]IZW)$$M&G/]\LA[I\YO70?Y1L-%DD=."?6GSPJB8/$
M*CE5VMULL"YP?"EG%9]B_,0BP<[V8[.1WWB?0MVUC''XOC9R;2/NEO65?X['
M0]O$)%,18<)"A9#BH4G66^XGDY,*]B?J[OVI?T@QH'"Q^"3DY9I,D63RNWS6
M:S;$/@4>&KSA0U3)JZVAH7/RJO<C$!5VJZ\W7-@YRN&.VD%?OW1,/AFS2KZ=
MY6)F.EY:&GYQ]P7,;@M)[]^WQ%4L39LKS/= )U[$*02RNIL'?BK1%NPJFI[U
M")-]T< YPZ0A^?_3TI=@SD:._?K6+?V?+[_/_NDSFSBL <!'T/]H_#?NM@68
M_5WK7[LL[JS6F<3/^= 17O(VZ#"G^/OQ\7K&^S>VARE[6@2,F_!<'<7XQ]T9
M?N=O<M\!<UOQ.^8<LFB<-Y)J>M'0:2ISH\W%\DZ?4M;[WJ8PN+=ZJ<U*:^:;
MKY.=<L%/LXR4%U=51&%2Z[B F?(;2Q))[^ROWG>;6)E.>F:J^ #RX?,?9;JL
M6YIXLF@DF?S$Z)WDBI',$Z/_)6%LU=J7!.8^]S X4?[R_;NP5#D=J,[INEDB
M47XX5>*(975UL*=.S=CW2A<C!T3,[\OAW,=<MFO_I\7Z?UJL_Z?%^O]%BU5A
MHW3K93/W1SH<@))A40*Z,W71RL&;.?N"AKXNY@\>JQ$YA7NU8%;JQ;%>:>SI
MQ.97G[/'5_;1UP,6N!09E@OA7IF/UQ$F):G1BQV4C\C6B&/#=)6RT4E 1TD3
MRS5?MR%=ZIWFHO[>U\]VW'+ 3PE[S"G>ZU5MCEO&^?<FDFK[$D?-5T+ZC9,\
M8BBP/\I_G%)+A66-D*_\7^R]9U236[<VG&U#!46Z%(F*"%(51#K9BH+ AD@-
M/2(" M)$)&A(MM*[BH B$!$1J0&I(A A%.G2!6E)I+>$&DC[;L!S'I]RWO%]
M_]XQOO-#!P-RKZQ[S3FO.==<:UZS.Q$6A]5125:1J7OO5%M82YPE3 G656MH
MG>K)55,,SC Y[_WB]FLH;6/:)[RY,$TX4-+']EK20/M'#N4#/\U7JK#LX6F<
M/"\G+GY$'YMU/BYTO-(WR_2(#5](C#7O7%VF:G=*W_4..2D#0KXT\]"%[!-7
MOLWAA/+0'Y\CTK8T)6KC6: [T+L?T]-&^]T[CP4F]P>DKW!+?WI3%3MD\KPZ
MIEOZRI@U\]N80(T0ZBNXF$SU(!CJ],OSX<>;R$GX3O;,-H'D(8, 5\UPBG/Q
M'I!C26FR0;[S^M;D\9-]?M?<U7TF1[@$"#(L4 ET8:^,APCFA-:%9F'R- O$
M@W2;QA<(VMA(X4]Z7Q:!/76S#F'F^OM]F$TJ?YB8'B -]4>C?94F)GH7=38+
M/ M$]:82<)%Z=JF?X^$&IK6>:B29L3/UB%RB*#A\62-,&*J _ZEJI!?:*NGH
M8S9\O]$\ WH$[**2I9^7J<UE19BUR C+#O;+NK'YEW*W(A[,J8(.)]<<0!A&
M$8Z*$Z-KWAM'$:-I$1=>]4O(U9I'517R^O 5Q:]_>VT^7:>2<E;PUHP#1:52
M92(LZRKC*+ ?NXT$7BIX@%0]%;MTDWL&?+A$5>FJLRJ<JE>EDV2M]9CWV;,5
M*<NL<+_C8V(MGWL\+/=<E^:D\RX1_>EGX:(+55PNJO'Z5!L"S4Z<=%BCB @Y
MUG3T<WZ[R"OUIN^WR4R,U'@ 3.WVS$80;'II_L1XH/PX>CZ;,T[#^,Q#1T39
M@ 452S28BSAM5D3NM48M<$6W=366Y1)BU([<D8GE,)T=N+X(^@.Y!:5*0><[
MYKL-R#3B<.R\U0A=8ISM@7.S3-O8,;U;T#//]33=5UPI&.Y)I@9%5]A[X(])
MU$DGNF!(=NTK<XT#6FE[8NWLY>X7(?HBLX,:ZTJ*E'!E)/U4*>\:86$CWQS2
M\4?PP0_4@-I-MJZ@)T@5$B?/LM?A%?@QRJK&M4ZIR5=VMIU<KPFW/Q#/J[K7
MFK0I;+WT"P(L//<>UJ3:=9FDL%5"N*SO=P)\A<R60(,S:Y_>4?Z8OQ11"MXS
MC+ @/FI^;D6B!HVK\LL*F%4_Y\[G34[,>G=GZ^?<LKKE;,@94Y$V+'VTG:._
MQ\#+A[?0]K+,T\Y]726FVA>-3"PS(^JJ[C7.-I_QS/DZ:_[WR4@F!N>"_J$[
M/K; 2<PW_<+<TX5T(HRX&W9)4$Z54XRBWK@^J R)*9V(Q2#Z%:;M3P^8&'QV
M]9I/MO1,[->3'6[]XY7LH@:F'O=CBO GU9RF1VV_NQ!2$T3"@^L-.21?-+*%
M3W[R> "Z/1Q^DW*MK'3"YLJD^J-S,@G<QX=43&=0L9N3CL]\-L)%]J;^/-[!
M'3!Y&BO\TU8]-E?H8ZMC>%YZ5*TQ5NC^J<CH0O-"T;I,M8M+NM+83CX5/=V)
MFH1AY1<4^1 F/R(=CX3^3<K$(ZQ%17R4^29*7'14J\@5:->_VRX<=^VO-ZO5
M%PSAZ)SCS1G(O:OC%V8V.=/!G31?@P%<.RF)V;9DP0+U70Z M\6@#8?0](Q8
M.$VQVH8%,M\_@5906H5<&R-2/[- +GL%6*#,6YVI6[=9H+U?,#2EEV"&&.B_
MZJ=7PX ->#4+%&^]766ST0C>XD^%MY-V$\S=8#KW!M/0K9/9-'8</6WM]X A
M#_G9T\4"?<1*L$"]MM]6F$_0RT@?R/I5E[&MU\_!3] \&A L(I?45-_)276\
MVD?7Q;JA>:H"C[Y^>T?-8[$H=Y9'(GSMU:BTK#(TE+B\>#7TG//M)X*"MV+U
M#AZ,OHHAMX-+_!G"+%#C&%U)2YT%FCCB?X%N7$F5IEE3,X@QB<^\L'8("'&@
M7IU:$I7[2>9FC;(0+KQD,M*@(KWB.2C[8;=TG@+RZYOL?0,C64SV_<2.L;UT
M=2IUP 1"PT8RV+0ZJZQ;/I!'CH+&;3&1]RI3E!/-&TB^(K1#+_K27ZK="R87
MIH<W$"9,4KR_X?O-S41L<UI$VFL;4/YX$:7Q6+](8IMN1(W8U+!P2C=QF!C+
M)M]2X2Z<>J-^(O*=!(?37T8">R-#I+H;H *7O[T@B1\^EMWJFB7?C!-"JE)#
MR,L&[&@PE:?1_@#&5.]]STU*6,@:CJ/] _[NUR2%[TWYEH.:PP^6+NJI_\B+
MXC$0^FI6&83?C;G7V1;<:59NN%+[[/%J4S.R,V:<-#YWQ+[N^%VEJ%1;^!%[
M8@M1S^DYL;&^SN&29'AXW.='BN>_\*V!YZ5I>PPI%UW!@DPE2SU'<O^YT[U5
MTN.T[Z/L&-$FSJ5;?6LW%X0'$><K,W[HX#LI&OK+V,'5LT^F+#<H3#$6*%L+
M[$#]W"!R5B"TV%-_E:)Z%!Z5\:H7^S+0D4?DJ$V"6:;UNPL5*?;\"4++/KGS
MA2U^.42W;^EA^2:8H 2J*0O$Q58_#-V'4(]I]/&\GNN00T#$7_PRT'+.8;DS
MAR#^<G*P7:KWG%DK^:6,AQOU3K;Q.C7[2HB,N(B.!,^5A.N0\11 ,Q.+2&-\
M5#1IK%Y3P9TSK(:WUZ%?@R]K).(DIA%UMGN1WT[=U%(_#,TQ[4_._V'4]G1V
M*#6/7[+\ 9?;LQ< R*<S>X; ]4O<=W#[D>P?K.9$CU,?Y4#S$%G6Q4]MK6=%
M58_9S1C/)"KF;)K\H+I#/^'*/WTN3[3T+)6U6!PX?#_]##."YL$"U5Z>%X;V
MUAQ M6^LKR>+\#?]25&NE]T7&/G=ZD?8QPIRT]\UG2)<E]_G7<A_QQ3[6,_S
MPZN<O$D3NY9C0"W\=7X])2KB[<7GLR'D0'>C2!^224-H:/X%":/SR;G(Q,EC
M#T>J)KH*/0O&E4B;8$U\0JS-YEJJH?GFF2&AX#]"TK>F(FW]:].$$>AH,F<=
M\K[B=\>BBQ2MLSYT,UY$F")>_T7FBY_+65+/K)P.5[B93:@IY1#2P]Z37[@[
M2D2V%;T,=U^39QXZQ ))G".A::=&Q0$[WB!DHJQALW Z-P_3R+21!5K7KC(
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M*1*P03!1L6]T[:P9(9]>SSRQ7G19J>.#45&*++UL7>U!G,^]>UIRZ%HY.IH
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M&"X$*HA_*86$FO+(2=>241")QG$J.H(RJ(A'/+:W]#P44( .:G;_B52WB;S
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MM_ASXL%8[LZ2[9/_1RV86><_?MZ]W_5A)T']3Z<D U=W1'CR?X2+#]N9ZWT
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ML-R8_T4B(&XXY)EUK$9][^'PJIL74F+=61>V[C?"DM",RU ,NA:Q8O47RAR
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MLI-\*?'PB-XPHGK Y]F7C;YY*_#K+<&M? Z8_!3-_:3'O/"(ZR,T9&-I."$
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MTRT\$ )(!%WN>4/OTR_2U\4\/Y$1)8 R2:F;#&O."S1_H-B(5V0_0X0#MN6
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MZ?U #AQCD/F[L'P)3X823_ZWL0-EU,(1$Q_$H_<\HNGY(NLX0Q@@/>]1FKR
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M*DN;UX! KG::%5!(4-0]_&-N'#=P4,@&&-5_"58"?A\A3TU=:!,:/BM+-VM
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M:+O6:61@#8 G="Z6DU>;252;@IY.C\F6&)!ETWA"[K.=,1G5Y)"\S-I/QE5
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M!)2FEJS"*D"(\I_:>3+BZA%=W1>-YBJG[]W;Z<,MO@B<8;P"/9W9=#R0_^2
M3NY1IPM-=_.1GUE^"QN&7>RK!<R)G?QPN9*[JFK[;;'A1TSL;WQL;6\U"DBH
M&*=JR*>IL7@WM713(!U5)"1; H4?#$I9D>,D! >(3NSWLKBIITJ4#80?MLC[
M&[]YEZOPX.7:@0/D&>Y%0KZV_*(^=?+;&EB2J+(-7S#0Q33M+VCKC<U]G&Q$
M#E:8&L^^L*S:5+KE6G):,!<2H0-?ST.]JY-ERY)Z%A-,9=GC/ZPY'CSW$=,
M]F3/!=\29>J'0N2^QUB2YQ1=FJQ]:I>W[-*8NT<M8L:%^J&XZJU#F7[@Y8F
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M9.J3(=,9JL\_/;75*?.N"IPLTWCU_*5U[2$V+O&F:^TOZO#3E&O1R+UL/#C
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M34RR\.JBRWVVDCX3?<PCGBQTM*.]_O*0ET\T(DL?64B?L.]D\*%*0A,@_F5
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MG]VV#=KG1-];WN%EZ4QE0F4Z?0-]7TQFJQ8JRRK:E$DF_R2V$R0(CF#?O4&
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M7,O,]>EV)O8>]#>TD>TYMFYZD]C3 7Q%;NGP5W$EF]&US=@8LB)YJ%?KX?M
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MICS0\-?)?TI=-0#T.5^-R,_OL/&;/S?=$!5%OPJ-4RP/_ J0804PD:N.W&L
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MGQ%1VR!:;7']MY4 EO<HK;F6E<G(R*0-)N7 &G2[8N&6@!J=>,_[\'!5Q\E
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MNDW6A 'G=5;]$[BA/#^U^0?IUI\_WRWJQ[K:3\K/Z-XW/SB^+?[XN?+H_H.
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MW:SYWO-9^'.MG*V0_J^U?CXQ-(3X5T3")*(!1PE!D+&_"G10),;.[.HP<()
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MYV@TT/^Y_#_<&9QA_@Y:AQ\NO>=WA\BO_D&1;C?H@/ R-&'K'*QT;I\6:*>
M'RY"6_I6$,\HW$0G^:V/@$IT6? [1T_-%:I?V94RKZ&RK<A[N34PL3'9GXA8
M,G1%@\8*!%(- 06:$6,8S*.C 0CK2.PD&S7X,P_F>F=HPG)VM$W"?%P+?]A
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M<&+H6ELV;W>EG1,@_5Z$K<(0&ZB2FLO6\K4T(TO-19#BDBM>%N >R+:Z\+0
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M0N!K*FYNEOOKM)-7)4QQ:B6U[M(7)P-1ET[EX <?_W2<EP=C=?+:IRT[@.(
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MH@9):;<V)$?+\R(C79,*!6!Q?V^/DG^%E!@DJY'38M9]5>TS;/H:;,'X]*3
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MDM]ER1\AS#KB=+41Y%S<;*U$>XL!D2-"1D<">$K%D,UB?H%1O*W2G_S@865
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M/[]"]$*8&1?W5MYUG5-T-TKA:B)-'7YJ6 ?\'<FLPA$[<PQH)'4 2,IY>39
MMU,3$UNS R74%KP^W=VUV'E*<%5<HG[T5RP64F)7W2>/?^M#AT^,@^N@J[$4
M-2H): -WX>(%>)]H7R868<7>P!0>[H)0H1XQRFB.;/DKC6-R*XNJK6(42'P0
M%_)"1FW/=(^*^;WO?Y\H<W5_EO];:.O[:L<0:4:DOP&24!G"8^_(^RMZ $C6
MMF/-%'QU2Z%5X:XV1R)^GD^H6B'7)4GZI-Z=+V^+W4A2=@ERHBQ/BJ%30R6.
M+-"I7KAY#YAMX97,QKF\5R3)(3).OJ=JK91$!GSUP4_N8W6OEFMQQ;>/%EHD
M>B>#(RWQ*IK6Q38=5]'5Q<Q!Q8RO=.V=BEW0W<%)">KF7I_EU2YV8ECA9\E,
MJ\FT2\#3.?]V9!SN3/EM,B8BJ3*/KD+&M#O*.CHVCQ56^HD,.L=U;75.6FDV
M_WC>FV__T17FJU*\^O!' -)M;5(3RH'H@I[:!;FNH="U@RO=-&W&T"QHS^)@
M>'P0['LV18=$F(B%>."2(!P.-+OA31R@WWJ6;D"&Q-$OG,>.KZVI8-B N)%K
MC*]C-2P<K'490]\S)F)X31D^11A;\"^S.;JIW?H-G> D>SE>#H)O%;Q:HT>1
M7;1M+M"?6?%8>XB<:V+[PJN3A,!2<1\\"TU"NR< "'$M,0I2^,R<CE 8*39.
M9B/IAQCP[^3:RN.UP[VQMRH!++N68D\)\;Z31WKI&C@:/]Y&='.4+XO86VI3
M#^CW!-Z5'.-SI9SJ^&21L L*P?GY3^K5L/E33P\A+B F6WEV,' W,HKHE]PY
M&)_A_WX7=)PN5 $(DZ>_ -U71UU'$"(P# &%QQT;)/9#+8=7:OEJ+V(VV:Y"
M:KUF)]?ROTLX5]5 C.$6P#Q9C1JZ-R)80(G!S%F(^+0+ K7*(09W08)!,/KE
MDA][!A3KYTY"QR%9?X7M@IYD2."G=D&<L,7WDT&E&9@HWU]KG%?8"YZ_W\KH
M9#SQ+_9R,XZWSC%1Q;W2E*Z"Z#'X[>]!7^Z"[A$O 2?)D-A6<( .AQ3A)^^'
M2QI;'$!^!F%CFJC.6B_:LTYOCJX,<?&+Q-M\I&@\XBDEH?)7JL5>$:6LNZS:
M %QFN#]7$F,@WY9+Y!Q!1*)'FA1X@Z38X=Z(9KJUY/Z9-Z;S+E^?J;1J;D*;
M39F9L &W@T*0E 8!46)T*1>\S-4)K@%W0%!JX!JS#G\PLLT!XEYF.?>>7)A4
M *C-#7YYNA>+5*'C<9YFPL;E3EJ 61OB++D&?73J)GG;I+"7)QEC%EAV8\C;
MC"<_&/-C,BB140)>#];CWG+AA&FDP(P-M.V$;!P3.CUZQ?/CRE+(_B?(=\%+
MO]G96WF/K59@95-NB25WC>?(\\=WD0*%]"5[.6,SVLS?WWR0!\DB(32[ DK7
MUTK-.V_FI84C'KHF#%9CMS&U?24C93'?RK+< J394)&>-_-0>(*7N7F^D3RG
M)9>YU+.+;^)V_@;^>A-W$?3_]86Q!*S)& < 719O_!<U5"RS:W*\9N@%]]L+
M/VF76_6_;)X<Y3RJ(?7X]\AJ[%^/Z#* ?1G<='R\I^]R3K+G]^V!JJ'4Z('3
M@=_P63(3(T7G3UQI3Y[IC9E@V]G? ;5P<]DC=-],,VS+R)JV))FK/3B>I[)4
MO\R_&)BU?)+RLT:6^<?(PRVE.DC])EW;P<F,&A:^_13/"O[FL2JP\V871)$?
MV@7%_#%WY#W%8Q@97R&E%I>;])$N\C%@U"J-.^#:W7<$=W0OBXUZ*_A#P+-L
M >5\@\N#GF9RJ?8I%-YM]U_"VZ?FL/;MXY2M[LF&<JYM57*TY(#3SSH.-8JC
M1KMU0#++_?;(XMOS+WNY30A*";/'+HYCK*T_5H6.4BK[JF50ZQ(,?G\"E$[S
M@0)JZ%U0[!M<(QAPA7SA8,1(/(&0>6B[H!=%&+(;X[S\*O\NZ.TP!;P7 O(*
M_$:.0C8W/+:;&16(0?EM7<2^;B?ODUW0[SFD.N9_GQ^&KCW;!?$?_;^"H/H"
M@^K/D*P:H2F"/,\J:#^/LWX#$ZX&B 2F'6NZ*"&H/YQIA9ULBZJY<+DWZ=+;
M[,IB!OTMM\AC)20[Q[OS,MY%<44QN>9G7*VM;DD]^?2'BXM/$O7^=ID$[6-G
MF+TLX7@KF&+B/RE/^XAY1Z!73UG9+5%VQE133N!^A]A(R4^&M&=.Y17A&D;
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M7UTVQ_GPR<I#31M:FG@T*^H::3(B@A0,M8^LWT*)IX93@M^O16S+XS$@1+]
M,FH-+O@&JE>(B87?>N@SR_KUXR[H9$&Q._>R0AB4U<[+QL(D'+.4&K7)YK>9
MF:AKZ5FFC62!JY*2P / 92+,3!,?P''273O(0+L__PDA(5EL@!)28/GJ)MZ
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M.#$_MMOX5!7C(G':U%V#*+:39[SU=_=(<GZ7B"@YRK=9-1*V)=I7^8SB\QA
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M?:(MFW'GRYK(HLH#H3648M9Z&JLY_E:U4WRTNAE;?)\B5M7-F#?^_7T<V^V
MT8K3^:B.6^0&;'N=.)I:6OSI6YY*!+6$8B;0D";;OVYZK$?2(UWMU$*Z[+T+
M)3%=[NF+IP-,15F>]%'X@YQ4N80[L'K1;=;=^@7GH^6YH]Y;Y)J[!V2[:U;
M!N\B.I%MEK*H*,9>+[3I,,!>U<Z[(%<8<BZ\;^A"%2BM7A</97VXV=*<="&)
MW[_=P4S:N-[7I,@IWG-U."35K+36SY_J]0DREXJL<EY<-=];;#$NJD"X'"[7
MT7/;%N]3XF/R:+;++!]ND68V*O>MB6(6Z>8G+GL:?&K*]*E%=O_\UZ<L_-8.
M8?Y)$*_B5:0G$A ?7,%0\JYL8%307YHV&<?H>M5Q"_R9URK11D,/A;5LQJRS
M#.-'")@_33QO\E>3+@Y;OS2X\ E =\U.,1$*.]"?I><X5NISOR,T:X GY)(N
M 8D8;=U2[\F[3YB>8F1^?64AJJ9K.ZCF>A!]=NX1?_S4AA9@#<,)JYKBT2P+
M(7FP,E(C'7UQ+FLQ3EVTW847C]<N3)Q#BL"FV+KMHW43<FPS[SPO3*>T2I7[
M5@*ASS"1L":- >N$_-@\25,K):G3!?-&;^_N@JS[8=V2A')%BD&LSZ!8\5.2
M_%%U-<XV.]8U)M9>J0$W[>:GET:KZA]C3#YURL@ZY2FUC^''$MR8?P=YCMXL
M,;WI!%YE(2(_AW5L<T0^7/M,(GATXYC@ECJJ(P)A@P(S>"1/[MO+J7G'6C-?
M._Z GL*Z(69$,SLL/2U^$*=,(VSL/*[?B^P7X@J?Q2"F9ZOKN\J4\#E']N9[
M,J)'1VI$Y_SWIGO9A5<H+/A)T_Q<G\H?+ZZOLWG[")89M.NH?E)N+._8JM?4
M3T<2LZ6V"1@YV8>S:-IE)#L=@O&>X9FH,>/ZSHLI6&X5&OOU-4QO]/9U]^=X
MFV'Y<Z/*4Y])#4F>%\(<>V$>UW(D71\ER#QKXK&DR9/,INJIG#M%I5A)(G)R
M%T3U!E(@G?U'KL9?P5$DVB\[#,LJ6=9%$ I/B"QVSYQLU82GG?[J\L6K"2LP
MUA7A7U[JNQG?\"WU)W($:SC'F]8=4;$6#3<BK31+E*#'\[KH6MU\/3G2Y&B/
M5S(7BG9!'L2 +P76E@H? _G,87!K29+"F0JTS9O%"/1/IUV0#GDK2:=%3KZ\
M(1X_<*)[H69=4P6F%J.N=A+,"BN1>V_,)8!SP=]:GQ[@8YV5S[:&<MCP&7$'
M&'/:Z_*#9R]2(#6%*TIDIC8D*T,0,0&NQG5D0[O1U86QVN&$KVJ=H69Q1-F0
MUYX9Z%BYFEY:9O@5&65A#QK$&%?MSS+K&9H3+Q$KL_A<JSA(:\7L0O@$G=>
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M]5_=X9@Q2$#*]Y^"_!]*_!VD>M7W+U?,#P#)8@?J0M8'R.ZT0V3W8:(U+O^
M#*;GV!VTA%.ZOH.A0#XE_;<,E<5_X<PE 0?M8CYHEQFF=Y//2OY 7<KD/^."
MW0=NJ^U3@O6"_T_HZ@,";->5?]55GS[(6I?_JSD'$D>B[ON@:17&#SKD59&W
MQR'FO#S&=P=Y3;'E?V@BV1SQ_C?$_1^R3_S_Q6$;_Q>>548@8] +!YU[YXRY
MWLV(N(NO__R_]6K1(@2WK_H3[]75J4I1FTQ*\I8%\+F7[-M-X455JOUABM^N
MG-#VZ$_C3$['L>KP^2"Y5#I&5CA7:YH]$C<3G3^]DO'[^/&:Q'SJNO71*R<D
MT#.&,=V0X30Z5PGCY)A:5WJIO+^O/%R6#&ZO?Y<Q4Q<WOEV8%.3X2+_I4XUT
M@?.(TXWW;,'.?Q"&79'5CFNC+A=S=T%B.$_<ZIGDH87G9/![9!'%?QB9<$DU
MUT@J24V"_$*L:ZB)^%,Z(>6&&K49/VI7^O1\9Y?5;V&918T\F=HY13IM1W+[
M5/@)<HX<81E8([7XVI[8$81I\0ZZU'QU$O<GI@9$EGB2T<Q%3;#B.:G;9\F-
M77Y/O4L+5Q5+WY4J] HG?]QS:(ZN[-G;1X.4<C\=*K5]HQWW!UP25KFL.>J]
M_P-4KO.[+%_]5)ZM9A*H=,MGDLS!D\*UDS.+>$WN9-IT)R!9@+ V%Y$AN@3A
ML@@>SQ D[T0*W$W,\_I;MC8)[>;;?#OB1!HEQ/W!AIG21^UU0^7GU[NCZ/*$
MM6.P, ,R.O)7& <'X(^GGO+*4$TL^*MN7#,\L6HU[L1Y:.=\2F^_]N"%C8\7
MA@U%_6T!A?=T#AV!''^TQY=6K7CL%>+*(U%-$D)MP&>\:U'[2A:IQ(PWH<26
M/R[[AC$>:^V0(BJ0(FRT>8'"AY*J,@)_-XA'R!+I!IWS(::6*028 3[I5/MP
MCSK+XZHXJXIT XYO@)%Y.\$_JKTK1P#VF^ U4FB1K^F=*O+<[L;YJ!-J5F_B
MI'\=H9!^G_X_[&Z[(&^.WRC1_U 3GA_HQDG;[:\,+S"*,0/-N@[]ARZ!UC_.
MXYK.[9_>Y!XS\_.7G:9,O6_.3XDH6KELG^QNGGH[%&1RQ26=\%5TY51X05#G
MUYZD$PM\IOQNNZ!PP$O3+7*E8X,4$-!N'O@H,*W9B&/5N)FQ$ISVT5DUV5BZ
M=_$5T5H,-AQ5Z/*&=JFU9Q=TS_]KW$1IAK?,4.4(8<0OKPZ5Q3;\,4&Y*NMG
MX*SP,[.O-YG*'/\CA0857Y1*'/#KL=QZ.[/: MW\M*-XAF!T*M]4Z@SAA#YG
M7%6"E84A,G.LQ='7YU\"=KK6^S)FB?__6=W_"V=UEL[#RE["$><E@^^>E7H7
M8?\J!P0Z;?A=<FS!195RW-AS//E3<OWUPN*YL@K1"D+^MZ?M(@D<^1'M5EW$
M<U=STH*S5H-,,[R,_(=_B(V;R!7PT9VUN9E<0M>;K_(:#MR;KH0&/GCT*,X_
M/\FM4V!Y62UQOII%T.^C;^3?X&K3WA'XJ]^!/=VUH3\')2SK]^?Z:\S0]YN%
MT7FF41?7V[.L+)9H/<[S$L$28W6#@SZVQ;$I#ION_19O?[^E0MTOI%WOM-=[
M:'B^Y8RY\Z7]X3W4$?Q/SV@=6/U#UE#3P4C<W__,DT.2>-@^@\DKI4@^>5%^
M]-!\'E*$+/];?<+G@,54;2%U4%/#8OA@-=8?,*?DJQD2NZ"Z[ F4CC3].AGY
ME.X^Q\$*##H/8;DIQZ7ML!Z$,*TN9\$.X]L7:)*C,EG:9A?.Z__IV?&@PNYI
M\XFSZ_3)_TCRV1,J[+1EX=9P52XV%":Y3,A4LY;Y3+'U7O^B\J.CX,Y&]Q,H
M*KG1N;H< K59BP)GO"PLK'ZT2U=S)702/0E%1 6[N%_WK=Q1;19E+F4.=D9<
M&$M.33Z'P)>YJ#P9/>^Q>=/GD6(.90[E<D%B$BYQ%\LW3O/^EY4JY?$/ANK!
M'+8Z6!3"!U1,Y>U#OM&; ]-\"G+@?XW".+H92H SL5^B&\F!U2L"S+H$CK@8
MYL%0ABFNHP^_R/^BM4BMKKH_?&:^.+)6ONI<=UHTFYKB>VG^G](KJ:)LT5V$
MY3G*JU ^K(A<HI.J-$MLOFFK(%<TYJ0%!M5QLX1_N.QJK61/MH.UJ%209,_-
M+'=^92J>J,!W0X_5AJ?%5U6:S6'O,;'XL6PA?3"G?D"Q?@OSZ+S RQ*+8K[1
M?)NL/,W !(^3DA?&LJ&V8RH[CI830?U7-VS':\OTMVS'59SUB8[]NI9C*M+I
M_BIL5[=_/@KYB9&_MY"QL$3T"/'(L4W5][AM&G[&]LXYYIM1FO<3-1^2^"P+
M3Q1=/15A'GF.+Y^O2\%((<'"W/#"\VNF@47S%F_S-08"LQ8U-$P#7UB\S)=4
MG9=4G=XOB#/5+'W([2M>.B"W39@7I1SN59;_<<J<]IVQ/P\VJ]'3^VO5]+_%
M<,H.2&P]J(Y6Y O10Y_XS-+AKNIXZ'PV_WN+/12<;)*W_7U-JL7NW6:+#DY^
MU(>0MM/\^[ 82\E![8?2?]S7[OM5=ROW"6U&A\0^V4/QR>EA09S9V*D#ZIZP
MX8%A"ZK1X=Z@?\X]H-8=6K2H Z>O^.T_WI01]K>R ]?]W+O-VR7CS_8WT*)]
M#YS[T#\//<24-)8R>-?I0T?^X79>/MCJ"@Z7W+Z'JKM_N<;]3PB+T\%,O0^D
M#:[?.9##+'IG>UAR&KNO@JF</+D+XMHY<=B^V(-))W/@WQ\^56"_86</&O9R
MFXXSC_H?#JKC?K22=[ F;/]!ZBO\1Y5NFZ']7W2'^R>DVF.%1H),HDG!3W3^
MH.N,TA7R #R1>[S:Y\V2BV++V,-=$)O#QUS QX&B-^6=EB$>3Q2V.//"[--/
M0KUJALKRY6^IE)Z*]^O3NH2Q;8\]O^O!+NCE"T0?A,H/H'9![\*(PG#;./B5
M5^2T:!W1 !LSJ4O]#1Z/ 5R,8B-14NK7N5??IB&O%M0E;7/%\QP2 M2]3?/%
MAXN/751]T?B+SI5"4!I0(@B] //W'LD*T+F20G(SNI=MZ*K$.G$RLJ,K^UIF
MH9I^S:CXB_LI;U.&>AB#2/*-Y$DF:B:03].C@X$ HGS4)1B.ZC$>=)FIRZTC
MYRS%-+, ]L)R1%N/"&6I$3F)K2:;%HL19[QS^%IH0JVB=60LTJ.Q,O5'F?U/
MM]K?@W-F*XT4+=+B*O@UHE=3X/L,,U!<#J Z<[@SIH@R30.Q!;!@*-DFF<@&
M[1#PB!4T'-*^4OICZY$;WB$UZY/NFQFCC#>=_II7.#-@R+!=T.TU7E@R81?4
M"0;D4<EPX7?]N;#F-A'>G5RL,\'YWJ16R#UE)"?@WP$!UV9S6-?'_12,M[\[
MLJDE[=B0UQ@1%OR<VSXW5?'#K"ZBUX67S+LZ0C-F?$22+9%/506"4:UG :@3
MA0./FX(2LC/P][;E$^X 5TAL1_#(TP^GPA?"6I0<<S:,1Q"3(C]J904VKJ6Z
M^I0 ;EU&Z ]">K\R*$>>4EQDB4JE.M:,8G>A8\]U(]6?IS*OH;1O]F//M05T
MF:51Q(5=<D3%B'02-U2^)T#QI6O4P*7/0JDMJ8&11;C7#Y*9 .CEW/>CZ]L-
MLZM8)->"Q6!5+!'YS:_MLXAF&?[5BJFY+2G_U1T[9F6*W9*DALU[FXX%Y9_K
MVQ3D$_2?NZ"Y##1?JPYLA)I+=GE&49L#/^:EZH___.4?C[@$%),@9P#;]Y^Z
M"WT02I\VV8*-*,<P3U2>@5&E8F2YZO"08B!C F_L4V#H'J1]?3"8#1U(0@,7
M#%9%7],E)QB*=#D 15-CC+8RD\OR!_*(DKB['/&GZ::CROV*G?Z9%CB>8!%^
M\OJ25T&BSN+JHU"9[9R25]]XMN$+DQM[ 47N;'4A'89LZT13F0#\+JB8:54-
MRH=L.[$+(NQYKG@\_(]=T E;:AK]/)H<2=^+]Z/:J/[R-'G&*0Y -\AL96UU
M5HGA#"'<0;8?HX(EMG9!>TO]"PWWJ?4KU# =5DV<5AP4@$W)$6?XWL\CV._
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M.K'XJ-:/]I?E;ZGDV^V-P]B1/^6J_HM=P'+E$IM5>%V8_<W'4-(#: 64$##
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M^)BHN;_G6!UR5*YHA03*4[O_=A'X;Q>!_[==!( 5X<L!F)Q>IF@3>%U=\3B
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M8OSO)=?(KYZY?N/6C1NW&&ENTS#^?[;+[P!ZRNNR%._(K_$"R.BOD=-?N^P
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MHW<<&)T2>^^9M^:0!'>WKWB)"F<H2?[;)6#I\)]UC;J9R&C!MC$DL)$'V!&
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M+MDY6<D49[)QJ+1KZ:*BI4[=AZ@>UVNS5+32^A7/98VFK_A^/>)0+.@Z/-P
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MVR)#?/=S4_BO"&3Q&5R&J(8/6P5^>/ZN3IU_#"%?]OOEO_68/R(BDB_>2SY
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M-#?SM]61HI.;?NBL+73O74CYD78^\3$F><:RUN"J12TMH[K5RX#?JD?,+)/
M1Z"CF9XV074.K'-M 9>T_]YLA2)P]6C=:63'YF\\0U*.[81:#EPQPV&$H6HC
M1R_CW[W7S*#G<Z8I5^C++?=V9?Z>+E? $L2:L)&-KS(#S4U"N,Q_51IO KA2
MWNYR< +\^\$+Y;=-TG5?=Y_<_?O#4H(-8>&$KQX)!V&0O63I:OU<V:Z@?ZC?
M]]*:Z I\=\O7+ZI_:A/#&ZT9,:!:ITM7!O?"''E#4BZ51$]]H0=$>.PCXN%
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MLS[[;L_L)C6S[/LLV(L">#;)YWW=6D,U<4WR>WZJD00S5&^ZOF9*;NY%4\#
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MW,0@R5S:^_T(F_\=VO*=L(ZFR4V)JDX\#S$2B3"UZ 1BGB@L$$PMH7_%_E$
M#SG41 .>EJ%?GXFWF&C/@S'/5N"SVM;4/'J?24[FQ&,%7LP<NO3!HIJ,T!<P
MNX<=J 7T =S>5\ZD!G?YTM?>CC?\4S'WU$";FE1W#8GRD+-L53,* "J%Q ^;
MIH4)S$8J) MEWM2N&!F$B+)"?L(Q!@%S!(GM G(^-_)<::8'6;>U#UN!S<;J
M8])'8D\BK$TB7GI\WN3+?OR(;OJ>PK[F7LN6\C8(+8,7ZQC9+\NG /X^.J4
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M<5+Z5$Z;(2:DOV(><A,&+XXO%/"H7&JF  #$1NIDX?@H(#/Y+YSIP.5%E4&
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M(3B7K@M4Q*F7DA-U%V)%E*36@W<PM)TL5S43<,BAO^HJZ6S]0>[D)]=8<^G
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M%S-%0'O75*<^G4_>8ZO=06,J_]_##\4[FXVHY#.;C.>T&_Y">JDV<M>M:K'
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M*](K<BQVGY^^J[ ?G3.)45K.^#]$O7546\_W!9JZ(:6XM\6*%@LNI10HKB%
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MD/?\+G]%.-,K_7<02ZIUVJ\#<\?L*!O]A'WA?9K*'ZQ%(VDW5A\+9)7(W#9
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M]M$EM&$SIO?!T]?_5>#\] 3B)VBBV]1IAR9>"&>'!-K@[NZO)HC?M19C'4_
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M\+UG0EHWAN2'KS_6=;K@R3PCJB]U5//N;D,(TCY&Y)ZAYIGLVT?,X5Y*S=>
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MB^O5K\2X^1+T>3T[VNBJ(NMT\STC36O.W<OS9H!CLP,)T:<Q CTBH[<4-3\
M"DSO$/Z%--!L#L'\*<9?5Q#K"%083_2:6YGB_W[N=NHN>7ZF;QVKO#*"*6:U
M[[$GS7.=/^&,[(!)4GXS<52MCR+RRUE6^:%\>'J[*.#QW@#\)OQ; R)T%*6L
MEY+[C+ B\XSPP&]C]*5/VRD%'Q">:M9[?>OH,ZG4_*6O&XLNLE9]\C8%DW$W
M/0-ISORR(79W?KN84" _M"5<^YKV5(2*7\G>D?H(%&L73L%5I';CH^\KLS=X
ME/Q(<8(<.<6W*SAA5"0EF4(S5=#Q!GF0&DQAF?3HGCKG+$^823+ (C8&-MY
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MI)5M/MM'K$OUWZ^H!K; UP!Y:WC +LG_GH L56WIS/J"E](O[F"N <M WYP
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MGQ<%VR"%ICYK$UM"?@)"B\1_'Y& 5:A6</W0[?,=00"^7[7ZX1RKSV*+8K
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MUA@@2B*V@!.D'^OA#3'3",JN=46)J5M,8^-K]3>>)CG9VN!?G18\K$C*9XM
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MD_"^9!CV3\= $BWUB^@&1<:R^H<;?=YB1L,H<;TR9S^1/3.<^:LI$0B]2*7
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M&-2L(;'\H2*R)X_IC5YBC R=G)O.M1*,C,(+F+0[\WO&V('+R2)^-?FXUT'
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M8@ TL'NDB[;E9 NN\]U[8\A9=(10#E;ILUNE2U=N?AZW;W HQ  6OMX"?2:
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MW20WQ'#>M=MANZ95R (-UFM)*VJ1U,DSBLK+BGS1"@NAY1AWF7K\W%(Y^A5
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M1L/V;@..\-*?&VZ2.Y'#HNE2=DC)/37[Z&'HP'&GDF!RR'!/>,X4R!(DO&7
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MD4>F[NB:!<F_L8Z*U);$XY3V9<-1?:OGYIW58L<I>08URY3$I*PY\5_R?:[
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MA5BI:U53X+1Q>T<<\IT7R/YA*#.IK>3SH&,7%T7E[A)7#6-#&<O+C+XKYJI
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M $FBX-_.CAXIE6+D.T0Q'D)@TY%3%@<A( L/R:+]JO;7:A(/^C7[?7+GI5N
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M'*F!!R Y4(>-LFIR"0CZ-C%4TT*Y/UW_^KGDL-6F1:7M=]B*" J;WN$KHWR
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MN[K"MR[Q=?V>VPFA/G[#^6TZJ?22O9SKS<,>ZKG_65<OH)Z.\J J42YY^[1
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M%N$B7NR<IDFL;.H<9Z;4#KLS7YI#<W;#16=Q]DBR_5#6D;U*QA->R(6!(!^
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MMTHXWEAHO=\6<L1>NN?ZY_:]O-M0QSF.+50H.R^^C$*HMT9KG1<Y[^ FRQ-
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MG/V: A7KM*C*(CR _\<-+WB?3K,HNJVI0BL$1X\V>#_J9*-V?%]-;48V+XX
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M1;/HQ<X3U?"69&9"SV.<+,4KE[3G_^+JO8.:C)J^X:@@BB""1) J3830>T=
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M_+7>6;"/;A20Z\.FY/0Y&_:7/S7.,$B].?&6.?WJ)G1;Z/KWX,VB/\2/JBK
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MT^$3-K=5&4N1L-;YK0W\PF:'57#'(&$+TJJ^^Z$5ZC7DRXD;+W46E XW%YB
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MK:= #OZJEWJ!J#MQ<6D?^WL (44S:CY7@_G"YN87=H@X3SC"%O'>T)OF%/A
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MQ>H%JS*>GV]-T0UNGVWQ=&_,XXZY&ZG]7$G_1U7UOI]TEUCA;VL;]_"Q6 _
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MX3O+Y-#]I:*_FS^X0>UJTG6R\C0L1)!8?#T@L#_B"*I]>VXO-5YDI*2DS/R
MXRC6XTV?RR"+XLN!$Q@UQ!R3&D=);&G4T%B]_/.OI919B\5A7X/661^X"J.1
M(1PM16)O0.7C?;PK_%S9E=R2BR%9Y^+G[?[/#JF,Z@FJ8^JHT&<[#(JY%S#6
ME\;E%AP>4G< AJZ/I5KG5?7"FY[F).C/"U6/.2T@-_!,0@1&,+OLUY*,K0^0
M_-L:][%@%/JH3SG/7)XA7L>9F;?7&=O>V]]/!6<AK)O^I@C9://XFN[H9KN?
M1"MME20L:; N'&'[SZ#BTQ3E+.2-L,=7!\K)G)QIX1JJ'K ,R)/UB]B5%][#
M-.>W>J?]7=<'T-=COEY #].B5 9W J97%U<&:?0;1LV,_.QN,_CZ[[43CGXC
MNWNT[6[%*F>X+BBU!E+G>%[E= ON2?%A8L/N (_,"S$.'E.2O<W,2@GW_XZ(
M4!ZH8TO6*$=_MBB]38X;(7<?@)'E='A2$)D9YNYL(45[34&:3[/$3?=T>1I;
M[#<LN<S-I)#-6%O8$]'4+TL4$[,3Y^GP;)[)3U,[(&"CX] <7BR/1L"XRJ6<
M3'7CQ(Y7T7K#J^PSE/\CC)6'QV5\TD=O#A]] 785LMI3VX>^*2?%LX4PEFH>
M*4$O1OHG#@\1" S7Q1OQ=58")D'D%ZSVX<K:T&16_MF1>=D&-[D<#)MBI'>1
MNV,O]<U2$+;NQSYK1$+>@_<1D:QAG A)9YKJGBD)[)+9T-M,:-[_A*7#KT\@
M\X'ZTD?CP#<%ZU&J3PF[FG4M$S3O .8MB>95="_A"$HK#J%0>JC]7IF+G_-Y
MVE<]__WKJYGUUMR,(KKF; 5+V5C&]WWC=ON1;<RS;=V$[Z#?(O&_4(7%;H6]
M4E)$&DOQG!AE9LXF@A/%^ WFM".UE'#]%.%)I:*>8F4Y$3H]&BQ,F')BBXT0
M^&15VEP<U/NPI+AI)WVKEMCH\K*L0(;.M)+LT%UL)RJ_R8:30;#/@:HH+2=#
M,-FS1%@"83K;FP%U2(Z&'P[/4E!';)?RVPJ:H*B;IX,;?V>Y?)C9RWE\!]BD
M^-^I!J"1P67S#'3>K8S!?ZMZ$F@MOIUS![<?ZT%>_I\<QW]GQOZ_20X7K.H=
M@$6G,^><JNI_2GJHK[_> ?Y_-3WA8_YOZ"B4597-BD9#R+7>TLU?2]\B;H5O
MLA$FDHQ*@F8/;4^8I]P!HV2-^Y@?,@J2F,Y#8K\'=P 2?<0??O1YM_3Y\X!;
M88O'6N_7*9HX-53?C3>WK^\OC-\\7Z3'O6R_ U#GW=*5E?\[@$3E': SXPZ
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M*UY$:2:)ZZ]+D$S5V FRQK5=1J3F2=:\OMAF!,AZA-9(@R5[S)?,SX9YK=R
MB?)E4G/YQ;>-=":E35%MJJKD=MYN/UIA?0UBI2B:\JT/0]-9.]9V:<:0['=^
M TH<%1,E[69EI\]VAR@IR^6%>"I2)V?V[?^.OSY]DI9T6+2HW: X#7808=6<
MY>$Q:N2&L=EVX#RWBTV9"NU9H4XU;C:R5:#B;SJF<;.X39/IO*V M[]$",_R
M-DG@Q;L52 #PWYG!O]S1]9<901G<K"A]H'07%&-O^]<DMQ/LL^T\TQC@>"I+
M_RHNQ:_=@:_*Z_>,T4T]-R]1>,O8J=O<GW'M M6T5E/!IS!TE20B2-!AKE)?
MI%=$N5NZPJ#?@N)(RAWD4/0GKO&-S D)[9^U$,@!\(D7O3_/VE \.:YC+:[4
M)^&OQ?;S>7'6=+/2O: _H<^L80=I?,N_GDPMLN'<<A['WTDKM#HNVF=XW-8\
MTSYAF;H2>[ZI@>_+V&KP#DV/&/_:22G0B[NX&FOGST[V%/R<+8R"^)%(',-I
M%F8;:=<2C+A]<%ZI,7^T_M=H64 VG5!I(D3>$U9ZR&X3(!:#[IGT3)$.[<DG
MY3DXMHW533I(:[KZ.PZ;W-[?-\\(1:?T+,J#@IE(#FD;&1,*">E/AJKCVG&K
M')E8IA["$[?&&,:H,S^+?L9YN-XE?.;;RR.>H?[EHUF)1N;&4=_%F"EB^&"P
M!RE3B\=>+P73[&QK2IN?G?NHRO@G/'6EF1'8,^50P>;6,$UK*S!X.M01+5U_
M:&$:I(EBX$%0Y6V]X=4MB-$44% :E/D[YFY.B@D%/6TG:P>Y2\U_'/^Y]@F
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MZU9-28K]?XS""#(::LGK@X5=41*O$(Y(WMU"9+$P)WRI]XX ]I,/.RZ1<?<
M>B?T+^&$^=CCWGUZJGH/P+'^3S8J=,ZI_BX$V'(/2.ZZ<'EY%4H1) 9A@2_)
MW1&L_DR\RA'FP^(E8AT4L>0C[YA/1?<L,$^8,;![@%'=Q!7F;OON_;_P_]B5
M@5;L(W28O<#\<Q"P SP3W0/^SZX+L7)-<OMT(?%_[N\!_]<9\[Q?]296"W4H
M;^$9VMOAQ7Q-#V'^GZOX?WOZ=++&'7G[EL$]VW#BO B3S7T/R$\\"MUP8*BG
MZ)Q )D;-!,(G%TCBA5[+4"X6)V2P28P2E[$/ O#,L=LYMURXZ]"#KFHL68+T
M^Z62)L05@P(?XMO %/].'8?ZTL7SI.!$RC)49A >R9?MCEEA+>): +O7G>J'
M)4N\XW/*0YV^J0%MO=^J67RUHV7C\8H$%4#!%S9SWLICHVJ24.91!:,_N%7!
M%9Z*<[R'AY=U#ZBE<:S.'[3& AEX9BLOKO6S/1D\6!7NC"L#O\>1YFFH;#58
M- SY.=L$?DOV.]%D'J&MZ.B;:\NW]_O9717T A/X%%F_L++C1DT0\9+_[9+-
M,PGB@6;Z97QY#>(].E-]9V<'3_P,H?23M-P_^)4YUWG\30MMS$RFC**(U5ZE
M&BV%6+((JS!^(E8LU[CP4TU(/'3L'L"]>$6':?_HTIYYLTJB[W6RQZ\-,MFY
M/G7=\] 7D7"-\$HNW2UC^4.\Y;]QRIY<\VC;B2@'( 8@<N/BV5IFU\M"#09L
M93)DND V!D1D5LF_>1=MOO09JS#8-7-)??,& (J'N*1U6'MN5@G&[(77(O03
M!40YDBSA?-6(5OT<>(YW)8]ZJ #$8[+G.P]7SOFHMTSV[UC&[F1&#<T=FI#W
MVFH)(!E$P)RSIWW #$@EKB69.@;R5(#FV ;6L.-4U,K<P?^**1.7$8>3 +=L
M8ZO3%QV2O3W&ZKQOOOM[(?-[^)@['3P*N[S* U+AI"=/Z-?M+QZ_D GJG%X0
M)WBBUM0D^9FE0U0'U34:HM*3VEL9YP:969[ 35[J"8.S%ANK AUA:CR%>YQ]
M/B&SX1*LY"*20,=)2-U%1=+\Z73#824Z@4MD;$:)I_+:W5AS/D&L@NJB<S;@
M%;^.IQY9@PCK=%6OC33GJ.;LC_5^KBS#JD9KQM<IQNCI!I$9#\*?M5_\0? 8
M:'.4PZZ9_(QE3'][5#6EO8)N*)=^6F4'EXP\YZQP6VY/I'*7*Y]*UY/TRFS3
M1JZ/<RSN1F]X95LJ)GM,(#QIR4[N)HU95L_=-:D%#P\3BYT,>^/LP/(EAX?Z
MZ1/.VN3,],[FG.)'(I=E[>$)G!$G=65@[LS<!9J%;_@/9[3-N;R$HT+=IE)
M8H[])@^GW6O;S<;#C.I7?JUPB4B_55XINM'H>%PRDK"DYYM>$%B0 ,'/;6F=
M?=S!D#.;)E[^#&*B4$14]ZL$.J(W5>XM7NQ!""<]&M,&?6A2@<^WIED6_N"V
MY<F@[1=1_> #SG^YD"XMH]S]JJ5TE%<G[X996.K?9ZUL]6S(]GD&,A[I]5".
MB\E.&QYW=U+UJ=#<W78#>)I'6:_UD]JF;MVEL762/Z-,H^9\JC:RZ2/VU\MH
M5O?J$WX'2!&1G1Y'2KOA4]6(3E^9Q4_N6<\Q4"L>S* +2*:Y4BRFQJ=G^K!"
MW[P*24JXY5RNCBC6M;.MUC3BKJ8H'=I*Z(1(Q\<7#1^R/J@]L3<)KU/+*0T/
M$GR<HM_R]6QPS'5A5R2#6LVE]K>TH+;9?OK)N^?UN%Q02HV>@*04H\U<=Y8L
M [6_G48#4G/LK=.6DW>SK^)-.3W<U5 \8VFS16 ZSGK^*E_DRUCB7$2PB]IJ
M.^%_!_D2F&U=M$*!/\W3C;=]]4S?KUI_S=**W4 [%O;2J1:*NW/*D]Q:*C+,
M#=VYWX:<QL6<W@/(340@E']K]05[UM+Q*2'L_8?@^*_F.F\>BXH6]%N/>7FU
MBM@/SK3+\<8B#9TFC@N3L'T^8/I^$1FVIIF/V2*PH() 7$,ZXFR1X@K'DY7S
MKU0?YIHBG=5+;<+.[O;$1156$SAU0'*_BJQ>E2EZ-Q]:]&O9MPXZY >*TBMJ
MF49]*XW511^E"F<_XV_Y?%X5WK<@W;$:6\7X \ R7'9LZAOEU7;*W9J?#CV
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M<[5Q>V[#V2GO8,KCB[3GUO:4+J:EP-JM;#,?<3Y:OSH><B1QO"6! ^_ZW^[
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MG/!C'J7N,,E276C)I+O1(YES$=BNTK!]<UY;$DV_X!#EQU1GZI??/\LI)NO
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M66L#@\^ (>5 E"WD%>7%?2,B8',5E@IWMCB7T8J GE(3 4B0A8H?[_>&;B*
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M4'*U=(4D*,))!<#8(M(>6>7:7+-_0!@#D!33#$$[WXP49V2)@OI'Q6(KC[1
M+*\*55#3J6$TM$E^B,1#]RVS@'3'^>3WDQ,YHB"E'OOH/6"7NG/'(%;K3ZB4
MEI;C HB<GX<YLGWF:8K77A%-75*E:T\#OTA%J^/@O+MN?KWA&G!QC$:D?!R_
M33F1TQRZ-FOT+M%P?C]:+\;$)"E2EIE$>][L>?0-\RNP-')F&Q38+"DG51FG
MA>GIT-G/AVFK%^\F<%3%I-*YJ/TUXY+)YT209KH4#-U;OL_:62Y&][D79,Y;
M9/628SR=-*O^R/I0U,2UD3SZAF'9AC/G5 C+CB++43'27:/E>VY>DPXXZ'&(
M2H6AAE& ]C_/0O7\M[,IBZ45@><)SE)2)5,MSTY&<Z,+0D3WADY%X7EZ8'Z/
M<\F&H0S&3PDF];COAT4%,H&1/ X-B[8E-<6C2IYT",H'C?X9!@*GW)/.6<N4
M"RO/FIE8C.5TIJZ5D?1G?E.=LD9OA; 5O45.Z:+UV2-!5-_;F9'F=D%C21)Q
M_X_UL>\:263C57WY#2ML?M4&N<9Q,\PKN1B;*;D\ZI[[0B$,DFAP 7_"<@N2
M BKME-3+1D#K/ZGHQ?K7$A>8#E5KWBKVYMM-5'2&Z)Z61ET.1':_4'*_:(B,
MR3R;I8'[0$.3>E'^<?_]3ZA.=#T/^6"\/2X^V9?9)1YC5_G"B"K]N8I:HNH$
M8;AZ<7CVP:CH:W]%L3V/V>FH1J=#;/$U^&9[HW^$VKR].HH<,>EP97IQ69?M
MNKIPAXE-S"E-\S*METHK*7I:]CU%2O%/>9<7T>N_/<?HYF_F2O9B8^N@/92%
MZ>V<-M0BRXQ'<%934-YK,(="OH5XP(&L[ERN9%+BVP4"<DI_RRE*>/^!)U)C
MBK$PRWCS4Y(FZ7YMVMOD]_;U7\88S\L;7](,0KIT):1'@MF%>V168E_FHT\E
M]-@E<VO$9PM#T<OJ$E8=_YK*I#5*P<GN)BUV_ -G/;8F<R!V8,8+^4WQHMQ_
M&KE(]6=M6B_))H+K^,#)DBZZ3O8S$FV4F):AEVPM9&EKLI0E*A5C)6K81.;*
M-TZQ4WNO==/-)LP'OEE_=(^$_XKR9U<V1.GI;[H:\U2D1F]PY,]4_&P^UC'9
M?-]N*/U\"7+2"[TX&=]L7JM/+=H*/RQVCRE)0R_I@IY./4FMJ5?L X9XK_^!
M+9ANZ^M7U7!\#]3^METG6RJ09[]$=><<&K\/I/8S8Y; FL;]4.X*D5/R_A(N
M"Z4)+;$1J7JH/I@U6]+3/B,&Y3.ZOYL7G;'>F/T(XH8^ZYQ\HSPKL.2A\D<C
M<7XW#S0Y[B&GN62:H!Y>N1I@;4J@L7B'Y3!(AG&HT/F8YG[(:SZK).F2E ["
MF;%N<:A$?Q"]*7+[FJ-5FII:T_;:A<U?Z53/9KH5T=WFB.WMW=ECK.@M^+@Z
M9Z'(N?++^>3OECQ/HB'&:;[?O=BAW$TF7A=/AIJIQ^"E/]$G?GB:<<)0V=!Y
M30:__KJ0]ZXKN,>+.?U%O/FPFKX)$0=W)ID;.8NB4B(*L%JA=LW\;6@1@Z&#
M'O=WN(I6<2S#M5OQ2/AJ'7Z)4$<M4$#)<9%[SQ&T%4]M%2;JQ86"Z\VYL#PS
M+*KQWRDT.#4&RJB?ZS$Z:_J*QF!3 FOC:,%I%J>18I]-!Q=-PUU'I6BB<K?.
M]&O TK(P]AA9E*0G;]8#WT;,?:>BURY"HTY+?DX+8+Z5SF>3!@DG*0(BNRFQ
MN;5)O)RV[A-]DXE.\F$)D(GY$=?"#I+J/+[A:DH+M=A%A3+PW]9JTK0[;S]<
M(O3 !5V>:!Z/EF2J\(5@S86ITTI%)U(GNCX$TNWW$G]H@YT4 U?3N7C3MO2@
M]IJ+KJ>/8+ID2BG2M%CEDX8+]UG5E+Y_6YQW"3CYF9&$ K](F\KKZ(\PO&9K
M=F=S0*9LF'65](;#-J6V ;I1U2K!?G0MGG:?>JEHF'>6X1+D!R[IV=$>R,7]
MM@\^F"^87/!!:*%^6L8IS*REW[SS$7A! 4[&VH4+%.&NW:@Z0^RKOYJ^EJ$W
M\#L&O3'<86ULN+W'^/'Z3>PUV_>S7?F\5!G>_]'&;?430Z)%&K41!ME;;WY2
MG=5'!%28*3?9"<74E5C^W8AE"!A^."#\A#K1%+%+!)0A(0B49LF=#\Z?\H_\
MVZ\?-B1X[,C$O.Y<%*MJ];6-4VIMM.!; 0I.%+A!J=,&>GKR)F,,QY @H+=Y
M'_\RDY-Z>YOT]*XXSUL#+I8>>/ AA;N%@F".$PSR]O8S@R96X]C5]::X<%;Z
MY"Z5YNEH].?1ID27D5HBX&+'I8N5BA$:AI<I,UZ(2E?5RI:2];SU4#XX>[!R
M5,MJI$2?-OK@&@FI8S!>@<UT/>IEA[F+U)3?NV3M K6.*D?5][@UJK#,%XZV
M%UC-Z1CY<_+H:-]$(W/Y*FEH5"MN3N(LO,#UX##[Z$#'$>F'E \IN$J7]_S[
M1L4\YX((L)B(\&VYY12>\",+=CRU3GB$<R0@.B]26T/5'5:Y'B24Z.0QO&1I
M3CN09UE2%#LB77I^TY32/&,:2&:^9.;0_(-N9-WBM?!"XR&$_@J8)'>\H-FG
M-UY1ZTM9J^+I/":XM$P>>TVS3W5R5ZH\UTN;E)V7,+VA@4^<="YXV8]N@OCW
M6/>O^33G_9Z'H:QH'HOFR4+^G\9_)#Q\&8VF_M#..@+C%EJKUL*T9VV(-X&+
MXH4R!Q&PZT@94>9=;E^?YI4.7E>G.78#4.K>2@#79Z(3-1&R]R9C?$8?&8!.
M#JE/D=_8K^+QLL7ICW>P]4MN@A%7&@&>YP'3%^*73F\;+*IMOST[!#;DL7UO
MHCE'U/\!.;&]"?!4QI^XX _Q@Q4L;X;T%W_Y!%71(/-L>T"<!O&E1K4*:7D"
MJB,&LC*H*Y4>Y%IR7+[Q@'_QHNJST#NA1C\GQ,;YJ_M"\,*EN$GSVO%:==ZZ
M!VI;G4JW^!.T8+]/Y,H.A$*!-?!0(L#.Y>Z"8QMG8Y@NMF"Z1=E+PK)6GSG7
M)\/396A1C@R$@>X",5?[GG>7IV2=_%GGHHHQ%AQV \&LD3)95Y<&_4 :H/VU
MOKYK^SGF<6KL2UT_P[4-1#H7G1N4*#_^/5-B83 NM/-ZU55/^&6#!!O9_N3L
MP,GQP97I[JZ?)PH8"J3-Q3+-"E8[67NSUT67!7^/2SI?X?.NN'I_F@O'5:SL
M2<_L"L3&N/)$Y%DU_6L@<=U]N6<AM"$NW@J[5?),8O9AJ#Y+^"88M)Y4("F5
M#[MRUH6 [S+R9>2O(DP(8?E^.G6M?_%Z[DX/.GSUW6L<-D4G4O,W=UQM)Q;5
M>FC<].)HQL;05N6FS\_VQR09K$;]MR["PAFWQ0+G/-X)F7M;F?\Q[<VNUE#;
M/?=YR26HYY^Q,MAR+"B8?GMM.58J^6%?4 :S/WA>GAPO.&'9+"F98_T3/U[#
M'&TP5M^@HXB:_KU8V%:!(W%@BVQC,3<=9AJN2U9-G?JN%^S[@Y!W6,YCQ?Y^
MP4 CU99!P^^Y]QHG#T'%"HJ2$S5M-;D;*%XQ[^24L9HG>"]^:RI [[ O1HR?
M""#')5^"IJP.*P7R^73OWY2AVE41'W<@ ACKY(1TU7^$6$.6@*)9JL#!/V>G
ML1BYN!Z78&/*'JT'KYOM?^G"([Q=A#(28S>7<DXKW^H9SEBT^+(T.3\JO%F!
MI=)/'JN15QH1=&03^0$Z,-<^54HJ6:'1X"@3!NE&6[O@H!93LG(>#8S^\\D3
M)/@''1>Q)WO&%M&UL"BDJ0\P@MW04Q5!>U;R==!?85]. 482$F*/G)=KC>#X
MI#VU^F+/S&/;9"&Y&.LJ1J/E(PWR?!E1:V?';)L#KSX4T#2(-_,341YT(P4S
MF=K$>\&X)Q(G7V\]VQ]EG:'FV(@]\=H>/XU3FZB>^*>JB9R4]OYDXV[$TMK'
MR=?Z8H-9%_DI>CPC<J%MTF  *,@O/[-@];'ND>JBR,2Z9HX_AT;(UKNM^L-%
MC3\UD8BVR01-UQ'CR>78:5)(>9IX=%/#LX1A_R6U\O[3Y=^;_)H2U*H.B)FF
M<$$^#:H1_Y+,FLFT!EE4'@F,>4(N!_2"+C+'EUV90NKQHWYKMVIK1I]AZV>_
M8A6X%M>SGXE9_Z9__.BO.>\AKMR!IH%JL9:C]?RSS[39]JS8L/6[=!G_;9*6
M"N.4D$_W/JY\7"]>=UQE]8Z+=$C\/.;H/^S?7JK!G?Q/CB\^."F"X[).+V4B
M>\/YT_LD2?>W/=^3T+GV5X[>;7K+TRZB7XS'19.UGR:]*JU69OI51BVGT/C.
M;E O>=XV[U)0PX3#LX2.R5UI^%Q-P%Z.CZ$"MZPWD[)>G/9J2'-5*G7)3@QN
M,^;84&M;</Z9=S[VO>0N82J7VL!(B52>AXY7M6\/M#9=;SJIIOUYC2]\RR_!
M5^][V$067:2@O$YV@C^O;'-3=<I0+GJ-S]LVQ<GH\*KD/L?I+R_^CQETXMP)
M#GK"JL\EAT9858]+DAPN[1MW#2ZE"NO^F")Y&7CG7[X]K3\M%*^S=QKAZ^8]
M(O\^#'8,R7E6;TSUKI5DHD0UC(1_2.R7WA$8=&KAV!(_.!BEP\_H^\J@3M*!
MI9@F9-'^J%1B1'GD%?75KXL)IKP=W=EMKH1 AIS3KAT=3NQ)>?:+R1DU14GV
M-ODZMP>O2G9,T<..W5]8CV.H_LUNKPD?&2@5X7*6>SGZ5LR=6&99MN=]OM&O
MQ^?*F?FY2@Q[%QV5TF4))'Q:?WV.R*[,]W=X<"ZW[:VAFSII#H[A"G#L:YPB
M_U+>)'3WX!W(]4#!OO5,)L[8<<2H%_T-^(<4:]OM/MUOMV5(->\[?6GD'IG.
M(AP_833LQC_71C'2 OH_^^02 AD&]7AF(N"[QL&5%]O%G?SX\KJ(@Z6[)@1!
M:-!U6A&V(P+R)MH\KYJ@JWORG$3 /RTBP('3GQP33(U]W4'(GJ.%7LCQ;\#F
M4@B:DVB+JV BX#3!P(NMY#"U%R/+%\E3.;FA&,GSZ^;_==W.34C^>D_F?[;*
MM5^1*W'R%)(4YT;>DM*)5%#C_;H-*7P?RG.C,XLW,*NV6\X!G??XY)=RY3>T
MADEG<Z#%9G/!?KQ?MM=Z)VHY*2 ZG\H<D1LPETU3ODNMB1 WH61Q("<"7A !
M= Y_MX4;IA?\KJ?JC_@6Z3-N?<:8:,*F1!F;329K202PA[4/R8EL$4YSEO\8
M@Q]DM3AE^T%3BRAO$486!3= N'CTP<W^!7:L?&C*)F7AI3ZS;_P)+#-$SGYM
MMRN]63["8I9UTHP)SXF-0XV%*UPF(QAK#,V $[SOH-)FT%,A'%;6P1L8*MBJ
MY%Q6SU_&HK.(HSDVJZZQFJ,Y&IR^$C*$CQ=1.YPUT(I"Q]0=C"7P4Y$"@NA6
M7Y9Z&(82;1<V&YJ'N>P^M?1I35-JU^JH_T#P'%BR/[MXDRY4[OPINW NW%CT
MG,JL,.I2&:_[]V849?@B3Z#X%MMIZQX]$?"UANK"P*$H8![*7#L]Q];--& P
ML3V#]+ORZT>6+=(U0WRFHLQ/KGW\$/;C#@$(.]9X>W9I$;:;#ORA^(. 9'WY
M/>!(&?.IZ'(,E:X#/6;\DO+1B74CN$*U;7I_Z-(1<B*\NI5%5<^>$]7E%<26
M]AYQNHKKH:0U?U8UT7?UTMY+F-"FZ;!H%E$K0V##O(W[9AR0@&",S43#0Z67
MHH\S-:S>M(T_LH%/1B9?K=+?9L[LXELAL]\HEFOH.?@'ZVXCPY0OBF/&YL27
M2/.5T19[_ QB5VJ]P@-'>VOW5"T."A4ZI$C28)CK8(O")6&!/5@' C\.40R1
M>6VXB#[2H::G5P[B?&88F!S?S'=VMNGHYW-5(DX9GO81(MDER5@0]DU \^X4
MC'7EW70&\SDBH8HS0C;\J ZR$]+MBT?2[;MM0VPJANN_4)F:#&*TJ,EB#?^5
ML9-\;X\-9CTYIKQV*LX6D6D4Z33IV[32OZ-O&]61OSI<]JE.&IM:18PIYANG
MX=[*\W*:W]/?CT;I%P@%ZLO_M)@[0GL3 <D^;(0;0"* N83N]!R7 5W+"KM>
M+ TBH(]_/:0DN9$(J#HD LZQ;(V3.S_C-NPFHBY]_32 AV.OB8!V+B)@Y<?)
M52N!B^W<+H<(6*:&8@?/ZQSUBJYB4HB L?"K[BMW*OSNA1+4A3+"CF"TF8V[
MM81WRP(Z'T1 C\;>_*\QDHX"3TMHRRZ9!(F ;*K+\(MU[O/98Q>\I%TW['PC
M]WI@)BC6(^;2$Z_VY&L:CWSN"!S7?+Z8G'TJ848$R+.?49_,:^'Q=@98:G11
MI#R?H_8B+E$WX0I]2XGBIM(=.:\G[0PGVZXC;A;&QDHPM<<H9;['$R /9=F)
MS/G,V2F\.)8$XM)S*IGEU*U]@"0";$?WBOYYPCY@=1F_A(N#8!X0N^11Q;L.
M\:V];B)]ZR31%X@8O SVECD#UBO37PXV]Q0$L*^^\9*]T!<QE27QA]R;M!+I
M/5E;MOK^47[!EX=Y7HJQK1O8\FT'#@]M@R@#^93FAD/"([RX*=7:9O).T-S#
MUZ::.=P7LD3 ON0A[/64X)-$5';781C50+YBOTC 5NAS@P>>]\1$;ZHLN*Q9
ML$42GL?-5JL2 ;\GS@F?4'L_Q(+XC8T3-2C#]ML&B@I+W(;3!6SYUZBS6SMB
M*61TXY$]]/?O2)4V&)<:UT_,(Y*J+F[+IYF/KLF]?E/;C)E.:H/E(<<\&=E5
M)Q].')BG0N;(2"8C5V5?<_:<="44/>^)Z*OPRG:.W JP&W7,_XO<?_[O.#^A
M+7()0]&DE\T>M1-P:K#W[RBBPJ8N;F-%;.[+ L,3VV88E7$'A^4/N[2@-^,K
MAS]9,QUC!<T$K;HKUI+Y=?A:__Z^V1Q?]&KK]XVL$V9I:^W^992*\>V<SD6C
M_EW222.$S]OV4/;8NFV!_!ZNF7LW9[P*BCI^QYX76.M:C\G4-"2H(!7HBT^<
MI.T'?S\(!#?6C"O.GP^*9,[4UJDSV07SOH+TY_9/IF8I$ %W3D;6>A6ILWST
M*^)"*M_,13K1;#->SZ<^5^OY9SZIRN6TS3=5KAF,%??7>.7BI*^MG)MASJT$
MOL)T3"_:H75]*UOMI.GY=.''=S1R4A4/E$U<*" !.SHM@LE>51$<PK]L>U\M
M/R)[/S\U/W-/QT&EI-]>_K;$YR$^$X'I8?NWGV5SG[+?Z#QX$C)60G_28VL$
M&>H3X.PIA]_/5P%UNZK5_$1[C%(.SY(A("O(E@<?MP] (8/N\\Q><KQ^0J6F
MV^E#;3=/RDV9,_<1"Q>%/O&5Q;V3D0E'\,V_ K]B*I#KMVL;XVD*&A[=O?5)
MA;_Q\S]9:\\2\4SYJ=*DCO[2BZ28D9'QST0 GZ1C;;-E:YPS$9 )MF\ LYHI
M,:BG4LWB/O*V-@%N4VH;1Z!:Z*ULGVK))_FJ0010]D:]:R4K-28(X9+S[#7M
M?8>EJH3(%C<?>HS]J9-[TBN5B0H-,>U/$70)KN:6Z+%H9.BWBLIXE!G;I2*:
MZ4>@?JKD@&Q,]+,B/?,F.1_K^X@J]:)D$]_4'$,N:X,$&G^TY!-:T[..?CP_
MHZ>5WE#\XMRIG*PM:2&%V(:1D889&#;B\>=8E# H8#CP[-N6NOA>^<YOGA$;
M2(W%@I@7]GZ5#.2D_$J^<WLAJ/\NBR;8]I+5N,C3VQF\X% UWXL6/BNME5:=
MG!QV/Q1R#-7P,-E_]?G?LL'+,LB$4M3 C^^@7L=$[@2--!]8!"V_+16,)N77
MP;3LS,O5L^*50&#5>=SHRK=LGVV\7.'KJRQS6=O"X1F=:/TP <^"!9-YFC@N
MV?4TI%7OHNWGA1ZO^M_KF#Y!X;2U5F^8\6:5VL,8%*14NTD>D2MFHNG;0KLL
M\FVFFE%J]P>?Q(Q [71V*"L'87'".4IB'?F9/W5JS_-N78EP_*/!!Y*LZ"*=
MPS4)XYDM&.ISD>7VM$FW<9<16/]SH((7$EP[.2OHH8\DRWPX<%+IK$'!8ADP
MQWWQSW3\<7.B3GY!J41E+92CQS.F(X6K5@SZS'Z51V5H2M\F)3RD6WB.JC$N
MH0;5[,^FGT0?SSSHFM5;I-A4P&G7-(&<*YICM,]^XDDS@@M"X2]"_Y"6?)I+
M!(I$9FO9-MBE<LS37\W/%*:B5>H:XYE^]"J9>DS_5+M4^O'A+VV?\4W+F*UO
M(,ORN9%2]?Q^UV?'K+EUGOP]TWE&*U()HJ;S 70)E]V_=UZT+03=S_O#[1RB
MDBK3/XZ]7;WEABSTZMZ+[&NML_<L".3BY&"@63*U!Z&EXCG87*OYM?U8'M2H
M\/<=%;=SZ%?E\0I0&/^\\+!QD*GI+L2T.*;AL0O)MU7V1QQ,<#Z+;'PRN&Y,
MR<$H/QS+&L&DVD#UH!JFPQ_9DN;IL.+9O\TO>?>U>QM].-K+#HAV>6BX&9E<
MVL&N?ZXDV</X-H #4VK6.=L8',%NN<W/>=Q"2:,%=8$(2\.&C!GE]]@[SB06
M[7YB P%RCHQ.IDB1F)<\^"@"U?0'+&FBF"3[X)\8T9.>CSOF?& ) "@^)F:$
M:N Q%=)<Z;*$PZSRMEL;1W4#82+TI>"+ZGHM<=H6&2M.^C9;9[S,M/G%RKN&
M!,UW^Z9GCZ_<#9RXW\6*?=11'D46V7@6;C;'&UK?.'7S!X=A[:(X&V>L(+FV
M;SCLZE[*V^712)0L@)Q]%N(ZY[)I%]3=G7RJ*H:-R#/<3<.B\&2NOQ:VJM_V
M.^_^*T_7HJ@E LCPBDTU,=JK]BKO%$H9B8#81P05T7WG@%/W-&<03#0KI:Y
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MOH6V&5D$001IJOIQLMRO<_XN/>(G+JB;#AFRSGF7]F _\HA/35*^CTPSW^I
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M7%:1Z?@>/MQ)J+)VLV+&Y84:U]=@)=!C'D5(_U+@YR[&6?LX:;W"I@(;Z]T
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M?B".;>P$1I=J?F7HU<"].&LPFO^1_QX2'V5&58N4B.AUW&OOT_VR\JQM4Y1
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M5/](1+,Z+EF:BU6_R6<4CN.")GR'U@2Y\:V"0EGJB_I8@H%T]9C#<#DPSX1
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MS]U6 G^?13U[E[I.[W5Q;M:-5&_QOAA%;:\+2.3*=&EDZ)U*?:F4"AX]QD*
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M\DP1"3CJ_'T=D=9AP=C(EPW>UFYY '3-/@"0G+T7R.G.79W_^\S54:=V%?<
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M8IH+,E4%RAE)+VK?]VN^$^,F?N?499MA&?>?T:&[:Y;]WTSSR1AQD>)SU0=
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M8:>S)AWH/381JE#H%ZDU*2U@X\T*#\_-^G*Q@5+D8OF>_WBAIC7I[3B>ZHA
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MW!"8Q0A^ ,@[+F;.*(9Q#%4W'4 >5=YMMAMY7K3%*?V+NBNT(!$ P_Z_RIM
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M8Y@T/(NANI4C0S(AAD]@I2I[#V9Q39&8\OWQT;5::GN^5.H_K =;4!EHTTI
M5/YDIEU1\N(J]:![3[>!9@EKH5].%G6%E+I FLE[SOL)J0GO>,JKL8(SNX\G
M.L?(5JW60=KI_%M5W Q+3QJD0_=6%0M+C! NE?8HV:B7L81<U/1#+K.B-WJ?
ML#(IP+_RRP+W[C+< 'J?"Q'VAHU6[Z6[<4PUKGL?S1&X97&J*6CG,1JN^':=
M&T XY#1J.S4!N'["/[\-;T2_Q&Y\115,[V%N.86#%K%XW6U\ ]C6HV0F%[Z
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MV^UDLT[XBD(S&0B!/\"9"OJ7V=OG;FEB#A+L5^:"JGH']V4LY&#/G?/W6DZ
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M92]<"A=X/&Q@8?" Y 3N',&4R]D>;)YITYA;H;*R/GY:A4U +,T,BT2JM^/
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M82T!9#9JJ%KKJ*L^N HCT)%=/9:_ ;QK@P\C8L$[">@)4FC'OLM*X\G5KZ%
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M>%=G <SR>'Y+\)]6\<&D=OMTP T@J2IOT:Z#;)HD0-EPJ4OM_NR^4XSSFW"
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M/,R(OW<.(%!$#,E_R/Y1XS\I9)!82:'ELL=CDP]ZX*'J_^A[GTQQE!KWZKQ
MJG@%N!0;FJNF=;N!D>U6L1YZ>J_L@S082')8&@:LE+Q>;S;)DA,WUT/I$Q4@
MBZ:/F2 _IOB;?R ?U\ETD6FFSF.\:\X.R0JL-M7<+<U/2N'\9UN9RX' "E)1
MT\P[;HRC:U>[.RYPB6-# ;_G$JI0Q4AC4Z^*EH&.U&,]9WA5#H3C4/M"4WB-
M(H#!K#L$=Q2_(5'Z5V9J-[<F]]OZI PQ;H/-:<@&6R*#R#SJ>*YX&1?S5EDO
M)1_HW?%@>J[S!E!SWNW':XVW_L?E/$R#GQ6C6E),<=Z"9DQ%Y].>;B9<I\:B
MY4U)?P ]&E (XSJ/OG(3,\-NGKF^Q_&"_0%ZD"%9[?8+"^NOHE@F=1^=/],I
MU5'YW:.A+<FO<#7=4<5&RO+.21%4-,GJ;O\'5$"KO]X+\,^))M<_MA97L23N
MYZD>A%>WZ+\ ;NST)_$5[#YBJ-V^8\_@*ZN#PAIEKI-G-+JD GG=4\I#R@/4
MFO7H8"E#6H[OR/$KYNI>[3V)OVR/'T7A#Q5X>>[L9IXI-"A<S0C.#YDO&/\
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MJ6*5)&(8\BBZ*]F-,2KQ@5#)'U%6),*V1R/6HY"!S4W&J94DB63AA5-HC"Q
M.Y:U'4,IJM!:M-V)I7*Y+#(!&P^>,9^E2_V2LYW(J@?2M&WTIOE.TGUXK6M]
M-:-<D4<Q/LVSF/[ 9E/ _"HUT>2/H/K7:K;*J^].73U9>1BBX>SMH<5_9[^A
M-2?V)*P&%-=HNEQA1@59CL@%^[3#D9PBZ,5;+H:G_LOT'%=L=/#?PYIG]BAS
MSQ2N5RG#2:<ZYV\U5DMI ?NX->AMHRKCY:9)H(="=@SBD6D><26\AZK^E1FS
M/=:[.XT?:QXQ5%]+96X7BC4V4#FEL^>1S[5/';_[61[UO)H[2'[M7[?PB[*L
MCQN(ST;!Q2U*Y;'/PP#KUK0C0QJ,J0#T.*Z6'P>]KY;M;OLD^XV.#7I6B?!4
M:IIJ2RWT,%R>1"Q'2A1;,ISA35YL\85F7L35E5G9>%Q[U[_:_"C1O!E]:RZN
MZWS3D(D"CN>]:VH?"?0M0UZ<1C[-;+$&95_A8U7*S#ZY23\NY\U"WN=PXJQY
M$X[$FOI>3PCX+\%:+=RW7EWKQC/S$$\]J\IU+QUI<C.FEZ)# ",;Y.32Y3:E
MBE5;Y(.QRVEZ#J]XH\BQGE4]U0XKJ-+^&OBF^;"Z=)&/^FAP*Z'0_C5=V-J(
M?LMNB(-H(45-\1/BIJ5C'IPL=2R]Q%OD5/X?;]:+('5Q'-RJ*5RWH_P'U*11
M/J%W'9@=54]J@L/A-INNZE>QC6U$%JVV3IFN N/B1K^H8$NH3%>X#8K-77KR
M-KAX9GC67A\'[WUI678UC#$N[E/[D=]XB^'?A'0YE/\ ;)F3:<[3GFM+PIXG
M\!:'9J&TIKEP 3)*N237CLT[R1@;MW/>GM=-(BQCY0HHY3H]DY1Y9S;_  />
M/%WQ&\,ZGX8FM-/TV.)Y!@?+@CWKRS3_ !KKVG-'''J,JPQ]%!QQZ5BV<<DN
M"3\@K5V)>8'EA$457*.G1ITX\J5_74]F\.>-+_6-!M)I9Y$W!@R[^#\YK1UG
MQ=JFIPI ;EQ @VA5/%<EX0AC_P"$=M @(^__ .AM6P8POO7;&.A\[5454>G5
MF]^UA(W_  P1X+9SEO\ A(N3_P "O:_.R22OT1_:[PO[!/@O'_0QC_T*]K\Y
MF:O2:T7HC\^A_$K?XY?F)(]1;J&J.FHF]R97J57JL#3U:K42&RTK5JZ%XGU;
MPS=I<Z5J-SI\R'<&MY2O/N!UK&5JD4UHD92LU9GZ"?LO?';59] @&H>,K75+
MVZ#-+IZ1>5-;!<_*YS\X;@\"OJC2/%6D^)KJ.[U&T=I5A\M9U&U8R/4#C.:_
M*3X!_#;QAXV\86M[X:TZ^EM]/E66[O;:)F2),\@D>H!&*^[M6U6_L[$6EG>R
M*&7=-;@XV-C^?2O;PMYPTT:ZGYCG="GA\1=.Z?2VS/5[;Q!=:@07U".T\F;8
M+=G.[;_>!'&#_6MJ]\0)H\UFMOJ4-Y:RR[V@SQM'=AVSSQ7ROK%_KUGIL>H0
MK,8F<Q&7!*EOKZUUGP_L_$.O:=J.I;U>6RC)>.3 R/0>IKU/J_)&[DK'Q<L3
M[6KI!IK2_2W_  QV'Q8\06VL:])>Z JY2$><ENI7H,L0/;/Z5X[-\1+J^E73
MUE8ECA9&;'/;)-8_B/69H9I[^TU Q3(K>9:RMSUY^OTKA-(N9M0OTE$K-*6W
M*B+U/;&*ZZ%*,5=[HX\3*I4>C?*]UIMY,]+\8ZEJ>H6\=MJOG)+N18V?(!SW
MIGA9C#-(+F1]/LH\PI?B E&DZX)XY_6NI\3:Q!XKA\*V_B#S+*\7$4MQ$068
M9 R5XYQTZ5Z1XPT;PI'X!30]/UID**+DVH!D$DQ4Y9F/3G P,US2Q$$E%JWH
M=U/ U7*3B^9:-WT;TT\TSS>W^(EOIEI!/;V_V\!&BG%UAUSGJH(Z8KS/XL7T
MGQ \%MHEPD O;B6."WN+DXCM4WY+9&2 H!X%.TF&36)Q:VRYGSM*22*@&,YZ
MD?Y%8WQBT6/P[8VNEW;17,US%ND\BYW+DYZ%<8QZ<USU(P<6KW9Z^#E5IU82
MY>5)K]/O/&OC4O@;PSH>B>%/#,5OJ>KV!:34O$$)/^D.>-@]A^GYUY#YE?4_
MAGX#_!O7-$C^U>*];L-8>$DB0P>4)<#@#.2!S[U\R>*M+M]!\2:GIUK>IJ%M
M:W#PQW2# E56(##ZUY%C](H5HRCRQ;?J4?,I/,J#?2&2KL=#D3^92B6JWF>]
M)YE4B.8Y%?FJ0QY6F+\M3+\W2MHG@QW*DB"H&2M!X<DU"T-6SOCJ9\BTQ?O"
MK4D9IB0G<*S-3Z'^!^GQQVL,A')&<U[G'J(['%?._P )-?2UMXXBV"O&*]<C
MU7N#D5YM:+;/:P37+8[>/5-O(;!JM?7OG_,37,+JW'6HIM9PIYKB<3UDC6N+
MP,"C'BL6^2/8>F:Q[C6':; .<FHKB^D.>M96L="C<;)"K,?2B&Z>Q8%#E?[I
MICW VYJB]XN>.:S9O%6/1?!GB9KF\6(@X':O8[.X7RTP,9&3BO / ]PL5]G'
M4]J]AMM2&%.>,5JHW6AS2=YV.RMI!Q6]9M UO\VW/O7!V^J 8^:KRZN OWJE
M1(G#F-7488I"W Q7">)='@GC<,H(-;]SK2JA^:N4UK7%*L-U-0+2TL>4ZUX1
M@AO&E5 #G.<5FW-GCC'%==JET)F)SQ7,W\R]N*^PP5-TZ2N?,8Z2<[(P+I-C
M56;%:-Y'N3=63))VKN9X,HZB[MM5[BZ\L>M/SNZ4GV7<?F&:1%BM!J+>81CB
MKJS,<'M5:YMQ'\RI@U%%?,/E(H%OL:RR;JD1N:STD/6IEN.U,S+S/\M132?N
M^M5_M':F/(6RO4FDS.3L4GPTAYJW;V<EP,1HS_05IV'@/5M44200C#=,FO?/
M@IX#M;2T:/6;95DZY(SFN>4U%:'!4JQIJ[/*? '@R8ZM#-=6V^/(QD5]1:;X
M6L+/3HWCMEP1Z58C\/Z?]H$=I"I"GL*Z"WTNYN-L.W;&/2N:5Y:L\.MCTWRH
MXR[^%MIKTBRF)0,YQBM:/X>V$$:6RQ 'V%:&M>)!X781,,U9TWQ9!J%C]H&-
M_IBLVI?(=.O*WQ'!^,_"(TN/_1@3QG ZUY_>6=Y!;O+*F%49YKZ#M[.+78VG
MFVC X4UP/CG0+FZM9XK9 L>",XK&5&-3?<]K"9QB,+I!Z'FGPE\10ZWXHEA
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M:N,F/9CBFP1*@!8<T%HN6Z8'7G%/FD$<>T?C5;S&4YIC,6;FJ41N78>OM4R
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M ,*HE\%P7)>3^T#XR2[92F%\OR?LY!!SOSN]L=Z5K&LI7/#?^"6O_)F?A/\
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M:GF7;[5NJ1@ZQZKX/;_BF[3M]_\ ]#:ME<>8K,>G05@>"Y"WANT_X'_Z&U=
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MV@VEU;RI:!;2X?@2QC&*/AT1T4<3.2U1\8Z5^QSX@N82MUK<=MNY*JU,U?\
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M_AR:_'\SM]C2IKXM?O/;_B?^S?\ %;P+N63PA>W-A&/^/[3,7:;?4B/+*/\
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M+270Z2W\FU7$2*J^M:-KXF@L+.YC%LKW$GRK*W.T>PK.\-Z#=^)K@V]FOFS
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MM[KY00<U8%WTHY3;G1Z[X+C"^&;,AO[_ /Z&U;#2  X-<]X+8R>&+,@_W_\
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MA7C[R.W#XFKA9<U*5CTB/]IO3[J:*""W;SY&"!<=S7VA\*;=$\,VEY(@6:9
MQK\I9K9M&UJWN@/ECE5_R-?IC\)?&4.L^!]-FB?@1 '\J^9S##PH)."/L\LQ
MU;&RE&K(]LM]>:R!V'DBLS4-7\YF9FR37(3:Z%_BK-O/$(Q@-7B<UU8^BIX5
M*7,EJS:U34 5;FO-O$FJ&,L >:UKK5O.C;Y\<>M<'KMT9&;YLUG*)[-"/*['
MFGQ4T2'Q9I$JWVZ1%/K7GT?P6\/ZUH<4%A92>?C)E;(Q^->XZQ>>'K'PZ]TS
MM=7T?+6Z\YKQGQ/^T+:ZI"-)TZV_L9U.UI&4 BG'GM:)K+E;>AXEXI\!1^#]
M:DMI9RR=EZUSVJ>)+71(3%:6REVXW;<"O3+WPUI^KW4M_/J+7\[#/SOD?E7G
MGB2RLI+V.UF38@;[P]*ZH.YQU(M*Z/.KZ\>YD>:3[S55AN?W@ '-=/XWATNU
M:&.P R!\V*Y*WW).K@?=.1Q71<\6HY1FDCU;X7>#YM<\46,=]!,EDQ#-($)
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MHRM7Y(,5 \5,AE4TVI67%1L*"!M%(:2@BYSU+116YQ#EZU=A .!5$5;LVW2
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MQ2EL=?-%:G2ZY?V?B"Z1)9!R>3ZUKZAH7A=]"%LIC>X(QC(KQRYORN6#G?\
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M7D]:ZFUL8$12ZC-86GQA9/.<9JYJ&H[%SG;6,Y.;Y4==.,**;L= 9K2/&XJ
M*KW<]G=?(NTUYUJVK2O)\LO'UJK9:I/'(&WDU+HZ;B>.=/62T/0[CP;#>1%U
M4!NU<5K7AR]TLLPA9ESP<5T>C^-BVV)S\PXKT'0]2L=7LVM[Q%(88#5FW.GY
MHSE1PV.C[2*U/!K6WDD.7X;TK2V+:PEWQG'2NR\7>%X=#D,\/S1$Y!KRW7]4
M>:4Q(<5NI*2NCY3%49TJCC,H27'G7\C]LTZ28Y)%41&8U.3\QHA9I&VXS1<\
MPN+<$\FIX[KM57;Y9 IZ?>IW%8MK(=U2>9Q5,S 9Q3HY"1UIW T(=SXQ6G;8
MAY;K5"UQ''N-/:X##BG<1=FOCL9B<>E8ZL9)"W7FDFD:9@HZ5=LXXX5W2"@#
MUK]F&XBM?BA8/,  1\N[UK]#)M2 &<U^5OACQ1)X?\36.H0Y589 3CT[U^@7
MA3Q_!XFT&TO()0X=!G![XKY?-H2YE/H?:9%RU(RIO='HKZI_M54EU+.?FKEI
M-9!Z-4#:M_M5\VS[:-%+H;]S?9SS6-?76Y3S5&;5!C[U9\VH@YRU9LZXPL8W
MBO3+36+62"[C62-A@Y%?.6H?!MO#_BI;S2-,34(9'RT;=!S7T/K5P&C)#5Y_
MX@\076GVKK;3>62>325T=48]5N.\=^"Y/^%?RNGA*UENI(]H\HC(.*^!M>\,
MOH-S=BZ@D@N%8_N?[M?2'Q&^(?C_ $6Y@DT.YFO8'X:$#<*^>_&\_BN2^EU/
M6;?RY)FW%2.E=U%/H<+ZG!S7MQ;L%EMF4GD;AVK0GU>34K!;?R% 7J:FEU[^
MU+R$WL*I$O!*BL[4M8M]/O'%H-T9%=?,OM,X9/D3;9GW^V%=JC;ZUZ/\"_#'
MA/4+XW/B#4HH7W;4@D( .?K7FFH:L-2C1!'L;/)KZ;^!7P.^'GB#1;:77-;5
M=2E8,I67 7V(SBLJC1A1O4K<T4FEW/KWX8^ =(TCPO%-:ZNQMG7A&??&!]":
MEUSX9^'?%;FWAEMS<]F@&"/RK>\)?"?1]#T"&*TNWN[-%PBI)E2*[GX9^"=,
MT?4Y;BRMU(FYD$AR5KS+-NUSZ*5948.HNA#\$/A!)X'TZY%[*)H)SE(>WUKU
MB.UMK=<1V\:C_=%#2A?E' [8IGF;C6\4HJR/D*]6IBINI4>X3PPS##Q(P]U%
M8VH>$](OE/FV<>?5>*ZJWT.6[CWYV#M6-J$;VDS(QY7BG*#2O)&>&K1E/DI3
MU1P&L?"VPF4M:SO;MV!Y%>9^+M';P;"\VH.WV<<^<B$C\:]TN)SR<USFO31W
M%NZ2HLD;#!1AD&LE%7N?10JUFN5RN?'7C3]HK2-%M98=%#7MZ<J)&'RJ?6OG
MG5=0O->OI-1O)3-<7#Y9CV]J]^_:,^ L5HTOB+P]$$BSNN;91P/<5X<NGYM8
MPH^92#7T&!M9MG#B8\S36Z'Z9:O ZOTP:[!=2_T0(3STK-M[7S(4PO.*KR9C
MF8DXQQBOIL/I$^>S6IR4].H^]OOLORH=P-4EF,@^<X6F/)YKL3228X'\-=29
M\)+5DC"-SD'@5#),K#:./6JMU>+;+A3DFJL<[S9P.?6G<@M[OF.!FG+N9MNP
MTENOEQCU[U.&;KT%*Y5B:-?)7.,&OJ']D&1I/@_^T4>W_"+MC_OQ=U\JM,.=
MS<U]3_L=2[OA'^T2H/'_  B4I_\ )>ZKEQ#_ ';^7YHI+4^7?.(/'-+)>O$I
M P"14<:A\#TY-5]IDF.!D"MKE(N0\IQD'K3+HB/:V23TIUME7??QQT-,N_N;
MO0T^AJUH0^:<Y--:;)]35=G+=#BB-MI]347,R;:S9.<4]0/J?>H?,^;@T[=M
MHN,DIF_R^K8IK2,5X-1A0W+<FBXSO/ /Q#FT*5K=[J1+9A@BNGGU^/Q&YVR$
MC/RCDEJ\D2,'VK5T/Q--H%WYL6UL*5&\9QGO3C*QQUL-&I>74[.^FBMF,07Y
MAP217>>%?&IMO#BVGEEO*;(Q[UY'H^MIJ%X\ER&F=SDMVS74Z?K%MI-K=-*3
MYC\(F>![UT.THV/%E2E3G9FCXGU]]7OF93@ ;15*WDM;>WV3QEW+!B:R8;Z*
MZD+;O?BH+B9Y;@LI_=]!BM>56LCGC)QGJ:M]-'(Y8HJ1KR%%85YJ19CM3CL*
MBDO#EEWYX[U6696Y)Y/ %"T/1IP<II6W,.ZDEO+S$FY5QP0."?2C[&ZR( N&
MS_">];L-JB\LH<!MRD^M1SKNDW;1GUQ6<JJV1]U0RM)1G)V:(?)3RQN7FOLG
M_@F["(Y/B.0.#_9O_MU7QM[GFOL__@G'][XB?]P[_P!NJ\K$_P *7]=3TL='
M]Q)^GYGVC2TAHKPCY@6DYI*=2&?)_P"Q;#)'\7/VFRZ,@;QU*5+ @$8;D5Y%
M^R%^UI\*_@3X5\>>'/''B2;1-9D\:ZM>+;?V1>W&87= K;X877DHW&<\5^AA
MR:44A6/%]2\-_"/]MSX<:/JLZ7'BKPM#=226<T<M]IC><N8WRH,4AQR/F&.X
M]:7Q/\2_A-^Q?X&\,>']7OKCPUX??SH-+A$%[J+':V^0%U65^LF<N>^!TKV@
MFDS0,^#?^"7G[0G@33_@_P"#?A-<:M/%X]FN=0D32VT^Y"E=\UQGSO+\H?NU
M+<O[=>*],T]7^(G_  4SU6:X5CI_P]\%QPV88$JEY=NK/(/<PRE3CLHKZHW8
MIWF'UI-7+B[*S)KA@S<'-18I\*[VJ5E5MV!C%%[:&G*Y:E8T4K<4VJ,1ZR%#
MD5^6WQV\57%U\5?&EN[DK%K5[$H]EG<#^5?J-FOR3^-TG_%Y?'HSQ_;]_P#^
ME$E=.'@I2=SZ?),14HRJ1@[)K4XJ_C^TAB>O6L-K,>_-;PD4*2?2L??@DYZ&
MO6BCT\0XO5E/[.03@YYZ&F-'\W.?PJ\?WAWX^7K4+?,<5J>6[=!EK'F3F3"=
MZT&ODC^13\HK.9)-I53BJ[PR?4U#BNHN9QV-5[E2<[J:L[-(%!Y-90\U1QS3
MHIG5QD8-0X%JHSJ_#=K:W^L)9ZC=K80$$M.>1]*BUB2*QOYGM#(^GAMJ2GUK
MG9)CYF2*?+>R31"%G/E_W>U3RZD\TF[IG1:'<#5))/MLGGPI&Q17?N!Q2:9J
MMUI#O]B=XHY!M9EKG;>1TX0A<<YJU]O+)L$GS==M%K;&T7>3<W<ZI;J%F0.I
M<GECG)K7M9(Y$ @F!Q_"QP:X&.^*YPWS"KL.H/M 7EF.!5*3V9VJI!ZVL=E=
M"9N)"/SKF;K3VEG*Q,=Y.,BI-6M+W0Y(A=,/+D 9G5LA ?6N:UC6)=-U*18'
M8KP58]P:UC42U1S5)4:VS.HN-+O-/@Q-<LT>,[0U<3X@\2LL;6UNC1CN[<9J
MW'XPN+E8K:X'S!ODE'7GL:PM7\RZE*R'<RGBIJ5JM3XF/]S'2GN9UKJ%Q;Y\
MN4J6Z]Z[ZP^(<<WADZ9J&F1RW"_ZF[4885P=K;QPW2&Y1C#GG;UKJ=0ELET^
MVDAM621&RK,>&'O7'.,96NBX5)1V9VFBW3:KX?N([ZS66W4@B60[2#_45P^J
MZ#$UX[6@(VG[T>2*;<>(K[50B32_NUX"+PM:>DZC-99=$WQ]"*CEY-8FT'*M
M_&?X%GP[KE^+?[%=6R7<*\K*1\X/;)]*EUS4A?6KBW"1F(_ZOGKW(K1CFLY(
M;>:+='+(I$RKW-8^J:>UG<,S(RQ-TR,9I*5WJA2PW+[T&+X;\136,-V[1QO(
MB;1YK$%<]UKKM \70ZA:B%C(TP7YFD;))KSNX6W9"4#(_0YJ.RDFL[A98N=O
MIWK>%D[G-K&;;=SUJ&^:3."-O6O1?AAX^BT6.6VF.U)#E3FO'[.3[99)(IQN
M'/M5C3U>.3!8D"O:PU98>:J06IFW-2LSZDM_B-"N")?D^M))\1K>:=0S>8OI
M7@5KJP6,(3N_&I+S7I(8R(B%/K7U<<WPLHZIW(:K1V>A[7JOC2UN).T:?6KF
MC?$'P_:PM!=1QW ;^\.E?,-YKT\LF7F8GTS69=>))+60,&)_&N.>9QJ/EC3N
MC2GC)T]Y'UEJ/Q*TM;5[33PL,<@P=O%<I_;T2 K%)@?[->-:1J)N%CE+-D]L
MUUFGS-)@UE5S:=+W*4$CTX1^L:RD=K_;5Q(=BR,R]@3Q74> ]"F\1>([.U;Y
ME=@TA_V1UKB-,0[ S' '4UV7P]\<0Z3JUR]O\TD:;2_I7SN)Q-?&RM-G74DL
M+0E*GO8]O^+7BN'0M'CTFS95"IM(6O!+3S+K4HV;NV:I^*?&4^N:C+)(Y8YJ
M+PSJ#2:I'N;C-8X6C%-1>]SY7#TW!7ENSUR'4C90QJ6QQ5O4-6GL].^T%OEQ
MZUR>NR2K;AT&<#(KA=6\:7UQ$;5V(1>,5]CBJZPD8WZG5&<F_=.NU'QG)<1.
M2W%<3<7?GS,Y/)-9ZZDS1[3R:@^U?,?6OE\;6=>2:V.YU)22N;MO<*HYJW#;
M_:T8J<8KG;:9II B#+$X KT/PO\ #?5-5C#EFC1NPKCHTG*6QK3]YVL<1<';
M,4/45#>*+FW>"0 JPQ7J%[\%;A<N)&+5PGB+PE?:*S97S%7TZUTNC4IZN)TN
MG4BKM'S1XWT-M"UIPH*Q2'*UA%G]:]?^(VBMJVGB2--TR\X YKR>33Y86*NC
M*W<$5YU6"C+0Y[LAVNWUIZ1R*U3QVYSBK7E@L!P!7.45XU?// JUY_R !0".
M]1R95>#3-Q'%/EN1S6T'L2S<]*23&/>D+';P,57DW$Y%5:QFY$VS/<BF,C=F
MJ(2.W0&F><ZOSTI:&3F>Q>!8R/"ME\W/S_\ H;5NMD]#7.^!YR?"MB!R?G_]
M&-6_O/85G9'GREJSO/VN3_QKJ\!?]C-_[-?U^;NZOTA_:Z;/_!.GP"?^IF_]
MGOZ_-PFN=;L\A/67JP)II-(332U6.XX5-'5<&IXNHIDW-&V%:MJF:R[;M6O:
M]JI(DTK>/I7:?#SP7)XT\0V]B"4MP0\\@_@3//XUW'[-_P /](\6_P!N7&MZ
M>;R!(5AMF)("2$Y+<$9X&/;=7T3X%^%>EZ/]LBT.UMK9]ADE>:=59@#T!<\_
M05Z5##\UI2V,JM94TTMSE]9^$^@:U;Z=!YETMII^WRHV<9.  <D#IQ752+!^
MZ)2.1XU"(Y49 'O6CJVFS65\;)]CW$7$GDN)$[<A@2#U%=#H/PLOO%6DM>:=
M/#*4.UXF?# ^F*]Z2I4USRT3/$=2I+W5J7_@[JFG6?BJ!]02)E(*HTS!5C;^
M\<\=*M?'J_TJZ\164MBL3Q20-YEU:R*Z22 \#@D9'&>_->7^(K"]\/WSVMW$
MT%Q&?F1JA1KSQ2VR&P>:Y>4LTL*')SVP.!^%0\->JJR>EB5.T>5E2Z<-+EA\
MR,"-P[CD'!JN?#MOXMU*&">V@DNI66)'GQL&3ZG@#/>N@\1>$-4\+K%_:D)@
MDF7>JR$%B/7K6397;0R.8F6,2(48L@;C.>,]#QU%;2C&I#W=4$*SIRNS/\0>
M'[.QTYM$DT33C-%.TDETL8+L"  F<?='7\:\<\<_">WFADN=+@%M<J-Q@4_(
MX]O0U[V[V<L,TMS/++=.X.TI\I'.23GKG%8MT8+K,>=C= WI7%4HPG[JB=]&
MLT[MGQW-H]U)'-(EM*\</^L=4)"?4]JQ+B+%?4_Q'US6-+T,:+H.G0I;WK?Z
M0R#.6QMR$^[DY/S')Y[5\W:_HMWH>H3V5_;O:W<+;9(I%PRFO&K4?9.RU/14
MG)7:L<Q-'5&:.M>=:H3+UKD,Y&3+'55UYK2FCJE*M28,YK;1BG8HQ6QS#<4N
M*=BC%,!M36\WER*:CQ246&?07PCUN)+.--P!QBO5%U3;_%7R7X7\3RZ)<##'
M9GD>E>O:'\05O(U7.XUQ5*5SZ3 XR,8\LCU?^U#(P4-R:Z#2;'S\,U>8Z;JT
MD\X;80M>C:+K"K"H)YKGC26Y[,JW,O=.XTNUBA7IS1J11<XK$@UH>M+=:H&0
M\TI01$+W,W4W7J1FN=NI(+AC'L&:MZKJ8R>:Y_\ M)(Y"2FXUPU%8]>@NY)_
M9]G'>1>8NW+= *]P\'_9[738S" />OFWQ!JE_).AMP N<[B:]4\ ^)BVGI'+
M)DXK2,;Q)K?%H>V6MXI9<GBM^:^MVL\ @G%>6VNO;<9/%:L.OJP^]4<A+CS6
M9LWD@VMZ5R&K3#S"16G>ZTC1G#<UQFJ:IEF.:JG3]XVOIJ:G]LR>7Y;/D51F
MO$&3FN3O/$ 1B W-95SX@8 _-7KTXZ'!*.NATFJZHJQL-U<;)JG^EG![U2U#
M7"ZGYJYYM4_?9S71RI(43OVU0>7R:Q-6OEFC*YK$DUC='P:S)-6);DU:M;4=
MM2Q)"5D!%='I;JT8!KG(IO.7-;>FJS*, URR78Z8RLS<>S1D]ZHS:>-I/>KL
M6=HR:AN+@(?:B-]@J*,M3CM=MV*,,5R4FDRR9/:N^U8BZ;:@R:2VTD>1RM=\
M&XH\:O%29Y-?V4ENQR*@MU+&N^\0:(/+8XKD(;?RY2,=ZZ$[GCRH6D;7A1O+
MO K5V^K(&L7 ]*X73SY=TC#K79^8UU;;>N5KPLPCRU(S/K,I][#SHL\AU)O+
MOI5_VJA62K7BFU:VU5^/O5GQHQY->Y3ES03/SG$4_9UI0?1EM9&;I5A&+  U
M1$HBJ1;@>M:W.:QHQ-M88K0AN1&/>LE+A5&<U(LQ;O5"-^PUB2UO(9@QQ&X;
M'T-?</PG^),&L>&[9%F&]5'&:^!5FP*[SX4ZUXBCUB.#28I)X2WS 9P*\_&4
M55A?L>SE>*>%J[73/O67Q5M7&ZLZX\5%<G=G\:P_#_A_5=0TV*2[C99"O/%2
M3>#[XMPK8KY*?+%V/T^BXU$F0ZKXD>8=:Y:[UAX6:3S/+QWKJ)/ U_*IPK9K
MC/%GPP\17$;?9RRCZ5S.2D=G-&"/._'WB34?$C?8X;@L,XZUH>#?A1=ZA:BX
MD.\+R=HKG[[P/XA\.R/)-$7[EL5/I?Q<U7PW8SVCJ74C&1P15N#DK1)5:$%=
M;G,?&+4)]!NHH-,3,ZO@B3^'%<3XD^,6NQZ3%;SP+#< ;?,4\50\3^*+V^UZ
M6]E5IF9LA3SBJ6I6<WC2,11+Y3?[O(K:,+;G)/WE?J0:7XQO=1U"&>XN3&T9
MR-O2O7_#MKKGQ#VVMC?N !C<IQBOFOQ'H>H^%;C8\IQV*FNQ^"WQ,U?P[XBM
M[2.YV1W$@!D<_=H<4]4<RK*+Y9(^[_@3\--8\%W#SW^H-<@G."V>U>Q-K85R
M"W2OG^;XU:1X%TFVFNM46[NY@/ESD_@*Z/P[\4M-\76J3PW"1R/_  DTN5R5
MS;FIPE9/<]?77!_>ILVO!5/S5P4=U-(,QN''^R:;)/=$8*L:CE2W.I6ELSIK
MSQ(5S\U8U]K@NE([UC30WDH)6)C^%,AL+L0EVC;/TKOP:C[2_8SK6C IZK=
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MUQTB_O#4VGW4FGW<5Q']Z-@PK2#Y9)HGF[GOUYO@N#G..HS6YX4U18M6A+C
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MYR3;1RVP!B/<XKMFNQGK7*FMSLQBG4DH/H7I&W]*@FC;;DH0/I445Z(YE;J
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MF_:.3Z4[6W#FDWH1SV$D<>4=7]=IJGY:>7SQ(.]:<VGO9H7DD"_[(-06MO\
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M^=2^=_=7-(">.ZEMI$D1VCD4AE93@@CH0?6OOKQEXP7XN?!GP'\<;<"35=*
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MK7C+?:6Q'.5KRR\7R[AU/8U%-^Z>IG%-*JIKJ0LN5--1"O>C=3UDVMTXK0\
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M,UR9 58@#T452+*I)IJ"6XU&*(?LR-[FF-:AEP.*LP%7<\X ZU?>&U: M%<
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M9&*L5!Y-2XZ$QLSK/VMC_P 8#^"?^QC'_H5[7YZPCI7Z#?M997]@/P0&Z_\
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M6_A34]>CBU67<,JHAP1N(Z L*7M4TF]#-U+JY\]:?X@O_#MVUSI]P;><C;N
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M.*X.7N=U^Q D95<8P*=M^6GM(N1\U.C/F<8X]:K0>I79AZ?E3.?0FKWE!<X
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M;3CRWQ9XVUWQM-ITNNZG/J<FG646FVC3D$PVT>?+B7_97<<?6NVTG]J[XO\
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M\:+BUE\;>*M0\0_9<^1%=2 11$]2L:@*I/&2!DX%/E=P/KKX;_#=?VR?A/\
M :YF47%]X*UP^%?$;'[QTE4^TQ2,3T18HVB!/\3FOG?XW_&!/C'^U3J7C-I@
MNE2ZW#'9,W"QV4+K'"<=LQH&/NQKUC0?'G@C]DSX/?$+2O!OQ._X6!XQ\;V2
M:8L.D6<UO9:;#AP\[O)]^7;(ZKMY4G/0U\>XI1CJWT$?2G_!0KPOK%G^UA\1
M-0GTN\CL)9K:9+IH&\ID:VA4,'Q@@MD=>H(ZU[Q^V3KGPUD^('A[7=3^#&N>
M-M%UK1+%M"UW3?$TUK:S6PB 6".)('5&0YR@;/.[ W5\=>(_VC/B;XO\!Q^"
M];\:ZMJGAB-8U&G74V]2L9!0,2-S!2JD DXVCTJU\.?VG/BI\)=#?1O"7CC5
M=&TEBS"RCD62*,GDE%<,$)/)VXR>:?([+R [G]M[Q-J?B+QQX+MM8\"3^ +O
M2O"EC8PZ?>:NFHW+VHWM \SA%9)-K8*2#?QD]17SGMK5\0^(=4\7:U>:QK>H
MW6K:K>/YEQ>WDK2RRMZLS$D\#'X5G;:TC&RL!%MHVU+MI-M589+&M6%45 O%
M3*],R)@M."TQ6J16J@#91Y7M4BU(JT[ 6]!G-C?1OT&:]HTV^%WIZX.2!7B4
M8VD&NO\ #OB4VJK'(V*RJ4^9';A<1[&>IWOVK::&U KQFLV'4H+O!SS[&MC3
M=!EU%AM1MI[UYE2'*?7TL5"25F9-]JQ7C=4=G.9CDUWUK\,5N,-(N?K5V7X?
M1VL8*J*\Z4E<].$^8X=K.2XA.U:R9M)GC8_NR?PKU;3= 6/Y2N:UH?!Z7F0$
M'Y5K"\=4*51;,\,6UFC?@8-=#X=A^U7 28X Z5W&J>!_LTA&S-8?]BR6%QO3
M:N/6HEW9M3FGL=WX6\-A;B.1)>!VKU2QD$<:H.BUYEX+U1V4+(58]/EKMK;4
M-K=:EQT&VI2.UTF2+SQYOW:M:U- <"/&?:N4AU %<@TZ34!M.6J.47+[W-<@
MU288;-<3K$P99![5L:QJHY -<AJVH+#;NS'DUK3@:3=HG :I )-0?TKG]>C$
M<)Q6K>:B)+B1P>,USNL7GF_+FO6LE'4\Z-[G.16<EU,<=*T8=%DR %R:W/#^
MGAUW$<FNWT7PWY[ABO%>?*3/0BEU//H?#,S<E34&H:'-"AP#7MW_  C:+'C;
M^E9.I^'5\L_+7+S2N=*Y;'SQJ4,T<A4@TR#1I9TW8KO?%&AK;L6V]Z;HMFLD
M0XR:T]K)&;IQFK,\ZDMFM9<$8-07@,@ )KJ/&5C]CEWXP*XZ:Z![UUJ?,KGG
M<O))Q-"S\/\ VI PYJ:7PSY:YQ4_A?6$$OE.:Z:^DC9>*ZJ:<M12MLSRW6]-
M:T;>O!%7O#NL>81%(>:TO$GE^2V>M<.DK6\P=#@@UW5**J0M(^7EB99?B_:4
MWIU/6[51MZ\&N4\:V)5?, XSFM/PQK OH54GYAQ6GX@L1=6+<9.*\.E%X>OJ
M?9XJI',L"W![H\HQ2;35F>$PS.A[&F<5]/HT?E+3B[,AVFG"G&FTG$09KZV_
M94\4QKHOV1G =25QFODBNQ^&WCN;P7K*2AB('(W8[>]<N(I>T@T>A@<0L/7C
M-['Z'1ZQM/WJNQZT,?>KR#PK\0K+Q'91R)<*'(YYKI%U)^JG</8U\O.@XO4_
M4Z.(IUHJ46=ZVK!A]ZJ<VI#^]7'_ -K2=.:22^F?@ UC[,Z[F]JU\D=J6W9:
MO/M8\07MJK/;SM&![UJ:A.ZPEIF(4=J\L\:>,$CW009)Z4<JN3S<J+.NZBGB
M:UD%XWF2KQ\_]*\UFA>P,FTL@R0"#VK3L=4F=B!EBQYHU^)4L_,<C=CI6_NH
MQLY:I'#WCRVCO<1.RMUW \TSP_XCU2^U0+]HDC Z.2<UN6>G/,JW%P@6!3R&
M[UNW6K^'YK18K/RC=#@$+C::PJ.YHH.+/2?">EVVI6"/K&L9C_VB!BNAMV\%
M^#7:[MY%N6[[CG->(6?PUU7Q$6N4U4QQ#^ L<?E6]:^ ([> 1WVI,XZ$ X%1
M%(:M>[1]'?!S7M.\=:A<7EO9HJ1D@-LQTKW'3;55.<"O(O@#X9T_P[X5S8MO
M#]6SFO8;&0"HGOH81DY-RD='I*H+B('INK:\87T/EQ118P!SBN:MYMF&STJK
MJ%\96)+9--.T6CDE1]I6C4;V,W49AM:O.O%$G[M\5VFJW(6-CFO./$%UNW#-
M$5[R/6IK0\B^)UN?[/27N#7F;3 "O4/BM=I;Z&,]2:\9FU ;!CK7OT=$</=%
M+4E\ZX.*8MC^Z)Q4JC<VX\DU;4A8CZUZ%'<Y:D;IF?:0[&.[I7$>+I%DU A#
MPM=GJ5\+*V=N^*\ZN)#<W#R-U8UWO8^,S.HDE3+WAMRNJ0@=2:]1AT<:K((G
M^[WKRWP^NW5K?ZU[5I:>6F\'G%>7B9N,E8];)HQGAY<^US8L].M=%M5$:K'M
M'+5CZC\2]*TUS&\NYAUP:P/B!XEDL[,01R8=N*\FF8RL6;ECU)K.G@HU??F+
M&9S4PTO94>A[UHOQ>L%NE>"Y\I\_Q=*[ZX^+']OZ>+::."9,8W+UKY :,+TX
M-7-.UZ]TR0-#.V!_"314RV#7N.QST.(9\R^L1N>Z^(O#^G:TC$PJA/<"O,?$
M'@:72\O!^\CZUL>'_B(MX%ANOD?UKJ7NH[N'((="*X(RQ&#E9ZH^CE2R_.:?
M-'27?J>+8"L0PP1V-)N -=_JWA6VO9"T?R/[5S-UX5O+>3:(]X]:]JCBHUHW
M3/BL9D^)PL[<O,NZ)?",1N-47 )"]37<ZX!]C8>U'@/0[32;662^XD8<5FZY
MJ"EW56^3/%<%3$J59*/0^MP.7RHX'EJ*S>IP-PNV60>]5F9AVJU?-_I+U$J@
MBO:W5S\ZJ1Y9M$6\^E&XYQBI_+%>G?L[_#5?B5\3M,TZ1=UK&XEEXXV@]*B;
MY(N3Z!"+J245NSO/V?OV0]7^*L":KJC/INDYRNX89Q7V!X5_96\&>"[0);60
MFF YFDZFO7=+L[70=.M["RB6&WA4(JJ,=!6M9K8SQDW$^P^E?*UL14Q#:O9'
MVF'PU/!Q4VKO[V>27'PGTY%Q"GE@=@:QK[X9JHPFTCW%>M:I+;QR,(7W)V:L
M*YN%.>:\MQ=]SZ>G6<DF>'>(/AO<QJQ@VJWTKQKX@:/XPT*WD>Q,;HHR=J\U
M]<:I*FUJ\U\4^3(KY /UH6AUIN:/@ZR\:2-XXM?^$FGE>S\S9,AXVCZ5V?CC
MXXGX?^-+4:/?'6M#2,&.SN&W*GJ!6M\7/A3H^I:_%J-S<?V=9R';)(O3-5])
M_96\*^+H1_9?BY'N2.!(PKLC+2SV,7"[YUNC-\9_M/:)XV\,S:<GAF"SN9UV
MM-M''OFOG/5H(4NC'&3.IY^6OI#Q5^Q3KOAK2KF_36+6:&)2R[>2WZUXII.F
MRZ'KD,=X(XI0>4F&/YUUT_9J+Y3"ISRTD</?6JHJJ(6B?_:&*S;A JCFNO\
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MW=3S4T=B/4TO>*T+UC&]TW XK1ETV01_=XJ;PO#"M]#YR[T# E2<9&>E>O\
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M:@B)24$VSO?!>GKIMJH(PS<M7L'@'2;+Q%?/;W-]'9 1EE:3H2.U>007@AC
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M/.:DU#QY)8VK0PQJ6Z9-=/)RQ.=/VDM3R*;X0W7G37,TXAV\A%YKS_5M>O\
M1[^6Q$JE4.-PKW:T\/Z]XVDD"WQMHW_AB'-<;XE_9UO]-DENI;MIF;G:>2:P
M51+1LZ'&70YOP7\7]:\*N%AE9HNZ[L5[-X%^/5QKFM10W92)&]6S_.O#]+^#
MVO:E>",*+:$G'F-7L'@/]G#4-)OH[R2\CN%&#RIX_6MHRBF<\[VLCZ$M?$$4
M:^="XR1G@TG_  L#3IIA#<MY<GK7)V?A^\N-<M].0@+_ !%..*]'O?A396]L
M#Y8DEQR<5M*I%*YQ^SM.U]1D.H65PH:*\7'O39-4M+?):[0CZUR>J>$Y;-F5
M%91[$UR][H$^3EG_ #-<[Q$NB/1IX=R^T=CK7C73K-6,;^=+VKQWQUJVM:ZK
MN%9;8?PKU-;[>'923P:LV=JT/[J5=R'@@U=.HV[L=7#\JNG<\"U!B^1CD5AM
MF.3\:]8^)'@[^SIA>VZ_N7^]@?K7G%Y:[?FQ7J1ES*YP/4BA.[K5AX=RCBGV
MD.[%7'AVJ*WI[F$U=&/-:[E.1VKFYHOWS#WKL;YUAMV+>E<E(VYF/K7K4U[I
M\=G%E*,1]B!'<*:[;3-5VX4GC%<&LA5@:UK:Z(Q7!C(ZQD=^1U%[.<"[XCN/
M.+ '(S7,MN[5J:C-E">]9'G>U=.'^ \K-_XZ]!ZJQZFG^74:S4_S,UU6/#$*
MT[%)NYS3@<T[ P"U+;S-;Y&?E-"J*ECA4^]#@I*S-*565&:G#=%>XN-V>:S)
M<[B:T+V$(,]JSI&W+Q7AU:/LY6/T;"XM8FBIH2R?]X:TE4DUF6*GSZVPH4=:
M]3#ZP1\=FD>7$-]R)4KH_ GB:?P9XFL]4@)!B?Y@.Z]ZY_S%6KVDZ?=:Y?1V
M=A;R75S(<+'&I)-;RBFFI;'E1<HR3CN?=WA_QE;^+=+AOK"995=0653RI[U+
M<W\H)!R*\[^"_P"R?\1;98K^;4_["MGPWDM\Q(^E?3&F_!M(+,1:A>?;9\?Z
MQ5VU\;BHPIR:A*Y^FY?CI5*:]M!IGC<U\_\ >JA-=M)U->U7GP5L6Z32"N?U
M;X/K!"WV>8N_8-7#S,]Q5Z>YY/-,?6LR\N(UCDEF<+$@R234WQ @\1>$XY/)
M\/M<HO25&R*\ZM;ZYO-'NKK7(F6:XRL-L#C;[FKA%S=@]M[32!SNN?$K7].\
M3"ZT/4O[-@7A8Y#\DGX4_5OVK?%NDZ3=Z7-';M)<+A;J'DK[]*JZMX,TG7K=
MH8[F6>**$N]P$)5'_NYKY^FEO(+Z>")FN8HW*A@I.0#UKJ48-6:.*<^63BCK
M+KXBZK)9W+-?+-)(2S%TYR:X&3Q!%=WGG:@IG85K2B2: AHU3U/>J6L:/IEO
M8VTT,_FSO_K(_2NGE4?A.*JYR6C,6YN([B1I(E$:9X%5'42-DG)KH[K3]';1
MDDAFVW>>4S65+8>7&&# U,HR9R\CZDV@^"]9\73>5I&G37KYQ^[7(S]>E>AV
M7[+_ ,2H[=+F#1;I6_N*!D?K7/>!_C/XB^&=G=6NBS10I<G+LR9;CT/;I7O/
MPQ_;'\<>=IR7&F3W5@K"*:\6%G7DC+$@=N:Y9<RV'3CAY.TF[GJ'P"_9JN_!
M-Q;ZSK-W</<L@/V=CMPWX5](KIJS*J11LS]@O6J.E:Y=^-H+2YM;NUOK9U7F
M%2KJQZY'I7K.CZ#!I-LJ@;YR/F?WK#G2C=[GH5(^S:C'8\DU#3_%FFS;[6=5
M@_YYSC=4$>O:G#_Q^06[^NQ2*]FO+))P0RY%85SX4MYLXC!_"N:52;>AV452
MM[Z/.?[=MI!^\LW0^JM5>>]MI$/DQLS?W2<5WMSX&@VY:,K^%9-QX%CZH2E.
M-2IW.APH26CL>8Z]XP.BPEFT1\YQOD?BN1U/QGJGB"+R25M+;_GG#P#]37LV
MI^&MMNUO<Q+<0,,$,,UY3XL\,KX=FWQ9-H_*D_P^U>E1ES.S.-P47KJ>9>(K
M-69%[]369'.+&UD<]AQ6AK%ZLDKL3QG KEM4O-\:H.F:].GHVR:K]U(M:2IN
M)#(>K')KL;&U'E\BN/T.3! KI-2\1VV@Z>TLK?-CY5[DUUTH\ST/.K34(N4G
MH>:?% )%K2*,;MO-<>IJ_K&H3:YJ4MW-U<\#T%01P>M>Y&+2L?G>(J*I5E-=
M1(P>N*F">IJ58PJ^E12RHHQU-78Y]R.22./W-57WW#<?*M2K#YC9(JS'#CM4
M\K91':P[, 5H0QXY/2HE"Q]32M,S_*@_&M+)&>K)IIUC7 ZUU/PO\ W'Q UK
M:^8=*MSON;CH,?W0?4UA>&?"EWXKUFVTZU4O+,P!(Z*.Y/M7JGQ"\36W@'0H
M_!WAY]A5<7=PG5F/49I;LQJ2:]R'Q/\  T_'OQBLO#UB/#_A6&.*&W'EF9!\
MJX]/4^]>%ZEJD^H73S7$KW%PYR7<Y-0O+_".342_*W W-2;>RV-*-"--76_<
MGC\V2-4DD=HQTCR<#\*]<_9UTU+KQC<R,N%@M6<?F!_6O*H RC<_%>R_LXS*
M=:UG!RRV3'_QX46LA8A?NI'(_%[6EU#Q=<QA_EM_W?XCK7,0V6NW7A._U"V^
MTOH%M=PV]RRL?*$TBR&,$=SB-^>W'J,L\21M>Z_J$[_,TDS-^M?H#\)?V<EO
MOV+;WP]+;@:WXDMFUE-PPPGP'M1GJ!MCBS_OMZUE7J^SLWU9I3@J<(Q/SG6-
MSRW%6$P%.*DD@:-V1E97!P588(/I3-NWKQ6O+8Z"O/*_9<TEG+/!<QSI)Y4D
M;!EQUR*=+(.@YJ.%'=QV%3RZEH]@\4Z:GQ&\#0:]:Q*=1M%V3A1RV.O^->--
M<2V,C1C(CE7#*:]&^&WC>/PE-=P7J--87*895Z@^M<7XH\BXN+FYMUV1-(71
M?1<UAB:?-2=MSKRF<J&*Y)?"_P!2E9*205'%7))/*ZHW/0XJ#2I0RK@UT,$*
MS8#8 /KTKR*.,E27+)71]?B\JI8M\\7:1C1S2M@*OYU.869LR-^5;MUX5NHK
M=9U7$3?=<<K63<6=S"0&4_4=*]FEB*=79GR>(R[$8?5QNNZU(_)_N\"FE3N"
M@5<M[5O++L>!4AC0X/0UVI'ELIBW)Y_"I%MU'49_&IG(7IS3&FQ@<9JK(G47
MRUV_=P::T8VY ICS,K8YS].*:LLAP 3FIT*46/ATVYO-SP1/,8QE@J$X'J:B
M:$[03QU'3O7HGPA\02Z)KTEC-Y4EMJ">6QD7OU S5+XC>![^Q\4+!8V[2?;3
MNCMK=69@<$XQ^%9\ZYK,SY[5.1G N"RC"D <'FEV_-]XXJY=:;?::TEO/I]U
M')&VUUDB;*GT/'6M;P=X)U'QE-?"%?LT-G!YTDDJG:.0 OU)-#<5J;\RBKO8
MYCRD;):3I[TTQQCHV#6CXFT$:/J0MXW,P\M6=MN &/45Z-JGPST>S^$]EJR1
MS#56"O),6^4@G&,5',M E4A%1;>YY0RQ#'S%C4B0K(O"&K,=BB<8W&M&&R*K
M]W%:*)H9:Q-&NT(*M0POLY'2KOV-BV=IJ0PNG09-78ST,B>)XU+#G':HU87"
M^9NY7M6Y]GW+EASWK$NH1:W#$?<8\UY^(AR/VB/?P%958.A,M0PAE/>G,NU>
M@JG;71MVVGYD;D&I9+@MG XS79"2G&YX]:C*E-P'R*%0,.355;DI(588]*;+
M(^W X%5V1G^;&33;(C'N69)-S ]JV?#?A76/&FI)IVBV4U]<M_#&O"CU)["J
M?AG0[CQ!K5II\8)DG<(/09[U]L:/=^'_ (1^"TT3P]"@U&1/]+OB!YDC$<\^
ME1)RMHC.;Y=$M3Y\L?@"VDS*NNW:M,/O6\!R%]B:[?2=#TO056.QLXT=>-VW
M)K3D6ZUJ;=!#++(>NT$Y-0W6GWUG\UU;20MG@E<5TJ\5=&T8NU["37\F,DA6
M!Z 5#-K;E@$++VYJ/[;Y<+(T8.X_>/6J'FAF/.6_G1S:;[FW3<UX?$$\ ^]F
MLCQ';V/BBV,=W$GFD?+,HP15:1BK$9^M5)KC;QT-$9-$[Z,\UUWPO/X<F<OB
M2'/R2"N>EN'D;(QBO6=1CBU&SDMY?F5A7D6K6%SI6H20$Y13E6]13DE\2.6=
M.VJ$<%OO'%0,JY]:1IG[D9JK)YI[<UG<QLRV(P><<>M='I,,:%40Y4]ZY%KJ
M:-?N<5K:!?-(K1D$,O-=^"J1C4L^IA5@Y1.JOT$,BA6SBETV\,=] Q7S0KAB
MGK@]*RVGDDP#DGZ5<TF06-X)KCY$49YKWW+W#RY4]36\<P0$)J4"B-I3S$O\
M/%85GJ@V %L&J^N:\U_)(@XA)R*PI9)+5E?!"]J48OD29P5(\LG)'817S.Q
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MN.YONBO+^NU2#XC\!_L.>-? N@ZA,FI^'9->N5V12_:)_+C7Z^3G]*\\OO\
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MWH:S[E79=Y/RK7H_Q TB,(65=CCO7E]Y<-&I1CFO.JTY8>7DSCJ4W0E8J27
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M^E9:Z@PA:,'*MUK4T_3KR.V%Y(WV.U/(DD/WOH.IK:,;O17/045<@O+.:-R
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MNOB!UB#^VUS^;,WU">MX;W#_*RS+ #5%A ,)8^L4STI7*/"POO_MX*]K2YG
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MZM5[2]&=0^8#(U=I(!VRHKU]Y'\+57J(*CRP;S/C.H[:]O? _'?=?Q%#6&?
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MPD#_QOGP"H)_;OL?RPO];S%V5R-]U,\$YGJ&7+Y=R+&@V@U]4NU<*V,/.0[
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MS+4DGI];JNWJZHA>O[#QZ@3>)N(H]':?3"YD4XN>=SUD+"JZ]]_^[Y!DYG>
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M?\J=>]_,),0M<!\2/+.X &T R7#4X^BV-9U(?Q;/2LLIGB*8CFD(HVF7YQU
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M;-BB 9WT \G]L[**,8\GCCUJB5/PWB Z22K#FQ?8CC63QTJ<:22V36(.)<F
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M-<_?0I(#D"I;B\ZY-9UQ>#GFIY;L[8+E6A@ZMI,;9(6N;GTL*Q.*ZZXD\YL
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MIFJ13*/FS73!QEL2]#;B9FJPL3-VJ*UG1@,&M".1:TL9W*,EGD'BL?4+7;G
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ML))(8Y0V1QS4<FEQ_6.:7*>/ZSI>FW=]M9D$B],]*YS7OB#%X8/V:6P2>(#
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M:WCNCG]\88A*H9AP57& 17W<: $W&DI: *0QNW/6G!*<%IP%,!FREVT^E H
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MU8RJ)+35FG*>]?!7X0V_@_0H[FZ16NY!N=R.<UH?$/QDNBQ^5",YXXJ;Q?\
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M(H(;/XUY''*R_=.*O0:M)#CDUZ4,4GI(XW3['KD>K))WJ[#>(W>O*+7Q(Z$
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MM!-TQG4;?E,(/X2?\<WUYTW% ;<.#U4V8:<,SZ 1'++@@,*2DA"3MF/ILGM
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M.)D*B[WKRG]PI,1[-.&&^>G60+/^W>"Q,]H+YW^2;O\_DJ,GO:M4L5>TMQ_
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M:E*39DO#X=HQB5\@]_E%7'U%7;J3\)[IT8VF/W[377835IZW+JTNAYBJJN?
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M;BDW5*IP70R>-Q,M'-E9=)M$((A7(]JF6UA'2-?RI^ZC=5<L>QC*O5EO)_>
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MQW47X1N7[XV9 R!7W[H?P?\  _A34HM2T?P=X>TC480PCN[#2X(9DW J<.J
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MS^](Y'W2#S18:E<^F-Q7I2^>_P#>(IAHJK$N3%:1FY+$_4TE)1FF3=BT4E%
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M-?EQ_P $J-,N9/CQXAN%@D,'_"-3Q^;M.W<;JU(&?7 /Y5^J\>GI'@SR!?\
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M6S;ZS-9ONMY3S[U3:'4]4U438WQGKQ73BI4N3W6B,5C.=6N/L8_[/TFYE?\
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MA6=\?V=[]F2TJG6PIYJ!MCU<U*[QU=8[C3O& ;<FQOS^&N_@;<V#XX;HG]P
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M_5-\[0(@> &@(5DOF5-7>\,60\B5E%F2X%HD$_/S5G*5P>7_306<MRJ5!+N
M"H4O +N;VZCCE#2@$%92Y 2V:'TFUT+*5OHGTZX)W-+?/,&"CIT##@6$;.].
MGX>@+@ I <@+@.B>NG+Z$7S&G33O[U%P1O-3XHQ8<%9>=QJ;1+;-!KBG>@'X
MKW%F(RFNX&\+5"13DO _/0V'F   SJ\0M/B]H.OW!>":-7!/#;0S_4_6Y0+P
MV_#2!0!C> &((]-=%^+!WBF:5+  VEV] '#^LQ-D9WZ\P#/IP)).<SQ1MZ7_
M*& A]@(PWW !&".0<>1O6%E I\ %H#WX E!A0]:.+7\O0K;9_%@LH./\#JEW
M+P0^.6)-\A*TW>T(^*U?? $0JR(/&Q5I'D=UQ%MVKG,!."L'G<;&#?(<"IT;
M=5P %KM)&L!=T,N@K,DQ(_-U&&F&!#TFFT,%O0#DF),-I?AGZ 6@80"T\CU@
MGMREL1(_BQ3G"T"N5,K9\06@-9T\(TH'>2GCYFV1!$.JY^E;!=VH(V_<N2[5
M?]J*)K'F7@#TZOYK!W8?Z=="REM(V5W\;Y]_7 !&HDZ$YI4.,B8FT?X^_YJJ
M6XDC]_I?6X1VSUD2I<_,N56]6L!M3YCFUEC1;;^<E>F"#-3X)3V3"T!UGES6
M29/\O$+@+H]J5Y29@]J>?8H.:01(X#>_X@]LS5P^O-<Y<_[NMGYL]</;'#,J
M8Q[T;06YK"(TA<<5 :=:G@OG18ZS80'NEI>K+P!-\KR#LO;YXZM&!^G.N8@X
MC5K;7)S@FH\?@!D@"7CM;+!NYJ?:Y5*GL.=;]JCA=1:W!H\:N7="['U4ZX]G
MO]TPU;4Y>&%X:,Y2_<8KZ23A[2$EWZ=_9X 6K+//4P*-<FPWI.&U7)X1UH(C
M,7D3F;DFOL^'-A0Y^CG>[.?Q4TKB.D#9/<O4<(DP0EJ&7Z4)T!O+6975IKE:
M<?.D_PX2;N3[>Q]A:_/#]K1,"CY>FYENFQ"\R@=L3BJ-IC[^.#W]-SSC.WE'
M]G=G\@H_@UI2)\!W[Z^Q_\UI&^^"!TF76V:NX3JT?H(Y@Z);<ZMX9 N5GM9\
MXO[NEUVK8;YSGBU;A_"=DY46[1 +8NS96:Z%$>1=_/.U_[DG&R_Y_F0M<EK^
M7UH64_M&/J;OYEYZ8LKK]P'7_?DTMB:-PQW0..(37PW&'5TY0Z6]@I[-(-"]
M:O$9 58&^_RIVCXK>LE'Z /Q8_@<X^#6)E(<==/4ZP2Z-QCAOY/NB]]GN>-3
MSC^2R<(+%0^>7_(T6(N-Y=U5)8(TSURW%I7*/V[NA7QK;N"4'?KJF:!>'0PG
M<%!+\IE)36V.I$-_?C5&_-EDF&J]_^<LE[@7$,[*NGTY7^@^AT/.XE7_Z[6G
M5[Z_6<&V0B6&-_SA$7^VOQNZ\KXW,TH/T"B+7LMY!Y)B'O@[+:[9HE]<:[%E
MDA&Z9JMI96Q 5%%^]08M3UCJ;)FQ!XIL2<:KME%MB%6#L/)8'V;56[2233YY
M9K2]M< CS5F3(:N@07H+0?4\ZMNW=S''IG5PU)TSB<K(6(FZ.E2&\.W$T^1/
MM0%'XZ>*GE6S@0N=FO-Y>VY2*(V/$5W2M*1M,H7TM\8T1\^E;71GM1U9TH5$
MH6UV6CI23U^>&0!I?.'.XLESO?@Q?.7>)&D0A/:RCM8_0SH%U;+AX8,)B>.C
MH-<-4ZG!.$:]@2CN8S$O<9\_Z7_RI.*)6=35&'/. O($>HE5Q"-"E!4T[PW4
M\<:U83M@A6 MSKA65K1M.\[+K2)4#Z*U-E/B*T/FD[3X:V$Z_!J/YT=_T #C
MUG6,.@62ZCMOE>ADMQ4EWC?2S:816\BOC.]OD'J1)2,?G#I.ZCK)[# R;9!!
M3;]!S9OU3@4$1QUQ-91N5[\6O:N\8=M>>V<,4<L]],08[V_#]N7*?)1\0 $+
MWP2(D%$6^2C*45[RA/%<B3,],">9ZXY&\PEBPU^H$;WMQO'3$XG4'P);:JD%
MU<LP=.Z6Z,[.F:$5&3XZ4-&D9"/"_9Y:  #.2#L)^DUS749-F93;N X')0%3
M JK[&!:[;G+VWE0J'U7O':/O/9#8%]Z3]]E)'HU^1:Q\W X9<C$Q/HO(BZ!P
M1F(S.YF]OT6M@(3EXPLR:KD]*5X.G0$=\Y>+E:A#@!TY2EC/Y-#,OV8=I6L-
M'?[H%B4:QI(QO*V#FV(,[LDM3,K=,^B[S*,H+6E9HSHPHOYH,@]>&8LE?4%6
MD-;AJ^9W'<0(IZH/+)D_\7W8U@K<:#1WO-U-OY^_!BK*Z9^MO*U:$)RYW.I@
MMF45[N>.ZQI\&#/+3Z!%%5P WFFXWQECFFME*C0DT6V[)0-OW]MJN)Z37W"0
ML)H0C.)=E,JOT-5<3F^#LK]K6VO=)&R+V5\?N^Q)@YL.N*^"G0"+66\D#@%E
M/]E^^O7:JF D+D+NM^:D49N;I8-^F006F2("7_/6:A2B5YHYE=1MOPQE3H1U
M@.AE'SL]EA@TGL7(:_[N?T^S=K!+"U@(71:8*WV;_)C3+[<=_RE<]>ZGX13P
MEXY$84B!G,]Q^NSW??S+ =V.)\&0&F=,!14RY?WF(_H+P-NAGEK^(T?+@F41
M%68^>DABUK*Y],JSI\ME?<;%CL*EHN9)"Y)V^H8<6#Y<_[F/ "YV43LZ4$;%
M[0(0)&Y_!H9S2CQDN #80)<<\8NGT7S^XBVM')['.KG'Q.9AA9^GL 3F^DG:
MS/URBV@2D\TFZPPW:3?K#%&-V<>6+T"[!\OA[Y(=Z]@E9B%>G"%60FN-S7%W
M=,T;HZWM9*T=;UFQC08_0B[WS9JVEH&?1DVYM-1XB30@DZC[E<2;=.J*T?G>
MA=-C5]/A?779$Q-GRE'';ZE8Q\=W]?A]30Y<@@WI[V^:5+9@T!:L:)$N89?>
MSN1 _N!K&D;41.DDV,RU\STK<?1/VS@9K$5G.ZN*.%NS'*]>1'7.7R0Z:6'#
M[R[=%:7;>$V>^_SN%I+PMD^9+Y"SU@5,C]F#\I1L,70T(JW((+>F:(6W?K8O
M)YH\6_/V$B/VI<?*\%9]SW2LSK'A.><S?)H/<0V'GX;8#V);)C+CAZLPW3$2
MXTG=!X,)#O)Z.O"'38,]*;'"Q[ [Y<0-[%J/2^/&W-$':M\0))ZKD2EE>J:\
MOC\A>^>QRPN65Q.2-='I]_6PV]"UI'>.787O=1QP?X(W! ./W4.SJ43*%J$C
M._JR?UJVLUPU<&WR;EJ+PBO-\5$^?5(X5\W&4^.[Z=2A*:J>X1> 2IM"P;+O
M"39-,NUVLW \$XC*S/R#1>!W/]X8]2=?PZ!S'9E-3]Q"IEATM(Y?-VSE"I_)
MU8U=^DK2.P9:)BU0TXTH<?(XV0Z*@3[322PQ:L66&D^%.=VN#CT>S F;*)4=
MB5^@O3O6$OQUN)(2;;?@$%D(5#U,HIL6_S1&)?_J$<SV G #%.1V]#PRO4LN
M5WDZ8]_ZF@,;EL*FJ7@>N'9\:-EN=\YGK;&EB,OF%C;^IRRGTUU?ZOI6S 0(
M,<9(H&0%,HP#6578EZ',TG7574;#Y[!;Q,P-3SW@#?<$U+&%TC2,_8@K]U#A
M&$8P/W/NX>\_MA#=:W+!X-9IK"KNOZ+JT8\(?](_&V&/@1[!4ZB(1$JC4]>M
M^S9I2<^O_?<@V3=*(P!/?53L]UM@ZI)?$+5_+VH$J+6%;=)B/UZCUD%>IRZ!
M/*^/_?>!:)P'#_</BEP]Y, =;L1K@]-QA$09C(4G9X"-P!E3)LT#RU:9X,\[
MD%R&?%=UITEC#-)NB#2!/EU>0>'J%X%6J0FEF%;86\)J:6X1S0I?=Y+4JQ.$
MP5<H+)3O^W)KA31CM+VD@*5'1#*4S2!?^70 _O:.WJ>^^O4EV[1D3LC8;B'#
M.]Y5BV43HGU.NU/[$";2(68;L_<FY$N9O.7]J('/U>(*!T0OM_U(XQHA5@(1
M1U<L"Y^VU3U*4RK]B(FSYQPI3FI6<Q-UQEW'CF),RW]\NPW_G?U1 X2]TN]=
M(ZDLQ_L$Y\1C, #%#$=Y)?=? "20P4X./'"7M!J"U@)P :/U]*3OCGBXW$UW
MCL.WR6_VT]T56G'7Y#I%'$!^7/&;*J48_6]4N]P/]'Q4<,?^>S>^J:@MZ/F;
MUT@X3.Q=DHA72MK4]A=+U0"H+#+*-F=^6=?A[1%N?VR&>"$J@3#V41%D0O!P
MENU= &[)<,,C>@WU\)2JN]:I@;\LA*,(]&--GR9L@RY18Y;WS.\&OCYD/H4N
MO2GKLZ3\8(5_X9GBU]TF);[H]WY$+9;B+^2/92"JI"#W[&Y[0R5W^5<9BXE>
M[[("8NHVL-$6>+?QP/LU+([>JEMAPV>(84;K:[2I82B3UOBKZPQDQWS-Z;V$
M )?19J!\D:RL@]7&LG8OG7NXB[W.BLJ"R\;BDUS^,9JL>!3VZ6*-G6]_QMQ&
M:^W?O<D21B3R)L=NR*KF;FQJVH<GHMZ01: 1$@GXR;DOVS<XR[*"I;[DGCD^
M$>A'T!;>QXZ-=P*,;)'AN+TL[LRKX3QBDT_[;#*NA@HH%T&](<]I8Q56=5L\
MVB?%GS_C67URAZNB1KHO8Y/"RN8\F^6YYZZZK0_\KE([]$H?NFI(]N?>?*7<
M"?,+5#I.;BC^34G,MW?,C)\T:%H>7=G#W10>0Z(=$IV89RK>?4(I^EUCY4?C
M]:/\ ^F(;X&_$%7P?- 7$K1(**-95-.XF8*+8BNO%BL8ML?>1*_BJS<BM8LK
MPXHMXY=-'YHY@)P1X,I01^'+_FB07E;X;".#W7C2T)]Y8RU'U? \)F)E@0BM
M@\5,8GT?T"5U&G$@_3CQG>NIQ[[2(SMC(H8<JJY](BK\80NQRPMZNE#LZ9V;
M6NUZNPBQDB.Y25[]6N2P)O\;?KZKJ2$R4#YYHG?*6-<&9]8W%:!YZQQ@(1^3
M\D8>/<HBV/-,PC\FP,KP\Z>6'>P:X@+ XS\J1"9A?V;DZ_UXR(&OBM$^V"6
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MZT3R1EJ9G8B#M8F_)OQ_=VC\3%^.XRP4>-H[;%/YY6O<M*&T]$9(JBT)%&%
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MXBNA4\3"-QZ##ZS!RG: ZEE8:I65U/#!.J1O1$+T 6C23.E:N&")S#KBIJ(
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MYB\/,ULSV7A1QO5-R';IT=N0C5.JA>:@MQNL)YV4@I7"4F *J^&OP*,>;*#
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M8Z3$N0B69:B-U%9Y;M8>5OCM4 J =O=0ZD!KHRF0P!(Z<H,-[I618!EX:^I
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M!]800!9FD,4R"%RT"'K)X9XU+&D^2P7$!YTN6%0I<36C#!9!7%\-8"N(ID%
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MPH0Z(0KK1<)Z3BOECS<38(#1_VU.RC;/71+?@A5OMR;\1IH>/\VY!P];3EH
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MQ-?GX^K?[[XC&\NW+"1X:C#,I62OK , =D!J9@M0R\>75?0!<?61B[=4ONX
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MGU"V2&:UA:'5<*[8PM!#@Z&]!XY#+2@E[W-12NX7BY:THRT>K8B%ZZU>].
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MYAYZ)L]+,%??J]/3'- *5N$A&@!==P&]WK4.=+/^A.WQW/NSMSNKE] L:&[
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M6X.S'#N8'">G_"G9&&*0#\_7?9M4^5]0]G8.IAZ(Z-[/M[_P39YQ=3N=-68
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MQ=M=O#^CJM-.X7M.'+ZU#&+D?ERO:^AUL33P.$<,5*">QG4NS2$#F)[W4<0
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MI?VT. >"T2';BHI.TDJ\^FN5[O_NA*U"^\A'!MV9@\XSKI,K*9_-(^$.P3-
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MO5?GU_&W=Z_V#AX^3I.?"_"^N ]^/ML[?'!$?_\[/6W]T?W][^__AQ8F'9K
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MN .R9Z<<;D*I(5>O! (DKB=M2S502PH37CO$N$>;J?H1+K6];GFKPXXO!"$
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M%FQ#I^V=<9J\) %/YJE>IW<OY3;Y?E#29%NI[NB]=!H+SMZ&>' MCH3 =O]
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MB@NFM>]$GH.7N5(\2%,CHHK0FRE-$1Q!=:WZ'PL)O)PS4G QW#<AIMO29P7
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M152/=HR?S#F@:A<=A1<\M3&DNC<(HWJA2X2'QAB5#/EC;E.< *"W"P#Z8 *
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M>SB(:1\ GH+3.5T5T7SN$);]W[FK"I Q&4FQS%H<SQ@J@(JL6:IQE,-J<@)
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MQS]IS4%:9>-#::0H1FF("6Y\5<EP;=#GAM608R=O/EA=!%(G['CNZ8;5[ES
M+MU^*:5MK.3M$(Q"8=P*=<RM#BM#QJVO\,HQ&DY:)H6KH]39(X*D9#*^!,^"
MR$DJV<+DT;J'E;@\WC A4]/W\E!CM.QZF/2 _RS2O7SK/?57EV2WPY1FJ&Z
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MFO?0O)DV'K[J_KVI.[IXU]!BXN;"QV7=2[$]J<^SV4\'.@J^_$*^_P6TG"P
MCXE_P,=T-WE1U.21AG7WLM#N7 9L;RBX%"_NI\>OSNTA6,;.<Z22"_:JJ&A3
M05I!PU6^-&N5__CT1<A9]4)4NL,OKYZ???7UU[*U\'5=7X[2%=Z_>^\!'H&%
MT7B3>ER4_\2^A,<#ZS)=J<^R^3",&2='JCJT(+N5ZKLME6(VTKK'[="P/[3V
M6XVE^2]Z^3!/Q_/9KYU=.G[*!SF-7JAOM)[0 70:W'O\4;NE$TCF=H%DOIU
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MK;E"7CC30Q(@O:E+%;A75-9QNII!=W(I/!VB7H_;1[]X]/K1%_3<>,22$WP
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M1OU)9L#0Z-%S<JTL7%_&TJ)]O$C.62?V<K5-CDL_=7<XJU=G^WK!*&493<C
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MF= [4Y(%Y$W:DY\IWR8=S"TX+O'0)Z+6H"78'URM$$"Y3,_N^+8G%N3R6@?
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M0JR]2Z [2J'A9N*1ZTC*F(1YW_$Y"QZ>AO7@WO[F'%WE35 /'L]+BXYM0D<
MK>,\F91P?QC,%5>RQ:46O[2P5]1H '3C5] _9V%?Y&_M]GDIH^1RJ0&NXPQ@
ML)S:OE+R:6.HJZ1-ALTR&_7$KNF; ,ED],!_*)U_"W;M#^ O!(:0?IC'1LJ.
M->CA,SCS9U#VV5GN)WBOMVJ,;X*]=U0VG>4=A_9)HTI+^GAZ:+.8Z1)0'0=>
M:7]P%I)2=7?@Z$7(ILN* WDDZ>+4S'ZNV\,X! D'DK8U#!HU&U8KYLTG$,N
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M@4:DW91[55EM.PC'<H=-Z*ZIK=_&F70L^JFZZ>1R3+9]\[;]<_206V: #/B
MO-WX_DGH1_.W KTM"AG6=V"UJJJ@2/% &[8B%O)E;()0PBB#LJ +V9QLW++G
M<5^O%V%: M,2^)..B[55;H_!^?[CZF 3'EKPT)<FQ.X.2!HP"F<8XU72R2BX
M%F:\A78D:\F?HJ\V"($ZE2R_%FD_!7M7&/(NXZTI%X&R1"8]01U/TKJ?2G_3
M-U-_TR?3W_11;Y(?"%-H>%%AYFZ50[S)161>!,Z-4KPMJI)V.DEWAOQ0"P;_
MDD5P$(J0\147N5$3T1^*SQIE]^L0FVMCS>AR3^%.(W8 &KE2%)V<*#3$17-!
M@5O JK\ICK."SKGZ6!1)UR\<;)DEG1:Z<B9PB^ !R_R)6!8%@'55%5N YI8U
M3L80?/)MY!L4-ZX*I^X @NS8DB18)#YB&?6L3?+*BQU3Y^&)S8WOX<UH6Z.I
M:XZ,^]S08I#@M0?W\[ GHT9)N.7IVL*26?5_&DYH'G>Q<6?@[D&=1<?Q$MRZ
M=SW,?5B5+)2Q*4U\>' ])CRZ*)?T[^B"S/T53F*YX-, (0^OD6:J$5K] XN
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MJ-KP@S\.0LCYMS:$L#=CUB'PT?4F<;QV/(A^.S5&[:UVYA68YW(;#+FBQ:*
MCU[A%[)0.&IEHJFW'[;'?L" PB\)=1+_51;ZS/8D(8B)K+!L8B</EJ#4-VJC
MLC0,SN:;$BU<1:10>O@W[-["E;'%"<P/(J="1YL"*CB_CE($^R29).1"J4A
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MEIK?"?NHZXC@Y\M "=;LL]C-[!/&I,EGS&WIL;AJESOBA#02E!D8<-//6*:
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M9Q, @;;N,#9H"V@+0-P;OT=E'/TK^$37"23-%3ZZ*G]+K=I!H]UU$[NUE!X
M"R&Y#(-ZND9%O%W SL=HQ-M8I*0,9''R;-6LDFH5-F"_NF9YDAN5.;8',E+P
MEK"ARQG#F#!_WEA=KH#@6\ P_N@>1CO.[#VL<;<(3J<LF==S.-%B3_]606I
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M1LF5"F_,E$)HP?[(JP?$ D8O ANNVTVIHWM2E>-F!%$^#0^/CL.#TR-+!-"
M<HFE)2_];Z8U\-<N:O2N&1_OA0?[X_!P[WC52N:MC>5:"99KB@\,T3X180'4
M<"_*;'B&Z>U2&J:2+3Q/7@2C#B'[A"YL&9P%!\/#'X/7WJ1]L"OS25+6,]$H
MX^9=2&-X<7%<Z^<)/>_@J.-9/ZWYF"Q?\80[K\I1>++TXDN"]R?[_U-)OS;Z
ML2WWBU(D$39ILI@5K_^H[5U/A3$I.OBQ5VLQ#/YH]!*[J3455LK!JU$E@71,
M\Y0\M6_NTLLK^[MY 17M[V9C&J5)T]9.\3>2WT=&S>JE,9&/Z2%BJB+*RDC#
M+;8O#8=NR+W'Z(<-PCB5PE0""0-2\+_JQC_4*'EX6%B X_7&&;:K6QQ 4_WJ
M]%K.5)N:TFW'8*U)"8_$I:4,?GO+(DV9>P3./%6#BG(L:V(=*3B6U;&VH73#
ME&+Z1J,\H<7VYQQ#7-<+0:C8&1@&'SS%07+$DX2]C#)R'%%P2X_2U6BU-ZB<
M*=@D1GH+^I&;LK4MN4E8 PT1VK9P]LC!A);?6IJ',D"V)SARKI#4@69#&Y7C
M08/.EC:D]IJ6\VF#CF);3%IWP"2.YMI@@8BVD^%3NI\=#X(J#E_/N7/"-9?U
M\2#N4OO>>-&E1G_QO*JJU+@&]6WT"+^X XSHK+L!M77_3>O$HLSYUW;>RU,0
M?KL]T0_-,LQN&!FBIK>M3?*CMP'7)#0V @_><GNK;SI!7;[>AGL\%AAM@S]M
MV)O3N1SC(L5V8:(4C%2,_)MY,B7=;Q8)_^$*.O%7K]__S[LW@]&IO;A+OIM]
M4,NB%B271%!;=9/,QJ2.DW YY+;(X/5O[V$,KS^^+WU;N-'WD1%E5Q=PYDF)
MY%9MI8?>.?_Y5<M)8&2/;$7." (UG#.UF&^PN; Y%C2C<90Q85=T/8BJP07U
MJ"OXY$6, <(FL._U(D?V1>GPR6M:)O#B4<%H:J^5G8B0E6XZPAA4<U.;<-MN
M4QMTISRTS)Q'@A*19K9"=8I-Q:_%N)+#K #E4R(E18ZU*$:\N>DU0A38&K@.
M_=F81R#Y%?;5M;:XUX&;Z$=09D,U/<!W.9=.V25RPN  ;!&LM'_5?:*=!N=)
MI98P,MW9/K!L'G'FS-HL,I?<%'7IO94V,"#0).RH 8[NVFNX3<G*:(K8 #$*
M"9;.34,9,4!>65DQ8H,MO!;Y@"X@G7LU(6/@:$TR?@&FZL/OI%NW8&2\\:KN
M&@:O;=/NI&JPD5-.!_Y)Z<:LR-.4A$#N1>*"Q>"U!.L3BF'_VU)Q@ [2[NE"
MSR;]%>6>Y5+,'V&I6$[+N>5&CJ*0C"L<\9AN2F;^WL#)!\?'#A9A-]J,F[(-
M-%6LDJ>$(##%93+59N\>3@.,N*(6YB ISM+18CMR$.)D@;ZLC?-3KW>2-9P\
MV*(S\&Y!;:(V\!XH,0RQKDD?<"369%3+OR ,P O7S#0C)).N^54WWMHN<,.7
M>^,=#W[/8_H[6^I[7,!@&..29TA<C+1#$7L[3H#8Z"-'DMJ,^)]ZC>71D]7%
M98F1?NI.$@GEA+,4R5UHYDHW%$K=7Z&QC H5+,B\P"H'2S@@IYI(A'(OXQ+@
ML:9]I]T&"V7VEO>JNTW$FBHQ;6R81P^ 2X(:AVB1=,NT!*'S2!4%(#+GB4)%
MS#S@4"&256&*%%&0I:!_V[M=H2D/TE1<,TM399DI;0\88P=6@L9,Q*^]H;D1
MU[\PR(]W;??J*T#FP2P<*A"R50-)0R3AQ,$SK:QG3+%4L=O=8'KTNDC;!M -
M:;92I4 8.B(99PYZB,]%U.Z>;/K\@:3;A#Y(E"TJRT8XCIVL!=N >AS2,V@6
MX;R+T8OR)QPAIDQ>HM !NM1; TIS4IE.XA]2RF/J1)57167 RR?Z/!Q-I<^"
MOY9>629?ZNB[*##06-2U,),GPNO1V9-(S0#/:B52B@5U[>9WZAR0FBJAE^Y%
M=20[M9-$)%1<@G*'-#:WJH',9X85P!=^\O;-F7*Z1UQUA16M8)VN2-Z*_"P=
MLHVHFX@:O:;.H@"S4/N\320F@\0V.6P5]X[\(^N/1&I=K5YFBX=GF D5>^&>
M_%>=3#^G3'!C*YJ7H(5][GF[<L_'?>ZYSSUO>ISJGI&8?V:$53-.+7I,@IZ&
MM-9UB2%K+(OFHX1Y)O]5<S-YL8)O.5'(JG<AQ9V.?_R2YA.8G<;LMT\BR7-R
MHHGBK\3%&9MR@990@/U3R%9QQLLYWW:*/%Y5"\"G]/)+G/(P28A4\PG0F2J\
M$16SL18* L#]$!;<,,7H"T.9$Z3O+2^(3]-GJM1Q>:YYB/$+-N1FJ7.3P6 W
M5(PMOGAYD<S0\+,7@^8T2&''5M $L]W:B#H,X.;H%H$=@91=%(HAW%G)Q*99
M6<^9]5/H*IL7V$5A-A!G8]&W=>;UOY/'8YD. 9<Y&!-*]9TNS[6P"C16^]SD
M&%^JQ+M0\_#YS*<-;I/M9^<YOO['&IX6#?[YN8@43?>N+"*3#OXSFD<D-3/0
M!U7Y@A'V3@B4,5Y75<Q6\)#S5(C8(L&OTC_\]'6K5 !?%2T[F?86X3%S"VIL
M!SS-(J\Y]Z$&-JY90WX^P0S R(/_0=:QZ^ G^#X$^ZV 9?YHI*J7/\3A?8)=
M'5% BS^;$M59['FX_@+DRCHP!3V0P^I;QY9>$SQ1/$#+9F786Q.3I+_A;\'8
M5=I7O^J,HETEQVNX*RC/+I9K4NDO%[D1NT#*6!+RB_^\2%+CP98E/4T$.'ZG
M.HK7V(ZX-&N,OB0V-0L$=L;WS:L(^B$BD;>.U@I+/_>QUGYSA]5T-,1CHU!J
MVQ?>\<RV!9!*GD$&$5"J,JA+X5'2=6>O4/XXK\?<&3F3K;C@X^US<8.[9FD_
M=OF4^L-!&,2%4RF;21#7,Q7R5N9$<N6=,M3N!^TYQ\S#:9HD.EPZ>*X!&(VI
M7KJJ_T;88%9$<].,>UU$,NH;<S*A'PK'-Y*8>7-#DLYDA+8J,Q:O3(*OPJ.)
M\8T_;J:.ULU"L(A$58I_".5%AUEF:5F$-  NNLBOB$52%^8"M6AVKAQ4&$=/
MD);^'2^D)K$$%."=SFHG+ ^-V;-%78$D8"?DD"HOE: 4U51&AR$JX-A,*&0L
MSW!DT\U*S9#_Q@ ]K@ ?_W1!2H2L<++P4.9$*-M%WJFX<HR=2_Y"STS/JA$9
M]KOMV$"<=MRQ\XX,,DBNLE4*X&GJ.KDZAO8V=[:A$CGNA!I5D42U)8/:N0/%
M".$M2'BP@LL,,%94P'J4%&/K/! Z_!$^T2@OA(%7.A_<G7SE,ZF9M(E.#3:T
MO%A4J_P 8W-\N+_R.O&\0L$6Q01J(TKQQ5XUS.<6GYQWS+[R>N50OZ=B_LKR
MJ0NO*E=,8X^=TGUG[1A* " (Z947W.R:E:T2Y >OVI&89 &K3MD/6 ^7T7>.
MJQ3.2 "1CA!L3("!1K#A4=UA"0[('CHGH74A$!DF#J[),!)S:43TG:AQ)A-A
M-QB@?J[Q? [[#]32UY0;7O0B[&X;'%K6.$+#%:BMG_O4 J$W#&]COK! 0'+3
M:._=G%'A<E;I*)9(EH"$%V2K$.?%G=*R[[G4B*SHSG$P,/ RPFF\UC8T(#J^
M-Q"2W8M>DS/HPL9HW2CQ#FE>QX(G@R<5X*@6V#@,#PP+FC)S,$F7DTJV6G0I
M>ZD9/$E8^YI+W8>&WI-T.PP-]<24Z(14M=B<3_M.-J#,%GT,^S6J3/>-Y^"&
MJDU-3 8.VGDA:E,I([IGGND@"NWCY UCI]4#&KKJST9NNC%,RRR/3INWNNE5
M%P6Q?A#>8A!5531%KY;_A-U;U R1G^.Q2A$T+M<SE:(?)>T@$IG9^KA\-N/T
M5Q'5,9^*R)M!KDO #7\NK=V2.G1CK%E"AC>R#D%9D$>4^>("0:=3"RP0"@[\
M)8]?"Z]Y\"5+2T0>/-WY*B_26%$X\E3MW@<3 HZX<H'#J2M9.KP*_DGA(:7H
MD!*#J0)XYH(*;B@'VXK.R[(BH9WBJ.%<KY'[Z )&3A >'D' <+S00Y \=SE4
M7C1XEQE9J& 6U*4!?>M-CL&NB+S]*@[S1)E^-*"/!AB<R@O)(F(3"L9C\!^P
MIZ_ W3_7[JQ426*]E+P1VI/+,#K5E"/WSLOJL#$6?2@ZYXW0$LZ[YKHX^O6W
MZ#M6!G/4=GPD2M!(4$HS3" V,OEO&&M3T39#\%!4>&IT'OV=%^XN#.,7@;G-
MZ-.<VV6=HCA; GT/TZ';DS5HQP0U9HZ]*V6[\C#='LI'3BNFJ71Q#Q_](^G3
M)=Z1D-''$B:MBF2B+JNVI-YI=?KGW5?>"RPV=K\!_^V2D16D5VXQW@D$AU$V
MF"EC2%Q5(I[[* W>_[C7+[QK7OAZ>IJ#>655QF4"RE"L?%!_<[F6N*B\.[=0
MX]0V F/LXGYS1R]23TZ]OL#P<P;#'N2S@=I@=M0Z /3.A>JIK!#)D9V_\)4;
MJ# %$Z'+710YJ'ZL$\CG-$B[8UB^!R3?WJ?YK*+K)C52K. P:$^GUCKRKL%P
M0U3$]&\OZBZN"=FW%C'I6Q]><]JH+ V!^6,F!*-8+F'22[#=6(_32R3E/$1-
M(_83\NSF\WF=Z?E%Y0MH^1:D[G0XP^!CQ[M[LH.@P/,HHSH&,&7GB!-H'QV^
M@EU'_X<WG'K-LQL#0BDF<0A9XZ#(%EW7#49N3;+@0/,Y!=Q;?F0HZLEK^(J\
MYTAD_*5"BH<< R77<XL<Q(#1I?!F./B#%_*+EN4II$WH^K75F0(.$1BD! :;
M3#79HS*V"Y5QTJ,R>E3&-AI%%"#GJFC5N@SU#H-&SM=K(H4\G>S3._(T9;:D
MC+M_MP8(L^N0;SELE)<K.#IXW8#W[[3MNI1K\"I"8)VFQ.I-$1B=1R[ $/SL
M"G/'=S8X,!B5W(1/0I"V<%%PM>@&7]#!7F/V C4&4CO0EU.T^!2 7E>E%O/#
MQ&!\>[=]CS/7W!5-+C3E,3CB&,=R5\6CL0J_,.R6\(^7MZ?MI)E[!=/81'W'
M7=@@=O>B^ >EU1(I[(7ITSX-7&@N^;U$?5E7R@3&E2W$!2')0%?,ZI3[VTZG
M]+[*"EL* &N>QTPZ0'_%AF.D] >:E2"3:664?1A>I[B6B)?'JIC/]!'4MHV%
MOCO6R'9N79K;K5IGEUL\0T?^9&7E5$=B9:?W@$=AV"(\='A_JM^/D?NND9KR
ML&?/FSGZ9M6#=^$++A30^ C'\[ ,C\!BC5T@#K2WMNW]A TYJ=:(FY&VPMX@
ML_ R[.JO?!06%<5K-6[F6)*]N[(^6&HU&UV?6#:V)2H("6!JY$JKT"QIX(W'
M@?)E<U6_1DXUZ9+\"WN5"-VJ'-65S9""F9JUXI5)QGZT"1M(]8F141*%#3:>
M)!OW-E5'M$2D@) G-WACL/R,3QHARR1>#J50Y'(2I5YLS8?K<+76Q(2-IWCO
M 1.%B@<TG44%V*2=S]B)]29<#<(Z0YE+8H/'+--UTE#3;N$"([^@[:#JW#M
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M?V FS\!AG..\7<<O7_N1 B1B_LVRE7]0&C P*<_POV@@OY-\)?SS+(M_$XK
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MOQ=%_K?1Y(S-:_&?-EX#FP>S.2!*_W:M@I<VRC0IIO4<AL?]XO^X;?2J?I!
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MB:&3#!&&AH#<T)>"(E%XJ*@ VVB$9>?00^*VC@*]K7BKK7AIL)KR$Y43?UK
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M.<:7ZI>S11;FZE.]U)!A>'9>M)$];OS_6JUL.9*:Q=:GNE(>\%6=72>4-,=
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M]#4[_]?RZ3O=2CL_[%K8;G!2E^K_K0EEOAM5OQ^U%WM2')_J-+M==;/]Y=F
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M%96(TT20I33_J8/P-(@@XU8\L<<#>FTD 'U7'+4''D9MR3'KH^OU83HOXV+
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M,7C_X<WS__M_WOSZXN6[]]\-7O[7WU]]^!\8.]IE7.SI2$T8.PJS?4'(^L!
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MQ)"#VFNI!.#O$>GZR6)'"OS$F.BTQ4@ZHQ!WT2%'7/XG*I>(EL%8O(TP*'1
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M:*WQQ@@3G;#"2FM$G,Y^6.0&66XXBEZY\C]BTL:8OAWX5$,E]5!R"6JJRP
M:@K4%'A5H*^V-7)+*(NQY"AX'1%/5B,K:$*""Y*U3V3UB-@MZ*N=>55W[^4
M^@KT%>@KT%>@K_JGKUP(CCG&D;1%]UA?QCWJE#47]3XP017;B )J11(A5B <
M$D-<4X(,%P9%SG"@+-%(Z:/I*\+9D&-06J"T0&F!T@*E!17<.ZC@UED[LJ!0
M4DHA3HQ"UA."F&:&"$&$DG:C3S/VQOC D8F!(FZ\R4JR:%=#L1-&*X/3-I7D
M+8NUF1B:>\Q,!FT)==^@-D%M@MKLL:\GHPPB.(L\TUF-,6*0ELH@S*76AE,<
M^(8:2SPF*X-%,3B/N".X^'HB:T(N7(B.,O)XOIX:<@-9'YWS]):E$/F_-B^R
M?KE+:;J0V=LIE8N[?^V&#Z%$YL@TG<XG9>YZ+6NO/WRD3D>LDD%1:XRXSY:C
M4TD@(23V%CL2?7@R^'(Z?C:VD]_^\B1.T-_?[QB''E*3L6TJ?O_O/PR:GM4Q
M#.;3P2RF<?3SP?Q3'!"4<0 1D=_<;,4;4\K7Y2]E8#LYFXW& ]%4>3R]Q)QK
M>[)SCKR;D;-S?MR/ .Z+D3YDAK'>3T_SLYSGJP=ERZM!:=*<'VZ4+_MM9L>#
M,SN;#Z:I\%=FJ/SU6@W8PDAI-+$3/RJ]G>?YC;J'^M,K] RCSP,_ME55S/+?
M(FI1OBRP9(O\M;Z@I<3_HM$DQ"_/$/LI\_07%$:S6.NJ9YE&B]/)3V&46=F>
M/RN?;JB0IR)K@K+8MIRL*(8B)J-TOEQU_444)^&GLVE5-WI_-HMC.Q]]CEG]
M?"DD+F1;::(OMS1POKDKO6$*J2Z!0=Z<]M^REY]6%7OM>D:3\6B2'VR>>>29
M7<RG/UW^(%.Z>;O9^KINSZ:\W&=V_(<]KWYZ\N.*2:[UW<J6KG'%E=W=[B8>
M"HI=[-=M.%?OBW,W:A6W39BW^2DK&^+@Y]%T.'@U\5>AJ;M0?SUMS-9(\WP=
MQ=^OL+O _+H3<ET0\4[ M+TGKNNNU4^#ASS2KJG:^&P]9[)M6JJC2;8:IHO*
M3D(U',0O/A8OLAX#84^GB\QQ/^R=6GLV-VO/[XI6+?JD49N7C:6RG'(YRB;0
M=-%>TMR)X.P)_WEY?>: L3VKXK,J9NLM2_>2+(W37'_OR=4B_,^C:N1&V5$X
M?[;\_C7E]<WMJ'RJC?CSNKIMU]GHVQ]O^!YYE*_(I\J8KC[</;ZBGG)V6.O1
M3'?UX6!_#G ]],#P0(M=R,]76K.HK[9FN4Z%7M^O9=-KNL79W2Z.Z=2>C(KV
M#M\]SU]WL]%WPVP<5:B*LU%ZC$Y80,I[#[Z57YM\>\]#CJ\=]^V=\KMM.O0_
MT<X&+R<A.Z!7VPZQ73+V5S;@/F=,^V+^W77AVA;4/P*T7Q.#.YPMZC&2[W$^
M^5Y1N@O\N%O4?CN+*<YF==1PZG_O)%!W81< %0 5NL2/NT6%Y]/3T^D$( $@
MH3^00+<""9WEMMT*_$E>=3/5^S_<[,>_OK6C@$:3^O5S>S::V_&_/SJG=H'J
M_93QPZ<<2/U6I-[[Q>EB7)(&:E%_$=/(C^; KR#IG:$<2/HV)/W#=-ZJ]O5T
MH._J=S:R7(!U(1Q[^%L$7M;^4!@"+S=L0]-]$4(N  8 !D</!B=U2BV  8 !
M@,'1@T%C&>PT"@MH &@ :- +-&A, T #0 - @SZ@0>?Y$:0=I!VD_5CX$:0=
MI!VD_5CX$:1]*W/K?294\C"W?@]SZRDTB'U<;'E(V\>.D.Z1J;0E%CO2CJPI
M22E9<BCK(HHX)AJYI"CR2>KHL"%2;4Z+HHZ9,E8^8.\1#]$B1[%'$7MG2YM)
MJV)W)\:#T'5'Z #7>T2ZG77M!H#?(<!'Q6+"0:*4F$5<,88,I1QQX47@(67$
M5UL!^.X,63],\0.$!X0'%@-@7P([U\232 ,R6&K$;<S [JQ"7@=JH\26L0W+
M/0FLHDD6$2^S"K#"(Z=,0#80%0+C)#*U>\N=&#FD^NX#\T#HNB-T@.L](AU8
M[GT$>&&\5<33;'L+C#@/&FFGLPT?M69",)+1>BL #Y8[('P7Z 0(#PA_5 @?
M."%>.8V<T!FM(\DFO'(<"4*<I#011S<07LB0J*$8.2P4XCZ_L@D[Q)*3.% :
M)&>/-_J:DJ&4 G ><!YP'G"^)SA_\-.BL16":(91C$0BKES*>D5BE#V &+QG
M@@I^5:\PKA-/AB(9;$(\>)+U2E((<V>YTM@1C/<P+1J;(3%PR/LPZ8<QSZ!I
M0-,<@T?!)(]&1XHLDP9Q*@/2(67OP"M"HI/.%Q2_C/S!ZD BS<A/C,Y>2-3(
M6"E1I,0;Z8-@(3RB1S'DR@#>;\VAN'.V[;(A$F3;;DE27\?Y8#RM[M-<!I3P
M<2OA?D84;JM[MT6Y!SEYMY^928$)>\2$@',](ET_60QP#IAP[TP(.-<CTO63
MQ0#G@ GWSH2 <STB73]9#' .F'#O3 @XUR/2]9/% .> "??.A(!S/2)=/UFL
M&SD !Y]M1B(71E.-G.8)\10YLMYQ%(WQ(D4:5117<PY,=$YI3Q 1I%2E"XRT
MCQIA$8FSB5,F^=6<@]=Q_FKBIZ?QUVE5;3W1C X9-!.!/#-0+:!:0+5T1;7$
M:(DP3B O&$;<$8(,LQ11IG541$@6Y5750I--E)"(A+$"\:)5+!4",2&)C=1I
M1@BHEH-0+=!)<M^Y;74>*'*VBJ4Q[>E9G%2VEM_XI;R. SL)@UFL)]T._*?\
MI/<:L@9& A@)AVLD0)P-F!!P#G"NKRP&. =,N'<F!)SK$>GZR6* <\"$>V="
MP+D>D:Z?+ 8X!TRX=R8$G.L1Z?K)8MTXQ'OT0S7*I0J.6R2\CXACIY&.3"+C
ML?:!8>:UN7JH%J-A)#B&L&0.<2<),A0+E#Q74DFCA;)7#]5.PC\7U?PT/TKU
M87J2Z5^>P8[?VE%X-7ENST9S.ZZ;2]?'!\_73@_>Q7\M1E5>^OLX^SSR\6V<
MC:;A7?33WR;UK_RW'2_BECI.2,KA;*['4@R*HD>DZR>+@4$,3+AW)@2<ZQ'I
M^LEB1VH06^ED],$C+W! G J*LGE,D0Z6FT %ESAL(\L,#.(CE&+HO[;O'+57
M5;4HTXT'TU1RU$ZGY393_WN1@L'G6,WS+Y3/9OGE;.1+IEKS>9&F:CB8Q'GY
M.)Z>C:?G,0[^&,T_E=:'Y6MS^V4P'EDW&H_FY]T <; 3>D2ZP[83P!\")@2<
M YSK*XL!S@$3[IT) >=Z1+I^LMB1QGVB2ZX>GDM%\HASH9 F42)NG0KYA30B
M78W[6!P4H<X@G(3+W_$<&1$HPH$1Y4@D(<FK<9]W*\>R+I=J!NH6KS2&UW'^
M)C5O_#*=?;!?_G'A7%;?&+2+OQ''X4.L()+39[D$Z.\1Z?K)8F#B A/NG0D!
MYWI$NGZR&. <,.'>F1!PKD>DZR>+ <X!$^Z="0'G>D2Z?K(8X!PP(70#ZTNF
M529ZG U>+C.HZC#XX.UBYC_9*@[>CNVD&Z@"BJM'I /%!8H+F+ G= *<.S(6
M YP#)MP[$P+.]8AT_62Q(\V=$@%[SAE&+&").'4:.4((8E&2%*QG/N!MY$[5
MKF*3*_5B,<L/VY2^-2E32X>ROFCI3A9O\J&I4W1(N8#4J1Z+)2!_CTC73Q8#
M"Q>8<.],"#C7(]+UD\6.U,*-4B?)&$/$4XNXP!K98#&*F!F)B314D6VT2;O!
MPJT[.MQHX&ZIU0-18.3V6#(!_'M$NGZR&!BYP(1[9T+ N1Z1KI\L=J1&KN'&
M69LPHDR6-F:)(2.E08'P9+P*+/]G&ZW/P,@]$,F$=F:=3;(;38J@3F(CWZ5+
MV2!^B3,_JNIK_["SF9W,8?PFJ'10Z>"Z !,"S@'.'0*+ <X!$^Z="0'G>D2Z
M?K+8D89H4J *1^P1D80C'JQ#VNF(HN!$V9 83>HAF79G>;%?3[-[DY[7?F9]
MT=_/II-_-*[DR]:[_%:VW:O7OWPK1,/ET# *<9H>BR=H@!Z1KI\L=J0:(!AF
MDN8146I51G.6-8!7 1FM5,H*P";\H%SKKVF .D)_-P7P@$@]*( >2R<H@!Z1
MKI\L=J0*0(I((B<NV_R&(BX"1B9*@610D2>!J;+B(:F(W5$ 0\8-*($>2R@H
M@1Z1KI\L!O%N8,*],R'@7(](UT\6.U)CURIO#78>.9GM7*ZY0DXX@:R(/N*H
ME*7Q(2F)73)V!09C=W^IB7WI_[<U 7](;N**!;:0J6@G896.6-(6_U\[6=C9
M^8!BR@9O4HI%(E>#5T?+G_'3*E^?W_G3<OOWZY6'Q$RD&-'LEA?0$<A8S1%F
MBH00K Y:7P4JK)SSAA D:/XB%RIFF$L)">M-)#ZIZ-35W.FW]KR>&?TFK5"K
MD.-YH<:6H$C@K>=(@YT%*'Y8=A;XD\"$@'. <WUE,< Y8,*],R'@7(](UT\6
M.]*XF5&!)FL%8H9F=Y1%CHPS!CGJL'$Z*JK=0]S1.FYV$OZYJ.:U._IA>I*)
M7Q[ CM_:47@U>6[/1G,[;L-E373M?9L-^J!VC(P,E89SX3X+)>!^CTC73Q8#
M^Q:8<.],"#C7(]+UD\6.U+Y5E.H@*$><EX[C#GND.2-(29D8L4PHO'$NC*66
MU&""$K/YBRY0Y(*BR& GHXW4,VJN'K?<V<3=TAD,'1(IP<;ML6 "]O>(=/UD
M,;!Q@0GWSH2 <STB73]9[$AM7.DE)3@0Y(4WB%,ID?/6(4N(B8HIK:*]:N,F
MQ2P5-E_)2MQ7IE N5\A3Y[W!7FFVT7,<;-S#$,R#[<9X\"F/)V>ST;AG"8\T
M<<HPC8B(Y!''1B 3"$-$J<B2\9@2>16==/X,NPQ,,;J,3E8;9"VV2&K&4K*8
M<;Z/A$<M."0\@G'5!0SOKG$%3B0P(> <X%Q?60QP#IAP[TP(.-<CTO63Q8XT
M6,:)HD)8BK#//BE7GB(CN44E3,:"Y-&ZC83'N[BC.TQX_'9'3(V'2D%U<)_%
M$I"_1Z3K)XL=*?(GJ0/AD2#FHD0\4HV<=1Q1IC@E(1"GMA*(W-<Q"?3![+-0
M N[WB'3]9+$CQ7WGH_0X!*0YT:45?D(VI(!$<)R[1"TF&\?C7#J=#!,HPW_6
M%08;9'3\_]E[T^:XD6-M]*\@%,?AF3=8-);"ICG'$1QJQJ_N'8\4TLQQW$^.
M6DEXFHTVT"V)_O4WLPI;+Y2X=+,!=CG"&I*-!@I964_NF3[)F)_S)!<LWIY6
M>"S<C\\BW^G\4SZ8#OLG1+IILICS:CLF/#H3.IR;$.FFR6(GJN-FF1]*7V4D
MUKDFE.<9R43,B<CS5.HH]FFR-9$[810N3AE)& <=-Z"*L"A/2"A2'0F?J93Q
M,>FXSK]QQ!10U_5R)"F@']5BJ6ZXJB:6!JIS&OJ)R @/ '*HCE/"L+(RTID.
M.*>"ZZVX6QBK7.6Y(GX>2;#"F0]6>*A(%.DX"T(5I3P[0AIH1&.7!NH4K#'@
M^'@5+&=(.B9T..=P;JHLYG#.,>'1F=#AW(1(-TT6.U&'F2^S/$N$(C+*%/;X
M86".IAGQ$["JTSA5"7N2.7K4-- @CL_RV+6^G/*Y=- _(=)-D\5.%/I%&N4I
MSS5@/=>$AI(3IJ4@0293+02+6![NPQ-YM'89#O<G?"@=[D^(=--DL5/%_3P%
MA9^&)/#S@% A ,,I941'22"83A*NMO+_-?4U#Q@ ?2AS,!-41'@8Y$3&,@V2
M/),J'$V,/#A+TKWW)W$'TV&_P_Z7PV+.K>V8\.A,Z'!N0J2;)HN=J(X;QRIF
MJ<\)J+,QH8%I=^]+DF=!'.9QII7>:G?/J-!IZ(<D#[4DE"8AX3J,298*/X9[
MQ7X^FG;WJ..Z5J!'S .=2BO00Q)^K^>X/TG>LO0J)8"0WO):><4-W-*D=*HO
MJA)%K;Q%50@%U]28ZCGWRM6R7K(YDJ1/$:W4C"V5Q)O)\O/<,[L'WRP_%36<
ME7H<\.PT@ F1[F5K ,[2<4SH<,[AW%19S.&<8\*C,Z'#N0F1;IHLYG#.,>'1
MF=#AW(1(-TT6<SCGF/#H3.AP;D*DFR:+G6B$3BI%DQ!G[H64$LID3GCL"Z)]
M'J3*CVB4;'4C5"J/ LDCXB<1)Y0G <E#/R9:T#1)DSR+TZUA?4WT[4WY>?X!
M0P _*[9<5>KM7%2*U>J-LO]].__IWZMB>7MQ Q<M@WV%Z5R,;LI'TZ'_A$@W
M318;!_H?L*'/=Z/HNI,(E:5A+@E/0T:H2CC)9:1)%/)4!S[5(MZJ=<D5YVDF
M A+$ 7PGC7V2P6V('ZN ,YSFF-#GEC8U;"'\Y,3.8S(4[L]$WX\#')S\F1#I
M7K;\<5Z6DV'"%]L3<0RY<)\M(7DYDP_@Z1_9#)OWG7F@0-BFAU%P9AH?C@-%
M7JB@XL# JFIH%R^67EW."NFUN[QG"&F>UOPE/ _QB;)<\9G:>N0+@)G]$?KA
M3/QH4H_#7'MV\XE'49!*"?92D.:$9M0G7.249#@K, U]1>F6^10'29#%80 O
M'0M"DU@3IH6"[V02[*H@#+38-)]LWY=W?3[ODUO A+Y_YC]B+,A='&GSOOWH
M60__UD-?V/%W0LH)J?$8___EI-6TI546)SQ-6$9D*&-"\R DC#*0092*5*L(
M?MDJ_GJ4M,+&VM>@R:NJMOZ\HW6N<>+*B2LGKB8MKL9%:">E#FY3Z2QA,HB)
MIEE :,0%R6,MB9)Y%.6AG_MRJ_-FZF=:1QK$DF*:T%AQDC/)B=0T#>. <>$G
MA[>I0%*>^?'#8TQ.2#DAY834I(64LZE.5EHI%J4L(+GO@TV5L91D41R3B+'0
M#T7.1+ ?:74HF\J)*R>NG+ARXLJ)JU,05[EF(<T30:A@":%A) E+0I^H4*5*
M"QZ$*MX45YP&.=6)(JG,0%Q)E9%<@[@* \D2%ONQ#+>RRP\FKH(H/,N"AX_Z
M=$++"2TGM)S0<D++)<5_2TA&@:_C//()C7()_V2,,*D8X0&(P83&21Y'6W$R
M)I-$)P&)%(] 2$8)6(0@75/.A!\$B19BKS;=/1/>P^ L]IV)-PH<<LGS3FQ.
MB%V=V)RXK4=I%"@J)5&,@ZT7"$EXJ#,2I['(1,YIDF[9>B"RJ&:Y(($(%:%Q
M!K:>S'T"QJ&,PU0$,MV:8W0X6R\XBX+(":^QF7IM(03\E\%+FA\/>9P>)E/Z
M9W_M<4^@PS%>]T$Z]QY?_KO_\[UG.Q#;EL&5TC,EEJ8!<4#@])(@AC_"6:D5
MK!6 P*L7LV+I*:WA.O@2P-'%HBIF7FP*,^CYD2GY@AFG%VYC8)W?@$68$.4-
MK.46KO;FY1)NQ2KX,X@HN.RJ8C-OP2K3Q!HX"E@(OF[0VK2HUL6<S44!%]5+
M^(/I)K_)/K+XY(D9JVM4GZ\4:< 87Q!3.OYJ+F@H\1]2S*7Z\II$/P 7?R&R
MJ)01*:^!1JN;^0^R .9EMZ_QTRVD/X\!L/%EFYHOQ&\\&(6^;=_:?)&HN?QA
M4=:FY?UKTVZ[^*1 2GQ!$B/9.H'QY9Z*R#=W93),D61K @4VI_D7]_*Z*ZMK
MWJ>8SXHY+&P)//*:K9;E#^L? *7MG^W6F^(ZIN%U7[/99W9;__#J+QV3[+2Q
M<$L'7#'87?\\Q0_WNX\O!<CZ+;O'2R?'XMVMDL)]T^4]K+)F4GD_%N69]W8N
MGE.VM;0QROX0-O_9@^4_!:NO_ZEGY>?ZGV,EXN40\3\V2]_E!AS-BI<URJM+
M(*WW,Y+V9"7\=\4<Q':YJME<UM]OD,&8!AMXCC!F 7M=3.-+XN4$A&^Y:BZQ
M3PQ\,)7^U%X/;SICBUJ]KA7H#< K+;&L566^]VJS1AL'6_ "E-+;U^WW=U1?
MV\<ER7F>1W\:HGSSOA;F_W+']X+S)'S$MQ[QE? \RR*__]]C[G'J[_>52O[\
MJU-M=AVM)Y3W[ZU%1:L?[,">_*#0<ZR^*(=P@>^+4L_O @<NQ4_^YU7R:A\T
M6W=H?<VW.SI^/&R[B?]/L<K[":P%N=9PXI#\^Y6]^+IK<0R[<3"N=P ^^BUR
M /X8  \=@!\2P-$![=#:08&# @<%CVL2YJ!@[XJ;T]:.OR\.HH]G;CMN<Y0[
MF.$[E1ZDAT2#O>;:_:J6WJRL1STG>[K0>C_B'; )\?/QX1XS<9^'U\:11ON@
M8&>^S^J3_'G2=OU ASR) Q)F 78'"!G)*64D54&2)TD:TGPK;3?2<2*TSXAB
MJ20TT2EA-*,DB7.F4IY&5/'-M%T LK=S4=ZH7P#-]EYX0L]HE$UHVL(8S_VH
M"T:<C!DEZ9R,<3+FVS)&2RSJ9RFA+(L)#45 >"@Y49$02OJIGV1R4\:$FNDP
M"!0!F0+?P8D_+,1.-W$2,!7R+ J"YY4QX5GTB [6[MQ_4\:,-+SZ,JS,Q[FK
M;1&&R>JT=1CPD2AFRILW]BC^%7_&E$]O52OI%7.O7*B*+3'Y'@_'IV)9J/JU
M\_^-*T3S)$&X+RKNE(.3=P ZTKF3>NB3^M)HYN@T1B^\>54L5)HOK?%S2+?\
M,%W?/&SX=/^'<>E3]]K+-PJ^) J&%L(X+-T7=!Q>OG7US%1Z4<Z49W=NL"Q1
ML8QS$H1Y@/T*-<E2&I,\]GTI6<*S--^' WV(*7OJ>/'P9A?NO(WGO#E(GQ#I
MILEBIPKI<:18'&<D2*4@-*4IR; /K10!RRA/E ZV(/TQ_NH#0#IUD+ZW\_9H
MO[2SNXZ5+57.B?%(]Y[HF6*U\M27A9K7:ARHZ@3WA$CG!/>$!'>H IIIS4B8
M:>Q!F 8D"V5&PD"$7&1")CE]BBVV@)=]#2"#&/.NA9A?$&%^L@"SMU:$3HY/
M^?@YA)\0Z:;)8B>*\#(*8A[ZFJ19'A&:1S')LR0E@6(ZR7G  QT^Q31[-H3W
M'SY=V!T_%R%[*9;:!R56584&FF9%Y7UBLY7R;N"<K2K;3 Z;GLT*9CII%<K5
MOSBY[N2Z2TG>7TIR'L8T$QE)I:*$*C#X.,\Y2:2*HH0&DJ;LR99B!W(_ \;]
M+T+<WP<(]T[_TN/;GM2*V-F-K@C&"1HG:*8B:)X=^#D/J. R(MJ/-,ZE5(3K
M+"=Q##(@433/F7BR 7D0X+]O*63L1( + 9ZL8?FVKE=L+A3:CZ*\N2GQ,3@H
M9%EZG]1<EI6S)9V(=R+^!8MX,.N2D,J$< K&&O7SF.0)!<&M(RDRF029VO(1
M/R8CLX6:=]K,)+N8RW^PJF(@X7\NJX^J^E0(5;^K+F>LN-F7@1=$3KQ/^4@Z
MU)\0Z:;)8B>*^GXB@TBEC A-0T)#2DF>9AGQH\"G8->I/-/[2-I\!M37Q1<E
MR7]452)G96$0_N! WP4+3]:FPW8>.-D1!^:5-9NA;;>H,,=S>>NQN?34OU?%
M GTKXT!@)^0G1#HGY"<DY!6+?.7[FDB?A6C:<9+Y7!!?QU&8\RQ,N;\/T^YO
MK)@CZKR;OS&88Z8ROM,7=:V6>W?9NIC=E$^B _L)D6Z:+':B8!\&L8JD!IRG
M 5AG*O))'@0!T8"<,E1YPOF3<CWW#/;.@ANM!>>B<D>VX(RKA'"&C>)P1KN:
MUZ;JU5AO9M@U?G -*W2IGDZL.['^DL5ZFOI91K. \#2,"(VSD.0LS4FL?":B
M-&69V(L-]Q'@1/V(D',Y0)P]Q>&2V-5O3/GL.7B?$.FFR6(G"N^YDI)FB21A
MHC6A8:Q(EB0!B9(\CE/.\CCB^[#:#@OOH7/*N8C;Z=IK[Y;7JAH'C#I)/2'2
M.4D](4GM^X+%DF<D\WTTQ"0G/ HY$8'/9:I\/]#)7O(DYZ+""OHWRO[W[=S
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M166T#WMUK*+DZV.6W<"424==G2V[MC>7]S98SSRN8)EX2\Q7OE6L&@=*.T7
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MT..IFI]OY_6J,O9F;RQ*Q9=K+4WAOFA?FDZFY?):59Y8P<'&'-.Z5F"E]A_
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MB3%.::5LGWQLLG1']3ZO-I!A3(LS+/J]2<UBC5^V53YVX-G93L=N/3@%)I8
MBK\T86)3EX#W6]L@#$(H$\(<?\)-E,8)XU(3)7.?T#!,"1<:@(4)G="<I2+<
M<L<]&DGL$+(W*PRPO3?Q=E,\4&^!RGI?!EO],<RY\;^5PQ6/.^/&OI&GF+@>
M<I=WK6:@D=[<*%![3<K66L*_%2N8F+@L;/SE#C:V<=0='WBLDTR-8KS)ZW<
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M!W5< 1^JLAT9TGV.J 5B6=K G4 NY2^T8NE_T7@:XK>WB/V0)O$;:EI8PX8
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M+>_)Z@&G-CL2MN\!UY[9?\;+G[>Z4?YF\Q;9L57%<>,RRD@C#XDZ!3Q57^9
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MO-9K.;3.+ JLF6]W7]YL6]SG(:%G=MRT;MC1AL?'%98;*8)'V%&@<!8 =!/
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MI7S59T9;2V"[Y3#=]03U:;TGU27PND^+'.UYS&XB@59[W[K<-R[3_LLD%IC
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M9)[@R3&8LBX7V5I'X*^.:L?M%63V./*JYX5MQ]? \;GZ-6YY*79Z-[[+K0P
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M=8 [?'$-UE90_GQ1LLI#M9+2JXL:@=7>_P (.Z!$]0/AO/LA]<X(H+M[A7?
MWB(\Y6DTQ(+9X?-XW/V_'<Z^*WA^VOU\Y=2]4\H_D/43DC4<;/ZTI"P/)/YX
M)/[KNG#DSV[^IW\_%-CK+=WWX72.0L /4F.0&@\J-?ZG7!5#(S3>P8;:S['\
MO*IBJ4H9RR Z!M$QB(Y!=-Q(=/RV'E]9?OT)+LFQVJ6=E-__-DZQ^N[_Y/JB
M[P>Y\B+E2K]W[ZJXT$-M[S4>LN+LOXW3J^M.\T"\R?]PX.P.OOG>@<+7[ZDE
M'C6L^: ),>MP2$F ^- VY0)@$]$ON:M?J.[L_7KH8WD0_?U, ><'%DJO;VL?
ME.A_WD\_'?;\*,EY.CO.C>W3'CX0>1Z$'(^YK^7ICRHE#N>*AH ]=[E7@M4"
M<0L_628E"H9@[3WGD:3.$ I-(WPDD>,D5V["/XY9CQ0WW MKM0M//4V'CC!5
M5Q:B#PS[HAEVT"<OASQWQ=[-=_3?CH!.7XUB<0G'@&E 0N04168$TC1())QR
MT3N+N>BD5SZ88GF*ODS7M;F# \?X\A*&@>$'?71L^NB OWT0IP\M3C_&^7DL
M'O3^4WD_MO\9@5B;Z/BL,H4\BTSIBV?]\N33^^69#I[U&WG6'S*9=%##]PWE
MO8P=?'[G^(O=VKX0YV"I/#6Q]0.J/<5841)-L%XA[P5'/-B K$L,4:,"9BK!
M?SI-\AFS*7J-43 *KI%2P37&($V%-('!A0X_L4>;C:C2(ZGUG3P( _OUC/T&
M67]T^W>\Q/9J9#T-/G@M)').!L03A9]4],@+R6R ?W#L='I_,%G?B^;_)_QN
M(<^!9WO&LX.".+K].UYB>UX%<;@?BXF:*4$XDCD=A8?$0:IK@11ED<0H\C2#
MSC11[$("G(P8]0YQ#0+=F2"08R9@:Z5GN?'=KBPOTO;'W.8P=P*)T[H4BK[+
MPOMSZ9_^X\7F*VTGZ'=?[3PTGH3WFZFR'Q:G<?[[J9U^*#,JM]N?K3+FVUSY
M=9K\5H)\GA!2'QP1DN=Q/*8NY2=&7#/N8^#F(^+F(2XP9-P_FW_U/^W%0X4$
MAI!][U+(CG=KGS^(\/KVO/?D/&"3WI#GJ_%1J2@)=YPB9J1%/#&&#%,!Q2BE
M<)(G%W!GJ)O@3%D)UHS.$PQ-X,@*S1#<R2A,8M T/G$\PE ZTO+R_MP#N[YH
M=AVTR4">/2;/5Z--,*<QTLB1D([G/OT2N9B#W01[++WBG'?JM1Y,FQQUQ&/@
M\J/G\D$)#>398_+L8U0E)3 ^/"7(.NX1)](CT 0"!:VC Z&JC?#[^B(PZ3'V
M$=%D:>XN#U=+N) 2*U7D6JC4*<,:HBKRA/%[1%4&_A_J,UYB'&:HSW@:%_6U
M4\%_B^<3V_X\5&WT-1?F>'?P^0,N+W9K^T*< ]9X78E:3^C78IY$;KA#D1&-
M.!48N<0PHMQ3%^%#Q3K97XS&/.O*H>"# ]M& YXPUB&):231>T,H>>H^1%2/
MB!AJ-EX$\PV2_NCV[WB)[=5(>DVLMQ$[1"0#J8V#1$8[@6R(TAFF/7/AT21]
M'R(8\H2H04&\!)X=%,31[=_Q$EL?HPO$*2N,X\@ID\?WTH"T, 9AS5D@Q,C
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M\;0<!U!7F'V=5D5M5BG:Q1+.ZFL^-5<NO2C'6"_=/Z)?5(L9\!]8_U5N);B
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M9)0*%BD.-,I.)_;;U(M<#L/>U_4RAK^4TKN/H$9FX9Y^83UB5(VTY$-3]9?
M@H.\/[K].UYB>S7RWB:NJ#$482<\XBDHI"4U2%B- 5H'RR)Y*GG_[#[;$WDW
MC^W OCUCWT%7'-W^'2^Q]=&;*B2CV)"(,,^=_ QA2 MCD).&)NV)B-T!'$\D
MUGOE5!4G5 WC,UX.+PZ=E>[666G([WWF"<HMUKV1?W4(;@_![1Y+^E<=W'X4
MZ?#=??JYW,,YD'SR3%"/O T14*3QR$;#D17&2QX%B4D_#HI<R\,'] >3D19\
M),60E?68J9@WJH<;--B@P08-]HHTV&']PJV@1C"*I,(8<14I,HYHT!I,>4:2
MI;:3\_6(^N7Y_<],#+KI=?+\H)(&\NPQ>;Y E?3__-^:$CH0\) [^RIS9_&0
M._MDWMU?9O,4,V0<5?';^7@>0S6;5]Y.?9Q,AIS:HXR;W[&IT@N1Y@].CO?O
M4?52<,ES.7M=D,Y:G!!A@B >"<E#2!+\@P6SPJ6H'BEE8"T>?VZ$XX?Y3RO1
M^(#N7XI[D0A\YW9>SZX$']@'/&BTGFFTONS?4>BKUZ*-#NL*YJU1S 5$0Q2(
M$Q61L]C#&Q"P*12V1MYKJLB]=<6SNW+5B#-=*G:?7^4,C'V$FS5HD==*;"]0
MB]S"USJ08\_(<?"<[GE.R9 7V[.^M_P((F@O&4(\57QLUW="3VAVGH39,L^.
M>PU>UZ<CX3OO] L$+X=-8,,TEQXK%*2CB"?-P)RU$47L**/P+],=$SCQF*P,
M8 *'7)7E"$:&"X&2XL*%"!<2^O3]<^4('C^BA/4Z]^A*BNR=Y_2XN;\ON_CB
M%%A?-K9/>SA8S;=3/$+IH!.WB"6C0?%XAQSFH$Y42(%3D8A^I*39'K77Y2>B
MW^IJX/1!$0V*Z#629Q_;020?>3!<YH9N%G'C$G*@$A#3QAH/'SA)GUIG]*P/
M!)%#<]V>L>U+3Q!^$9TCX&<+-GB1.VDV6TQGB]A(G5]__[N.7-,H,!*)4I2'
M/R#M*6!53(.P,3+. /9].YN\G=CIY__W39RB__IT,WHF=&\#;G$8_UC6BW&Z
MN -XWZ.Q>GD.\GVS2'F"V37+NM4!5/?)!2PK,@^VG-]/8Y4?D(!#8YY1>G8V
MRVN:^7]67U=N^L]-E^ *)/ZVR[X*)3>C6L ]LBBO8KG'I7[\'KQN=6J_Q,I6
M<,#G,>NF"E3Y67DQL%KRF\PC**I8Q6]^LLQOD^:SL_*&0!]^F?D-]F>6RI^^
MKB:-VD;Y5?/U@%&_47_5!/3?R0[7;7'5 <T4QE]NQ"SR.7AE;SD/<RR_S.9K
M*JHO(Z-R2MOS$/NP\E%9]T^S,UC+!9R_CR"/ W#,K*Z!9.I3X*Z9CS'4F6CL
M.?SV#8S=19Q<5/]VZ$5NL<JGF"=GI%2>8T0QH$N>I\19KQQBS&@9&2,1=R&F
M$1H''1!3"2 F8: >(A$H><:8M,R$L)[?L*S19VO/WWYL-^D7X+;<:RQG?WU(
M/Q5I]"D+HUWWPZ>_K!T,<MO!@,1UZ<(GE]?B]H&<*KA^DK>_2*1CHQ89#$E$
M&P34D=N.TH T)1I%IA/Q\%GRG<XB&%"##%0A1H+-TP<3,@P(3C(,'QD98Y3/
M1RV7=Q7I$[6,0/#4Y]%G+#BY&#4Z*[;>NR)X#NKUD^I#H\<.2:NU*$M;LKD5
MS7W:@TNGY?9A<:-CX-I %%;12R2]4@#G,4-6BX28!: ?A9<J=&>&WH)KBQOA
MU[A8<>T#,2<YN;SRHP]GOQ;EQ4H#KEG,+H'7*TX%<#W=@CVXT#,M# C+]J>%
M#5=W*]RZNA+8=NP!C]H5WV;C+3]P&YS8(@GV^86>5+_OW_;<7IS!2VS=#SYQ
M%SMW&T^K_[#3I9U?%*[KX-N\$6/XO#V7C&G!MGP>6/MTA]YQC.1WAG>O?':C
M95[X'%$;],[KR7'^?R]?:)?ZOV@,(O;;6\1^2)/X#87Q/!;:A@V=+,^F/X1Q
M?3ZQ%V_SIQTWR(D83\O:5EEM\&N[)ZM%E@L1R/$#;@0W^Y9W)+_E.C#_[8:>
MJ&LW\8ICVWA4^\"XFN[0<K'&UO1[NDX<;-]G/)V,I["PA9TOWMKE8O;#[@>P
MT\V?FZ,O:84VP>N^M9.O]J+^X<V?UD1R, ,T'^D65>R=[L,>XA.%5QZ=ZS;G
M54[OD/,\E[IH'RER)&'$(Z=(*YLG91M!E'&.I<X\T]LXSU=8]2_CVD]F]7+>
M(-3S.*V+3/RM$;@_S>I%$S+]T8(&^-A(WOIW>.B/DX)D(VC'<[CA8KYLU3"(
MU1C>+6[Z%G\G-SO\YW,G-'X4(-=)>!P"D2?5S_]:CA<7U?MI%C; )]7'B9W6
MVS336_?DHVS)^RGH;<)&U=]^_%39,#LO$ 44?/YK]?/9^61V$>.H^DM10+/Y
MJ)BD/\VF]7*R -AR>$-'U7> &8 !BIV0KP#+)*<)A,91DDL&*/ZA/"-_O_Q.
M?OC^Y*!-T2^<S$5B#M,$2_!Y@J47R%G.D!+,"1F--3'M2PP O%QR^)(.DL,U
M<+7C),)/EC*I7"*)[4N,+3OV)WL^7MA)D0_U;[&.<T!BO\SFORP7(%!6IN^M
M,@5+[ W =$YMK^/TS;__.NLWC$[+>7;+5A;P,MBE7P%55RY69S;$*CNMYQNJ
MS11U<DN6?CE.5.#H=V '3#(>)SM^R5*HHWZHJT(<IR!FX[QNW$M?6J[_"*]4
MYRW]<3P;9:8^*;<YS.75=SN\G+_V_N.&E=\=-#3N'P9X:+?M/'OPX9_^BQ[G
M'<-.*"2P #5/ T>6A #H0Q#GK;!,V7W1X[3141B-&.9EYEN> <0]<DH+'YP7
MBIFG%3U=&YZID="RW_*GO%6?5E2OPD\M=_^QWO4KS-O#*HZ#5(ZK&K?GE9T
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M7J=(EB2SH\MTYHG$X!Q'7$2<W0T6F0!(RU,GD](TR/@@T.HO$>R#^:7VVO\
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M7Q5^ZD;+/%KFT3(/SS('J:QP$#RQ+)6$<TF)R1TC@AOK1*Y4[GHXYH_227B
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M2!6L#AXL,_&DF 7C%5;(Z%VW&%8GW@Z8%UL_>T=V['H;LCO=Z[E1SCH.D4@
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MP]T<J/&X!XKS<^^*BH3)_^D7MBC1)IV@7H_9E5GSL4=F9AN5TQ'0\*14N<1
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MAV!6.#%M+V51X,8.V^AB=QN35E4O>05\ZA.RJ3?R&A#H(GA9F;_B\K]O"UG
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M$7.]!&^@[,-?,57Y'W*0UHPFA,:6@[FM#HF8%Q#;3V ?(8VHOY=Z%5.0_W8
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MBS/LO]$U[)@.7]5"_.C@IX7XA(3X?;F G8A2+[4Y\6,O)6X0!21FJ4-\WV;
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M]$D84C#C:,)\B_/82@]9">;N)8(]LX-02P1MVDWL&*8B:[2T_BX$8\!-7BD
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M\X+#,FLCJXU%"?O/LZ\\OR+P;D&*<C4WOL ;3;X"TEOQ]=&V])+%@1*^Y,)
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M<>A8UD3(S9[O;D(Q"30Y7G)S1I)VJZ(,VO1_PW\-EH-L1C/EC!-E7."*84I
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M.^*B7^=. $+HA@)*$.N#L?X$F" T8*JJG5_E*PG_2H%9<E()GAM?4/O>A*P
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MYD7T=HPA*H-D.#5P-I5.FO %*)FKJCV7'=2X;1#EQ]P9UZ.%2CUI2[7PD1Z
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MUAE^%A@M K+=R?<=FFM8JTCO (R6$"B+_&K'D)<8Y55B<0X"#+!E(5TA(O$
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M U1@S,HDQ0YI 94'$8+^Y7X^P'J<2R2Z,Q&%$'F5(L@[&V2C773+99AKI=:
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M1<Z%IM+(C\(/(!!NH6PD@ZK4:FD7%1@?KR3KETG("]2 T+@2UI?2K<2) 9G
MT>,-I]6 ]@4RX&V?BTQ=H\$@+T;;5J7TG38YF'RP8F 0"S"AA9J%(P!]")51
MVC[2=@1&@G?3!FO6N4E'G9L4ZMPDG9OT( R;[_6 F#R$]NX)V/ 5RAQ<X224
M&O4[$2\TGBI'F/RMNYR\Q9&X:>\,_ 54O,&3-FVALPZV)!8O\+)0&P8"M52M
M8.!(G+6^. PNI9CD(6@>G:.8(X+.@TXAW)Q@&,%2-Z64FH5BK!>!!H??*BY-
MG4YN#L*(<BIYJ51H=T(HUPCCUHV9\PO,F9(76%:MR)?JFE"9\:/TJ+=WXUK?
MB[R#@V'<5L&\!A"]';@Z+VMT>0IE&=: %Y;1:BIP51O')C(QQ-'.$)B8*"+4
M?G5_%]W4J"O"?Q^UJG>Z=K!P-C7O=+#N6C'*,Z5XMZ&<#@5$,J.TAL0M3\KD
M@8L L3K]<[R,'O/5)68AB!!/TN49H;%3M*255?+&<^>3Z^\TCRX];^ADG0X_
M=,M3P!SI!QB$S:XC+4$18GVPG*?9LU%JX0R^P:]&:4DX+7S=/LHS0^7E;(L-
M (25LV+!::'<=\*I]_V AE"4%_2K)(5LC4R'.Q09HW(K>/9JCIH/5G).9?J
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MWLAB#)V.%+[R*R-M"D4063UP/P]I&&V?"J$YH% @1B9ND_02*BEA?8/(<9=
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M(]84D@ 5)8&PH@6<FRB\O<CJ.L/[V5BL1+P !U9=9( 3+XQ%6:@!<*I25>:
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M]*99F".MTXC,5;[V9 &0FI][MYO^'*I(V2F'[/.\XG>WS]C;<DB//'#/V?K
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MCSQ_/HY#=YC$J5&K<^65/]4FUM*&:5%UW"JE797%=3/EGO323%VJ;:5&3^P
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M3YD.^_:*@W&V,C2Y,H*[Y$B=MJ_B]- (%D-$5%G[%J[A=&3<0I]9@Y@B\B0
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M)83E,PO+2\^S/DM)>DDX0@A "%0.*0B!/0F![T'L>.#Y)Z'D>Z<&C$9*<6K
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M;U9'W]0\U@S4L[7)M8;25[B7,OUE%^N!+N8C"?)&5Q(, V^\G_5Y4Q1;7\*
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MCIE.OQL9F:T,_3%SXY@<Y8B7FR0OL[*=N]\"JK$UK). #!)W8KDQ74!J5_]
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M/T$:@^?=GDO)BN=(58D8^+5^$%M7B2.;)!I?L:E9M<M-9AM0>]9$9/IKO<-
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MJ] (-0<':S:4M+I9&J/G!3?ET4GF01*.IB*2IV3Z186GS@(_S>2+V7P+.?.
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MO[J#>\ M_4:GVZGJX,X:W>H.[F'$TWXBXFD\B!9:9P\97J/=?]C;GHJ3'C9
MDGA/M5KWOV70Z+0/B34>)!V:3P4!,<9==Z4'FQ<UN3'5!V3?L"MZ%9*W/CXU
MUM)$_EMM+16.1=1. W^QP@A8<<[\/@Z5'SR+H_#(D^:!4P5P6C&I/>*V.I8
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MG9+LAV^? 2U(M0ZDVG_5:K]J-UL] %RI:,2A8KM3XFTU0;40L[7$$U)@9U+
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M\#SN^#%H%7@"3^ )65IU;($G\*PHGDCNK?X: 4_@6;7@*Y)[0:HU(=7VJ]:
M]PG: !B^1-V(%WE]D+5UQA.B8&>B8 "BA1  GL 3> +/*BDF)/>"_)[3+FKU
M&GUT[@4-0J4<#$^;F%T',3L0+/ $GL 3> +/8\+SN /'H%7@"3R!)V1IU;$%
MGL"SHG@BM[?Z:P0\@6?5@J_([06IUH14^Z_XC+]F&P?\P9>H'?$BMQ>R]O#Q
M1&;%L5'=;KN;VYWV&4@0)%@[P0<\@2?PK*'*03XSR.\Y<Q^[:%4,$H1&.2"6
M-F'*#L*4(%C@"3R!)_ $GL>$YW%OFX%6@2?P!)Z0I57'%G@"SXKBB73FZJ\1
M\ 2>50N^(IT9I%H34FV_ZB.;&:Y$+6D7V<P0M8>/)Q(KCHWJ=GL0N=T[0S8S
M2+!^@@]X D_@64.5@VQFD-\SDE^GCVQFD" TR@&QM(Y2(ID9] H\@2?P!)[
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M(I\9EN>AD%^GCVQFD" TR@&QM(Y2=A"E!+T"3^ )/($G\#PF/(\[> Q:!9[
M$WA"EE8=6^ )/"N*)W*9J[]&P!-X5BWVBEQF4&H]*+7_JM5",G/U"!:;J<=&
M=;L]F=4^[V$_'R0(P0>JJSK5[=:>>?0A$R# 8R/ *H@]X D\@6<-%0X2MT%^
MSYGEV47B-D@0&N6 6-J$9)&Y#8(%GL 3> )/X'E4>"+;$+0*/($G\(0LK3*V
MP!-X5A1/9&Y7?XV )_"L6O 5F=N@U'I0:N=5N_VJW6R= V"X$K4C7A MI&PM
M\8000$OFFI(N\ 2>P!-X'BZ>R.Q%6N6AD%]KT&TBMQ=$")UR0$QM@G9M!.U
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MZ>9SC] =>NHE[TW2;4,UX?BS!."SO+28H,J2F_(H.TR/0R9(B#(@ WZM.?9
M!J;'O8,5LF&ZWO*X=_0"=L(A4P_D#I !O]8<>R #.^%.?$9<7N!)0NB2Q:!_
M\4I9DX7@A"[2"!*=_:R+UASIFE2J9ALFI@1 'LE-!_+MDID3J]"5!$YG3(A'
MG+3I2(1"C<4V<;G>E%LW<:?'GR;S;Y+EZJ65$B,GTMFR^FM^C3M6H4G=D-SE
MQ7+[)[)BLJJ$UW0O[)D#IG+(1R #?JTY]D &]LR=^,PXZ]XAXV'!B1EV6GC
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MJG [/S=KU9$^?,VQ#\OD7FJ,4/1#)/RVLTX)YLF29Z?O>U3OA [Y+??OA?"
MC@L/N:7?:#^@4<,#WM1I-)_F10^Y9= X!PK[HH6[LF"'Y"NQL^*/3XW$G,A_
M#TR/-8'JC3F.C6;K=IJC%NZK,AVS*+M\TVZT>]S$D].VK%2ZIW=IH6%>L.>0
M_(Y;OVW7XHHD];W227<(M2:+9J="8#\Z/_?6MD813UI*_N5O+]HO0,8[)>/W
M?#C .R?T]5'%7SA!C6QVZ<QT\LM+4/@34?@.\ 14@ IR\XGDYF<=1;_4 ;"[
M][9X@J?=1O_LO/A?;UWMT^J1"6S]QH#NNIT,L?W83UI\UL=.>\_>@UBA52 J
M 56=H8)6V9>$_"[12$C()Z'E^X=C1B.E.!RS,O*R5:1EY6265F[FCL>>JHJ
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M.T149Y<_%VE)W"&[>G^#=X#_J;/+7A*1A;5YIN<=TD9$(#P>80KW ;OW1_@
M)\PT7-S9;OR,=\00-#!P\.&9ML\_)(FX,HPEP9+3%LB01U4/>,:ST]$Z,R&/
M"Y[3.?]=$JRXQG-GVK.ACH>- J.$B15.F-BFA(F4,)&2SY0D<>+,\*S2$"S$
M@B)I'&,1\$QZ%]SW[+3:3#F]9&J6'FYRI5MVMF;;S2TRQ1AZ4VN9>IV]=[J#
M)-X^,<>4EVS9+1)+;O;X;))49OFA#7$Z8'IR0YP-R)X?.;/4YJO,,*-\6NKH
MP4)B&;0'*9',X<<E+9E),N3BJKCL23+DXMHFVGZU2P>K^@&19X+H53W=F3*@
M^(_K:7I@K(*%A2I%$!$8# ]I[,],Z,YJ-U%#,QKM54%?+W8130TJ4VLU5AE4
ML]:3,ECD"58\(S!)##40KCRBZHQ&L P/0O3Y97\EC#AI_63>?IRI%9HQW5IM
MS;":HH71S _6I>;+_+[9Q/.V6]E:>'^RM0ZO@31WDV3(UJJX[$DR9&MM8VO=
M\7$D*QZD45/9B/#YS3^,7A*I1K[P'HIHFC,X&SRDJ/[%C;H#[GGL$S0" YSJ
MUW6-W0YP?W*UI:6OSD&RNZ5EZ'6KL<S2LK3F2M>5M%:2U@EWTYI4)*GM,N<A
MBS:D17:P5IKG^4^A#&NW]&G^PA'["L\1W9*F@4F2<\C[#AT7^Q?>P[+3WXG[
MB@8:QD+&99FQ! M]1RK;,MPAPO2**H0K8Q>NL@8M2S.;K4VOM_"KEM8R6YJ(
MA9/;U]YDF=AVLQ(_CGJQ/!; ;CUG1!8C$8@D4W')D+[2J"2+L<3RN<E8)N8R
M#]UBGN?W-S*G\X<;;47J+A6U+I*-1?"^:!K)(O6.R.:%)J:+G%=FCO/HN)X(
MIQ#ECF8<1TG^+K\K3A'V6)Q$[:OL71SZZ@&LMY&R")/P,Q%+-E/XWE[M#[3R
MM5+;]?;,X=-LD0U3,PQ[W2:LJ6V5!P_O9)=D#U;NOQ( "  DF6I+AO251B49
M;"66ST:#;8V3+ENH8\'?=RRFG)G-4U&H*6<T-;/37&?*&5J[N54\75-KO,R4
MNP933G0X67+5UF\B TF&++F*RYXD0Y;<RRTYP#K/& 3Y!,FM-ISL/"/B9LVF
MS#9MNWV8<+@^<[ PP8I]4)"\W;&71,6IWVVY,6K:FFZU*#BN0EI(\S=)ANRM
MBLN>)$/VUD;YO./1$_J6TMS_LJR/I'[Z82?)L/7)D:UW/(W=17P\<$8N!_O*
M^9<FO"U7 :9O'3GL*G2'0T?&<^$7*DG9]X"/0O3$H?$ [X@F0IBUV] 7)^RV
M.KN=S=GJ!NHWCLQ)AOEVT2\F3$)I#,F(L[34DANL2>PU+;,T<Q!#-'C! I4V
M$%B>SR V:0U-S3M9XW;I(Q/+2OH+Y<_&;I!F-I.6K+BHSBZ[79CGX&>8\P.D
M@MF2,2U;8L>I #:9!R6M'H7?J/)HO8R9.Y>NU=*,IKDT]8<R;H77,0F1F\N)
MN\+.DUF&HVD5B'F1+,L;*[+F:FWT$"K9K.J(M976EITM66&*)SY'RUSRR"5K
MC;7/76+!+SYV:\OU=.GWXEG]=8[_DT".3R ES+]1DAP+)1Z#)9$0F:9K\IWD
M[0?$++>M-+5K9B\7$ZR!4?K!!4ORGKM@"PKK92#+7::G., XPKRO//&1";-2
M6^KE,W:(=(,&;G3TM>J=F;(&"R<ML S $_>@<=-MQ]DMR6PMUB2;AS*LUI]>
M:&I--'7D._>4V846CZC6FI8/?7'^#S)>2CA/DD".6R!DO%1P#)9$0F2\O*+Q
M\BD&HBM?QJSYDNQ>RD3]B/>9/4RY::D\8K/'5!>2@JRHK.DYH^5FCJD9N9HY
M=MWNK#5S]MZC7+,EV3!;==-*"BEEG$N%6#R46;;"F64[E%F6,LN>=F996J65
MT" D@1RW0&B55L$Q6!()T2KME5W,9CNS2),+%J?;Y1Y' Z&7W7D7<8]+]K-;
MFMY<%<#)!MSKL?O)DB/CXL31^[0<FSIS)(^1B^_@:EC!N-/S2-F<U&9'W_1(
MC+N8/_BT\JP3^7VK/'F10(Y;(&115' ,ED1"9%&\HD4QS31H-C)VA7", :;=
M$59A!7 _NE@+3'IR9<Y!C&44?Q..V 5SH2N@/:W>BJ: _*R?F@F^0OE\Z*1P
MZJ;'8I8]-%O)3-@TJC@K1B%FJZJAUS>IHX:.7_3G:JJR?<@XB-E%-PT\5MU
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M8,-0I+$'5MW'D2);U\6E'QM"_^"=Y1))WA@OZ,=@_\X; +"RP5IA(^A>P,L
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MW.?_ZOG=OV[$C]VQC(9IVKK>T6WS'"-.V[4_#LV>I6N8=Q//D?EF2K%:^>*
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MT*"0G!B%$'H]@B8]0.TJ4WNGEB.BL4OJ/4*OBI#Q;<[1P*I_XW$-\VT&B+2
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MB==;S$66?KMTW9](RW'1F)H[Y^^_BMXVXQ+;#T2/WBTG06,R[A"G^'H"[)V
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M,K7PJXS6#2(O75.<;+>^IJLT!"%.LSC"3;4UJHU<B"A52[=I)6C_$<97B.\
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M90J]96G5%!_\/-;,WXUH8HJ/<NR%:V;$-R25)D5-XOJ3/X^DQD/+Y'V)XGO
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M%G@-"TSRX*0;QB0CSW. )9C6 3*I"TEKX91&H?EQ&!+]/-]DZYHZA]]FIO,
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M$QRY,+/E0U#[C5)$S_;:S/S_V:89QX.:2?_0C1?X5]$9<PZ)E/\APK8R#AB
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M+HOK:7ZKR]V,5)^PB2-:LX8(S[1F-.. UI66/*" 2=U$_;C'M*XV!3!-F''
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ML5QZQ)%? O1UQK51GW!;DC\)7@8QK J*(;!7,FDP78&#(^&AQ*NLM$4\'^3
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M6=)#"?G3EB0?*[ZG<R"Z*NQG$,]X,)4058Z$J/)7$E5^>L%5^I@_WND?(R-
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M W=.<HIX]Q;MWX(!+#["/)?&-'26Y$(K>J>],J:A4]S$0"2Y$F=;P IB)H'
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M8*4(J2&C)&V,6)V:G!A)&DW[K_2O"CT%*(O?C@%?:?V"'M&6YFSAOW\+/()
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M?+<K(^E;?:A_LWWU?!0G88"4-<4J+?1/6JJ&5?TXH[YC>W=OLF'D"3#ST?:
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M6K4Z+V^ED1%35U1:("*"_E@ 05,Z[-IV8 C)[.'!?%OU^6>JQOK/$ZB#68E
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M=TC=V@ABGK"BC.)E\>"K;Z2:YF:0DYG4Y4\)$0R-)<\<NA3_[-NK$<QI)M3
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MB+4L0MVKH-BJK?1S7\!_^MP>*NJS04J=< 1D<<0Y0GRK>.7NO1A!_%##9 ^
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M$ H/A-\O*/$<VW\'5)A^TL4H&@HEM4B3%[S[_H7*Y05;?O2.0] =AV#9&8=
M_H7^S.#W3.SW3.SQ)!*^$%81F;!+ AX>4$3D32O)I/SX'71D_%N#E-/I<F.P
M#XPB0EVAN.U7)N3)=SPT;;XT@:R6VDG=%^:047M<5*W-F7[S0>E:R-O8 *HF
M%?DL8LZ[I'LH=-FSB:A^#\NO8<Y[6/[H(DE]W4\1 6N@97>\7+33CQ5^CZ >
M10'@ZMM9Q">^A[M.N)-DP/VG'I'8AE>MWK-G$BW6D5_*-\II1T#UY%-)E)]V
MD$I/'LF$U+@1&*:[*;,?XKN-Q0;@WQZ7AY(&<6>4-+@)5*WU(^.P)-NX@0!U
M>XWPCJ\H2-$-/I/@_(?)_.8E+\LT3C"OH^OOCI_"(8-@)_P_=VU_5Q#7IR=M
M9-_CT\47@VXKGB==OX+-WVDCB11)1''")J0\0\56^I!>64H'5YT:&*]L;@P!
MEW;L.2UG3]MJF_IO" +2D;MXQ5MYRZH5XQ=2^69M6)/.W1A/<-T:=NM#)UXO
MPMH7 $-=88GLAR3KAQWW7 @[_TR]"-)='J+0(9&:<0VD;^\>]<(\*J6UZGZN
M_\@847/E^6FB]-6I6IMV^MB\VKKONO9BGF[15:?01\(7%. )^?C$+]R=%W@@
MOR$SH)Z0IJ]&1LUF;IM@"Y(FSU[XS8XB&YZ3*HC'CA_KVT<HH=OA+HQ5<6#%
M-GI!XE,G22/&4=5\)0W-X._BU?9\\$2L0\'6P%*KZM2"KKV8\UAM^T@U8,J-
MYT#6T@S[5H.)0YKA434GG$5(1Z,YI8@\T<-P<19L;&W;$-E9L1Z,RJJ?*:L"
MM"4H/08QJ\D,40 ;DK_XSV)3]349B/SK^ H_"[YVN!Y:G.NSP-[K>$T,,(><
M!3M[71=-YI6SX-R0NR,SX9P%IR:\/=16I+/@[!CWQYD@2W:Z-QHM8&<19]?I
M;NAJE!N5@^:^,+J<T*+%;Y+8NZ,^E3([XYD@__7=1FT,FV>!W=9IHTF,I6?!
MI Z[3*W]GD5L9[_M)!'OIPW4UF%#=7\DS!<@:V3<)_XI9E7B8>%>C..7(@-^
M.J[0T*,$KVD;RV!0M,*3[2.6''-O[_!?UUA1C_'QPMNB%K*FQ8<C._S9(^(V
M<%.'2I-MA.A1D")6M/Q(/V(*/:!8/=N' 4'B:@'\(OU&7X12<3:U&T?>UA#4
MC5KH$[,P3X0,YF8,637B3LVW^DD["NRF]#GV7,^.#H)(K#O"RO9G51I>(>2?
MT#XA!PO_ZL?5!I\W?#VJQ7M=<Q/ 26KE2;6=&<%0DP:;*=9]@55XO]V:JYKJ
MJV0N+Q93N_;UW^B5!#0!\8I8V?#SW@N9>X576Z(YL&GDO-@Q@@H3:FVE7V\C
M[ZVO]@%^V+RSY TUAE46RY_4;BA%8]-V$LF75BY]MWW4T-?(N^@*.?RF:;&5
M:EJ;MB1BUO%-&#VAZ-5SE/&A'3L9>1%^L8,4:T[M+@IU8].6@.SD@2N@Z$/C
MK?CW-*;0TNM0<=V17?.,#ZP+[T$4Q,0<]8BP:AE["6)$4/H>D1-N ](+*S6J
MN%@G'G9LA;?N/*TV@H[X#3^8F3GC^CN*'*\:Q#U&C_/01W@Y)GDM.]2;(T%*
MY56@'K!BS>W<^.2N[>\0R0RO++C'ZS(I^G1G"@/(>E6FW8OX=EV-_6!I(6>X
M\9%,BDY0^J#IV971HKTPX0&RNMB/:1<W70E(1HABJH(^[7U/F?_4M1=].9N4
MZU?A6_ 8IH%[@^PDC1!^_T=0?@1KM^3/VX"9#'>X4?))077/SH[/C?.W3S\=
MI1'O;Y_^8HB_N&4)<66TYZC9 GMZ.!,[2DSRJ;=WV65A>2U<9V>1;M'*Y5:(
M<I$[MDX=];76GZ<&$#S/O=3&_W;6$,)-#K("<UH(MY-G6'ML7+D<.QL&U6L)
MZNJHHR:%G(Z:4.M\/8M\FM87G\3'>S;@U&JQI);T9\.<6I$DS_ 8-8G(P-R%
M'I)(&0YP%GE7K:500^3!63!K4"6!45ES?/*H=[C'>>#"=Y=;BE"3LV!7:ZFE
MBFLY"RX-.IA-T3/G47Z@^[&LB]TY#YX-OPXDX2EGD>G78[O51"F=!\L&RSCU
M9GLOAS%':-5\)36,9?8HT5F,CW]]Y^.@*##&QI_/F(W#X\BX">Y,W')=N-@R
M&(US\+1MX"V.<^_@-\[!,S%)#;[%2U%TG'WO3^0>$7F<>>\OO?[Q?9R'[^\7
M1?A?QJ%1WRG4Q7P=&(5LUM<+#]&&&9M&?6&HV70" "X/9$%>4.(YP!G&Z7<P
ME\F (>P#*Z^8W31VX*"Z\A:UG[Q#O A$G7".Y3NHBWY0ER-$8'B'<WF'<S$1
MQ<#,1&QST6/,PS?1#J=F[-ND7L4[CRR&29SI)\ZS]RRBN8*I3Y8W[]E#[]E#
MVN-ASS1[:.RPSC-Q![ZG?8RREYJ#P\[$.?H>KS]]MMZ).XK'3RP:U3E\Y!NL
M/6K$#.Y@(SUXJ\W2CE]N_/ M5T??/7+'#U(\?*IAX."=<1N\HA@*ORP"-RN-
M1KC88-%O__WD5L' I<^$@G4,\]A/7:B8NG <B V)'^P#W.=0,<]QHA2?=;'8
M6QM+XA@#:5OP:N1,5O2'A7(UK'B'#@PB\B%">]MSKYA\Y^4! Y=4B(7BZTIG
M><_.]'NQ!*'?WB]7_40_(<?@C@.^P?]!-+QB%08+@#QV%WZ!MT?Q!T++AN49
MIV^MK,$S+,\K66+)>L!BHPXEM]VW.F]ZF-I#%+YZ6/A?'K[%< 7DUR%66U^)
MQ&^Z1[MWI#W@:!VR>N1XUO@*2 Z0V\FO1U*_O"'\J$4'&MWK^[U/!(OM<YEX
M&VS":$<?0PT"M>77&F](_'K!6PN"N/'>4UY]Q59F +E"%AA6,'U4T*'7H>P
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M[:=F6 ';08_76E[F,_?I+#+=9+0IP,W6F4=.-<.XR;@"#.IHUSA55K6U@62
M]2VL$J?.*[4A(^-2LX'A5)DT)'*B9!\X51;U,JEF6TMMPCA5?M7;CPK*@<1
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M"\.:3^-\?BD3U($_05I[&!"')B_4\:X.S'8Y$+Z_A#[><C&%G14KIC!4^49
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M#QEA+:U:DX_15#KGD5.]DK,-Q2OBI@F6:8$+>%.!>_T=10Y>'YA"W62']66
M&'EWZ-0+H(&;Y2STV3G<82>K2+6HY?DNXN<3A^6*DHLW.W+)IJ6AP3$\JNCA
MBN-T1W_640\;91"CF"6&4(MT+!R\B;F2TH=!'3LVA2G/Y;GG";R$"H(;7?C)
MM\!+!K%KW"$-8"2'AG]"T:L'\;^R/;'PR33 WK=A*5X0H(>?\2$-VVO/Q;''
M.\*[>13A]Z[RC"8FWZ,A9Q"N9X'KT87)HPO>^6 ^3%#ARY6%CE%[/_KR0L*+
M'<&+$KF+5Q396W2?@GV>29*NBGN7O@P@?8&?D*[GI_"0? */#_$"77]W_!1O
MKALL(.!$IPD[QEU+,DTPD!G"LDLMIYX;;0HE"8_[')IU[?3CY'C[]KR,1W45
M+H_Q%CJC.I<4U66U)\$KP9; NW#/_>&KG< 9:&<6Z-.3 7<5T=A3!Z9';.J/
MR+<3U/4-WZX7,V3CX *?O?;,6;S.![.V\[X\KXNF4)OM&&^6$RG0)KS9-QOD
M)!D !Y[G(]ZFDEBQ#O;0[ET:P B>LXVG2].,\9GMG\K>K3<SA%_'^G;#]M!9
M7">].=IQ,Y[9)2(I)GB,=\G1EQ0LGO#5)M,H'Z)PXQ%;)KRYV<3C=0AQ]J'O
MN: (-<G2D3HW0Q!T*4PX%E?/*QW\TRK:VH'W+[JJ@7N9QEZ WSD,^.FX)(,$
M$J9!.-1]H;,0!T?<>+"C5?0$H=\N22[@)K<:XTO3EQK%'MY2 7*Y^7#A..DN
M):\[?&][CJ=:I!8?&E82;Y$L[2@ZX,D2WJM6J]6W9DCB%D>KA%'8O(7/Q";?
MD75MCLE9Q"ETW7+M3N(4T0>J36?"!=^R.#$'>L2<3H$!QW3M/]E9H/.]O<-_
M74=V$.-M@J=;BZ71XL.1LR!NT'.4XM6 W[ 8[-O 32D J1HSH,UG^FQ!/#.-
MAE*#JS ,R-E3X\K4?Z.-E-)L:C>/O*VVJ2]<UZ/2Z\'VW-N P2=*]U2[;_1M
MJ/0Y]EP/[W?A@-9M)F7[L7.86HG2.P483*\N-)[J<MY(I;29\FPW?ZGOF!A0
MSG[0[I)!E77^7.^NNHWC%"NSQ,-' QAIS$YEFZAOCVZ]Z*Q,*Y01RP%8E0]=
M17-#<*EK)R]M.O(1X6.PI"V\ P"IG(PH.Q)US<UXX[177;/<R%8JY%FXB5HI
MGN(34:'>G3JZ3ZU6*_*G08<\CTW5I'P6/(\MCN^I[JXA&G&!AVT4S;/8>AU*
M-W72%=]W8%%K+NP^]7%_9UN+@]M%ES]IJ_4HF[%>H3E5,+"Q-J3ZM36GT=]L
M!E;V7C_F3\'04]J*\G?S29=?'\JZY@?^?,7637#<R>JP9>QE%9%XT4Y>&8GM
M-%8@Z1A#>(J$%2L^-5AJ6WVJS9+&9G<;X/6%9:TG(F\VL@6MS<8A/WE$#O)>
M"^&AHFFM5S_3T (JO!-Y#-DA<&]0[92ES2>:&2M\?><YA$MULRHWU6CRW8>Q
MQY90:>L5VVBW3M]X079-L!UXCYKLU(J/M!%#3DOQ6-4;W&L^T"WEI#*XGIHV
M7YIAINER18DZ8?4&. NK5E=V#;BF3MK , 8_Y5?E60#R#&);Y1X_Z9?<4$%7
MTB#F>[8=):_J51C&O#^_,T_"O#J5B3'NIW?&J561>C6-<7#<LO=A8OO'9VXA
M[,D-RD=L7SF1%*GB!FX,K%(V'_G=+]TGLE>_O*'>MV>Y2GC=L[/2U@QYV#%E
M1+V+SN)EUI);=3O[+%Y<'7>5XC!-\LHZSNMTX3A1BD1D!AUWJ4*&P^SC=4@5
M<L_V,Z>\RO_0]JN1[QK&1.9=BQ_L@RHR7-%RFODL<4O/L?UUA+F@C,Q5-YYH
M5E^7W)94-QVAU33SN/(BY.!OGA(/C^/63:;25&,^SG[OD\UL^]\"1-"*X5^7
M*$ ;+XF?(-8'#CO_@2ILOW,_TRS"+Z$78)GTBOQP3Z)MFG>&\A-MB\*!&I;A
M[AD+'1"1BL*<&41=O0%^0(>:]=;*;=+";Z+^2&=J4B<Z.I$P=R!(^ULT4S%5
M%]I)Z^(#F26[;4]:)Q_*+U$/.&F_QT!&5165DW9Y].#6 .WHI#TB S>>6CD[
M:5?(@ TX1!/\_^U]:9/C-K+@7WGA[[:G?<R,)]YLA.KJ5X[N5JU*-8Y]7QPL
M$I(XIDB91U5K?OTF>(D'3@HD $H1N_/<)0!$)A*)O'/67I(S<,H3+$?QC<P
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MX7"S#V954WE:1'>9?='S:T.*Z8L-SQ8YUPX#^N-XE2#OEP)Y(4IGR/<ON./
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M]AW1J4T$J W[ NJ5G_SQ$"/T&*8(%(<4-R!3C7KA[\X#I=B,BQ6:?T4!+!,
MU4V%5,J7%;,UI5O&(O-R4UQ.$G,<[V/VO9.L(\>%G6BZS8@?M._&YO^S0D #
MB9]6ZE[!\YGX4_XM?7[Z,G:2 LQO?KI[##W<D#)S@D60;P)Y9"24+BN:?W^$
M+\W/3)$;ODHA9&KK1.O;]G%$KE"WV&[C/#\*Y(S8#Q/?S?E9H<NJ9I=G[F:&
ME%VO5$SJXF-R:N?MQ[[GC$MS=?Z(-L-1?P?V,9JN&:;M;U7-2#A?TQ>?<XXP
M,/Q]-R[UI1HU('%@C(1]XQ*'R $C==(0(?+_HM!"*Y'?1=O<BSL0$A6:Z.@D
M",P=&P))!DWL<(+YYXXM8O:(0,5M<H; 1; ??OWV-H.:.PE=&TX,X4?T&R>4
M.'%9-XTI/8Z2D7$A18Y$),QV?L<8B#&.\!2\BHU$DHM &?]5[&2ES+VAB33?
M%TR%N2QJXG/^D3)LQFA,8AR:Q0P,S32=N?=K(:;.24D;@U*!*K1^-ULQF/\^
MM,P8<Z>SD45;?OK4&"V";.-OY"2LB\#,F!F-'666E3%6X5HMWS,/VUSFQ[1:
MSKZ=EQ@S'):Q-T;)4P,U^:DN-#5YL,+SQ5]E1GWQ^7:2.^<&\S,WQRBV>X%W
M6#S3M$+XI5SF"0W, AD;8]1$MA3W4R>U7FLH3Y]C>BVKK"'O=)32RR:^J9K1
M+I,,.TK59KO/1'T>;(7D2W:@T--J*^S,V^^AFRD,E0@_S-PH.>ZQB.?M5NA6
MJJ]?T4W/Z:T0KE3#MPSA8R<%5SB^JI7CY@Y7>+[JD*.E%U<HOFJ,(Z4A5PB^
MY,8\$R<L5Q$/5XNKQD3FZA#F'O>KF_*Y"<W505SUT(F3FBO$*]4TK;T!HR4Z
M5VB^:ICBZ= 5SL;MN6IL/[MG=X>\+$#+3:V$+#=-@Q+RRI9W-9*OO>[,ZPBP
MK)3&HK,HS0K8Z3Q*1LBTFU"+["1.&XB&?YV0#/_X?85A(!:^[OXZZ;8^^R$.
MK*5NK/W[]!@C='QI_W;MP254V\N('EQ3% [LW?B3+:L#Z;3?GO96%^'R]%O=
M^MVBXQ0H2ZIG#^8^W H(^ Y;VT"H&OILJ]S"+!$]?4E8]@9LTK:FEEQG7:F
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M-E?!N'=B;+VK8;EQ$M_M*7>=-YLS25^&*JO^U#-R@73SDF=.$(!.=2S')>5
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MGT(1""N3U11(-M%@=>*C^>7'#2W]($N1=QI7<-*F><LNNQ9 4G3JP/ LW@
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MXZ\F7@MR?('EX,M=!VZ@PAC8^)N!Q%"%.%@.K]SIGQDZ,0:N_FXJK@1B*\;
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M-GP&KVZO8]K#79S$"KWAWHC%33P$/K7,L>PJVL ML7X7O8>K* N]!^2D68Q
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M8V.$1%F.3-7"F#X)=D*DC2:,\8.P+,><&CE,)K3+<H2-+7P(Q)M9CD$UDHA
M,)OMN?I"$HG,>V$Y0H;+&7(!A9:C2;4$P8I*M!Q5HQIQI@MYM/P4)GE2I:(H
M+4>H^A=VFDX+QA6$'R(=6XZ841[97I"LY4A2_<128VTMQ]-4EEK)T%[+L7H>
M>Y<+);:]IM4Y;)Z)4,L1,PJ;9\=T6XZQ\WB^3#2XY8B:BNES8L\MQZ(B&7[R
M&M#&->E1I.-;CJOA_'Z"Q /+<3L5PZ/%15N./O76BF9*Q&7TJQ4-#K(<&V=$
M&HR9GF(Y5B?3TB726RQ'J5KI33Y5YB(Z4DMP \OQ,9SO#4A+LAU72JZ>3'J3
MY7W+U2!LZE0INXJI8\\MG&,6H]OC*^Z6"Q($;'[E)W]\=D)GFU_19T!NBK9'
MP-3'Z W%&/](27%U^-YWV^CM>_?H%6EO\!^G;#?XQ^^RVZ(4##QK*25I?NI!
M)=5I'[Z.+B!O(B?VEIL[/X;K$\7)$C=M]K>[= TT?A/TJW\-744K@#C^RT]3
MA);Q<_;J5O\"QG.(P@3W* :AZ0S0AZYO*&GWQ*LSR/N3VM8*9P&;JWJ@G&'W
M'U;2D@0+2A[\XF^.A?R4#X;_7,.W'5!\9$A!S8<,0A/.$-KB,_4> F<[$ 6=
M172!5^X'#J2P@ #JQV8-JC]I)&6<>T-(*^D"=!7A_CZG34K!1I^L_]S6.S_V
MGIPX/=Z'6_C;@/M,7D(_:$^EAP_'<50W*6E>)7G.);*B+L!/QU S"'A,RJ?%
M=W,[S^GU$81=?E'SSWTH7Q)>5A\*4E"+G2 X+G*=%YMK5J 7@X[[&AP_^7^@
MX+B.NJ-6:.MC?2I,Q2^$@N_HIQ.<'A.G?M+BS>?3B?BRMM*))&)4?<P@^?!T
ML"IXS'D?T'^1>)QQA0XX\3O*15SUKVY_>>LJ$JDPJ&';ZAG6*DNK%9QINJ(B
M[3P-<$[(E+4("=#A6=:6>>)6@0%*!O%=^XVE&<)CW7[E)J$YX5<90Q YJ M"
MG*H'O7$ \\2>-EXY,EU.D/ Y%L-DV$?GA*FI:9!BG;4T'6TLXI,U^<X)?=-0
MY #;LJ79-/II=&36J0N'4[%.%29P2_,CQJ=="9/YG'!H!^V.C/P)@N$G5.=E
M+/B6QC?K?\H(AG^[HG"3*JW@VS!*T;=__=;#E6NU=2"B)CETNP_U!^IKF]1I
MG\#>L,*0UT&-VNNHZ_HZ<!J=LV9H[#>/4]-@%UE>0N>K3R,4PD!#-OW%V:.[
MG+<);;TQW'8 ?@>^YF2!1O*Y#9PDJ8MU@!"2ZWMT*J*/-PL$YG&P9LP#C)$(
M*XG3!BCPKQ,8\(_?;W$Q:10?L/$ $SF!CJC#)MTH""M9[.Z<!"VV,<I?H^ZF
MB)B7FSL_D,XF*TI_M&7L@QKE!*>TLFH?R>>6M-OLA\:?I/LNYZ4&1*YP<Z!B
MU#Z#!HF2#T]Q6:DC_]1R\^GFF8Y9[AS%>UP$J9_M/\;1>[I[R$+OTQ-];]2Q
M^J7>YF$RGE#Z>.5''_JXPAVH<PAW0=C[21+%QR^@WM05\/PX@7U$V+3!HH<A
M"VD5S@BR.D,V(XU63>-UV1L"OUJ&B$'Q8C.G)YYG7 W"4T$]I)6FQ/_Z/1J(
M_]-,U=W199Y"]4\@95?K'4[ SI?^X2\??L%G2-\5?;#B7?V:!4?XZU_8VR&,
M4BW&N&F4 \O;"GG@=#>804H"LQ3O\\DYNCOD8LMMBMS2O;B-G?WM8G7_O'!3
M^F9%IUH7)'QM6\H%FFF_,QH#/L"&^U%]Z[54@S82Z':]=A<ZFAW*$@R4^N0(
M**AU55M0P2 &KI6N56R%94BR!!<LLE"%C#D0",_JAE$A:1VR!!DD"E&.#4M(
MA/^D\OP5=4DP 4N<Y:B@V^9J)/!M9I;B8)"AN$8+W4QG-#J$7EBN$8_PJ+1(
MR&04[&#EV,U>T;<U,CA8:#GPZ=)6@2"301=G""S'6X,S##*I6HXA@5")+HT0
M[:^6IJA(/Z*BMEZ3\:& 9]#%,9,!GYYC$.WHEJ;2J+TK#;N\R?A0^+XRY!!+
M4UFD*6)BU4,5"A02 </"86F:B#01,!Q-EF8;2*. Y-6R--A?W@Q!]J19&ITO
M#;Z(Z\[RPN+"N!!V#]J5;G!2D/"I_NTV"@+G-2J[-B]"[Y/OPB-RLM$D'ZZY
M"-=<!+-S$1987BG2A3 )?X&[=_K+&OXK<?(+3 X_&+J*XG"$WL7#355 '%FA
MO#WQ<@/__1+Z>2Y5>EQN;F'2)HI#WZ''*9R]IK8C7</:RTWC2!B!C>2QET6-
M8T5(]RB(%M;(&WT-A;')\CKW4!B!_F/#;G$M/I[/SHU&H)!SB\G$FX0DC6Q+
M<,,*)QD+.7;$#BBT6E$0:3+TZGQ?W$?:9NWTY[H[W&?DX#\6P&%"2+1II?6>
M/OG.JQ_D/<C*[7G+<(5M)S&NY>@D?O(21J\)BM_PCA_#0Y96C2Q]IT0C4Z\=
MY5/:Y&*%T+!T:^6?T9A/%/MOL)$W=#)8X>(8S&1[QA0# +D%:1VS,,RS.9GK
MC"ES 60LI0U_"4@\C[""I]5#A7EO^1KX6X>N>LK-G04?X>3HC?(IU>DV>5_Q
M,K2N<NTS\FP8PZW5T<=\DYNBIOHGS&0I55A&'^ME;P=WL1Y#D]$HFG?#?^S)
M^" ]19;@@YV%HPXA=NC$0MY+O@!2JX7B8H#E6+&1_<\H.E6"))G"BLVFBA^>
ML_W>B8_+S;._#?."Q6&Z<%T<A@HD\10%O@O4<H=2QP]R^TP&8"F6!(6V0#,Z
M#%I"M2PK]'F2]B\]75^ @(/+V.<7 4>?+#<-$RY3DQ28J+H6!'J-,T H_J6\
MK(^AE[FY&,^H"B$P37]\QOV?&?":VVA_B,+<M"Y0.8<X1QLHG=TPB8<\5I^/
MO(Z^?G)\[S&\=0Y^Z@1LCSASCCZ"REY!MO*!WAL7E$5,U/$:[P1L81<%(#HD
M!:&L$'9,HOR'YP-(.M2;P9^I%ZS'),F0=Y=AP>P)1)7(>]XY,2XAW-DG_?++
MK:(-W!4"-<G'-;UOG63W!81-$$<;9I8.7-3A&JVK1=KK;92DR2US\\2ABE^_
MZAL%76,*P)V/\B^27CW6<.L,:^?(DR=A7T::LUP%%9?J3ODF(M*5T6B1RW!F
M"5Q-+9LBUAB-"3Z!,(6U5K@'6S0R&@UB!,$3F%IQ=0+WRFB4T"GC7!XK);V9
MC".NGV&H;:"%)3K566J 4TH_,F*RR?B:AI;83YK)*<,3T!-=#S$YC78"Q)#U
M&TLS:Y5H"$P5RV9WP$_$R,72^J\_=!&W%4N+;#^6(ZN(-HY;?BT\O_1@N;O0
M_S.C>Q0F^ZS^4"2UD F%-X[Q24-L5[!G_'\P5W@#80UN#OFO3'/Q64MJ0\1G
M$"2.GYWX#Y3B4F=L$"F#M6W^)DO@3B8)"$2O?IA3&"4&H:+98X,]YEYR"J0J
M5M:&EL<0W@UT2JF*BF:V#!\!:X8^TNP@E!OZRIA@#!#XV<;BRLJAU$V7F&@:
M@3$/ASUG/J 8T.J,^-"P>IW1)UP?:$7ISN<GJ&,[)&@O6 )[1O&;CRM'+3=E
M$2DG. 4M)ICO)>2?F'2M]!/Z7/VN&V>H+:6RO/RTX<8\&1C7C-M+'6X4  ,?
M;OWWCD#BC,.@C;ZR#;%/Z#]O>"60$[OX);A#;RB(#KGA]>L!9[SRWA?N3,.$
M@EJY/UF3I&0$TGR;M$%NT,IY:ZI.L]OAC//D,:S1OMQ0=D,*&)&9;M(A/J.#
M ]M"P1&'M&]#_S_(:Y8A.#FP3U28+%R@TJ*3.RF"9O3/61>!,[7-EICG,(I9
MTV17M$ @API-J(ELFL7/<C3IH%LE]D>3\2Z?D3FB8Z*)>::)TV2,"E R7WUJ
M76<! Z/1"!&*X1(P:0N0AQ4!7&+9JBH18DFVJE@'.:[QDQXZ(ONV6H(M9H^Y
MR=!E"9'QV?,8%I56/"[5?FDTXH1N)\^TR7K89E9N0 TJ++E50L3!L;2V2O I
MO8.6H(Y%39IP9PGY\9FZD!NX\Q3RS<0F!RX;JE)+V*E-QJZQBC/]V;$TBMPR
M^\_8X>FJ,&XL 5-?.DN#_770K[PWR63D&DNJ+.7:TBP,P[BM(M?@_#(_%@#_
M&T#T$,4Y/JLC6:2GVQXNVA7$=&>+7-LOC;U9$JG@-A&]VG%)NWA<TB:46IC)
MUZ)%0HWR+0,J,5]K8RNIC7W9I:0E+P7E3N1)U-PL.*7?LJJ8M)6'^A%NU:<H
M <'<#3(0%Q[#>R<.8=A$!\WXOC84ET?-#+]LC[$V_NK:_HL?)J96?#$:=]=:
MWF.U<;*XP/NLZG9/Z- 8E\UPA#3+<3=UV6UC'0U:B(@E%%J.3U'"HLB"-MON
M?NZ74E-3L/UJBS/>%G<;[?=16-0YRRN?+;)T!Y3\GQ.1=5.P&#.NU>55 O64
M<R3T%#B,TO.<P?IOP;7@O$82:EQ6)O7TQZG=<A*GC>W"OTY;A7_\OL(^8.(&
MN[].NJW/SE=_G^VI&VO_KN^J838,@AHNL;?'D5]%#'ZC?_+-\33FR3GFT0KO
M3NSE_Y/'WH0><(X0LT VNQSC4XJ-N4\QPAEER.,;<FE#]=W7P$F2\CUB'@1A
MH&J;. C$\+C_]!2!-/WS$XK=0C-_0W'J@\P"N"NJ&-*YR_!UIN<^A&>I_9N9
M#%%_I0)3&X%P,%S+&A]1M(V=P\YWG8!"!/2QTVZY,/(W-T'D$>RQ]FW9 !JO
M"*#)=D4$V=YX??6(ZO>7ONWVF*L\,^Q3:LDU0>YWV^CM^R0]Q 7R\'\U;AG\
MZ_>[^^Y]*O]J@N+QY,3+.+\17FZ*!!$@1RE?%:'.5-[RQLT?4_S+<@/2B!]N
M&]O@RY%R"ZB.5<$\9O$2^JP=]@=-JTGY(5N3:OVN&$$O88RV?I(B+&3F)BLZ
MGJAC]7'#0GX6$+=%9F@T9C5W(VAKY$P:D0VLT &^!<P^=PG(<0#FW#$N_XW(
MY;]1<?DINP"(*[LC'U7TP1.P=3D>;M:ED7Q(!2>K)X78=T6,+Y21BO?SV3FN
MWZ/U+LH2)_36[T!U^ _\[8E-5&YT.:3YPHU/+^JOPU3$)V3I-=3'SI)M.WFC
M"_CKRR%/4,,==G!\QV81! 5KIT33#EUM DIZB+*8?R*",T<QX/T@$,Y*'*AX
M-PNX[,$95"TUW\S>JU_0.S-46G"R>K+&?ZP=AXNMT"LN,DWQ3G]U0MPXLL^5
M,07P=RPS??2=RY*_Y K*-2@/Q>^QGY9ZK9_FMA&* "(T1?$.#>S9+L@(I6A8
M?+*9+-"X]M,T'Z(D-QR%#:KR)I;;6<8K?[M+OV1X4\O-,P[QRQ-E;YT@0-[-
ML=IV.9#:I^',5<?3\@1D'<9HQ?OZ@M*G.'(1\I*'.-I77=YJQ!&E7?XDC;JH
M!#""DU1K'DZR:\1OK5" U=VR&DY2&.H;U_0!452. <MH.Y9E'F8*CQ;ZBKQU
ME+/,*HKS&:5ID2&T"%(4A[D]*BG-:*<4;,K9J5C9+-:WS-(DA5<3GA,9WM:<
M9A9 ]U]1[/H):,9^\UY5K/:##)3<M72GW>&;5^RE<2!K%.\I4'*G*>8^L/QR
M\P0B":H*<!&Y"VF8XIU4D'<ZB_;W0AYH@M.P8"6% "@:B%R.-F?[ OR&-<6P
MI[ZQ5ZG7OCE/X]E0S(A-TFF;$JE')K^2(0Z$.__-]Q"P0QPH7@3B.5LQ]P%E
MJC[ BE",*K:&Q>F$IJ@6_N'X08JLDH0B+^\236L#(C1EU!UR7PK6<",%@P%"
M@7(C0GU/EIN/<90D%7\D6A"H@T?<5<ZRB(\L<^AXFC)')U;]Y8^8%NZ I=%T
M(=HH_54^%MZ_LR2WJ7*5</8<(W*V*NM1XPE]#!LZ.,U**+.$"8#FRA7';T\=
M?BTF8E/M S&@F?F7MF- ."FSB1%:UJ/1R!"JCR*4$ME$!27QT&A,\,F"F4Y)
MN1M6$ $==$I*#P:6D&=H*9!3A._7I3VH27Z6(X^> 'BJ:C(H,<]HO##9)S%%
MK[HZK5ME"8RD#AJB0%K2ZD+L/>1E#K:D0P%APEZ4"&4D5N3 2*JS! .T&W ^
M"F9U/WA9ARUAB?!PV(\"8M9BBRV,(FQ8@CA6*R8MF+/C]BFLWLBXHB9C@*.J
M<+.V<S9<)9Y:7E%0VDY#3\.Q'1-2]IHAF;.6(XAKN:#EXUH*-\]LT4[JM13(
M2<T6]%1DR[''MEL(Y3*;C &5(@-=Z[6\A*K82\I+!+<="><]HNR\<\MQ(_%^
MWHS^?DY)$U,\+8P<?,O1)V 39Z7ZFPS]&*HHV;MH<NO$D=Z6:16U*9$A_\;0
MRC)8C@FQ%T6P!H3EN!!R'<J6ES 9)PJ89\?M9GD[5#:3/+LXA^W8D>>:HB4_
M+,>,&!>EU!.Q''8!KBE7NL1D?"@4-SO^I3&@_MD4SBE;W<5V9 QBE/PB,I:C
M18Q+2A6IL1PC KQ3MO*-R1A1)&\R@ES&@/ZOIG!1L4I"MJ- GG<*E2ZR'"UB
MO%.B--(8^/B;*3=E<"DEV[$B?WFFESC^;AJ5G%WER78LG>5QFT2?_<44FA&M
M3#6*+]ZXY#LM6# FM&UXR:Q1\&)<H(*2REJCH,HXOQN_VM8H>##&M'YFD:Y1
MD&.<]8Q?QFL4/)BE_Q*+A(T"MS':#*LDV2B0FR>AT^J:C0*^,<*F6%VT4<)S
M+!$U6R751D&$,=+F68781D&-<0*G6+&V47!AG$3)KN\V"@Z,D2;%*LB-@@-C
MA$9^C;I1X#=&6!0K<3<*#LP2'!E%]$:!WACAD5VL;Q38C9$<^V4!1XE#-$9*
MI!8C' 5LXV1"3E'#49!@G/0G5PYQ%)P8)P72*R>*P?_?WW? AZ_]T?B9\&L+
M.^AKBG"1J6IO+?#?W]^_PQ<W<3STZD??N='^^ZK$Z/>I\S4*H_WQ^QPA=WZ"
M,9K%Z$N4HI]S@'91X)WLR>X.>5D-;.NWRIIX>OA!&"B-BCB^Y ZECA\DW^AK
M^$,[2EI7]-- C5V*2"$ZM T7@\SJ_6!S,PMQERVCX"MEX@1-9.OB<V<W"1=8
M2=\A\<IS=<^&.MZLBV-%TQ0):C2P4_WYM,?+F*4ES!9/YF.8I'%6&)#2'8K7
M.R<LW+E-_?DWA \)>8LW%(.&M4*8?^3X"-,8>$KF!-@O1:5WH_9XX<UNF4&4
MC=1HJ<MR_J*J>T=F6]"/FG>W3,J1 FO *HKAN(E];XO*V'#X^0-(M+]F0?Z?
M4J ,6VC49I'/4>"[/LS%)KM6-0<IR,Y?5#7M!4'.I^1(C3OI6M3>AJIP-H0#
M&5O9_BP]PFA,7<O\SJ=0E'%689."Z:QC+1-S%/.LZ48I9];CW*[2"6:7XE&@
MJII<8V <I W1?$W.)1X'2P/U:LN32\].&QRDLE]>KJ6 !<!FM^Q?JZ<?1]S
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M=SY2FYOAX<BT3-:EX5WDP<A'F"FW3XVR1WL]9\KLAS/VM)&M W5=7(+YS'*
M1Z**Z<QV1N-?R)M),L UD=FE2:,A5D!Q9YCQ.BX^EM7+:"P*T0W1%J8F1X>%
M:9,1I]!=WKZ5EKN";>/R70NGR>A72'.=&VU["K]E1->U^MI>*, R]$_447C*
M#"_+3D#:7&Q[00C+SD?:5FQ[A0G+SD?.4&Q[&0O+#D?&4&Q[30S+CF:0J=CF
M*-2_W49!X+Q&<8["!)3L3[Z+0VP7VQ@5FGD9;;J&#0#,UXPY4X-"*7&6_ -^
M.<"E#=,'1.QF+#5?7S16PY0$>P06ZYS^LH;_2N#*8@"8H6:RJR@^JAYF?_/3
MW7H'O&>;,ZL-_/=+Z -#2H#=+#>W,&D3Q:'OT"-HSUYS^A;PU,[AS5^G;6G>
M;KS:VUC[=VV7 -MKEIL&$3-"$\ECIS]LPA;;OYF6G'K-L;WFV"H&*SHZ07ID
M9Z1W!BE^>;XD_L\__O"XW7R@OR2],=.RX';CVSX+;OVND43?4)BA!]""*D4!
M/[BW69+"C8KA8@597MPD21#\/V_M?*62K/Q*BJFBQ&E=B 7VD?B@0N;,@$0B
M[ FJ=^<'H$5'(2HUO"Y7I@Q2+5Z#+E57^UUN/J-XB^):VB(*U.P9BO?W%$<N
M0KC@R0$^FQOMT@ADOMNW^#X!/?Z=M$7^)-7\)P^A6&YZTBJ1$5$'C[0KK.?[
M(<YGE]H?:YKBG9:O VX._!3%^+;A1KJO0?'=XCE?1S=P"WP/" ^GG#I;D/^6
M(5KO_!C(L%3B*FM)Z'5OS@JY"-2$;GS\Y)]7C+E?(S],^S(!\6"I8Q7O:>&Z
M<88\F:WQIBC>X>EP0>LG;J@S0I]AH$!,0:$^2FZS..XS9MYHU4RYY/UP/'[Q
M./:YV1T"3NL?:$^M[!+*GSTG29:;WW+[2+J,5]A86C&^_!])40R?_ **3E9N
M"PM3>'H!-;EY/?\4O'7 MYPO**U>/2QR/3L!6L8%0F$&V3 V=#'54+V=Q(<[
M7"K!?\WPF9=6B<4^RBB2B-!$];1?\O_;*$D?PR=X-("]8^Q1Z)PZ?+2=+3=P
M@J4 SMY4:Z2] =G74D9=H ?8SBW'QT 3>HVL\ZW7EB*08KC&B"$8CXT&4BC:
MEVEF;@41RE*4O;@AVK,K"F@1A[TP2AC&KS7/NEB@7!J3H;]6.QNS1F+7ZF\Y
MT.=*#WT/A*4(X4D#;3^&R4#:7/%QRN0"L>L^Q#%D,F844$=':+(]RX&O3W(<
M:K8G&0@@H.^SLSUR7\"*P'$1VAX;S\> @!/2]AAT/A(8/D[;H[S%@6>Z4F?=
MKG!Z/^THLJ59!EJZBW3>/1K%W,3S[J!(=$1?1I=#JE-[WIT(A_G.Y]TK4-8;
M/^_V?N=Z^>?=NT\F6F#>3?;XD0BCP&^6,$J+=[ YG_'OM]%^[Z>5&;IF!2Z\
MDH8D,GZ*DJ2UK]X)=8+2&!.TA=5]PD9*] DY"6H\MJPL1]8,S1E3>7VNS$VS
M&%#,3(RACU<>J9; A?2RW&?"[I%!&ZJ1-N",.VG2C*PIZG"]70JJ\\7H!4Z"
M'9?Q&ZO8/V^6_43^.[!S)PN&!]Z-0EI,6!@3Y@"$_A.YC9'GIP^.ZP>X,Q4+
M#.)0Q7SS,01)P E=]."'\'^P0^WDAJ;S4)%IFM_:Y2'W$X7;G!HP"2PW%4TP
MGUSF1,7H7VXVH$P]'QRW>.D?HO@VB@\X@A+]#W*\/S,G3E&</(:W3APDKXYW
MNZ"?RAFK&7(?&,\%8: AFY:^Q&=S(5$A:/T.U_%8_B],)2?]RLTUZEJO4(C>
M"P8O<:>;L[2!T]D2UJ*7FY<$X8 &&H-BSS$$E$^^\YH3.SMUB#/)*#+#.C,V
M\V _E 2=M:89!5!=G:E^XZ2N3V^R(:3'+@E 'JOO7/P0U(;V^_ 8POL,B@2F
MF+M<DV V69):PBA 3]X(:0![4XT"K+X<-U$<1^]8M75 ((-?)$!D+#)B#E?]
M_#^&OT7Q'R ]NMQL+N(<<PP1PK8'C<+D';;Y(N\&A)*-GV+1J]G#N>[^3@-%
M>+I1#U#]WK^$7OE*(N_^JPM#B?F7YZVE6FMK?3YYR'#AT-(?Q"JN(33/VJ1(
MOIV^Z9)G&L0MS_+@&A ;KE>*V=ID# A',@LX/=HD0;.#FXP-L1PP01-Y/P.*
M2$66X*.T<HR.D-J>8@MB&(3"<P;Q+LR,2$0-*BPA#OZKPC(ZU@^*D#W?<D0,
M$338W@#;$<)UD-7T<8[#P6@L"3%7NK.A23'DBV8)]"R&.AS\<9GHA&'B9XCF
M5&>*R2@92U8GD9+)>)CD66EYHV:1BRI)%5RAWF2D*"<1CH?/\O3=<W#1=Q%:
MGLI[/N]HNQ@M3_)5P4K[#DK+\W[/N3"C5CV9,-]"DC"D/*26)P6?CYJ^3]7R
M!.'S4<+RQMJ>[BN&'4$OK^WIOW*D0O(3VY[\*X<!<:>S[1G"Y\LB KYJV_.(
M)7B)F//;YIRX7[Z@%",$N&;>%M&0/+A[)\8O6;VM&R?QW=XY=>(E.)/T-?IS
M=_ .!? >$7=X<\1YB5&8)VHS>P%*KZ,/9%X7SH36AO/47#[T,*O^XNP1,^A\
ME$\I;[2"'C)\><LL?'*G0>90??'_K/H!S\@%N2(O,^$$ ;RQQVK;Y4!JAL.9
MJ^KK&5$3#3U]HSW&K).[_PKRL9^@I]AW4?UCC=@/,N?%74MUSH>3[+A]IOJ#
MK(TR$WL%6V7XY9\:HWU]"KI(G_'2-&K44?BWY<B3)["S7P.C,2;D6">^ %(M
MR >1I,F($Z_W.E04;E6X:A^ Y:Y817>0_ZY;[H\4QQ--5IB3GGZZ2(LP]3T_
MR%+_#9T8\/U77#,:>45-Z?TA2\MR:%TTE@J_-DV?7HNHJ^?U!^I3;XEEJVD;
MUJR+GTD@S!05-6L;AAJNR8$[31M ]_M#$!T1>DXC]X]ESMV8O:_IXPT[$V&2
MNCF2%V"IZR-^T3 TGDW:^HO*Y/XLWTV1EQ/M"SS#R>KYA=?BG3%'&RBED,;<
M>GN,ZE:M*,:$"G+2&XI3'YXIT'0W*(Y+1-'-E((SK36]7+L>T@L,JY$G+,>5
M*']M8H[Q.AN-#3&SR/CO-I\*;3&8""8Q&(93.]++%+:F&A7_EMNMAC! CNQF
MN85J"$8Z(J#E<?(R&) 20&TVW7WX4/9N<;X:4V?Z%-B$@Z& !H^;*,9F=6[!
M:9&9!E3(ZFZ.9:CCS=(&3DTWBRS=Y?3/L&)0!FO;/.ZO4#B^@B!ZQVG:=^7-
MQGO$:4&W.^P0>PR9%D;I90PZ+::EA3K<=@#TFXA@'R!H^.XM)HCXR+2OD,<:
MR,&DF9=F]\@B]' KU^!7D (2SW>YMFC>+,6VKQ=@)3$\QF%-QT^X_R!\CUC/
MBC7<6BN7A!A SM>B/+.S4 \%A8E^*^/^@VTR/@3$^H%D(B\!&(TG(2L86V1C
MT\J,#%?GH\$.6Y/ Y>%)5:U,);+@8KFE2/DK8SU&9&B"*TQ9;C63I Z^[&:U
MK>B'YT+&>PP!"_O\]3R%>JT02(0XV;=J;0D8PT;H$H4 _6FUQG_ICO J(%JA
M ^YJ'&X;H/&,34)3#<CK8NSSYEC^*);9);Z26K"3.&V #/\Z@0O_P$W:<2;U
M,GY&\9OODI)?J,-T;!3W]ROWD!"-&.RQ]FUY)*,+9^LXP#8*?"^GS_PV4G=.
M':K?U%)>*W)2'F^TZDS!Q:?']7NT#-'_HCBZQ[';C%Q!ZF#-5$!A#Y2!MI'L
M6"V-X')O8V=/J8%/'*)X!Y_0UG')]M+^[_HN;KI#,2ZU!E+F#CAAO[\][0[S
M)^H%ZB,*@<L$L+5FA8HW7J\7D:G7/A6#W@9.0XK^.&MMP3)B.CGE5$(*-MJF
MPS3T\:1AC!J.5&<)\"3[WMG06V_6$Y$AB%:LKI1I,?Q<C>64.$T79XV&G\L"
MV#)O=0WHA&()]#0><![X=C"! 4G-TG8@.J9FX3B4E2G(:I"EQGXY3ME6O4P&
M><I[098U3,;."+="1N^UW!ET%FJXVK/ET=5#D3-5!= ):S@.II.^7F^ N[!E
MN\Q1@,V6"'G[[^_QO 0'QM^'V;YT\WWR\1E.:35=^RGFXX^AY[_Y7N8$O_GI
M;H6"PNNX\P_KZ#Y,:1&C0U:8UBB\\]'F_BMR\\R%HF]03#2#\D:;+)6=<9"U
MG,I"E,*;Y#J!FP6._%62\+S7Z5\GX1MY-TZ  ]6>=P@1KUAC8\33))Q6TCPN
MV,N/]5DEV;[@6=_ZL!,RI\OCY(B\#&0CX&;I$1>*PLU'[O_,_%P8^(([;IS(
MZAUAM3N7<+B,?G+P\BR?713 9A,,P*EU="L/S_/\8M-/CN_A?ET'/P4(;(&R
MJJJ,<YU"3PQFTBC[P"5!UOBY[HEB"63%;:QW3;J4Z  D6HH7<-BY9-J99A6P
M5'&[^/E+%+H=N#X8#M>0VXCKTOEI;L"%.:WRX3;"S92-VX7@+3Q@!N&RVU2=
M%%ZCX6.3;&Y.6N&@OQ!Y54KZPG6S/=XD\HJ82=P4P?7M@7G(I6T1O'UPDD"Z
MR1(X5MS 8/_JA_EB-3-*6_4.61?8="1PGUE<W1'S8?@_^/C?G"#GS&D>/PS(
MP*DGR!IP20*1,'_N2A6F RO^WD9A/K9]EC\:#I[865:5@'+-&WD,B=AT>.EO
M[:G8![ZF!"[TD^&@B5%JNV!%FUA-AY#SV-RA&%@KMO0T!EIXD&)W$D2D.,/B
M4=E5OGL338>2?A/)ZN?/AL,C=6H,#CH;.'%28/+D'+&CM OD7^6 G*@&:8LB
MNY5&BQ^U;8YM/B5NF3E%8[4%VC/5*[#0&ZB/-&@673*M4$9KV[ZH-MJ!@SO-
M!(#X>S=BFQU>2=]M-5 S&V3OMSU&(U,4,%]3>"-_IM[DBKZ]F@@(>:R^)EXL
MPS,1 -8,_0D5=.,R^32X\PP!J6=+%@"G.T=Q-I>X#;BU5[FYVM!_IB64>#SG
MK:F/1XA90\G<0FBN(9>L;_2481K:GZ&^49/*P%O#M+<389@IB1#PYQG0/J)K
ME21"0AVN4T3KVQMI(EEOI+Z:C#Q;(A$$WBQ],CW-6$B6[BFC=6]?^$+3Q^L$
M@6@0H^V?-+@?EM@)/-01ERC:^"UO@(?3 '#!;>2=QI7O1Z.[VP\F1#+"!@O1
M$6]S\0;[PD>QCAK/76D,*2$BF4%;BU@32:4$]+)4_%WT'JZ F+T'Y*1 )+!P
MC,6<.U3\W\>PL"45-14_# W:F>82#T9,YW[+KV,&R"+@:.]/)4UQ1)@&+F8D
MBR:&CM=_3)8;+"P^!-&[&9PW[X7:5O#:<BV\(NT_-$;" 069!\H4O$N'*'&"
MCW&4'?)W)W%SY1@$@U,%NO.C=4QGYKJQV?M8YQ-F<WP=V".8/";;PM4H-+8.
M3[H! KH\89J=;TV#V S@CJ"<1Y7YK9!A.L6KVL6?4Q3#J=1#^D_ MT:^ 40A
MCABL::&V0BU^U7F%Z'GH18<T6&'APO6*L>7C*8[<W+*>V), 0SQ$QEF?\&4-
M'<O<UMPSRIAA278(]^[:#Z+H#>Z5!; -/O9!KH Q@3A6]&D,T]AQ4YSN?)LE
M*<R*3UPJ 10E>5L*:U @='-S5^Z#'SJA6Y[QR:!>ZN.<'!DSV980?7/+@0Q+
MF)C(2L0[WJ[%B#I>8SNQCG!'W'AWU-4N)^$4YVZ8-%+_ME4459U,TQPNY=*4
MT,$KZHV?DV5)G$G7@L1RFQX@RE"@DE])<6":A$32 D%RLK;#&E;&6Z*"MT76
MJ=H38H1Q"J5X/\!3WWP _N;XDF >6S\X"Q<03DV'Z[NJ*(%FUA@X*/BHKQ@;
M'RMT<([E,3_OHCA=HWA_AUZ)!AXS%0D* A[#-]R'C8> IQ+\=52^U]0$(7LP
M<I9SY G8<>3U[TGYI,#;DC=\7 %[N-]LD$O,=),A2KOOV6"^0X^OM,9^82R=
M$>^^)4A536>=L#DLFO0" :TI/''>8Y?K8<C+^^T])DF&PSA!NCG%%UF#!V-O
M'I%,+4&JZIM7IM-5#9.):76D&B%F"A5G7KU2S"I?NW4$*BE667%$'TQ^B(K(
MV!M G <7$F,JW]#<\5-4RR^0L]R4"O!CZ&5NKGQ57*KMVOG)4EP,U]'PA:EG
MEYGCS1*I?[44(P,>KI)&[K^BV/6;CFK)\A$6HR!_J[%^=@+^;W8"+W@C.+SQ
M[W8"+_ET+#?YN9-9XM\M90"B++&65G,<@ Q1LH$$OYQE5Y)E?!LX_OZ$E%_L
MI M!G'QT_! [PY9A$<:95Q=9;CIRU0?CK37#L%!F>.,D.BP_.7Z<!W1^A@<S
MBRO#+=&H\&'&",%IA3"U;=/M1?[,^[&X0X<8N7[[B?AAWN8U<DK9#T96U)*'
MM!_!(+J QL 183\+):1$=+YIY\B0:L3.D;2 1I\UU3]$\4S3QIMV3@S_D-@Y
MD1;05U% PHU%!%)B 3OSC@9;/55F'LEOPB .SO)8"3)QQA(& 2KF,A$$66@Q
MG14T>2X1,KO@SC/H/,4,\8+G*;28]G= WL[.?!6DEU,<;29L(6]!(375('JE
MF[M%967: D;PF;X%F\MB>E., *1IA^:"T!BLK\RPS-U7?+.5L3:R'9C)OHA3
M]%UX.6,N^<Y+K:$OBI9MHR6"QIZCO+ZFA 6U_[C(3%>\<[:IL[]5YGB-)>6:
MQDHB/;2&V)E:9$ZL=[LPV8_-5JEEG;%G;*R-C\M-NQIT4DFX9=VUXCJ6<TR(
M"Y<H>TUH]EB7];,F'E42WD(6%CC2LD.]B_PWK*_:$SAY!D*>L]?$C?T<&HR5
M!V11V-HY<$>;]!VDO$\@+;2*'IC>L6K@98>G!,L3'1>QZ4V!!@-;6"@*?T(A
M]);#*:%3<X(^']6>V^VW(^D&OG9O.!^LQC/+@N$T3+4=:= #2# J#5EG'%C(
M;Q=UR\3A(^VL][K0=]4=JE,A:3X1-(VD,4;C5MD,GK)WYB2]Z>D4?DT$A#'!
M=LVKRKIW#56UF*UX:AF3"(4UZA471O*S>WZG]0FOFY9N2I0W@T(M_1>#/%"W
M8$,X?@$AC8Q.*WE6WZEM$,/BMDJHF58YLN.TMX9K20-Z"W_U89OKV'<"NPK(
MR</Z^;97W=%TXXXTD'=^C%Q@<\^I#Z!Z]IATA""M!M_(-_FRKA6T##Z>L\,A
MR)U.3O 2HCS*"O_K!H5HXZ?),WI#N4)=_<&:SLK2%^#7R _3?EDN>_+DI Z^
MD,VX_;.--'7I;V!$D45I0D!?&*6,'&<_I+>:NB7"X)%VU7Q5Z=MIC!IG'_V'
MC[J9WE";&F"R[\@9"^J+2I)_O(BPRZ\S#B727R J15*G:#802')HSB0+=%PE
MK=I,4'G%NVGE@)%DB[GW::,"?ME=VEIH&=RCK5C%#'!EP[6FW>JU0YL09_[P
MH3BLM?,5)2>VC.N49G HQP>$)9N@'K0 8<#'*0OX=&_0)LJQ4/QF$)^N]U0^
M^:5L0F)+]= 5<J/0A<<U7YRRPB(M,5)CZ#3?2>TQ:9Z/H+R4+;S<G^#Z!@TB
MLL;2>3X*OD3X0F9NZ@.[+E?YC)P 1P#<X^K]<!_"5I%3TPVC CC)!6P)A%01
M]-:83,>A"W+>1ZOID^FVTQ&( _Z/7RC.RPU^7=(T]E]!$2"6()HC4BJ_ZUT7
M,_;4&SK_OMSFZ=D@/84.SN[NOJ4?YO^25!BHXHCP7<A=\#C[I8 D"*+W5BC]
MAQD\)ART%)8/[]]9DN[;#5PE'Y')<DY9 /<33(FC]6]?C23,!EK)-TQ#%5TF
MED$&=173P)60?V7@%U]6L:5YD%3;MSX/6<:&HV6)L.>>+V-M?8?,D$[/.G7Z
MNM/ RA(ZA0%C+&(:,=/D2QFBI:QA*JA"@N00^$46-@TI?3%2!O+>;'O-NM7A
MG<RY^1%B6</("-,&L1%*!I#2\FJ8&N.;>7G&UZWE D*'O3Y54H%::P G0]&Q
MII )8X7A6VY>$I2CSAIC?._,/\:=OLU=H,M[6\0$L)JKFPZO[+5FV4/L@5KV
M9G<)PS*(>5>:31>=K%#KH)>]U<1*TW,%EM(>TG33)A]<ZLA3J2"8<0OZ_W$3
MQ>].W$@J,#UZ_ SH\S"!5HW'IKX/@F@=5LCWEYD><GX&FNKNUN2FV&9'H+.?
M=TKF=&>P"9MGO=)T*(BSM(/#>H(IL!"G*#90"<KQ?:.4V$3M:"=??1[Q%(/'
M0S5%>V!BF3S'' 0+V[>,-F )2L 2G+0[=VRJ8I0>%)@P]NZ873*$IIA &GQ!
M4HSR&2N8 Z82B5$,'RH^90[BN#*D&%)XRPA;P\M?\?^\ NJ*/__W]P##/YS#
MP0\W$?Y3^8<PC-)\A?QO^$^H2$+Z+]\K;^HS.H#H_8KB]7NTWD59XH0>[&W]
M#J..:\ J6FX %B#OS_FP;_XK=/: ?OEYQ;%Y:?PM_J_D'UZT=_SP$599P[^_
M^:\D>TU2/\WP?N'MS@[__ 8?H_^/4C?(__N0-ZE8%TME<<D@0S_(@_W_^4T*
M#^LW_^7 2K'CIN6_OZ>#_R7Q?_[QA\?MYD,;O/[?C=Q^73H:>7<91G;1Q"._
M64FKY\'+(0K[Q<W+LSQSE0(U!81)/FEDM&R<(&'B)<\I*++MZNK'R\WGR/,W
M/O*6<=7,Q#M%(!2H&#"Q"3W@":5.?)P$_G+R:U'YY)_?P,Z]*O*)C!8X5Q?#
MM@680*%: 0,*\<H%[+1?NY1_*,;I/N.B:'T&O-0YA8!TF!1KB)$7^C9PDJ3N
M![&,<UVL?S5_R\T5R%O@K-$M6B&\==Q.(0KS#V5.\,G?U">K>M4FR5=0ZR:'
MLCS?8@M/3]$M"GU-;X*\34R!!=:(+C&DU4^ZP8)7%+;]?'!<E,O0#U%\&\6'
M")9&_X,<[\_,B5,4@X !HF>0O#K>[:)]"<Y9P<@[\N0<W1V"BQU'*7+Q:O!?
MV]C9WRY6]\\+-VW#+SS<2&")5_=+AG>\W.3_2(J+S+SKY E*WVT_3%('"\1G
M$#O?NE+ R!^G^%$6!J[[)N.($^:3W&-*N(71>@?,=UNT:8#_?@E]X,@)*,X@
MC,$DT"]#WVE3^?GK&$G^O<9()P#;\ L,-!+ ZF;VSJ_61.@#FD3NARF<=*SY
M C^@UQB>DR/6JWLGLD*'P"G^LZ%2D"4W!0L9>=Q/U<87^%J286>/,1.L&#UD
M. "/ A'M9R.!>8;U4+( J1>X91Z3"_LO'IR<T+J&$+'11H+ZV?GJ[[/]8@M<
M90OR8*L*3P4A9Y!%^B]1-EIF*69\N&>@"K5JR'(FZE-?HA WB'W<@^*0+C>5
MN><IAG<(&S'39=@$M;S8=3/&NLI#WIHX@=V<7K015C:&"/D"']PA]]@1WEI_
M,Y)3U,5TG_UMZ(-&B3LO%Z7EL/T@"GP7V."Z*$97<D:9*2U=),4V"2[ 7OJ/
MW1$;H[)7]#CFXU;;Q;!OXC%\ CH$(03?[;[IC##$4/L9UZU'T;6ZPZQ1M99N
M&L$% Y'R+SBZOV,E(?]HYETD.LX6F$]N\Z$WQ].0LL_D GLD:Y,VG&2V+_IL
M8((%)IR7W*EO[G@?,/0RL#L6UN\68XP]+U ;@.0APU68/H-D D)>U96TOA9"
M8TUA <HEP)9L,E#LZZQ!N #Y7=)] PH]Y@>*(X7\HY'<$;/O9!T5363\(NN]
ML)@LRC5.%YH_<H!<,BYXM + !4BT7^VYH<\H]'&;8!<8#1;Q]WZ21/$1GU7=
M1MB/D_0VB!)"5,*@R4;2<1UA@4.F.4$8I"%& E5'!N7B0*=/=EO@) ZQYY6M
M^\25["7<-N2G]C$*#37R."F=<4K9@?RC*:R(>X)WR*TNUT_5Y:HMF5P+]M#9
M1I[S[5M<.Q[N_*2HM !KEI)@4:JSEH_$!AMSE07B9EH6^>?<<I%&\2+T5CCN
M-L&J?^J_(2Y1*%C(3/H [KPJ2EA$(0 9ML&F_FPD,(TJ!>MHX0%MY*E 3WGS
MSUOGX*=.4/FD<D]Z$2A7BV!#IRMUQZO1">J:!Y6R<])R<!FA0K/)RRSG_].-
MN!D^OTL8QL3C+ ZQ'TC&RLK-,?).M%IV5&$6N0GW6/QO[^QE9IA[VK3^'2UM
MJ_^S*3*.P-.&P]*1EY1]8W'"6@J$BN 1OT_<.'H_^7"Y PVU[1'M-955AA4
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MVS82_MY?@7,G5V=&E"79<GJ4FAG'L>?<WB49GS_<5Y!<2CB#! N DM5??[L
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M[-HWA_X'4$L! A0#%     @ @X)X6A&CY,B![P( VDT# !$
M ( !     &EM9S8Q.3$Y-#@V7S N:G!G4$L! A0#%     @ @X)X6CX&G LD
M#@8 (!0& !$              ( !L.\" &EM9S8Q.3$Y-#@V7S$N:G!G4$L!
M A0#%     @ @X)X6E.)ZGL:.00 K[<U !$              ( ! _X( '!A
M;&DM,C R-#$R,S$N:'1M4$L! A0#%     @ @X)X6G]-!'(-:P$ +C\5 !$
M             ( !3#<- '!A;&DM,C R-#$R,S$N>'-D4$L! A0#%     @
M@X)X6N61FYBV P  .A$   \              ( !B*(. '!A;&DM97@R,U\Q
M+FAT;5!+ 0(4 Q0    ( (.">%KH)R_E  D  ,I&   /              "
M 6NF#@!P86QI+65X,S%?,2YH=&U02P$"% ,4    " "#@GA:1'>:'/P(  "X
M1P  #P              @ &8KPX <&%L:2UE>#,Q7S(N:'1M4$L! A0#%
M  @ @X)X6A]*P?*&!@  0"0   \              ( !P;@. '!A;&DM97@S
=,E\Q+FAT;5!+!08     "  ( / !  !TOPX    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>pali-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pali="http://www.palisadebio.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pali-20241231.xsd" xlink:type="simple"/>
    <context id="C_800199c1-afa8-43b6-9911-358e1907566a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_818ca5b3-48b6-4160-92ed-c3b213c95caf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_81df8d1c-b732-4f34-b1db-4b541732537e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pali:InsuranceFinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8426ec92-90f5-4884-8a80-f0b476e31550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8645eaec-898b-48e4-befe-b013c00071ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_871f11a5-0df3-4821-9459-e430d23f2e22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:April2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_89ee88e7-ca37-400a-8b0f-b936d897aea2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8adee270-45e0-4d2c-a675-0eb8595fa4df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:WarrantInducementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8b845079-c037-4485-9046-bc648460b149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_8eff58aa-d87c-40ad-9ed7-ea2c72cee31b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8f070788-1b85-4e49-a494-ec7bbbbb19f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8f0ecb26-e051-44ad-94f8-a05944e7fc18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:SeptemberTwoThousandAndTwentyThreeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="C_9360a9a6-4319-458b-a705-b8de13df423c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_94a47a15-71e6-4ad0-8919-73628f2b0419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:WarrantInducementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_96ce46ae-4e1d-4e12-9e91-5be0b6992fac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:JanuaryTwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_9845b157-d40c-4027-97c2-a0fd4385089a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:LegacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_989d323e-90bd-4bc1-84ab-7e972e39245f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:JanuaryTwoThousandAndTwentyThreeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="C_98ae9a8f-1e7d-4c2d-ba28-e6b7c8ca5a22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_99e41a4e-a74b-43bc-991a-d6f51c9aeaa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassAUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9a5cce76-d0fc-4cb9-bb7b-be35e5885dd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="C_9a79efb8-eb68-42c2-a8fa-55c0d8aa5fda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_9b87aaa7-9c2f-4572-baaa-95cb98ab911a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-13</instant>
        </period>
    </context>
    <context id="C_9c31b2dd-531d-464b-9a92-f5f7289500d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2023-12-16</endDate>
        </period>
    </context>
    <context id="C_9c3eea55-6dac-475a-8dd9-570c44c3ad63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9c81c8a6-3ae0-4c51-b74d-11500c011143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_9e634a16-0f0c-47a0-b175-926c827758d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pali:InsuranceFinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9ebb78c1-151a-4750-8ce8-05e1baf42364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9f691187-dbba-46aa-957f-8451263e8080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a049a491-7334-498c-b8d3-99fbfcde6601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a0bdf278-32cb-4874-b9d5-b39d0aa6c3f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a24647e4-47f9-4d57-a123-b33e432c6857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="C_a4cf7202-92fd-4462-bf25-87c0570b5099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:September2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a6268737-830c-4d22-b51b-e3c071317b8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassBUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_aba08c8a-3298-4ff6-87c6-223993191a45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ad71c156-c72e-4679-bf89-118f467d7baf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:August2024OfferingSeries2CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ad8d582e-2dde-4db3-8d6f-4a779f360888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b1540c36-2dc4-4c82-81de-598e5062281b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2023-12-16</endDate>
        </period>
    </context>
    <context id="C_b326ac9a-3edc-4669-a12a-a44223068a1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b4194f6e-7d8f-4de8-9fdb-21da6a505d2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b47952f8-e25d-4791-a542-4d8bd701e282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b74d1b57-b99f-46a7-91d3-48efac8c1858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="C_b898e598-304f-4ea7-864c-b785cdbc5739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b957477c-5568-4340-967f-f75d2478e99a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:AprilTwoThousandAndTwentyThreeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="C_bb50a5e7-6ed1-4053-bfca-ab15e7b28b4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-30</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="C_bc157d16-357e-4df0-8664-94e2436271d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bd03d751-b219-4043-84ae-de9c81d5698b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bd447e9d-307f-412a-8859-7e1a2091a009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:UnregisteredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="C_bfdab209-cc24-443e-af8d-5930cc4c3149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pali:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c88b6c40-1467-497e-aa09-abf945fe9976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="C_cee46443-8d64-412f-b41e-41a2367bf1f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2013PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d0f8faa6-225c-4d7d-8f77-da0c5084bd1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d36c00ce-2fa2-47f1-a66c-21a67e4857fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d3c9c2d7-95dc-49bb-98bf-59ffcaac2dcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d5ec44e5-acfe-425d-94c1-cba3b6c5a935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_d8e2d363-b0b1-4013-b25f-43acf427f165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_da789c28-414e-4ccd-947d-5e1f11d5ee32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_db7afb64-6e06-473b-8d9a-ceeac08c60c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dc6265aa-95b8-4ea1-85f9-00aa6ae27844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <instant>2025-03-19</instant>
        </period>
    </context>
    <context id="C_dca63de9-3d4a-4b50-a74f-1090217fcb16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:RepricedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="C_dd1ca615-f781-4979-a8ac-e2d5b4aab50b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:AllOtherCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_de9ce026-379c-4626-83e2-28087fada0ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e3a8e347-dc37-40b0-851c-4ceba3d07be3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementReplacementCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e42cccf2-0558-4a1d-8434-967432a7ef50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e4f02a44-93b6-4104-9ffb-23aeab786d9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e5488fc7-f4ab-4fdb-a268-96c258ed7b00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e55e3216-27d9-421d-a685-8982258e7fbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassBUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e678878a-0c3f-4ca9-be27-f1041b0e7025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e6fca467-ed31-4675-ab98-dc0f25b03fbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_e7194555-4ab8-40fd-b397-92bd0b1f7bb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e786d4a3-2e6a-4337-8144-697692254d24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="C_ee8693bb-92aa-44a4-880d-83926ceee699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="C_ee931db3-063b-4b61-9205-fc476769857a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f15cfeb5-6c1f-45a8-9c16-b9c0acc83ad6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:Series2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_f399e54c-6ccd-4ae9-97a2-1db3bdc4468e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:BridgeJanuary2021AndJuly2021CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f3aab31d-1085-44a6-848c-14e1390b99a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:StockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f40fb1ae-32d9-4be3-b219-d5d71698de2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:September2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f4816ad5-6544-4cc3-8edc-993c725f05ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f4c47b93-0a6c-459a-94b1-6b86830d25bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:August2024OfferingSeries2CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f4efa6da-edbc-4b10-9455-f745bdeb2312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f507e9fa-1c64-4a5c-b79d-ad17dd341e37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f73a25a6-b329-46fd-a117-c2bcc90c783a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:January2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f9f17689-3835-44ab-86c4-7ce94e9a6825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f9ff4d32-3399-4339-9015-2a14b777cd9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:PALITwoOneZeroEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_feec2dcc-5780-4073-a999-74c92a2f28c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ff902a0c-401a-4796-873a-f487d5f3927d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ffa661a6-473a-4c79-8a7f-48832923f5d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentSolicitorAndRepresentativeCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_00c99cd4-9ed2-49c9-94cb-b920b598790f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_01126dbc-d04a-4b1c-9f6b-d2a1bf5c9e96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_01f7368c-fa1b-4d5d-a9c9-07ba03a45b8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0396c3a7-c3c7-4970-b67a-c7d717b609c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pali:InsuranceFinancingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_04026d27-31da-458f-9340-63004096eee6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_05d7c843-a34b-479a-88d4-a12a886a60f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_064f0da6-66e3-4594-9a33-dd0538609aca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_065287e3-70be-4640-bc93-2e29518133d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_06862901-f3a4-4bd2-bd72-90b6eae2c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:January2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_070fbbd6-0133-4fd9-a92e-3a59027648e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0769ff66-ee84-425c-88ee-5721d253b14e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_07bbc911-5220-457e-b6ff-5ac9e1cf7eb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:January2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_09342590-da6c-45b7-8387-a049a00b0407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_099a2990-8f62-4736-908a-75e3e70bef39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0ac0e42c-71fc-4569-afd4-fccf25d6e52e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0ce6c868-1e07-4b9e-ac58-05460a42652b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021EsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0cf6a60b-d394-429d-82ae-cbe7825fb226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0d1eb655-c370-425c-8e10-3bf6703f37a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-06</startDate>
            <endDate>2024-05-06</endDate>
        </period>
    </context>
    <context id="C_0e805a01-b80a-43a2-b2d3-6b7c1b32fbd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0e9b1aec-3b94-4255-8d2d-686c1a773637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_11a397d8-f76e-4123-8ffc-90b0d4bba3ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-06</instant>
        </period>
    </context>
    <context id="C_12a10425-82c0-439c-a876-125097f2fbf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:RepricedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-12</instant>
        </period>
    </context>
    <context id="C_12dc02fb-eac4-4610-bad8-fe8e9ad4d610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_15b1b95a-f0a8-45cc-8b88-bb5a5b75d92d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1647ede8-9b3a-4985-acc0-f4909695082f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_16734ac9-5f7d-4564-bb8b-aff2052903ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-20</instant>
        </period>
    </context>
    <context id="C_16f011be-773b-4769-92b0-515dab2809dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:LegacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1ab29fa5-66c6-45ad-818c-b0bfb6693551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pali:OfficeSpaceLeaseForCorporateHeadquartersInCarlsbadCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1b2b7036-6d4a-4dda-b9b5-3fef242b5750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1daf9a02-8b5d-48fd-8804-9977e84acb12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1e5799eb-2dde-4495-859d-82b3ce5341eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1ea433f0-bf37-4d98-8e23-9f24084ab798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:Nsi532Igf1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-27</startDate>
            <endDate>2022-10-27</endDate>
        </period>
    </context>
    <context id="C_2007472e-785f-4e66-8b90-31974e6c2d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="C_210c21f0-b090-4433-b5b4-a390a090d368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_215542bf-2dd7-470b-b7be-f61e7050c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_22d62b69-795d-4d94-914a-263cdadcd8a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_24d8c3be-2445-4bb1-aa0d-5f552876a8bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:AllOtherCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_25437a64-b804-49d4-a583-6149701ed82e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:MayTwoThousandTwentyFourOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_25e9e99e-093d-49a0-982e-33f5812e37b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:September2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_272eb503-8300-45b6-8c62-5bd2086f945b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_281c192c-92de-47d8-8a46-d3ac8f6e44b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pali:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2a44715d-6d67-4a8c-9146-cda1c95f1181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2faf211e-59a5-4ce8-a255-3561ae2b8311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_32effecb-dcdb-418d-b9ab-602e1ecc9121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementReplacementCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_339a2504-3ac9-410d-8ca6-961361ccd1aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_33afec80-d974-4667-ab99-82569d37d0b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_348f4f92-6daf-4dc1-aff7-04ba4780b100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_386963f7-adcd-4589-ad1e-18c92d7f72e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pali:LicenseAgreementsWithTheRegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_39580d8d-37fd-4134-8e15-fc3336a39dd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_39cecd10-468f-4aba-9f46-454343174b91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3d9e481b-d117-4e88-951d-c039596d2643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ec4089f-24f1-40c5-a1ee-41580353eddb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:RepricedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4166f110-68a3-43b8-9e9a-a8db08091181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_418106b0-0eb9-4bd1-a9d8-1a674eb12eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_456ae310-d956-4c7f-aca2-b537a393db0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_46b8f935-7e06-4909-98e0-8a09b69ca511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:April2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_494b0e96-ca6c-4dd0-aada-9c385796b28c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4a7340ec-c1ef-4e8f-b685-40b983c0d414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4c38a0f6-0e17-4097-a741-e8528d218109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="C_4d65b8a8-159b-4e62-9b59-1b4091249817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f54001b-6421-4019-8e41-db056882bcd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4fedbd90-4e26-4897-b395-ac4b7cdb1342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pali:PALITwoOneZeroEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_51618521-fa5c-465f-afce-888db78121fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_53120144-37f7-483b-a872-d0f02ddccfbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:SeriesA4Point5PercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5506b90a-1f64-4934-8403-8f83e8522373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:WarrantInducementAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_56df2920-b057-4c20-af0b-3fb60d22d643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_57444f7a-2496-4f31-9eac-285e8dbbc2a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_582ecc46-b417-4c17-b3ac-7494c5aa8bda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingPreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5ad66f61-3eb3-4d36-903d-7bac0116fcc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5affaffb-555c-4738-91d1-a014135e69c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5b7ce63d-492e-48d6-b155-482c37907109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:ReplacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_5b914c39-e156-49cc-b150-f585bc3b48b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5be85942-60b4-4ca7-b41c-6a7af1aea32f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-06</instant>
        </period>
    </context>
    <context id="C_5c1b7f20-1f1a-46c6-b1ce-e72714e8e6c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="C_5f66a802-eff0-4fee-9465-2edf3990258c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_659e2af0-b6fd-4530-954e-5b638bb46b1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pali:CostReductionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-09</instant>
        </period>
    </context>
    <context id="C_66aae2c0-5abe-49b9-befa-ef1108555742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:BridgeJanuary2021AndJuly2021CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_671d8ff9-d06e-44e8-8753-0d285732a4c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_691877b9-f2f5-489e-a81b-02e81e212a3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:AprilTwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_6a4f9f7a-6ab6-414e-a396-2c7f3c0ae7ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:April2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6b08194e-e220-4a67-9b3b-b24bf7d2dc89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pali:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6ffb0979-629b-4688-a29a-73f1f89ce426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:May2024PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="C_708ff3fe-8eaf-45eb-9adb-df47251abc06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_70ce8c11-9f45-440b-9b1d-6046060ca1af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="C_73bb4959-69c7-4db1-8a36-8a4200ea4201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pali:ClassAUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_73c82250-26a7-4e8c-bbde-5150f68a53ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pali:ReplacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:February2024WarrantInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-30</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="C_76e3614d-9c9a-46c6-a850-919f190aaaca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pali:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_790040b9-b57e-4116-8804-a4572f9ba17c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_795c51ad-a42a-4991-8de6-80e768ef9af0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="C_7b587e1b-52d0-4b29-b97d-1630d7f21d83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="C_7bdff01b-c6cb-4014-8bf2-6623ec18a56e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="C_7d3732a3-912c-4fce-90de-1cf88fb0bb7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357459</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pali:ContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Days">
        <measure>pali:Days</measure>
    </unit>
    <unit id="U_Segment">
        <measure>pali:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Agreement">
        <measure>pali:Agreement</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_0adc1245-a6ae-40b8-bf92-6e192f60c11d">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_ee9de4a7-011c-465a-b950-4735d28ab749">0001357459</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_6194d79e-72db-45e2-89e2-cb51e1ab1a1d">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      id="F_41a02ef9-ef41-402f-a4a8-05fe4612c034"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      id="F_1ef91e9f-cd0d-43f4-90e4-9dfe50bab27e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_0ffa1e3a-3c65-4853-b3c6-1a6c686c9e2d">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_a24d421d-7967-41bf-b49a-e381503e1600">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_ca9fd075-3b0b-48e6-a17b-5dce988d59db">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_bea2a263-4d90-4447-9d4d-f86e5a60fde7">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_3be08f57-5463-468e-ac05-0e5cf68788f7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_63f2eb06-28c7-4385-a8c0-f8afd82af0f9">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_a87dcac2-2700-4cfc-be9a-cc9c4c720a21">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_89087063-d005-415b-8a4c-9c54bcab9c46">001-33672</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_01d5fbc2-d243-485e-95b4-89aee47be85f">PALISADE BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_2f6b1304-eb44-4394-9ade-03a9038a2d5d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_08ee8fb4-e20b-41ef-b374-ca7cff50e7f5">52-2007292</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_423e17b4-e34d-46e3-b9dd-7e1ae77186ca">7750 El Camino Real, Suite 2A</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_53beb5e4-86b5-43d6-82ad-ab72f0fd11b5">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_8c148566-9a0a-4c04-b963-69aaa5080f54">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c68724b4-4347-432e-ae46-1cd49b4e671d">92009</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c97224c2-df23-4cb6-a779-61f89f7132c0">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_5f9b8018-d300-44d8-85f8-0be090fd202a">704-4900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_b4f215ec-5154-46e1-88d9-5aea9b152674">common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_fdbf22f6-1b0a-4b7a-883f-67b06d52e24f">PALI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_94bba7fa-9ed5-4316-ba17-bdc2c2624fdb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_3fdd609a-c6a7-4bf0-9744-397bbffffa87">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_0d893492-4a59-4cf9-94da-b389730dd4ec">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_78edcef9-f9c9-47f1-b142-30989ce203a7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_f6504e39-1604-4c03-8772-16e20561db80">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_7f50356a-b9d1-4ed1-a354-e0079d45e4f2">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_47617a90-2ba5-48e7-8000-bd9d6fbbc956">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_f535781b-2dd4-4bdc-b42b-eb30fc799a85">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_6a3322ea-c1f2-4da6-bb26-fd7e95b5dbbe">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_f576efe9-5301-47b1-a537-facda5f4a7a7">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_358c5caa-a3bb-456b-b2e9-adc9b128be02">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_e6fca467-ed31-4675-ab98-dc0f25b03fbd"
      decimals="-5"
      id="F_9ea8f85c-af1e-4688-a950-87af61da3734"
      unitRef="U_USD">4300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_dc6265aa-95b8-4ea1-85f9-00aa6ae27844"
      decimals="INF"
      id="F_d18a7461-8e26-40fe-9f18-b452cc21c17b"
      unitRef="U_shares">4396646</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_e66df829-0892-42d5-90ad-f6cade468dfa">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_a3d263bf-295a-4075-9be6-3b4f5c8dfe41">&lt;p id="cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of our business, we may process proprietary, confidential, and sensitive data, including personal data (such as health-related patient data), intellectual property, and trade secrets (collectively, "sensitive information"). We rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, employee email, CROs, and other functions. The secure maintenance of this sensitive information and our information technology systems is important to our operations. To this end, we have processes designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein. These processes are managed and monitored by our third-party information technology consultants and include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse, or other security incidents or vulnerabilities affecting the data and maintain a stable information technology environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are planning to establish an appropriate confidentiality framework and document management system in order to safeguard sensitive information in addition to the safeguards provided by our third-party service providers&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Such confidentiality framework may include the use of third-party information technology experts to manage and oversee our sensitive information and to work directly with our management in overseeing cybersecurity risks&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and appropriate responses thereto. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, we plan to consult with outside advisors and experts, when appropriate, to assist with assessing and identifying cybersecurity risks, including to anticipate future threats and trends, and their impact on our risk environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the last fiscal year, we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not identified risks from known cybersecurity threats&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including as a result of any prior cybersecurity incidents, that have materially affected us, but we face certain ongoing cybersecurity risks threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks faced by us are discussed in Part I, Item 1A, &#x201c;Risk Factors,&#x201d; under the headings &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;If our information systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d; and &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cybersecurity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c5e5c658-26cc-45f3-b2c7-b0c2df49f99a">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_bfc5121e-76dd-444d-90e8-c60f5db89151">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Such confidentiality framework may include the use of third-party information technology experts to manage and oversee our sensitive information and to work directly with our management in overseeing cybersecurity risks&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c1172081-615b-4dd4-ba69-03184e49fce0">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_9a33d724-3692-4b4c-b820-d7866e17934a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_3b3a8c39-9e35-483f-9280-e4ef8323c3f4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_88ec83e0-c574-4a75-893c-1869e265121e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_65e47340-c120-4bed-9a6d-90dced339d50">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures. &lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <dei:AuditorFirmId
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_340890f8-65a0-4cbb-bcd2-4c94fbf2d5e7">23</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_8baab0c4-0305-4db1-b140-4812ed861c91">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Palisade Bio, Inc. (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_2a68927e-2862-439d-bb63-2d970b6b8085">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_984e6062-4d8c-4cc4-9ce0-970016ec9f28">New York, New York</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_8ab97b15-1ce9-4e52-8c9e-7c7c81ec4fae"
      unitRef="U_USD">9821000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_621c7479-74dc-4344-8512-1b2fbc7b5f81"
      unitRef="U_USD">12432000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_3934918b-4718-43df-bc8e-e833f463e128"
      unitRef="U_USD">673000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_f7cb5eec-6726-42f1-a22c-68d5c2d5d6e1"
      unitRef="U_USD">896000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_1ec24756-eff0-43bc-8601-1539d7b7e619"
      unitRef="U_USD">10494000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_ca539a83-5364-4646-ab25-16b3fd1b6df3"
      unitRef="U_USD">13328000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_f4fb2f02-ade3-4caa-97ed-ab57dfc7b9ae"
      unitRef="U_USD">26000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_27ae678a-6b4a-4746-a137-2d2c66037ad0"
      unitRef="U_USD">26000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_8b941c89-62d6-44ff-a17c-f0d3ac525147"
      unitRef="U_USD">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_c6b72aa9-bb5b-4557-a4c9-1be71fb85751"
      unitRef="U_USD">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_c3eb35cf-3625-4678-a5ee-671531df136b"
      unitRef="U_USD">84000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_ccf838e6-e50d-4f43-abe2-4f582402ee88"
      unitRef="U_USD">198000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_0953df7e-fa39-4194-8ccf-447f934bbc42"
      unitRef="U_USD">273000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_4b9de1ea-1e5c-4ae7-a7a8-4a00eb93b50f"
      unitRef="U_USD">490000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_dad86e35-a29e-4341-bdfa-6d0cf08f506f"
      unitRef="U_USD">10880000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_c4d7afb9-140d-4068-97fd-db57317381d5"
      unitRef="U_USD">14052000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_7fb629a0-5ea2-410e-98fc-5ff1f57a4300"
      unitRef="U_USD">1105000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_4747d17f-f4a9-449a-8366-53444d5c19ae"
      unitRef="U_USD">698000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_7edb23f0-7437-4b95-ae4e-4e1939682e88"
      unitRef="U_USD">1240000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_1522b827-c2d4-42b0-9715-82fad570ccd2"
      unitRef="U_USD">831000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_edb69110-f6b4-4675-815a-cddb7a750e0d"
      unitRef="U_USD">722000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_a2f25888-94ee-4920-b497-7d9003c54da3"
      unitRef="U_USD">778000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_78d8d338-e858-4448-a38f-338cd1689ad9"
      unitRef="U_USD">90000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_910a6735-4dfe-4ec3-9959-55cb192d2732"
      unitRef="U_USD">121000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_e58bce1d-0907-4163-8d97-77494dad9699"
      unitRef="U_USD">79000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_e36d2417-38f4-4755-81ad-a96e4e4ccb10"
      unitRef="U_USD">158000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_283fa600-c634-479c-9db0-7fa48f349d46"
      unitRef="U_USD">3236000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_3427f157-1d6f-486b-ab49-2808064801ee"
      unitRef="U_USD">2586000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_d266df3c-8da6-44de-be97-452e3f7b87c8"
      unitRef="U_USD">2000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_ce6e71b0-36a6-4f29-a674-d0822ce82f37"
      unitRef="U_USD">2000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_3123c5f0-5e8a-424b-a8a8-091aa484833f"
      unitRef="U_USD">150000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_e346ae51-392b-4541-8b65-4761adfce3b2"
      unitRef="U_USD">61000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_9ff763af-ae84-410b-a87d-15f4be44786e"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_065d7c9d-5e34-4fce-a81d-98fe3939eef1"
      unitRef="U_USD">90000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_0981c04f-9af9-4d36-8d58-096301de2189"
      unitRef="U_USD">3388000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_d7f5be41-c354-4e72-846a-942b93a3f040"
      unitRef="U_USD">2739000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="INF"
      id="F_4ca3a71a-8761-499c-859e-e94bd021cc79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643"
      decimals="INF"
      id="F_4965c34a-9ef6-4729-b623-cd888bac8a87"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="0"
      id="F_49e381e8-17f2-411b-b278-7d0a55c2edae"
      unitRef="U_shares">7000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643"
      decimals="0"
      id="F_1ac6391e-0c49-4b16-88a5-df15c6f7f705"
      unitRef="U_shares">7000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="INF"
      id="F_23e2bd00-ce2c-4930-874d-9080b15c3357"
      unitRef="U_shares">200000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643"
      decimals="INF"
      id="F_9128f495-63ce-4c11-b02f-b888f932ce58"
      unitRef="U_shares">200000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="INF"
      id="F_41cc03e5-a6bc-4213-8eb2-35fb439a9cdf"
      unitRef="U_shares">200000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643"
      decimals="INF"
      id="F_0d468110-78d0-44fa-9a9a-fb461b3240d4"
      unitRef="U_shares">200000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="-3"
      id="F_95c81f85-a4a2-447a-8a7a-3107bbdbf05a"
      unitRef="U_USD">2000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_3d9e481b-d117-4e88-951d-c039596d2643"
      decimals="-3"
      id="F_7af99c5e-069d-479a-bba3-3a5b056572a3"
      unitRef="U_USD">2000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="2"
      id="F_3e497643-ec10-4932-81f7-637deddcd2cc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="2"
      id="F_f8f53c02-35e2-4783-b06f-f7ff344db3b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_5ec52d6a-89c4-4faf-8c7e-06656a7dd576"
      unitRef="U_shares">280000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="INF"
      id="F_339ba632-8a01-40d7-8561-0571920d80a0"
      unitRef="U_shares">280000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_91f57b55-6c59-4025-b189-8d5f1d6ca3d2"
      unitRef="U_shares">2768646</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_e43455ae-61f9-4bd6-98bf-b11d459cdcac"
      unitRef="U_shares">2768646</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="INF"
      id="F_bfa9805e-3f6f-4f7e-bf66-468741566564"
      unitRef="U_shares">618056</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="INF"
      id="F_81f7c44b-9c37-42ea-98f7-a976fa7623f0"
      unitRef="U_shares">618056</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_86102321-745a-4a9f-a767-3b4bbc94ede0"
      unitRef="U_USD">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_3358f4e0-b6f3-4332-8301-e71ad4ef3650"
      unitRef="U_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_81c26ca4-87f1-4839-9e39-6b72007cf11d"
      unitRef="U_USD">143407000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_317d609d-5a1d-46be-8d4c-36b4920fb07f"
      unitRef="U_USD">132811000</us-gaap:AdditionalPaidInCapital>
    <pali:RetainedEarningsAccumulatedIncomeDeficit
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_18e330f3-4d50-45f4-8b85-4fb56067b44e"
      unitRef="U_USD">-135944000</pali:RetainedEarningsAccumulatedIncomeDeficit>
    <pali:RetainedEarningsAccumulatedIncomeDeficit
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_b81d8e06-b061-4d3a-bf81-cc126a364ef7"
      unitRef="U_USD">-121506000</pali:RetainedEarningsAccumulatedIncomeDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_7a8193d6-6512-4019-ba64-23c55b0ad4cd"
      unitRef="U_USD">7492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_fb1d47b2-0603-4c72-b230-d8ee824ed834"
      unitRef="U_USD">11313000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_50ab1f42-1f1b-469a-b89e-221efaf7e68f"
      unitRef="U_USD">10880000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_13094e7e-11c4-45fa-874a-e6a5f7d67c18"
      unitRef="U_USD">14052000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_3d891136-1f89-4f61-a542-ac567f637fe4"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_8c29f43b-9227-486c-a0b2-96e7053b572c"
      unitRef="U_USD">250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_1086025e-f7cb-4c4e-b309-af420dd0e680"
      unitRef="U_USD">9063000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_2458fb54-1fba-4bdb-90b5-93212b1849bc"
      unitRef="U_USD">6893000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_8531ec98-e13b-41c8-bd66-c8be609c1020"
      unitRef="U_USD">5796000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_ee2e60a5-2b70-4810-a87c-e74634a33c03"
      unitRef="U_USD">6202000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCosts
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_09de3416-eca8-4aac-b7d9-2a56e7c79f78"
      unitRef="U_USD">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_3f4cb9ea-2f23-4b31-8ad0-3b463e8ea1ea"
      unitRef="U_USD">225000</us-gaap:RestructuringCosts>
    <us-gaap:OperatingExpenses
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_6e7a6927-0883-41ff-892e-75ececda7133"
      unitRef="U_USD">14859000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_101b6a2f-00fa-461b-91c0-9bc50868098f"
      unitRef="U_USD">13320000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_a267f00f-fb98-45d5-95aa-ac3b988609ac"
      unitRef="U_USD">-14859000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_e4cb13d5-39c0-4f62-8668-34394e0edcda"
      unitRef="U_USD">-13070000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_e533d2c5-c047-4bd5-8f32-b20e597f4df2"
      unitRef="U_USD">12000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_de925185-c70d-43da-b004-c1d9ecd8701b"
      unitRef="U_USD">15000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_354db0d1-b380-4b6b-a7ad-392430b9aa37"
      unitRef="U_USD">433000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_ec58f525-a24e-4d3a-8b9d-9dbe6300ced5"
      unitRef="U_USD">785000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_3181c1c6-ba48-42e1-9553-ab93bb2e5afa"
      unitRef="U_USD">421000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_d10bd205-e8a6-4524-ac55-646b0abf9d6f"
      unitRef="U_USD">770000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_133ea55e-5f0f-4bdf-9b39-f512a6653553"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_3f036d5b-30a9-48c7-9a3b-85d36263a364"
      unitRef="U_USD">-12300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_a5683f02-c99c-4352-af9e-3d47271d4ac0"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a2e26012-c904-4ba6-a480-ec2385c0fc0b"
      unitRef="U_USD">-12316000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_0f258028-16ee-47ec-b30a-a72e7909933d"
      unitRef="U_shares">1416471</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_f295b006-8721-42a1-9ac3-52f7a33c05b0"
      unitRef="U_shares">1416471</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="0"
      id="F_2d214d75-f0d4-46b6-a346-1086df1e7442"
      unitRef="U_shares">456014</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="0"
      id="F_ccbb254a-2085-465e-8ec8-ae210579281a"
      unitRef="U_shares">456014</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_3befa2c4-75ca-4fc6-ae21-d8d6d7a77d6d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-10.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_52f8c5ac-0778-4aeb-b48d-5ca369d4f1c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-10.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="2"
      id="F_bb5c5b37-1ce9-43b5-b2e5-323e82bd6b35"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-27.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="2"
      id="F_dd2d9c2e-d568-4109-9a93-3600a95d4bb8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-27.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="C_51618521-fa5c-465f-afce-888db78121fc"
      decimals="INF"
      id="F_d235f4ef-de95-455f-8655-3d689d2865b5"
      unitRef="U_shares">200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_51618521-fa5c-465f-afce-888db78121fc"
      decimals="-3"
      id="F_ae0358d7-f0a6-4a2e-a9c7-02a47e0b1588"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06"
      decimals="INF"
      id="F_d36e42da-1750-4bfd-8ccc-25d155d540fb"
      unitRef="U_shares">618056</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06"
      decimals="-3"
      id="F_6d752654-4a66-4b6d-98c9-36e92bc3213d"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b4194f6e-7d8f-4de8-9fdb-21da6a505d2a"
      decimals="-3"
      id="F_5efb6687-ed6e-45e6-9dfd-e297f64b1113"
      unitRef="U_USD">132811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5ad66f61-3eb3-4d36-903d-7bac0116fcc6"
      decimals="-3"
      id="F_5f9c0fd8-2f97-472e-8ecb-fdd099c59940"
      unitRef="U_USD">-121506000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_0ce5ecd7-b7a7-41b0-9b85-607c055451bc"
      unitRef="U_USD">11313000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_de9ce026-379c-4626-83e2-28087fada0ba"
      decimals="-3"
      id="F_15b636a9-51c8-4f2f-91b9-9158ef424787"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_dc622baa-97ee-4cf1-a1a0-36d9715d675a"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_09342590-da6c-45b7-8387-a049a00b0407"
      decimals="-3"
      id="F_b9fb2141-4746-4cf1-a213-25ff041b13d7"
      unitRef="U_USD">652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_55e61c39-8c24-40b6-be6a-30e8360930fd"
      unitRef="U_USD">652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550"
      decimals="0"
      id="F_913a4536-6c4b-4315-bf67-d5c1533e34fb"
      unitRef="U_shares">32632</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_09342590-da6c-45b7-8387-a049a00b0407"
      decimals="-3"
      id="F_598beaea-107c-4159-af0f-159afd92aecb"
      unitRef="U_USD">135000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_212dd2ef-0df3-4aa8-8dae-fb266695c9ba"
      unitRef="U_USD">135000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550"
      decimals="0"
      id="F_bdd775a9-38c9-4488-93ee-6a859c8265b1"
      unitRef="U_shares">18046</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_09342590-da6c-45b7-8387-a049a00b0407"
      decimals="-3"
      id="F_9745b3d0-2782-465e-b09b-34f7e43e40e7"
      unitRef="U_USD">-25000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_6a7a84ff-01e2-4b45-97f4-a9be081de18e"
      unitRef="U_USD">-25000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <pali:StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises
      contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550"
      decimals="INF"
      id="F_a9aaa239-ef30-4d3b-a071-c1561afdc27d"
      unitRef="U_shares">1626496</pali:StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises>
    <pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
      contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550"
      decimals="-3"
      id="F_a2c67c24-ea99-467d-b763-290b87654180"
      unitRef="U_USD">16000</pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises>
    <pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
      contextRef="C_09342590-da6c-45b7-8387-a049a00b0407"
      decimals="-3"
      id="F_6f3be1d1-75d4-43bb-ba1c-fefea07a2041"
      unitRef="U_USD">-13000</pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises>
    <pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_e0168a34-86e3-4e41-ba65-4af4a89bba6a"
      unitRef="U_USD">3000</pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550"
      decimals="INF"
      id="F_b466cb16-964d-49e3-96e0-9a33a892309c"
      unitRef="U_shares">2256</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_09342590-da6c-45b7-8387-a049a00b0407"
      decimals="-3"
      id="F_58475b22-3533-4cb1-afde-56be185c8979"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_7097f060-8b45-429e-8f8a-8a7d7c688d4c"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_5506b90a-1f64-4934-8403-8f83e8522373"
      decimals="-3"
      id="F_22a896a6-1ed1-4884-8c8c-3ccc6f3eded1"
      unitRef="U_USD">2412000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares
      contextRef="C_5506b90a-1f64-4934-8403-8f83e8522373"
      decimals="INF"
      id="F_e7cc059f-57cd-4370-8109-52aebcece734"
      unitRef="U_shares">228162</pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_5506b90a-1f64-4934-8403-8f83e8522373"
      decimals="-3"
      id="F_25fe3de5-adc1-472b-9089-7ffa1ad3b53b"
      unitRef="U_USD">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_94a47a15-71e6-4ad0-8919-73628f2b0419"
      decimals="-3"
      id="F_e1dac30b-227b-4798-a021-13173d491f7b"
      unitRef="U_USD">2158000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_8adee270-45e0-4d2c-a675-0eb8595fa4df"
      decimals="-3"
      id="F_afc2c3a2-e6e9-4e5d-bfef-af591fe43ebd"
      unitRef="U_USD">2160000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0769ff66-ee84-425c-88ee-5721d253b14e"
      decimals="-3"
      id="F_c92fbdeb-4398-4ce0-a1db-98586bf8e596"
      unitRef="U_USD">705000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares
      contextRef="C_0769ff66-ee84-425c-88ee-5721d253b14e"
      decimals="INF"
      id="F_89a5ab14-b2e0-4738-a557-61eb27d9e8b7"
      unitRef="U_shares">85100</pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_0769ff66-ee84-425c-88ee-5721d253b14e"
      decimals="-3"
      id="F_32d51079-3301-4b4a-876e-bfb122660164"
      unitRef="U_USD">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_8f0ecb26-e051-44ad-94f8-a05944e7fc18"
      decimals="-3"
      id="F_223c3c04-379a-4125-84e0-9d7da2e2a28a"
      unitRef="U_USD">3543000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_215542bf-2dd7-470b-b7be-f61e7050c227"
      decimals="-3"
      id="F_f7a3fddb-5c66-459b-adf2-160b894ea37c"
      unitRef="U_USD">3544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_76e3614d-9c9a-46c6-a850-919f190aaaca"
      decimals="-3"
      id="F_56c61d87-0860-471e-be8a-14648727b385"
      unitRef="U_USD">1403000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares
      contextRef="C_76e3614d-9c9a-46c6-a850-919f190aaaca"
      decimals="0"
      id="F_cc72025c-7121-4942-ac82-720a8dcaf5c6"
      unitRef="U_shares">158000</pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_76e3614d-9c9a-46c6-a850-919f190aaaca"
      decimals="-3"
      id="F_199eb8a0-6b97-4beb-b1bb-be7bf186d9a0"
      unitRef="U_USD">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_05d7c843-a34b-479a-88d4-a12a886a60f7"
      decimals="-3"
      id="F_8cc691d2-c99f-43b3-b37d-ba6cb755b8af"
      unitRef="U_USD">4135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_418106b0-0eb9-4bd1-a9d8-1a674eb12eaa"
      decimals="-3"
      id="F_15f75e40-073c-43e8-ac2a-0e987d922024"
      unitRef="U_USD">4137000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_8426ec92-90f5-4884-8a80-f0b476e31550"
      decimals="0"
      id="F_9511cfd1-2c72-40fd-82a4-ff06fe15d67d"
      unitRef="U_shares">-102</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:SharesOutstanding
      contextRef="C_4166f110-68a3-43b8-9e9a-a8db08091181"
      decimals="INF"
      id="F_6c9e916a-4a75-4606-a0db-0f45cfc09a92"
      unitRef="U_shares">200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4166f110-68a3-43b8-9e9a-a8db08091181"
      decimals="-3"
      id="F_5b30db9c-8c44-4e5f-b265-8c71a5c06e24"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_8f070788-1b85-4e49-a494-ec7bbbbb19f8"
      decimals="INF"
      id="F_319d8403-72a4-41d4-af2c-c72e7618880c"
      unitRef="U_shares">2768646</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8f070788-1b85-4e49-a494-ec7bbbbb19f8"
      decimals="-3"
      id="F_f57a0064-dc8e-4fa8-a52f-54517bbe3c18"
      unitRef="U_USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_871f11a5-0df3-4821-9459-e430d23f2e22"
      decimals="-3"
      id="F_bddb3b34-6a85-4acb-b78f-4f2ccd352734"
      unitRef="U_USD">143407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_00c99cd4-9ed2-49c9-94cb-b920b598790f"
      decimals="-3"
      id="F_986a83d7-f777-4197-ac11-38391551576a"
      unitRef="U_USD">-135944000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_6e6d5dba-c387-4319-8679-046889420d4a"
      unitRef="U_USD">7492000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e"
      decimals="INF"
      id="F_ff6663fb-f032-4018-bf72-cf68eb091678"
      unitRef="U_shares">200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_82b390db-d0cc-4dea-b20c-e0cba4c77a7e"
      decimals="-3"
      id="F_e73ef0d6-ff3a-4733-9224-45c5d4df0187"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_f507e9fa-1c64-4a5c-b79d-ad17dd341e37"
      decimals="INF"
      id="F_481c1e2d-9068-4ae3-9ba7-c8d2ae60a338"
      unitRef="U_shares">196287</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f507e9fa-1c64-4a5c-b79d-ad17dd341e37"
      decimals="-3"
      id="F_59ca71c2-b250-44d8-8b8a-4e88355311e3"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_56df2920-b057-4c20-af0b-3fb60d22d643"
      decimals="-3"
      id="F_d411c7b8-b584-4e13-97b4-511b622f1b23"
      unitRef="U_USD">121665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_348f4f92-6daf-4dc1-aff7-04ba4780b100"
      decimals="-3"
      id="F_0a551830-ee16-47bf-9760-dd3edcc35254"
      unitRef="U_USD">-109190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd"
      decimals="-3"
      id="F_364e98e2-a369-426d-8dfb-3c711eb6bc00"
      unitRef="U_USD">12479000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_9ebb78c1-151a-4750-8ce8-05e1baf42364"
      decimals="-3"
      id="F_1e459828-b84f-4fe4-acb4-e99c5fe2e7e5"
      unitRef="U_USD">-12300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_eea159b5-c530-4b11-93a2-2388e71563e6"
      unitRef="U_USD">-12300000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ee931db3-063b-4b61-9205-fc476769857a"
      decimals="-3"
      id="F_2467db4a-5cce-40b8-8e36-9c08cd303c89"
      unitRef="U_USD">624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a6b6ecdc-c50d-4252-b4a2-8da49d25460d"
      unitRef="U_USD">624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6"
      decimals="0"
      id="F_ebfb9068-25fc-4457-81e6-4ab7d1e6695f"
      unitRef="U_shares">4074</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6"
      decimals="0"
      id="F_5d0c4430-3d06-42b8-b111-3e61fdac3cd0"
      unitRef="U_shares">2245</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ee931db3-063b-4b61-9205-fc476769857a"
      decimals="-3"
      id="F_e68f6333-1c2a-4508-ada0-e03960169271"
      unitRef="U_USD">17000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_949baaf0-2365-4cf3-9669-d14f9c7d34f9"
      unitRef="U_USD">17000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pali:StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises
      contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6"
      decimals="INF"
      id="F_fd270e0c-1614-4dab-8b8e-e5417adf32f7"
      unitRef="U_shares">146932</pali:StockIssuedDuringPeriodSharesOfCommonStockUponWarrantExercises>
    <pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
      contextRef="C_a0d712b9-0f5b-44c4-95d2-0d317b1e1df6"
      decimals="-3"
      id="F_d939f84e-22a7-443b-8c7d-9877fdf3af00"
      unitRef="U_USD">1000</pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises>
    <pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
      contextRef="C_ee931db3-063b-4b61-9205-fc476769857a"
      decimals="-3"
      id="F_65e1e41b-e592-45d0-9e65-6d7e4f5027a5"
      unitRef="U_USD">1349000</pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises>
    <pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a7ca90bc-b6d0-4847-b5b5-a5ece0e77a2e"
      unitRef="U_USD">1350000</pali:StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_07bbc911-5220-457e-b6ff-5ac9e1cf7eb7"
      decimals="-3"
      id="F_6df39e20-2e59-4ce5-9a84-0371ddda8d88"
      unitRef="U_USD">507000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares
      contextRef="C_07bbc911-5220-457e-b6ff-5ac9e1cf7eb7"
      decimals="0"
      id="F_97d2faa5-3929-43e4-9b99-b2b09b8e728b"
      unitRef="U_shares">31789</pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_06862901-f3a4-4bd2-bd72-90b6eae2c329"
      decimals="-3"
      id="F_7228d524-4406-4b0c-8431-766f31a3570e"
      unitRef="U_USD">2166000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_f73a25a6-b329-46fd-a117-c2bcc90c783a"
      decimals="-3"
      id="F_6c6210d1-c5c9-4266-bcab-a119e73787ea"
      unitRef="U_USD">2166000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447"
      decimals="-3"
      id="F_2f42302e-15fc-4095-9d13-177e3f9c0216"
      unitRef="U_USD">854000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares
      contextRef="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447"
      decimals="INF"
      id="F_417255a2-0c2e-47c2-964a-37873d64eabb"
      unitRef="U_shares">80770</pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_877e0b29-eeb9-4a89-aa0a-6833ffa03447"
      decimals="-3"
      id="F_f68d14e1-3be6-4e28-bab4-237421dd1b76"
      unitRef="U_USD">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_46b8f935-7e06-4909-98e0-8a09b69ca511"
      decimals="-3"
      id="F_bce6c0dd-8418-4daf-adfd-5db44bf2a01a"
      unitRef="U_USD">5300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_6a4f9f7a-6ab6-414e-a396-2c7f3c0ae7ab"
      decimals="-3"
      id="F_8802d0e8-5f9f-4b98-8c5b-c997df350469"
      unitRef="U_USD">5301000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_25e9e99e-093d-49a0-982e-33f5812e37b8"
      decimals="-3"
      id="F_f94206c8-b17a-4f57-abd2-3f8f1bb4cbfb"
      unitRef="U_USD">345000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares
      contextRef="C_25e9e99e-093d-49a0-982e-33f5812e37b8"
      decimals="INF"
      id="F_0d8986ce-d38e-4bda-ab78-06023757e6ab"
      unitRef="U_shares">155959</pali:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_25e9e99e-093d-49a0-982e-33f5812e37b8"
      decimals="-3"
      id="F_c7397b9f-06bf-42db-afdc-18d7fcca3a92"
      unitRef="U_USD">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_f40fb1ae-32d9-4be3-b219-d5d71698de2b"
      decimals="-3"
      id="F_c976ce42-1091-4cc0-944a-f361caf66be6"
      unitRef="U_USD">1674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_a4cf7202-92fd-4462-bf25-87c0570b5099"
      decimals="-3"
      id="F_55e5a70b-f665-410c-840d-98152958fefe"
      unitRef="U_USD">1676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="C_ee931db3-063b-4b61-9205-fc476769857a"
      decimals="-3"
      id="F_dee46229-4244-4ad9-b50c-f0b17e03436a"
      unitRef="U_USD">16000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="C_9ebb78c1-151a-4750-8ce8-05e1baf42364"
      decimals="-3"
      id="F_6ce8729d-b72a-4e6b-9d3f-32b7f104fc52"
      unitRef="U_USD">-16000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:SharesOutstanding
      contextRef="C_51618521-fa5c-465f-afce-888db78121fc"
      decimals="INF"
      id="F_b3317ddf-3179-4840-bc94-8873d720e442"
      unitRef="U_shares">200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_51618521-fa5c-465f-afce-888db78121fc"
      decimals="-3"
      id="F_856b76a8-d2d5-4912-a4ac-444c7fe3a4ae"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06"
      decimals="INF"
      id="F_bf86ad15-f481-43bc-95fd-ed93392090db"
      unitRef="U_shares">618056</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_708ff3fe-8eaf-45eb-9adb-df47251abc06"
      decimals="-3"
      id="F_bfea37a1-9005-48a7-8355-3aa202c9ac1b"
      unitRef="U_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b4194f6e-7d8f-4de8-9fdb-21da6a505d2a"
      decimals="-3"
      id="F_9fa2496c-4ca6-423d-a620-e2e7efcb12e5"
      unitRef="U_USD">132811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5ad66f61-3eb3-4d36-903d-7bac0116fcc6"
      decimals="-3"
      id="F_310f5930-439d-438a-adea-b14f66456953"
      unitRef="U_USD">-121506000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_4431e4dd-eab6-41cd-b2f8-575c8c9b4675"
      unitRef="U_USD">11313000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_01f2b651-281f-452a-944a-7e1696672495"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_fdb419a7-4a85-42c1-b2db-e3cced07068d"
      unitRef="U_USD">-12300000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_a86e5d59-1291-4def-8745-9500dda6b879"
      unitRef="U_USD">3000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a53ea558-17dc-4747-8de8-dc1a84b6ef19"
      unitRef="U_USD">4000</us-gaap:Depreciation>
    <pali:NoncashOperatingLeaseExpense
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_2e148ffa-28f6-4171-82d8-21c2bc8cd694"
      unitRef="U_USD">114000</pali:NoncashOperatingLeaseExpense>
    <pali:NoncashOperatingLeaseExpense
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_d315b20f-7893-4935-9867-1eaf69b1b1f2"
      unitRef="U_USD">102000</pali:NoncashOperatingLeaseExpense>
    <pali:RecurringFairValueMeasurementsOfLiabilities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_f92548c8-7de4-4e84-bb9b-6de33641d47a"
      unitRef="U_USD">54000</pali:RecurringFairValueMeasurementsOfLiabilities>
    <pali:RecurringFairValueMeasurementsOfLiabilities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_bb14cbd3-f03f-4cae-bf89-55e846e499ac"
      unitRef="U_USD">-145000</pali:RecurringFairValueMeasurementsOfLiabilities>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_8c8624d6-b40a-4095-9645-4f3dc8d618e2"
      unitRef="U_USD">135000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_06d13e7a-cf42-4244-9788-03104e49e98f"
      unitRef="U_USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_ea30e00f-d0a2-409b-80bc-0f5329b827b0"
      unitRef="U_USD">-4000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_215e3df2-4415-4e30-9111-fdecd2e96bb2"
      unitRef="U_USD">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_77088481-b723-4582-9a79-5e0ac377a8c0"
      unitRef="U_USD">652000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_9edd486d-26ff-425e-8661-369557ba953b"
      unitRef="U_USD">624000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_00ca5db8-8003-45db-b32b-c10bd7e001f6"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_785da57a-2985-474d-947b-96cb9063bc48"
      unitRef="U_USD">108000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_57d2d8f7-e67b-4964-8ee2-e5cc65af1096"
      unitRef="U_USD">-750000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_039e667d-a0e9-414c-a68e-5fdf1e758aec"
      unitRef="U_USD">-705000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_73dab088-f1a3-4491-bf82-5af4bcf024d7"
      unitRef="U_USD">818000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_345a3549-b3f2-45ef-b180-6ce586864cf9"
      unitRef="U_USD">-492000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_41a5248d-35b5-40c5-837c-cd3784f17538"
      unitRef="U_USD">-56000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_1e66d7bf-8b11-4155-b530-57bf4fa4730c"
      unitRef="U_USD">292000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_dc46a8e9-84cc-4af2-a116-d761490b5e2f"
      unitRef="U_USD">-121000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_6f80715c-a936-4646-902d-6089509c2349"
      unitRef="U_USD">-105000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_61db4d36-43de-48e7-8ee1-0a873ce1c1f1"
      unitRef="U_USD">-12193000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_116988a2-2a93-4931-8d2f-334af9f280cc"
      unitRef="U_USD">-11133000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_8bd3762f-038c-45f1-bd07-a2646e6db407"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_f4188521-b4c2-4d99-9389-4152443bfc1b"
      unitRef="U_USD">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_a12ee8c5-5afc-4687-89ce-d6fabb9b4d3c"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_4d5dc061-a33d-4714-be4c-acef58b59e1c"
      unitRef="U_USD">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_cc3d3ac5-79d7-48f4-887b-7d5f89e230fb"
      unitRef="U_USD">426000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_cccc2507-ef63-45b1-b00f-ea56f35faf1f"
      unitRef="U_USD">391000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_2aa03c7f-69c9-4241-99a5-2f1795805735"
      unitRef="U_USD">8435000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_d422fecd-cc79-4640-9876-f14d043605b2"
      unitRef="U_USD">9419000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_c0f05dd0-9e74-48e3-a364-6971ed767476"
      unitRef="U_USD">2506000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_8fc263b3-a537-4b2e-8cfe-41114ecd060b"
      unitRef="U_USD">2758000</us-gaap:ProceedsFromWarrantExercises>
    <pali:PaymentOfWarrantInducementIssuanceCosts
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_a598fe82-798a-486a-aaea-61bfecb4e4c8"
      unitRef="U_USD">343000</pali:PaymentOfWarrantInducementIssuanceCosts>
    <pali:PaymentOfWarrantInducementIssuanceCosts
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a8b9447f-9564-4b4c-89e8-e0138a461554"
      unitRef="U_USD">0</pali:PaymentOfWarrantInducementIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_beb13d2e-380a-42bd-88b2-076de2c64885"
      unitRef="U_USD">576000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_c024f0d8-0760-4e20-9129-27f8527bbd0f"
      unitRef="U_USD">617000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_d83d2b81-165e-46f1-8beb-e32b9b2861dd"
      unitRef="U_USD">11000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_8400fbaa-f497-4b4d-ba68-3a1cbe855277"
      unitRef="U_USD">17000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_fc864d6d-aa9b-4869-85e5-3743de7ccab1"
      unitRef="U_USD">25000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_cf23aa24-e000-465d-b0c2-dba656883ac4"
      unitRef="U_USD">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_2a13dbad-e01f-455f-bc90-4e473be0eba2"
      unitRef="U_USD">9582000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_bdbc51da-ce5e-4d7d-8fe7-f44d465af567"
      unitRef="U_USD">11186000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_a795206c-261d-4a56-a1b6-01fbc7cc9cec"
      unitRef="U_USD">-2611000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_92174de5-d9df-4879-9351-9b2f7e22e4d3"
      unitRef="U_USD">49000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_d7b9cc41-c404-4757-9e03-c1827ab13895"
      unitRef="U_USD">12458000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd"
      decimals="-3"
      id="F_ffbbb4e1-14e2-41ee-9848-ce087e8b1381"
      unitRef="U_USD">12409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_f504a6b3-2f08-4c9c-966e-22263271f064"
      unitRef="U_USD">9847000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_cc40b64e-3958-4b60-b827-88eafcfd8214"
      unitRef="U_USD">12458000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_a5fa7361-d788-4553-9eb3-f026f4680667"
      unitRef="U_USD">9821000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_83255ffd-1523-4324-ab84-007f7c258be2"
      unitRef="U_USD">12432000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_96dbe452-df01-4857-9db1-3fee8e16c92f"
      unitRef="U_USD">26000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_1ee585c6-0fa6-4961-b9be-cdf1eb8d9cf7"
      unitRef="U_USD">26000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_42472918-b6c2-4437-b068-398fcae32c52"
      unitRef="U_USD">9847000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_aa247662-0ad9-4395-946e-9f4e493f8501"
      unitRef="U_USD">12458000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_c2931552-88af-4f60-a735-6e936e98f196"
      unitRef="U_USD">14000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_59aa336b-a289-4d5e-a2a5-8c840a904c80"
      unitRef="U_USD">14000</us-gaap:InterestPaidNet>
    <pali:WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_18ea44e6-6086-4429-95f7-ab3392abd485"
      unitRef="U_USD">176000</pali:WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities>
    <pali:WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_7814e577-677b-4669-a52d-2acf97342628"
      unitRef="U_USD">0</pali:WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities>
    <pali:NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_d3d0a7f5-de15-4d5e-bde1-6f24f4c0c578"
      unitRef="U_USD">0</pali:NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions>
    <pali:NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_e58b69ba-fc8d-48d5-b965-e1ad7e6c84d7"
      unitRef="U_USD">16000</pali:NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions>
    <pali:FairValueOfWarrantsIssuedToSolicitationAgent
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_69e96883-9dfc-4102-8e78-4ee3e62c740a"
      unitRef="U_USD">94000</pali:FairValueOfWarrantsIssuedToSolicitationAgent>
    <pali:FairValueOfWarrantsIssuedToSolicitationAgent
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_50faad6b-2c95-4bae-8102-cbd2e570e7b2"
      unitRef="U_USD">0</pali:FairValueOfWarrantsIssuedToSolicitationAgent>
    <pali:FairValueOfWarrantsIssuedToPlacementAgents
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_7194a42d-ec72-4f31-b6ee-1fdc84aaed53"
      unitRef="U_USD">249000</pali:FairValueOfWarrantsIssuedToPlacementAgents>
    <pali:FairValueOfWarrantsIssuedToPlacementAgents
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_190f985d-a438-4913-baa1-e7fa507237fe"
      unitRef="U_USD">384000</pali:FairValueOfWarrantsIssuedToPlacementAgents>
    <pali:FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_825f5826-5f6f-42ae-843c-c0680bd47b80"
      unitRef="U_USD">278000</pali:FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter>
    <pali:FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_9f588a02-692e-4c9f-82e2-47a5a0a01ae5"
      unitRef="U_USD">0</pali:FairValueOfWarrantsIssuedToRepresentativesOfUnderwriter>
    <pali:DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_3df2767b-bb0a-4cb7-9f69-6e505d24ec07"
      unitRef="U_USD">37000</pali:DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities>
    <pali:DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_74371af1-0552-462e-adb6-74bb52e8bfb0"
      unitRef="U_USD">6000</pali:DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities>
    <pali:NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_ae35c277-3afa-44a9-9f07-c80de39306f3"
      unitRef="U_USD">347000</pali:NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets>
    <pali:NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_f7daa70c-5913-4043-a1ab-ecfe8435c83e"
      unitRef="U_USD">461000</pali:NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAssets>
    <pali:IncrementalFairValueOfModifiedOrExchangedWarrants
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_ee5d00fa-ae2a-4ede-b285-4fcbe0a37cd9"
      unitRef="U_USD">2237000</pali:IncrementalFairValueOfModifiedOrExchangedWarrants>
    <pali:IncrementalFairValueOfModifiedOrExchangedWarrants
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_5385c097-2333-46ae-bf54-e0055ded5164"
      unitRef="U_USD">0</pali:IncrementalFairValueOfModifiedOrExchangedWarrants>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_cbbf94d8-3733-47b4-bd0c-947b8bf9ffc8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Organization and Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unless the context indicates or otherwise requires, &#x201c;Palisade,&#x201d; &#x201c;Palisade Bio,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; or similar designations in this Annual Report on Form 10-K refer to Palisade Bio, Inc., a Delaware Corporation, and its subsidiaries. Any reference to &#x201c;common shares&#x201d; or &#x201c;common stock,&#x201d; refers to the Company's $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value common stock. Any reference to &#x201c;Leading Biosciences, Inc.&#x201d; or &#x201c;LBS&#x201d; refers to the Company&#x2019;s operations prior to the completion of its merger with Seneca Biopharma, Inc. ("Seneca") on April 27, 2021 (the "Merger"). Any reference herein that refers to preclinical studies also refers to nonclinical studies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company's lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease, or IBD, including ulcerative colitis and fibrostenotic Crohn's disease.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a limited operating history, and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operations since its inception. As of December 31, 2024, the Company had an accumulated deficit of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and cash and cash equivalents of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company expects to continue to incur losses into the foreseeable future. The successful transition to achieving profitability is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s costs. There can be no assurances that such profitability will ever be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on the Company&#x2019;s current working capital, anticipated operating expenses, and anticipated net operating losses, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Historically, the Company has funded its operations primarily through equity financings. The Company plans to continue to fund its operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. Refer to Note 5, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for discussion of the recent financings undertaken by the Company. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company is successful in raising additional capital, it may also be required to modify, delay or abandon some of its plans, which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="2"
      id="F_0ee55816-00b1-40ba-ac07-3e8cb06f08d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-5"
      id="F_c0d6fba3-6082-4bd4-bf9c-1ab1600b2bd5"
      unitRef="U_USD">135900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-5"
      id="F_91116e31-3797-4dbd-997d-78d85d7082b8"
      unitRef="U_USD">9800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_f5f1eb2b-e1b8-4622-bdb2-f70be29b85af">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). Dollar amounts contained in these consolidated financial statements are in whole numbers, unless otherwise indicated.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, LBS and Suzhou Neuralstem Biopharmaceutical Co., Ltd. All the entities are consolidated in the Company's consolidated financial statements and all intercompany activity and transactions, if any, have been eliminated&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 5, 2024, the Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1-for-15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reverse stock split of its issued and outstanding common stock (the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; "Reverse Stock S&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;plit"). As a result of the Reverse Stock Split, the Company&#x2019;s stockholders received one share of common stock for every &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#x2019;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected the Company&#x2019;s outstanding stock-based awards, common stock warrants, and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data and shares of common stock underlying convertible preferred stock, stock-based award and common stock warrants included in these consolidated financial statements, including the exercise price or conversion price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents represent cash in readily available checking and money market accounts. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company held restricted cash of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in a separate restricted bank account as collateral for the Company&#x2019;s corporate credit card program. The Company has classified these deposits as long-term restricted cash on its consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Equity Issuance Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred equity issuance costs consist of the legal, accounting and other direct and incremental costs incurred by the Company related to its equity offerings, if not yet finalized as of the balance sheet date, or shelf registration statement. As of December 31, 2024 and December 31, 2023, deferred equity issuance costs of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, were included in prepaid expenses and other current assets in the consolidated balance sheets. These costs will be netted against additional paid-in capital as a cost of the future equity issuances to which they relate. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company netted previously deferred equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; against the additional paid-in capital recognized in conjunction with the February 2024 Warrant Inducement. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company netted previously deferred equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; associated with its shelf registration statement against the additional paid-in capital recognized in conjunction with the September 2023 Offering (see Note 5, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders' Equity)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;accounts, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and historically the Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows Accounting Standards Codification ("ASC") 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.148%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further information on the fair value of the Company's financial assets and liabilities can be found at Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including common stock warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option pricing model or other acceptable valuation models, including the Monte-Carlo simulation model. Derivative instruments, if any, are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and common stock warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its common stock warrants in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("ASC 480") and ASC 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 815&#x201d;). Based upon the provisions of ASC 480 and ASC 815, the Company accounts for common stock warrants as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement, or if it fails the equity classification criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified as equity. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at fair value at each balance sheet date with the offsetting adjustments recorded in change in fair value of warrant liability within the consolidated statements of operations. If the terms of a common stock warrant previously classified as a liability are amended and pursuant to such amendment meet the requirements to be classified as equity, the common stock warrants are reclassified to equity at the fair value on the date of the amendment and are not subsequently remeasured. Common stock warrants classified as equity are recorded on a relative fair value basis when they are issued with other equity-classified financial instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company assesses contracts for lease arrangements at inception. Operating right-of-use (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit, if readily available, or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the revenue recognition guidance established by ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC 808, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent Consideration Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 1, 2023, the Company and Giiant Pharma, Inc. ("Giiant") entered into a research collaboration and license agreement (the &#x201c;Giiant License Agreement&#x201d;)(see Note 7, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborations and License Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation consisting of milestone payments, which are recognized as a liability measured at fair value, and ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses third parties of any products developed from the assets licensed under the Giiant License Agreement. Because the contingent consideration associated with the milestone payments may be settled in shares of the Company's common stock solely at the election of the Company, the Company has determined it should be accounted for under ASC 480 and accordingly the Company has recognized it as a liability measured at its estimated fair value. At the end of each reporting period, the Company re-measures the contingent consideration obligation to its estimated fair value and any resulting change is recognized in research and development expenses in the consolidated statements of operations. The Company has determined that the contingent consideration associated with the royalty payments should be recognized as a liability when they are probable and estimable, in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist primarily of salaries and other personnel related expenses including stock-based compensation costs, and, to the extent applicable, may include preclinical costs, clinical trial costs, costs related to acquiring and manufacturing clinical trial materials, and contract services. All research and development costs are expensed as incurred pursuant to ASC 730, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Pursuant to situations whereby the Company performs any research and development or manufacturing activities under a co-development agreement, and the co-development partner is not considered a customer under ASC 606, the Company records the expense reimbursements from the co-development partner as a reduction to research and development expense once the reimbursement amount is approved for payment by the co-development partner. Expense payments made to Giiant pursuant to the terms of the Giiant License Agreement for qualifying development costs are expensed only as the associated research and development costs are incurred or other aspects of the drug development or related activities are achieved. In instances where the expense determined to be recognized exceeds the payments made to the Giiant, the Company recognizes an accrual of joint development expenses. In addition, there may be instances in which payments made to Giiant will temporarily exceed the level of services provided, which results in a prepayment of the joint development expenses. The Company records expense payments from Giiant, if any, as a reduction to research and development expense once the expense payments are realized or realizable, which is when Company receives the cash or has an undisputed claim to the cash that is probable of collection, pursuant to the terms of the Giiant License&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreement and the principles of ASC 450, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Gain Contingencies &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 450"). The Company has determined that Giiant is not considered a customer under ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Clinical Trial Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expenses related to clinical studies are based on estimates of the services received and efforts expended pursuant to the Company&#x2019;s contract arrangements. The financial terms of these contract arrangements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients, site initiation and the completion of clinical milestones. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense balance accordingly.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accrues for clinical trial expenses for which the estimated services have been provided but the Company has not yet been invoiced as of the balance sheet date. There may be instances in which payments made to the Company&#x2019;s service providers will temporarily exceed the level of services provided and result in a prepayment of the clinical trial expenses. Clinical trial expenses are included in research and development expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows ASC 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 740&#x201d;) in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some of or all the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation generally includes service-based restricted stock units (&#x201c;RSUs&#x201d;), stock options, and market-based performance RSUs (&#x201c;PSUs&#x201d;). The Company accounts for forfeitures as they occur for each type of award as a reduction of expense. Stock-based compensation expense related to service-based RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period, which is usually the vesting period. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model. The determination of the fair value of stock-based payment awards on the date of grant using the Black-Scholes option pricing model is affected by the Company's stock price as well as assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate, and expected dividends over the expected term of the award. Stock-based compensation expense represents the cost of the estimated grant date fair value of employee and non-employee stock option grants recognized ratably over the requisite service period of the awards, which is usually the vesting period. For PSUs with vesting subject to market conditions, the fair value of the award is determined at grant date using the Monte Carlo simulation model, and expense is recognized ratably over the derived service period regardless of whether the market condition is satisfied. The Monte Carlo simulation model considers a variety of potential future scenarios under the market condition vesting criteria, including but not limited to share prices for the Company and its peer companies in a selected market index.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not recognize any share-based compensation expense related to conditional RSUs, stock options, or PSUs that are subject to shareholder approval. When and if approval is obtained, the Company recognizes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;share-based compensation expense related to the conditional equity grants ratably to the vesting of shares over the remaining requisite service period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company offers to its employees an opportunity to participate in its shareholder approved Palisade Bio, Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP"). The Company estimates the fair value of 2021 ESPP awards on the first day of the offering period using the Black-Scholes option pricing model. The estimated fair value of 2021 ESPP awards is amortized on a straight-line basis over the requisite service period of the award. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of 2021 ESPP awards.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all years presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, ("ASU 2023-07"), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The disclosure requirements included in ASU No. 2023-07 are required for all public entities, including those with a single reportable segment. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 31, 2024 on a retrospective basis, with early adoption permitted. The Company adopted ASU 2023-07 in the fourth quarter of 2024. The adoption of this guidance resulted in additional financial statement disclosures and had no impact on the Company's results of operations and financial condition. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for disclosures resulting from the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 720): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("ASU 2023-09"), which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASC 2023-09 on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("ASU 2024-03"), which is intended to improve disclosures about a public business entity&#x2019;s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_6698a66d-2631-43c4-8280-f133e07ae46a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). Dollar amounts contained in these consolidated financial statements are in whole numbers, unless otherwise indicated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, LBS and Suzhou Neuralstem Biopharmaceutical Co., Ltd. All the entities are consolidated in the Company's consolidated financial statements and all intercompany activity and transactions, if any, have been eliminated&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <pali:ReverseStockSplitPolicyPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_3677f763-9c47-46b8-85a5-182c2ffdcc06">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 5, 2024, the Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1-for-15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reverse stock split of its issued and outstanding common stock (the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; "Reverse Stock S&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;plit"). As a result of the Reverse Stock Split, the Company&#x2019;s stockholders received one share of common stock for every &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all the Company&#x2019;s issued and outstanding shares of common stock equally. The par value and authorized shares of the Company's common stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split also affected the Company&#x2019;s outstanding stock-based awards, common stock warrants, and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately. Unless otherwise noted, all common stock shares, common stock per share data and shares of common stock underlying convertible preferred stock, stock-based award and common stock warrants included in these consolidated financial statements, including the exercise price or conversion price of such equity instruments, as applicable, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/p&gt;</pali:ReverseStockSplitPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_4c38a0f6-0e17-4097-a741-e8528d218109"
      id="F_7cf82529-34d2-4e2a-8aa2-060c11dd5085">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_4c38a0f6-0e17-4097-a741-e8528d218109"
      decimals="0"
      id="F_3756abdf-ed90-4227-bcf9-3acf649a7c2a"
      unitRef="U_shares">15</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:UseOfEstimates
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_fb76f54c-4753-48ab-ace9-51ae4e53d023">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_2f11979b-ce0c-4df5-a32d-e254785fb07f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents represent cash in readily available checking and money market accounts. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_8d483bd0-1db9-47b3-be39-59654ea0685b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company held restricted cash of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in a separate restricted bank account as collateral for the Company&#x2019;s corporate credit card program. The Company has classified these deposits as long-term restricted cash on its consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="0"
      id="F_7edcbfd7-2994-4460-9d40-27891e1327e3"
      unitRef="U_USD">26000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="0"
      id="F_64cc3a5f-b350-466c-a136-3b01c711133f"
      unitRef="U_USD">26000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_35f9c7eb-64f3-4766-9113-6b87461bf175">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Equity Issuance Costs&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred equity issuance costs consist of the legal, accounting and other direct and incremental costs incurred by the Company related to its equity offerings, if not yet finalized as of the balance sheet date, or shelf registration statement. As of December 31, 2024 and December 31, 2023, deferred equity issuance costs of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, were included in prepaid expenses and other current assets in the consolidated balance sheets. These costs will be netted against additional paid-in capital as a cost of the future equity issuances to which they relate. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company netted previously deferred equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; against the additional paid-in capital recognized in conjunction with the February 2024 Warrant Inducement. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company netted previously deferred equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; associated with its shelf registration statement against the additional paid-in capital recognized in conjunction with the September 2023 Offering (see Note 5, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders' Equity)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCostsCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="0"
      id="F_d5226bfe-79ea-4945-b6c0-3c20fc24fe2c"
      unitRef="U_USD">75000</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="0"
      id="F_1ac9bda9-682e-43fa-b712-6678c20e49ef"
      unitRef="U_USD">112000</us-gaap:DeferredCostsCurrent>
    <pali:DeferredEquityIssuanceCosts
      contextRef="C_db7afb64-6e06-473b-8d9a-ceeac08c60c0"
      decimals="0"
      id="F_73043d06-3cf2-4ef0-87c8-ae4b162d6065"
      unitRef="U_USD">37000</pali:DeferredEquityIssuanceCosts>
    <pali:DeferredEquityIssuanceCosts
      contextRef="C_ee931db3-063b-4b61-9205-fc476769857a"
      decimals="0"
      id="F_dc173782-ca93-446e-8d09-1db61c62ff7d"
      unitRef="U_USD">6000</pali:DeferredEquityIssuanceCosts>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_ace29a3d-98d4-40e6-8b32-c5b86dce2b81">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;accounts, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and historically the Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_0b1072f4-5340-47a0-9e6d-e0cc6a85588d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows Accounting Standards Codification ("ASC") 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.75%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.148%;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.4628571428571426%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.148%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further information on the fair value of the Company's financial assets and liabilities can be found at Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_03f09fae-05f1-47e2-9a3c-9a51a9f54038">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including common stock warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option pricing model or other acceptable valuation models, including the Monte-Carlo simulation model. Derivative instruments, if any, are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and common stock warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its common stock warrants in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("ASC 480") and ASC 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 815&#x201d;). Based upon the provisions of ASC 480 and ASC 815, the Company accounts for common stock warrants as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement, or if it fails the equity classification criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified as equity. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at fair value at each balance sheet date with the offsetting adjustments recorded in change in fair value of warrant liability within the consolidated statements of operations. If the terms of a common stock warrant previously classified as a liability are amended and pursuant to such amendment meet the requirements to be classified as equity, the common stock warrants are reclassified to equity at the fair value on the date of the amendment and are not subsequently remeasured. Common stock warrants classified as equity are recorded on a relative fair value basis when they are issued with other equity-classified financial instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_39a40624-decf-491b-939b-a983ac32be99">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company assesses contracts for lease arrangements at inception. Operating right-of-use (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the lease commencement date equal to the present value of future lease payments using the implicit, if readily available, or incremental borrowing rate based on the information readily available at the commencement date. ROU assets include any lease payments as of commencement and initial direct costs but exclude any lease incentives. Lease and non-lease components are generally accounted for separately and the Company recognizes operating lease expense straight-line over the term of the lease.&lt;/span&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionSoftware
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_b47044a5-d5f3-4d6b-8381-5d699ce24981">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the revenue recognition guidance established by ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC 808, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionSoftware>
    <pali:ContingentConsiderationObligationsPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_97727ae7-5bb0-4db6-8dba-0dcbc1816b5b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent Consideration Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 1, 2023, the Company and Giiant Pharma, Inc. ("Giiant") entered into a research collaboration and license agreement (the &#x201c;Giiant License Agreement&#x201d;)(see Note 7, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborations and License Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation consisting of milestone payments, which are recognized as a liability measured at fair value, and ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses third parties of any products developed from the assets licensed under the Giiant License Agreement. Because the contingent consideration associated with the milestone payments may be settled in shares of the Company's common stock solely at the election of the Company, the Company has determined it should be accounted for under ASC 480 and accordingly the Company has recognized it as a liability measured at its estimated fair value. At the end of each reporting period, the Company re-measures the contingent consideration obligation to its estimated fair value and any resulting change is recognized in research and development expenses in the consolidated statements of operations. The Company has determined that the contingent consideration associated with the royalty payments should be recognized as a liability when they are probable and estimable, in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</pali:ContingentConsiderationObligationsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_0e0e9d33-bd74-4cfa-9bbc-01a4b9ab9c09">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist primarily of salaries and other personnel related expenses including stock-based compensation costs, and, to the extent applicable, may include preclinical costs, clinical trial costs, costs related to acquiring and manufacturing clinical trial materials, and contract services. All research and development costs are expensed as incurred pursuant to ASC 730, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Pursuant to situations whereby the Company performs any research and development or manufacturing activities under a co-development agreement, and the co-development partner is not considered a customer under ASC 606, the Company records the expense reimbursements from the co-development partner as a reduction to research and development expense once the reimbursement amount is approved for payment by the co-development partner. Expense payments made to Giiant pursuant to the terms of the Giiant License Agreement for qualifying development costs are expensed only as the associated research and development costs are incurred or other aspects of the drug development or related activities are achieved. In instances where the expense determined to be recognized exceeds the payments made to the Giiant, the Company recognizes an accrual of joint development expenses. In addition, there may be instances in which payments made to Giiant will temporarily exceed the level of services provided, which results in a prepayment of the joint development expenses. The Company records expense payments from Giiant, if any, as a reduction to research and development expense once the expense payments are realized or realizable, which is when Company receives the cash or has an undisputed claim to the cash that is probable of collection, pursuant to the terms of the Giiant License&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreement and the principles of ASC 450, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Gain Contingencies &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;("ASC 450"). The Company has determined that Giiant is not considered a customer under ASC 606.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pali:ClinicalTrialExpensesPolicyPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_050646f3-bbfd-40ba-a160-f5c2cdd6f912">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Clinical Trial Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expenses related to clinical studies are based on estimates of the services received and efforts expended pursuant to the Company&#x2019;s contract arrangements. The financial terms of these contract arrangements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients, site initiation and the completion of clinical milestones. The Company makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense balance accordingly.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accrues for clinical trial expenses for which the estimated services have been provided but the Company has not yet been invoiced as of the balance sheet date. There may be instances in which payments made to the Company&#x2019;s service providers will temporarily exceed the level of services provided and result in a prepayment of the clinical trial expenses. Clinical trial expenses are included in research and development expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</pali:ClinicalTrialExpensesPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_4a190c39-95dc-4683-943d-8d3a47f4f3cb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company follows ASC 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 740&#x201d;) in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some of or all the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_e6fdc468-635f-4b33-ba2c-ba53a384e3db">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation generally includes service-based restricted stock units (&#x201c;RSUs&#x201d;), stock options, and market-based performance RSUs (&#x201c;PSUs&#x201d;). The Company accounts for forfeitures as they occur for each type of award as a reduction of expense. Stock-based compensation expense related to service-based RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period, which is usually the vesting period. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model. The determination of the fair value of stock-based payment awards on the date of grant using the Black-Scholes option pricing model is affected by the Company's stock price as well as assumptions, which include the expected term of the award, the expected stock price volatility, risk-free interest rate, and expected dividends over the expected term of the award. Stock-based compensation expense represents the cost of the estimated grant date fair value of employee and non-employee stock option grants recognized ratably over the requisite service period of the awards, which is usually the vesting period. For PSUs with vesting subject to market conditions, the fair value of the award is determined at grant date using the Monte Carlo simulation model, and expense is recognized ratably over the derived service period regardless of whether the market condition is satisfied. The Monte Carlo simulation model considers a variety of potential future scenarios under the market condition vesting criteria, including but not limited to share prices for the Company and its peer companies in a selected market index.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not recognize any share-based compensation expense related to conditional RSUs, stock options, or PSUs that are subject to shareholder approval. When and if approval is obtained, the Company recognizes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;share-based compensation expense related to the conditional equity grants ratably to the vesting of shares over the remaining requisite service period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company offers to its employees an opportunity to participate in its shareholder approved Palisade Bio, Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP"). The Company estimates the fair value of 2021 ESPP awards on the first day of the offering period using the Black-Scholes option pricing model. The estimated fair value of 2021 ESPP awards is amortized on a straight-line basis over the requisite service period of the award. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of 2021 ESPP awards.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c649637f-752d-41a7-88e4-a1b6ea796146">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was the same as its reported net loss for all years presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_60c29014-c74e-428b-983b-c1fdda2fb97b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, ("ASU 2023-07"), which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The disclosure requirements included in ASU No. 2023-07 are required for all public entities, including those with a single reportable segment. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 31, 2024 on a retrospective basis, with early adoption permitted. The Company adopted ASU 2023-07 in the fourth quarter of 2024. The adoption of this guidance resulted in additional financial statement disclosures and had no impact on the Company's results of operations and financial condition. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for disclosures resulting from the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 720): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("ASU 2023-09"), which prescribes standard categories for the components of the effective tax rate reconciliation and requires disclosure of additional information for reconciling items meeting certain quantitative thresholds, requires disclosure of disaggregated income taxes paid, and modifies certain other income tax-related disclosures. ASU No. 2023-09 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASC 2023-09 on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("ASU 2024-03"), which is intended to improve disclosures about a public business entity&#x2019;s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_2b476b0d-456f-4d9c-8283-d0bb0a3070a6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Balance Sheet Details&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid subscriptions and fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid software licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred equity issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other noncurrent assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance, less current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued chemistry, manufacturing and controls ("CMC") expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued director stipends&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued severance and benefits (Note 8)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued joint development expenses (Note 7)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of contingent consideration obligation (Note 4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_4e12c78f-02f4-4adc-85d4-8be0f7339ae5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid subscriptions and fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid software licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred equity issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_c07addaa-9901-4f63-8c17-0a032d847922"
      unitRef="U_USD">384000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_46de5fd3-fada-4bb2-8dcd-e6ce184bd4ad"
      unitRef="U_USD">428000</us-gaap:PrepaidInsurance>
    <pali:PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_e248cd60-35ed-4545-84fb-95c8a74a6759"
      unitRef="U_USD">24000</pali:PrepaidExpensesAndOtherCurrentAssetsOtherReceivables>
    <pali:PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_0cfcde5a-ec90-459b-a8a4-d8153297665c"
      unitRef="U_USD">148000</pali:PrepaidExpensesAndOtherCurrentAssetsOtherReceivables>
    <pali:PrepaidSubscriptionsAndFees
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_ee6c4033-7231-47c7-8916-1c0feb5f5d95"
      unitRef="U_USD">116000</pali:PrepaidSubscriptionsAndFees>
    <pali:PrepaidSubscriptionsAndFees
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_58153d06-d010-4a8d-8744-7e355e5850d3"
      unitRef="U_USD">138000</pali:PrepaidSubscriptionsAndFees>
    <pali:PrepaidSoftwareLicenses
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_40e4189a-2232-419f-8fc7-161f5e7793d0"
      unitRef="U_USD">57000</pali:PrepaidSoftwareLicenses>
    <pali:PrepaidSoftwareLicenses
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_6f45d53b-0d94-4de0-a4bb-fbc35ed2ebba"
      unitRef="U_USD">64000</pali:PrepaidSoftwareLicenses>
    <us-gaap:DepositAssets
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_8296eba2-fd91-4f5c-8bd4-19c0a272c21c"
      unitRef="U_USD">12000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_40272a8a-620c-49bf-b5be-bdb14d72d75b"
      unitRef="U_USD">0</us-gaap:DepositAssets>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_c8e80e18-aebc-49d3-9f88-f284868f2a04"
      unitRef="U_USD">75000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_a72a7846-ef68-40ba-a74f-83f02c76c9a5"
      unitRef="U_USD">112000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_bde7cfba-3042-48e3-babf-c107fd884f1a"
      unitRef="U_USD">5000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_4fa76709-b1d7-4e36-9253-b33014668136"
      unitRef="U_USD">6000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_f1ae7f5a-6996-4162-8df1-ce134687ece1"
      unitRef="U_USD">673000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_0acbe27e-5b05-4dba-81aa-1903108f030f"
      unitRef="U_USD">896000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c7d639b9-0466-4e1a-86ca-ad65c11e55a3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other noncurrent assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance, less current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_a5043290-5896-4325-a454-6febe2dd424b"
      unitRef="U_USD">273000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_d7565576-2d35-48c6-97b0-f2fe2237be03"
      unitRef="U_USD">478000</us-gaap:PrepaidExpenseNoncurrent>
    <pali:OtherNoncurrentAssets
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_2f509dc2-834f-4ebc-86f4-d4024935d092"
      unitRef="U_USD">0</pali:OtherNoncurrentAssets>
    <pali:OtherNoncurrentAssets
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_6f523ca8-c9b5-4012-a21f-6b9fcc251776"
      unitRef="U_USD">12000</pali:OtherNoncurrentAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_5af0f01c-628c-468b-aacb-88afdc343a1e"
      unitRef="U_USD">273000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_507496f5-0a33-49f2-a11d-343105203fdc"
      unitRef="U_USD">490000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_2382cbcc-b063-4432-b181-9a9eb6155650">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued chemistry, manufacturing and controls ("CMC") expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued director stipends&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued severance and benefits (Note 8)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued joint development expenses (Note 7)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of contingent consideration obligation (Note 4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pali:AccruedAccountsPayable
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_4499a250-8814-4ab3-9c7c-95d2a9b58867"
      unitRef="U_USD">109000</pali:AccruedAccountsPayable>
    <pali:AccruedAccountsPayable
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_902db2fa-c39c-4b42-8d22-73db71e7e6c6"
      unitRef="U_USD">146000</pali:AccruedAccountsPayable>
    <pali:AccruedClinicalTrialCosts
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_0dd8abcf-dba6-4fe4-b08b-9ef0b459a951"
      unitRef="U_USD">0</pali:AccruedClinicalTrialCosts>
    <pali:AccruedClinicalTrialCosts
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_fdab3b25-34f7-46f7-a144-39bef40b487a"
      unitRef="U_USD">20000</pali:AccruedClinicalTrialCosts>
    <pali:AccruedCMCExpenses
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_0adcc0e9-2f5e-4f0f-a94f-a1a3d649a8c0"
      unitRef="U_USD">606000</pali:AccruedCMCExpenses>
    <pali:AccruedCMCExpenses
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_5adcfbaa-4700-4349-b1bc-9d219f0f4e96"
      unitRef="U_USD">5000</pali:AccruedCMCExpenses>
    <pali:AccruedDirectorStipends
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_dc8e04fa-4662-4dec-bccf-91af38273362"
      unitRef="U_USD">59000</pali:AccruedDirectorStipends>
    <pali:AccruedDirectorStipends
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_befba055-eab4-4c0e-a86f-5386f6e660e8"
      unitRef="U_USD">106000</pali:AccruedDirectorStipends>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_aa763c77-69d9-4e60-8612-2f66d382bc61"
      unitRef="U_USD">0</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_190d6314-da91-4b1e-9502-5b882063d69c"
      unitRef="U_USD">131000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <pali:AccruedJointDevelopmentExpenses
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_a60b336e-f894-4a5a-b990-ea8fb92e9c02"
      unitRef="U_USD">223000</pali:AccruedJointDevelopmentExpenses>
    <pali:AccruedJointDevelopmentExpenses
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_813ef374-5681-4331-9a29-c1d492497596"
      unitRef="U_USD">98000</pali:AccruedJointDevelopmentExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_1dc03c6f-0a5e-4df7-a62c-6a27c88c726c"
      unitRef="U_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_a7c01244-d349-438f-94a9-741d850ee1db"
      unitRef="U_USD">143000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_c9f9bb2c-fe73-4b4b-b1c7-e72310c19ec1"
      unitRef="U_USD">243000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_894bcec4-4235-4031-8103-e4b31c81c715"
      unitRef="U_USD">182000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_60a65301-1df7-4588-bcd0-d9e8f5759a3d"
      unitRef="U_USD">1240000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_8256b7f7-a91b-416b-8fb8-779f33332502"
      unitRef="U_USD">831000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_d24532b7-a57b-4c1b-8bc9-e8f0aeab3fff">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist principally of cash and cash equivalents, restricted cash, other current receivables, accounts payable, accrued liabilities, insurance financing debt, liability-classified warrants and a contingent consideration obligation. The carrying amounts of financial instruments such as restricted cash, other current receivables, accounts payable, and accrued liabilities approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#x2019;s insurance financing debt approximates its fair value as of December 31, 2024 and December 31, 2023 due to the market rate of interest, which is based on level 2 inputs. The Company&#x2019;s liability-classified warrants and its contingent consideration obligation are carried at fair value based on level 3 inputs. None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a nonrecurring basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests its excess cash in money market funds that are classified as level 1 in the fair value hierarchy due to their short-term maturity, and measured the fair value based on quoted prices in active markets for identical assets. The fair value of the Company's cash and cash equivalents invested in money market funds was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent Consideration Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Giiant License Agreement, the Company incurred a contingent consideration obligation related to future milestone payments. The Company has an obligation to make contingent consideration payments to Giiant, in either cash or shares of the Company&#x2019;s common stock solely at the Company&#x2019;s election, upon the achievement of development milestones. On August 2, 2024, the Company and Giiant entered into an amendment to the Giiant License Agreement, which among other things, reduced the milestone payments due to Giiant upon the achievement of certain development milestones (see Note 7, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborations and License Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for further details).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the contingent consideration obligation is determined using a probability-based model that estimates the likelihood of success in achieving each of the defined milestones that is then discounted to present value using the Company's incremental borrowing rate. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The significant assumptions used in the calculation of the fair value as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; included a discount rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.29&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and management's updated projections of the likelihood of success in achieving each of the defined milestones based on empirical, published industry data.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;summarizes the activity of the Company&#x2019;s Level 3 contingent consideration obligations, which are fair valued on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contingent Consideration Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Initial fair value at the original issuance date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the entire amount of contingent consideration obligation of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was classified as a noncurrent liability in the consolidated balance sheet as none of it is expected to be settled within one-year of the balance sheet date. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the contingent consideration obligation was classified in accrued liabilities in the consolidated balance sheets as it was expected to be settled within one-year of the balance sheet date and the remaining obligation of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was classified as a noncurrent liability in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The change in the fair value of the contingent consideration obligation of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 was primarily due to the reduction in the milestone payments that would be due to Giiant upon the achievement of certain development milestones pursuant to the amendment to the Giiant License Agreement, partially offset by an increase in management's projected likelihood of success in achieving each of the defined milestones as a result of the Company's commencement of a Phase 1 trial in November of 2024. The change in the revaluation of the liability in the years ended December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is recognized in research and development expenses in the consolidated statements of operations. In addition, the initial fair value of the contingent consideration obligation of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and transaction-related costs of approxi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;mately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for the year ended December 31, 2023 is recognized in research and development expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liability-Classified Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has issued warrants that are accounted for as liabilities based upon the guidance of with ASC 480 and ASC 815. Estimating fair values of liability-classified financial instruments requires the development of estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;factors. Changes in fair value of the liability-classified warrants are recognized as a component of other income, net in the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the fair value of the Company's liability-classified warrants outstanding was determined using a Black-Scholes option pricing model valuation model to be insignificant due to the low market price of the Company's stock at the date of valuation relative to the exercise price of the underlying warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the activity of the Company&#x2019;s Level 3 liability-classified warrants during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9360a9a6-4319-458b-a705-b8de13df423c"
      decimals="-5"
      id="F_f94bb1c9-5cdd-4656-88f1-15cbf13ffda4"
      unitRef="U_USD">9800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4a7340ec-c1ef-4e8f-b685-40b983c0d414"
      decimals="-5"
      id="F_52610c4d-fdb9-4c6b-9e94-1baa1c55c7be"
      unitRef="U_USD">12300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_070fbbd6-0133-4fd9-a92e-3a59027648e0"
      decimals="4"
      id="F_191866bb-3b9b-47ff-9c0c-5bc3ebcf9c0c"
      unitRef="U_pure">0.0929</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_671d8ff9-d06e-44e8-8753-0d285732a4c2"
      id="F_0484eb84-6846-4b71-9a24-e91d63412b96">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;summarizes the activity of the Company&#x2019;s Level 3 contingent consideration obligations, which are fair valued on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contingent Consideration Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Initial fair value at the original issuance date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_e7194555-4ab8-40fd-b397-92bd0b1f7bb9"
      decimals="-3"
      id="F_083d5bbc-e9b1-48ba-adc8-1fbc42cb8b1c"
      unitRef="U_USD">204000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_4f54001b-6421-4019-8e41-db056882bcd4"
      decimals="-3"
      id="F_cf521a29-2177-4263-87b3-07fd56c2cca0"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="C_671d8ff9-d06e-44e8-8753-0d285732a4c2"
      decimals="-3"
      id="F_e21bbe46-29af-412f-874a-b5e242fd6cf3"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="C_7d3732a3-912c-4fce-90de-1cf88fb0bb7c"
      decimals="-3"
      id="F_64967128-e6aa-4a46-92f4-8e85e5393a6f"
      unitRef="U_USD">212000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_671d8ff9-d06e-44e8-8753-0d285732a4c2"
      decimals="-3"
      id="F_b81a96b9-98d1-4e97-b424-68267bbbff2c"
      unitRef="U_USD">54000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_7d3732a3-912c-4fce-90de-1cf88fb0bb7c"
      decimals="-3"
      id="F_5d74bc72-7cb4-41ce-a11b-88d9c2e02b75"
      unitRef="U_USD">8000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_e5488fc7-f4ab-4fdb-a268-96c258ed7b00"
      decimals="-3"
      id="F_3babe8c2-4288-4ac0-9c4c-65c43ebb7c3b"
      unitRef="U_USD">150000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_e7194555-4ab8-40fd-b397-92bd0b1f7bb9"
      decimals="-3"
      id="F_4170d778-5f12-4776-940d-cfb07c412b9d"
      unitRef="U_USD">204000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="0"
      id="F_6cdab90e-922c-4f96-a4fe-584be9823f48"
      unitRef="U_USD">150000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_01126dbc-d04a-4b1c-9f6b-d2a1bf5c9e96"
      decimals="0"
      id="F_c0b5fd5c-3979-435e-ac3b-a4d0da1cd951"
      unitRef="U_USD">143000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="0"
      id="F_ca4965dc-0b2a-43d7-91b8-2eeba5d9120c"
      unitRef="U_USD">61000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <pali:ChangesInFairValueOfContingentConsideration
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_0deee5a4-ee11-4945-822e-2130579d67a0"
      unitRef="U_USD">54000</pali:ChangesInFairValueOfContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0ac0e42c-71fc-4569-afd4-fccf25d6e52e"
      decimals="-5"
      id="F_504e3831-68a0-48b5-a050-e568bc9534f1"
      unitRef="U_USD">200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts
      contextRef="C_0ac0e42c-71fc-4569-afd4-fccf25d6e52e"
      decimals="-5"
      id="F_88f535f6-91ce-4b9e-bea4-a37955050411"
      unitRef="U_USD">100000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_f3aab31d-1085-44a6-848c-14e1390b99a0"
      id="F_2e8a53f2-7acc-41ad-bc05-da13cce0a819">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the activity of the Company&#x2019;s Level 3 liability-classified warrants during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.093%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.763%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_1b2b7036-6d4a-4dda-b9b5-3fef242b5750"
      decimals="-3"
      id="F_159087a5-f387-4827-8996-5ea92f60256a"
      unitRef="U_USD">2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_f4816ad5-6544-4cc3-8edc-993c725f05ae"
      decimals="-3"
      id="F_5ced32ea-bb7d-4f90-8df8-d5416b574049"
      unitRef="U_USD">61000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_feec2dcc-5780-4073-a999-74c92a2f28c7"
      decimals="-3"
      id="F_f9ed4c70-8a90-4d17-9146-43ebd9f94319"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_790040b9-b57e-4116-8804-a4572f9ba17c"
      decimals="-3"
      id="F_3d131b78-46ae-413d-acaf-b94b40065832"
      unitRef="U_USD">59000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_9f691187-dbba-46aa-957f-8451263e8080"
      decimals="-3"
      id="F_32916db6-0ecb-4b86-ab4d-58ff95ac3416"
      unitRef="U_USD">2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_1b2b7036-6d4a-4dda-b9b5-3fef242b5750"
      decimals="-3"
      id="F_9163f382-fc85-40f2-8e1e-aef2f6a8b954"
      unitRef="U_USD">2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_8e07b59f-6ef1-4c33-b57b-1387f393aa01">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Classes of Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company was authorized to issue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;280,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value common stock. Each share of common stock entitles the holder thereof to one vote on each matter submitted to a vote at a meeting of stockholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 5, 2024, the Company effected the Reverse Stock Split. Accordingly, the Company&#x2019;s stockholders received one share of the Company's common stock for every &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock that each stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all of the Company&#x2019;s issued and outstanding shares of the Company's common stock equally. The Reverse Stock Split also affected the Company&#x2019;s outstanding stock-based awards, warrants and other exercisable or convertible securities and resulted in the shares underlying such instruments being reduced and the exercise price or conversion price being increased proportionately by the Reverse Stock Split ratio. No fractional shares were issued as a result of the Reverse Stock Split with any fractional shares that would have otherwise resulted from the Reverse Stock Split paid in cash, at an amount equal to the resulting fractional interest in one share of the Company's common stock that the stockholder would otherwise be entitled, multiplied by the closing trading price of the Company's common stock on April 5, 2024. The amount of cash paid for fractional shares was immaterial to the Company's financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result of the Reverse Stock Split, on April 5, 2024 the number of issued and outstanding shares of the Company's common stock was adjusted from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,771,015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares to approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company was authorized to issue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value preferred stock of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares have been designated as Series A 4.5% Convertible Preferred Stock ("Series A Convertible Preferred Stock") and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of which are issued and outstanding&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company's Series A Convertible Preferred Stock issued in the amount of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; preferred stock shares is convertible into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Equity Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;December 2024 Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 12, 2024, the Company entered into an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) pursuant to which the Company agreed to issue and sell, in an underwritten public offering by the Company (the &#x201c;December 2024 Offering&#x201d;), (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Class A Units at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.525&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Class A Unit (the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Class &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A Units&#x201d;), with each Class A Unit consisting of (i) one share of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and (ii) one warrant to purchase one share of the Company's common stock at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of issuance &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;December 2024 Offering Common Stock Warrant&#x201d;) and (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,120,688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Class B Units at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5249&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Class B Unit (the &#x201c;Class B Units&#x201d;, and collectively with the Class A Units, the &#x201c;Units&#x201d;), with each Class B Unit consisting of (i) one pre-funded warrant to purchase one share of the Company's common stock &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;being immediately exercisable, having an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and a perpetual term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;December 2024 Offering Pre-funded Common Stock Warrant&#x201d;) and (ii) one December 2024 Offering Common Stock Warrant. In addition, pursuant to the Underwriting Agreement, the Company granted the sole underwriter a 45-day option (the &#x201c;Overallotment Option&#x201d;) to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491,803&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional shares of the Company's common stock and/or December 2024 Offering Common Stock Warrants. The Overallotment Option expired and was not exercised by the underwriter.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued warrants to representatives of the sole underwriter in the December 2024 Offering to purchase an aggregate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196,721&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the &#x201c;December 2024 Representative Warrants&#x201d;). The December 2024 Representative Warrants have substantially the same terms as the December 2024 Offering Common Stock Warrants, except that the exercise price of each of the December 2024 Representative Warrants is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.51625&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The fair value of the December 2024 Offering Common Stock Warrants was recognized by the Company as an equity issuance cost which reduced the additional paid-in capital recognized from the December 2024 Offering.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The December 2024 Offering closed on December 13, 2024 for net cash proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, consisting of gross cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million less cash equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which excludes the grant date fair value of the December 2024 Representative Warrants of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the incremental fair value of the Repriced Warrants of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, described below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 12, 2024, the Company entered into a warrant amendment agreement (the &#x201c;Warrant Amendment Agreement&#x201d;) whereby the Company, contemporaneously with and contingent with the closing of the December 2024 Offering, reduced the exercise price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,040,217&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; outstanding common stock warrants (the &#x201c;Repriced Warrants&#x201d;) held by an investor that participated in the December 2024 Offering which expire between July 31, 2027 and May 6, 2031. The Repriced Warrants had their exercise price reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Other than the reduction in exercise price, the terms of the Repriced Warrants remain the same and unchanged.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Warrant Amendment Agreement is considered a modification of the Repriced Warrants under the guidance of ASC 815-40. The modification is consistent with the Equity Issuance classification under that guidance as the reason for the Company's repricing of the warrants was to meet a condition of the holder's participation in the December 2024 Offering, which raised equity capital and generated gross cash proceeds for the Company of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As pursuant to the guidance of ASC 480 and ASC 815 the Repriced Warrants were classified as equity instruments before and after the modification, and as the modification is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as an equity issuance cost netted against the additional paid-in capital recognized in the December 2024 Offering. The amount of the equity issuance cost recognized for the modification of the Repriced Warrants was determined using the Black-Scholes option pricing model as the incremental fair value of the Repriced Warrants as compared to the fair value of the warrants immediately prior to their modification.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;May 2024 Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 1, 2024, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company sold in a private placement, (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a purchase price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,142&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants to purchase shares common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5014&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant, with such pre-funded warrants being immediately exercisable, having an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and a perpetual term, and (iii) common stock warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;922,863&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.314&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of issuance (the "May 2024 Warrants") (collectively, the &#x201c;May 2024 Offering&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued warrants to the placement agent in the May 2024 Offering to purchase an aggregate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,914&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the &#x201c;May 2024 Placement Agent Warrants&#x201d;). The May 2024 Placement Agent Warrants have substantially the same terms as the May 2024 Warrants, except that the exercise price of each of the May 2024 Placement Agent Warrants is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.727&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and the term is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from issuance. The fair value of the May 2024 Placement Agent Warrants was recognized by the Company as an equity issuance cost which reduced the additional paid-in capital recognized from the May 2024 Offering.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The May 2024 Offering closed on May 6, 2024 for net cash proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, consisting of gross cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million less cash equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which excludes the grant date fair value of the May 2024 Placement Agent Warrants of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Recent Equity Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 11, 2023, the Company completed a registered direct offering of common stock (the "September 2023 Offering"). Gross cash proceeds from the September 2023 Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and net cash proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting cash equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 3, 2023, the Company completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "April 2023 Offering"). Gross cash proceeds from the April 2023 Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and net cash proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting cash equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 4, 2023, the Company completed a registered direct offering and concurrent private placement of common stock and warrants to purchase common stock (the "January 2023 Offering"). Gross cash proceeds from the January 2023 Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and net cash proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million after deducting cash equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants and Warrant Exercises&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;February 2024 Warrant Inducement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 30, 2024, the Company entered into warrant inducement agreements (the &#x201c;Warrant Inducement Agreements&#x201d;) with certain accredited and institutional holders (collectively, the &#x201c;Warrant Holders&#x201d;) of certain of the Company&#x2019;s remaining outstanding common stock warrants issued on May 10, 2022 (the "May 2022 Warrants"), January 4, 2023 (the &#x201c;January 2023 Warrants&#x201d;), and April 5, 2023 (the &#x201c;April 2023 Warrants&#x201d;), as well as certain outstanding Series 2 warrants issued on August 16, 2022 (the "Series 2 Warrants") (collectively, the &#x201c;Existing Warrant(s)&#x201d;). Pursuant to the Warrant Inducement Agreements, the exercise price of each of the Existing Warrants exercised was reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.97&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Each of the Warrant Holders that exercised its Existing Warrants pursuant to the Warrant Inducement Agreements, received one replacement warrant to purchase one share of the Company's common stock (the &#x201c;Replacement Warrants&#x201d;) for each Existing Warrant exercised (in its entirety, the "February 2024 Warrant Inducement").&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Replacement Warrants are exercisable immediately, have an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.97&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of issuance, which was February 1, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Warrant Holders collectively exercised an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,162&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Existing Warrants consisting of: (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,865&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; May 2022 Warrants, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,267&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series 2 Warrants, (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,511&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; January 2023 Warrants, and (iv) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151,519&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; April 2023 Warrants. As a result of the exercises of the Existing Warrants, the Company issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,162&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,162&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Replacement Warrants. The February 2024 Warrant Inducement closed on February 1, 2024 with the Company receiving net cash proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million consisting of gross cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, less cash equity issuance costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The February 2024 Warrant Inducement, which resulted in the lowering of the exercise price of the Existing Warrants and the issuance of the Replacement Warrants, is considered a modification of the Existing Warrants under the guidance of ASC 815-40. The modification is consistent with the Equity Issuance classification under that guidance as the reason for the modification was to induce the holders of the Existing Warrants to cash exercise their Existing Warrants, resulting in the imminent exercise of the Existing Warrants, which raised equity capital and generated gross cash proceeds for the Company of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As pursuant to the guidance of ASC 480 and ASC 815 the Existing Warrants and Replacement Warrants were classified as equity instruments before and after the modification, and as the modification is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as an equity issuance cost netted against the additional paid-in capital recognized from the associated warrant exercises. The amount of the equity issuance cost recognized for the warrant modification was determined using the Black-Scholes option pricing model as the incremental fair value of the modified Existing Warrants and additional Replacement Warrants issued as compared to the fair value of the original Existing Warrants immediately prior to their modification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The solicitation agent fees associated with the February 2024 Warrant Inducement consisted of: (i) a cash fee equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds received by the Company, (ii) a common stock purchase warrant to purchase such number of shares of common stock equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number shares issued pursuant to the exercise of the Existing Warrants, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.97&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from issuance (the "Solicitation Agent Warrants"), and (iii) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of out-of-pocket expenses. The fair value of the Solicitation Agent Warrants was recognized by the Company as an equity issuance cost, which reduced the additional paid-in capital recognized from the issuance of common stock in connection with the exercise of the Existing Warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total equity issuance costs recognized in the February 2024 Warrant Inducement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million include cash equity issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, non-cash warrant modification costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and non-cash issuance costs associated with the Solicitation Agent Warrants of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants Outstanding and Warrant Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for the majority of its warrants as equity-classified in accordance with ASC 480 and ASC 815. The Company&#x2019;s outstanding common stock warrants that are classified as equity warrants are included as a component of stockholders' equity based on their relative fair value on their date of issuance. Common stock warrants accounted for as liabilities in accordance with the authoritative accounting guidance are included in noncurrent liabilities. The Company had exercisable common stock warrants outstanding of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,745,213&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,211&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company's outstanding and exercisable common stock warrants as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.996%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.378%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.858%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Warrants Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining &lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2024 Offering Pre-Funded Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,027,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Perpetual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2024 Offering Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,278,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.95&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2024 Offering Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;922,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.34&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;February 2024 Warrant Inducement Replacement Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;August 2024 Offering Series 2 Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.61&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Bridge, January 2021, and July 2021 Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liability-Classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Placement Agent, Solicitor and Representative Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All Other Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,418.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Warrants Outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,745,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; have a perpetual&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term and are therefore excluded from the calculation of the weighted average remaining contractual life.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Of the outstanding common stock warrants, only the Series 2 Warrants include a down round feature whereby they are subject to price reset provisions in the event future sales of the Company's securities are sold at a price per share less than the exercise price of such warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes all common stock warrant activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.951%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining &lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,327,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,854,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, expired or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,438.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,745,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company received gross cash proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, from exercises of common stock warrants. Of the gross cash proceeds received for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to common stock warrants exercised on December 30, 2022 for which the related cash exercise price was receivable to the Company as of December 31, 2022. The related cash payment was received by the Company in January 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_59519464-92fc-4892-8f05-4cf71d1c707e"
      unitRef="U_shares">280000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_3ae5201a-e226-4703-bc50-132111b6cccc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e786d4a3-2e6a-4337-8144-697692254d24"
      decimals="INF"
      id="F_addcf986-1b62-43d8-8e3f-b45cee5468ba"
      unitRef="U_shares">15</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_d5ec44e5-acfe-425d-94c1-cba3b6c5a935"
      decimals="INF"
      id="F_3e9edd90-0835-4974-80a1-e80ec5db5112"
      unitRef="U_shares">12771015</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_795c51ad-a42a-4991-8de6-80e768ef9af0"
      decimals="INF"
      id="F_3e52580a-4297-4af7-9131-442e3a8dde27"
      unitRef="U_shares">851302</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="INF"
      id="F_c2b7a7f2-5d47-42bc-8eed-ab0081d85cee"
      unitRef="U_shares">7000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_53120144-37f7-483b-a872-d0f02ddccfbf"
      decimals="INF"
      id="F_521e4455-2234-4d69-8fb7-f17ba7c28c6c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_53120144-37f7-483b-a872-d0f02ddccfbf"
      decimals="INF"
      id="F_8882c8ce-3562-4162-b026-dd365ae0a229"
      unitRef="U_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="INF"
      id="F_26246b3a-a5e0-4adb-97d0-222610ecae88"
      unitRef="U_shares">200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="INF"
      id="F_13197b82-1763-4f3c-a811-a83cc0716c0d"
      unitRef="U_shares">200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_b47952f8-e25d-4791-a542-4d8bd701e282"
      decimals="INF"
      id="F_3d350595-bd04-4603-b351-493804b81ffe"
      unitRef="U_shares">200000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <pali:ConvertiblePreferredStockIssuableUponConversionOfAllShares
      contextRef="C_53120144-37f7-483b-a872-d0f02ddccfbf"
      decimals="INF"
      id="F_4b7ce4b0-108d-426e-ae69-6d51c5a14fc6"
      unitRef="U_shares">8</pali:ConvertiblePreferredStockIssuableUponConversionOfAllShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_99e41a4e-a74b-43bc-991a-d6f51c9aeaa2"
      decimals="INF"
      id="F_95aaad5e-ce2d-4608-9a05-942afa1b7444"
      unitRef="U_shares">158000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pali:UnderwritingCommitmentsPerShare
      contextRef="C_73bb4959-69c7-4db1-8a36-8a4200ea4201"
      decimals="3"
      id="F_eac46836-476a-4669-bad9-5acaf53182d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.525</pali:UnderwritingCommitmentsPerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_73bb4959-69c7-4db1-8a36-8a4200ea4201"
      decimals="2"
      id="F_d3d5f012-da94-42e8-b7aa-ddbb416659b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc"
      decimals="2"
      id="F_633a99bc-1f63-48cc-a105-c9d561d79123"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc"
      id="F_ad84bb19-e661-461d-9cfa-131d4f76dd2c">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e55e3216-27d9-421d-a685-8982258e7fbb"
      decimals="INF"
      id="F_f55af14e-93ad-4678-81eb-f5cb76b0be85"
      unitRef="U_shares">3120688</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pali:UnderwritingCommitmentsPerShare
      contextRef="C_a6268737-830c-4d22-b51b-e3c071317b8f"
      decimals="4"
      id="F_09c008b8-c6fc-414f-bd3c-4557146c9ac0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.5249</pali:UnderwritingCommitmentsPerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0cf6a60b-d394-429d-82ae-cbe7825fb226"
      decimals="4"
      id="F_48b79baf-c14d-49e9-b613-772030e39969"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue
      contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc"
      decimals="0"
      id="F_24bcd83e-ec20-4085-8bb9-2d8bacbd925d"
      unitRef="U_shares">491803</us-gaap:OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_62ab2513-fad0-4e00-a1e4-b9d017af34dc"
      decimals="0"
      id="F_eee3af78-242a-40ca-88ec-129453860c6e"
      unitRef="U_shares">196721</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_bd03d751-b219-4043-84ae-de9c81d5698b"
      decimals="5"
      id="F_32f11677-b86f-4d7c-b31f-a8f1ecc4bb45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.51625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pali:NetProceeds
      contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c"
      decimals="-5"
      id="F_df619007-3097-47fe-b517-7081145e5f58"
      unitRef="U_USD">4100000</pali:NetProceeds>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c"
      decimals="-5"
      id="F_627dcbd8-2148-478e-a6da-2c7f459e8b03"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c"
      decimals="-5"
      id="F_88526896-564d-47aa-8958-1c99632cf508"
      unitRef="U_USD">900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:GrantDateFairValue
      contextRef="C_5f66a802-eff0-4fee-9465-2edf3990258c"
      decimals="-5"
      id="F_0575f091-de41-44bc-acba-e5f5c565853e"
      unitRef="U_USD">300000</pali:GrantDateFairValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_3ec4089f-24f1-40c5-a1ee-41580353eddb"
      decimals="-5"
      id="F_d6ee885b-bcd9-4da6-9a53-6ae957346a92"
      unitRef="U_USD">300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_12a10425-82c0-439c-a876-125097f2fbf7"
      decimals="0"
      id="F_af9763e3-bf9a-4b6a-a63c-6e41fa0166cb"
      unitRef="U_shares">1040217</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_12a10425-82c0-439c-a876-125097f2fbf7"
      decimals="2"
      id="F_6ffc1606-fe43-4a6e-8005-3db960a76caa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_dca63de9-3d4a-4b50-a74f-1090217fcb16"
      decimals="-5"
      id="F_2668e041-3139-4854-a9da-4db3dff9f298"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_dca63de9-3d4a-4b50-a74f-1090217fcb16"
      decimals="-5"
      id="F_2026b67d-9267-4adc-b25b-5df3b43b8933"
      unitRef="U_USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_b74d1b57-b99f-46a7-91d3-48efac8c1858"
      decimals="INF"
      id="F_94cb2b5c-d0c8-4ed4-aeec-26a651cd683d"
      unitRef="U_shares">85100</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_bd447e9d-307f-412a-8859-7e1a2091a009"
      decimals="4"
      id="F_d35e12af-b6d0-4c10-abc1-634eee5c51d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.5015</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_70ce8c11-9f45-440b-9b1d-6046060ca1af"
      decimals="0"
      id="F_9ba99dab-c6f1-46f0-a15e-eb43202c17c1"
      unitRef="U_shares">530142</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_70ce8c11-9f45-440b-9b1d-6046060ca1af"
      decimals="4"
      id="F_86dbef33-94d6-4b70-a1c2-675659a5c911"
      unitRef="U_shares">6.5014</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_70ce8c11-9f45-440b-9b1d-6046060ca1af"
      decimals="4"
      id="F_1fd6f657-3fae-4995-ba77-46fbdf311d46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034"
      decimals="0"
      id="F_2d754505-6049-4739-ba2d-11cc6bab7901"
      unitRef="U_shares">922863</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034"
      decimals="3"
      id="F_ddca2c95-a231-405f-8b4d-7d5bbbf90456"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.314</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_5e97bc3a-3cff-41d7-9b58-8a8e8aba3034"
      id="F_1ecc043f-21a6-4d4d-b4f7-39dbc629c3a8">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_6ffb0979-629b-4688-a29a-73f1f89ce426"
      decimals="0"
      id="F_1002229d-fa7b-4b1d-bcc6-331f4ead75ed"
      unitRef="U_shares">36914</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6ffb0979-629b-4688-a29a-73f1f89ce426"
      decimals="3"
      id="F_5515117b-42bf-4092-8ce2-02f3e2781d26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.727</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_6ffb0979-629b-4688-a29a-73f1f89ce426"
      id="F_fe08b489-48e6-4a59-aef8-14c99e9f7407">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pali:NetProceeds
      contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7"
      decimals="-5"
      id="F_0257e0ed-65ec-49f2-bed1-699243310fe0"
      unitRef="U_USD">3500000</pali:NetProceeds>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7"
      decimals="-5"
      id="F_4a73486e-801d-4d1c-9a99-9f657f496212"
      unitRef="U_USD">4000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7"
      decimals="-5"
      id="F_56a133fe-9756-48ce-80c0-4e7fb5ee7363"
      unitRef="U_USD">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:GrantDateFairValue
      contextRef="C_0d1eb655-c370-425c-8e10-3bf6703f37a7"
      decimals="-5"
      id="F_f36e300b-cab6-4725-ac1b-5dda33f3fc6d"
      unitRef="U_USD">200000</pali:GrantDateFairValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316"
      decimals="-5"
      id="F_84df41a9-8a51-42b0-8832-f9b72e56846c"
      unitRef="U_USD">2000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pali:NetProceeds
      contextRef="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316"
      decimals="-5"
      id="F_fdd559c8-a862-4289-93fe-a0755a339936"
      unitRef="U_USD">1700000</pali:NetProceeds>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_8f1fea76-aaf2-45d9-bb9d-33cb535ce316"
      decimals="-5"
      id="F_271f3b0d-e609-4abd-a265-8fdaf7bfabb2"
      unitRef="U_USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b957477c-5568-4340-967f-f75d2478e99a"
      decimals="-5"
      id="F_a31780ec-e11a-4018-9532-7c861c480c4b"
      unitRef="U_USD">6000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pali:NetProceeds
      contextRef="C_b957477c-5568-4340-967f-f75d2478e99a"
      decimals="-5"
      id="F_b1c19ae0-7535-4ced-9e86-434ac1f9f634"
      unitRef="U_USD">5300000</pali:NetProceeds>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_b957477c-5568-4340-967f-f75d2478e99a"
      decimals="-5"
      id="F_acf35c24-c5ee-4488-98e1-06f5a514b63c"
      unitRef="U_USD">700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_989d323e-90bd-4bc1-84ab-7e972e39245f"
      decimals="-5"
      id="F_d399a4f0-0dec-4b97-9387-95cfe2a6d08e"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pali:NetProceeds
      contextRef="C_989d323e-90bd-4bc1-84ab-7e972e39245f"
      decimals="-5"
      id="F_2c96e0fb-2e34-445c-aa5b-b94b0994a65f"
      unitRef="U_USD">2200000</pali:NetProceeds>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_989d323e-90bd-4bc1-84ab-7e972e39245f"
      decimals="-5"
      id="F_ea1a0a05-afea-41ca-b705-a932e2da310c"
      unitRef="U_USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af"
      decimals="2"
      id="F_e7aaa184-c4e2-40fd-b8b0-952525464c73"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_73c82250-26a7-4e8c-bbde-5150f68a53ca"
      decimals="2"
      id="F_fb1864cf-6166-44ba-830d-25e5699854d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_73c82250-26a7-4e8c-bbde-5150f68a53ca"
      id="F_9bd635da-391d-444b-a3dd-17e9710d2f97">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af"
      decimals="INF"
      id="F_8940bc5b-418e-4c58-8ed4-b8a2cde35bbd"
      unitRef="U_shares">228162</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_d8e2d363-b0b1-4013-b25f-43acf427f165"
      decimals="0"
      id="F_f3828a93-9fca-448f-b929-ef2d7663d749"
      unitRef="U_shares">4865</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f15cfeb5-6c1f-45a8-9c16-b9c0acc83ad6"
      decimals="INF"
      id="F_94867da9-80f1-47a1-8b77-37b6cca61f81"
      unitRef="U_shares">4267</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_96ce46ae-4e1d-4e12-9e91-5be0b6992fac"
      decimals="0"
      id="F_0faf7322-b831-4523-acb4-b884d5666607"
      unitRef="U_shares">67511</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_691877b9-f2f5-489e-a81b-02e81e212a3a"
      decimals="0"
      id="F_18c6df85-9eb0-46fa-a37b-22e59cf0aa74"
      unitRef="U_shares">151519</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_9c8530f2-bfc4-4a66-b8b2-3b673f0b32af"
      decimals="0"
      id="F_f8b13515-fede-4a91-b21c-a87ac6e6176a"
      unitRef="U_shares">228162</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5b7ce63d-492e-48d6-b155-482c37907109"
      decimals="0"
      id="F_6b6dfeb1-3aca-42c7-9139-c7f8dbad6988"
      unitRef="U_shares">228162</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <pali:NetProceedsFromIssuanceOfWarrants
      contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe"
      decimals="-5"
      id="F_e45e5f54-6db2-4e82-970e-5e04f5ad6624"
      unitRef="U_USD">2200000</pali:NetProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe"
      decimals="-5"
      id="F_439f37e3-c375-4b7c-8101-7ecd290803c5"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <pali:CashTransactionRelatedExpensesAndPlacementAgentFees
      contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe"
      decimals="-5"
      id="F_222827bc-bf27-457d-86ca-94e9f7d7e0c3"
      unitRef="U_USD">300000</pali:CashTransactionRelatedExpensesAndPlacementAgentFees>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe"
      decimals="-5"
      id="F_ac34b450-0544-428e-b02c-cf1c2279e437"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_a3def67a-3ec7-42f4-a8f9-4bdec444e5fe"
      decimals="-5"
      id="F_64b69d22-57d8-4546-9ac4-45fd5c7a4d16"
      unitRef="U_USD">2000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:PercentageOfGrossProceeds
      contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368"
      decimals="4"
      id="F_160aca49-3ee4-41bd-ad53-4a2e100282b8"
      unitRef="U_pure">0.0775</pali:PercentageOfGrossProceeds>
    <pali:PercentageOfShareIssued
      contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368"
      decimals="2"
      id="F_e1a6a76d-309d-4176-880f-d75e85ca01c4"
      unitRef="U_pure">0.06</pali:PercentageOfShareIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368"
      decimals="2"
      id="F_56e17f7f-ab62-4946-91c6-ab2f7bc07d7a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368"
      id="F_1a238553-7104-4bdd-aa52-0e9ac15f4e45">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pali:OutOfPocketExpenses
      contextRef="C_210c21f0-b090-4433-b5b4-a390a090d368"
      decimals="0"
      id="F_f037a281-113f-4ae9-848f-c61be9abd05a"
      unitRef="U_USD">35000</pali:OutOfPocketExpenses>
    <pali:WarrantsIssuanceCosts
      contextRef="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4"
      decimals="-5"
      id="F_c56ffc7c-0267-4ca2-9fcc-b2cc9e2fd58e"
      unitRef="U_USD">2400000</pali:WarrantsIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4"
      decimals="-5"
      id="F_5dab8dcd-6265-4311-b329-97a837b0c629"
      unitRef="U_USD">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <pali:NonCashWarrantModificationCosts
      contextRef="C_75f17b60-e75f-432e-9f05-53f0b0abcbf4"
      decimals="-5"
      id="F_1fe505ea-7339-4817-99f0-35e53d84b273"
      unitRef="U_USD">2000000</pali:NonCashWarrantModificationCosts>
    <pali:NonCashWarrantIssuanceCosts
      contextRef="C_bb50a5e7-6ed1-4053-bfca-ab15e7b28b4a"
      decimals="-5"
      id="F_3054accd-27f5-48bf-a46f-12504eb2fd5a"
      unitRef="U_USD">100000</pali:NonCashWarrantIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_9f118624-032d-4aed-bc63-5e27c54b1ef9"
      unitRef="U_USD">6745213</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="INF"
      id="F_96960af5-d08d-4d5f-ba57-0402cc61f68a"
      unitRef="U_USD">272211</us-gaap:WarrantsAndRightsOutstanding>
    <pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_cc453878-97a5-47fe-8420-3bd3affec9a2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company's outstanding and exercisable common stock warrants as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.996%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.378%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.858%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Warrants Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining &lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2024 Offering Pre-Funded Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,027,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Perpetual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2024 Offering Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,278,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.95&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2024 Offering Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;922,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.34&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;February 2024 Warrant Inducement Replacement Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;August 2024 Offering Series 2 Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.61&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Bridge, January 2021, and July 2021 Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liability-Classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Placement Agent, Solicitor and Representative Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;All Other Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity-classified&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,418.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Warrants Outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,745,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; have a perpetual&lt;/span&gt;</pali:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_582ecc46-b417-4c17-b3ac-7494c5aa8bda"
      decimals="0"
      id="F_dd0c4b53-7a85-4a53-a366-d9108cc44e1f"
      unitRef="U_shares">2027000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_582ecc46-b417-4c17-b3ac-7494c5aa8bda"
      decimals="4"
      id="F_bf0ed02d-55a5-4395-82d6-5b7becba0452"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_33afec80-d974-4667-ab99-82569d37d0b0"
      decimals="0"
      id="F_41e9dac7-cc54-4dad-abf3-297d037f97d8"
      unitRef="U_shares">3278688</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_33afec80-d974-4667-ab99-82569d37d0b0"
      decimals="2"
      id="F_2dcdc856-bb6d-4f26-b7ec-c563ad5630e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_a0bdf278-32cb-4874-b9d5-b39d0aa6c3f9"
      id="F_9e837514-6b53-4df4-bb85-723e1ee50a09">P4Y11M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_25437a64-b804-49d4-a583-6149701ed82e"
      decimals="0"
      id="F_7e614b42-396a-4f33-937d-ee665b64fbd0"
      unitRef="U_shares">922863</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_25437a64-b804-49d4-a583-6149701ed82e"
      decimals="2"
      id="F_042ee2e4-56b4-4586-bec7-c10c06c7444f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_d36c00ce-2fa2-47f1-a66c-21a67e4857fa"
      id="F_ff14bc21-ab4c-416c-a645-d88ebdec895c">P6Y4M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_32effecb-dcdb-418d-b9ab-602e1ecc9121"
      decimals="0"
      id="F_3c1e494b-e318-4250-bf30-24c2bec1e739"
      unitRef="U_shares">228158</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_32effecb-dcdb-418d-b9ab-602e1ecc9121"
      decimals="2"
      id="F_81acae0b-163b-40d6-98b5-ade6b938c3bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_e3a8e347-dc37-40b0-851c-4ceba3d07be3"
      id="F_1b7a59b4-b791-4c2d-8599-0843d1196d35">P4Y1M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f4c47b93-0a6c-459a-94b1-6b86830d25bc"
      decimals="0"
      id="F_64a98d7d-ea7c-4cb0-bc99-4bab828674cf"
      unitRef="U_shares">6748</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f4c47b93-0a6c-459a-94b1-6b86830d25bc"
      decimals="2"
      id="F_a0ce1c17-0f14-48ef-9864-b68ddcf996f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_ad71c156-c72e-4679-bf89-118f467d7baf"
      id="F_6de3b4a4-5d07-4eee-9d4d-3a29cec9e4fb">P2Y7M9D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_66aae2c0-5abe-49b9-befa-ef1108555742"
      decimals="0"
      id="F_c2f40080-58f3-45e9-84cb-6b944bceb420"
      unitRef="U_shares">1144</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_66aae2c0-5abe-49b9-befa-ef1108555742"
      decimals="2"
      id="F_0c9a58de-0f64-4067-8862-5cf4f10424d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">58.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_f399e54c-6ccd-4ae9-97a2-1db3bdc4468e"
      id="F_c81d39cd-c6d7-4eac-b95b-6f1c846d523c">P1Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_9c81c8a6-3ae0-4c51-b74d-11500c011143"
      decimals="0"
      id="F_400ba99e-c1c8-4878-a46b-10bf1c493420"
      unitRef="U_shares">274693</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9c81c8a6-3ae0-4c51-b74d-11500c011143"
      decimals="2"
      id="F_6f8fcfa5-2324-4316-a697-b383f3628396"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_ffa661a6-473a-4c79-8a7f-48832923f5d9"
      id="F_12ecdb56-2a73-446b-aef4-cc06566edc03">P4Y7M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_dd1ca615-f781-4979-a8ac-e2d5b4aab50b"
      decimals="0"
      id="F_03aaceff-407c-4b3d-8d56-1541f5d99b65"
      unitRef="U_shares">5919</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_dd1ca615-f781-4979-a8ac-e2d5b4aab50b"
      decimals="2"
      id="F_5e16f367-7179-4a42-85db-83e310217400"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3418.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_24d8c3be-2445-4bb1-aa0d-5f552876a8bb"
      id="F_674693eb-13dd-4467-a338-f954f18ba1b4">P1Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="0"
      id="F_0190b23d-8df3-4c80-9a8d-d863afd3dc7c"
      unitRef="U_shares">6745213</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="2"
      id="F_e17dc50e-fb87-4771-bb28-42b133ce3025"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_9ec4bd57-f51b-4896-87de-7ea6b3c54805">P5Y1M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_09379391-a5e1-4afb-b622-6440ed5dd9ed">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes all common stock warrant activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.951%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining &lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,327,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,854,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, expired or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,438.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants outstanding, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,745,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-5.159pt;white-space:pre-wrap;font-size:7.37pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <pali:ClassOfWarrantOrRightNumberOutstanding
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="0"
      id="F_e662b12e-ee2a-447f-8987-696ca8e9900e"
      unitRef="U_shares">272211</pali:ClassOfWarrantOrRightNumberOutstanding>
    <pali:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="2"
      id="F_2588f178-5583-45af-a6b8-509d42a461d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">144.78</pali:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
    <pali:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      id="F_7fefb8c8-215f-48d8-84bb-41f1fd07427e">P4Y1M13D</pali:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife>
    <pali:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_de0ee860-249f-4ea5-a15f-2253e20d2e60"
      unitRef="U_shares">8327864</pali:ClassOfWarrantOrRightIssuedDuringPeriod>
    <pali:ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_af472992-0b5c-4fd7-8629-5a80bacda3e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.68</pali:ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice>
    <pali:ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_5632091e-04bc-4913-8599-b692f8c15eb4">P5Y3M7D</pali:ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife>
    <pali:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_fcfc352c-cade-499c-ae94-a59c64e51ef8"
      unitRef="U_shares">1854658</pali:ClassOfWarrantOrRightExercisedDuringPeriod>
    <pali:ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_4a529532-6700-47e2-9b18-4637c31fa2ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.35</pali:ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice>
    <pali:ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_bd6baa0f-1351-4e11-842f-84053a5bfe74"
      unitRef="U_shares">204</pali:ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod>
    <pali:ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_3ca973bd-2de5-417e-ba0c-fa1bac70a96d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17438.12</pali:ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice>
    <pali:ClassOfWarrantOrRightNumberOutstanding
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="0"
      id="F_93846c07-d6b2-4f83-a4ae-e0b232e0b38d"
      unitRef="U_shares">6745213</pali:ClassOfWarrantOrRightNumberOutstanding>
    <pali:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_578d8f4a-3f98-4fcb-b04c-47dfd425f18e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.53</pali:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
    <pali:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_fce4d946-4eaa-49bf-bf56-389a9c946b62">P5Y1M28D</pali:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_39580d8d-37fd-4134-8e15-fc3336a39dd1"
      decimals="-5"
      id="F_e9667c40-20bf-4a9c-ac7b-33986e331e02"
      unitRef="U_USD">2500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_04026d27-31da-458f-9340-63004096eee6"
      decimals="-5"
      id="F_6d91f189-398c-4f2d-8218-e38f1c91ffc8"
      unitRef="U_USD">2800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pali:NetProceeds
      contextRef="C_04026d27-31da-458f-9340-63004096eee6"
      decimals="-5"
      id="F_d1707ec6-6c77-4203-a85f-3a8e4e5c67de"
      unitRef="U_USD">1400000</pali:NetProceeds>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_a9738ce2-b1f0-4e42-87a7-6995179bb3f9">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2013, LBS adopted the 2013 Employee, Director, and Consultant Equity Incentive Plan, (as amended and restated, the &#x201c;2013 Plan&#x201d;). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; further awards will be made under the 2013 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2021, the Company&#x2019;s shareholders approved the Palisade Bio, Inc. 2021 Equity Incentive Plan (the &#x201c;2021 EIP&#x201d;). As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,586&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s of the Company's common stock reserved for future issuance as equity-based awards under the 2021 EIP, which excludes the subsequent evergreen share increase in the number of shares of common stock reserved for issuance under the 2021 EIP that occurred on January 1, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Also in April 2021, the Company's shareholder approved the ESPP. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All employees are eligible to participate in the 2021 ESPP while employed by the Company. The 2021 ESPP permits eligible employees to purchase common stock through payroll deductions, which may not exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in a calendar year or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's shares of common stock each offering period, as defined in the 2021 ESPP, at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair value of the Company's common stock at the beginning or end of the offering period, whichever is lower. The 2021 ESPP is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; intended to qualify under Section 423 of the Internal Revenue Code. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,501&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock issued under the 2021 ESPP. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,086&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock reserved for future issuance under the 2021 ESPP, which excludes the subsequent evergreen share increases in the number of shares of common stock reserved for future issuance under the 2021 ESPP that occurred on January 1, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compensation expense associated with the 2021 ESPP for the year ended December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2021, the Company's compensation committee of the Company's Board of Directors ("Board") adopted the Palisade Bio, Inc. 2021 Inducement Award Plan (the "2021 Inducement Plan"). The 2021 Inducement Plan was adopted in order to grant equity-based awards to individuals not previously employed by the Company, as an inducement to join the Company. On August 7, 2023, the Company's compensation committee of the Board approved an increase in the shares of the Company's common stock authorized and available for issuance to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,666&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,941&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock reserved for future issuance as equity-based awards under the 2021 Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company believes that stock options align the interests of its employees and directors with the interests of its stockholders. Stock option awards are generally granted with an exercise price equal to the market price of Company&#x2019;s stock at the date the grants are awarded and a term as determined by the Company's Board but generally not to exceed ten-years. Stock option awards to employees vest in equal proportions each quarter over three years and stock option awards to directors of the Company's Board cliff vest after a period of one year. Vesting could be accelerated in the event of retirement, disability, or death of a participant, or change in control of the Company, as defined in the individual stock option agreements or employment agreements. Stock-based awards are valued as of the measurement date, which is the grant date, and are generally amortized on a straight-line basis over the requisite vesting period for all awards. The Company's equity incentive plans allow for the issuance of both incentive stock options and non-statutory stock options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of options granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023 is estimated as of the grant date using the Black-Scholes option pricing model using the assumptions in the following table:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average exercise price per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expected volatility. Due to the Company&#x2019;s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biopharmaceutical industry.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expected term. The expected term represents the period of time that options are expected to be outstanding. As the Company does not have sufficient historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity and related information under the 2013 Plan, the 2021 EIP and the 2021 Inducement Plan for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, expired or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;335.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;349.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted during the years ended December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share an&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, re&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;spectively. The grant date fair value of the options vested during each the years ended December 31, 2024 and December 31, 2023 was approximatel&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;y $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, the Company granted no RSUs. As of December 31, 2024, there were no RSUs that remained outstanding.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;following table summarizes RSU activity and related information under the 2021 EIP and the 2021 Inducement Plan for the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.17&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The grant date fair value of the RSUs vested during the years ended December 31, 2024 and December 31, 2023 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in each year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Performance Based Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 6, 2023, the Company granted to certain members of management a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,580&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; market-based PSUs, which &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;vest (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% when the volume weighted average price of the Company&#x2019;s common stock over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consecutive trading days is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or greater ("vesting Tranche 1"), and (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% when such volume weighted average price of the Company&#x2019;s common stock over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consecutive trading days is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or greater ("vesting Tranche 2").&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The PSUs were conditional subject to shareholder approval, which such approval was received at the Company's annual shareholder meeting held on June 8, 2023. The fair value of each of the market-based vesting tranches of the PSUs was determined using a Monte Carlo simulation model that considered a variety of potential share prices for the Company's common stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of vesting Tranche 1 and vesting Tranche 2 of the PSUs was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per award share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per award share, respectively, and was determined using the following key assumptions: (i) a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, (ii) expected stock price volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, (iii) a cost of equity of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, and (iv) an expected contractual life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9.66&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. As shareholder approval of the PSUs was received, the Company is recognizing the share-based compensation expense associated with the PSUs ratably over the derived service period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years for vesting Tranche 1 and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.48&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years for vesting Tranche 2, regardless of whether the market condition for vesting is satisfied. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,144&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; PSUs remained unvested and outstanding. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the PSUs vested during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;year ended December 31, 2024 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; PSUs were forfeited during the year. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; PSUs remain unvested and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The allocation of stock-based compensation for all stock option, RSU and PSU awards is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To reduce the ongoing administrative burden and expense associated with the quarterly vesting of the Company's time-based RSUs, on May 28, 2024, the Company's Board approved the immediate accelerated vesting of all unvested time-based RSUs issued to employees that were outstanding as of that date. The accelerated vesting was accounted for as a Type I modification under ASC 718 and accordingly, in the second quarter of 2024 the Company recognized share-based compensation expense associated with the time-based RSUs subject to immediate vesting of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in general and administrative expenses and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the unrecognized compensation expense related to outstanding options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.49&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; there is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unrecognized compensation expense related to outstanding service-based RSUs as there are no outstanding non-vested service-based RSUs as of that date and the unrecognized compensation expense related to outstanding PSUs is immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cee46443-8d64-412f-b41e-41a2367bf1f3"
      decimals="0"
      id="F_45f3b02f-facb-41c5-ba43-753b56e9a9ef"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b898e598-304f-4ea7-864c-b785cdbc5739"
      decimals="0"
      id="F_bcb30b57-5050-42d4-a1dd-a451bca5a37a"
      unitRef="U_shares">37586</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d"
      decimals="INF"
      id="F_937c0d00-bb1b-49c4-9799-19bd2e22b057"
      unitRef="U_USD">25000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d"
      decimals="INF"
      id="F_ea71ff99-1451-4f72-8991-c7a5c2a657cd"
      unitRef="U_shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_d8dc99f2-3fe8-4cd5-89d8-5a185a95870d"
      decimals="2"
      id="F_6fbeea50-79ba-4624-83dc-b1b9af3b2a20"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_800199c1-afa8-43b6-9911-358e1907566a"
      decimals="0"
      id="F_8d1c98ad-5e8d-488b-9768-bf0e27cc53cb"
      unitRef="U_shares">4501</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0ce6c868-1e07-4b9e-ac58-05460a42652b"
      decimals="0"
      id="F_d143dac6-b80d-4f58-98a7-c39ebd57e2b5"
      unitRef="U_shares">19086</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="C_800199c1-afa8-43b6-9911-358e1907566a"
      decimals="-3"
      id="F_4f1edbb4-45e0-4f7a-9dad-c2b6f782d6eb"
      unitRef="U_USD">19000000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
      contextRef="C_98ae9a8f-1e7d-4c2d-ba28-e6b7c8ca5a22"
      decimals="-3"
      id="F_15efd55f-2ce2-4553-92e5-81ad143a70d4"
      unitRef="U_USD">18000000</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_9a5cce76-d0fc-4cb9-bb7b-be35e5885dd3"
      decimals="0"
      id="F_5115c726-8bb5-43ff-b68d-2dcc65d08948"
      unitRef="U_shares">66666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6b08194e-e220-4a67-9b3b-b24bf7d2dc89"
      decimals="0"
      id="F_cfb327f4-761c-4e28-ba28-c56e89460059"
      unitRef="U_shares">52941</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_9784eb55-14f8-4d60-8064-2efcd8a21a4d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of options granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023 is estimated as of the grant date using the Black-Scholes option pricing model using the assumptions in the following table:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average exercise price per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_7ee1027a-0b05-41fe-aa13-c39f0bd7f26d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="2"
      id="F_8fef615c-114b-415d-a8bb-3267134fa1e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_3a6ea49e-50da-4f35-ac48-6f9f98267dde">P5Y7M24D</pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm>
    <pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      id="F_44525c56-8c82-466d-b4a4-3b0430126ecc">P5Y7M28D</pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm>
    <pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="4"
      id="F_7be465a9-d3aa-4d40-ac89-1cd361a1c2c1"
      unitRef="U_pure">0.0403</pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate>
    <pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="4"
      id="F_93fe61b6-5193-47cb-be07-1d80665a4ce2"
      unitRef="U_pure">0.0408</pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_f89c6d84-2538-4481-b7d2-64bcd67997d5"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_8aff0d27-c77d-4903-b7ad-96a4caa2a1ac"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="4"
      id="F_b076f003-ca31-4150-bae6-10fd7fb18339"
      unitRef="U_pure">1.1174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="4"
      id="F_597c5443-4288-4444-863b-9a7979273704"
      unitRef="U_pure">0.7835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c9b82888-659c-4bb7-9f49-95b857a11751">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity and related information under the 2013 Plan, the 2021 EIP and the 2021 Inducement Plan for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited, expired or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;335.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;349.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="INF"
      id="F_25f930e6-5aea-456f-8327-67d7baa76097"
      unitRef="U_shares">44276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="2"
      id="F_311ffa6e-0a2f-4cdf-a628-9314e6ac2461"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">233.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      id="F_ccea63ef-0442-456b-9f40-1a5b23ee0881">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_c165d07e-cbc0-4131-a7be-7e05944ae3d0"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="INF"
      id="F_e5d6cca5-e6ce-4225-b88b-4d7c77dcc55d"
      unitRef="U_shares">12300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_3af02d65-1f42-4aaa-9d26-6f88217d0b73"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_cb84b657-f82c-4942-ad81-b385e8776bfe"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="INF"
      id="F_0bbb2e6f-845c-4c57-bdb6-0ed929b54cb6"
      unitRef="U_shares">5902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_f1ce8015-6fc4-4916-bd8b-06370f8a70d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">335.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_2461fab6-5b9c-4de5-87d1-e7aaf3843d20"
      unitRef="U_shares">50674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="2"
      id="F_540126a6-f376-4f8c-affc-8628e4da85db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">166.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_1f692d69-0f53-489f-858a-bac8f04d4f5e">P8Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_03a2b54e-84ee-4d12-80b1-085b5593cad2"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_a376aa1a-405b-4494-93b9-773ada73cc06"
      unitRef="U_shares">50674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="2"
      id="F_a94918c9-5f2f-4ce2-89fc-1a2956995336"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">166.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_32a8cabf-db86-4568-adde-5530f471db71">P8Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_5cb399f2-76ed-480f-a436-8018c69001e6"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="INF"
      id="F_0ad108d9-70a2-4d25-b638-e230d271879f"
      unitRef="U_shares">22825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="2"
      id="F_de78ad50-656a-4652-b4a2-384496ccf42e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">349.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_0485a5e9-f5c6-471a-9fda-69a0291e388f">P8Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_9ed20538-e4cd-42a0-a27c-8550ca7bb242"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_b371ce1e-92ac-45e5-b426-4f38bf28d2d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="2"
      id="F_56845edd-114d-4ea4-8057-0cef1bea202e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-5"
      id="F_39bf1e1a-8fd4-4fed-a2f6-81127e3719f0"
      unitRef="U_USD">400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-5"
      id="F_1b646d00-1fb0-48e3-8d20-ddbf7f72b29b"
      unitRef="U_USD">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_214f272c-c0b6-448a-b339-26a9e4044a9a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;following table summarizes RSU activity and related information under the 2021 EIP and the 2021 Inducement Plan for the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.700000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;Restricted&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Remaining Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.17&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_8645eaec-898b-48e4-befe-b013c00071ad"
      decimals="0"
      id="F_ddd82bbf-bb36-4d05-b55c-704cef9af499"
      unitRef="U_shares">24195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_8645eaec-898b-48e4-befe-b013c00071ad"
      decimals="2"
      id="F_6eae4294-d36f-4141-a479-e5c3b492b308"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_1e5799eb-2dde-4495-859d-82b3ce5341eb"
      id="F_34d0167a-a96a-4677-adfb-27e63a6e8ccc">P2Y2M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca"
      decimals="0"
      id="F_8612c889-ffb6-4c23-90c1-78b83e51b253"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca"
      decimals="0"
      id="F_0b81b094-df24-4364-8d82-4f01cebf88c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca"
      decimals="0"
      id="F_13cb5498-996c-4519-93f3-1ed85343c232"
      unitRef="U_shares">23067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca"
      decimals="2"
      id="F_7df9a70a-7f55-4192-b4e5-eb0746fea843"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca"
      decimals="0"
      id="F_af43076f-aa25-449c-8ac8-b50f41210674"
      unitRef="U_shares">1128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_064f0da6-66e3-4594-9a33-dd0538609aca"
      decimals="2"
      id="F_e62d44d9-2bca-49da-8baa-5630709e6e04"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_22d62b69-795d-4d94-914a-263cdadcd8a8"
      decimals="0"
      id="F_378a933c-fbcd-4740-b3c2-943386544c8c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_22d62b69-795d-4d94-914a-263cdadcd8a8"
      decimals="0"
      id="F_66b6cf63-009f-47ce-957b-3a82e313aee0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_57444f7a-2496-4f31-9eac-285e8dbbc2a7"
      decimals="-5"
      id="F_4bff12f3-899b-4ca5-b8c9-bdffc053b454"
      unitRef="U_USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_12dc02fb-eac4-4610-bad8-fe8e9ad4d610"
      decimals="-5"
      id="F_52974fb4-8255-49dc-bdfd-1d8c64bc8509"
      unitRef="U_USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_2007472e-785f-4e66-8b90-31974e6c2d75"
      decimals="0"
      id="F_dee227d5-845b-41dd-97f8-c03e944724dc"
      unitRef="U_shares">4580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_7b587e1b-52d0-4b29-b97d-1630d7f21d83"
      decimals="2"
      id="F_d4a55480-c460-4958-91e2-4b7d94fdf1a7"
      unitRef="U_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <pali:NumberOfTradingDays
      contextRef="C_7b587e1b-52d0-4b29-b97d-1630d7f21d83"
      decimals="0"
      id="F_6c607b7f-1bfc-4f84-b26a-332993f65c95"
      unitRef="U_Days">20</pali:NumberOfTradingDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_11a397d8-f76e-4123-8ffc-90b0d4bba3ea"
      decimals="2"
      id="F_57faa40d-6bc8-4e77-924e-b0b86fd98c67"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_7bdff01b-c6cb-4014-8bf2-6623ec18a56e"
      decimals="2"
      id="F_fc121055-8aba-4e0c-8afc-f9b10eaf1ac8"
      unitRef="U_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <pali:NumberOfTradingDays
      contextRef="C_7bdff01b-c6cb-4014-8bf2-6623ec18a56e"
      decimals="0"
      id="F_368fed1f-eae7-44e6-a6b4-8d80b1b755ae"
      unitRef="U_Days">20</pali:NumberOfTradingDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_5be85942-60b4-4ca7-b41c-6a7af1aea32f"
      decimals="2"
      id="F_b5c5a70a-f84e-4fa4-ba7d-698c0d022919"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">63.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_89ee88e7-ca37-400a-8b0f-b936d897aea2"
      decimals="2"
      id="F_15cb966f-8627-41bd-b3e0-b2000508c560"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2a44715d-6d67-4a8c-9146-cda1c95f1181"
      decimals="2"
      id="F_eb453445-6f29-4bb7-8f72-2660ff29ea6d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2"
      decimals="4"
      id="F_a1e8946e-c81e-4fc0-839b-2e03525db794"
      unitRef="U_pure">0.0374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2"
      decimals="3"
      id="F_e3804927-baa5-44d1-b5a9-f13fa21fd370"
      unitRef="U_pure">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity
      contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2"
      decimals="4"
      id="F_94400bb7-fb56-4487-9e13-530e6b5a869e"
      unitRef="U_pure">0.2799</pali:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquity>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2"
      id="F_1674dd2d-a5c2-4351-8642-fc99cfd62536">P9Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_89ee88e7-ca37-400a-8b0f-b936d897aea2"
      id="F_471efafe-b7fa-4fad-98eb-b68bac8569e7">P1Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_2a44715d-6d67-4a8c-9146-cda1c95f1181"
      id="F_b749601d-1063-43db-8a95-95cf64699f90">P2Y5M23D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_0e9b1aec-3b94-4255-8d2d-686c1a773637"
      decimals="0"
      id="F_fe31b0f8-2c19-4e45-90fb-ca7d7719918c"
      unitRef="U_shares">4144</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2"
      decimals="0"
      id="F_6ecf61cd-cdcf-4b6a-a843-6edc62b0c32c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_bc157d16-357e-4df0-8664-94e2436271d2"
      decimals="0"
      id="F_b71d9a2c-b43e-4d73-a7be-54b9b33e1d5b"
      unitRef="U_shares">1192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_9c3eea55-6dac-475a-8dd9-570c44c3ad63"
      decimals="0"
      id="F_bd92dde5-b2f3-46dd-a7dc-6b8ab12f467d"
      unitRef="U_shares">2952</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_b109db76-19b6-414c-b28f-b8d01b461cd7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The allocation of stock-based compensation for all stock option, RSU and PSU awards is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_39cecd10-468f-4aba-9f46-454343174b91"
      decimals="-3"
      id="F_c03d4685-4516-462a-b6ae-69f400d61f05"
      unitRef="U_USD">263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4d65b8a8-159b-4e62-9b59-1b4091249817"
      decimals="-3"
      id="F_336c842e-ddc4-4966-bdc2-da078d19fc70"
      unitRef="U_USD">240000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_da789c28-414e-4ccd-947d-5e1f11d5ee32"
      decimals="-3"
      id="F_1fc4e04c-9fe1-4d5e-8114-5e04a12fd3f8"
      unitRef="U_USD">370000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5c1b7f20-1f1a-46c6-b1ce-e72714e8e6c0"
      decimals="-3"
      id="F_efd3a784-7851-4296-a94b-8f2b032c4a41"
      unitRef="U_USD">366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_418c6e4d-3080-4693-9d88-06af3d2c8262"
      unitRef="U_USD">633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_316d9936-7839-4077-86a4-fefdbf633f11"
      unitRef="U_USD">606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a24647e4-47f9-4d57-a123-b33e432c6857"
      decimals="0"
      id="F_d1583e3c-ff07-48b4-b407-3e85bf2ce3da"
      unitRef="U_USD">129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8b845079-c037-4485-9046-bc648460b149"
      decimals="0"
      id="F_1cd04c02-c815-4e83-9204-a1f30d4dd2f5"
      unitRef="U_USD">125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-5"
      id="F_d47d3949-18bd-4ccb-8dcc-b35e2ed2122b"
      unitRef="U_USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_a67da61f-4a18-4bf1-98db-891cb6dfb90a">P1Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_b326ac9a-3edc-4669-a12a-a44223068a1d"
      decimals="-6"
      id="F_bcdce0a9-9a91-4b96-80cf-3456e4d311d8"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <pali:LicenseAgreementsTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c6107b13-2e9f-4bd2-8de2-10a997b5c4dc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Collaborations and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research Collaboration and License Agreement with Giiant&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 1, 2023, the Company entered into the Giiant License Agreement whereby the Company received an exclusive, worldwide license (with the right to sublicense in multiple tiers) to develop, manufacture, and commercialize substantially all of the assets of Giiant, including: (i) the PALI-2108 compound, and (ii) the PALI-1908 compound and the associated intellectual property around each of the foregoing (the &#x201c;Giiant Licensed Assets&#x201d;). The Giiant License Agreement has a perpetual term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Giiant License Agreement, the Company and Giiant established a joint development committee (&#x201c;JDC&#x201d;), consisting of one Giiant appointee and two Company appointees. The JDC will be responsible for: (i)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;overseeing the day-to-day development of the Giiant Licensed Assets through Proof of Concept (as defined below), and (ii) creation and implementation of the development plan and development budget for such development (the &#x201c;Giiant Development Plan&#x201d;) and any amendments or updates thereto.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to receiving regulatory approval to commence a Phase 1 clinical trial (as such term is defined in the Giiant License Agreement) (the &#x201c;Proof of Concept&#x201d;), each of the Company and Giiant was solely responsible for all costs and expenses incurred by such party for the joint development of the Giiant Licensed Assets, except as set forth in the Giiant Development Plan. Prior to reaching the Proof of Concept, the Company reimbursed or advanced Giiant up to an amount in the low seven-digit range for costs and expenses incurred by them. Upon reaching the Proof of Concept, which occurred in October of 2024, the Company became solely responsible for all costs and expenses incurred for the development, manufacturing, regulatory and commercialization of the Giiant Licensed Assets. For the years ended December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized expenses related to the joint development plan with Giiant in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which are included in research and development expenses in the consolidated statements of operations. The Company recognized no reductions to its joint development expenses for payments from Giiant for either the years ended December 31, 2024 or December 31, 2023. At December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company accrued joint development expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, in Accrued liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Giiant License Agreement, as amended (see below), the Company will (i) make certain payments between the mid six-digit range and low seven-digit range upon the achievement of development milestones, as defined in the Giiant License Agreement, in either cash or shares of the Company&#x2019;s common stock, at the Company&#x2019;s election (&#x201c; Giiant Milestone Payments&#x201d;), and (ii) pay ongoing royalty payments of a mid-single-digit percentage of the adjusted gross proceeds, as defined in the Giiant License Agreement, upon the sales or sublicenses of any products developed from the Giiant Licensed Assets to third parties (&#x201c;Giiant Royalty Payments&#x201d;) (collectively, the Giiant Milestone Payments and the Giiant Royalty Payments are referred to as the &#x201c;Giiant License Payments&#x201d;). The Giiant License Payments are subject to a maximum payment cap in the very low eight-digit range, which will be increased or decreased on a dollar-for-dollar basis based on a formula related to the aggregate of development costs incurred by the parties (&#x201c;Payment Cap&#x201d;). The Company has made no Giiant License Payments since the commencement of the Giiant License Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 2, 2024, the Company and Giiant entered into an amendment to the Giiant License Agreement (the "Giiant License Agreement Amendment"). Pursuant to the Giiant License Agreement Amendment, the Company agreed to increase the amount it would reimburse or advance to Giiant prior to Proof of Concept under the Giiant Development Plan by an amount in the mid six-digit range. After taking into account such increase, the amount that Company will reimburse or advance Giiant for costs and expenses incurred by them will remain in the low seven-digit range. As consideration for the increase, Giiant agreed to (i) a reduction in the Giiant Milestone Payments that would be due to them upon the achievement of certain development milestones, and (ii) a decrease to the Payment Cap applied to future Giiant License Payments, as set forth in the original Giiant License Agreement. The amount of the reduction in the Giiant Milestone Payment as a result of the Giiant License Agreement Amendment is in the high six-digit range and the decrease in the Payment Cap is in the mid-six digit range. There were no other changes to the terms of the original Giiant License Agreement as a result of the Giiant License Agreement Amendment that would have a material impact on the Company's results of operations, financial position or future cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event that Giiant desires to sell or assign any rights to receive the Giiant License Payments, they will be required to notify the Company of such offer or proposal (&#x201c;Offer Notice&#x201d;). The Company will then have a right of first refusal for thirty days from the receipt of such Offer Notice, to acquire the rights and obligations contained in such Offer Notice on the same terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may unilaterally terminate the Giiant License Agreement for: (i) convenience, or (ii) a material breach by Giiant, that is not cured within the applicable notice period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Giiant may unilaterally terminate the Giiant License Agreement only for a material breach by Company that is not cured within the applicable notice period provided however that upon the Payment Cap being achieved, that right will terminate and the Giiant License Agreement will become perpetual.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Co-Development and Distribution Agreement with Newsoara&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;LBS entered into a co-development and distribution agreement with Newsoara, a joint venture established with Biolead Medical Technology Limited, as amended, (the &#x201c;Newsoara Co-Development Agreement&#x201d;). Pursuant to the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Newsoara Co-Development Agreement (and subsequent assignment agreement), LBS granted or licensed Newsoara an exclusive right under certain patents to develop, use, sell, offer to sell, import, and otherwise commercialize licensed products (the &#x201c;Newsoara Licensed Products&#x201d;) for any and all indications in the People&#x2019;s Republic of China, including the regions of Hong Kong and Macao, but excluding Taiwan (the &#x201c;Territory&#x201d;). The Newsoara Licensed Products only include the drug asset referred to as LB1148. The right includes the right to grant sublicenses to third parties, subject to LBS&#x2019; written consent, provided that both parties agreed that Newsoara would be permitted to use a certain partner for development purposes. The Newsoara Co-Development Agreement obligates Newsoara to initially use LBS as the exclusive supplier for all Newsoara&#x2019;s requirements for Newsoara Licensed Products in the Territory. During the term of the Newsoara Co-Development Agreement, Newsoara may request to manufacture the Newsoara Licensed Products in the Territory, subject to satisfying certain conditions to LBS' reasonable satisfaction. LBS is obligated to approve Newsoara manufacturing rights without undue refusal or delay. The Company records the expense reimbursements from Newsoara for any research and development or manufacturing activities it performs under the Newsoara Co-Development Agreement as a reduction to research and development expenses once the reimbursement amount is approved for payment by Newsoara.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In consideration of the rights granted to Newsoara under the Newsoara Co-Development Agreement, Newsoara paid LBS a one-time upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In addition, Newsoara is obligated to make (i) payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the aggregate upon achievement of certain regulatory and commercial milestones, (ii) payments in the low six-digit range per licensed product upon achievement of a regulatory milestone, and (iii) tiered royalty payments ranging from the mid-single-digit to low-double-digit percentage range on annual net sales of Licensed Products, subject to adjustment to the royalty percentage in certain events, including a change of control, the expiration of certain patents rights, and royalties paid by Newsoara third parties. To date, Newsoara has met all of its payment obligations under the Newsoara Co-Development Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company recognized license revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million earned upon Newsoara's achievement of a development milestone under the Newsoara Co-Development Agreement during the first quarter of 2023. During the year ended&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; December 31, 2024, the Company recognized no license revenue from Newsoara under the Newsoara Co-Development Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Newsoara Co-Development Agreement will expire upon the expiration date of the last valid claim of any licensed patent covering the Newsoara Licensed Products in the Territory. In addition, the Newsoara Co-Development Agreement can be terminated (i) by either party for the other party&#x2019;s material breach that remains uncured for a specified time period after written notice or for events related to the other party&#x2019;s insolvency, (ii) by LBS if Newsoara challenges or attempts to interfere with any licensed patent rights and, (iii) by Newsoara for any reason upon specified prior written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreements with the Regents of the University of California&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; license agreements, as amended, with the Regents of the University of California (&#x201c;Regents&#x201d;) for exclusive commercial rights to certain patents, technology and know-how related to LB1148. Concurrent with the Company's decision to terminate the development of LB1148, on October 20, 2023 the Company terminated &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of its license agreements with Regents. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the only license agreement remaining with Regents is that entered into with LBS in August 2015, as amended in December 2019 and September 2022 (the &#x201c;2015 UC License&#x201d;). The 2015 UC License was retained for the sole purpose of maintaining the Newsoara Co-Development Agreement under which the Company may receive future milestone or royalty payments through the term of the license. Accordingly, pursuant to the 2015 UC License, the Company is obligated to pay a percentage of non-royalty licensing revenue it receives from Newsoara under the Newsoara Co-Development Agreement to Regents &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; percent to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; percent of one-third of the upfront payment and milestone payments received from Newsoara. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in sublicense f&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ees and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in license maintenance fees due to Regents in research and development expenses in the consolidated statements of operations. During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; sublicense fees and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in license maintenance fees due to Regents recognized in research and development expenses in the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2015 UC License will expire upon the expiration date of the longest-lived patent right licensed under the 2015 UC License. The Regents may terminate the 2015 UC License if: (i) a material breach by the Company is not cured within 60 days, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable, &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(iii) the Company files for bankruptcy. The Company also has the right to terminate the 2015 UC License at any time upon at least 90 days&#x2019; written notice.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contingent Value Right&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Immediately prior to the closing of the Merger, Seneca issued each share of its common stock held by Seneca stockholders of record, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; contingent value right (&#x201c;CVR&#x201d;). The CVR entitled the holder (the &#x201c;CVR Holder&#x201d;) to receive, pro rata with the other CVR Holders, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the net proceeds, if any and subject to certain minimum distribution limitations (&#x201c;CVR Payment Amount&#x201d;), received from the sale or licensing of the intellectual property owned, licensed or controlled by Seneca immediately prior to the closing of the Merger (the &#x201c;Legacy Technology&#x201d;); provided however that the CVR Holders are only entitled to receive such CVR Payment Amount if the sale or licensing of such Legacy Technology occurred on or before October 27, 2022 (&#x201c;Legacy Monetization&#x201d;). Pursuant to the terms of the CVR agreement (&#x201c;CVR Agreement&#x201d;), CVR Holders are only entitled to receive CVR Payment Amounts received within 48-months following the closing of the Merger. The CVR Agreement also provides that no distributions will be made to the CVR Holders in the event such distribution is less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;NSI-189 &#x2013; Exclusive License and Subsequent Exercise of Purchase Option&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to the Merger, Seneca exclusively licensed certain patents and technologies, including a sublicense covering a synthetic intermediate, of the Company's NSI-189 assets (&#x201c;189 License&#x201d;), along with a purchase option through December 16, 2023 (&#x201c;Purchase Option&#x201d;). On October 22, 2021, Alto Neuroscience ("Alto") agreed to terms of an early exercise of the Purchase Option under the 189 License and entered into an asset transfer agreement ("ATA"). Alto is a U.S. based public, clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the terms of the CVR Agreement, no distribution was required to be made to the CVR Holders as the CVR Payment Amount after deducting costs and expenses required to maintain the 189 License was less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In accordance with the terms of the CVR Agreement, the net proceeds from the sale of the NSI-189 assets, less any applicable transaction costs and expenses, were deposited into the CVR escrow to be used to pay costs and expenses associated with the monetization of the Company's other Legacy Technologies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, Alto will be required to pay the Company up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of certain development and regulatory approval milestones for NSI-189 (or a product containing or otherwise derived from NSI-189), which is now known as ALTO-100. If Alto sells or grants to a third party a license to the patents and other rights specific to ALTO-100 prior to the achievement of a specified clinical development milestone, Alto will be required to pay to the Company a low-double digit percentage of any consideration received by Alto from such license or sale, provided that the maximum aggregate consideration Alto will be required to pay to the Company under the ATA, including the upfront payment and all potential milestones and transaction-related payments, will not exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 22, 2024, Alto announced that its Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint. Notwithstanding, ALTO-100 is being evaluated as an adjunctive treatment in a Phase 2b study in bipolar depression with topline data expected in 2026. Upon the enrollment of a patient in a Phase 3 clinical trial of ALTO-100, if it occurs, a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will be due from Alto under the ATA. If this occurs within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-months of the closing of the Merger, the CVR Holders will be entitled to a CVR Payment Amount, with the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the net proceeds deposited into the CVR escrow. If the milestone is met after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-months of the closing of the Merger, all the net proceeds will be paid to the Company. There can be no assurance that CVR holders will receive CVR Payment Amounts from the sale of the NSI-189 assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;NSI-532.IGF-1&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 27, 2022, the Company entered an agreement to license NSI-532.IGF-1 to the Regents of the University of Michigan ("University of Michigan") for maintaining NSI-532.IGF-1 cell lines, continued development, maintaining patent protection, and seeking licensees. The Company received &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; upfront fees for the license. NSI-532.IGF-1 is a preclinical cell therapy being investigated as a potential therapy for prevention and treatment of Alzheimer&#x2019;s disease. The University of Michigan shall bear &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the costs for patent filing, prosecution, maintenance, and enforcement of the patent rights. The Company will receive &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of net revenues received by the University of Michigan from the licensing of patent rights through the last-to-expire patent in patent rights, unless otherwise earlier terminated, less all reasonable and actual out-of-pocket costs incurred in the litigation of patent rights.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;can be no assurance that NSI-532.IGF-1 will ever be successfully monetized or that CVR holders will receive CVR Payment Amounts from the sale of the NSI-532.IGF-1 assets.&lt;/span&gt;&lt;/p&gt;</pali:LicenseAgreementsTextBlock>
    <pali:JointDevelopmentExpenses
      contextRef="C_39cecd10-468f-4aba-9f46-454343174b91"
      decimals="-5"
      id="F_dd1037bd-4717-4258-8b5b-68ea99e11280"
      unitRef="U_USD">4300000</pali:JointDevelopmentExpenses>
    <pali:JointDevelopmentExpenses
      contextRef="C_4d65b8a8-159b-4e62-9b59-1b4091249817"
      decimals="-5"
      id="F_36c3fc6e-6267-4ce4-9e1d-60958e022e5c"
      unitRef="U_USD">700000</pali:JointDevelopmentExpenses>
    <pali:AccruedJointDevelopmentExpenses
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-5"
      id="F_9569355f-bba7-4d2e-b127-74193974dd24"
      unitRef="U_USD">200000</pali:AccruedJointDevelopmentExpenses>
    <pali:AccruedJointDevelopmentExpenses
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-5"
      id="F_6cb97864-03e9-40fd-86a4-db0531fc2b52"
      unitRef="U_USD">100000</pali:AccruedJointDevelopmentExpenses>
    <pali:CollaborationsAndLicenseAgreementsUpfrontFee
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-5"
      id="F_936beec2-5d07-4423-bf8c-1d66b2099a5b"
      unitRef="U_USD">1000000</pali:CollaborationsAndLicenseAgreementsUpfrontFee>
    <us-gaap:RoyaltyExpense
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-4"
      id="F_7769262c-2d65-48f7-ae91-3cac9d77dd2b"
      unitRef="U_USD">6750000</us-gaap:RoyaltyExpense>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-5"
      id="F_549ab71c-8024-48ad-a63b-dea3976b47b5"
      unitRef="U_USD">300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <pali:NumberOfLicenseAgreements
      contextRef="C_339a2504-3ac9-410d-8ca6-961361ccd1aa"
      decimals="0"
      id="F_e442f8de-e8fb-43bc-97d0-c0bd9f798d69"
      unitRef="U_Agreement">3</pali:NumberOfLicenseAgreements>
    <pali:NumberOfTerminatedLicenseAgreements
      contextRef="C_16734ac9-5f7d-4564-bb8b-aff2052903ed"
      decimals="0"
      id="F_3b8504d9-0c05-450b-a1c7-43e599e9cf55"
      unitRef="U_Agreement">2</pali:NumberOfTerminatedLicenseAgreements>
    <pali:RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived
      contextRef="C_e42cccf2-0558-4a1d-8434-967432a7ef50"
      decimals="2"
      id="F_fe3f1eff-1068-48eb-ba63-e2639ce017e7"
      unitRef="U_pure">0.30</pali:RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived>
    <pali:RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived
      contextRef="C_a049a491-7334-498c-b8d3-99fbfcde6601"
      decimals="2"
      id="F_ab17b162-bbe6-4d5a-ab13-f75f304f2d36"
      unitRef="U_pure">0.35</pali:RoyaltyRatePortionOfSublicenseIncomeToBePaidPercentageOfOneThirdOfUpfrontPaymentAndMilestonePaymentReceived>
    <pali:SublicenseFees
      contextRef="C_386963f7-adcd-4589-ad1e-18c92d7f72e4"
      decimals="0"
      id="F_9193d1b6-ae7f-411c-9755-0c1e715774f6"
      unitRef="U_USD">25000</pali:SublicenseFees>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_1daf9a02-8b5d-48fd-8804-9977e84acb12"
      decimals="0"
      id="F_9229e331-fc53-45e5-a0ba-e8ebfeec5076"
      unitRef="U_USD">21000</us-gaap:AccruedRoyaltiesCurrent>
    <pali:SublicenseFees
      contextRef="C_065287e3-70be-4640-bc93-2e29518133d5"
      decimals="INF"
      id="F_83769c52-5263-4d95-abf3-317ae83a4206"
      unitRef="U_USD">0</pali:SublicenseFees>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_d0f8faa6-225c-4d7d-8f77-da0c5084bd1b"
      decimals="0"
      id="F_5d79c9a6-2209-42fb-8eec-17f79cbb31b5"
      unitRef="U_USD">16000</us-gaap:AccruedRoyaltiesCurrent>
    <pali:PeriodOfExpirationOfLicenseAgreementDescription
      contextRef="C_e678878a-0c3f-4ca9-be27-f1041b0e7025"
      id="F_aeb5b586-47c1-4a33-a266-ffa2dc30a990">The 2015 UC License will expire upon the expiration date of the longest-lived patent right licensed under the 2015 UC License. The Regents may terminate the 2015 UC License if: (i) a material breach by the Company is not cured within 60 days, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable, or (iii) the Company files for bankruptcy. The Company also has the right to terminate the 2015 UC License at any time upon at least 90 days&#x2019; written notice.</pali:PeriodOfExpirationOfLicenseAgreementDescription>
    <pali:ClassOfWarrantOrRightNumberOfRightsIssued
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="0"
      id="F_fa7e605b-85cf-4e2b-ba33-4d67aa7d7c71"
      unitRef="U_shares">1</pali:ClassOfWarrantOrRightNumberOfRightsIssued>
    <pali:ContingentValueRightProRataNetProceedsFromSaleOrLicensing
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_7933ed09-2ba2-4c4e-90dd-060a6a45304d"
      unitRef="U_pure">0.80</pali:ContingentValueRightProRataNetProceedsFromSaleOrLicensing>
    <pali:CvrAgreementDistributionMinimumAmount
      contextRef="C_ad8d582e-2dde-4db3-8d6f-4a779f360888"
      decimals="-5"
      id="F_e394543c-2483-4091-b41f-583c31ce762c"
      unitRef="U_USD">300000</pali:CvrAgreementDistributionMinimumAmount>
    <pali:CvrAgreementDistributionMinimumAmount
      contextRef="C_b1540c36-2dc4-4c82-81de-598e5062281b"
      decimals="-5"
      id="F_e4b523ca-7730-463b-aac0-0e089d407779"
      unitRef="U_USD">300000</pali:CvrAgreementDistributionMinimumAmount>
    <us-gaap:RoyaltyExpense
      contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6"
      decimals="-5"
      id="F_6c3a55f1-e87d-4f1d-a307-d54ce66e5ebc"
      unitRef="U_USD">4500000</us-gaap:RoyaltyExpense>
    <pali:MaximumAggregateConsideration
      contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6"
      decimals="-5"
      id="F_f5b0b785-beed-4c48-a985-a8061064aeab"
      unitRef="U_USD">5000000</pali:MaximumAggregateConsideration>
    <pali:MilestonePayments
      contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6"
      decimals="-5"
      id="F_e78ea50a-a86e-4a52-9841-5fdfea616625"
      unitRef="U_USD">1500000</pali:MilestonePayments>
    <pali:ClosingPeriodOfMergerAgreement
      contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6"
      id="F_01594f2f-a77e-43db-a3d7-caf6a36e766e">P48M</pali:ClosingPeriodOfMergerAgreement>
    <pali:ProceedsDepositedIntoTheCvrEscrow
      contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6"
      decimals="2"
      id="F_1aa642d2-b234-4664-997f-f352ef169444"
      unitRef="U_pure">0.20</pali:ProceedsDepositedIntoTheCvrEscrow>
    <pali:ClosingPeriodOfMergerAgreement
      contextRef="C_9c31b2dd-531d-464b-9a92-f5f7289500d6"
      id="F_b96497a0-30fc-4be6-97ed-eaf21014a63f">P48M</pali:ClosingPeriodOfMergerAgreement>
    <pali:CollaborationsAndLicenseAgreementsUpfrontFee
      contextRef="C_1ea433f0-bf37-4d98-8e23-9f24084ab798"
      decimals="-3"
      id="F_9ab67cf0-d0b9-4808-a40b-77e7b46027ac"
      unitRef="U_USD">0</pali:CollaborationsAndLicenseAgreementsUpfrontFee>
    <pali:PercentageCostInPatentRight
      contextRef="C_1ea433f0-bf37-4d98-8e23-9f24084ab798"
      decimals="2"
      id="F_0b23b213-cd0f-4902-9d4f-ed786a2ac6a5"
      unitRef="U_pure">1</pali:PercentageCostInPatentRight>
    <pali:PercentageOfNetRevenue
      contextRef="C_1ea433f0-bf37-4d98-8e23-9f24084ab798"
      decimals="2"
      id="F_2b5cc97f-338d-448a-8566-1f5424fe8eaf"
      unitRef="U_pure">0.50</pali:PercentageOfNetRevenue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_e4b9dcd4-edff-44af-9d87-d9bddd22826c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Corporate Office Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is party to a non-cancelable facility operating lease (the "Corporate Office Lease") of office space for its corporate headquarters in Carlsbad, California. The initial contractual term is for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;39-months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; commencing on June 1, 2022 and expiring on August 31, 2025. The Company has the option to renew the Corporate Office Lease for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period at the prevailing market rent upon completion of the initial lease term. The Company has determined it is not likely that it will exercise this renewal option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Corporate Office Lease is also subject to additional variable charges for common area maintenance, insurance, taxes and other operating costs. This additional variable rent expense is not estimable at lease inception. Therefore, it is excluded from the Company&#x2019;s straight-line expense calculation at lease inception and is expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized an operating right-of-use asset related to the Corporate Office Lease in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which included in Operating lease right-of-use asset in the consolidated balance sheets, and an operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all of which is included in Current portion of operating lease liability in the consolidated balance sheets. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the total remaining future minimum lease payments associated with the Corporate Office Lease of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including imputed interest of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; calculated using a discount rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, will be paid over the remaining lease term of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. Other than the remaining maturities of the operating lease liability due in 2025 related to Corporate Office Lease, as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 the Company has no maturities of operating lease liabilities in 2025 or thereafter.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized operating lease expense associated with its Corporate Office Lease of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Insurance Financing Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2024, the Company entered an agreement to finance insurance policies that renewed in May 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financing arrangement entered in June 2024 has a stated annual interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and is payable over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period with the first payment payable on June 30, 2024. The insurance financing arrangement is secured by the associated insurance policy. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the aggregate remaining balance under the Company's insurance financing arrangement was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and is included in Insurance financing debt in the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other than the remaining insurance financing arrangement payments due in 2025, as of December 31, 2024 the Company has no other minimum debt payments required in 2025 or thereafter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restructuring Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In order to better utilize the Company&#x2019;s resources on the implementation of its refocused business plans and corporate strategy, the Company committed to a cost-reduction plan on September 9, 2022 (the "2022 Cost-Reduction Plan") and a reduction-in-workforce on October 27, 2023 (the "2023 RIF"). The 2022 Cost-Reduction Plan consisted primarily of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% reduction in the Company's employee workforce to better align the Company&#x2019;s resources with its proposed business plan. The 2023 RIF &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consisted of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% reduction in the Company's employee workforce, specifically research and development employees that were no longer deemed critical for the Company&#x2019;s development of its lead drug candidate, PALI-2108.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; restructuring expenses related to either the 2022 Cost-Reduction Plan or the 2023 RIF for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024. For the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized restructuring costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with the 2023 RIF, consisting of severance and benefits payments pursuant to employment agreements and the execution of severance and release agreements. Total expenses related to the 2022 Cost-Reduction Plan and the 2023 RIF through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively The Company does not expect to incur any other significant costs associated with either the 2022 Cost-Reduction Plan or the 2023 RIF.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the change in the Company's accrued restructuring liabilities under both the 2022 Cost-Reduction Plan and the 2023 RIF, which consisted solely of employee compensation and benefits and is classified within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities in the consolidated balance sheets as of each year shown (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of the beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net accrual adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of the end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company through December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#x2019;s business.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_c88b6c40-1467-497e-aa09-abf945fe9976"
      id="F_1096e106-1661-4cb7-a389-e5df2c16b65c">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_c88b6c40-1467-497e-aa09-abf945fe9976"
      id="F_e1f85430-4252-473c-84bb-aee462114d35">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6"
      decimals="0"
      id="F_f012a590-4066-456b-85ad-fa5b4b076c7f"
      unitRef="U_USD">84000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6"
      decimals="0"
      id="F_dbb9c689-99c8-4121-b48f-595f20e69718"
      unitRef="U_USD">90000</us-gaap:OperatingLeaseLiabilityCurrent>
    <pali:OperatingLeasesFutureMinimumPayments
      contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6"
      decimals="0"
      id="F_d6c75990-4b20-4160-a2ab-6c4e52d3feb5"
      unitRef="U_USD">93000</pali:OperatingLeasesFutureMinimumPayments>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6"
      decimals="0"
      id="F_2be73ea4-6b68-4ad0-a7a5-366faaf99e61"
      unitRef="U_USD">3000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6"
      decimals="4"
      id="F_bb8b02b2-412b-4f42-962a-db1808e346a7"
      unitRef="U_pure">0.1075</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_e29fe4d7-3280-44e5-a3dd-933a5c132aa6"
      id="F_ee20d146-e551-4254-b2a8-29899865715c">P0Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_1647ede8-9b3a-4985-acc0-f4909695082f"
      decimals="0"
      id="F_cd3715fe-9c7a-4317-bf20-6c1133209cba"
      unitRef="U_USD">130000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_1ab29fa5-66c6-45ad-818c-b0bfb6693551"
      decimals="0"
      id="F_75981048-eca7-49c8-b4d9-b40187d816b1"
      unitRef="U_USD">130000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_0396c3a7-c3c7-4970-b67a-c7d717b609c7"
      decimals="4"
      id="F_8452ac77-593e-47ee-8fe0-3499800cdd17"
      unitRef="U_pure">0.0842</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="C_0396c3a7-c3c7-4970-b67a-c7d717b609c7"
      id="F_e5aa41ff-09a2-46fa-aaa8-5975a00cf98a">P9M</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_9e634a16-0f0c-47a0-b175-926c827758d4"
      decimals="-5"
      id="F_12c23808-8d39-42d2-a904-7f74fdf298fe"
      unitRef="U_USD">100000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_81df8d1c-b732-4f34-b1db-4b541732537e"
      decimals="-5"
      id="F_aa425be0-3122-4263-b9ed-541324bdc04e"
      unitRef="U_USD">200000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <pali:PercentageOfReductionInWorkForce
      contextRef="C_659e2af0-b6fd-4530-954e-5b638bb46b1b"
      decimals="2"
      id="F_cbf64205-79b8-432e-8c7d-72bd503f046f"
      unitRef="U_pure">0.20</pali:PercentageOfReductionInWorkForce>
    <pali:PercentageOfReductionInWorkForce
      contextRef="C_272eb503-8300-45b6-8c62-5bd2086f945b"
      decimals="2"
      id="F_1401972d-7d2c-4509-bf17-d5c1dd498e5d"
      unitRef="U_pure">0.25</pali:PercentageOfReductionInWorkForce>
    <us-gaap:RestructuringCosts
      contextRef="C_5b914c39-e156-49cc-b150-f585bc3b48b9"
      decimals="-6"
      id="F_00fd9403-cc29-48ab-8095-2962a351dcd1"
      unitRef="U_USD">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_456ae310-d956-4c7f-aca2-b537a393db0d"
      decimals="-5"
      id="F_b4782e65-0629-469a-9dd3-66f5a9bf6715"
      unitRef="U_USD">200000</us-gaap:RestructuringCosts>
    <us-gaap:DefinedBenefitPlanAdministrationExpenses
      contextRef="C_5affaffb-555c-4738-91d1-a014135e69c5"
      decimals="-5"
      id="F_4243943e-ae08-486b-b6f2-29d488a17e5e"
      unitRef="U_USD">400000</us-gaap:DefinedBenefitPlanAdministrationExpenses>
    <us-gaap:DefinedBenefitPlanAdministrationExpenses
      contextRef="C_5b914c39-e156-49cc-b150-f585bc3b48b9"
      decimals="-5"
      id="F_f099eaae-28d4-4c9e-af13-8fb8e2b7a973"
      unitRef="U_USD">200000</us-gaap:DefinedBenefitPlanAdministrationExpenses>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_4ed9ab60-2265-466c-875c-341057ab5340">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities in the consolidated balance sheets as of each year shown (in thousands): &lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of the beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net accrual adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of the end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_f195dede-dea4-46fb-83cc-2fef47ea0054"
      unitRef="U_USD">131000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="C_da8d1e22-6198-4ee8-9a66-e21c96cd53dd"
      decimals="-3"
      id="F_c7f1c25e-0041-40b9-8877-cfc3c1ddb1fd"
      unitRef="U_USD">180000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_b55bba93-f567-4ca4-8c4c-6457e860e764"
      unitRef="U_USD">-3000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_2e6eddbb-3f63-458e-b198-a95129e3fe5e"
      unitRef="U_USD">225000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_21080e41-be5b-4ab4-88bd-12288ec7e7ee"
      unitRef="U_USD">128000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a3604d0a-a916-4472-8172-3b429c592406"
      unitRef="U_USD">274000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_c5bef77a-bc3f-4150-940f-d265247647d1"
      unitRef="U_USD">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_0c39ae85-e542-4236-9763-7f0ef59f7287"
      unitRef="U_USD">131000</us-gaap:RestructuringReserve>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_d64bd9df-c0c6-4ddc-9c8c-d5c113fa4adb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basic and Diluted Net Loss Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period, plus any potentially dilutive common shares, consisting of stock-based awards and equivalents, and common stock warrants. For purposes of this calculation, stock-based awards and equivalents and common stock warrants are considered to be potential common shares and are only included in the calculation of diluted net loss per common share when their effect is dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's Series A Convertible Preferred Stock and certain of the Company's outstanding common stock warrants contain non-forfeitable rights to dividends with the common stockholders, and therefore are considered to be participating securities. The Series A Convertible Preferred Stock and the common stock warrants do not have a contractual obligation to fund the losses of the Company; therefore, the application of the two-class method is not required when the Company is in a net loss position but is required if the Company is in a net income position. When in a net income position, diluted net earnings per common share is computed using the more dilutive of the two-class method or the if-converted and treasury stock methods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the December 2024 Offering the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,120,688&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; prefunded warrants with such prefu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nded warrants being immediately exercisable, having an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and a perpetual term (See Note 5, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). The prefunded warrants were determined to be equity-classified in accordance with ASC 480 and ASC 815. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,027,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of these prefunded warrants remained unexercised. Pursuant to the guid&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ance of ASC 260-10, the Company concluded that because the equity-classified prefunded warrants were immediately exercisable for little or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cash consideration due to the non-substantive stated exercise price, all the necessary conditions for issuance of the underlying common shares had been met when the prefunded warrants were issued. Therefore, the underlying common shares have been included in the denominator for both the calculation of basic and dilutive net loss per common share for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As the Company was in a net loss position for all periods presented, basic and diluted net loss per common share for both the years ended December 31, 2024 and December 31, 2023 was calculated under the if-converted and treasury stock methods. For both the years ended December 31, 2024 and December 31, 2023, basic and diluted net loss per common share were the same as all common stock equivalents other than the prefunded warrants discussed above were anti-dilutive for both years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In computing the basic and diluted net loss available to common stockholders for the year December 31, 2023, the Company has deducted the value of the effect of the down round feature on equity classified warrants that was&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;triggered in each year as each was determined to be anti-dilutive. The value of the down round feature on equity classified warrants for the year ended December 31, 2024 was determined to be immaterial.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted net loss per common share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss available to common stockholders - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares used in calculating basic and diluted net loss per common share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,416,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;456,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effects would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants for common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,718,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,771,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_9b87aaa7-9c2f-4572-baaa-95cb98ab911a"
      decimals="0"
      id="F_9a3722e9-651d-4916-a9ce-8524d32187d4"
      unitRef="U_shares">3120688</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9b87aaa7-9c2f-4572-baaa-95cb98ab911a"
      decimals="4"
      id="F_319d0bdc-6922-4a4c-bb36-3923d1a69cac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d3c9c2d7-95dc-49bb-98bf-59ffcaac2dcb"
      decimals="0"
      id="F_2e6fcdc2-b0b2-4e2b-91bf-9693c79ef632"
      unitRef="U_shares">2027000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <pali:CashConsideration
      contextRef="C_d3c9c2d7-95dc-49bb-98bf-59ffcaac2dcb"
      decimals="INF"
      id="F_6dfc4621-cae7-4b3b-8aff-3f4d1841eb5b"
      unitRef="U_USD">0</pali:CashConsideration>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_79a43597-0621-405a-99e8-1ae832bd5b5b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the calculation of weighted average shares used to calculate basic and diluted net loss per common share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment to record the impact of exercise price reset on outstanding warrants related to down round provisions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss available to common stockholders - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average shares used in calculating basic and diluted net loss per common share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,416,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;456,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_5c9ce210-385f-426c-b72c-745314d366e4"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_b752c87e-29f5-4cbb-b5e1-5910d8eb6395"
      unitRef="U_USD">-12300000</us-gaap:NetIncomeLoss>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_47eabbd1-91a1-46e3-8830-025fc974b3c6"
      unitRef="U_USD">0</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a7fa7e6d-d8ec-4d66-9ae0-bbaa6a808b41"
      unitRef="U_USD">-16000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_ad949fbe-353c-4474-93a5-4889e2c01c1f"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_c3f25a5e-85b2-4904-a064-7cb61633ea5f"
      unitRef="U_USD">-14438000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_3942e842-ba49-409a-a30b-9d56e138d9e9"
      unitRef="U_USD">-12316000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_44b21ed6-6e79-4495-be31-e48187518460"
      unitRef="U_USD">-12316000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_fdd17d92-6517-4691-aaff-44bc73fd8761"
      unitRef="U_shares">1416471</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="0"
      id="F_dc860a40-b925-4255-9c9c-4500e8234f1d"
      unitRef="U_shares">1416471</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="0"
      id="F_cebe6505-85a8-495f-8151-6537af3c5edc"
      unitRef="U_shares">456014</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="0"
      id="F_7b449db8-7688-480b-9af8-8bf21d989d62"
      unitRef="U_shares">456014</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_d6ed2350-e321-4a7e-9d4b-fe76b2130c7e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-10.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="2"
      id="F_0ca0f4c3-a63c-40a2-a601-0131dfa7f5c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-10.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="2"
      id="F_0651e22d-e90b-454b-8b8c-fef9c45dd8ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-27.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="2"
      id="F_8e34ecad-ab13-4883-9c57-26db838a9a65"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-27.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_45a8d613-df0a-4e98-bbbb-e519264730b0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effects would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants for common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,718,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,771,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e4f02a44-93b6-4104-9ffb-23aeab786d9d"
      decimals="INF"
      id="F_afd6667c-862d-4146-94f6-3d8ff4717df3"
      unitRef="U_shares">50674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ff902a0c-401a-4796-873a-f487d5f3927d"
      decimals="INF"
      id="F_c655152a-bde7-46c0-b530-d0386ef2f0e5"
      unitRef="U_shares">44276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0e805a01-b80a-43a2-b2d3-6b7c1b32fbd6"
      decimals="INF"
      id="F_9639f0c4-11ca-4ffd-83e2-6ef9a835a26a"
      unitRef="U_shares">2952</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_818ca5b3-48b6-4160-92ed-c3b213c95caf"
      decimals="INF"
      id="F_2428db4d-595d-4741-8ed8-71fe22962183"
      unitRef="U_shares">28339</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8eff58aa-d87c-40ad-9ed7-ea2c72cee31b"
      decimals="INF"
      id="F_57880153-db53-42d6-b380-ee59a1936408"
      unitRef="U_shares">4718213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_15b1b95a-f0a8-45cc-8b88-bb5a5b75d92d"
      decimals="INF"
      id="F_25e95639-2b5f-4f57-a39a-3eb7115e908f"
      unitRef="U_shares">272211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_281c192c-92de-47d8-8a46-d3ac8f6e44b9"
      decimals="INF"
      id="F_a1210629-fa6c-4925-8fee-6ecb7baf8fd3"
      unitRef="U_shares">8</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bfdab209-cc24-443e-af8d-5930cc4c3149"
      decimals="INF"
      id="F_0df7f399-b01c-4250-8686-05d84add1aa0"
      unitRef="U_shares">8</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="INF"
      id="F_534e33c1-87b9-4bee-90ea-08758a0e8417"
      unitRef="U_shares">4771847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="INF"
      id="F_93c4d312-1b79-424c-8dd1-2e43c76a71d2"
      unitRef="U_shares">344834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_1832fc3a-622b-4874-9b5a-ee8244a2a07f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Employee Benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company participates in a defined contribution 401(k) plan adopted by LBS effective June 20, 2016. All employees are eligible to participate in the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; plan beginning on the first day of employment. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation. No matching contributions have been made by the Company since the adoption of the 401(k) plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_16740a3c-9f8d-4e08-bd52-c819bd3eea89">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has no current or deferred income taxes as of December 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes vary from the statutory federal income tax rate applied to loss before income taxes as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Statutory federal income tax rate of 21 percent applied to loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes - net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Meals and entertainment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expiration of tax attributes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets and liabilities arising from differences between accounting for financial statement purposes and tax purposes, less valuation reserves at year end are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities are recognized for temporary differences and unused tax losses to the extent that realization of the related tax benefits is more-likely-than-not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods when the deferred tax assets become deductible. After considering the history of operating losses and uncertainty regarding its ability to generate positive pre-tax income in 2025 and beyond, the Company has concluded that it is not-more-likely-than-not that its deferred tax assets will be realized, and therefore maintains a full valuation allowance on all deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The valuation allowance increased $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal net operating loss ("NOL") carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;llion and state NOL carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Of the total amount of federal NOL carryforwards, approx&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;imately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million arose in tax years beginning after December 31, 2017 and will carry forward indefinitely. The federal NOL carryforwards arising in tax years beginning before January 1, 2018 of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will begin to expire in 2025 unless previously utilized. The Company&#x2019;s state NOL carryforwards as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 may be carried forward for 20 years, and will expire at various dates between 2027 and 2044.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the provisions of the Internal Revenue Code ("IRC"), the Company&#x2019;s NOL and tax credit carryforwards and certain other attributes are subject to review and possible adjustment by the Internal Revenue Service ("IRS") and state tax authorities. NOL and tax credit carryforwards may be subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the IRC, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Including the recently completed Merger, the Company has completed several equity offerings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the IRC, or could result in a change in control in the future. The Company has not completed an IRC Section 382 and 383 analysis for all relevant tax years regarding the limitation of net operating losses. The NOL deferred tax asset does reflect the limitation resulting from the Merger; however, there could be further limitations due to prior changes in control. Due to the existence of a full valuation allowance, however, changes in the NOLs included as deferred tax assets on the Company&#x2019;s consolidated balance sheets would have no impact on the Company's effective tax rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and California. Because of the NOLs, the Company is subject to U.S. federal examinations for tax years 2006 and forward, and for examinations from state taxing authorities for tax years 2008 and forward.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for taxation under ASC 740, which clarifies the accounting for uncertain tax positions. ASC 740 requires that the Company recognize the impact of a tax position in its consolidated financial statements if the position is more-likely-than-not to be sustained upon examination based on the technical merits of the position. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any uncertain income tax positions as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 740 requires the Company to accrue interest and penalties where there is an underpayment of taxes based on the Company's best estimate of the amount to ultimately be paid. The Company identified no unrecorded material uncertain tax positions as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, consequently no interest or penalties have been accrued by the Company in either period. The Company does not anticipate a significant change to its unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_c499d0f7-23c3-48a1-aa40-3c318618fc77">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes vary from the statutory federal income tax rate applied to loss before income taxes as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Statutory federal income tax rate of 21 percent applied to loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes - net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Meals and entertainment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expiration of tax attributes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_06cb0210-9d0c-445b-9f02-792d6844a5f9"
      unitRef="U_USD">-3032000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_c58a7f37-3608-41f8-9d4a-bb822ae94695"
      unitRef="U_USD">-2583000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_ffb0b75a-0252-40cb-9c1a-de60bf4ab8fd"
      unitRef="U_USD">-660000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_1f6ac84d-06ea-4f06-bb8e-b63665dd1132"
      unitRef="U_USD">-810000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_b8636d52-7f63-47e8-9d5f-97ca7ff06197"
      unitRef="U_USD">1000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_32ccf782-6ff5-41a0-af36-30590472f804"
      unitRef="U_USD">3000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <pali:IncomeTaxReconciliationNondeductibleExpenseWarrants
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_dc800055-0db8-4698-befe-dfac2b80a94a"
      unitRef="U_USD">0</pali:IncomeTaxReconciliationNondeductibleExpenseWarrants>
    <pali:IncomeTaxReconciliationNondeductibleExpenseWarrants
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_f337bd58-512d-40f3-bf05-a29772d44f7a"
      unitRef="U_USD">-12000</pali:IncomeTaxReconciliationNondeductibleExpenseWarrants>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_a38496f8-d399-4059-b3fd-58e7f005d6b9"
      unitRef="U_USD">371000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_83afc96a-c0eb-419a-b783-f7c24f7340a8"
      unitRef="U_USD">522000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pali:IncomeTaxReconciliationOtherNonDeductibleExpenses
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_ed54b743-0c73-45ae-85fe-65b9ed10bf43"
      unitRef="U_USD">16000</pali:IncomeTaxReconciliationOtherNonDeductibleExpenses>
    <pali:IncomeTaxReconciliationOtherNonDeductibleExpenses
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_407c5298-2ac1-44f6-b055-0d7f5e5d0a7b"
      unitRef="U_USD">-89000</pali:IncomeTaxReconciliationOtherNonDeductibleExpenses>
    <pali:IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_7d3f3978-c52a-46e0-80ec-98ced9efa3d7"
      unitRef="U_USD">184000</pali:IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes>
    <pali:IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_dc1621e8-7607-417f-9d4b-49c8f4e556ce"
      unitRef="U_USD">484000</pali:IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_39aa5f2e-6b5f-4797-bcf3-662cbaca9e11"
      unitRef="U_USD">-346000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_3c0107de-c772-4bbc-b5c1-88020bbded9b"
      unitRef="U_USD">207000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_27aa32e4-cf90-45c9-aaa1-366d59c216a1"
      unitRef="U_USD">-49000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_c7b33955-72f4-46a8-b77d-e896307afc49"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_73ace2f0-b80e-448a-b1c8-1c8cbdcd2d6e"
      unitRef="U_USD">3515000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_a970a23b-c3c6-4e06-88a4-4adc61eeb1f8"
      unitRef="U_USD">2278000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-3"
      id="F_d95d7a34-a124-40f2-a22d-091783274b2e"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-3"
      id="F_8522747f-8b44-438b-8927-77e7a8205f62"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_7884fca5-39cd-4230-b07d-cc6d0e9171f0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets and liabilities arising from differences between accounting for financial statement purposes and tax purposes, less valuation reserves at year end are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <pali:DeferredTaxAssetsAccruedExpenses
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_a68c2051-4808-41d2-8aff-d7609f76af10"
      unitRef="U_USD">122000</pali:DeferredTaxAssetsAccruedExpenses>
    <pali:DeferredTaxAssetsAccruedExpenses
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_f5386040-c3cc-471a-b267-c94a76441df4"
      unitRef="U_USD">128000</pali:DeferredTaxAssetsAccruedExpenses>
    <pali:DeferredTaxAssetsDepreciation
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_b0dcaf0c-0c31-4e3e-a102-8b03f5dba40f"
      unitRef="U_USD">82000</pali:DeferredTaxAssetsDepreciation>
    <pali:DeferredTaxAssetsDepreciation
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_519aef29-fa1a-41b1-8b80-095dff0a4eb1"
      unitRef="U_USD">245000</pali:DeferredTaxAssetsDepreciation>
    <pali:DeferredTaxAssetsLeaseLiability
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_023df9ae-3255-4197-843e-f5e73ab3f56a"
      unitRef="U_USD">25000</pali:DeferredTaxAssetsLeaseLiability>
    <pali:DeferredTaxAssetsLeaseLiability
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_23223515-64de-450e-b222-ae8630a25273"
      unitRef="U_USD">55000</pali:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_4b97e49e-9f16-4286-8e6f-3c2b221cea7a"
      unitRef="U_USD">27383000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_15661f01-8d14-49fc-ae71-a5bfc2219051"
      unitRef="U_USD">24703000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_bc77f194-c527-4136-a46d-149616dd4a58"
      unitRef="U_USD">1216000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_f19b2771-0f14-4d56-b956-600591bebae5"
      unitRef="U_USD">1470000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_427cff55-9523-45f5-9288-a61baf98d4d0"
      unitRef="U_USD">3771000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_6b372f70-50da-4a54-b462-9f82b4a8d484"
      unitRef="U_USD">2515000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_f9cea35d-3002-4c0b-8bcc-867433df8f3d"
      unitRef="U_USD">32599000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_ed775b3d-c4f6-4576-9f2b-6bbb8e3c0170"
      unitRef="U_USD">29116000</us-gaap:DeferredTaxAssetsGross>
    <pali:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_d3bff432-d51a-4ff9-ae7b-c96a282d8315"
      unitRef="U_USD">23000</pali:DeferredTaxLiabilitiesRightOfUseAsset>
    <pali:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_b15ad6eb-aff1-4c95-9ee9-2d9eaae818f5"
      unitRef="U_USD">52000</pali:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_60b2d78c-748b-4b6d-9d91-d7be99b32b88"
      unitRef="U_USD">108000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_e1e31fa8-c703-4cbf-9cf8-3379b49c1b13"
      unitRef="U_USD">112000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_548002ca-80db-48ae-895c-366924e54e75"
      unitRef="U_USD">131000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_4466a6f2-136f-4c1d-8313-4a7fffa9f0f6"
      unitRef="U_USD">164000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_6c55c4f7-6aaa-40a9-86cf-ea9cba888680"
      unitRef="U_USD">32468000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_96408d55-fefb-4a8d-a03b-2b9be64378f8"
      unitRef="U_USD">28952000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_6015a4b9-97a2-406c-8f7b-175afebc4a53"
      unitRef="U_USD">32468000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_3ef941da-ae0f-4fcb-beb4-1255a6a70268"
      unitRef="U_USD">28952000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_f4efa6da-edbc-4b10-9455-f745bdeb2312"
      decimals="-3"
      id="F_6495e50d-3516-46a5-8bc7-c0bef9db28d5"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_03d4fa9c-1c2e-4588-9d90-7efd527c1d78"
      decimals="-3"
      id="F_5f1a2801-3d58-4f11-af14-3d096d7f030a"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="-5"
      id="F_e35e71de-4a91-4751-8bff-fec03f57bf7f"
      unitRef="U_USD">3500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="-5"
      id="F_449d57c9-afbc-46f0-9661-01c91a1493de"
      unitRef="U_USD">2300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_01f7368c-fa1b-4d5d-a9c9-07ba03a45b8e"
      decimals="-5"
      id="F_a41f1888-09b4-4170-b048-2fe9fa42b009"
      unitRef="U_USD">109400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f9f17689-3835-44ab-86c4-7ce94e9a6825"
      decimals="-5"
      id="F_91ffff21-6830-4b90-ab8b-4fb66c0f207e"
      unitRef="U_USD">63000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9a79efb8-eb68-42c2-a8fa-55c0d8aa5fda"
      decimals="-5"
      id="F_07626587-27ab-4945-8346-8d8cbfcbf7aa"
      unitRef="U_USD">77800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ee8693bb-92aa-44a4-880d-83926ceee699"
      decimals="-5"
      id="F_526e6a26-85a6-412d-b566-13a34f438ac6"
      unitRef="U_USD">31700000</us-gaap:OperatingLossCarryforwards>
    <pali:UncertainIncomeTaxPositions
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="INF"
      id="F_163ff97c-1021-4f60-8bc8-4f7b9ee4d571"
      unitRef="U_USD">0</pali:UncertainIncomeTaxPositions>
    <pali:UncertainIncomeTaxPositions
      contextRef="C_2faf211e-59a5-4ce8-a255-3561ae2b8311"
      decimals="INF"
      id="F_6de43d9f-83c4-4a5e-b2ca-c9840bb62d09"
      unitRef="U_USD">0</pali:UncertainIncomeTaxPositions>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_7a14279a-3afb-4079-9f5e-612d7d171fea">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, focused on the research and development of novel therapeutics for patients, including the advancement of PALI-2108 through clinical trials. The Company did not aggregate multiple operating segments into its one operating segment. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0ffa1e3a-3c65-4853-b3c6-1a6c686c9e2d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief operating decision maker&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;CODM&#x201d;) is its chief execut&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ive officer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's CODM uses Net loss that is reported on the consolidated statements of operations and comprehensive loss for the purposes of assessing performance, allocating resources and planning, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;monitoring budget versus actual results, and forecasting future periods. The Company&#x2019;s CODM views specific program spend within research and development expenses, research and development spend that is not allocated to specific programs, as well as general and administrative expenses as significant segment expenses. As a pre-product revenue company, the CODM considers budget versus actual results for expenses that are deemed significant and cash forecast models for assessing performance and to decide the level of investment in the Company&#x2019;s operating and capital allocation activities. &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to significant expense categories included in Net loss, the Company regularly provides disaggregated significant expense amounts that comprise operating expenses to the CODM to assist when managing the Company's single reporting segment.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation to consolidated operating expenses as our single segment operating loss for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 is included in the table below (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PALI-2108 program expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legacy program expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PALI-2108 program expenses are those expenses directly related with the development of the Company's only asset currently under development, PALI-2108. Legacy program expenses are those expenses directly related to its legacy assets, primarily LB1148, which the Company ceased developing in August of 2023. Other research and development expenses includes primarily employee-related expenses and research and development facility expenses, which are not allocated to specific programs, and non-cash losses associated with changes in the fair value of the Company's contingent consideration obligation. For the year ended December 31, 2023, Other research and development expenses also includes the initial fair value of the contingent consideration obligation and transaction-related costs related to the Giiant License Agreement (See Note 4, Fair Value Measurements). Other general and administrative expenses consist primarily of salary and employee-related costs and benefits, professional fees for legal, investor and public relations, accounting and audit services, insurance costs, director and committee fees, and general corporate expenses. Excluded from other general and administrative expenses are intellectual property expenses and business development expenses that are allocated to program expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the other segment items that the Company used to aggregate Total operating expenses to arrive at Net Loss as shown on the consolidated statement of operations include, if applicable, License Revenue, Interest expense and Other income, net.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not provide separate segment asset information to the CODM because the CODM does not review segment assets at a different asset level or category than those shown on the consolidated balance sheets. All of the Company&#x2019;s assets are located in the U.S.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="INF"
      id="F_260fcbe6-2cbf-4963-95f4-ebe466d636ce"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      decimals="INF"
      id="F_2d902210-8537-4796-b9e4-3f85c8a66cfa"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_4d5e2c29-76d7-4253-a01e-bc61cd012e8b">The Company's CODM uses Net loss that is reported on the consolidated statements of operations and comprehensive loss for the purposes of assessing performance, allocating resources and planning, monitoring budget versus actual results, and forecasting future periods. The Company&#x2019;s CODM views specific program spend within research and development expenses, research and development spend that is not allocated to specific programs, as well as general and administrative expenses as significant segment expenses. As a pre-product revenue company, the CODM considers budget versus actual results for expenses that are deemed significant and cash forecast models for assessing performance and to decide the level of investment in the Company&#x2019;s operating and capital allocation activities. In addition to significant expense categories included in Net loss, the Company regularly provides disaggregated significant expense amounts that comprise operating expenses to the CODM to assist when managing the Company's single reporting segment.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_bbf28b9a-076a-4b0c-8507-897f4203f316">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation to consolidated operating expenses as our single segment operating loss for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 is included in the table below (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PALI-2108 program expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legacy program expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restructuring costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <pali:ProgramExpenses
      contextRef="C_4fedbd90-4e26-4897-b395-ac4b7cdb1342"
      decimals="-3"
      id="F_c23ee955-573c-4304-b81c-d78d024ba51d"
      unitRef="U_USD">7070000</pali:ProgramExpenses>
    <pali:ProgramExpenses
      contextRef="C_f9ff4d32-3399-4339-9015-2a14b777cd9a"
      decimals="-3"
      id="F_9cef9748-76e4-4676-b99f-f2893b2f5cab"
      unitRef="U_USD">736000</pali:ProgramExpenses>
    <pali:ProgramExpenses
      contextRef="C_9845b157-d40c-4027-97c2-a0fd4385089a"
      decimals="-3"
      id="F_cdd1e31e-e7fa-4f88-acf5-5a3114453efb"
      unitRef="U_USD">155000</pali:ProgramExpenses>
    <pali:ProgramExpenses
      contextRef="C_16f011be-773b-4769-92b0-515dab2809dc"
      decimals="-3"
      id="F_34e822a8-294f-420f-af1f-105e5a1badec"
      unitRef="U_USD">3303000</pali:ProgramExpenses>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45"
      decimals="-3"
      id="F_07239f91-0bbf-4816-9e65-9f2620061ca3"
      unitRef="U_USD">2156000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39"
      decimals="-3"
      id="F_9230d02e-4798-4e0d-9ae4-5657c7324fb4"
      unitRef="U_USD">2987000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45"
      decimals="-3"
      id="F_39242558-b0a9-4b82-bd8c-350cc90fe5f9"
      unitRef="U_USD">5478000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39"
      decimals="-3"
      id="F_7a9297c3-662f-4471-9cb3-f01be65320cc"
      unitRef="U_USD">6069000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCosts
      contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45"
      decimals="-3"
      id="F_86645a48-f53f-4f86-8ca5-717206a2fa06"
      unitRef="U_USD">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39"
      decimals="-3"
      id="F_81ece89f-c2ab-45e9-89fd-8b25e098ab18"
      unitRef="U_USD">225000</us-gaap:RestructuringCosts>
    <us-gaap:OperatingExpenses
      contextRef="C_aba08c8a-3298-4ff6-87c6-223993191a45"
      decimals="-3"
      id="F_17dde6cf-b771-4316-a8f6-51590586a14f"
      unitRef="U_USD">14859000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_099a2990-8f62-4736-908a-75e3e70bef39"
      decimals="-3"
      id="F_3ebb77db-009c-4b64-acf1-7162730be34d"
      unitRef="U_USD">13320000</us-gaap:OperatingExpenses>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c"
      id="F_ed1512d3-a82a-423f-88df-a26ff4a6fb30">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c"
      id="F_a5279440-32f1-4032-b294-0837fa4e2761">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c"
      id="F_fe4baedf-6fba-4f71-a1f8-cf183eee4bba">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_494b0e96-ca6c-4dd0-aada-9c385796b28c"
      id="F_2c33737c-40d7-4d10-a169-d3a4b4103ec8">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_ff05127f-d773-4134-8b79-bcb7ee6b5544">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_7380a179-dd07-4de1-a082-768152624e25">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity awards are discretionary and are generally granted to our named executive officers the second month of the applicable fiscal year. In certain circumstances, our Compensation Committee may  approve grants to be effective at other times. The Compensation Committee &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;does not grant equity awards in anticipation&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the release of material nonpublic information and we &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;do not time&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;release of material nonpublic information based on equity award grant dates. No equity awards were granted to our named executive officers in 2024, as the equity awards granted in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 to our named executive officers were intended to provide retention and compensation for service in 2024.&lt;/span&gt;&lt;/p&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_757c4d6e-0c71-4ccb-8d9a-5f67a5ea27e9">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag
      contextRef="C_3f56cf0a-ea7d-46f7-a484-659ae7b734eb"
      id="F_ee10d2bd-82c2-4143-b27b-8603cdbe26a5">false</ecd:MnpiDiscTimedForCompValFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_bb5c5b37-1ce9-43b5-b2e5-323e82bd6b35"
          xlink:label="F_bb5c5b37-1ce9-43b5-b2e5-323e82bd6b35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0f258028-16ee-47ec-b30a-a72e7909933d"
          xlink:label="F_0f258028-16ee-47ec-b30a-a72e7909933d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_52f8c5ac-0778-4aeb-b48d-5ca369d4f1c9"
          xlink:label="F_52f8c5ac-0778-4aeb-b48d-5ca369d4f1c9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2d214d75-f0d4-46b6-a346-1086df1e7442"
          xlink:label="F_2d214d75-f0d4-46b6-a346-1086df1e7442"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f295b006-8721-42a1-9ac3-52f7a33c05b0"
          xlink:label="F_f295b006-8721-42a1-9ac3-52f7a33c05b0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_dd2d9c2e-d568-4109-9a93-3600a95d4bb8"
          xlink:label="F_dd2d9c2e-d568-4109-9a93-3600a95d4bb8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ccbb254a-2085-465e-8ec8-ae210579281a"
          xlink:label="F_ccbb254a-2085-465e-8ec8-ae210579281a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3befa2c4-75ca-4fc6-ae21-d8d6d7a77d6d"
          xlink:label="F_3befa2c4-75ca-4fc6-ae21-d8d6d7a77d6d"
          xlink:type="locator"/>
        <link:footnote id="FNT_1cae901f-db24-4481-ad3f-2ed437509eae" xlink:label="FNT_1cae901f-db24-4481-ad3f-2ed437509eae" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Basic and diluted loss per common share and basic and diluted weighted average share used in computing basic and diluted loss per common share for the year ended December 31, 2023 has been adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bb5c5b37-1ce9-43b5-b2e5-323e82bd6b35"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0f258028-16ee-47ec-b30a-a72e7909933d"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_52f8c5ac-0778-4aeb-b48d-5ca369d4f1c9"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2d214d75-f0d4-46b6-a346-1086df1e7442"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f295b006-8721-42a1-9ac3-52f7a33c05b0"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dd2d9c2e-d568-4109-9a93-3600a95d4bb8"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ccbb254a-2085-465e-8ec8-ae210579281a"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3befa2c4-75ca-4fc6-ae21-d8d6d7a77d6d"
          xlink:to="FNT_1cae901f-db24-4481-ad3f-2ed437509eae"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_58475b22-3533-4cb1-afde-56be185c8979"
          xlink:label="F_58475b22-3533-4cb1-afde-56be185c8979"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0d8986ce-d38e-4bda-ab78-06023757e6ab"
          xlink:label="F_0d8986ce-d38e-4bda-ab78-06023757e6ab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bdd775a9-38c9-4488-93ee-6a859c8265b1"
          xlink:label="F_bdd775a9-38c9-4488-93ee-6a859c8265b1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_319d8403-72a4-41d4-af2c-c72e7618880c"
          xlink:label="F_319d8403-72a4-41d4-af2c-c72e7618880c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_32d51079-3301-4b4a-876e-bfb122660164"
          xlink:label="F_32d51079-3301-4b4a-876e-bfb122660164"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e1dac30b-227b-4798-a021-13173d491f7b"
          xlink:label="F_e1dac30b-227b-4798-a021-13173d491f7b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f57a0064-dc8e-4fa8-a52f-54517bbe3c18"
          xlink:label="F_f57a0064-dc8e-4fa8-a52f-54517bbe3c18"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e7cc059f-57cd-4370-8109-52aebcece734"
          xlink:label="F_e7cc059f-57cd-4370-8109-52aebcece734"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c976ce42-1091-4cc0-944a-f361caf66be6"
          xlink:label="F_c976ce42-1091-4cc0-944a-f361caf66be6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b466cb16-964d-49e3-96e0-9a33a892309c"
          xlink:label="F_b466cb16-964d-49e3-96e0-9a33a892309c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_89a5ab14-b2e0-4738-a557-61eb27d9e8b7"
          xlink:label="F_89a5ab14-b2e0-4738-a557-61eb27d9e8b7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_65e1e41b-e592-45d0-9e65-6d7e4f5027a5"
          xlink:label="F_65e1e41b-e592-45d0-9e65-6d7e4f5027a5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_25fe3de5-adc1-472b-9089-7ffa1ad3b53b"
          xlink:label="F_25fe3de5-adc1-472b-9089-7ffa1ad3b53b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2467db4a-5cce-40b8-8e36-9c08cd303c89"
          xlink:label="F_2467db4a-5cce-40b8-8e36-9c08cd303c89"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_59ca71c2-b250-44d8-8b8a-4e88355311e3"
          xlink:label="F_59ca71c2-b250-44d8-8b8a-4e88355311e3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d411c7b8-b584-4e13-97b4-511b622f1b23"
          xlink:label="F_d411c7b8-b584-4e13-97b4-511b622f1b23"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_97d2faa5-3929-43e4-9b99-b2b09b8e728b"
          xlink:label="F_97d2faa5-3929-43e4-9b99-b2b09b8e728b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9511cfd1-2c72-40fd-82a4-ff06fe15d67d"
          xlink:label="F_9511cfd1-2c72-40fd-82a4-ff06fe15d67d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e68f6333-1c2a-4508-ada0-e03960169271"
          xlink:label="F_e68f6333-1c2a-4508-ada0-e03960169271"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d939f84e-22a7-443b-8c7d-9877fdf3af00"
          xlink:label="F_d939f84e-22a7-443b-8c7d-9877fdf3af00"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a9aaa239-ef30-4d3b-a071-c1561afdc27d"
          xlink:label="F_a9aaa239-ef30-4d3b-a071-c1561afdc27d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_481c1e2d-9068-4ae3-9ba7-c8d2ae60a338"
          xlink:label="F_481c1e2d-9068-4ae3-9ba7-c8d2ae60a338"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b9fb2141-4746-4cf1-a213-25ff041b13d7"
          xlink:label="F_b9fb2141-4746-4cf1-a213-25ff041b13d7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ebfb9068-25fc-4457-81e6-4ab7d1e6695f"
          xlink:label="F_ebfb9068-25fc-4457-81e6-4ab7d1e6695f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_fd270e0c-1614-4dab-8b8e-e5417adf32f7"
          xlink:label="F_fd270e0c-1614-4dab-8b8e-e5417adf32f7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_199eb8a0-6b97-4beb-b1bb-be7bf186d9a0"
          xlink:label="F_199eb8a0-6b97-4beb-b1bb-be7bf186d9a0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8cc691d2-c99f-43b3-b37d-ba6cb755b8af"
          xlink:label="F_8cc691d2-c99f-43b3-b37d-ba6cb755b8af"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6f3be1d1-75d4-43bb-ba1c-fefea07a2041"
          xlink:label="F_6f3be1d1-75d4-43bb-ba1c-fefea07a2041"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5d0c4430-3d06-42b8-b111-3e61fdac3cd0"
          xlink:label="F_5d0c4430-3d06-42b8-b111-3e61fdac3cd0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9fa2496c-4ca6-423d-a620-e2e7efcb12e5"
          xlink:label="F_9fa2496c-4ca6-423d-a620-e2e7efcb12e5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_dee46229-4244-4ad9-b50c-f0b17e03436a"
          xlink:label="F_dee46229-4244-4ad9-b50c-f0b17e03436a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d36e42da-1750-4bfd-8ccc-25d155d540fb"
          xlink:label="F_d36e42da-1750-4bfd-8ccc-25d155d540fb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_223c3c04-379a-4125-84e0-9d7da2e2a28a"
          xlink:label="F_223c3c04-379a-4125-84e0-9d7da2e2a28a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6d752654-4a66-4b6d-98c9-36e92bc3213d"
          xlink:label="F_6d752654-4a66-4b6d-98c9-36e92bc3213d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bfea37a1-9005-48a7-8355-3aa202c9ac1b"
          xlink:label="F_bfea37a1-9005-48a7-8355-3aa202c9ac1b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_913a4536-6c4b-4315-bf67-d5c1533e34fb"
          xlink:label="F_913a4536-6c4b-4315-bf67-d5c1533e34fb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bf86ad15-f481-43bc-95fd-ed93392090db"
          xlink:label="F_bf86ad15-f481-43bc-95fd-ed93392090db"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bddb3b34-6a85-4acb-b78f-4f2ccd352734"
          xlink:label="F_bddb3b34-6a85-4acb-b78f-4f2ccd352734"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_417255a2-0c2e-47c2-964a-37873d64eabb"
          xlink:label="F_417255a2-0c2e-47c2-964a-37873d64eabb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f68d14e1-3be6-4e28-bab4-237421dd1b76"
          xlink:label="F_f68d14e1-3be6-4e28-bab4-237421dd1b76"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a2c67c24-ea99-467d-b763-290b87654180"
          xlink:label="F_a2c67c24-ea99-467d-b763-290b87654180"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c7397b9f-06bf-42db-afdc-18d7fcca3a92"
          xlink:label="F_c7397b9f-06bf-42db-afdc-18d7fcca3a92"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9745b3d0-2782-465e-b09b-34f7e43e40e7"
          xlink:label="F_9745b3d0-2782-465e-b09b-34f7e43e40e7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5efb6687-ed6e-45e6-9dfd-e297f64b1113"
          xlink:label="F_5efb6687-ed6e-45e6-9dfd-e297f64b1113"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7228d524-4406-4b0c-8431-766f31a3570e"
          xlink:label="F_7228d524-4406-4b0c-8431-766f31a3570e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_cc72025c-7121-4942-ac82-720a8dcaf5c6"
          xlink:label="F_cc72025c-7121-4942-ac82-720a8dcaf5c6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_598beaea-107c-4159-af0f-159afd92aecb"
          xlink:label="F_598beaea-107c-4159-af0f-159afd92aecb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bce6c0dd-8418-4daf-adfd-5db44bf2a01a"
          xlink:label="F_bce6c0dd-8418-4daf-adfd-5db44bf2a01a"
          xlink:type="locator"/>
        <link:footnote id="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd" xlink:label="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_58475b22-3533-4cb1-afde-56be185c8979"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0d8986ce-d38e-4bda-ab78-06023757e6ab"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bdd775a9-38c9-4488-93ee-6a859c8265b1"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_319d8403-72a4-41d4-af2c-c72e7618880c"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_32d51079-3301-4b4a-876e-bfb122660164"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e1dac30b-227b-4798-a021-13173d491f7b"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f57a0064-dc8e-4fa8-a52f-54517bbe3c18"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7cc059f-57cd-4370-8109-52aebcece734"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c976ce42-1091-4cc0-944a-f361caf66be6"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b466cb16-964d-49e3-96e0-9a33a892309c"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_89a5ab14-b2e0-4738-a557-61eb27d9e8b7"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_65e1e41b-e592-45d0-9e65-6d7e4f5027a5"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_25fe3de5-adc1-472b-9089-7ffa1ad3b53b"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2467db4a-5cce-40b8-8e36-9c08cd303c89"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_59ca71c2-b250-44d8-8b8a-4e88355311e3"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d411c7b8-b584-4e13-97b4-511b622f1b23"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_97d2faa5-3929-43e4-9b99-b2b09b8e728b"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9511cfd1-2c72-40fd-82a4-ff06fe15d67d"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e68f6333-1c2a-4508-ada0-e03960169271"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d939f84e-22a7-443b-8c7d-9877fdf3af00"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a9aaa239-ef30-4d3b-a071-c1561afdc27d"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_481c1e2d-9068-4ae3-9ba7-c8d2ae60a338"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b9fb2141-4746-4cf1-a213-25ff041b13d7"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ebfb9068-25fc-4457-81e6-4ab7d1e6695f"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fd270e0c-1614-4dab-8b8e-e5417adf32f7"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_199eb8a0-6b97-4beb-b1bb-be7bf186d9a0"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8cc691d2-c99f-43b3-b37d-ba6cb755b8af"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6f3be1d1-75d4-43bb-ba1c-fefea07a2041"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5d0c4430-3d06-42b8-b111-3e61fdac3cd0"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9fa2496c-4ca6-423d-a620-e2e7efcb12e5"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dee46229-4244-4ad9-b50c-f0b17e03436a"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d36e42da-1750-4bfd-8ccc-25d155d540fb"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_223c3c04-379a-4125-84e0-9d7da2e2a28a"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6d752654-4a66-4b6d-98c9-36e92bc3213d"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bfea37a1-9005-48a7-8355-3aa202c9ac1b"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_913a4536-6c4b-4315-bf67-d5c1533e34fb"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bf86ad15-f481-43bc-95fd-ed93392090db"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bddb3b34-6a85-4acb-b78f-4f2ccd352734"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_417255a2-0c2e-47c2-964a-37873d64eabb"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f68d14e1-3be6-4e28-bab4-237421dd1b76"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a2c67c24-ea99-467d-b763-290b87654180"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c7397b9f-06bf-42db-afdc-18d7fcca3a92"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9745b3d0-2782-465e-b09b-34f7e43e40e7"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5efb6687-ed6e-45e6-9dfd-e297f64b1113"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7228d524-4406-4b0c-8431-766f31a3570e"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_cc72025c-7121-4942-ac82-720a8dcaf5c6"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_598beaea-107c-4159-af0f-159afd92aecb"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bce6c0dd-8418-4daf-adfd-5db44bf2a01a"
          xlink:to="FNT_2b8e07f9-e880-4c77-b7f5-5560ca0b1ecd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_e17dc50e-fb87-4771-bb28-42b133ce3025"
          xlink:label="F_e17dc50e-fb87-4771-bb28-42b133ce3025"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_fce4d946-4eaa-49bf-bf56-389a9c946b62"
          xlink:label="F_fce4d946-4eaa-49bf-bf56-389a9c946b62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5632091e-04bc-4913-8599-b692f8c15eb4"
          xlink:label="F_5632091e-04bc-4913-8599-b692f8c15eb4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_578d8f4a-3f98-4fcb-b04c-47dfd425f18e"
          xlink:label="F_578d8f4a-3f98-4fcb-b04c-47dfd425f18e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9ec4bd57-f51b-4896-87de-7ea6b3c54805"
          xlink:label="F_9ec4bd57-f51b-4896-87de-7ea6b3c54805"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_de0ee860-249f-4ea5-a15f-2253e20d2e60"
          xlink:label="F_de0ee860-249f-4ea5-a15f-2253e20d2e60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_af472992-0b5c-4fd7-8629-5a80bacda3e1"
          xlink:label="F_af472992-0b5c-4fd7-8629-5a80bacda3e1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_93846c07-d6b2-4f83-a4ae-e0b232e0b38d"
          xlink:label="F_93846c07-d6b2-4f83-a4ae-e0b232e0b38d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0190b23d-8df3-4c80-9a8d-d863afd3dc7c"
          xlink:label="F_0190b23d-8df3-4c80-9a8d-d863afd3dc7c"
          xlink:type="locator"/>
        <link:footnote id="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430" xlink:label="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded common stock warrants granted and outstanding during the year ended December 31, 2024</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a perpetual term and are therefore excluded from the calculation of the weighted average remaining contractual life.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e17dc50e-fb87-4771-bb28-42b133ce3025"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fce4d946-4eaa-49bf-bf56-389a9c946b62"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5632091e-04bc-4913-8599-b692f8c15eb4"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_578d8f4a-3f98-4fcb-b04c-47dfd425f18e"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9ec4bd57-f51b-4896-87de-7ea6b3c54805"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_de0ee860-249f-4ea5-a15f-2253e20d2e60"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_af472992-0b5c-4fd7-8629-5a80bacda3e1"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_93846c07-d6b2-4f83-a4ae-e0b232e0b38d"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0190b23d-8df3-4c80-9a8d-d863afd3dc7c"
          xlink:to="FNT_8e482e50-5f22-42a4-8c2c-402d5aee3430"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
